5,023 Matching Annotations
  1. Oct 2021
    1. Reviewer #3 (Public Review): 

      The work 'A B cell actomyosin arc network couples integrin co-stimulation to mechanical force-dependent immune synapse formation' by Wang et al. describes the importance of integrin mediated B-cell co-stimulation for IS formation in B-cells by fostering the formation of myosin II A driven actin arcs that are essential in the transport of IgM clusters towards the IS center. 

      The work presented here, i.e. experiments and analysis, is very thoroughly done and includes tests and controls using different labelling strategies and constructs of myosin II A, multiple cell types including primary cells and a range of chemical inhibitors to rule out artefacts. 

      The authors claim that the observation of actin arcs in B-cells co-stimulated by ICAM-1 - LFA-1 interaction is important for the efficient activation of B-cells in the presence of limiting levels of anti-IgM and this is very well supported by the experiments. However, it was a bit surprising that the paper did not draw much of parallels between the observed phenomenon and the reported actin arcs in activated T-cells even though some of the authors were very much involved in such work on T-cells. If there is a good reason to believe there is no ground to draw comparisons, this would then also need to be highlighted by the authors. 

      The work on establishing the drivers of actin arc formation and dynamics is well done, but it is important to note that previous work has analyzed actin arc formation in other cell types. Work by Bershadsky has already established many 'ground rules' for the formation of actin arcs and the role of integrin adhesion, formin activity and myosin II in the process (Tee YH, Shemesh T, Thiagarajan V, Hariadi RF, Anderson KL, Page C, Volkmann N, Hanein D, Sivaramakrishnan S, Kozlov MM, Bershadsky AD. 2015. Cellular chirality arising from the self-organization of the actin cytoskeleton. Nat Cell Biol 17:445-457. doi:10.1038/ncb3137). It might be very instructive if the authors could put their findings in relation to this work. 

      The formation of actin arcs is also well studied in U2OS cells and the results presented here could highlight interesting general features of this process observed in very different cell types (Tojkander S, Gateva G, Husain A, Krishnan R, Lappalainen P. 2015. Generation of contractile actomyosin bundles depends on mechanosensitive actin filament assembly and disassembly. Elife 4:1-28. doi:10.7554/eLife.06126; Bur-nette DT, Shao L, Ott C, Pasapera AM, Fischer RS, Baird MA, Der Loughian C, Delanoe-Ayari H, Paszek MJ, Davidson MW, Betzig E, Lippincott-Schwartz J. 2014. A contractile and counterbalancing adhesion system controls the 3D shape of crawling cells. J Cell Biol 205:83-96. doi:10.1083/jcb.201311104). 

      In this regard, the findings about the importance of myosin II A activity, integrin adhesion and mDia1 in the formation of actin arcs is not that surprising and the authors might rather highlight the important role of these newly studied structures for co-stimulation in B-cells as this is the more novel and insightful bit of the work.

    1. Author Response:

      Reviewer #1 (Public Review):

      Summary of what the authors were trying to achieve

      Background: Myopia (short- or near-sightedness) is an ocular disorder of increasing concern to human individuals and health-care systems; these days one speaks of a "myopia epidemic" in developed countries. Usually it is due to excessive elongation of the optic axis of the eye during the ages of most rapid growth (ca. 5-16 years in humans), causing images of distant objects to be blurred at the retinal photoreceptors. The optical error can be corrected with lenses or corneal surgeries, but this does not reduce the risk of continued progression and vision loss. Despite extensive epidemiological and animal studies in the past several decades, the underlying causal mechanisms remain poorly known, and therapeutic options are limited. Therefore, further discovery of new candidate mechanisms, drug targets and drugs for inhibiting the onset and progression of myopia is urgently needed.

      Rationale: The axial length of the eye is regulated mainly by qualities of the visual environment, including light intensity, spectrum, and spatiotemporal characteristics of images on the retina. Thus the retina encodes and integrates visual information over time, and ultimately sends regulatory "grow" or "stop" signals via the choroid - a vascular plexus behind the retina - to the sclera, the fibrous outer coat of the eye. Changes in size (area) of the sclera are responsible for changes in axial length, and thereby, refraction. The choroid is in a critical position, not only to relay "stop" or "go" messages to the sclera, but also potentially to critically modify those signals (or generate signals of its own) and further modulate ocular elongation and refraction. Importantly, very little is known about how the choroid fulfills either of these roles.

      Aims of the Study: The authors' purpose was to test, in juvenile chicken models, whether the 'pro-inflammatory' cytokine, interleukin-6 (IL-6) - synthesized and released in the choroid - might play a key role in the developmental regulation of axial elongation and refraction of the eye.

      Major strengths and weaknesses of the methods and results

      Strengths:

      1) The studies are focused on the choroid, which must be important in regulating ocular growth and refraction, but whose role is still not well understood

      2) Expert use of front-line tools for quantifying mRNA and protein (microarray, RT-PCR, ELISA)

      3) Immunohistochemistry: Good choice of antibody (raised to chicken IL-6), appropriate specificity control (preabsorption with chicken antigen)

      4) IL-6 mRNA in choroid was impressively increased during recovery from form-deprivation myopia (FDM) (preliminary results, Fig. 2) - i.e., during strong positive (myopic) defocus - a defocus-dependent effect confirmed by a similar effect of lens-induced myopic defocus (Fig. 5).

      5) Good data for the time-course of IL-6 mRNA content in choroid, with some confirmation of protein levels (though at only 2 treatment intervals) (Fig. 3)

      6) Choroidal IL-6 mRNA also shown convincingly to increase, going from darkness to light (Fig. 4).

      7) It's clever to compare the growth- and myopia-inhibiting effects of positive defocus, with those of other treatments known to do the same - in this case, atropine and nitric oxide (NO). The evidence shows that the effects of these agents on choroidal IL-6 mRNA are similar to the effect of positive defocus, with an NO-donor increasing the amounts of IL-6 mRNA and protein in isolated choroid (Fig. 7), and a NOS-inhibitor decreasing the mRNA levels at an intravitreal dose that inhibits scleral growth (Fig. 6).

      8) If my calculations are correct, 0.1% atropine sulfate solution has a molarity of something like

      1.3 mM. Since alpha-2A adrenoreceptors are present in the choroid, of mammals at least (e.g., Wikberg-Matsson et al., 1996, Exp Eye Res, 63(1):57-66), it might be interesting to explore the possibility that atropine is stimulating IL-6 production in the choroid by acting as agonist via these receptors (cf. Carr et al., 2018, IOVS, 59m2778-2791). The isolated choroid, with IL-6 mRNA and protein synthesis as read-outs, should be an exceptional (and novel) model for testing this and other possible signalling pathways in the choroid.

      Weaknesses:

      1) Immunolocalization of IL-6: The images (Fig. 1) are not good enough to identify cellular localization of immunoreactive structures; identification of RPE is questionable (no DAPI+ nuclei in labeled 'RPE'); nucleated erythrocytes should be visible in vessel lumina.

      We have increased the magnification and resolution of images in Figure 1 to better distinguish immunoreactive cells. Additionally, we have included as Figure 1 - figure supplement 1, both H&E stained and immunolabelled images from adjacent serial sections (both longitudinal and cross sections) of control choroids in order to compare immunopositive cells with the histoarchitecture of the choroid. From these images, one can see that nucleated erythrocytes are located in some of the vessel lumina. The nuclei of the RPE label weakly as compared with those of choroidal fibroblasts or nucleated blood cells. In order to visualize the RPE nuclei, we had to increase the intensity of the DAPI channel (blue, 405 nm) to a level that is not optimal for viewing IL-6 immunolabelling (green). Therefore, we included an additional supplemental figure (Figure 1 – figure supplement 2) in which RPE nuclei are readily visible.

      2) Many important details of methods have been left out. Spectral peaks of LED light-sources need to be given, lines 409-412; that's just one of many examples.

      We have included graphical and tabular data describing the frequency spectra for each of the three LED light sources used in the present study (Figure 4 - figure supplement 1), and in Sheet 3 of the source data file for Supplementary figures. Additionally, we have added the method of obtaining the frequency spectra in the methods section (lines 499 – 501).

      We have also included details of the antigen retrieval procedure performed during histological processing of ocular tissues and details on the methodology and analysis of microarray data (lines 544-547).

      3) Intensity (illuminance) of "red" and "blue" lights seems unnecessarily low (58 and 111 lux, respectively, far below the "medium" and "high" intensities of white lights that were used; Fig. 4).

      We agree with this comment. The intensities of the red and blue LED lights were limited by the red LED lights. We set them at their maximum intensity setting which registered at 58 lux. To compare their effect with that of the blue light, we felt we should set the blue LED lights at a similar setting, which required us to use its lowest setting, which registered at 111 lux. We realize that these intensities are low, compared with the medium and high settings of the white LED lights. Perhaps at higher intensities we might have observed a differential effect on IL-6 mRNA with red light compared to blue light. We have added this explanation and possibility in the Discussion section (lines 333 – 353).

      4) Also, given that red and blue lights have been found to have opposite effects on FDM in chicks (e.g., Wang et al., 2018, IOVS, 59(11):4413-4424), the similarity of IL-6 responses to red and blue in the present study strikes me as a point against a role for IL-6 in regulation of eye growth.

      We respectfully disagree with this statement. The Wang et al., paper reported that continuous exposure to red LED lights for five days had no significant effect on refraction or axial length in either control eyes or form deprived (myopic) eyes. In contrast, continuous exposure to blue LED light caused a significant hyperopic shift in refraction in both control and form deprived eyes, but had no significant effect on axial length in either control or form deprived eyes (although a trend toward a decrease in axial length was observed after five days in both control and form deprived eyes). Since refraction was significantly affected (in blue light-reared chicks), but axial length was only minimally affected, we suspect that continual exposure to blue light may have affected other ocular parameters (such as corneal curvature) that would have a significant impact on refraction. We predict that choroidal IL-6 expression is involved in the choroidal and scleral remodeling processes at the posterior pole of the eye that result in changes in vitreous chamber elongation, as opposed to having effects on the anterior segment of the eye. Our data shows short term (6 hr) exposure to red or blue LED light had no effect on IL-6 gene expression. If IL-6 gene expression is involved in the regulation of eye growth, we would expect that exposure to red or blue LED light would have no effect on scleral remodeling, vitreous chamber depth, or axial length, which in fact, is consistent with the results of the Wang et al., paper. We have added this interpretation in the Discussion section of the paper (lines 333 – 353).

      5) I admire the thoroughness of confirming that some of the treatments did in fact have the predicted effects on ocular enlargement, by performing assays for scleral proteoglycan synthesis. This might not be essential to this work, although it is well done, and the scleral data won't detract from the value of the paper if retained. But the induction of opposite effects on eye (scleral) growth by such manipulations is well established, and much simpler (cheaper and faster) refraction and/or caliper measurements would have served the same purpose.

      We elected to use scleral proteoglycan synthesis as a “read out” for axial elongation, since we can detect significant changes in scleral proteoglycan synthesis much earlier (within 6 hrs) than we and others can detect changes in axial length or vitreous chamber depth in chick eyes (≥2 days). Since our studies involved very short term exposure to myopic defocus (6 hrs), we felt measurements of scleral proteoglycan synthesis would be more likely to establish causal relationships between IL-6, nitric oxide and scleral remodeling.

      6) I don't buy the argument that the source of NO is not in the choroid (lines 337-340), based on the failure of L-Arg to change significantly the amount of choroidal IL-6 mRNA (Fig. S1). Several thoughts come to mind here: (a) It is solidly established that the choroid is richly innervated with NO-synthesizing nerve fibres, and that its content of NOS is very high [e.g.: "NOS activity is widely distributed in the eye, (choroid > retina > CP > TM) …"; Geyer et al., 1997, Graefes Arch, 235(12):786-93; also (among others): Wu et al., 2007, Brain Res., 1186m155-63; Hashitani et al., 1998, J Physiol, 510(1):209-223; Fischer & Stell, 1999, cited in the present MS.]. So, there clearly are sources of NO within the choroid, in chicks as in mammals. (b) It's extremely unlikely that "NO, released from the retina … diffuses to the choroid to stimulate IL-6 synthesis", because NO is highly reactive and has a short half-life, restricting its diffusion. But yes, NO generated by iNOS in the RPE certainly could reach choroidal targets; is there anything in the literature to indicate that iNOS mRNA and protein are increased in the RPE, under conditions or treatments that inhibit axial elongation? (c) The critical experiment to test this idea - treating the isolated choroid with a NOS-inhibitor, to block synthesis of NO by cells in the choroid - was not performed here.

      That would be a complicated and difficult exercise, however, requiring the invention of a way to stimulate NOS activity to a new base-level, and then being able to detect effects due to the inhibition of NO-synthesis. It would be good to discuss the issues raised in this point, but acceptable to suggest this as another of the questions that would be suitable to address by further experimentation beyond the scope of this paper.

      Based on these comments (and the comments below) by Reviewer #1, we carried out additional experiments on isolated choroids using 50 mM KCl to depolarize the plasma membranes of choroidal cells in the presence of L-arginine (0.05 mM – 5 mM). We found that in the presence of KCl, treatment of choroids with L-arginine caused a significant increase in IL-6 mRNA. In contrast, L-arginine in the absence of KCl had no significant effect on IL-6 mRNA (as we found in our original experiments). We interpret these new results to indicate that choroidal IL-6 can be upregulated by endogenous sources of nitric oxide. We have included this data in new Figure 8 of the revised manuscript. We thank the reviewer for providing this insight!

      7) Since it's overwhelmingly likely that NO is synthesized and released locally in the choroid, alternative explanations must be considered for why the NO-donor, PAPA-NONOate, caused increases in IL-6, while L-Arg didn't. Might it have been the case, for example, that the NOS- containing choroidal cells already were fully loaded with L-Arg, under these particular experimental conditions? or that the administered concentration of L-Arg was sub-optimal? or that the proportions of cellular mass to fluid volume in the choroidal samples were highly variable, causing high variance of the individual values? or that the parent compound PAPA- NONOate, however attractive 'his' name, had destinations in mind (molecular targets, actions) in addition to or other than sGC? Any one of these hypotheses might account for the fact that L-Arg reduced the mean level of IL-6 mRNA by almost 50%, but with p=0.14 despite the sample size n=16.

      Please see explanation under item 6 above.

      8) The results of the bulk assays - of whole choroids - are a good beginning, starting to build a map of largely uncharted territory; but they will never be completely satisfactory for constructing signalling pathways or networks for visual regulation of scleral expansion, and will leave one struggling to make sense of it all (cf. lines 345-347). Better immunolabeling, with better image definition and resolution, the addition of single-label images and bright-field images (to locate the RPE securely), and possibly FISH would be helpful for this. If you're rich, have great local resources, and/or are well connected with others who do, scRNA-seq of dissociated choroidal tissue (with RPE and sclera as controls) would have great potential here. If the tissue has been perfused intravascularly or well washed and drained, to get rid of blood cells, there shouldn't be very many cell types to characterize (but, my, wouldn't it be exciting and illuminating if there were!)

      As stated under point 1 above, we have increased the magnification and resolution of images in Figure 1 to better distinguish immunoreactive cells and we have included both H&E stained and immunolabelled images from adjacent serial sections (both longitudinal and cross sections) of choroids in order to compare immunopositive cells with the histoarchitecture of the choroid in supplemental Figure 1 - figure supplement 1. We agree that scRNA-seq would yield valuable insights into gene expression changes amount individual cell populations within the choroid. We feel those studies are beyond the scope of this paper, but are ones that we are currently undertaking.

      9) The relationships between the studies and outcomes reported in this manuscript, and the possible role of choroidal IL-6 and other inflammation-signalling molecules in myopia, is hardly touched upon at all - just a short, very general statement near the end of the Conclusions (lines 368-374).

      We have added additional discussion regarding the possible role of inflammation in ocular growth regulation (lines 358-365, 370 – 372)

    2. Reviewer #1 (Public Review):

      Summary of what the authors were trying to achieve

      Background: Myopia (short- or near-sightedness) is an ocular disorder of increasing concern to human individuals and health-care systems; these days one speaks of a "myopia epidemic" in developed countries. Usually it is due to excessive elongation of the optic axis of the eye during the ages of most rapid growth (ca. 5-16 years in humans), causing images of distant objects to be blurred at the retinal photoreceptors. The optical error can be corrected with lenses or corneal surgeries, but this does not reduce the risk of continued progression and vision loss. Despite extensive epidemiological and animal studies in the past several decades, the underlying causal mechanisms remain poorly known, and therapeutic options are limited. Therefore, further discovery of new candidate mechanisms, drug targets and drugs for inhibiting the onset and progression of myopia is urgently needed.

      Rationale: The axial length of the eye is regulated mainly by qualities of the visual environment, including light intensity, spectrum, and spatiotemporal characteristics of images on the retina. Thus the retina encodes and integrates visual information over time, and ultimately sends regulatory "grow" or "stop" signals via the choroid - a vascular plexus behind the retina - to the sclera, the fibrous outer coat of the eye. Changes in size (area) of the sclera are responsible for changes in axial length, and thereby, refraction. The choroid is in a critical position, not only to relay "stop" or "go" messages to the sclera, but also potentially to critically modify those signals (or generate signals of its own) and further modulate ocular elongation and refraction. Importantly, very little is known about how the choroid fulfills either of these roles.

      Aims of the Study: The authors' purpose was to test, in juvenile chicken models, whether the 'pro-inflammatory' cytokine, interleukin-6 (IL-6) - synthesized and released in the choroid - might play a key role in the developmental regulation of axial elongation and refraction of the eye.

      Major strengths and weaknesses of the methods and results

      Strengths:

      1. The studies are focused on the choroid, which must be important in regulating ocular growth and refraction, but whose role is still not well understood

      2. Expert use of front-line tools for quantifying mRNA and protein (microarray, RT-PCR, ELISA)

      3. Immunohistochemistry: Good choice of antibody (raised to chicken IL-6), appropriate specificity control (preabsorption with chicken antigen)

      4. IL-6 mRNA in choroid was impressively increased during recovery from form-deprivation myopia (FDM) (preliminary results, Fig. 2) - i.e., during strong positive (myopic) defocus - a defocus-dependent effect confirmed by a similar effect of lens-induced myopic defocus (Fig. 5).

      5. Good data for the time-course of IL-6 mRNA content in choroid, with some confirmation of protein levels (though at only 2 treatment intervals) (Fig. 3)

      6. Choroidal IL-6 mRNA also shown convincingly to increase, going from darkness to light (Fig. 4).

      7. It's clever to compare the growth- and myopia-inhibiting effects of positive defocus, with those of other treatments known to do the same - in this case, atropine and nitric oxide (NO). The evidence shows that the effects of these agents on choroidal IL-6 mRNA are similar to the effect of positive defocus, with an NO-donor increasing the amounts of IL-6 mRNA and protein in isolated choroid (Fig. 7), and a NOS-inhibitor decreasing the mRNA levels at an intravitreal dose that inhibits scleral growth (Fig. 6).

      8. If my calculations are correct, 0.1% atropine sulfate solution has a molarity of something like

      1.3 mM. Since alpha-2A adrenoreceptors are present in the choroid, of mammals at least (e.g., Wikberg-Matsson et al., 1996, Exp Eye Res, 63(1):57-66), it might be interesting to explore the possibility that atropine is stimulating IL-6 production in the choroid by acting as agonist via these receptors (cf. Carr et al., 2018, IOVS, 59m2778-2791). The isolated choroid, with IL-6 mRNA and protein synthesis as read-outs, should be an exceptional (and novel) model for testing this and other possible signalling pathways in the choroid.

      Weaknesses:

      1. Immunolocalization of IL-6: The images (Fig. 1) are not good enough to identify cellular localization of immunoreactive structures; identification of RPE is questionable (no DAPI+ nuclei in labeled 'RPE'); nucleated erythrocytes should be visible in vessel lumina.

      2. Many important details of methods have been left out. Spectral peaks of LED light-sources need to be given, lines 409-412; that's just one of many examples.

      3. Intensity (illuminance) of "red" and "blue" lights seems unnecessarily low (58 and 111 lux, respectively, far below the "medium" and "high" intensities of white lights that were used; Fig. 4).

      4. Also, given that red and blue lights have been found to have opposite effects on FDM in chicks (e.g., Wang et al., 2018, IOVS, 59(11):4413-4424), the similarity of IL-6 responses to red and blue in the present study strikes me as a point against a role for IL-6 in regulation of eye growth.

      5. I admire the thoroughness of confirming that some of the treatments did in fact have the predicted effects on ocular enlargement, by performing assays for scleral proteoglycan synthesis. This might not be essential to this work, although it is well done, and the scleral data won't detract from the value of the paper if retained. But the induction of opposite effects on eye (scleral) growth by such manipulations is well established, and much simpler (cheaper and faster) refraction and/or caliper measurements would have served the same purpose.

      6. I don't buy the argument that the source of NO is not in the choroid (lines 337-340), based on the failure of L-Arg to change significantly the amount of choroidal IL-6 mRNA (Fig. S1). Several thoughts come to mind here: (a) It is solidly established that the choroid is richly innervated with NO-synthesizing nerve fibres, and that its content of NOS is very high [e.g.: "NOS activity is widely distributed in the eye, (choroid > retina > CP > TM) ..."; Geyer et al., 1997, Graefes Arch, 235(12):786-93; also (among others): Wu et al., 2007, Brain Res., 1186m155-63; Hashitani et al., 1998, J Physiol, 510(1):209-223; Fischer & Stell, 1999, cited in the present MS.]. So, there clearly are sources of NO within the choroid, in chicks as in mammals. (b) It's extremely unlikely that "NO, released from the retina ... diffuses to the choroid to stimulate IL-6 synthesis", because NO is highly reactive and has a short half-life, restricting its diffusion. But yes, NO generated by iNOS in the RPE certainly could reach choroidal targets; is there anything in the literature to indicate that iNOS mRNA and protein are increased in the RPE, under conditions or treatments that inhibit axial elongation? (c) The critical experiment to test this idea - treating the isolated choroid with a NOS-inhibitor, to block synthesis of NO by cells in the choroid - was not performed here.

      That would be a complicated and difficult exercise, however, requiring the invention of a way to stimulate NOS activity to a new base-level, and then being able to detect effects due to the inhibition of NO-synthesis. It would be good to discuss the issues raised in this point, but acceptable to suggest this as another of the questions that would be suitable to address by further experimentation beyond the scope of this paper.

      7. Since it's overwhelmingly likely that NO is synthesized and released locally in the choroid, alternative explanations must be considered for why the NO-donor, PAPA-NONOate, caused increases in IL-6, while L-Arg didn't. Might it have been the case, for example, that the NOS- containing choroidal cells already were fully loaded with L-Arg, under these particular experimental conditions? or that the administered concentration of L-Arg was sub-optimal? or that the proportions of cellular mass to fluid volume in the choroidal samples were highly variable, causing high variance of the individual values? or that the parent compound PAPA- NONOate, however attractive 'his' name, had destinations in mind (molecular targets, actions) in addition to or other than sGC? Any one of these hypotheses might account for the fact that

      L-Arg reduced the mean level of IL-6 mRNA by almost 50%, but with p=0.14 despite the sample size n=16.

      8. The results of the bulk assays - of whole choroids - are a good beginning, starting to build a map of largely uncharted territory; but they will never be completely satisfactory for constructing signalling pathways or networks for visual regulation of scleral expansion, and will leave one struggling to make sense of it all (cf. lines 345-347). Better immunolabeling, with better image definition and resolution, the addition of single-label images and bright-field images (to locate the RPE securely), and possibly FISH would be helpful for this. If you're rich, have great local resources, and/or are well connected with others who do, scRNA-seq of dissociated choroidal tissue (with RPE and sclera as controls) would have great potential here. If the tissue has been perfused intravascularly or well washed and drained, to get rid of blood cells, there shouldn't be very many cell types to characterize (but, my, wouldn't it be exciting and illuminating if there were!)

      9. The relationships between the studies and outcomes reported in this manuscript, and the possible role of choroidal IL-6 and other inflammation-signalling molecules in myopia, is hardly touched upon at all - just a short, very general statement near the end of the Conclusions (lines 368-374).

      Whether the authors achieved their aims, and whether the results support their conclusions:

      The authors have made a very convincing case that myopic defocus stimulates the synthesis of IL-6 mRNA and protein in the chick choroid. The effects of atropine and NO-related drugs further support the association between this action and the inhibition of excessive axial elongation and myopia.

      Likely impact of the work on the field, and the utility of the methods and data to the community: This work - and in particular the use of assays for IL-6 in choroidal explants to assess the actions of candidate signalling molecules in the choroid - should be seen as an important step forward. The methods are up-to-date, but well established and straightforward, and could be easily duplicated by most workers in the field. The chick models for myopia induction and recovery have been used and refined for decades, so they are easy and almost foolproof (used successfully by many undergraduates in my lab). Once the foundations have been laid by studies in chicks, they can be translated rather easily for making similar studies in mammalian models such as guinea pigs and NHPs

    1. Rule 1: Black English is about a whole lot more than mothafuckin. A s a criterion, we decided, "realistic" could take you anywhere you want to go. Artful places. A n g r y places. Eloquent and sweetalkin places. Polemical places. C h u r c h . A n d the local B a r & G r i l l . We were checking out a language, not a mood or a scene or one guy's forgettable mouthing off. It was hard. For most of the students, learning Black English required a fallback to patterns and rhythms of speech that many of their parents had beaten out of them. I mean beaten. A n d , in a majority of cases, correct Black English could be achieved only by striving for incorrect Standard English, som

      this is a very important passage because it goes to show how different the black english is from regular english. it gives many places of where you would hear it.

    1. 4. Build-Measure-LearnThis loop is the fundamental activity of a startup. Iterating through this loop helps you learn. The faster you iterate through it, the faster you’ll learn and make progress.

      Quale è il loop alla base del metodo Lean Startup?

      Si tratta del loop B-M-L (Build, Measure e Learn), l'approccio con cui si segue questo loop è quello di affrontarlo nel minor tempo possibile. Alla fine di ogni iterazione del loop, infatti, ci ritroviamo con l'aver imparato qualcosa sul nostro target.

      Più iterazioni facciamo di questo loop, nel modo più veloce possibile, e più ci ritroveremo con avere imparato qualcosa di utile sul target.

    1. SciScore for 10.1101/2021.09.29.462326: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Study approval: The study was carried out at the Ramón and Cajal University Hospital in Madrid (Spain) and was approved by the local Research Ethics Committee (ceic.hrc(at)salud.madrid.org,approval number 095/20).<br>Consent: All subject unable to provide informed consent or witnessed oral consent with written consents by a representative were excluded.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">The prepared QCs were analyzed at the beginning of the run to condition the CE system and then every seven randomized samples to reduce any time-related effect.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Authentication: Then, the supervised methods PLS-DA and OPLS-DA were performed followed by model validation.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then, raw data were aligned and processed with MassHunter Profinder software (version 10.0 SP1)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MassHunter Profinder</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The resulting list was imported in Microsoft Excel, and the data matrix was filtered before statistical analysis by removing metabolites with a percentage of coefficient of variation (% CV) greater than 30% in the QC samples.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Microsoft Excel</div><div>suggested: (Microsoft Excel, RRID:SCR_016137)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">), MATLAB software (The MathWorks, Maticks, MA, USA), MetaboAnalyst 5.0 and SPSS version 24 (IBM SPSS Statistics) for different purposes.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MATLAB</div><div>suggested: (MATLAB, RRID:SCR_001622)</div></div><div style="margin-bottom:8px"><div>MetaboAnalyst</div><div>suggested: (MetaboAnalyst, RRID:SCR_015539)</div></div><div style="margin-bottom:8px"><div>SPSS</div><div>suggested: (SPSS, RRID:SCR_002865)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">This tool joins several databases, which are available online, such as METLIN (47), LIPIDMAPS (48), and KEGG (49), making the identification task faster and easier.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>KEGG</div><div>suggested: (KEGG, RRID:SCR_012773)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your code.


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Our study is also subject to some limitations. First, the samples were collected during the first COVID-19 wave in Madrid. It is unknown yet whether the emerging SARS-CoV-2 variants could lead to different metabolic consequences. Second, as expected, cases in the severe group were older and had more comorbidities than milder cases, so we considered potential confounders in our statistical approach. Third, in the subgroup analyses separated by clinical severity, the statistical power to detect differences in metabolite abundances was lower due to the smaller sample sizes. In summary, in this work examining for the first time the metabolic changes associated with COVID-19 by CE-MS, we report the discovery of new plasma biomarkers for COVID-19 that provide mechanistic explanations for the clinical consequences of SARS-CoV-2, including mitochondrial and liver dysfunction as a consequence of hypoxemia (citrulline, citrate and BAIBA), energy production and amino acid catabolism (L-glycine, L-alanine, L-serine, L-proline, L-aspartic acid and L-histidine), and endothelial dysfunction and thrombosis (citrulline, L-ADMA, 2-AB, and Neu5Ac), and we found interconnections between these pathways (Figure 5). These biomarkers deserve further attention as biomarkers of SARS-CoV-2 susceptibility and COVID-19 clinical severity and as potential targets for interventions.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.24.21264081: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">6, 2021 vs June 27 -August 27, 2021).7 In descriptive analyses, breakthrough infections and available anti-spike immunoglobulin G antibody (SAb-IgG) levels were assessed relative to baseline, defined as the date of full immunization.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-spike immunoglobulin G</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody values range from 1 to 20 U/L, with minimum detectable level of ≥1 U/L per manufacturer, although the DCI Lab validated threshold of ≥2 U/L was used.3,8 Statistical analyses were performed using SAS v9.4.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SAS</div><div>suggested: (SASqPCR, RRID:SCR_003056)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. Higdon, M. M., Wahl, B., Jones, C. B., Rosen, J. G., Truelove, S. A., Baidya, A., Nande, A. A., ShamaeiZadeh, P. A., Walter, K. K., Feikin, D. R., Patel, M. K., Knoll, M. D., & Hill, A. L. (2021). A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease [Preprint]. Epidemiology. https://doi.org/10.1101/2021.09.17.21263549

    1. SciScore for 10.1101/2021.09.27.462006: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: All donors signed informed consent forms approved by the Ethical Committee of the Santa Lucia Foundation.<br>IRB: All donors signed informed consent forms approved by the Ethical Committee of the Santa Lucia Foundation.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">To avoid gender and age biases, an equal number of female and male volunteers, as well as an equal number of subjects 22-45 and 45-66 years old, was included.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Evaluation of anti SARS-CoV-2 Antibodies: The measurement of anti SARS-CoV-2 neutralizing Abs was performed by electrochemiluminescence sandwich immunoassay (ECLIA) through Roche Elecsys Anti-SARS-CoV-2 S (Roche diagnostics, Switzerland).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Antibodies</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow cytometry staining and acquisition: Post-culture cells were pelleted in V-bottom 96-well plates and resuspended in 30 μl of antibodies at pre-optimized concentrations and diluted in Brilliant Stain Buffer (BD Biosciences), then incubated for 15’ at RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BD Biosciences</div><div>suggested: (BD Biosciences, RRID:SCR_013311)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data was analyzed with FlowJo v.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Statistical analysis was performed with GraphPad Prism 9.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

  2. Sep 2021
    1. SciScore for 10.1101/2021.09.27.21264163: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: The S3 study, the COSCA study and the RECoVERED study were approved by the medical ethical review board of the Amsterdam University Medical Centers (<br>Consent: All participants provided written informed consent.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All S constructs were verified by Sanger sequencing and subsequently produced in HEK293F cells (ThermoFisher) and purified as previously described22.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293F</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudoviruses were produced by co-transfecting the SARS-CoV-2-S expression plasmid with the pHIV-1NL43 ΔEnv-NanoLuc reporter virus plasmid in HEK293T cells (ATCC, CRL-11268), as previously described48.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: ATCC Cat# CRL-11268, RRID:CVCL_1926)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Shortly, HEK293T/ACE2 cells, kindly provided by Dr. Paul Bieniasz48, were seeded at a density of 20,000 cells/well in a 96-well plate coated with 50 μg/mL poly-L-lysine one day prior to the start of the neutralization assay.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T/ACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">They were ordered as gBlock gene fragments (Integrated DNA Technologies) and cloned in a pPPI4 expression vector containing a hexahistidine (his) tag with Gibson Assembly (ThermoFisher)22.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pPPI4</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirus construction: The WT, D614G, Alpha, Alpha E484K, Beta and Gamma pseudovirus S constructs were ordered as gBlock gene fragments (Integrated DNA Technologies) and cloned using SacI and ApaI in the pCR3 SARS-CoV-2-SΔ19 expression plasmid48 using Gibson Assembly (ThermoFisher)c</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCR3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudoviruses were produced by co-transfecting the SARS-CoV-2-S expression plasmid with the pHIV-1NL43 ΔEnv-NanoLuc reporter virus plasmid in HEK293T cells (ATCC, CRL-11268), as previously described48.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pHIV-1NL43 ΔEnv-NanoLuc</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The inhibitory concentration (IC50) and neutralization titers (ID50) were determined as the NAb concentration and serum dilution at which infectivity was inhibited by 50%, respectively, using a non-linear regression curve fit (GraphPad Prism software version 8.3).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      There are several limitations of our study. First, our study includes substantially more female than male participants, reflecting the gender distribution among HCW at our institute. Second, the age distribution in the four groups is not identical. In particular, the AZD1222 group is, on average, considerably older as a consequence of restrictive use of the AZD1222 vaccine in individuals aged 60-64 years in the Netherlands. As immune responses tend to become weaker with higher age, this is a relevant factor when considering the weaker responses in the AZD1222 group. Finally, the samples we tested were taken at the expected peak of immunity. It will be relevant to study the durability of the neutralizing antibody responses after vaccination with each of these vaccines. Some studies suggest that immunity induced by adenovirus vaccines might be more durable than immunity from mRNA vaccines8,45. We have only analyzed known VOCs and VOIs and cannot predict how our results apply to future variants. One consideration is that current VOCs were probably selected based on increased fitness and/or transmissibility, while future variants may very well be selected based on escape from immunity when more and more people are vaccinated or have experienced COVD-19. Such escape variants may be more resistant to neutralizing antibodies induced by current vaccines than the VOCs and VOIs studied here and may render vaccines even less effective at preventing infection. However, while circulating ...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a protocol registration statement.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.18.21263605: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Human Subjects: Research protocol and consents were approved by the Western Internal Review Board (Study #1302611, Expiration Date: March 19th, 2022).<br>Field Sample Permit: Sample Processing Device and Protocol: Saliva samples were collected using the Orasure® Oral Fluid Collection Device (Orasure Technologies, Bethlehem, PA), which consists of an absorbent pad on the end of a long wand and a collection tube with preservative solution.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Internal standards consist of SARS-CoV-2 IgG antibodies (Absolute Antibody, Oxford, United Kingdom) diluted in 1% (w/v) Casein/PBS solution at varying concentrations in the linear range of the assay to provide a standard curve.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary Antibody and Reporter Enzyme: Subsequently biotinylated Goat Anti-Human IgG Fc (ThermoFisher, Waltham, MA) was diluted 1:500 in 1% (w/v) Casein/PBS solution and 30 μL added to the well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-Human IgG</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.27.461930: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Chilled on ice, 100 μL of each sample was added to the VeroE6/TMPRSS2 cells and TCID50 assay was performed as above. 4.7.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6/TMPRSS2</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.25.21264117: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: All protocols were approved by the Hamilton Research Ethics Board (#10757 and #11471).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Measurements of anti-SARS-CoV-2 antibodies: Anti-SARS-CoV-2 full-length S protein and RBD IgG and IgA seropositivity were identified via validated serology ELISA as described by Huynh et al., 2021 [15].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antibodies</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Anti-SARS-CoV-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>RBD IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After washing with PBS, plates were coated with diluted serum (1:100) for 1 hour at room temperature, washed, and incubated with 25 μL alkaline phosphatase conjugated antibodies goat anti-human IgG (1:2000) or goat anti-human IgA (1:500) (Jackson Immuno).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-human IgA</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Unstimulated wells served as negative controls, and polyclonal stimulation with CytoStim™ (0.5 μl/well, Miltenyi Biotec) was included as positive control.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CytoStim™</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Data and statistical analyses were done in FlowJo version 10.7.1,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, GraphPad Prism version 9, and R.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. QH" 19:6-2

      I thank you, O my God, that you have acted wonderfully with dust, and with a vessel of clay you have worked so very powerfully. What am I that you have [inst]ructed me in the secret counsel of your truth and that you have given me insight into your wondrous deeds, that you have put thanksgiving into my mouth, pr[ai]se upon my tongue, and (made) the utterance of my lips as the foundation of jubilation, so that I might sing of your kindness and reflect on your strength all the day? Continually I bless your name, and I will recount your glory in the midst of humankind. In your great goodness 10. my soul delights. I know that your command is truth, that in your hand is righteousness, in your thoughts 11. all knowledge, in your strength all power, and that all glory is with you. In your anger are all punishing judgments, 12. but in your goodness is abundant forgiveness, and your compassion is for all the children of your good favor. Truly, you have made known to them the secret counsel of your truth 13. and given them insight into your wonderful mysteries. For the sake of your glory you have purified a mortal from sin, so that he may sanctify himself 14. for you from all impure abominations and from faithless guilt, so that he might be united with the children of your truth and in the lot with 15. your holy ones, so that a corpse-infesting maggot might be raised up from the dust to the council of [your] t[ruth], and from a spirit of perversion to the understanding that comes from you, 16. and so that he may take (his) place before you with the everlasting host and the [eternal] spirit[s], and so that he may be renewed together with all that i[s] 17. and will be and with those who have knowledge in a common rejoicing. vacat […] 18. [And, as for me,] I thank you, O my God, I exalt you, O my rock. And when you act wondrously[…] 19. […] that you have made known to me the secret counsel of truth and [you have given me insight] into [wonderful] myster[ies, and you have let me understand your wonders,] 20. [and] your [hid]den things you have revealed to me, so that I have gazed upon […]°° y kindness. And I know 21. [th]at righteousness belongs to you, and by your kindness [they] are judged […] h and destruction without your compassion. 22. As for me, a fount of bitter mourning was opened to me […]and trouble was not hidden from my eyes 23. when I knew the inclinations of humans, and I un[derstood] to what mortals return, [and I recognized the mour]nfulness of sin, and the anguish of 24. guilt. They entered my heart and they penetrated my bones l °[…]° ym and to utter an agonized moan 25a. and a groan to the lyre of lamentation for all gr[iev]ous mourning[…] 25. and bitter lament until the destruction of iniquity, when there is n[o more pain ]and no more affliction to make one weak. And then 26. I will sing upon the lyre of salvation, and the harp of jo[y, and the timbrel of rejoi]cing, and the flute of praise, without 27. ceasing. Who among all your creatures will be able to recount al[l] your [wonders]? With every mouth your name will be praised. 28. For ever and ever they will bless you according to [their] insight, [and at all tim]es they will proclaim together 29. with a joyous voice. There will be no sorrow or sighing, and iniquity [will be found] no [more]. Your truth will shine forth 30. for everlasting glory and eternal peace. Blessed are you,[O Lord, w]ho have given to your servant 31. insightful knowledge to understand your wondrous works and [a ready an]sw[er in order to] tell of the abundance of your kindness. 32. Blessed are you, God of compassion and grace, according to the great[ness of] your st[ren]gth and the magnitude of your truth, and the abundan[ce] 33. of your kindness with all your creatures. Gladden the soul of your servant through your truth, and purify me 34. by your righteousness. Even as I waited for your goodness, so for your kindness I hope. By your forgiveness[s] 35. you relieve my pains, and in my troubles you comfort me, for I depend on your compassion. Blessed are yo[u,] 36. O Lord, for you have done these things, and you have put into the mouth of your servant hymns of pr[a]is[e] 37. and a prayer of supplication, and a ready answer. You have established for me the wor[k of …] 38. And I reta[in strength] l […] b […] l […]°[…] 39. And you[…] 40. [your] truth[…] 41. and ’ […] 42. °°°[…]°

    1. SciScore for 10.1101/2021.09.25.461776: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following three more HBS-T washes, 0.2 μg/mL of a secondary anti-mouse IgG antibody linked to alkaline phosphatase (Sigma #A9316) was incubated for 30 minutes.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>a secondary anti-mouse IgG antibody</div><div>suggested: (Molecular Probes Cat# A-31553, RRID:AB_221604)</div></div><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: (Sigma-Aldrich Cat# A9316, RRID:AB_258446)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In the case of fluorescent-conjugated tetramer staining, cells were finally resuspended in 1% BSA in PBS, while in the case of Fc fusion protein staining, cells were stained with secondary antibody conjugated to AlexaFluor 647 against human IgG-gamma1 (Jackson #109-605-006), washed, and then resuspended.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>human IgG-gamma1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Coverslips were then incubated in TBS + 2% BSA containing the indicated dilution of primary rabbit anti-human LRRC15 antibody (ab150376) for 1 h at room temperature, washed three times in TBS + 2% BSA, incubated for 30 minutes in TBS + 2% BSA containing highly cross-adsorbed goat anti-rabbit Alexa Fluor 555 conjugated secondary antibody (2 μg/mL) and DAPI (0.2 μg/mL), then washed three times in TBS and once in distilled water prior to mounting slides with Prolong Glass (Thermo Fisher) followed by overnight curing.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human LRRC15</div><div>suggested: (Creative Biomart Cat# CPBT-54314RH, RRID:AB_11420140)</div></div><div style="margin-bottom:8px"><div>anti-rabbit</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Blocked membranes were incubated with primary antibody (LRRC15 [LSBio aa393-422], ACE2 [Abcam Ab108252], GAPDH [GeneTex GTX627408]) in 5% milk +PBST (PBS + 0.2% (v/v) Tween-20) at 4°C overnight, then incubated with peroxidase (HRP)-conjugated secondary antibodies (Peroxidase AffiniPure Goat Anti-Rabbit IgG (H+L) [Jackson ImmunoResearch 111-035-144], Peroxidase AffiniPure</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>GAPDH</div><div>suggested: (GeneTex Cat# GTX627408, RRID:AB_11174761)</div></div><div style="margin-bottom:8px"><div>Anti-Rabbit IgG</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 111-035-144, RRID:AB_2307391)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293 cell culturing: For both binding assays and the production of recombinant proteins, suspension HEK293-E cells (Durocher et al., 2002) were grown in Freestyle media (Gibco #12338018) supplemented with 1% (m/v</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 S1-Fc protein was purified from serum-free supernatant of transfected 293T cells by Protein A affinity chromatography using hiTrap MabSelect PrismA columns (GE Healthcare) and the Äkta-Pure liquid chromatography system.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK-293T and hTERT RPE-1 cells were grown in Dulbecco Modified Eagle Media (DMEM) supplemented with 10% fetal calf serum (FCS).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">VSV-G lentiviruses were produced by transfection of HEK293T cells with a lentiviral expression vector and packaging vectors pCMVΔR8.91 and pMD.G at a DNA ratio of 3:2:1 using TranslT-293 (Mirus) following the manufacturers recommendation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Production of SARS-CoV-2 viral stocks: A total of 1 μg of pCCI-4K-SARS-CoV-2-ZsGreen plasmid DNA and 3 μL of Lipofectamine LTX with 3 μL of PLUS reagent in 100 μL optiMEM were used to transfect BHK-21 cells (ECACC) in 6-well plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BHK-21</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 microscopy infection assays: RPE-1 or CaLu-3 cell lines were seeded into CellCarrier-96 Black optically clear bottom plates (Perkin Elmer) at a density of either ×1×104 cells/well 24 h prior to infection or ×5×104 cells/well 72 h prior to infection respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CaLu-3</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Individual CRISPRa guides were cloned into pCRISPRia-v2 (Addgene #84832).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCRISPRia-v2</div><div>suggested: RRID:Addgene_84832)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ACE2 and LRRC15 cDNAs were cloned into pHRSIN-cSGW vectors expressing puromycin, blasticidin or hygromycin resistance cassettes driven by a pGK promoter.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pHRSIN-cSGW</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">VSV-G lentiviruses were produced by transfection of HEK293T cells with a lentiviral expression vector and packaging vectors pCMVΔR8.91 and pMD.G at a DNA ratio of 3:2:1 using TranslT-293 (Mirus) following the manufacturers recommendation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCMVΔR8.91</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pMD.G</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Production of SARS-CoV-2 viral stocks: A total of 1 μg of pCCI-4K-SARS-CoV-2-ZsGreen plasmid DNA and 3 μL of Lipofectamine LTX with 3 μL of PLUS reagent in 100 μL optiMEM were used to transfect BHK-21 cells (ECACC) in 6-well plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCCI-4K-SARS-CoV-2-ZsGreen</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For data analysis, single-end 35 bp reads were trimmed down to the variable sgRNA segment using FASTX-Toolkit and aligned to an index of all sequences in the library using Bowtie 2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bowtie</div><div>suggested: (Bowtie, RRID:SCR_005476)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Phylogenetics analysis: Homologs for LRRC15 were identified by BLAST searches against the human LRRC15 amino acid sequence, filtering for species reported to be potential SARS-CoV-2 hosts (Liu et al., 2021; Mahdy et al., 2020).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BLAST</div><div>suggested: (BLASTX, RRID:SCR_001653)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Multiple sequence alignments were done by the Clustal Omega algorithm using default parameters (Madeira et al., 2019).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Clustal Omega</div><div>suggested: (Clustal Omega, RRID:SCR_001591)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Phylogenetic trees were drawn using Jalview (v. 2.11.1.4) from average distance calculations based on the BLOSUM62 substitution matrix.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Jalview</div><div>suggested: (Jalview, RRID:SCR_006459)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The data were visualized with the Scanpy package (v. 1.4.5) in Python (v. 3.7.4)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Python</div><div>suggested: (IPython, RRID:SCR_001658)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">These data were exported as .fcs files and analysed in FlowJo.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 36. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.24.461616: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: Animal studies were carried out at Galveston National Laboratory at University of Texas Medical Branch at Galveston, Texas, an AAALAC accredited (November 24, 2020) and PHS OLAW approved (February 26, 2021) high-containment National Laboratory, based on a protocol approved by the Institutional Animal Care and Use Committee at UTMB at Galveston.<br>IACUC: Animal studies were carried out at Galveston National Laboratory at University of Texas Medical Branch at Galveston, Texas, an AAALAC accredited (November 24, 2020) and PHS OLAW approved (February 26, 2021) high-containment National Laboratory, based on a protocol approved by the Institutional Animal Care and Use Committee at UTMB at Galveston.<br>IRB: All animal procedures and operations were approved by the ethical committee of Wuhan Institute of Virology, Chinese Academy of Sciences.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Rhesus macaques were randomly divided into control group, low-dose (10 mg/kg of 2G1) and high-dose (50 mg/kg of 2G1) groups with one male and one female in each.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Rhesus macaques were randomly divided into control group, low-dose (10 mg/kg of 2G1) and high-dose (50 mg/kg of 2G1) groups with one male and one female in each.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Biotin labeled RBD (Sino Biological), PE labeled streptavidin (ThermoFisher) and 7AAD (BD) Single memory B cells with potential SARS-CoV-2 antibody secretion were sorted out by gating 7AAD-, CD19+, CD27+, IgG+, and RBD+ using a BD Aria III cell sorter with fluorescence-activated cell sorting modules.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD27+ , IgG+</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The transfection efficiency was examined by flow cytometry using S1-mFc recombinant protein (Sino Biological) as primary antibody and FITC-AffiniPure Goat Anti-Mouse IgG (Jackson) as secondary antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-Mouse IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antigen-binding ELISA: Enzyme-linked immunosorbent assays (ELISA) were applied to study the binding ability of antibodies with SARS-CoV-2 RBDs (Sino Biological) and S trimers (AcroBiosystems).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Antigen-binding ELISA</div><div>suggested: (Ling-Chu Hung / Animal Health Research Institute, Council of Agriculture, Executive Yuan, Taiwan Cat# 12-Hung-03 m& 20 ORF3 7D3, RRID:AB_2827541)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After pipetting off the unbound antibodies, plates were washed 4 times with PBST and further incubated with 100 μL per well of goat anti-human IgG (Fc specific)-Peroxidase antibody (1: 5000 dilution, Sigma) for 1 h at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG ( Fc specific)-Peroxidase</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ACE2 competition ELISA: For experiments involving the competitive binding of antibodies to SARS-CoV-2 RBD or S trimer, recombinant hACE2-Fc protein was first biotinylated using EZ-Link Sulfo-NHS-Biotin (ThermoFisher) as the instruction described.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Sulfo-NHS-Biotin</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody-Dependent Cellular Phagocytosis (ADCP): In ADCP experiment, CD14+ monocytes (Allcells) were cultured and differentiated for 7 days to obtain macrophage cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Antibody-Dependent Cellular Phagocytosis ( ADCP)</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After washing, a Goat Anti-human Fc HRP (Sigma) was used as secondary antibody with 1:6000 dilutions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-human Fc HRP</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In brief, HEK-293T cells (ATCC) with 70% - 80% confluence in a 10 cm dish were co-transfected with 12 μg of plasmid pHIV-puro encoding RRE and ACE2 genes, 8 μg of plasmid psPAX2 encoding gag and pol, and 4 μg of plasmid VSV-G encoding G glycoprotein of vesicular stomatitis virus(VSVG) using Lipofectamine 3000 Reagent (Invitrogen).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">500 μL of filtered lentivirus supernatant was added in a 24-well plate with Jurkat cells (ATCC).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Jurkat</div><div>suggested: TKG Cat# TKG 0209, RRID:CVCL_0065)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The culture medium of ACE2-293T cells was removed and then replaced by the antibody-pseudovirus mixture.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2-293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The mixture was then added into a 96-well plate covered with Vero cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">This recombinant S protein was overexpressed using the HEK 293F mammalian cells (Invitrogen) at 37°C under 5% CO2 in a Multitron-Pro shaker (Infors, 130</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK 293F</div><div>suggested: RRID:CVCL_6642)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pharmacokinetic study and toxicity test: For the pharmacokinetic study, BALB/c mice were tail intravenously injected with 2G1 (15, 30, or 60 mg/kg), or equivalent volume of PBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">mAb preparation: Heavy chains and light chain genes were inserted separately into pcDNA3.4 and amplified in E. coli DH5α.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.4</div><div>suggested: RRID:Addgene_131198)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In brief, HEK-293T cells (ATCC) with 70% - 80% confluence in a 10 cm dish were co-transfected with 12 μg of plasmid pHIV-puro encoding RRE and ACE2 genes, 8 μg of plasmid psPAX2 encoding gag and pol, and 4 μg of plasmid VSV-G encoding G glycoprotein of vesicular stomatitis virus(VSVG) using Lipofectamine 3000 Reagent (Invitrogen).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pHIV-puro</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>psPAX2</div><div>suggested: RRID:Addgene_12260)</div></div><div style="margin-bottom:8px"><div>VSV-G</div><div>suggested: RRID:Addgene_138479)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">S protein over-expression cells: The coding sequence for full-length wild-type S protein (GenBank: QHD43416.1) from Met1 to Thr1273 was inserted into plasmid pHIV-puro1.0, followed by an internal ribosome entry site (IRES) and puromycin resistance gene.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pHIV-puro1.0</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Expression and purification of S protein: The prefusion S extracellular domain (1-1208 a.a) (Genbank ID: QHD43416.1) was cloned into the pCAG vector (Invitrogen) with six proline substitutions at residues 817, 892, 899, 942, 986 and 98739, a “GSAS” substitution (instead of “RRAR”) at residues 682 to 685 and a C-terminal T4 fibritin trimerization motif followed by one Flag tag.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAG</div><div>suggested: RRID:Addgene_74288)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The resulting bulk transfected population was sorted on a BD FACSJazz Cell Sorter (BD) with the BD FACS™ Sortware.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BD FACS™</div><div>suggested: (BD FACS Aria II, RRID:SCR_018091)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were analyzed with GraphPad Prism Version 9.0.0 and EC50 values were determined using a four-parameter nonlinear regression.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 RBD (Sino Biological), S trimer (AcroBiosystems), mutated RBDs (Sino Biological), and mutated S trimers (AcroBiosystems) were coated onto High Binding ELISA 96-Well Plate (BEAVER).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>AcroBiosystems</div><div>suggested: (ACRObiosystems, RRID:SCR_012550)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The defocus values were estimated with Gctf43. Particles for S in complex with 2G1 were automatically picked using Relion 3.0.644–47 from manually selected micrographs.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Relion</div><div>suggested: (RELION, RRID:SCR_016274)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 17. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.18.21263550: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: The study protocol was approved by the Ethics Committees of Shenzhen Third People’s Hospital (2020-010).<br>Consent: Written informed consents were obtained from all patients.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Enzyme-linked immunosorbent assay (ELISA): RBD and nucleocapsid (N) specific binding immunoglobulin G (IgG) antibodies were measured according to the manufacture’s protocols (Sinobio).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines and viruses: African green monkey kidney Vero cell (ATCC, CCL-81) were obtained from ATCC, and 293 cells stably expressing ACE-2 (293-ACE-2) were obtained from Vazyme (Vazyme).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293</div><div>suggested: RRID:CVCL_DR94)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A total of 4 × 105 ACE2-293T cells (Vazyme) in 100μl complete media were added per well and incubated for 48h at 37°C and 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2-293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The mixture was added to Vero cells and incubated at 37°C and 5% CO2 for another 96 hours.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All statistical tests were calculated using SPSS 20.0 for Windows (IBM).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SPSS</div><div>suggested: (SPSS, RRID:SCR_002865)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.20.21263837: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We used constant comparison to ensure that our thematic analysis provided a comprehensive overview of themes and subthemes evident in the data.40,41 Our coding strategy allowed us to conduct a statistical exploration of patterns in the data.42 Using Microsoft Excel v.16.52, we conducted Chi-squared tests for independence to examine the frequency of three key themes – ‘returning to normal’ (code N), ‘becoming more social’ (code P), and ‘becoming less social’ (code L) – across five demographic variables: gender, age, ethnicity, education status, household size, and presence or absence of underlying health conditions that might affect one’s vulnerability to COVID-19.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Microsoft Excel</div><div>suggested: (Microsoft Excel, RRID:SCR_016137)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.23.21258047: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: Deionized water in a 1 L Nalgene sample collection bottle was used as a field blank.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">2.4.7 N1 and N2 Standard: Armored RNA Quant SARS-CoV-2 control, which encapsulates the in vitro transcribed RNA template in a protective protein coat and targets the SARS-CoV-2 viral nucleocapsid (N) region, was used as a positive control and run in duplicate for every set of reactions targeting N1 and N2. 2.4.8 Limit of Detection, Limit of Quantification, and Limit of Blank: For the determination of LoD using RT-ddPCR, the Limit of Blank (LoB) was elucidated from eight replicates of negative matrix samples derived from influent collected at multiple WWTP throughout eastern NC.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>N1</div><div>suggested: RRID:CVCL_Z404)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">2.4.2 Detection and quantification using RT-ddPCR: RT-ddPCR was utilized to quantify SARS-CoV-2 RNA copies targeting N1 and N2, described previously (Table S1), and utilizing a two-step reverse transcription and RT-ddPCR.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>N2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">RT-qPCR runs were analyzed by Bio-Rad CFX Manager software version 3.1 (Bio-Rad Laboratories).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bio-Rad CFX Manager</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CFX</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Bio-Rad Laboratories</div><div>suggested: (Bio-Rad Laboratories, RRID:SCR_008426)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">KingFisher script is provided in the supplementary material (Table S7a).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>KingFisher</div><div>suggested: (Hamilton NIMBUS Presto and ID NIMBUS Presto Assay Ready Workstation, RRID:SCR_019998)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.14.21263556: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Written informed consent was obtained from all participants, and the study was approved by the Research Ethics Committee of Hubei CDC (approval reference number: HBCDC-AF/SC-08/02.0).<br>IRB: Written informed consent was obtained from all participants, and the study was approved by the Research Ethics Committee of Hubei CDC (approval reference number: HBCDC-AF/SC-08/02.0).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then, 50μl of an HRP labeled goat anti-human IgG antibody (Cat# ab6759, Abcam, UK) diluted in 1×PBS containing 5% skimmed milk were added to each well and incubated for 1 hour at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: (Abcam Cat# ab6759, RRID:AB_955434)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Quantification of SARS-CoV-2 neutralizing antibodies: The neutralizing antibodies against SARS-CoV-2 were detected using a commercialized surrogate neutralization test developed by Suzhou Xinbo Biotechnology Ltd. Company (PerkinElmer, China).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: All the statistical analyses were conducted using Graphpad Prism 9 (GraphPad Software, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Graphpad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      A major limitation of this study is the inadequate follow up, which do not allow us to compare the persistence of antibody responses between PLWH and the healthy control. Despite of this limitation, our study demonstrates that the inactivated COVID-19 vaccine was immunogenic and safe in PLWH stable on cART.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.16.21263693: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Using a R code script, 50 randomly selected values from the extended sera sample cohort (n=345) were used to set quartile thresholds according to the mean values derived from the bootstrap iterations, a process which was then repeated 10,000 times.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Serum anti-SARS-CoV-2 RBD antibodies assay: RBD+ Ig levels in sera were determined using 96 well ELISA plates that were coated overnight at 4°C with 2μg/ml RBD in PBS (pH 7.4).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 RBD</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ELISA plates were then washed three times with PBST and 50μl of horseradish peroxidase (HRP) conjugated goat anti-human IgG (Jackson ImmunoResearch, #109035003) / anti-human IgM (Jackson ImmunoResearch, #109035129) / anti-human IgA (Jackson ImmunoResearch, #109035011) secondary antibodies were added to each plate at the detection phase (50μl, 1:5000 ratio in 3% w/v skim milk in PBS) and incubated for 1 hour at room temperature (RT), followed by three washing cycles with 0.05% PBST.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 109-035-003, RRID:AB_2337577)</div></div><div style="margin-bottom:8px"><div>anti-human IgM</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 109-035-129, RRID:AB_2337588)</div></div><div style="margin-bottom:8px"><div>anti-human IgA</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 109-035-011, RRID:AB_2337580)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Computational and statistical analysis: Bootstrapping & quartile establishment: We stratified the RBD+ antibody levels to quartiles by musing the bootstrap method.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RBD+</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The cloned region encodes amino acids 1-740 of hACE2 followed by 8xHis tag and a Strep Tag at the 3’ end, cloned in a pCDNA3.1 backbone.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCDNA3.1</div><div>suggested: RRID:Addgene_79663)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All statistics were performed with GraphPad Prism 9.0.2 (GraphPad Software).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. C l o t h i n g I nvo l ve m e n t a n d t h e E f fe c t o f G o a l Fr a m e s o n T P B

      This journal article is divided into sections. It starts with an abstract and introduction in order to introduce the issue at hand. Then it is divided into sections about research. It starts with the theory, and then continues into how that is used. The theory of TPB is mentioned variously throughout the article. This shows how important it is to fast fashion.

    1. AC K N OW L E D G M E N T S None.C O N F L I C T O F I N T E R E S T The authors declare no conflicts of interest.AU T H O R C O N T R I B U T I O N S

      Mentions acknowledgements, conflict of interests, and both authors contributions.

    2. T A B L E 1

      One table was used to back up information talked about in the article, includes different studies and their results. This table was summarized by the authors but the results within the chart were from secondary research.

    Annotators

    1. Find parametric equations of the line .

      To find a parametric equations for the line \(L\), we need to know what the point \(P = (x0,y0,z0)\) and the vector \(v = <a,b,c>\). \(P = OP1 = <1,2,-1>\) and \(v = P2P1 = <3,1,1>\). Thus the parametric equations of the line \(L\) are \(x(t) = x0+at = 1+3t, y(t) = y0+bt = 2+t, z(t) = z0+ct = -1 +t\)

    1. T h e r e i s a q u a l i t y , h o s t i l e t o men i n t h e v e r y e a r t h a n d a i r h e r e . A s i f w e were n o t m e a n t t o make o u r homes i n t h i s o d d l y e n e r v a t i n g s u n s h i n e . . . . C a l i f o r n i a w i l l b e a s i l e n t d e s e r t a g a i n .

      Interesting and pessimistic perspective. What leads the writer to feel this?

    2. The I n d i a n s would b e j a i l e d f o r d r u n k e n n e s s o n t h e w e e k e n d s .

      Non Indians? Challenge ideas of slavery and ideas of modern California liberalism

    3. K e a r n e y made t h e m i s t a k e o f m a k i n g f a l s e a c c u s a t i o n s a g a i n s t t h e McFadden b r o t h e r s i n a S a n t a Ana s p e e c h . R u l e c o n f r o n t e d K e a r n e y t h e m o r n i n g a f t e r t h e s l a n d e r o u s s p e e c h , a n d K e a r n e y d r e w a g u n on R u l e .

      What were the accusations? What was Kearney's relationship to McFadden? Was the author justified in calling him a "bully"?

    4. H i s t o r y r e c o r d s t h a t n o t o n l y d i d t h e " D e v i l Winds" b l o w down t h e c h u r c h a n d i t s h e a v y b e l l b u t s e v e r a l y e a r s l a t e r t h e t w o - s t o r y , n e w l y b u i l t Ear lham H o t e l .

      Santa Ana winds

    5. One of t h e s o l d i e r s was J o s e A n t o n i o Y o r b a . F o r t y - o n e y e a r s l a t e r h e would r e c e i v e o n e o f two S p a n i s h l a n d g r a n t s i n w h a t t o d a y i s O r a n g e C o u n t y . The 6 2 , 5 0 0 a c r e g r a n t which h e s h a r e d w i t h h i s nephew J u a n P a b l o P e r a l t a was known a s t h e Rancho S a n t i a g o d e S a n t a An

      Key player?

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      1. General Statements [optional]

      This section is optional. Insert here any general statements you wish to make about the goal of the study or about the reviews.

      We thank the reviewers for their constructive and helpful comments on our manuscript and are delighted to find their consensus that the manuscript represents an important contribution to the field. We provide a detailed response to specific points below. In addition, we propose to include new data showing that our method can be applied to experimentally infected lung tissue. Namely, we show highly sensitive detection of SARS-CoV-2 RNA in infected hamster lung section.

      2. Description of the planned revisions

      Insert here a point-by-point reply that explains what revisions, additional experimentations and analyses are planned to address the points raised by the referees.

      Reviewer #1 **Major comments:**

      The authors used approaches provided in FISH-quant (Mueller et al, Nat Methods 2013) and big-fish. However, these tools to analyze RNA aggregates were not designed and validated for such massive aggregations as observed by SARS-Cov-2. They were developed for cases such as transcription sites with much smaller aggregations, with a few tens to a hundred molecules. With a regular spot detection approach, usually a few thousand spots can be detected in a cell (e.g. King et al, J Virol 2018), but this depends also on the used microscope and the available cellular volume. Higher RNA concentrations cannot be resolved with a standard approach, because RNA spots start to overlap. Decomposing RNA aggregations can help but will not work reliably for the high RNA densities observed for SARS-Cov-2, especially at later infection time-points. The tools will then not provide accurate estimates anymore. To my knowledge, there is currently not accurate quantification method for such massive RNA levels in smFISH. What has been done in the past, is using cellular intensity as an approximation and perform calibrations with cells having lower and thus still resolvable RNA counts (Raj et al., PLO Biology; https://doi.org/10.1371/journal.pbio.0040309.sg003). The authors proposed three expression regimes (partially resistant, permissive, and super permissive). My concerns here apply mainly to the category super-permissive, where an accurate estimation can't be performed. Here a more cautious quantification should be applied. __To a lesser extent, this will also apply to some of quantifications of gRNAs per factory, with counts exceeding 100s of molecules. As mentioned above, this does not affect any of the conclusions, but would reflect more accurately what kind of reliable information can be drawn from such experiments.__

      We agree with the reviewer that approaches like FISH-quant and Big-FISH cannot reliably quantify RNA spots with high spatial density such as our examples of “super-permissive” cells. Single molecule quantitation of such cases is likely to underestimate RNA expression as noted by us and King et al 2018 (doi: 10.1128/JVI.02241-17). Therefore, we integrated the combined smFISH signal intensity within entire cellular volumes and compared to the median intensity of single molecules in cells with lower infection density. We will (i) revise the methods and results sections to explain more carefully and explicitly the quantification of RNA in super-permissive cells. (ii) Provide a calibration plot for the quantitation as previously reported (Raj et al 2006, doi: 10.1371/journal.pbio.0040309).

      We agree that high local RNA density has the potential to interfere with quantification of gRNAs within viral factories. We have used the “cluster.decomposition()” function of Big-FISH to quantify viral factories, which is conceptually similar to the “Integrated intensity” mode of FISH-quant. Applying this algorithm to non-super permissive cells allows us to use the mean intensity of a reference single-molecule spot to estimate the number of molecules in a cluster. We are confident such estimates are reliable in the majority of viral factories, which contain less than or equal to 200 single gRNA molecules. We will revise the methods section to clarify this method of analysis.

      Reviewer #1 __**Minor comments:**__

      1.Page 6; the authors state that "smFISH identifies ... cellular distribution .... within ER-like membranous structures". However, the authors didn't directly show such a localization, could they provide an experiment with an ER stain?

      This text was based on previous light microscopy and EM studies that reported SARS-CoV-2 RNA in ER-derived membranes (termed Double Membrane Vesicles - DMVs) or co-localisation of anti-dsRNA (J2) with ER-markers (Cortese et al 2020; Hackstadt et al 202; Mendonca et al 2021)*. We propose to clarify the text on page 6 including the citation of these publications and to tone down our claim that the virus is located in ER-like membranous structures.

      *Cortese et al 2020, doi: 10.1016/j.chom.2020.11.003

      Hackstadt et al 2021, doi: 10.3390/v13091798

      Mendonca et al 2021, doi: 10.1038/s41467-021-24887-y

      2.It might be worthwhile pointing out that the probe-sets can be used in different host organisms (Vero - African green monkey; human cell lines).

      We propose to revise the text to emphasise more clearly the applicability of SARS-CoV-2 probes for the study of many different host organisms.

      3.I really liked the experiment, where the authors showed absence of signal when infecting with another virus & elegant control with the J2 AB. Maybe the authors could explain more clearly that the used a different coronavirus & that based on their sequence alignment no/little signal would be expected.

      Thank you for this supportive comment. We plan to follow the reviewer’s suggestion and expand our explanation of the rationale of this experiment in the text.

      7.The experiment with the isolated virions shows nicely that the smFISH approach has single-virus sensitivity. Did the authors compare the intensity of these isolated virions with the signal in Fig 1B? This might be a question of personal taste, but to me, this section might actually fit better in the first paragraph of page 4/5, where the authors describe single virions in cells.

      Thank you for the interesting question. We have not performed a direct comparison of the spot intensities of intracellular genomic RNA molecules and those from the isolated virions, because isolated SARS-CoV-2 requires poly-L-lysine coating for the coverslip attachment while our infection strategy utilises cells growing on uncoated glass. Nonetheless, the isolated virion spot intensities follow a unimodal distribution, and their shape approximates to the point-spread function of the microscope. Since spots at 2 hpi are largely derived from non-replicative viral genomes and they are measured in the intracellular environment with the same background (autofluorescence), they are a better ‘single RNA molecule’ reference.

      We also thank the reviewer for suggesting rearranging the text section. To address this point we plan to move the relevant text to the second paragraph of the Results section.

      8.Page 6. The authors state "+ORF-N and +ORF-S single labelled spots, corresponding to sgRNAs, were more uniformly distributed throughout the cytoplasm than dual labelled gRNA". This is difficult to appreciate from the image. Is this something the authors could quantify, e.g. with the metrics proposed by Stueland et al, Scientific Reports 2019?

      To address this point, we plan to: (i) present an alternative image illustrating a clearer example of differential spatial localisation of gRNA and sgRNA, and (ii) perform quantification of spatial dispersion indices for gRNA and sgRNA using the suggested method for our revision.

      9.Page 6. The authors perform a FISH/IF experiment including a co-localization analysis, where a "limited overlap" with sgRNAs was observed. I was wondering if this overlap could actually be simply due to rather high density of the sgRNAs. Maybe a control analysis by slightly changing the RNA positions could provide insight here, and give a threshold for what's to be expected randomly at a given RNA density.

      The reviewer’s comment is correct, in that a high density of sgRNAs and nucleocapsid protein could lead to signal overlap due to chance. This is why we excluded “super-permissive” cells from this analysis. Our co-localisation data showed that gRNA spots had a bimodal nucleocapsid immunofluorescence intensity distribution (data not shown), suggesting nucleocapsid-associated and “free” gRNAs, providing a threshold for this analysis. Nevertheless, we agree with the reviewer that the analysis of randomly positioned transcripts of the same density would provide a valuable control. In our revised MS we will include: (i) a random distribution analysis comparing the overlap between sgRNA and nucleocapsid in the “Observed” and a “Randomised” simulation, and (ii) a plot showing a full distribution of co-localised nucleocapsid immunofluorescence intensity for both genomic and sub-genomic viral RNAs.

      10.I don't fully follow the argument about stability on page 8. The authors also see an increase in the RNA levels. Couldn't this increase compensate for loss of RNA due to degradation? Would it be possible to perform an experiment at a very high REMDESIVIR concentrations which would blocks transcription?

      Remdesivir is a nucleoside analogue that inhibits viral RNA polymerase activity. While this drug inhibits viral replication, the inhibition is incomplete and using higher concentrations results in cellular toxicity. At the present time there are no stronger polymerase inhibitors available, so these experiments are the best approximation possible to assess viral RNA stability. We propose to revise the text to discuss the limitations of Remdesivir for modelling RNA stability.

      12.How did the authors define/detect replication factories? I couldn't find information about this in the methods.

      This is a good point raised by both the reviewers. Please see [Reviewer 2 General comment #1] for our response.

      Reviewer #2 **General comments:**

      1.The authors' definition of viral factories, in part as foci with at least 4 gRNA molecules, comes across as arbitrary. Perhaps a clearer explanation of this cutoff would be helpful to the readers' understanding of this definition. Additionally, confirmation of the functionality of such factories by immunofluorescence with anti-RdRp, for example, in addition to identifying staining of gRNAs and (-) sense viral RNAs at each focus could provide valuable support to the authors' conclusions.

      We thank both reviewers for requesting further information on our explanation of viral factories. We defined viral factories as smFISH signals with spatially extended foci that exceed the size of the point spread function of the microscope and the intensity of a reference single molecule. We then filtered these candidate factories based on the radius of the signal foci with EM-measured radii of double-membrane vesicles and single-membrane vesicles formed by SARS-CoV-2 (150 nm pre-8hpi and 200 nm post-8hpi) (Cortese et al 2020; Mendoca et al 2021). Our terminology encompasses both replication and viral assembly sites. The threshold of 4 genomic RNA molecules was selected as a technical threshold to limit an over-estimation of viral factories at later timepoints. For our spinning-disk confocal imaging system, we found the threshold of 3-7 RNA molecules provided satisfactory results. We propose to revise both the Results and Methods sections to clarify our rationale for defining and quantifying viral factories.

      As the reviewer mentioned, we have shown a partial overlap of positive sense genomic RNAs with negative sense genomic RNAs (Figure 2D, S2C), suggesting these viral factories represent double membrane vesicles. The use of antibodies against the viral polymerase (nsp12) is also a possibility to detect replication centres. However, replication centres are not the only ‘viral factories’ as there are also double-membrane structures where viral particles assemble (Mendoca et al 2021) and they, in principle, lack negative sense RNA and replication machinery, so neither smFISH probes against the negative strand nor a nsp12 antibody will comprehensively detect viral factories. We appreciate the valuable suggestion, but the classification of viral factories into replication and assembly sites would be challenging due to reagent availability and is beyond the scope of this manuscript.

      2.The random distribution of super-permissive cells in each cell line was demonstrated early in the infection, primarily at 8 hpi. The authors do not show how this pattern changes over time (8, 10, 12, 16, 24 hpi, for example). Do clusters of super-permissive cells appear at later time points, or does the pattern of 'highly' infected cells remain random for each virus? Any strain-specific differences identified from such patterns may be important for understanding infection progression. Finally, the authors do acknowledge this point, but it cannot be overstated that these data were taken from cell culture systems that have limited similarities to the human respiratory epithelium. A better model for such studies might be primary cultured human bronchial epithelial cells, but of course, these cells are not as readily accessible as the cell lines used in this manuscript.

      We share the same view that the presence and the spatial distribution of “super-permissive” cells can provide unique insights into SARS-CoV-2 infection dynamics. Our findings suggest that even at 24 hours post infection (hpi), not all cells become “super-permissive” and the culture maintains a heterogenous population of “partially resistant”, “permissive” and “super-permissive” cells (Figure 3C, S3C-D). We agree with the reviewer that the spatial distribution of “super-permissive” cells at later timepoints is of interest. To address this point, we plan to: (i) analyse the spatial distribution of “super-permissive” cells at 24 hpi, and (ii) compare the distribution of “super-permissive” cells at 24 hpi between VIC and B.1.1.7 strains.

      We appreciate the comment on the limitations of the cell culture systems to the human respiratory tract. However, Calu-3 and A549-ACE2 lung epithelial cells have been used in many studies over the last year and we feel it is important to publish single cell quantitation with these models to enable comparison with the published literature. We believe our results provide valuable information on the intrinsic nature of host cell susceptibility to support viral replication. During the review of this manuscript, we applied our smFISH probes to detect SARS-CoV-2 RNA in infected Golden Syrian hamster lung sections, which show an uneven distribution of infected cells. While the identification and spatial characterisation of susceptible cell types in the lung are beyond the scope of this manuscript, we are excited to include this data in our revised paper to demonstrate the utility of this sensitive approach to track spatiotemporal viral infection dynamics.

      3.The difference in early replication kinetics between the VIC and B.1.1.7 strains is an exciting finding that may have implications for clinical outcomes and transmissibility of these viruses. However, the authors did not clearly demonstrate how these differences in RNA production correlate to infectious viral load released from these cells (in bulk) at each time point. An explanation of this omission would be helpful.

      We will provide data on the level of infectious virus secreted from VIC and B.1.1.7 infected cells at all time points in the revised paper.

      In my opinion, findings related to specific cell lines are of much less importance (and are much less biologically relevant) that identification of replicative differences among strains. Such differences could be used, in part, to aid prediction of the transmissibility of VOC, for example. I think this point gets a bit 'lost in the weeds' of the rest of the paper.

      To address this comment, we will revise text on the differential replication kinetics of the SARS-CoV-2 strains to make this more prominent in our paper.

      3. Description of the revisions that have already been incorporated in the transferred manuscript

      Please insert a point-by-point reply describing the revisions that were already carried out and included in the transferred manuscript. If no revisions have been carried out yet, please leave this section empty.

      Reviewer #1 __**Minor comments:**__

      4.I might have missed this, but they authors could also mention the positive control data about but Calu3 infected with SARS-COv2. One thing I was wondering: why did the authors use two different cell lines for this experiment?

      To address this point, we have added a sentence about a positive control visualising SARS-CoV-2 in Calu-3 cells using our probe set (page 5 – line 17).

      The experiments with HCoV-229E were done in Huh-7.5 cells because SARS-CoV-2 and HCoV-229E have distinct cell preferences. Using the J2 antibody we show that the levels of the dsRNA derived from viral replication are similar in the two cell lines and with the two viruses. Therefore, the lack of smFISH signal in HCoV-229E infected cells supports the high specificity of the probe set.

      5.Fig 1E. Would be nice to have the intensity scale for all time-points to permit a comparison of image intensities along the different time-points.

      6.Fig 3B. Would be important to have intensity scale bars to judge the signal intensities across the different time-points.

      The fluorescence intensity scale in Figure 1E is applicable to all timepoints, except for the lower panel at 24 hpi, which was intended to show wider dynamic contrast range. To address this point, we have provided intensity scales for all time-points studied in this figure and also Figure 3B.

      11.Fig 3C. maybe indicate the two groups with dashed lines.

      We have added a dashed line at the 102 mark in Figure 3C to visually differentiate “partially resistant” and “permissive” cells.

      4. Description of analyses that authors prefer not to carry out

      Please include a point-by-point response explaining why some of the requested data or additional analyses might not be necessary or cannot be provided within the scope of a revision. This can be due to time or resource limitations or in case of disagreement about the necessity of such additional data given the scope of the study. Please leave empty if not applicable.

    1. t wa s onl y afte r th e wa r tha t I foun d ou t wh o ha d knocke dthat night. I t was a n inspecto r of the Hungaria n police , a friend o fmy father's . Befor e we entere d th e ghetto , h e ha d tol d us , "Don' tworry. I'l l warn you if there is danger." Ha d he been able to speakto u s tha t night , w e migh t stil l hav e bee n abl e t o flee...But b ythe tim e w e succeede d i n openin g th e window , i t wa s to o late .There was nobod y outsid

      so close

    2. "The yellow star? So what? It's not l e t h a l ... "(Poor Father! O f what then did you die? )But ne w edict s wer e alread y bein g issued . W e n o longer ha dthe right to frequent restaurants or cafes, t o travel b y rail, t o attendsynagogue, t o be on the streets after six o'clock in the evening.Then cam e th e ghettos

      Current vaccination policies

    1. SciScore for 10.1101/2021.09.14.460338: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Blood samples were collected after obtaining signed informed consent in accordance with institutionally approved IRB protocols.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After incubation, plates were washed three times and incubated for 30 minutes at room temperature with cross-absorbed goat anti-human IgG-horseradish peroxidase (HRP)-conjugated secondary antibody (ThermoFisher Scientific; A18811) diluted to a 1:2500 dilution in ELISA wash buffer.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG-horseradish</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For this assay, 293T cells are transfected with SARS-CoV-2 spike expression vector and co-cultured with either a FcγR2a, or FcγR3a, CD4+ Jurkat reporter cell line, which expresses firefly luciferase upon FcγR activation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Jurkat</div><div>suggested: TKG Cat# TKG 0209, RRID:CVCL_0065)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To quantify background (i.e., IgG activation-independent) luciferase production, reporter cells were co-cultured with the spike-expressing 293T cells in the absence of any IgG.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lithium heparin-coated tubes were used for blood collection and plasma was isolated using Ficoll-Hypaque (GE Healthcare; 17-1440-03) in accordance with manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GE Healthcare</div><div>suggested: (GE Healthcare, RRID:SCR_000004)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Polyclonal IgG was isolated from 200μl of donor plasma using a protein A/G spin column kit, followed by desalting using Zeba spin columns according to manufacturer’s instructions (ThermoFisher Scientific; 89892)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ThermoFisher Scientific</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The optical density at 450 nm (OD450) was measured using a BioTek Powerwave HT plate reader using Gen5 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gen5</div><div>suggested: (Gen5, RRID:SCR_017317)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The data were quantified using Flow Jo software (Tree Star, Inc).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Flow Jo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Statistical and data analyses were performed using GraphPad Prism 8.4.3, R 4.0.4, and R Studio 1.4.1103.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Graphs were generated in Prism and R Studio and statistical differences between two groups were calculated by Mann-Whitney U-test.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Scatter plots, bar graphs, heatmaps, and polar plots were visualized with ggplot2 (v3.3.3 R Studio).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ggplot2</div><div>suggested: (ggplot2, RRID:SCR_014601)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The completed data were scaled to unit variance using FactoMineR (v2.4 R studio).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FactoMineR</div><div>suggested: (FactoMineR, RRID:SCR_014602)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      One caveat to the previous studies that found FcγR activity to be critical for effective humoral immunity is that all of those studies were conducted with neutralizing IgG. Therefore, we cannot rule out that FcγR activation in the absence of a neutralizing response does not contribute to severe COVID-19 pathogenesis, as may be the case with individuals with anti-S2’FP dominant IgG profiles. Therefore, it will be important to dissect how IgG-targeting of neutralizing and non-neutralizing epitopes influences the relationship between FcγR activation and disease outcomes. Additionally, it will be important to examine the contribution of FcγR activation to systemic inflammation and control of virus replication in animal models that faithfully mimic human FcγR-signaling effects. In conclusion, the data presented here demonstrate that immunological history—particularly antibody repertoire from seasonal betacoronaviruses—predicts and potentially determines COVID-19 disease severity. Specifically, an anti-HR2-dominant Ab profile represents an efficient protective recall response, an anti-S2’FP dominant Ab profile suggests a deleterious inefficient recall response, and a predominantly anti-RBD profile likely reflects a protective de novo response. These data become particularly important in assessing epitope-targeting early in disease, which could allow earlier interventions with treatments like monoclonal Ab therapies, preventing progression to ARDS. Additionally, assessing the humora...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.15.460454: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: All cell lines have tested negative for mycoplasma contamination.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines used in this study: 293FT cells were obtained from Dr. Kosuke Yusa’s Lab. 293FT.Cas9 cell lines were generated through lentiviral integration of an EF1a-Cas9-T2A-BlastR construct at low MOI to achieve single-copy integration.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293FT</div><div>suggested: ATCC Cat# PTA-5077, RRID:CVCL_6911)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To generate cell lines permissive to Spike-Pseudotyped lentiviral infection, 293FT.Cas9 cells were engineered to stably express SARS-CoV-2 receptors ACE2 and TMPRSS2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293FT.Cas9</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For in vitro transcribed mRNA, 293T cells were transfected for functional testing using Lipofectamine messengerMAX (Invitrogen) according to the manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">293FT.Cas9.ACE2/TMPRSS2 clonal cell lines were harvested by trypsinization and resuspend at a density of 70.000 cells per 30 μL.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293FT.Cas9.ACE2/TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In vitro transcription of S protein mRNA: Templates for in vitro transcription were generated by cloning P1 and P13 between NcoI and NotI sites of pTNT-B18R-6His (addgene plasmid 58979, a kind gift from Steven Dowdy (30)).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pTNT-B18R-6His</div><div>suggested: RRID:Addgene_58979)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For transfection, 1 μg of lentiviral transfer vector (pCSGW-GFP), were mixed with 0.72 μg of gag-pol expressing plasmid p8.9 and 68.33 fmol of S protein expressing construct in 500 μL of optiMEM media followed by the addition of 2 μL of PLUS reagent and incubation for 5 minutes at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCSGW-GFP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>p8.9</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">These PCR products were both visualized on an agarose gel as well as TA-cloned using ‘TA Cloning Kit with pCR2.1 vector and OneShot TOP10 Chemically Competent E.coli’ (ThermoFisher) according to kit instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCR2.1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The template used to align the ALKBH5 reads to was constructed manually, by performing in silico Gateway cloning, inserting the ALKBH5 CDS and mRuby3 CDS into the pLIX_403 vector (Addgene plasmid #41395).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pLIX_403</div><div>suggested: RRID:Addgene_41395)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Full DNA sequences of these plasmids are found at a Zenodo provided doi: 10.5281/zenodo.5470001. “Wuhan” in plasmid names refers to the S protein DNA sequence from the Wuhan-Hu-1 isolate (Genbank: MN908947.3) while “18F” refers to the removal of the last 18 amino acids of the S protein C terminus (ER retention sequence) and the addition of a FLAG tag.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Zenodo</div><div>suggested: (ZENODO, RRID:SCR_004129)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data was analysed using FlowJo software (BD Biosciences) and displayed as % cells infected at 1:500 dilution of pseudotyped virus, normalized to the intronless construct infection rates (Figure 7).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Staining was developed using 20X LumiGLO® Reagent and 20X Peroxide reagents according to manufacturer’s recommendations (Cell Signaling Technology, #7003). cDNA analysis: RNA was extracted from the frozen cell pellets using RNeasy Mini Kit (Qiagen) and treated with ezDNase (ThermoFisher) before applying oligo(dT) guided 1st strand cDNA synthesis using SuperScript IV reverse transcriptase (ThermoFisher), all according to manufactures’ recommendations.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ThermoFisher</div><div>suggested: (ThermoFisher; SL 8; Centrifuge, RRID:SCR_020809)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All reads were mapped back to the original construct DNA sequence using SnapGene software to assess individual mRNA splicing events.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SnapGene</div><div>suggested: (SnapGene, RRID:SCR_015052)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After another round of bead purification, samples were pooled and submitted to Edinburgh Genomics, where they were further processed, barcoded and run on PromethION platform.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PromethION</div><div>suggested: (PromethION, RRID:SCR_017987)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      The main limitation lies in the quantification of the observed events in comparison to the reads without events which can be influenced by size dependency of some of the sample preparation steps as the full-size S protein cDNA is over 4kb long and many of the observed splicing events can be shorter than 200 bp and depleted by many sample preparation methods. Reported here are distributions based on the full length read population alone within each sample, but care should be applied before comparing these frequencies to other datasets with different sample preparation methods, such as the ChAdOx1 Nanopore RNA direct data (Sup Figure 8). Hundreds of randomly spaced splicing events characterized by the cDNA direct sequencing approach for the S protein and similar events seen in other proteins highlight the fact that even when the transgene’s CDS is apparently well designed and expression of full-length protein can be detected, the status quo design is just not optimal for RNA expression as transcript heterogeneity will inevitably impact both product levels (yield) and homogeneity. The impact of this will be dependent on the nature of the product, whether it is expressed in vitro or in vivo. In vitro expression offers opportunities to improve homogeneity by application of purification methods. Two thirds of cryptically spliced RNA molecules would be out-of-frame and would not just impact protein yield but any translation in vivo would generate novel peptides with potential immuno...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.15.460487: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: All animal studies were conducted in compliance with local, state, and federal regulations and were approved by Bioqual and City of Hope Institutional Animal Care and Use Committees (IACUC).<br>IACUC: All animal studies were conducted in compliance with local, state, and federal regulations and were approved by Bioqual and City of Hope Institutional Animal Care and Use Committees (IACUC).<br>Consent: Subjects gave informed consent.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Thirty 6-8 weeks old Syrian hamsters were randomly assigned to the groups, with 3 females and 3 males in each group.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Thirty 6-8 weeks old Syrian hamsters were randomly assigned to the groups, with 3 females and 3 males in each group.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Board certified pathologists were blinded to the vaccine groups and mock controls were used as a comparator.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After washing, anti-Hamster IgG HRP secondary antibodies measuring total IgG(H+L), IgG1, or IgG2/IgG3 (Southern Biotech 6061-05, 1940-05, 1935-05) were diluted 1:1000 in blocking buffer and added to the plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Hamster IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>total IgG(H+L</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgG1</div><div>suggested: (SouthernBiotech Cat# 1940-05, RRID:AB_2795558)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Goat anti-Monkey IgG (H+L) secondary antibody (ThermoFisher PA1-84631) was diluted 1:10,000.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Goat anti-Monkey IgG</div><div>suggested: (Thermo Fisher Scientific Cat# PA1-84631, RRID:AB_933605)</div></div><div style="margin-bottom:8px"><div>anti-Monkey IgG</div><div>suggested: (Thermo Fisher Scientific Cat# PA1-84631, RRID:AB_933605)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The stock was produced by infecting Vero E6-hACE2 cells (BEI Resources NR-53726) at low MOI with deposited passage 3 virus and resulted in a titer of 1.99×106 TCID50/ml.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6-hACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The stock was generated using Vero-E6 cells infected with seed stock virus obtained from Kenneth Plante at UTMB (lot # TVP 23156).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero E6 cells (ATCC, CRL-1586) were seeded in 24-well plates at 175,000 cells/well in DMEM/ 10% FBS/Gentamicin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The mixture was added to 5×106 HEK293T/17 cells (ATCC CRL11268) seeded the day before in 10 cm dishes and the cells were incubated for 72h at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T/17</div><div>suggested: ATCC Cat# CRL-11268, RRID:CVCL_1926)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">: Vero TMPRSS2 cells (Vaccine Research Center-NIAID) were plated at 25,000 cells/well in DMEM/10% FBS/Gentamicin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PV production: SARS-CoV-2 PV was produced using a plasmid lentiviral system based on pALD-gag-pol, pALD-rev, and pALD-GFP (Aldevron)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pALD-rev</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pALD-GFP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmid pALD-GFP was modified to express Firefly luciferase (pALD-Fluc)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pALD-Fluc</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmid pCMV3-S (Sino Biological VG40589-UT) was used and modified to express SARS-CoV-2 Wuhan-Hu-1 S with D614G modification.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCMV3-S</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Customized gene sequences cloned into pTwist-CMV-BetaGlobin (Twist Biosciences) were used to express SARS-CoV-2 VOC-specific S variants (Table S1).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pTwist-CMV-BetaGlobin</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The titers that gave 50% neutralization (NT50) were calculated by determining the linear slope of the graph plotting NT versus serum dilution by using the next higher and lower NT using Office Excel (v2019)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Office Excel</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analyses: Statistical analyses were performed using Prism 8 (GraphPad, v8.3.0).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04639466</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the P…</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04977024</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">SARS-CoV-2 Vaccine (COH04S1) Versus Emergency Use Authorizat…</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.12.21263373: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: All studies were approved by the Institutional Review Board of FAH-SYSU and written consent was obtained from all participants.<br>Consent: All studies were approved by the Institutional Review Board of FAH-SYSU and written consent was obtained from all participants.<br>Field Sample Permit: Cell isolation: Blood samples were collected into the heparinized tubes and processed right after sample collection</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were incubated with IFN-γ detection antibody (1μg/ml, MabTech, #3420-6-250), followed by Avidin-HRP (1μg/ml, Vector, #A-2004-5) and visualized using the ACE substrate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>#A-2004-5</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, Tocris, #4536/10) and IL-2 (20 ng/ml, PeproTech, #200-02-10) for 3 days to secrete a detectable amount of antibody28, 29.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IL-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>antibody28</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-CD69-Super Bright 436, anti-CD134 (OX40)-BV605 and anti-CD137-(4-1BB)-PE antibodies for antigen-specific T cell analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-CD134</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-CD137-</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>4-1BB)-PE</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">As for phenotype analysis of SARS-CoV-2-specific T cells, cells were further labeled with anti-CCR7-APC/cy7, anti-CD45RA-BV650, anti-CXCR5-BV711 and anti-PD-1-PE/cy7 antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-CCR7-APC/cy7</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-CD45RA-BV650</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-CXCR5-BV711</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-PD-1-PE/cy7</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were washed with PBS and then stained with the following antibody cocktail: anti-CD3-Pacific Blue™, anti-CD19-PE-CY7, anti-CD27-AF700, anti-IgD-FITC, anti-CD38-BV650, anti-IgM-BV605, anti-IgG-AF647, anti-IgA-PE all from BioLegend at 1:100 dilution.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-CD3-Pacific</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-CD19-PE-CY7</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-CD27-AF700</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-IgD-FITC</div><div>suggested: (Miltenyi Biotec Cat# 130-099-633, RRID:AB_2659770)</div></div><div style="margin-bottom:8px"><div>anti-CD38-BV650</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-IgM-BV605</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-IgG-AF647</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-IgA-PE</div><div>suggested: (Miltenyi Biotec Cat# 130-093-128, RRID:AB_1036158)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were washed 3 times by PBST, processed to 100 μl/well goat HRP conjugated anti-human IgG antibody (2040-05, SouthernBiotech) at 1:3000 dilution in PBST for staining in 30 minutes at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: (SouthernBiotech Cat# 2040-05, RRID:AB_2795644)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">FlowJo</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.13.460111: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Mouse studies and in vivo infections: All mouse studies were performed at the University of North Carolina (Animal Welfare Assurance #A3410-01) using protocols (#20-059) approved by the University of North Carolina Institutional Animal Care and Use Committee.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">For Matute-Bello scoring samples were blinded and three random fields of lung tissue were chosen and scored for the following: (A) neutrophils in alveolar space (none = 0, 1–5 cells = 1, > 5 cells = 2), (B) neutrophils in interstitial space (none = 0, 1–5 cells = 1, > 5 cells = 2), (C) hyaline membranes (none = 0, one membrane = 1, > 1 membrane = 2), (D) Proteinaceous debris in air spaces (none = 0, one instance = 1, > 1 instance = 2), (E) alveolar septal thickening (< 2Å~ mock thickness = 0, 2–4Å~ mock thickness = 1, > 4Å~ mock thickness = 2).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">For Matute-Bello scoring samples were blinded and three random fields of lung tissue were chosen and scored for the following: (A) neutrophils in alveolar space (none = 0, 1–5 cells = 1, > 5 cells = 2), (B) neutrophils in interstitial space (none = 0, 1–5 cells = 1, > 5 cells = 2), (C) hyaline membranes (none = 0, one membrane = 1, > 1 membrane = 2), (D) Proteinaceous debris in air spaces (none = 0, one instance = 1, > 1 instance = 2), (E) alveolar septal thickening (< 2Å~ mock thickness = 0, 2–4Å~ mock thickness = 1, > 4Å~ mock thickness = 2).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For virus titration by plaque assay, the caudal lobe of the right lung was homogenized in PBS, and the resulting homogenate was serial-diluted and inoculated onto confluent monolayers of Vero E6 cells, followed by agarose overlay.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In vitro assays for antiviral activity: A549-hACE2 cells were plated at a density of 20,000 cells/well/100 μl in black-walled clear-bottom 96-well plates 24 hrs prior to infection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549-hACE2</div><div>suggested: RRID:CVCL_A5KB)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Even groups (n=10, or less as indicated) of 10-week-old female BALB/c mice (Envigo; #047) were used in all in vivo efficacy studies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data was fit using a four-parameter non-linear regression analysis using Graphpad Prism.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Graphpad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Because of this caveat associated with our mouse model, the time in which to intervene with a direct acting antiviral and sufficiently improve outcomes is curtailed in mice as compared to humans. Our recent study with RDV exemplifies this where we found the degree of therapeutic benefit in mice infected with SARS-CoV-2 MA10 was dependent on the time of initiation (17). Here, we show that oral administration with GS-621763 prevents body weight loss, loss of pulmonary function, severe lung pathology and virus replication when administered at 12 and 24 hrs after infection. While we observed improvement in some metrics with RDV initiated at 24 hr in our prior studies (17), GS-621763 therapy initiated at a similar time comparatively improved all metrics assessed. Thus, herein we provide proof-of-concept preclinical data that the orally bioavailable ester analog of RDV GS-621763 can exert potent antiviral effects in vivo during an ongoing SARS-CoV-2 infection. Lastly, we show that GS-621763 therapy provides similar levels of protection from SARS-CoV-2 pathogenesis as MPV, an oral nucleoside analog prodrug effective against SARS-CoV-2 in mice that is currently in human clinical trials. Future directions are focused on extending these studies to evaluate the efficacy of combinations of antivirals in our models of SARS-CoV-2 pathogenesis and in other models that can evaluate the blockade of transmission such as hamster and ferret. In summary, we provide preclinical data demonstrating ...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.07.21262725: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Research Subjects: Blood was collected from 67 volunteers with informed consent, who had been previously infected with SARS-CoV-2 corona virus or been vaccinated against the virus or been unexposed.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Qualitative Detection of anti-SARS-CoV2 Antibodies in Human Serum: Anti-SARS-CoV2 antibodies in human serum or in a drop of full blood were detected by a two-step incubation antigen sandwich ELISA using the RBD of the S1 protein of the SARS-CoV2 virus.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The vectors were transfected into Flip-InTM-Chinese hamster ovary (CHO) cells (Life Technologies) using the Lipofectamine 2000 Reagent (Invitrogen, #11668-019), together with the plasmid pOG44, providing site-directed recombination.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Flip-InTM-Chinese hamster ovary ( CHO )</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Expression and purification of RBD-His and NP-Strep: The various CHO-spike-RBD-His cells and CHO-spike-NP-Strep cells were grown in suspension in ProCHO5, 4 mM L-glutamine and 600 µg/ml Hygromycin B in flasks to submaximal density at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CHO-spike-NP-Strep</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Life Technologies) by adding the signal sequence METPAQLLFLLLLWLPDTTG at the beginning and cloned into the plasmid vector pcDNA5/FRT via BamHI and XhoI.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA5/FRT</div><div>suggested: RRID:Addgene_31983)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The resulting vectors were called pcDNA5/CoV-RBD-His and pcDNA5/CoV-NP-Strep, respectively, and allow for expression and secretion of RBD-His or NP-Strep into the culture medium of mammalian cells under the control of the human cytomegalovirus (CMV) immediate-early enhancer/promoter.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA5/CoV-RBD-His</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pcDNA5/CoV-NP-Strep</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The vectors were transfected into Flip-InTM-Chinese hamster ovary (CHO) cells (Life Technologies) using the Lipofectamine 2000 Reagent (Invitrogen, #11668-019), together with the plasmid pOG44, providing site-directed recombination.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pOG44</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then, IC50 values minus blank values were calculated for each sample using results from all dilutions with SigmaPlot v14.5.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SigmaPlot</div><div>suggested: (SigmaPlot, RRID:SCR_003210)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical Analysis: Statistical analysis was performed using SPSS software version 26.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SPSS</div><div>suggested: (SPSS, RRID:SCR_002865)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1 (Evidence, reproducibility and clarity (Required)): In this paper, the authors use a previously published method SHAP for interpreting deep learning (DL) models (specifically LSTMs) that are trained for predicting physicochemical attributes of peptides (such as antigenicity and collisional cross section). The paper shows that it's capable of identifying some amino acid residues contributing to the prediction results of the DL models. Reviewer #1 (Significance (Required)):

      1. One main ideas of the paper is to use SHAP for determine the significant amino acids at each position (or pairs of AA at each position) contributing to the prediction. Some of the interpretation results are consistent with findings reported previously. This is very nice; however, most of these findings are statistical results such "XX is often present at the second position for the peptides with the positive outcome", which are relatively straightforward and may be derived by using some statistical methods without using DL models. We expect more complex patterns can be discovered in addition to these statistical observations.

      We thank the reviewers for these comments.

      First, to the point about discovering complex patterns, we note that one use of PoSHAP we discuss later in the paper is that PoSHAP enables interposition dependence analysis, which depends on interactions between residues and would not be reflected by summary statistics.

      Second, we agree it is important to show whether PoSHAP produces different residue importance maps than simple statistical summaries of amino acids in each group. The strongest binding peptides, or the highest mobility for the CCS model, were determined by taking only peptides that fall above a linear regression best fit of the ranked experimental values. Statistical summary heatmaps were created and then compared to those from PoSHAP revealing some similarities but also many differences. We added the following text and new figure to the results section to illustrate these points:

      “We wondered whether the patterns revealed by PoSHAP simply reflect the summary statistics for the high-binding or high-CCS subset of peptides. As expected, due to known differences in amino acid abundance across the proteome, the prevalence of amino acids was different across the training data and were also heterogeneous across positions (Figure 5A). To determine the subset of high CCS peptides, peptides were ordered in the training set by their CCS rank and then linear regression was performed to get the average trend line (Figure 5B). Any peptide above that trendline was defined as “high CCS”, and the frequency of amino acids at each position in this set was summarized using a heatmap (Figure 5C). Compared to the statistical amino acid frequencies, PoSHAP suggests a greater importance to arginine at both termini, the importance of tryptophan to increase CCS becomes apparent, and interior glutamic acid contributes less to high CCS than the frequencies would suggest (Figure 5D). The same analysis was repeated for MHC data (Supplementary Figures 9 and 10). This demonstrates that PoSHAP found non-linear relationships between the inputs and the outputs that are not present by simple correlation. “

      Figure 5: Amino acid summary statistics differ from PoSHAP values for the CCS data. (A) Amino acid counts as a function of position for training data. (B) Procedure for picking the ‘top peptides’ with the highest CCS. Linear regression was performed on the peptides ranked by their actual CCS value. Any peptide that fell above the trendline and overall mean were defined as ‘top peptides’. (C) Counts of amino acids for the top peptides were summarized in a heatmap. (D) Mean SHAP values across amino acids and positions from PoSHAP analysis.

      We also added the corresponding supplemental figures showing the same examples for the MAMU A001 model and human MHC models:

      Supplemental Figure 9: Amino acid summary statistics differ from PoSHAP values for the A001 MAMU MHC I data. (A) Amino acid counts as a function of position for training data. (B) Procedure for picking the ‘top peptides’ with the highest CCS. Linear regression was performed on the peptides ranked by their actual CCS value. Any peptide that fell above the trendline and overall mean were defined as ‘top peptides’. (C) Counts of amino acids for the top peptides were summarized in a heatmap. (D) Mean SHAP values across amino acids and positions from PoSHAP analysis. For the MAMU model, the amino acid frequencies of the input peptides show no obvious preference for amino acid position, but some amino acids are over-represented overall. The presence of the “end” token is more likely to be a high binder statistically (C), but the PoSHAP reveals that this end token is not the main determinant of binding (D).

      Supplemental Figure 10: Amino acid summary statistics differ from PoSHAP values for the human A1101 MHC I data. (A) Amino acid counts as a function of position for training data. The distribution of amino acids in this data. (B) Procedure for picking the ‘top peptides’ with the highest CCS. Linear regression was performed on the peptides ranked by their actual CCS value. Any peptide that fell above the trendline and overall mean were defined as ‘top peptides’. (C) Counts of amino acids for the top peptides were summarized in a heatmap. (D) Mean SHAP values across amino acids and positions from PoSHAP analysis. There are clear differences between the summary statistics of top peptides (C) and PoSHAP heatmap (D). For example, the end token is prominent in the summary statistics absent from the PoSHAP interpretation. Also, the preference for S/T/V at position two is tempered according to PoSHAP, but would be determined to be very important by the summary statistics.

      Although the interpreting results reported in the paper largely agree with previous reports, the paper did not explicitly model the frequency of different amino acid in the training data. For instance, if the amino acid 'A' happens to be over-represented in the positive samples of peptides in the training data, the DL model may consider it as to contribute to the positive prediction, which may not be not true. This issue might become more serious when pairs of amino acids are considered. The authors may want to analyze this potential issue in their results.

      We agree and understand the concern for the overrepresentation of amino acids that might skew the training of our models. To determine if this is an issue, as part of the response to the previous question, we looked at the amino acid counts for all peptides (Figure 5A, Supplemental Figures 9A and 10A). In general, the PoSHAP heatmaps (panel Ds in the same figures) look very different from the frequencies of amino acids (panel Cs in the figures), suggesting that amino acid frequencies have not caused any problem.

      Even on a balanced training dataset, the LSTM model to be interpreted may still contain arbitrary bias due to invertible overfitting, which the authors did not discuss. It will be more convincing by training multiple models using different hyper-parameters and optimization algorithms, and then see if similar interpretation results can be reached among most or all of these models.

      We assume the reviewer meant ‘inevitable overfitting’ instead of “invertible overfitting”? If so, the original manuscript did assess overfitting in Figure S4 based on the training and validation loss over training epochs.

      We think the reviewer makes a good point that different models might produce different interpretations, so we trained new models without optimization and with different hyperparameters and with a different optimizer (RMS prop). We see essentially the same PoSHAP interpretations. We added the following text to the results section along with these three new supplemental figures:

      “Given the dependence of the model interpretation results on the model used, the same model architecture trained with different parameters might result in different model interpretation. Given this, models for each of the three tasks mentioned here were retrained with different hyperparameters including the “RMS prop” optimizer. Each model produces similar or better prediction performance compared to the earlier version, and the model interpretation by PoSHAP was almost identical to the previous results in all three cases (Supplementary figures 12, 13, 14). This suggests that the model architecture drives the differences in interpretation, not the model training process.”

      Supplemental Figure 12. PoSHAP Analysis of Mamu A001 With Unoptimized Hyperparameters and RMSprop. A new model for the Mamu data was trained using the same architectures but with different hyperparameters and RMSprop as the optimization algorithm. Loss was plotted as mean squared error compared to the validation data. (A) Similar metrics for MSE, r, and p-values were obtained (B). Similar patterns are also observed for the PoSHAP heatmap of A001. (C) A dependence plot for A001 shows similar patterns to the Adam optimized model, including the positional dependence of proline at position two for high SHAP values of serine and threonine.

      Supplemental Figure 13. PoSHAP Analysis of A:11*01 With Unoptimized Hyperparameters and RMSprop. A new model for the A:11*01 data was trained using the same architectures but with different hyperparameters and RMSprop as the optimization algorithm. Loss was plotted as mean squared error compared to the validation data. (A) Similar metrics for MSE, r, and p-values were obtained (B). Similar patterns are also observed for the PoSHAP heatmap of A:11*01. (C) The SHAP ranges by position plot for A:11*01 shows similar patterns to the Adam optimized model, including the largest range of SHAP values at position two, nine, and ten.

      Supplemental Figure 14. PoSHAP Analysis of CCS With Unoptimized Hyperparameters and RMSprop. A new model for the CCS data was trained using the same architectures but with different hyperparameters and RMSprop as the optimization algorithm. Loss was plotted as mean squared error compared to the validation data. (A) Similar metrics for MSE, r, and p-values were obtained (B). Similar patterns are also observed for the PoSHAP heatmap of CCS. (C) Dependence analysis was performed on the dataset and the combined distance-interaction type bar plot shows similar relationships between the groupings, notably charge repulsion’s split.

      For the dependence analysis, it is not completely clear why the distance is used as the variable, while the relative position of the amino acid residue in the peptide is ignored. For example, if there is a strong interaction between the first and the last residues in the peptide, their distance changes depending on the peptide length. In figure 6, the authors showed strong interactions between amino acid that are 8-9 residues apart may suggest the peptide length actually plays a role here.

      We used distance because as the dependence analysis is a calculation of the difference in means between two distributions of SHAP values, dependent of the amino acid at another position. We believe that the distance between these interacting points is a natural choice and among the most informative metrics to explain these interactions. We agree with the reviewer that peptide length is important to the magnitude of the interactions between amino acids. We also recognize that there may be interactions between the peptide termini that could be obscured by the interactions of the longer peptides. To better explore this possibility, we performed the dependence analysis on each of the different peptide lengths separately (8, 9, or 10 here) to see if this is the case. Unfortunately, given the smaller size of these data subsets, we were unable to show significant differences in the interaction groupings. Though, interestingly enough, the significant interactions for the peptides of length eight only occurred between neighboring amino acids or the termini. This may suggest an interaction between termini that could be explored in the future.

      We added the following text and supplemental figure 11 to the results:

      “Finally, to try to ask if the absolute positions of amino acids in the peptide are relevant for the interaction, the data was split into 8, 9, or 10mers before analysis (Supplemental Figure 11). This revealed that there may be interactions between the termini, but this effect may be difficult to observe because there are significantly fewer 8mers and 9mers in the CCS dataset.”

      Supplemental Figure 11. SHAP Values of Collisional Cross Section by Peptide Length. The impact of peptide length on SHAP values was explored for the CCS data. The dataset was split into peptides of length 8, 9, and 10. All SHAP values were plotted as violin plots. The mean SHAP values were plotted in heatmaps by position and amino acid and standardized. Significant interactions by dependence analysis were plotted in bar charts by distance between interactions.

      To further support our decision to use distance as an interaction metric, we have also now included an additional box plot for Figure 7, demonstrating the interactions between each of the categories combined with distance. We have found that some of the bimodality of the interaction categories are explained by the distance at which they interact. Most strikingly is charge repulsion that decreases CCS when neighboring but increases CCS when the interaction is further.

      We added the following text and updated Figure 7 to the results section:

      “Additionally, there are interesting differences in the interactions of the amino acid among the significant set of interactions (Figure 76B). All significant interactions from the CCS data (Supplemental Table 3, adj. p-value Though it is evident that the mean of each interaction type corresponds to the expected impact those interactions would have on CCS, each of the interaction dependence plots are bimodal, with some interactions increasing CCS and some decreasing it. To dissect this observation further, we combined the two methods of splitting the data to see if the bimodality of interaction types would be resolved by distance (Figure 7C). Though definitive conclusions cannot be made for most categories, likely due to the ever decreasing sample size by splitting, of note is the difference between neighboring charge repulsion and non-neighboring charge repulsion. Neighboring charge repulsion seems to decrease CCS while distant charge repulsion increases CCS (see adjusted p-value from Tukey’s posthoc test in Figure 7D). When distant, charge repulsion makes intuitive sense as the amino acids are forced apart, linearizing the peptide and increasing the surface area. When neighboring, it is possible that the repulsion causes a kink in the linear peptide, decreasing the cross section. Overall, these analyses demonstrate that the models were able to learn fundamental chemical properties of the amino acids and through PoSHAP analysis we were able to uncover them.”*

      Figure 7. Dependence analysis of CCS model. (A) Significant (Bonferroni corr. P-value = charge repulsion, * = other, and δ = polar. For the distance analysis, interactions were grouped into three categories, neighboring (distance = 1), near (distance = 2, 3, 4, 5,6), and far (distance = 7, 8, 9). * indicates significance (ANOVA with Tukey’s post hoc test p-value

      Also, it would be better to show that how the result looks like when applying this method to peptides in the negative samples (e.g., the peptides that are not bound by MHC in the antigenicity prediction experiment). Will the interpreting results also be negative?

      We agree this is an interesting idea. We updated the supplemental figure showing PoSHAP of top peptide subsets to also show PoSHAP of bottom peptide subsets (supplemental figure 8). The results suggest that certain amino acid positions are detrimental to binding, for example D/E at various positions. We updated this section to add:

      “We also performed the same analysis with the eight peptides with the lowest binding predictions (Supplemental Figure 8). These PoSHAP heatmaps are primarily composed of negative SHAP values, suggesting that using this subset reveals amino acids at certain positions that are detrimental to MHC binding.”

      Supplemental Figure 8. Pooled PoSHAP for bottom and top predicted subsets of the data. The mean SHAP values for each amino acid at each position were calculated for the peptides with the bottom (A) or top (B) 0.013% predicted intensity (top 8 peptides) for the “A” Mamu alleles. Due to the small sample size, most of the amino acid positions have a value of zero. The positions with extreme values, however, illustrate important amino acids for prediction. Notably for A001 and A002, aspartic acid and glutamic acid contribute to low prediction along the peptide, suggesting charge may inhibit binding. For the top predictions, phenylalanine or leucine are important at the first position for both A001 and A008. A serine or threonine at position two is important for A001, A002, and A008. All alleles demonstrate the importance of a proline near the middle of the peptide.

      Finally, it will be interesting to see the interpreting results when the method is applied to the DL models on more challenging tasks such as the prediction of tandem mass spectra of peptides. The authors may want to discuss these applications.

      We agree it would be very interesting to apply this method to interpret predictions of tandem mass spectra. In this paper we already demonstrated PoSHAP on three different datasets with three different models, so we feel that adding a fourth model is out of the scope of this work. We do agree that we would like to explore this option in the future. We added this idea to the discussion section:

      “Altogether the advances described herein are likely to find widespread use for interpreting models trained from biological sequences, including models not covered here such as those to predict tandem mass spectra (reviewed in 33).”

      I am primarily interested in algorithmic and statistical problems in genomics and proteomics. We have develop deep learning models for predicting the full tandem mass spectrum of peptides, and am interested model interpretation methods to explain the fragmentation mechanism resulting in non-conventional fragment ions in tandem mass spectra of peptides. I review the paper in collaboration with my Ph.D students, who are developing deep learning models for computational mass spectrometry.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)): **Comments to the Authors** In this study, the authors developed a framework named PoSHAP for the interpretation of neural networks trained on biological sequences. The current manuscript can be stronger if the following issues can be clearly addressed.

      1. As interpreting model with SHAP is a vital part of this manuscript, it would be better to provide descriptions of the underlying principles of SHAP to enable the readers to understand the paper easily.

      We recognize that understanding the principles of SHAP is vital. To better explain SHAP, we have added the following text to the introduction:

      “SHAP is a perturbation-based explanation method where the contribution of an input is calculated by hiding that input and determining the effect on the output. SHAP expands this using the game theoretic approach of Shapely values that ensures the contributions of the inputs plus a calculated baseline sum to the predicted output.”

      It is emphasized in the manuscript that PoSHAP is introduced to interpret neural networks trained on biological sequences. However, it is not clear why the authors choose the Model Agnostic Kernel SHAP, which is based on Linear LIME. Although it can be used for any model, the performance of which may not be optimal. In this regards, perhaps Deep SHAP or Gradient SHAP is more appropriate, both of which are designed for deep learning networks [1]. It would be better to provide some additional experiments on Deep SHAP and this work will be more convincing if the same or similar contribution of each position on each peptide as that of Kernel SHAP. [1] Lundberg, S., and S. I. Lee. "A Unified Approach to Interpreting Model Predictions." Nips 2017.

      Our goal in using KernelExplainer was to demonstrate that PoSHAP was not dependent on model specific interpretation methods. However, we have realized that this intention may not have been clearly stated or demonstrated. To expand on this, we have included a new Figure 8, which shows PoSHAP analysis comparisons to other classes of machine learning models, all using Kernel Explainer. This result was interesting because it revealed that even though the XGboost model technically performed better at prediction (Figure 8A, reduced MSE and higher spearman rho), and produced a similar PoSHAP motif heatmap, the interpositional dependences from the perspective of distance (Figure 8C) or chemical interactions (Figure 8D) were substantially muted. This is also apparent with the other standard machine learning model ExtraTrees. This result shows that the choice of model architecture is important, and this direct comparison would not be possible if we used the DeepExplainer.

      We added the following text and figure to the manuscript:

      “ PoSHAP uses the SHAP KernelExplainer method, which is based on Local interpretable model-agnostic explanations (LIME). Using the general KernelExpplainer method enables direct comparison of interpretations produced by different models trained from the same data. To ask whether PoSHAP interpretation changes based on the model used, the CCS data was used to train XGboost or ExtraTrees models. Surprisingly, the XGboost model performed better than the LSTM model with regard to MSE and spearman rho between true and predicted values in the test set (Figure 8A). ExtraTrees was slightly worse than the other two models. The model interpretation heatmaps from PoSHAP were similar between the LSTM and XGboost, but the interpretation from the ExtraTrees model was missing the high average SHAP due to n-terminal histidine or arginine (Figure 8B). Even though XGboost produced a similar PoSHAP heatmap, the interpositional dependence with regard to distance (Figure 8C) and chemical interactions (Figure 8D) was muted. This shows that the choice of model is important for revealing amino acid interactions.”

      Figure 8. CCS PoSHAP of Various Machine Learning Models. PoSHAP analysis was performed on two additional machine learning models, Extra Trees and Extreme Gradient Boosting (XGB). Predictions were plotted against experimental values and the Mean Squared Error and r values are reported for each model (A). PoSHAP heatmaps were created for each model (B), illustrating an increase in model complexity as more sophisticated models are used. Dependence analysis was performed on each model and the significant interactions are plotted by distance (C) and by combined distance and interaction type (D).

      As described in the manuscript, "Correlations between true and predicted values were assessed by MSE, Spearman's rank correlation coefficient, and the correlation p-value." As an important indicator for evaluation, the exact p-values should be provided in the seven subgraphs in Figure 2, not p=0.0.

      We agree with the reviewer that reporting accurate p-values can assist in evaluation. We have updated the figures to reflect the p-values as far as we were able to determine them. Unfortunately, we are limited by the nature of the double data type in python and so reported that the p-value was less than the minimum value allowed by a double in six of the seven graphs. Additionally, the scales have been marked symmetrically as you mentioned in comment 4.

      It should be noted that the coordinate scales of Figure 2B and Figure 2C need to be marked symmetrically. And from Figure 2B, we can see that, the IC50 with smaller (0.8) values cannot be well predicted. Can the authors provide a detailed explanation about these results?

      We understand the reviewer’s concern with poor prediction of extreme values. Figure B represents the IC50 prediction for the A1101 human allele which was the smallest of the datasets we used for training. It only consists of 4,522 entries, around 1/10 of the data used for the Mamu alleles and CCS. Because of this, it is likely that there were not enough examples of datapoints at the extremes to reliably train the model to account for them. However, given the limited size of the dataset, we were surprised with the satisfactory predictions. More importantly, the purpose of our paper is model interpretation not model prediction accuracy, and this shows that even when predictions are not perfect, the model interpretation by PoSHAP can still be effective. We thank the reviewer for noticing this and added the following statement to the results:

      “Remarkably, this was achieved for A\11:01 using a total dataset of only 4,522 examples, which shows that PoSHAP can be effective with even less than 10,000 training examples. “*

      References are needed in some descriptions in the manuscript. For example, "one might train a network to take an input of peptide sequence and predict chromatographic retention time", "RNNs have found extensive application to natural language processing, and by extension as a similar type of data, predictions from biological sequences such as peptides or nucleic acids".

      We apologize for missing these references. We have now cited these statements and have added many additional references as part of our revision.

      The description of the adopted three models in the section "Model architecture" is a bit confusing. As described in this section, "The LSTM layer outputs a 50x128 dimensional matrix to a dropout layer where a proportion of values are randomly set to 0", "a second LSTM layer outputs a tensor with length 128 and a second dropout layer then randomly sets a proportion of values to 0". But as shown in the Supplemental Figure 3, the output size of the first LSTM was 10x128. Also, as shown in Table 1, the dropout rates were not 0. Therefore, the section should be adjusted for clear clarification.

      We apologize for the confusing wording. We meant that dropout layers randomly set values=0, not that the dropout proportion was 0. We reworded this part to read:

      “The LSTM layer outputs a 10x128 dimensional matrix to a dropout layer where a proportion of values are randomly “dropped”, or set to 0. For the MHC models, a second LSTM layer outputs a tensor with length 128 to a second dropout layer. Then in all models, a dense layer reduces the data dimensionality to 64. For the MHC models, the data is then passed through a leaky rectified linear unit (LeakyReLU) activation before a final dropout layer, present in all models.”

      Reviewer #2 (Significance (Required)): Pls refer to my comments provided as above.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)): **Summary:** The main goal of the work is to provide the interpretation of Deep Neural Networks (LSTM in the paper) trained on biological sequences. For this purpose authors used the framework introduced earlier - SHapley Additive exPlanations (SHAP), in particular - the slight adaptation of this method called positional SHAP (PoSHAP), because they are interested in the impact of each position of the input sequence to the model output. They demonstrate this on three regression tasks that predict peptide properties. **Major comments** The main contribution, highlighted in the paper: authors showed how PoSHAP discloses amino acid motifs that influence MHC I binding. Further they described how PoSHAP enables understanding of interpositional dependence of amino acids that result in high affinity predictions. Also they argued that this work also contributes to a method for accurate prediction of peptide-MHC I affinity using peptide array data enabled by novel application of a neural network that combines amino acid embedding and LSTM layers.

      There are some comments about the statements above: 1.Why was the LSTM model chosen? Recent publications showed the success of the Transformer model for biological sequences; however this direction was not covered in the related work overview. The architecture choice then should be better justified. Also the choice of LSTM for the biological sequences is not new and authors should better claim their statement about "novel application of a neural network that combines amino acid embedding and LSTM layers ". Where exactly is the novelty? Could the community use the pretrained embeddings for their purpose?

      The reviewer is correct that transformer models are highly effective for making predictions from biological sequences. In fact, many models do well, and there is no single correct choice of model for this task. Though there are many models to choose from, our models are sufficiently accurate. Importantly, the main contribution of our manuscript is not to train the most accurate models, but rather to demonstrate a strategy for positional model interpretation based on SHAP. Related to that point, please note our response to reviewer #2’s second comment that our approach uses the kernel explainer and can be applied to any model. However, we do agree that we neglected coverage of the transformer model in the introduction and have added a paragraph to the introduction covering some of the recent work in this area:

      “Many effective deep learning model architectures are available for making predictions from inputs of biological sequences, and there is currently no single correct choice. CNN models such as MHCflurry 2.0 (40) and LSTM models are effective at predicting MHC binding of peptides (41). Even simpler models, such as random forests, have been used to predict MHC binding (42,43). Prediction of other peptide properties like tandem mass spectra are often done with CNN or LSTM models (33). More recently, given the extraordinary performance of transformer models like BERT (44) and GPT-3 (45) for NLP, there is interest in transformer models for biological sequences (46).”

      We also want to be sure we do not overstate the novelty of our contributions. We have updated our discussion to better reflect the nature of our contributions. We reworded the statement quoted above to read:

      “Overall, the three modeling examples laid out herein serve as a tutorial for PoSHAP interpretation of almost any model trained from almost any biological sequence.”

      The attention mechanism itself provides the great opportunity to interpret the model predictions. In the introduction section authors made a statement that attention layers may limit the flexibility of model architecture when designing new models. Could they better explain this limit? Because recent state of the art models successfully work with long biological sequences and show better results then any other models (one example could be found here: https://openreview.net/pdf?id=YWtLZvLmud7). Authors should cover these limits more, that also related to the motivation of the LSTM choice.

      We added a paragraph to our introduction to expand on attention and its limitations:

      “Attention mechanisms have been successful in recapitulating experimentally defined binding motifs, but require that the model be constructed with attention layers. This may limit the flexibility of model architecture when designing new models. For example, attention mechanisms are specific to neural networks. Simpler models, such as random forests and XGboost, may also be more suitable for some applications, and these cannot utilize attention. Also, while attention mechanisms are currently very effective, there is always a possibility that new architectures will emerge that make interpretations using attention infeasible. Beyond this, attention is a metric of the model itself, while SHAP values are calculated on a per input basis. By looking at the model through the lens of the inputs, we can understand the model’s “reasoning” behind any peptide. Attention mechanisms also do not enable dissection of interpositional dependencies between amino acids. Thus, new methods for model agnostic interpretation are desirable.”

      Another statement was made about the PoSHAP - adaptation of the SHAP method. It is hard to follow through the explanation of this adaptation - it is not clear what exactly is this adaptation. For example, Kernel SHAP from the original paper computes feature importance, in this paper authors compute the impact of each position, that is basically also the feature importances. Thus authors should better explain the statement about PoSHAP novelty. Will it be possible to use PoSHAP for any other model trained for the same purpose? If yes, for better reproducibility, authors should provide the place where exactly in the repo is the code for this. Also mathematical notations are missing in the Positional SHAP (PoSHAP) section - it is better to explain the adaptation with them to increase the understanding of the section.

      We apologize for the ambiguous wording in the abstract stating that “PoSHAP adapts SHAP”. We have reworded this statement to “PoSHAP utilizes SHAP”. The novelty of this approach is taking the feature importance values calculated by SHAP and structuring them to include each position’s index to allow for the interpretation of biological sequences. As we demonstrate here, this allows for novel interpretations of previously published data and will enable model interpretation in future studies that learn from biological sequences. Although this is practically very simple, we are not yet aware of any examples in the literature that do this.

      The following two SHAP force plots demonstrate the difference between using SHAP as-is versus PoSHAP. There is a demonstrated need for such a framework, considering the dearth of biological sequence model interpretation using SHAP and the ambiguity within biological sequence SHAP interpretation. For example, Meier et al., Nature Communications, 2021 performed an analysis like our Figure S7C, which just shows the range of SHAP values per residue. Although we can learn something about which AAs are important based on the range of their SHAP values, SHAP as-is doesn’t reveal a motif. While our position indexing is a simple change, it enables all the rich, sequence dependent analysis we performed in this paper. We added the following text to the results section with this new supplementary figure:

      “PoSHAP utilizes the standard SHAP package but adapts the analysis by simply appending an index to each input and maintaining positional information after the kernelExplainer interpretation, which enables tracking of each input postion’s contribution to an output prediction (supplementary figure 5, showing force plot with and without index).”

      Supplemental Figure 5. SHAP Forceplots Demonstrating PoSHAP Indexing. Two forceplots were created with the SHAP forceplot method of the third peptide in the CCS testing set. (A) shows the plot with encoded inputs mapped to their amino acid. (B) shows the plot with the encoded inputs mapped to their amino acid and position. The addition of positional indexing removes the ambiguity of contributions, for example, glutamine having both a positive and a negative SHAP contribution to the prediction of the third peptide.

      We have updated the repository to include a tutorial that demonstrates PoSHAP on provided data and explains how to use PoSHAP with your own model and data.

      In the experimental section, authors first compare the results with previously known. For example, for the human MHC allele A*11:01 model PoSHAP analysis shows the similar results as was shown with another approach. Based on the provided explanation, it is not clear why PoSHAP is better than the previously published method. The advantage of the PoSHAP should be better explained.

      We agree with the reviewer that the benefits of our approach should be as clear as possible. The referenced section of the paper is to validate our approach compared to another model interpretation technique. We added a new third paragraph to the discussion section to clearly explain the benefits of PoSHAP:

      “There are several benefits of PoSHAP over competing methods. First, PoSHAP determines important residues despite biases in the frequencies of amino acids (Figure 5, Supplementary Figures 9 and 10). PoSHAP is also applicable to any model trained from sequential data (Figure 8), and enables dissection of interpositional dependencies (Figures 6 and 7). Finally, we include a clearly explained jupyter notebook on Github that will take any model and dataset and perform PoSHAP analysis.”

      In the experimental section, after the PoSHAP performance verification, hypothesis generation was introduced. However, it is not clear how many hypotheses were generated; how many of them were known before; what kind of other categories are inside these hypotheses (unknown, possible and potentially interesting, etc).

      We are unsure as to how to quantify the number of hypotheses generated by our approach. In a sense, the SHAP value of each amino acid at each position within a heatmap represents a hypothesis of the contribution of that amino acid to the metric being predicted. Each significant interaction listed in the first three supplemental tables represents a hypothesis of the interactions between two given amino acids at two positions. To make these into testable hypotheses requires some analysis, as we have discussed. i.e. the two binding motifs (L-T-P, F-S-P) of A001, or the distance-type interactions within the CCS.

      The README section in the GitHub repo is not easily understandable. An additional explanation for each step is required (e.g., links to the folders where the calculated SHAP values, the trained models, all splits and all-important benchmarks are).

      We have updated the README and repository to explain how to use PoSHAP, and explanations of each item in the repository.

      **Minor comments**

      1. The prior studies should be covered better (see Major comments).

      We apologize for not better covering prior studies. We have significantly expanded the introduction by adding two new paragraphs and at least 10 additional citations.

      The work consists of some typos, for example: "However, because many reports forgo model interpretation" - "t" is missed.

      We did intend to use the word “forgo” not “forget” in that sentence. We have checked again thoroughly for spelling and grammar mistakes.

      The hyperparameters table, hyperparameter search section should be moved to the supplemental material, that's technical details.

      We moved this table to the supplementary materials.

      Reviewer #3 (Significance (Required)): Interpretation of the model results is an important topic for biology. New findings here could lead to new interactions opening, new drugs development etc. That is relevant for the applied ML Researches and computational biologists. This paper aims to provide a way to do it. Because my field of interest and expertise lies in Machine Learning for healthcare, language modelling of biological sequences and Natural Language Processing, this work is of great interest to me. So I mostly evaluated ML methodology presented in the paper.

    1. SciScore for 10.1101/2021.09.06.21262027: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: Experiments on Cat and Dog sera: Serum samples were collected from cats and dogs belonging to owners who developed COVID-19-like symptoms and subsequently tested positive for SARS-CoV-2 infection by RT-qPCR.,<br>IRB: Samples and data collections were conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee Sciences et Santé Animale n°115 (protocol code COVIFEL approved on 1 September 2020, registered under SSA_2020_010).<br>Euthanasia Agents: Cells were then incubated for 72 h at 37 °C with 5% of CO2.<br>Consent: Ethical statement: All sera from the first cohort, and whole blood samples from the second cohort, were obtained from the Toulouse hospital, where all patients give, by default, their consent for any biological material left over to be used for research purposes after all the clinical tests requested by doctors have been duly completed.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">All the positive samples of this cohort, as well as a set of randomly selected negatives, were submitted to a repeat of the assay, which showed excellent reproducibility.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">After transferring the pictures to computer files, the hemagglutination tests were scored by three independent assessors, of which two were blinded.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: The Jurkat-S and Jurkat-R cell lines were both checked for the absence of mycoplasma contamination using the HEK blue hTLR2 kit (Invivogen, Toulouse, France) FACS staining: Before experiments, cells in the cultures of both Jurkat-S and Jurkat-R cell lines were counted, and sufficient numbers harvested to have a bit more than 105 cells of each per sample to be tested.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Reagents: Polyclonal anti-human and anti-mouse Igs secondary antibodies, all conjugated to Alexa-488, were from Jackson laboratories, and purchased from Ozyme (France)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse Igs secondary</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">109-545-129; anti-mouse Ig-G: 115-545-003 Anti-cat IgG (F4262) and anti-dog IgG (F7884) secondary antibodies, both conjugated to FITC, were obtained from Sigma. Anti RBD monoclonal antibodies: FI3A (site 1) and FD-11A (site 3) (Huang et al. 2021); C121 (site 2) (Robbiani et al. 2020); CR3022 (site 4) (ter Meulen et al. 2006); EY6A (site 4) (Zhou et al. 2020).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>109-545-129; anti-mouse Ig-G: 115-545-003 Anti-cat IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-dog IgG</div><div>suggested: (Sigma-Aldrich Cat# F7884, RRID:AB_259743)</div></div><div style="margin-bottom:8px"><div>F7884</div><div>suggested: (Sigma-Aldrich Cat# F7884, RRID:AB_259743)</div></div><div style="margin-bottom:8px"><div>Anti RBD</div><div>suggested: (BioLegend Cat# 944803, RRID:AB_2892509)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All those were obtained using antibody-expression plasmids, as previously described (Townsend et al. 2021).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antibody-expression</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For specific isotyping, i.e. for staining separately with either anti-IgG, -IgA or -IgM, as well as the pan-specific anti-Ig-GAM secondary antibody, we used double the quantities of cells and of serum or plasma for the primary step, and split the samples into 4 wells after the second wash, before proceeding to the subsequent steps as for the standard protocol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-Ig-GAM</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Monoclonal anti-SARS-CoV CR3022 antibody (BEI Resources, NIAID, NIH) was used as a positive control.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV CR3022</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lentiviral infectious supernatants were obtained after transient transfection of HEK cells with pLV-or pCDH-derived vectors, together with the packaging R8-2, and VSV-G plasmids.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The Jurkat-S and Jurkat-R cell lines were both checked for the absence of mycoplasma contamination using the HEK blue hTLR2 kit (Invivogen, Toulouse, France) FACS staining: Before experiments, cells in the cultures of both Jurkat-S and Jurkat-R cell lines were counted, and sufficient numbers harvested to have a bit more than 105 cells of each per sample to be tested.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Jurkat-R</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Each sample requires 2.105 jurkat cells, which is roughly the amount obtained with 0.5 ml of standard tissue culture medium, which costs around 50 €/L, i.e. 2.5 cts/sample.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>jurkat</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Experiments on mouse sera: Virus preparation and inactivation: SARS-CoV2 was grown on Vero E6 cells (ATCC) in DMEM (Dutscher) supplemented with 100 U/mL penicillin, 100 μg/ml streptomycin (Invitrogen), and 2% heat inactivated fetal bovine serum (Sigma).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sero-neutralisation assay: Serum samples and controls were heat-inactivated at 56 °C for 30 min, serially diluted in DMEM starting at 1:10, mixed with an equal volume of SARS-CoV-2 stock (previously amplified and titrated on Vero-E6 cells and diluted in DMEM to contain 2000 TCID50/ml), incubated for 2 hours at 37 °C, and 100 µL transferred to tissue-culture 96 well plates plated with 12.000 Vero-E6 cells per well the day before the assay, in DMEM complemented with 10% of heat-inactivated fetal bovine serum and 1% of penicillin-streptomycin at 37 °C with 5% of CO2 (medium was removed before adding the virus-serum dilutions).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">pLV-EF1a-SARS-CoV-2-S-IRES-Puro was created by cloning a codon-optimized version of the SARS-CoV-2 S gene (GenBank: QHD43416.1) into the pLV-EF1a-IRES-Puro backbone (Addgene plasmid # 85132 ; http://n2t.net/addgene:85132 ; RRID:Addgene_85132) using BamHI and EcoRI sites.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pLV-EF1a-SARS-CoV-2-S-IRES-Puro</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div></div><div>detected: RRID:Addgene_85132)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The lentiviral vector for the expression of mCherry was obtained by replacing the GFP sequence of GFP by that of mCherry in the pCDH-EF1α-MCS*-T2A-GFP plasmid (https://systembio.com/shop/pcdh-ef1α-mcs-t2a-gfp-cdna-single-promoter-cloning-and-expression-lentivector/</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCDH-EF1α-MCS*-T2A-GFP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lentiviral infectious supernatants were obtained after transient transfection of HEK cells with pLV-or pCDH-derived vectors, together with the packaging R8-2, and VSV-G plasmids.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCDH-derived</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>VSV-G</div><div>suggested: RRID:Addgene_138479)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The Jurkat-R cells were obtained by successive transduction with the pCDH-GFP lentiviral vector described above, then with the empty pLV lentiviral vector, followed by selection with Puromycin at 10µg/mL.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCDH-GFP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pLV</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Post-acquisition analysis of all the samples was performed using the Flowjo software (version 10.7.1) Cost of the Jurkat-S&R-flow test: The cost per sample of the Jurkat-S&R-flow test lies in large part with the price of the secondary antibodies used.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Flowjo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      As alluded to in the introduction, one of the possible caveats of using a human cell line to express the S protein is that some blood samples will contain allo-reactive antibodies directed against that cell line, possibly as a consequence of a pregnancy, or past history of receiving a blood transfusion or organ transplant (Hickey et al. 2016; Karahan et al. 2020). The third column of Figure 1 shows examples of such samples containing marked levels of alloreactive antibodies, i.e. samples for which the J-R cells show significant levels of staining compared to the same cells labelled with just the secondary antibody. Based on our results collected on more than 350 clinical samples, we evaluate that ca. 30 % of samples will contain allo-reactive Abs that will result in levels of staining of Jurkat cells that are more than five-fold that of the signal obtained for the negative control (and 3-6 % more than ten-fold). Of note, we did not notice an increased frequency of allo-reactivity in samples from women compared to men, which suggests that allo-reactivity after pregnancy is not a major cause in the origin of those allo-reactions. A difficult question with all serological tests is that of where to set the threshold beyond which the specific signals detected can confidently be considered as positive, which will be directly linked to the balance between sensitivity and specificity of the assay. Based on the analyses of various cohorts of positive and negative samples (some of whic...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. https://www.youtube.com/watch?v=rhgwIhB58PA

      Learning styles have been debunked.

      Learning styles: V.A.R.K. model originated by Neil Flemiing stands for:

      • visual
      • auditory
      • reading/writing
      • kinesthetic

      References:

      Pashler, H., McDaniel, M., Rohrer, D., & Bjork, R. (2008). Learning styles: Concepts and evidence. Psychological science in the public interest, 9(3), 105-119. — https://ve42.co/Pashler2008

      Willingham, D. T., Hughes, E. M., & Dobolyi, D. G. (2015). The scientific status of learning styles theories. Teaching of Psychology, 42(3), 266-271. — https://ve42.co/Willingham

      Massa, L. J., & Mayer, R. E. (2006). Testing the ATI hypothesis: Should multimedia instruction accommodate verbalizer-visualizer cognitive style?. Learning and Individual Differences, 16(4), 321-335. — https://ve42.co/Massa2006

      Riener, C., & Willingham, D. (2010). The myth of learning styles. Change: The magazine of higher learning, 42(5), 32-35.— https://ve42.co/Riener2010

      Husmann, P. R., & O'Loughlin, V. D. (2019). Another nail in the coffin for learning styles? Disparities among undergraduate anatomy students’ study strategies, class performance, and reported VARK learning styles. Anatomical sciences education, 12(1), 6-19. — https://ve42.co/Husmann2019

      Snider, V. E., & Roehl, R. (2007). Teachers’ beliefs about pedagogy and related issues. Psychology in the Schools, 44, 873–886. doi:10.1002/pits.20272 — https://ve42.co/Snider2007

      Fleming, N., & Baume, D. (2006). Learning Styles Again: VARKing up the right tree!. Educational developments, 7(4), 4. — https://ve42.co/Fleming2006

      Rogowsky, B. A., Calhoun, B. M., & Tallal, P. (2015). Matching learning style to instructional method: Effects on comprehension. Journal of educational psychology, 107(1), 64. — https://ve42.co/Rogowskyetal

      Coffield, Frank; Moseley, David; Hall, Elaine; Ecclestone, Kathryn (2004). — https://ve42.co/Coffield2004

      Furey, W. (2020). THE STUBBORN MYTH OF LEARNING STYLES. Education Next, 20(3), 8-13. — https://ve42.co/Furey2020

      Dunn, R., Beaudry, J. S., & Klavas, A. (2002). Survey of research on learning styles. California Journal of Science Education II (2). — https://ve42.co/Dunn2002

    1. SciScore for 10.1101/2021.09.10.459749: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">4.1 Mice: All in vivo experiments were performed using (8-12 weeks old) wild-type (wt) female BALB/cOlaHsd mice purchased from Harlan.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 strains were propagated in VERO E6 cells (ATCC—CRL 1586) in T175 Flasks using Dulbecco’s Modified Eagle’s - high glucose medium (DMEM) (Euroclone, Pero, Italy) supplemented with 2mM L-glutamine (Lonza, Milano, Italy), 100 units/mL penicillin-streptomycin (Lonza, Milano, Italy and 2% fetal bovine serum (FBS) (Euroclo, Pero, Italy).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VERO E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">4.1 Mice: All in vivo experiments were performed using (8-12 weeks old) wild-type (wt) female BALB/cOlaHsd mice purchased from Harlan.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/cOlaHsd</div><div>suggested: RRID:MGI:5653315)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The amino acid (a.a.) sequence of each RBD was inserted into a pTWIST-CMV-BetaGlobin-WPRE-Neo vector (Twist Bioscience, San Fransico, CA, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pTWIST-CMV-BetaGlobin-WPRE-Neo</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">4.18 Statistical analysis: Data were analyzed and presented as (mean ± SEM) using Student’s t-test or one-way ANOVA as mentioned in the figure legend, with GraphPad PRISM 9.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad PRISM</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. This review reflects comments and contributions by Ricardo Carvalho, Omaya Dudin, Sónia Gomes Pereira, Samuel Lord, and Arthur Molines


      The work by Lera-Ramirezet al. sheds light on the growth and sliding dynamics of microtubules during mitosis in pombe. The kymographs are beautiful and the figures are well laid-out. The data is generally convincing.

      A comment on the overall organization of the paper. Figure 2 has a major location in the paper, but it seems that its main takeaway is that these MAPs aren't really involved in the main process this paper is probing. While these are important findings, it might be more satisfying to move some of the central results earlier.

      A model schematic might drive home the main finding of the paper, and be particularly useful for readers who are not experts in microtubule or spindle dynamics. That said, the Discussion does an excellent job of summarizing the findings and explaining the takeaway message(s), even for the non-expert.

      Specific comments

      ‘In higher eukaryotes’ - Suggest avoiding the terms higher and lower when describing organisms, and instead, directly defining which organisms, for instance in animals/metazoans that would be a better description.

      Figure 1 E-F - It is hard to see the difference in the distribution, maybe a different color could be used instead of stars.

      Figure 1 - Data shown in pink in G comes from 832 midzone length measurements during anaphase, from 60 cells in 10 independent experiments - The pink here does not correspond to the pink coding in D, consider colour choice for clarity across panels.

      ‘Finally, yeasts undergo closed mitosis’ - How does this relate to the findings in the Dey paper (cited here) which shows it was somewhat semi-closed or semi-open. According to the Dey paper, the membrane disassembles locally twice, at the SPB and the bridge.

      Figure 1C - vertical comets in kymographs (Fig. 1C) do not correspond to non-growing microtubules, but rather microtubules that grow at a speed matching the sliding speed’ - For clarity, it might be nice to add: "(as the SPB moves away from the plus end in the kymograph)".

      ‘significantly shorter than in interphase, where growth events last more than 120 seconds on average [42,43]. Microtubule shrinking speed did not change during anaphase either (Fig. 1-Supplement 1D), and was on average 3.56±1.75 μm/min, also lower than in interphase (~8 min/μm)’ - This comment concerns the comparison of growth and shrinking rate as well as growth duration. The authors did not measure microtubule dynamics in interphase in this manuscript but compared their numbers to literature values. The comparison raises some questions for three reasons: 1) the microscopy method used is different in this paper and the two references provided, 2) the sample is mounted differently compared to the two references provided - 1) and 2) combined could lead to different levels of stress on the cells which could affect MT dynamics-, 3) (probably the most important caveat) the experiments are done at different temperatures: 27C in this paper versus 25C in the references provided. Microtubule dynamics are sensitive to temperature so this could explain part of the differences observed. Also, there are multiple values published for MT dynamics in interphase depending on the strain used and the microscopy method used. Suggest that the authors measure microtubule dynamics in interphase cells at 27C in SIM to ensure that the differences are not due to the technical parameters employed.

      Small item - should ‘8 min/μm’ read “8 μm/min"?

      ‘we observed two populations of microtubules (fast and slow growing)’ - Does this statement about thistle fast and slow growing populations refer to the data in Fig. 1C and 2A?

      ‘In some cells, all microtubules seemed to switch to the slow growing phase simultaneously (Fig. 1C), while in others fast and slow growing microtubules co-existed (Fig. 2A)’ - This is a very interesting observation, could we know how many cells (%) were detected in each case? Is it that in 90% of the cells the switch is simultaneous, and hence the microtubule growth is somehow synchronized? Or is it more random, e.g. around 50%?

      ‘On such a plot, the data points visibly cluster in two separate clouds and the variation of growth speeds can be fitted by an error function (Fig. 1F)’ - It is unclear that there are two distinct clusters, maybe the assertion should be toned down, or some sort of cluster analysis provided.

      ‘speed of interphase microtubules (~2.3 μm/min)’ - It would be interesting to see the dynamics in a les1 mutant (Dey Nature 2020) paper. Just as a control for presence/absence of the bridge?

      ‘Figure 2, Transition from fast to slow microtubule growth occurs in the absence of known anaphase MAPs’ - It looks like the overlap zone is larger on the mal3 kymograph. Is the size of the midzone changed in some of the mutants? It could be important to report. Related to it, is the spindle length changed in some of the mutants? (It does not look like it from the kymographs displayed).

      Additionally, adding the data about rescue localization in the mutant (equivalent of Fig 1 G) would be interesting to better describe the role of these different proteins.

      Figure 2, Panel G to L - Could the authors indicate the value for the average +/- error in each bin for the WT and the mutants? Also, it is hard to say from the plots, but it looks like the WT average speed in the first bin is different in every panel, that would be good to know to have an idea of the reproducibility/variability.

      The dots making up the "thick lines" are centered on 1.5/2.5/etc.. in some panels (G and K) and centered on 1/2/3/etc.. the others (I,J,L). Could the authors provide some clarification?

      Figure 3 - Can the authors indicate the average values +/- error for each of the distributions in Fig. 3D? Maybe on the plot itself, in the legend or as a table. This would make them easily available without having to infer them from the Y axis. This comment is also valid for Fig 4I and 4J.

      Figure 3E ‘Distance from the plus-end to the nuclear membrane bridge edge at rescue as a function of distance from the plus-end to the closest pole at rescue’ - The Y axis reads as "distance to the bridge edge" but it shows negative values, could this be "position to the bridge edge" instead? (same item throughout the text).

      Figure 3 ‘Number of events: 442 (30 cells) wt, 260 (27 cells) klp9OE, 401 (35 cells) cdc25-22, from 3 independent experiments’ - P values this small raise a concern.

      Presumably the number of degrees of freedom in the regression analysis should not exceed the number of independent experiments. Instead, the DoF listed under "error" in the analysis output is hundreds or thousands instead of 3. To address this, the regression analysis should use either the "Error" function in R or a linear mixed-effects model to account for the nesting of the repeated measurements within each independent experiment. Alternatively, it is also possible to just calculate summary means for each independent experiment, and calculate p values based on that N=3.

      See: Lazic. Experimental Design for Laboratory Biologists. p. 157.

      and the supplemental file of:https://doi.org/10.1371/journal.pbio.2005282

      and the additional file 1 of:https://doi.org/10.1186/s12868-015-0228-5

      and this for an alternative plotting approach:https://doi.org/10.1083/jcb.202001064

      Recommend either recalculating the p values by one of the methods above or removing the reported p values from the paper. The large effects observed in many cases are self-evident without a significance metric, so eliminating the p values would be acceptable here.

      (This comment applies to other figures through the paper that report p values based on number of cells or number of measurements instead of number of independent samples/experiments.)

      Figure 4 - Nice experiment. It brings the question of how cell-shape affects all these dynamics (probably out of the scope of this work). But a for3 mutant for example?

      ‘Ase1 is required for microtubule growth speed to decrease during anaphase B, this is unlikely to be a direct effect’ - If it is unlikely to be a direct Ase1 effect is the title of the section accurate? "Ase1 is required for normal rescue distribution and for microtubule growth speed to decrease in anaphase B"

      Figure 5 - What about an ase1 lem1 double mutant?

      ‘In summary, Ase1 is required for rescue organisation and for microtubule growth speed to decrease during anaphase B’- In this context it could make sense to discuss the observations from this paper (doi:10.1371/journal.pone.0056808) about the role of Ase1 ortholog's MAP65-1 in coordinating MT dynamics within bundles.

      ‘We initially set the microtubule growth velocity to 1.6 μm/min (early anaphase speed, Fig. 1F), and aimed to reproduce the experimental distribution of positions of rescue and catastrophe at early anaphase (spindle length < 6 μm’ - Kudos to the authors for detailing the model and its parameters in a way that even non-modelling experts can understand.

      Discussion - ‘Our data suggests that microtubule growth speed is mainly governed by spatial cues’- Is it right to assume that in the cases where fast and slow growing microtubules were simultaneously observed, the fast microtubules were not/had not yet reached the midzone?

      Methods - ‘PIFOC module (perfect image focus), and sCMOS camera’ - Is this Nikon's "Perfect Focus" autofocus, or some other manufacturer's system? And back-thinned sCMOS.

    1. SciScore for 10.1101/2021.09.10.459744: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ELISA experiments: 96-well ELISA plates were coated with 100μL of anti-ACE2 coating antibody (2μg/ml diluted in PBS pH 7.4) over night at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following incubation for 1 hour at room temperature, plates were washed five times with washing buffer after which 100μL of anti-Histidine detection antibody (diluted 1/500 in blocking buffer) was added for another hour.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Histidine</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Surface Plasmon Resonance Analysis: Recombinant SARS-CoV-2 spike proteins (His-tagged) were purchased from Acro Biosystems Inc. (Newark, USA) or produced inhouse by overexpression of respective constructs in HEK293T cells followed by purification via nickel NTA chromatography and size exclusion chromatography.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero E6 cells were cultured in DMEM medium (Gibco, Gaithersburg, MD, USA or Thermofisher) containing 10% fetal bovine serum (FBS).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Calu-3 cells (HTB-55; American Type Culture Collection [ATCC], Manassas, VA, USA) were cultured in DMEM F12 Medium (ATCC) with 20% FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: ATCC Cat# HTB-55, RRID:CVCL_0609)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mutations in isolates used at the Karolinska are as follows (with Spike mutations indicated in bold): Preparation of recombinant human ACE2: Clinical grade recombinant human ACE2 (amino acids 18-740) was produced by the contract manufacturer Polymun Scientific (Klosterneuburg, Austria) from CHO cells according to GMP guidelines under serum free conditions and formulated as a physiologic aqueous solution, as described previously (Haschke et al</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CHO</div><div>suggested: CLS Cat# 603479/p746_CHO, RRID:CVCL_0213)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Using BiaEvaluation 4.1 software, kinetic analysis was carried out by applying a Langmuir 1:1 (apparent affinity) and a bivalent analyte binding algorithm, which separates first step binding (A + B = AB; affinity) from the second step binding (AB + B = AB2; avidity)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>AB</div><div>suggested: RRID:BDSC_203)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Using BiaEvaluation 4.1 software, kinetic analysis was carried out by applying a Langmuir 1:1 (apparent affinity) and a bivalent analyte binding algorithm, which separates first step binding (A + B = AB; affinity) from the second step binding (AB + B = AB2; avidity)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BiaEvaluation</div><div>suggested: (BIAevaluation Software, RRID:SCR_015936)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Half-maximal inhibitory concentration (IC50) and inhibitory concentration 90 (IC90) were calculated using GraphPad Prism Software (La Jolla, CA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Visualizations of RBDs and full-length Spike protein: Visualizations were rendered with pymol software (the PyMOL Molecular Graphics System, Version 2.4 Schrödinger, LLC), based on a model of the fully glycosylated Spike-ACE2 complex described in Capraz et al., (submitted for publication) and https://covid.molssi.org//models/#spike-protein-in-complex-with-human-ace2-ace2-spike-binding. Primers and Antibodies: The following tables lists the primers and Antibodies used in this study:</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PyMOL</div><div>suggested: (PyMOL, RRID:SCR_000305)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Limitations of this study: Our study used two different cell types and should be expanded using additional human cell types and also organoids. Moreover, to indeed make a claim on universality, additional variants should (and can) be tested using affinity/avidity measurements and neutralization assays.

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04335136</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Completed</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) a…</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.09.459634: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: The number of animals for each experiment and all procedures followed the protocols approved by the Institutional Committee for Care and Use of Experimental Animals.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Six week- or four month-old male and female BALB/c mice were used for initial experiments, 6-month-old female and male Golden Syrian hamsters were used in the immunization studies, and 1-month-old female and male SPF Golden Syrian hamsters were used in the challenge experiments.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Experimental animals: For immunization and challenge, the group sizes were chosen based on previous experience and littermates of the same sex were randomly assigned.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Enzyme-linked immunosorbent assay (ELISA) tests: The levels of IgG and IgA antibodies against spike protein were determined by ELISA by sensitizing the plate with homogenates of killed whole virus produced in vitro.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgA antibodies against spike protein</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The following secondary antibodies were used: Mouse anti-Hamster IgG Cocktail, Clone: G94-56, G70-204 (BD Biosciences, Cat. # 554009); Mouse anti-Hamster IgM, Clone: G188-9, (BD Biosciences Cat. # 554035); Hamster Immunoglobulin A (IgA) ELISA Kit (MyBiosources Cat. # MBS029668); Mouse monoclonal (H6) anti-SARS-CoV-2 spike glycoprotein (Abcam Cat. # ab273169).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Hamster IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-Hamster IgM</div><div>suggested: (BD Biosciences Cat# 554035, RRID:AB_395220)</div></div><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 spike glycoprotein</div><div>suggested: (Abcam Cat# ab275759, RRID:AB_2892127)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viruses: SARS-CoV-2 isolates were propagated in Vero E6 cells in Opti-MEM I (Invitrogen, Cat. # 51985091) containing 0.3% bovine serum albumin (BSA) and 1 μg of L-1-tosylamide-2-phenylethyl chloromethyl ketone-treated trypsin per mL at 37 °C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">VLP generation, production, purification, and validation: VLPs were produced by transient transfection of either HEK293 cells or HEK293-1267 cells, with pGag, pS and its variants, and pM plasmid DNA, using PEI as transfection reagent.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HEK293-1267</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Six week- or four month-old male and female BALB/c mice were used for initial experiments, 6-month-old female and male Golden Syrian hamsters were used in the immunization studies, and 1-month-old female and male SPF Golden Syrian hamsters were used in the challenge experiments.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">VLP generation, production, purification, and validation: VLPs were produced by transient transfection of either HEK293 cells or HEK293-1267 cells, with pGag, pS and its variants, and pM plasmid DNA, using PEI as transfection reagent.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pM</div><div>suggested: RRID:Addgene_64179)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analyses: Prism (GraphPad Software) was used to perform one-way or two-way ANOVA on datasets with Tukey’s multiple comparisons test or the Bonferroni post-test, respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.09.459664: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Mice were housed under specific pathogen-free conditions at Boston Children’s Hospital, and all procedures were approved under the Institutional Animal Care and Use Committee (IACUC) and operated under the supervision of the Department of Animal Resources at Children’s Hospital (ARCH) (Protocol number 19-02-3897R).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Animals: Female, 3 month old BALB/c and C57BL/6J mice were purchased from Jackson Laboratory (Bar Harbor, ME), and CD-1 mice were purchased from Charles River Laboratories (Wilmington, MA).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The sample/virus mixture was then incubated at 37°C (5.0% CO2) for 1 hour before transferring 100 μl to 96-well titer plates with 5e3 VeroE6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">luciferase reporter plasmid pLenti-CMV Puro-Luc (Addgene), and spike protein expressing pcDNA3.1-SARS CoV-2 SΔCT of variants were co-transfected into HEK293T cells by lipofectamine 2000 (ThermoFisher).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To determine the neutralization activity of the plasma or serum samples from participants, HEK293T-hACE2 cells were seeded in 96-well tissue culture plates at a density of 1.75 × 104 cells/well overnight.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T-hACE2</div><div>suggested: RRID:CVCL_A7UK)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Animals: Female, 3 month old BALB/c and C57BL/6J mice were purchased from Jackson Laboratory (Bar Harbor, ME), and CD-1 mice were purchased from Charles River Laboratories (Wilmington, MA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>C57BL/6J</div><div>suggested: RRID:IMSR_JAX:000664)</div></div><div style="margin-bottom:8px"><div>CD-1</div><div>suggested: RRID:MGI:2686808)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, the packaging plasmid psPAX2 (AIDS Resource and Reagent Program)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>psPAX2</div><div>suggested: RRID:Addgene_12260)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">luciferase reporter plasmid pLenti-CMV Puro-Luc (Addgene), and spike protein expressing pcDNA3.1-SARS CoV-2 SΔCT of variants were co-transfected into HEK293T cells by lipofectamine 2000 (ThermoFisher).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pLenti-CMV Puro-Luc</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pcDNA3.1-SARS</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Each sample was measured in triplicate, and the intensity of the size distribution was plotted in GraphPad Prism 9 (GraphPad Software)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, the packaging plasmid psPAX2 (AIDS Resource and Reagent Program)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>AIDS Resource and Reagent Program</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 lung titers were quantified by homogenizing harvested lungs in PBS (Quality Biological Inc.) using 1.0 mm glass beads (Sigma Aldrich) and a Beadruptor (Omni International Inc.).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Quality Biological</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Statistical analyses were performed using Prism v9.0.2 (GraphPad Software).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04750343</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Active, not recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle V…</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04742738</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Active, not recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle V…</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.09.459577: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Size selected RNA was used to prepare libraries following previously described methodology (Barucci et al, 2020), which included the ligation of 3’end and 5’end adaptors each having four randomized nucleotides to minimize ligation biases.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were incubated with antibodies recognizing the spike protein of SARS-CoV-2 (anti-S2 H2 162, a kind gift from Dr. Hugo Mouquet, Institut Pasteur, Paris, France) for 30 minutes at 4°C, and then with secondary antibodies (anti-human-Alexa Fluor-647) for 30 minutes at 4°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-S2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-human-Alexa</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">From the total lysate (~0.5 mg/ml), 10 % lysate was saved as input and IP was performed using an anti-pan-AGO antibody (clone 2A8, MABE56 Sigma-Aldrich) and an anti-FLAG M2 antibody (F3165, Sigma-Aldrich) was used for control IPs.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-pan-AGO</div><div>suggested: (Z. Mourelatos Lab - University of Pennsylvania Cat# pan-AGO (7G1-1, RRID:AB_2827163)</div></div><div style="margin-bottom:8px"><div>anti-FLAG</div><div>suggested: (Sigma-Aldrich Cat# F3165, RRID:AB_259529)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A549-ACE2, Caco-2 and Vero E6 cells were cultured in high-glucose DMEM media (Gibco) supplemented with 10% Fetal Bovine Serum (FBS; Sigma) and 1% penicillin-streptomycin (P/S; Gibco).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then lysed using TRIzol LS reagent (Thermo Fischer Scientific) and RNA was extracted following the manufacturer’s instructions or lysed in RIPA buffer (Thermo Fischer Scientific) for western blot analysis. siRNA-mediated knockdown: A549-ACE2 cells were transfected using Lipofectamine RNAiMax (Life Technologies) with 10 nM of control (#4390843, Ambion) or DICER1 siRNAs (#4390824, Ambion), following the manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549-ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Immunoprecipitation: A549-ACE2 and Caco-2 cells, infected and not, were lysed in FA buffer as described above.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Caco-2</div><div>suggested: CLS Cat# 300137/p1665_CaCo-2, RRID:CVCL_0025)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were acquired on an Attune NxT Flow Cytometer (Thermo Fisher) and data analyzed with FlowJo software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Reads were aligned on the Homo sapiens genome (Build version GRCh38, NCBI) using Hisat2 (Kim et al, 2015)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Hisat2</div><div>suggested: (HISAT2, RRID:SCR_015530)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After alignment, reads mapping to annotated protein-coding genes were counted using featureCounts (version 2.0.1).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>featureCounts</div><div>suggested: (featureCounts, RRID:SCR_012919)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Counted reads for protein-coding genes were used for differential expression analysis using the R/Bioconductor package DESeq2 (Love et al, 2014) (version 1.26.0).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>R/Bioconductor</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>DESeq2</div><div>suggested: (DESeq, RRID:SCR_000154)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The selected 18-26-nucleotide reads were aligned on the SARS-CoV-2 genome (assembly Jan.2020/NC_045512v2, UCSC) or on the Homo sapiens genome (Build version GRCh38, NCBI) using Bowtie2 (Langmead & Salzberg, 2012; Li et al, 2009) v.2.4.2 with the following parameters: -L 6 -i S,1,0.8 -N 0</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bowtie2</div><div>suggested: (Bowtie 2, RRID:SCR_016368)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">First, a bed file with the coordinates of all the putative 22-nucleotide RNAs encoded by the SARS-CoV-2 genome was created and used to extract their sequences using bedtools.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>bedtools</div><div>suggested: (BEDTools, RRID:SCR_006646)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To compute the size distribution around a specific region, reads mapping to a specific region of the genome were extracted using samtools and size distribution was computed using bioawk.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>samtools</div><div>suggested: (SAMTOOLS, RRID:SCR_002105)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">2 complementary sites on human 3’UTR: The sequences of the 3’UTR of human genes have been retrieved using the Ensembl BioMart (database Ensembl Genes 101 – Human genes (GRCh38.p13)).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Ensembl BioMart</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      One limitation of this study is that we could not evaluate whether the presence and abundance of the CoV2-miR-7a.2 correlates with disease progression or with impaired ISGs activation in patients with severe COVID-19 disease outcome. Thus, future studies will address the relevance of the CoV2-miR-7a in the progression of the COVID-19 disease. Furthermore, the recent evolution of the CoV2-miR-7a sequence in the SARS-CoV-2 genome may facilitate the development of specific therapeutic approaches to potentially target and dampen the virulence of SARS-CoV-2 infection in COVID-19 patients.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.01.21262969: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Other reagents included LPS, TLR3 agonist (Poly(I:C); LMW) and TLR7 agonist (R848 and Imiquimod) (Invivogen); TLR7 antagonist (IRS661, 5’-TGCTT GCAAGCTTGCAAGCA-3’ synthesized on a phosphorothionate backbone; MWG Biotech); mouse ant αL integrin (clone 38; Antibodies Online); mouse anti-ICAM-1 (Clone LB-2 ; BD Bioscience): Arp2/3 complex inhibitor I (CK-666 ; Merck Millipore) ; Fc Blocking solution (MACS Miltenyi Biotec); Golgi-Plug, cytoperm/cytofix and permeabilization-wash solutions (BD Bioscience); IFNα and IFNλ1/2/3 ELISA kit (PBL Interferon Source); IL6 and TNFα ELISA kit (Affymetrix, eBioscience); 96-well format transwell chambers (Corning); IL6 and IFNλ by U-PLEX Custom Human Cytokine assay (Meso Scale Diagnostics, Rockville, MD) ; 96-Well Optical-Bottom Plates (Thermo Fisher Scientific); cell-labeling solution using CellTraceTM Violet Cell Proliferation Kit (Life Technologies ref # C34557, C34571), Live/Dead Fixable Dead Cell Stain Near-IR (Life Technologies ref #10119); Fixable Viability Dye eFluor 450 (Life Technologies); Zombie Aqua and Zombie Green Fixable Viability Kits (Biolegend); FITC Annexin V Apoptosis Detection Kit with 7-AAD (Biolegend); cDNA synthesis and qPCR kit (Life Technologies) ; poly-L-lysin (P6282, Sigma-Aldrich).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>TLR7 agonist (R848</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-ICAM-1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>TNFα</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>poly-L-lysin (P6282</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After surface staining and fixation with cytoperm/cytofix solution (BD Bioscience) for 20 minutes at 4°C, IFNα, IL6, IFNλ 1, and TNFα were stained by a 45-minute incubation at 4°C with antibodies diluted in permeabilization buffer (BD Bioscience ; antibodies are listed in the Key resource table).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IL6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">When indicated, the cocultures were treated with an anti-αL integrin blocking antibody at 10mg/mL.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-αL integrin blocking</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell Lines and Primary Cell Cultures: SARS-CoV-2-infected cells included the human alveolar basal epithelial cell lines, Calu-3 cells (ATCC HTB-55), A549 cells (ATCC CCL-185) and NCI-H358 cells (ATCC CRL-5807), Huh7.5.1 cells (Dreux et al., 2012) and HEK-293 cells (ATCC CRL-1573).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HEK-293</div><div>suggested: ATCC Cat# CRL-1573, RRID:CVCL_0045)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The A549 cells, NCI-H358 cells and HEK-293 cells were transduced to stably express the human angiotensin converting enzyme 2 (ACE2; accession number: NM_021804) using a lentiviral vector, as previously described (Dreux et al., 2012; Rebendenne et al., 2021).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NCI-H358</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The cells were infected at MOI 0.01, 0.1, 0.02 and 0.5 for, respectively, NCI- H358-ACE2, Huh7.5.1, A549-ACE2 and Calu-3 cells for 48 hours maximum prior to collection of the cells and their SNs for coculture.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Huh7.5.1</div><div>suggested: RRID:CVCL_E049)</div></div><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 10-fold serial dilutions of icSARS-CoV-2-mNG-containing supernatants were added to 2x10e4 Vero cells seeded in 96-well plates and fixed 24 hours post-infection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Live imaging of coculture with spinning-disc confocal microscopy analysis: A549-ACE2 cells were infected with icSARS-CoV-2-mNG for 48 hours prior to coculture with pDCs.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549-ACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PBMCs were freshly isolated by Ficoll-Hypaque density centrifugation followed by washing in pDC/PMBC culture medium (i.e., RPMI 1640 Medium supplemented with 10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine, non-essential amino acids, 1 mM sodium pyruvate and 10 mM Hepes).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pDC/PMBC</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Other reagents included LPS, TLR3 agonist (Poly(I:C); LMW) and TLR7 agonist (R848 and Imiquimod) (Invivogen); TLR7 antagonist (IRS661, 5’-TGCTT GCAAGCTTGCAAGCA-3’ synthesized on a phosphorothionate backbone; MWG Biotech); mouse ant αL integrin (clone 38; Antibodies Online); mouse anti-ICAM-1 (Clone LB-2 ; BD Bioscience): Arp2/3 complex inhibitor I (CK-666 ; Merck Millipore) ; Fc Blocking solution (MACS Miltenyi Biotec); Golgi-Plug, cytoperm/cytofix and permeabilization-wash solutions (BD Bioscience); IFNα and IFNλ1/2/3 ELISA kit (PBL Interferon Source); IL6 and TNFα ELISA kit (Affymetrix, eBioscience); 96-well format transwell chambers (Corning); IL6 and IFNλ by U-PLEX Custom Human Cytokine assay (Meso Scale Diagnostics, Rockville, MD) ; 96-Well Optical-Bottom Plates (Thermo Fisher Scientific); cell-labeling solution using CellTraceTM Violet Cell Proliferation Kit (Life Technologies ref # C34557, C34571), Live/Dead Fixable Dead Cell Stain Near-IR (Life Technologies ref #10119); Fixable Viability Dye eFluor 450 (Life Technologies); Zombie Aqua and Zombie Green Fixable Viability Kits (Biolegend); FITC Annexin V Apoptosis Detection Kit with 7-AAD (Biolegend); cDNA synthesis and qPCR kit (Life Technologies) ; poly-L-lysin (P6282, Sigma-Aldrich).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BD Bioscience)</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Thermo Fisher Scientific)</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were processed with nSolver software (NanoString Technologies, Seattle, WA), which included assessment of the quality of the runs, and combined, normalized, and analyzed in nSolver and Excel.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Excel</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow cytometric analysis was performed using a BD LSR Fortessa 4L and the data were analyzed using Flow Jo software (Tree Star).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Flow Jo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The quantification of mNeonGreen fluorescence intensity of infected cells and the duration of contacts between pDCs and infected cells were performed using Image J software package (http://rsb.info.nih.gov/ij).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Image J</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The set of Figures was prepared using PRISM software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PRISM</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 60. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.08.459430: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Ethics and biosafety statement: All animal experiments were approved by the Institutional Animal Care and Use Committee of Rocky Mountain Laboratories, NIH and carried out by certified staff in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International accredited facility, according to the institution’s guidelines for animal use, following the guidelines and basic principles in the NIH Guide for the Care and Use of Laboratory Animals, the Animal Welfare Act, United States Department of Agriculture and the United States Public Health Service Policy on Humane Care and Use of Laboratory Animals.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Sample processing for organic and lipid mediator extraction: Sample order was randomized throughout each extraction.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">After de-waxing, antigen retrieval was performed using AR6 buffer (Akoya Biosciences) in a standard microwave with 45 seconds at 100% power and 15 minutes at 10% power.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A mixture of anti-Mouse + anti-Rabbit HRP-conjugated secondary antibodies (Akoya Biosciences) was added for 10 minutes, then washed in TBST.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Mouse + anti-Rabbit HRP-conjugated secondary antibodies</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-Rabbit</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">T-cell phenotyping of PBMC and lung cell samples: The T-cell surface staining cocktail contained the following antibodies: CD3 BV650, CD4 BUV395, CD8 PerCP-Cy5.5, CD28 BUV661, CD38 FITC, CD69 AF700, CD25 BUV496, CD154 BV605, HLA-DR APC-Cy7, CD45RA BUV563, CCR7 BV510, CD95 BUV737, CD49d PE-Cy7, CTLA4 BV785</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD4</div><div>suggested: (RayBiotech Cat# CS-11-0132, RRID:AB_1228050)</div></div><div style="margin-bottom:8px"><div>CD28</div><div>suggested: (BD Biosciences Cat# 749971, RRID:AB_2874198)</div></div><div style="margin-bottom:8px"><div>CD69</div><div>suggested: (BD Biosciences Cat# 558063, RRID:AB_2275535)</div></div><div style="margin-bottom:8px"><div>CD25</div><div>suggested: (BD Biosciences Cat# 741144, RRID:AB_2870722)</div></div><div style="margin-bottom:8px"><div>CD154</div><div>suggested: (BD Biosciences Cat# 748984, RRID:AB_2873384)</div></div><div style="margin-bottom:8px"><div>CD45RA</div><div>suggested: (BioLegend Cat# 304139, RRID:AB_2561369)</div></div><div style="margin-bottom:8px"><div>CD95</div><div>suggested: (BioLegend Cat# 305646, RRID:AB_2629742)</div></div><div style="margin-bottom:8px"><div>CTLA4</div><div>suggested: (BioLegend Cat# 369624, RRID:AB_2810582)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">B-cell phenotyping of PBMC samples: B-cell surface staining was carried out using the following antibodies: CD3 BV650, CD27 BUV805, CD38 FITC, CXCR3 BV421, CD19 PE, CD20 BV510, CD21 BV786</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD27</div><div>suggested: (BD Biosciences Cat# 748704, RRID:AB_2873108)</div></div><div style="margin-bottom:8px"><div>CXCR3</div><div>suggested: (BD Biosciences Cat# 741005, RRID:AB_2740628)</div></div><div style="margin-bottom:8px"><div>CD20</div><div>suggested: (BD Biosciences Cat# 743611, RRID:AB_2741622)</div></div><div style="margin-bottom:8px"><div>CD21</div><div>suggested: (BD Biosciences Cat# 742764, RRID:AB_2741029)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The above cocktails also contained CD28 BUV661 and CD49d antibodies (each at 1 μg/mL), as well as 0.67 μg/mL of GolgiStop and 1 μg/mL of GolgiPlug (BD).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD49d</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Surface markers were stained for with a cocktail of the following antibodies: CD3 BV650, CD4 BUV395, CD8 PerCP-Cy5.5, CD95 BUV 737, CD45RA BUV563, CCR7 BV510, CD14 PE-Dazzle594, and CD16 PE-CF594.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD3</div><div>suggested: (RayBiotech Cat# CS-11-0110, RRID:AB_1228004)</div></div><div style="margin-bottom:8px"><div>CCR7</div><div>suggested: (BD Biosciences Cat# 563449, RRID:AB_2738212)</div></div><div style="margin-bottom:8px"><div>CD14</div><div>suggested: (BioLegend Cat# 348805, RRID:AB_2889063)</div></div><div style="margin-bottom:8px"><div>PE-Dazzle594</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD16</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">VeroE6 cells were maintained in DMEM supplemented with 10% fetal calf serum, 1 mM L-glutamine, 50 U/mL penicillin and 50 μg/mL streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Quantification of images such as selection of Ki67+ nuclei, segmentation of DAPI signal, identification of cell types, and quantification of BALT structures was performed in Imaris V9.5.0.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Imaris</div><div>suggested: (Imaris, RRID:SCR_007370)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The 10X Genomics version 3.1 chemistry was used to generate barcoded cDNA and to generate final libraries according to the manufacturer’s protocol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Genomics</div><div>suggested: (UTHSCSA Genomics Core, RRID:SCR_012239)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">FACSDivaTM version 8.0.1 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FACSDivaTM</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Subsequently, t-SNE analysis60 was performed in the FlowJo (Treestar, version 10.7) environment on compensated parameters (nearest neighbor = 15, minimum distance = 0.5, iterations = 1000), FlowSOM (version 2.9)24 analysis was conducted using compensated parameters and fixed generation of 15 meta clusters (set speed = 3)60.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div><div style="margin-bottom:8px"><div>FlowSOM</div><div>suggested: (FlowSOM, RRID:SCR_016899)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistics and data analysis: Most statistical analyses were performed in GraphPad V9.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">RNA sequencing data have been deposited in NCBI’s Gene Expression Omnibus (GEO) and are accessible through GEO Series accession number GSE183579.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gene Expression Omnibus</div><div>suggested: (Gene Expression Omnibus (GEO, RRID:SCR_005012)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Despite these limitations, the utilization of a large set of high-parameter techniques in one study to generate a time-resolved, multi-site profile of virus-induced innate and adaptive immune responses, has resulted in a comprehensive characterization of SARS-CoV-2 infection in the rhesus macaque model. Importantly, our findings highlight essential differences and similarities in the immune response to SARS-CoV-2 infection between rhesus macaques and humans that may be affected by age. As such, our study provides new insights into the age-related immune dynamics of SARS-CoV-2 infection and represents a substantial advance in available models of age-associated changes in immunity.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.08.459398: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Buffy coats from study participants were collected according to a study protocol approved by the Institutional Review Board of the University of Cologne (study protocol 16-054).<br>Consent: All study participants provided informed consent.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">The study cohort comprised 150 individuals with 50.7% female and 49.3% male adults.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">For reverse transcription, sorted cells were incubated with 7 μl of a random-hexamer-primer master mix (RHP mix) consisting of 0.75 μl Random Hexamer Primer (Thermo Fisher Scientific), 0.5 μl NP-40 (Thermo Fisher Scientific), 0.15 μl RNaseOut (Thermo Fisher Scientific), and 5.6 μl of nuclease-free H2O at 65 °C for 1 min.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">1st PCR product was amplified using Q5 Hot Start High Fidelity DNA Polymerase (New England Biolabs) and specific forward and reverse primers including adaptor sequences which are homologous to the restriction sites of the antibody expression vector (IgG1, IgL, IgK (Tiller et al., 2008)).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgG1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgL, IgK</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The final concentration of purified antibodies was determined by UV/Vis spectroscopy using a Nanodrop (A280).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A280</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-SARS-CoV-2 S1/S2 IgG and IgM antibody titers of plasma samples were also assessed using the automated DiaSorin’s LIAISON® SARS-CoV-2 S1/S2 protein ELISA kit according to the manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-SARS-CoV-2 S1/S2 IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgM</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-SARS-CoV-2 S1 IgA antibody titers of plasma samples were also measured using the Euroimmun anti-SARS-CoV-2 ELISA on the automated system Euroimmun Analyzer I and S/CO values interpreted with following cut-off values: negative S/CO < 0.8, equivocal S/CO ≥ 0.8 - < 1.1, positive S/CO ≥ 1.1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-SARS-CoV-2 S1 IgA</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Figure S4: Binding of monoclonal antibodies isolated from pre-pandemic blood samples, related to Figure 4 (A) Binding of monoclonal antibodies to SARS-CoV-2, HKU-1 and OC43 S proteins determined by serial dilution ELISA.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HKU-1</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293-6E cells were maintained in FreeStyle 293 Expression Medium (Life Technologies) supplemented with 0.2 % penicillin/streptomycin under constant shaking at 90 – 120 rpm, 37 °C and 6 % CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293-6E</div><div>suggested: RRID:CVCL_HF20)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">VeroE6 and HEK293T-ACE2 cells were maintained in Dulbecco’s Modified Eagle Medium (Gibco) supplemented with 10 % fetal bovine serum (FBS, Sigma-Aldrich), 1 x penicillin-streptomycin (Gibco), 1 mM sodium pyruvate (Gibco) and 2 mM L-glutamine (Gibco) at 37 °C and 5 % CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T-ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The sex of HEK293T, HEK293-6E and VeroE6 cell lines is female.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, expression constructs were transfected into the HEK293 EBNA cells using FuGENE HD transfection reagent (Promega).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: CLS Cat# 300192/p777_HEK293, RRID:CVCL_0045)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell-surface-expressed S protein immunoassay: HEK293T cells were transfected with plasmids encoding the full-length SARS-CoV-2 S protein (GenBank ID.:</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For testing neutralization at a single dilution, polyclonal IgG samples at a concentration of 1000 μg/ml, plasma samples at a dilution of 1:10, or mAbs at a concentration of 50 μg/ml, were co-incubated with pseudovirus supernatants for 1 h at 37°C, following which 293T-ACE-2 cells were added.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-ACE-2</div><div>suggested: RRID:CVCL_YZ65)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Evaluations were performed using FlowJo10 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo10</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">IC50 values were calculated as the antibody concentration causing a 50 % reduction in signal compared the virus-only controls using a dose-response curve in GraphPad Prism.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical tests and analyses were done with GraphPad Prism (v7 and v8), Python (v3.6.8), R (v4.0.0) and Mircosoft Excel for Mac (v14.7.3 and 16.4.8).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Python</div><div>suggested: (IPython, RRID:SCR_001658)</div></div><div style="margin-bottom:8px"><div>Mircosoft Excel</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A two-tailed unpaired t test (Prism, GraphPad) was performed to test for the frequency differences of SARS-CoV-2-reactive IgG+ and IgG- B cells between pre-pandemic and convalescent blood samples (Figure 3A).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.08.459408: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Ethics statement: PBMCs from healthy individuals as a source of effector cells in our ADCC assay were obtained under CRCHUM institutional review board (protocol #19.381).<br>Consent: All participants were adults and provided informed written consent prior to enrollment in accordance with Institutional Review Board approval.<br>IACUC: Mouse Experiments: All experiments were approved by the Institutional Animal Care and Use Committees (IACUC) of and Institutional Biosafety Committee of Yale University (IBSCYU).<br>Euthanasia Agents: All mice were anesthetized via isoflurane inhalation (3 - 5 % isoflurane, oxygen flow rate of 1.5 L/min) prior and during BLI using the XGI-8 Gas Anesthesia System.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Antibodies: The human antibodies (CV3-1, CV3-25 and CV3-13) used in the work were isolated from blood of male convalescent donor CV3 recovered 41 days after symptoms onset using fluorescent recombinant stabilized Spike ectodomains (S2P) as probes to identify antigen-specific B cells as previously described (Lu et al., 2020; Seydoux et al., 2020).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">At 48 hours post transfection, 293T cells were stained with CR3022, CV3-1, CV3- 13 WT, CV3-13 LALA, CV3-13 GASDALIE and CV3-25 antibodies (5μg/mL) for 45 minutes at 37°C before being washed 2 times in PBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CV3-25</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A mouse anti-SARS-CoV-2 nucleocapsid protein monoclonal antibody (Clone 1C7, Bioss Antibodies) solution was prepared at 1 μg/mL in PBS + 1% non-fat milk and added to all wells for one hour at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 nucleocapsid protein</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following extensive washing (3×) with PBS, an anti-mouse IgG HRP secondary antibody solution was formulated in PBS + 1% non-fat milk.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 48 hours, infected Vero E6 cells were detached with PBS-EDTA and were incubated with 5 μg/mL of indicated antibodies for 30 minutes at 37℃, followed by staining with anti-human –AF647 secondary antibody and 1:1000 dilution of viability dye AquaVivid (Thermo Fisher Scientific) for 20 minutes at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human –AF647</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Stained target cells were incubated with 100 µL of the titrated concentrations of CV3-1, CV3-13 WT, CV3-13 LALA and CV3-13 GASDALIE antibodies (0,625 µg/mL, 1,25 µg/mL, 2,5 µg/mL, 5 µg/mL and 10 µg/mL) for 1h at 37°C, followed by two washes with media.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CV3-13 GASDALIE</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody-mediated phagocytosis was determined by flow cytometry, gating on THP-1 cells that were triple- positive for eFluor450 and eFluor670 cellular dyes and GFP.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GFP</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">EXPERIMENTAL MODEL AND SUBJECT DETAILS: Cell and Viruses: Vero E6 (CRL-1586, American Type Culture Collection (ATCC) or Vero E6-TMPRSS2 (Craig B. Wilen, Yale University), were cultured at 37°C in RPMI supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES pH 7.3, 1 mM sodium pyruvate, 1× non- essential amino acids, and 100 U/ml of penicillin–streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CEM.NKr, CEM.NKr-Spike, THP-1 and peripheral blood mononuclear cells (PBMCs) were maintained at 37°C under 5% CO2 in RPMI media, supplemented with 10% FBS and 100 U/mL penicillin/streptomycin. 293T (or HEK293T) and 293T-ACE2 cells were maintained at 37°C under 5% CO2 in DMEM media, supplemented with 5% FBS and 100 U/mL penicillin/streptomycin. CEM.NKr (NIH AIDS Reagent Program) is a T lymphocytic cell line resistant to NK cell-mediated lysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">293T-ACE2 cells were cultured in medium supplemented with 2 mg/mL of puromycin (Millipore Sigma).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The expression plasmids encoding the heavy and light chains of CV3-1, CV3-25, CV3-13 WT, CV3-13 LALA and CV3-13 GASDALIE IgG were transfected into Freestyle 293F cells (Thermo Fisher Scientific) using ExpiFectamine 293 transfection reagent as per the manufacturer’s protocol (Thermo Fisher Scientific).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293F</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 293T cells were transfected by the calcium phosphate method with the pNL4.3 R-E- Luc plasmid (NIH AIDS Reagent Program) and a plasmid encoding for SARS- CoV-2 Spike at a ratio of 10:1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell-surface staining of SARS-CoV-2-infected cells: 8M Vero-E6 cells were plated in T-175 flask 24 hours before infection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">THP-1 cells were used as effector cells and were stained with another cellular dye (cell proliferation dye eFluor670).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>THP-1</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">METHOD DETAILS: SARS-CoV-2 infection and treatment conditions: For all in vivo experiments, the 6 to 8 weeks male and female hACE2-K18 mice were intranasally challenged with 1 x 105 PFU in 25-30 µl volume under anesthesia (0.5 - 5 % isoflurane delivered using precision Dräger vaporizer with oxygen flow rate of 1 L/min).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>hACE2-K18</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Light and heavy chains were cloned into the pTT expression plasmid (Durocher et al., 2002)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pTT</div><div>suggested: RRID:Addgene_44006)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow cytometry analysis of cell-surface Spike staining: 10 µg of the different expressors of the original SARS-CoV-2 Spike (Hoffmann et al., 2020) or the different mutants of the SARS-CoV-2 Spike (B.1.1.7, D614G, Δ69-70, Δ144, N501Y, A570D, P681H, T716I, S982A and D1118H) (Li et al., 2021b; Prevost et al., 2021; Tauzin et al., 2021) were co-transfected with 2.5 µg of a green fluorescent protein (GFP) expressor (pIRES2-eGFP) into 2 × 106 293T cells using the standard calcium phosphate method.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pIRES2-eGFP</div><div>suggested: RRID:Addgene_14998)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 293T cells were transfected by the calcium phosphate method with the pNL4.3 R-E- Luc plasmid (NIH AIDS Reagent Program) and a plasmid encoding for SARS- CoV-2 Spike at a ratio of 10:1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pNL4.3 R-E-</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Bioluminescence Imaging (BLI) of SARS-CoV-2 infection: All standard operating procedures and protocols for IVIS imaging of SARS-CoV-2 infected animals under ABSL-3 conditions were approved by IACUC, IBSCYU and YARC.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>YARC</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Image sequences were assembled and converted to videos using Image J.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Image J</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Samples were acquired on a LSRII cytometer (BD Biosciences) and data analysis was performed using FlowJo v10.5.3 (Tree Star).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cryo-EM data processing, model building and analysis: Motion correction, CTF estimation, particle picking, curation and extraction, 2D classification, ab initio model reconstruction, volume refinements and local resolution estimation were carried out in cryoSPARC (Punjani et al., 2017; Rubinstein and Brubaker, 2015).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>cryoSPARC</div><div>suggested: (cryoSPARC, RRID:SCR_016501)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Automated and manual model refinements were iteratively carried out in ccpEM (Burnley et al., 2017), Phenix (Liebschner et al., 2019) (real-space refinement) and Coot (Emsley and Cowtan, 2004).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Coot</div><div>suggested: (Coot, RRID:SCR_014222)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Geometry validation and structure quality evaluation were performed by EM-Ringer (Barad et al., 2015) and Molprobity (Chen et al., 2010).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Molprobity</div><div>suggested: (MolProbity, RRID:SCR_014226)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Model- to-map fitting cross correlation and figures generation were carried out in USCF Chimera, Chimera X (Pettersen et al., 2021) and PyMOL (The PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PyMOL</div><div>suggested: (PyMOL, RRID:SCR_000305)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Quantification and Statistical Analysis: Statistical significance was derived by applying parametric unpaired t-test or non- parametric Mann-Whitney U test (two-tailed) available in GraphPad Prism software (La Jolla, CA, USA) depending on the normality distribution of the data.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on pages 72, 73, 74, 76 and 77. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.07.459123: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">On Day 3, cells were incubated with 20ul of 6x concentrations in HBSS of either the small molecules/peptides or an anti ACE2 antibody (AG-20A-0037PF-C500, Adipogen) for three hours.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti ACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Top hits were analyzed using VMD 1.9.3 software [30]. 4.4. Plasmids & Cell lines: The Lenti X 293T cell line (632180) was purchased from Takara Bio.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>X 293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirus production: On Day 1, Lenti X 293T cells were seeded at a density of 60,000 cells/cm2 per T175 flask in 34ml DMEM supplemented with 10% FBS and 1mM Sodium Pyruvate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Lenti X 293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirus assay: On Day 1, 293T cells were seeded at 30,000 per well in white solid bottom 96 well plates that were either Poly L Lysine or Collagen coated in completed media (DMEM + 10% FBS + 1mM Sodium Pyruvate) at 37°C and 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">pLenti CMV Puro Luc (17477), pMDLg.pRRE (12251), pRSV.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pMDLg.pRRE</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">REV (12253), pMD2.G (12259) were purchased from Addgene.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pMD2 . G</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The Spike ORF was subcloned into pcDNA3.1(+) vector via Gibson Assembly (NEB).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.1 ( + )</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Δ Spike: 20μg pLenti Luc, 20μg pMDLg.pRRE, 9.5μg pRSV.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pRSV</div><div>suggested: RRID:Addgene_106453)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Firefly Luciferase, encoded by pLenti Luc was used as the assay reporter. VSV.G, encoded by pMD2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pMD2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For this purpose, DrugBank [</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>DrugBank</div><div>suggested: (DrugBank, RRID:SCR_002700)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">22] and PubChem [23] databases were used, merging both of them in a single database in SDF format.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PubChem</div><div>suggested: (PubChem, RRID:SCR_004284)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then, different conformations for each compound were found using LigPrep software [27].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>LigPrep</div><div>suggested: (Ligprep, RRID:SCR_016746)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">4.3 Molecular Docking: For the molecular docking, AutoDock Vina 1.1.2 software [25,26] was used.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>AutoDock</div><div>suggested: (AutoDock, RRID:SCR_012746)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data was analysed on GraphPad Prism software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.01.21262715: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Phenotypic whole blood immune analyses: Fresh whole blood (200μl per stain) was used to measure CD4+CXCR5+ICOS+PD1+ follicular T cells (Tfh) and CD3-CD19+CD27hiCD38hi antibody-secreting B cell (ASC; plasmablast) populations as described15, 49 as well as activated HLA-DR+CD38+CD8+ and HLA-DR+CD38+CD4+ T cells, intermediate CD14+CD16+ and classical CD14+ monocytes, activated CD3-CD56+ NK cells, MAIT cells, [δ-T cells, as per the specific antibody panels (Supplementary Table 6; gating strategy is presented in Supplementary Fig.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD3-CD19+CD27hiCD38hi antibody-secreting B</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>antibody-secreting</div><div>suggested: (Félix A. Rey; Pasteur Institute Cat# C10, RRID:AB_2725800)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 RBD ELISA: RBD-specific ELISA for detection of IgM, IgG and IgA antibodies was performed as previously described31, 50, 51, using flat bottom Nunc MaxiSorp 96-well plates (Thermo Fisher Scientific) for antigen coating (2µg/ml), blocking with PBS (with w/v 1% BSA) and serial dilutions in PBS (with v/v 0.05% Tween and w/v 0.5% BSA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgM , IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgA</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>antigen coating ( 2µg/ml)</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The sVNT blocking ELISA assay (manufactured by GenScript, NJ, USA) was carried out essentially as described51, which detects circulating neutralizing SARS-CoV-2 antibodies that block the interaction between RBD and ACE2 on the cell surface receptor of the host.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Colour intensity was inversely dependent on the titre of anti-SARS-CoV-2 neutralizing antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 neutralizing antibodies .</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 isolate CoV/Australia/VIC01/202053 was propagated in Vero cells and stored at -80°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cytokine analysis: Patients’ plasma and respiratory samples were measured for IL-1β, IFN-α2, IFN-γ, TNF, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23 and IL-33 using the LEGENDplex™ Human Inflammation Panel 1 kit, as per manufacturer’s instructions (BioLegend, San Diego, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MCP-1</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow cytometry data were analyzed using FlowJo v10 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Endpoint titres were determined by interpolation from a sigmodial curve fit (all R-squared values >0.95; GraphPad Prism 9) as the reciprocal dilution of plasma that produced >15% (for IgA and IgG) or >30% (for IgM) absorbance of the positive control at a 1:31.6 (IgG and IgM) or 1:10 dilution (IgA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PLSDA: Partial least squares discriminant analysis (PLSDA), performed in Eigenvectors PLS toolbox in Matlab, was used in conjunction with Elastic-Net, described above, to identify and visualize signatures that distinguish categorical outcomes (COVID-19 diagnosis, NIH scores, drug therapies).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Matlab</div><div>suggested: (MATLAB, RRID:SCR_001622)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In R, data were subject to arcsinh transformation and clustering using FlowSOM 27.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowSOM</div><div>suggested: (FlowSOM, RRID:SCR_016899)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      There are limitations to the current study. Firstly, ETA samples were only collected from patients with severe disease requiring invasive oxygen support, therefore, it is unclear whether COVID-19 patients with milder symptoms had less robust immune responses in the respiratory tract. Additionally, most patients in the severe/critical group received dexamethasone, which could be an intercorrelating factor for the differences observed between severity groups. Moreover, while the non-COVID-19 controls provided insights onto the immune status in hospitalized individuals, the comparisons will benefit more if there were larger numbers of non-COVID patients with more homogenous diseases. Overall, innate and adaptive immune responses are generated in respiratory and blood samples of COVID-19 patients. While immunological features detected in the peripheral blood can be associated with robust immune responses and predict clinical outcomes, monitoring immune responses in the respiratory samples can be of a benefit prior to initiation of therapeutic interventions for COVID-19 patients.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.06.459206: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: All experiments were conducted under protocols approved by the University of South Australia Animal Ethics Committee in accordance with the Australian code for the care and use of animals for scientific purposes, 8th edition (2013).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were harvested at 24 hrs, stained with live-dead marker (LIVE/DEAD fixable e660 stain, Thermo Fisher Scientific; 1/3000 dilution) and anti-SARS-CoV-2 RBD antibody (Cat # 40592-T62, Sino Biological; 1:100 dilution), followed by staining with PE-conjugated donkey anti-rabbit IgG (Cat # 406421, Biolegend), data was acquired using a FACSARIA Fusion™ (BD Biosciences), and analysis performed using FlowJo V10 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 RBD</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-rabbit IgG</div><div>suggested: (BioLegend Cat# 406421, RRID:AB_2563484)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were then washed and incubated with biotinylated anti-mouse IFN-γ antibody (clone R4-6A2; Mabtech; 1 μg/mL) followed by streptavidin-alkaline phosphatase (Mabtech; 1:1,000 dilution).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IFN-γ</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Memory T cell populations were identified by staining for surface markers with the following anti-mouse antibodies (BD Biosciences): CD3 APC-CY7 (clone 17A2, 1:400); CD4 BV510 (clone RM4-5, 1:400); CD8a PE (clone 53-6.7,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD4</div><div>suggested: (Miltenyi Biotec Cat# 130-109-536, RRID:AB_2657974)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Binding serum antibodies were detected using HRP-conjugated anti-mouse IgG (Cat #A9044, Sigma Aldrich, 1:10,000)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: (Sigma-Aldrich Cat# A9044, RRID:AB_258431)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were subsequently washed, incubated with biotinylated anti-IgG detection antibody (Mabtech, 1 μg/mL), followed by streptavidin-alkaline phosphatase (Mabtech, 1:1,000 dilution).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">MC57G cells (ATCC CRL-2295) for chromium release assays were maintained in Eagle’s Minimum Essential medium supplemented with 10% FBS, 2 mM L-glutamine, and penicillin-streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MC57G</div><div>suggested: ATCC Cat# CRL-2295, RRID:CVCL_4985)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Spike protein expression by flow cytometry: To confirm processing of the spike protein and surface translocation, 143B cells were infected with SCV-S or SCV control (empty) vector with an MOI of 1 or left uninfected.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>143B</div><div>suggested: ECACC Cat# 91112502, RRID:CVCL_2270)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ACE2-HEK293 cells were plated at a density of 10,000 cells/well in a clear bottomed white opaque 96-well plate and incubated at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2-HEK293</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Animal experiments: Specific-pathogen-free inbred C57BL/6J and outbred Swiss mouse heritage Arc:Arc(S) mice were bred in house or purchased from the Animal Resources Centre (Canning Vale, WA, Australia).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6J</div><div>suggested: RRID:IMSR_JAX:000664)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following washing, the membrane was incubated with anti-rabbit IgG antibody conjugated to horseradish peroxidase (Cat # A9044, Sigma Aldrich; 1:10,000 dilution) for 1 hr at RT and proteins visualized using Clarity ECL western blotting substrate (BioRad) and imaged using ChemiDoc XRS (BioRad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Sigma Aldrich</div><div>suggested: (Sigma-Aldrich, RRID:SCR_008988)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were harvested at 24 hrs, stained with live-dead marker (LIVE/DEAD fixable e660 stain, Thermo Fisher Scientific; 1/3000 dilution) and anti-SARS-CoV-2 RBD antibody (Cat # 40592-T62, Sino Biological; 1:100 dilution), followed by staining with PE-conjugated donkey anti-rabbit IgG (Cat # 406421, Biolegend), data was acquired using a FACSARIA Fusion™ (BD Biosciences), and analysis performed using FlowJo V10 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Thermo Fisher Scientific</div><div>suggested: (Thermo Fisher Scientific, RRID:SCR_008452)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were washed, resuspended in 150 µL FACS buffer, and results acquired on FACSARIA Fusion™ with analysis by FlowJo V10 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Memory T cell populations were identified by staining for surface markers with the following anti-mouse antibodies (BD Biosciences): CD3 APC-CY7 (clone 17A2, 1:400); CD4 BV510 (clone RM4-5, 1:400); CD8a PE (clone 53-6.7,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BD Biosciences)</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">IC80 titers were determined using a log (inhibitor) vs. normalized-response (variable slope) nonlinear regression model in Prism v9 (GraphPad)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistics: GraphPad Prism version 9.0 (GraphPad software) was used for data analysis and statistics.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Statistics: GraphPad Prism</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.02.21262995: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The initial value of ⟨ X ⟩ is set to N − ⟨ L ⟩ − ⟨ Y ⟩ − ⟨ H ⟩ − ⟨ D ⟩.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>N − ⟨ L ⟩ − ⟨ Y ⟩ − ⟨ H ⟩ −</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">An archive of the code used to obtain the data and generate all results is available on Zenodo at https://doi.org/10.5281/zenodo.5112578.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Zenodo</div><div>suggested: (ZENODO, RRID:SCR_004129)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Another limitation of the GISST model, as we have presented it here, may be that it is missing important covariates in the regression model for the transmission rate (Eq 4). For example, we have not tried using other mobility metrics provided in the Google Community mobility reports. On the one hand, predicting future values of such covariates could be just as challenging as predicting future values of COVID-19 indicators without them. One might address this problem to some extent by applying a penalty proportional to the absolute value of the regression coefficient of these covariates, which would shrink the effect of unimportant covariates to zero. This approach would be readily achievable with the optimizer we used by choosing the Orthant-Wise Limited-memory Quasi-Newton (OWL-QN) algorithm instead of the LBFGS algorithm. The use of this option is what we alluded to in the introduction as the ability of GISST to search for important variables from a large space of candidate variables. Variables identified in this manner may sufficiently lead the indicators we wish to forecast that they improve forecasts just by being available up to or close to the date of forecast. Knowing which variables are important for predicting the transmission rate, even if they are difficult to forecast, could also be valuable for the design of forecasts.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. One aspect of the charge_of c~ltur " ,, that is the texts that traditionally the idea that cultural st_ud1es ~eJ~Ct~ canon;d on the' previous brief forays into have structured _any given d1sc1phne. ~:s of the olitical, I wager that such an culture as an obJect of study and the ro I ct· ~ interest in cultural artifacts . . . eaction to cultura stu ies al accusation anses m r . l t xts and in reaction to cultur more broa~ly ~efined than ~tandard canl:~;~a di:interested analysis; aesthetics studies' re1ect1on of the notion of com~ y 1· . l vacuum Although I con-b re but not m an apo itica

      Culture does not exist and cannot exist within a vacuum, so it would logically follow that the study of culture by extension cannot be studied apolitcally. To study Germany's culture (or any culture for that matter) one will inevitably discuss subject material that is political, as everything is political by nature of it existing. The only factor or question is how poltical is the subject matter? Or in other words, how heated is the debate?

    1. 𝑏𝑙′𝑙logℙ𝜃(𝐴)⇒𝑏∗𝑙′𝑙=0+∂∂𝑏𝑙′𝑙[𝑚𝑙′𝑙log𝑏𝑙′𝑙+(𝑛𝑙′𝑙−𝑚𝑙′𝑙)log(1−𝑏𝑙′𝑙)]=𝑚𝑙′𝑙𝑏𝑙′𝑙−𝑛𝑙′𝑙−𝑚𝑙′𝑙1−𝑏𝑙′𝑙=0=𝑚𝑙′𝑙𝑛𝑙′𝑙

      too mathy

    1. I am accepting charitable donations,. ETH: 0x66e2871ef39334962fb75ce34407f825d67ec434 | BTC: 38B6vGaqNvMyTtoFEZPmNvMS7icV6ZnPMm | xDAI: 0x66e2871ef39334962fb75ce34407f825d67ec434 (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){ (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o), m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m) })(window,document,'script','https://www.google-analytics.com/analytics.js','ga'); <p>ga('create', 'UA-74743044-2', 'auto'); ga('send', 'pageview');</p> google_ad_client = "ca-pub-9608809622006883"; google_ad_slot = "4355365452"; google_ad_width = 728; google_ad_height = 90; "ceruelad." As a really brief aside prior to the introduction, the intersection of “Joseph’s dream” and the stories of Atlantis and the Lost City of Gold … among a great many other “municipal dreams” has long been (known or?) the primary motivation and drive behind spending so much time and effort on making this dream a reality. It also intersects a number of modern idioms, things like “all roads read to Rome” and “Rome wasn’t built in a day” – namely because I like to recall and recount how this vision of a city in the sky was truly re-written in a single day (which is why I haven’t re-done it again or elaborated more on the things that … I’m about to actually … do (just to link further to El Dorado)). It was written though … to describe a place that could literally be built in a single day–using various tricks like “copying from our reality” the base framework of the island, and then using “computer science magic” … here hidden in a place I call the Artificial Intelligence Samilicosm, little “tricks” that enable a single “interface class” to create a network of “island nodes” that would enable everyone Earth(s) to visit the attraction at exactly the same time, with concepts like K-nearest-nieghbor (k-NN) to create rooms that house millions or billions to appear to only have a small group of friends and family in them. That concept bleeds down into the boardroom concept, to help create a venue for a global-glactic conversation (GG-c?) on how the power of computer science can quickly show us how assimilation of this “demonstration” will quickly lead to a world without war and famine (and eventually absolution) by showing us how every war and argument fought over absolutely-falsely-scarce-resources have created dissension and conflict in a playce where the truth could build a much happier and healthier “venue” for interaction. Though there are two primary pieces that connect in different ways to what I call the “hardware and software of the road” something that links to the words “sword” and “Asgard” … among other perfect words like “hard drive.” One is “OMEALFHT” and the other is the “Rod(s) of Hey-Seuss the Anti-King.” Since this is still a sort of “decoder ring” for the hidden language, the link here to “hardware and software” and the letter “X” which connects the Xbox and “kisxmet” is that “cross-storm” (in T we’re Macy’s … “intimacys”) in a letter is also described by “gtk+” where you can see the “l” glyph of Brickell (off to see the Wizard) with half a X in “>lt” form. Since I probably haven’t put it on the main WS … Penrose sort of connects to the L’s of Hell where it’s now almost uncontastuble that the word Obelisk is pointing to a road aiming for the sky, as it is written, by the pen. While it’s probably no secret that those “ll”‘s aren’t the only version of paired L-words; it might be less known that I’m fairly certain “love and logic” are actually the best fit for why … combining them … keys the llave of Kurt Cobain’s “hey, way” … to open the gates of Hell and finally escape it. It’s in special places like the “light of the Son’s of Liberty” connecting both racism and sexism to name that ties together to show us that over time, our special history ended … specifically slavery … first by love–knowing it was the right thing to do, well before “logically” the jobs of picking cotton for instance would be replaced by gin. Though here we are again staring at “XIV’s” c (see arxiv.org as "kiss ar hive") … hive’s hiding the fact that technology has well before now replaced the need for the kind of slavery we fail to see prevalent here in this place, a darkness caused by … the same technology’s’ hidden use and keeping us from making very important connections between the illustrated teaching we call history and our present predicament. NO DREAM, THE SECOND COMING WILL END RACISM, A VOW Kiss me I’m fiVel; it’s the same kind of darkness that caused some bright kids I met in California to tell me point blank there was no “dick” hidden in John Hancock’s name or in Tricky Dick’s or … also in the Constitution and that sort of behavior is literally the cause of a slavery to lies and to watching Woodward and Burnstein’s lack of fire extinguish our freedom to think clearly, to vote with clear thoughts, and in poignant and direct relation … freedom of the press. We stand here refusing to see that our lack of action and seeming inability to discuss the “ridiculousness” of not seeing this information and my name on the news ins responsible for not seeing very clear evidence of mind control technology also on the news, and in our government’s legislation and that’s the cause of the slavery in the first place. “Theyanthem” was a happy and bright reVelatory “so … viandname” for me when I first landed on a sort or Elishan compound word describing the relationship between two anonymous “us’s” or “we’s” that played an early role in my introduction to the “red ties” of Gang-stalking and while Yusuf Islam’s key clue of nomenclature probably only told a few people that Pine Crest school and the University of Florida had yet another very clear tie to vithename Adam and how songs play an integral role in keying and linking and intersexling the m essage of the Revelation of Jesus Christ with American History kisxes … it was this new intersection that reaffirmed that link to the point where I see it needs to be made even more clear. I’ve noted before that it was very clear to me that the “oceans white with styrofoam” and the “good crowned with brotherhood” were very clear references to racism–and it takes not a logician to see that the simple Christian tenets that surround the foundation of America would tell you they were also a “thinly veited” admonishment of the same; it’s through “logic” and advanced technology that we can be sure that the Second Coming and it’s connection to pervasive “eyes to see” and “computer assisted intelligence” will almost immediately destroy the absolute stupidity of racism, jingoism, and the like. Pine Crest’s school song–which is literally the only other “anthem” that I know of, though I’m sure m-any nations’ will be added to the group of songs that are hallowed centuries and millennium into the future from this place that is the origen of … something special … an intergalactic network of races supporting goodness and morality. It’s single related phrase “like our towers so tall and white” (in tempo, even, highlighting the strangeness of the addition of color) preluding the very clear reference and explanation to “how” … our minds expand and ideas take flight. As an aside, it’s the words “as the years go by we’ll love you more” that I now see as a sort of … appromise specifically to me, in this place where I feel hated, for all the wrong reasons. The proof is "in the pudding’ of course, but it’s been so damned long already that I don’t see the world changing by “intro-duction of floating city in sky” or by “magical neuro-nalpmi-napatms” without at least having a story break and some actual public and recorded discussions–even if that’s really what I want, to see thing happen “swiftly” and without the possibility of it being “every day has it’s day of being forgotten”–by everyone but songs. It’s still ery clear, tho, that you don’t understand the message, and the quasi-veiled-doublespeak-response from … personas-non-识别 … that what’s happening all around us and without our input is very clearly tied to this same lack of acknowledgement that a working society has a “working press” and that failing to see this message on TV is undeniable proof that there isn’t a single working government on the planeth Eart… and that should tell us that “the skies” too … are staring down at us in sham. It should be abundantly clear that even with the knowledge and even the very technology of “how to build Heaven” in hand … you risk carelessly and without regard for the future the possibility that we will be finding ourselves in multiple-simultaneous-hells rather than any Heaven at all until we rectify the darkness surround “communication” and “government” that is so pronounced and obvious here–you should see it as a very clear lesson … one that you should also see you have not learned. So we’re staring at the focal point of the intersection of a message that certainly wasn’t written in a day, but is read as thousands of years of history–probably a very large “underestimate” of what it actually is based on and took to put together. Here we have … “lore come alive” to show us the “nard” … the salting of the road to Heaven is “explained” as a sky literally drugging me … around the time of the dissemination of a message that probably would have “gone viral” and made the news if it wasn’t for that … “salting.” It’s really difficult to say today if that “salt” is warming a road or “preserving a message” as we see … nearly ubiquitously that salt does good things for … the dead … and it’s somewhat toxic to the living to the penultimate “wife of Lot” – clear as day to me today that’s just like this message. The story of “Casper pointing to a gate … as a message all around us” is a godsend in Heaven and for “an Earth in Heaven” and without doubt poison were we ever “stuck” or “printed” or … trashed into reality for no reason. Just like the “love and logic” of the end letters of Hell … it was very clear early on that printing the Earth was not the point, but a sort of honeypot trap–and as the “hardware description” came to light much later it wasn’t just because we’d be pissed about the message, but because it’s simply the wrong path given the current state of “hidden technology.” Hidden, I’m telling you, be’cause your silence and our lack of acti on here threatens civilization. So it’s the “nard” of my grandfather’s name Bernard, of John 12:1 and of John Maynard Keynes that connect the “NES” and “salt” to the clear intersection of “Tea Parties” and Na-po-leon Bon-to-part-e with “taxation is the ft of our Christ” and “no taxation without representation” to … Render to Caesar …" why it is that “no representation” and “no free thought” are linked at the hip to “no free speech” and “no free press” and you not picking up the phone and calling a reporter. It’s linked to “IRS” in the heart of “FIRST” as in … the first to make the connection between “taxes” and an overabundance of food and “natural” resources … brought to light by nothing more than acknowledging that this message is “important enough” to allow the world to actually progress instead of stagnating. Below you can see that I’m putting together the pieces of software necessary to build a prototype “Sworpen of Caesarthor” … (hear: see’s Arthur) and I’m going to ahead and do it presumably all alone because nobody’s (very few, anyway) "coming out of the woodwork to help build a platform that will end forever the power of any government to censor a message … of this import (and obviously less important … messages also). I need your help … not being angry at the world for staring at me in stupified ignorance. rather than seeing (and building something with…) the light.    On April 23rd, 2018, a curious transaction appeared on the Ethereum blockchain. An anonymous activist sent 0 ETH to themselves, but the transaction contained many extra bytes beyond the ones used to complete the transaction. These extra bytes were the text of a letter written by Yue Xin, a student at Peking University, detailing a pattern of intimidation and threats made against her by the school in response to her attempts to investigate claims of sexual assault made against a professor (you can read the full letter by clicking “view input as” and selecting utf-8 on the etherscan page). She had initially posted the letter on the social media site WeChat, where it was widely shared before censors began to purge all copies from the platform. Chinese censors have consistently targeted the #MeToo movement, forcing whistleblowers to find creative means of sharing their stories like esoteric hashtags such as #RiceBunny, or 米兔, which is pronounced similarly to “me too.” By using Ethereum, activists have found a new and unique avenue to disseminate information and resist censorship for Xin’s letter. Because every computer running a full Ethereum node has the complete transaction history, Yue Xin’s letter is replicated across thousands of independent computers. These computers are all controlled by individuals and organizations without any centralized oversight or shared government, making it virtually impossible to remove the letter’s content from the network. The same technique was used again in late July to protect a censored story about corruption and negligence at a Chinese vaccine manufacturer. P.S. .... the preceDING world changing message is filled with gibberish.  Understand, "gibberish" is going to change the world.   .WHSOISKEYAV { border-width: 1px; border-style: dashed; border-color: rgb(15,5,254); padding: 5px; width: 503px; text-align: center; display: inline-block; align: center; p { align: center; } /* THE SCORE IS LOVE FIVE ONE SAFETY ONE FIELD GOAL XIVDAQ: TENNIS OR TINNES? TONNES AND TUPLE(s) */ } <style type="text/css"> code { white-space: pre; } google_ad_client = "ca-pub-9608809622006883"; google_ad_slot = "4355365452"; google_ad_width = 728; google_ad_height = 90; Unless otherwise indicated, this work was written between the Christmas and Easter seasons of 2017 and 2020(A). The content of this page is released to the public under the GNU GPL v2.0 license; additionally any reproduction or derivation of the work must be attributed to the author, Adam Marshall Dobrin along with a link back to this website, fromthemachine dotty org. That's a "." not "dotty" ... it's to stop SPAMmers. :/ This document is "living" and I don't just mean in the Jeffersonian sense. It's more alive in the "Mayflower's and June Doors ..." living Ethereum contract sense [and literally just as close to the Depp/Caster/Paglen (and honorably PK] 'D-hath Transundancesense of the ... new meaning; as it is now published on Rinkeby, in "living contract" form. It is subject to change; without notice anywhere but here--and there--in the original spirit of the GPL 2.0. We are "one step closer to God" ... and do see that in that I mean ... it is a very real fusion of this document and the "spirit of my life" as well as the Spirit's of Kerouac's America and Vonnegut's Martian Mars and my Venutian Hotel ... and *my fusion* of Guy-A and GAIA; and the Spirit of the Earth .. and of course the God given and signed liberties in the Constitution of the United States of America. It is by and through my hand that this document and our X Commandments link to the Bill or Rights, and this story about an Exodus from slavery that literally begins here, in the post-apocalyptic American hartland. Written ... this day ... April 14, 2020 (hey, is this HADAD DAY?) ... in Margate FL, USA. For "official used-to-v TAX day" tomorrow, I'm going to add the "immultible incarnite pen" ... if added to the living "doc/app"--see is the DAO, the way--will initi8 the special secret "hidden level" .. we've all been looking for. Nor do just mean this website or the totality of my written works; nor do I only mean ... this particular derivation of the GPL 2.0+ modifications I continually source ... must be "from this website." I also mean *the thing* that is built from ... bits and piece of blocks of sand-toys; from Ethereum and from Rust and from our hands and eyes working together ... from this place, this cornerstone of the message that is ... written from brick and mortar words and events and people that have come before this poit of the "sealed W" that is this specific page and this time. It's 3:28; just five minutes--or is it four, too layne. This work is not to be redistributed according to the GPL unless all linked media on Youtube and related sites are intact--and historical references to the actual documented history of the art pieces (as I experience/d them) are also available for linking. Wikipedia references must be available for viewing, as well as the exact version of those pages at the time these pieces were written. All references to the Holy Bible must be "linked" (as they are or via ... impromptu in-transit re-linking) to the exact verses and versions of the Bible that I reference. These requirements, as well as the caveat and informational re-introduction to God's DAO above ... should be seen as material modifications to the original GPL2.0 that are retroactively applied to all works distributed under license via this site and all previous e-mails and sites. /s/ wso If you wanna talk to me get me on facebook, with PGP via FlowCrypt or adam at from the machine dotty org -----BEGIN PGP PUBLIC KEY BLOCK----- mQGNBF6RVvABDAC823JcYvgpEpy45z2EPgwJ9ZCL+pSFVnlgPKQAGD52q+kuckNZ mU3gbj1FIx/mwJJtaWZW6jaLDHLAZNJps93qpwdMCx0llhQogc8YN3j9RND7cTP5 eV8dS6z/9ta6TFOfwSZpsOZjCU7KFDStKcoulmvIGrr9wzaUr7fmDyE7cFp1KCZ0 i90oLYHqOIszRedvwCO/kBxawxzZuJ67DypcayiWyxqRHRmMZH1LejTaqTuEu0bp j54maTj09vnMxA0RfS+CtU5uMq+5fTkbiTOe1LrLD72m+PVJIS146FwESrMJEfJy oNqWEJlUQ0TecPZR41vnkSkpocE1/0YqUhWDGSht+67DdeKUg5KwvYdL21d/bSyO SM4jnyKn9aDVzLBpYrlE/lbFxujHPRGlRG5WtiPQuZYDRqP0GYFSXRpeUCI46f49 iPFo4eHo2jUfNDa9r9BjQdAe4zVFn2qLnOy8RWijlolbhGMHGO3w/uC/zad3jjo4 owAfsJjH5Oa1mTcAEQEAAbQmRUFSVEhFTkUgPGVhcnRoZW5lQGZyb210aGVtYWNo aW5lLm9yZz6JAdQEEwEKAD4WIQTUJHbrYn3y2DzwTcnQP1ViZf5/FQUCXpFW8AIb AwUJA8JnAAULCQgHAgYVCgkICwIEFgIDAQIeAQIXgAAKCRDQP1ViZf5/FWM6C/9J gbRLS2AWGjdRjYetlRkSkCoTYnXWknbtipYYHlhV0YJFwFMm0ydZIhFX5VDoZyBV 0UBeF1KJmcMoIfrHyhq2QhCnjE14hE1ONbaYTGtpvj851ItbFWXMJIVNyMqr+JT9 CWIxGr1idn+iHWE3nryiHrdlA3O/Gcd4EyNmaSe/JvB7+Z1AVqWkRhpjxxoPSlPm HEdqGOyl3+5ibQgUvXLRWWQXAj80CbVwwj1X4r9hfuCySxLT8Mir7NUXZFd+OiMS U8gNYjcyRGmI92z5lgf7djBbb9dMLwV0KLzgoT/xaupRvvYOIAT+n2mhCctCiH7x y7jYlJHd+0++rgUST2sT+9kbuQ0GxpJ7MZcKbS1n60La+IEEIpFled8eqwwDfcui uezO7RIzQ9wHSn688CDri9jmYhjp5s0HKuN61etJ1glu9jWgG76EZ3qW8zu4l4CH 9iFPHeGG7fa/5d07KvcZuS2fVACoMipTxTIouN7vL0daYwP3VFg63FNTwCU3HEq5 AY0EXpFW8AEMANh7M/ROrQxb3MCT1/PYco1tyscNo2eHHTtgrnHrpKEPCfRryx3r PllaRYP0ri5eFzt25ObHAjcnZgilnwxngm6S9QvUIaLLQh67RP1h8I4qyFzueYPs oY8xo1zwXz7klXVlZW0MYi/g5gpb+rpYUfZEJGJTBM/wMNqwwlct+BSZca4+TEHW g6oN0eXTthtGB0Qls71sv3tbOnOh/67NTwyhcHPWX/P9ilcjGsEiT8hqrpyhjAUm mv7ADi+2eRBV8Xf8JnPznFf0A1FdILVeVHlmsgCSB0FW0NsFI5niZbaYBHDbFsks QdaFaYd54DHln69tnwc2y3POFwx8kwZnMPPlVAR2QdxGQD4Wql7hlWT58xCxQApf M98kbAHjUlVYLT0WUHMDQtj4jdzAVVDiMGMUrbnQ7UwI7LexSB6cJ7H+i7FtS/pR WOhJK6awoOO9dLnEjm6UYCKsBdtJr98F0T7Sb7PnKOGA77y2QN14+u9N9C1lB/Z1 aQRQ2Nc51yXOQQARAQABiQG8BBgBCgAmFiEE1CR262J98tg88E3J0D9VYmX+fxUF Al6RVvACGwwFCQPCZwAACgkQ0D9VYmX+fxU+KQwAtFnWjGIjvqaNXtQjEhbGDH/I Q5ULq/l/wm9SmhG9NYRu3+P6YctCJaZnNeaL+6WFk1jo4LMiJEUT9uGlCbHqJNaI 6Gll1w6QOVLSL8s5V1L477+psluv4WBpi3XkWYlhDOFENCcWd49RQsA2YCX4pW7Q 7GcoSEJoav38MxHmJHYPfjSEvUZXDQIt8PFHSEScvyDWfYtMdRzjmSOOPdzhDDEy 5JBOBcEdSTyDiyDU/sBoAY0e8lvwHYW3p+guZSGSYVhGQ8JECzJOzwc/msMW/tJS 2MLWmWVh5/1P8BVUtLC2AQy6nij6o+h6vEiNzpdYrc+rzT3X5cACvJ0RtCZcrnhl O9PLiona2LEbry6QX5NL41/SAJNno3i72xPnQEe25gn3nbyT+jCoJzw2L0y8pmNB D+PKrk7/1ROFFVN8dJeGwxLGdBcz1zk2xeumzy7OaV8psUyYsJNcjyHUKgclblBW rMR2DgqEYn8QdK54ziKCnmQQZeMPiC6wlUWgg5IqmQGNBF6RVyMBDADALD7NkJ5H dtoOpoZmAbPSlVGXHDbJZuq7J13vew6dtXDIAraeGrsBqkF8bhddwVLzWylMrYCG Bf2L1+5BDgvqu6G+6dcVSbBsnZAS0zfJ0H8EmTvUMxMF7qOZYyrxfLz+pQRq8Osz Icab6ZI/KB6qZyQRvEFPB6pJjt+VvuwgJZTObIwbBbgQri2i02VBkjchsVhiSX9l +eiK7O8ROHKb3P181oScIsHywBOZ9DxRAYbFk5dnBqxO3WKb02H0zqE6440cjXwq TrZZg6ayN/IlPajO8iJPYZ1aIBykxYq1WHo+nhFMYz/VVk2WJorFeOgWaLGXb73c ty96f3qXTdvMDAIWHx8YCD5LbuqasO6LNQm4oQxkCoB3K9WFf/2SvSYb7yMYykb8 clTPt+KO0dsxjWhrJnfnIhC+2Chqv2QvRbFz0S9CpUnGGDweJ1uRNV0y70tO0q7t xXSTDRU3ib6vAHA0K/2MFzwUcog4o5bj7E9uCNJH/DJLZKsMIe4xsvkAEQEAAbQk SEVBVkVOVUVTIDxBVkVOVUBGUk9NVEhFTUFDSElORS5PUkc+iQHUBBMBCgA+FiEE IRklfU/C1qukq3xMXcNH0t3P9ZsFAl6RVyMCGwMFCQPCZwAFCwkIBwIGFQoJCAsC BBYCAwECHgECF4AACgkQXcNH0t3P9Zs+kgv/XEuuWc89Bjg1QQqKZueKNUHjyjnE 2adfoZUH6Q7ir4JZyRBCVpAwrgssmiKid30+SIjwQcpb9JYa/X1XJcDUcJW/I21d Agz/zbEqn/Cou0dUpNCtxgm4BdSHWGoOtgfspXZlXBQ407tRMZ8ykmLB1Bt0oHvw PT0ZOtqXM4pyFnd2eFe5YGbNgl3zqvoC/6CMN3vqswvRlu1BpUuAjdW8AHO5Yvje +Bp852u+4Qpy6PMBiWGsBMYwtf6T7sckpMGlR0TsozwBlAm5ePKK28B0rLJPkZLJ Eo5p4rKRapEaZsWV5Qu1ajrVru7qmpUhZtX0/DddGHfXVuLssmKLP6TumpQB1zvQ vfoBltjvOx35Wps2vHuCzXLw2bROIOzhAxFB+17zxnSbE54N4LIGRpkELuwxwGbg FtD1fi9KtH7xcn33eOK1+UD47V+hKyJGrQgSThly2zdIC2bvfHtFdfp8lOFpT0AU xjEeoJGqdQVupptXyugPlM5/96UJP8OZG0ADuQGNBF6RVyMBDAC3As6eMkoEo3z9 TkCWlvS0vBQmY3gF0VEjlAIqFWpDIdK3zVzMnKUokIT1i7nkadLzHZT2grB4VXuJ FvpbYw5NPR4cDe9grlOMLEaF3oSJ1jZ4V1/rj9v1Hddo8ELi/NToVrt1SB5GCVXB DkYpNLtTiCqHSU07YqwaqH8a+qbDmPxSQdIybkZiTiCEB+6PfQQlBpENEDlov6jm zZF+IcfM6s3kZDX5KFULweH30gMjq8Se8bPtUzW013+tuuwEVr1/YRLrIh+9O6Z+ pdA7gLMRYnD9ZLDytEvpb1lBBSY++5bIJ7xps80//DNqPYqwFmZQgTg0V9XbHE2e wLcOF8a2lYluckU7D///sWQhW+VxuM7R2gEBvYBhOgjWhIF2Aw6NbymW1Ontvyhu eOZCXXxV5W44PxXT8uDdhl9CNcHoBKKJyED8tKjigtn4axpsQeUrnOSbqEXSyqES WnE2wYUDzALcwFkzsvtLyd4xaz55KkPQkAkk0BZd1ezgXxb/obMAEQEAAYkBvAQY AQoAJhYhBCEZJX1PwtarpKt8TF3DR9Ldz/WbBQJekVcjAhsMBQkDwmcAAAoJEF3D R9Ldz/WbAFwL/382HsrldVXnkPmJ1E2YEOFz4rcHRetJ+M5H65K/2p32ONQ5KCbE s8MRY6g2CkE70en2HlpDwr/MdATwxBzIjEpjgHbfqCqVVATY+kSpXsttaKKAUVHi bFgV4QkdDJNSpcHEj+bqaggRnuWiV9T6ECG7kQjHiEXPNojzsiaXMDiM5r+acZm6 82id9qOFySQ2cZEy5HbwXM+ITLQGngnppa7du2KdgiqDeqtODOTWZvLYAq2tmEwD 3TT6ttLUBwOOu2IWpDkXswlrk62ESorE5mpLxop9fsxD39E2H06JoC/YfUPIVkEv fj06e7LEdcx0I7kRfD1v6qOUUsMsLZnmyGIk24iFjLkwu1VToWfwXDN1D2+SeAat 9ydNt4M7oEbd1QaOXXjmqpdU+VUiWcBXg+p3/WdV60MkyAgc3x+YanLljy/Rh18h cZwVlinf/tgvAQLi5f9hpwrwUMoGKijEYHKuEvi3C12Si7UVDfuIR7yS0dKcfuKF MbgwdvNXqpD9W5kBjQRekVd4AQwApHVgw2PVlBDpVcyoymUOXFQIJzJ9wRtr6/sG zwv8rrQnUEtOkkna7TDU3/UTj9FUH0gbpAKGNNPaPj5q0dlLIvzxb15r1uvDGaGL MA+8GFaGFnkxzhg0aXrcKZAN0/Zhgi2B7P8oXQuug5mi1JVDkZN5SeCZNOubdQWL 3xz3jEHp3ixj1mdOdvfdWQFR4CVMXt/A6VI2ujLVb3Yalft/c5bbclAgcJQhgDUu NqGYJEJonESNRSd8fEvhNb6cx7+Djd9+Wyctr76mwOr3nRb1N1OGhFxWjIroUpfz b+6y3oQjT58cJA1ZHqmJ6UlZd81hNNd9KWpbDVwONEPpiqPzfSaonxuqQa0/Cy4W 403OhfoLM/1ZDqD4YrJ/rpyNEfSSdqptWiY0KeErLOYng7rStW/4ZeZVj6b2xxB2 Oas/Z1QYfJyFUki9vaJ5IyN6Y7nVdSP6mbAQC9ESh+VPvRUMpYi4pMGK4rweBVHu oMRRwzk7W5zVIgd425WUe3eCQFn3ABEBAAG0K0VTQ0FQRSBST09NIDxFU0NBUEFF REVTQEZST01USEVNQUNISU5FLk9SRz6JAdQEEwEKAD4WIQTvnDJqcmqzlF87/t82 pJ91j4NOaAUCXpFXeAIbAwUJA8JnAAULCQgHAgYVCgkICwIEFgIDAQIeAQIXgAAK CRA2pJ91j4NOaJVjC/4oo5yCHe7M2h1DiTXVcLI5rXQ1feY7B1feg+YJX/mI4+EV xjC/y5VVpV4syJk5GGZNXhKPHiGLaBYvglTlYOJ98RSEsHrwT3go6S8ZVvMNdP5v CEncn2vm5JGnp4k26PuOzMcJioQLOoUjWtcPFis3gG+ueH3NcPZ22oZUql2xuerh TQZegGp+jJ7bdxwYElx5jDDDkh196d5nlO2ZKENl0ZDp4GAzRNjnQ7KBV6R74J3U cLQDWY8vAFaRBZXIC5XtSzj9lr+jWgvxz7Il51+26VDTEtSafZ2uZfCOFk7GrzJg YFJD3zLnwUFXDWKRkep8TSwXnHmz/Ts/Mjyv6em25w7QTdnx1hNPxYNWMxPWNEAH pf70nNyOmcWcq27W+nAjVg8W3st/7J5CIebJQc5AUgm+fGOBW6XUQaNy2YF1YJlA 71/tls+R5IQZCYzbPOibgFS1HWKTwy0iI2rMDfxBtCXciv754jVI7L6R3J0j5Dy1 WZQVjaGgimznLN6XwYy5AY0EXpFXeAEMALvElrTV5hJG9DKu8cOqQEEVejtWJtki fZyvmiAKi2bZWiNfl1MxJt+o3Oc0eARJfnaPjrUY7hsbbSBAB4lFnDRtviARPaKM st5FkFgOh7Xx5ODc8bjqhMT9tbX37rkeDc12WAs3UxtEKWjyT7Xg/APKeK5FzpIs qew3LADdqFP9nOR0e5G8gxLTYh3ll3dLtp9DkJgA9q+0g31nNh5fZ29mcDzo/Mat Uk4PIxWC29LV9ALCJMIMesjOPiDa2KOy5QQH+/vn592ydBohOaY+B6jhEAdX8Dbp VHVFRBsiCOWGmdi6vHjMFD0tQdS6bXf+ZAG0E5HZETCxA2qfMf/vTeIJXYS5IZw0 anRkTXcTBrVE8uBpqtkNOrLJsaASkcoO5qF01J9zW8SR4jDgET7J02Fxf8CVPzb+ ZoNc9S0ZEO6Ubdh2vAkPtOV5sFkwIduN6ouAhEfJzC9XbJLpgsBKrRMAjr2FeEZP ruy8BkZbiyZ/b0S9qIgY4pqcyUJ79w7FLQARAQABiQG8BBgBCgAmFiEE75wyanJq s5RfO/7fNqSfdY+DTmgFAl6RV3gCGwwFCQPCZwAACgkQNqSfdY+DTmhD9wv/Zgav EHMuqF3765Fa4NapYh2kMS3skHn+ZzUEPLTlvrt7KHxomOzExNLSscZThMpur+yW MfNWbsw9GphiYAkMULrfJt/iWRVJ1FLgbcWgRGAwakOGwE29lMx3+rPIUQWU54Dw vE92Iz51ZGz1wgKcISuCw39g/HQ9uc3h3TfHLgfkc/GaIEa8jEOAcD67dVMoU4o+ p3nMri8z6sK176hQ/FM/8kekpeVfxmR8s6uoaJsXLRQk+i88ZwBR/5U+fBT9AtVw PL/MmZH7eCmZrn5hjaOw7tpkL8ZyAydNhOsSCqwNVtrIjgd+Gq1oSgw9EZfhKSUa +dBJAErA7MWjammQizEHDNnI8VNLngwCahGwaSgDhNaQtgNxvnkWO7XNYoCYXScP X++UmpWtSKMnD6ue36Ba1jqon0WY5cen3P+H1gL4ij5ynB9DrE8R1aSY6f+VZ48B RvjHm5LKTcAhiv2N/TyAg/fr2v9ZnEcP3CFxqAyB9JSKwoBkFvxJaRHTT3DxmQGN BF6RWE4BDACpgKWvQvPRDN03+sLYMXpJUPC7VhTjg5K/1+1vS/e/W65dYzn3JYxb ip2PcI5xajFnxzUrwwmhW+qz5REDyCtAObOpKsjtr4qu7mgOWnPa3k2Lm0bpCjDr BSFOiQsBVezTG/gJm+qELeqQMS9PHDSvZXeBROK7OkRE0nZ6yAj+QKEoVqeADpDm BHmhAA2OKBzq4rDWDh1jRQ7gLjlv/BFbhU1WuEfH/qzX8AUSsd0/hoPG0cPgC8gQ 3m6wr4eYqI853XQujWwisnlAE2bf9jsRjW+aLrJJTcADWk5Op5aQhI2lURYkryfC DFVcme7Hsrd+RFPK88J08YjBjOoYFwRU4AhHgucX9tW0S0v9hi3pKrF9O/JAIf+r h6BpnWo7tT5+8mVhtFvfEp9Y4xeUAKKZHBKhzHeOO8QQgHrIYa6HCcU03eyxy4Tq AsJdAJvxYFCRPdY9d0Z6uVsPhRy+3UmTxjl590T5/XjKPriAjBqXnKr4KexsM1gj 1L96bYDEgr0AEQEAAbQaRTFYNl8xIDxFMVg2QEVSTUNDT1JQLkNPTT6JAdQEEwEK AD4WIQSGisfXZ2Vg0m16Mzds3dDsq5BTxAUCXpFYTgIbAwUJA8JnAAULCQgHAgYV CgkICwIEFgIDAQIeAQIXgAAKCRBs3dDsq5BTxKq8C/48HSgecuI6MYtq84yqaQ1r x6cteRyn9BJDFTAUxn3X25kf0vVyCKQNAy2oybD5QHFLqhFCXJH+cnJ3xdviRUeW eO9fhkTmd12mHGrRDD02AHXZmaMp6ni7FuYpBGrw5dbXKTkSWfD/qb3odMx0jQby 6X+2eFhUpyh+yPB7P7HwiPwzdr0dBg3xE0vE0Vz+naMyt4YBHzrBbZo+y47Q86Ym TmBKxG5tlVsGDB4dDWSIvpBgnMFN1j46Uk2ihu4huohLkvSou+jYU+5Ppu8Fu1+7 i3RCILzeBtucR9+T4px1WVXx2sKOk0FfddCvI/fT/mhsgqQZwjj9b8HNfobhNxkL HBNFQ7FLJxKayPwMyJYDURUq7gz9p5JwHTmFg9n7zyK8qU2xR5t2247YinfEJQYL zQM6VKQCoDqydFfAPeGlx1KjroMGls4sP3XVlrR04YzaJ0vxRgog1gIO1aHMQ2Sj l8bG0GcerQ44rpn1v33Gw6KL/0SY9JsSSSjA9lgINWi5AY0EXpFYTgEMALy/jHsN kUQQVJK9QuAy5V2GePBTEm9NnjNCk+edGjSgqC1LemmP7EYh07J13d10VqD2Wtae bXlBeaMOcnoXQdfdK6nTKWRrH97JuRTrA3efLkl/R4EA/kHHV+YDgT+LBboUFYVU QF5YhfcvgBUcLXI3lX5wMEQbLb87cVjR0JtqVBFMIIvs4ibgr0U2SONiD9LcXZxf qYcX7CMM6RmuLzHTCEHyjp+KAw52K1i3+3M0OVZpa25rKE+S7LykQ1GrUUY3uVHg R2I3T5/Sns3Azc9wKuy/F71oiXyqCc3FwzTQHoki+eBf5dzs6h3GBTK3Dz6kl2mv 1TXpY1dk2EmuqKIeSr8CE52nkK8ZKY6cvX+v/p1EBAkJZKiasj+ukL72p3Lji5r/ iOarNJnURT5LJdYYL27dtQFSYyVWayeWi5358Ajh1H9OdpiGXcgG65ry6u50G8JR FCywwsdKpGjMG4FlkLkm50/piU+cgVeLET/C7C/OXNslL/pHV3x8kPRY1QARAQAB iQG8BBgBCgAmFiEEhorH12dlYNJtejM3bN3Q7KuQU8QFAl6RWE4CGwwFCQPCZwAA CgkQbN3Q7KuQU8SHSwv/agnEnhmo2yuKCLiKdTa5KZ8wh3umiX3S6rldW0NO2h8a cq2l7xHY1r2u4ieeMx27jtTqCp7ksFxPYwP9WxtVBy0teG8pKLhEffjyG2WKDzAN 7oXNZ7Ur6OQGfuOQzlMqOGtYQrbHAuX60PCldurX/6/0sKS6vESdeGMQPoZIDK5g HP298MMhlWYEG7uU31J1Cx9ZqiTosSckfrDq3weU8x9DZYaLZ+Y2akF5XpL/HjyA 6PM+lv6vnTA+b5DYCOJb6N7v131Net2JN7JVVGoc0FjsxN/W33H7eIDOZwqcCvzD i8EjjzZpZUDeYjlSXAqWvpeAASncMzXS2/S2V2u5X2iR7tDtRj9SuQehJkdTFNZH xh5nTdhPzgh/iOcm33VsQ17JWbovl0hbhYBPO4V+yIrN+oQGPhH+KCNNa39EjEzB iBIgirxQSaykwb4f2Kshh+d7rKHKb/mn6JBHU444mBf09m5wM/mhLSpuhMTcP2h9 jfFximAE9FBhdZhQsF29mQINBF6I/R4BEADotSG8PhhxxD9/96bgdWa1bzp2398W LaxP39T+Kzx2KL2xB+7B4EeTTzZ06kD+myCC9Ez+PqecfisJPfaiLD/+0/m3HLSS hxEaEqt1RBS3j6qJx8Lr51cAwGou4hGTo9H3me6FHO2ExZXd76A6kkUh0J4y3r6q aAoDP+MUczKzEjn6C6T7Uu0pdgYY1bDhuqlK0taqkqviGBYTAqmCrtcQhj+J/jbd OIZtpT3+PH6mWqguoONiE+glWcdThyuIvV3ix/GrhjmUZb/DQcvvbYGfDvGRBH4B Uj3f9WBM6HWSxKrCwWC3OcgZhtBcZjKrMPbNDNt7yAArv7nGpHmlpfF14Q6mVmVT 6Ulh+0xRx+6zFbqlDYYTneurK3RtqOBsMFG5rNDZYh/QOsHnSsxmU4LGdlEfQjYs 901zmzP7CQXjjJbtRXWIqPcn3OHIIasvjTACe5M+Lfk3u3rEiDYM64vg29sSyp9q 8hAzLTPcLj/Cc22jUEC/bbv5HfLyCZTCsu5ym1gDQZ6bDrJlFlXZJ2+vTCBsY24H RF9/J/z1JWYD1cAHpG0GRtYE9exKpu8/81jxIVn21qvvxSCPXw6IQIsEw51uk5TJ xAUIRCPN7S0UEtd22LSbM/IYx1cesCRUCmY7jDTro/jo2B4hLG64KBgqyjg0lwxd dy5S8LwFx1zskQARAQABtGhBZGFtIE1hcnNoYWxsIERvYnJpbiAod3d3LmxhbWMu bGEgLyB3d3cuZnJvbXRoZW1hY2hpbmUub3JnIC8gZW4ucmVhbGx5aGltLmNvbSkg PGFkYW1AZnJvbXRoZW1hY2hpbmUub3JnPokCTgQTAQoAOBYhBE+vDT4gih9MmA0P ZvtOzkoQkinPBQJeiP0eAhsDBQsJCAcCBhUKCQgLAgQWAgMBAh4BAheAAAoJEPtO zkoQkinPJ4gP/3U691086OKbWiQhMhV+AViuKnMgV4i1M8s+4Ep01h/dTE6R+rUu LcnY4T0HR5qxAYMiNpGo1vtvkMvV5DP1PFSl5EddKn8+Kvn/0+WjbLV5tdiFF1Ef xR6261UFoXAGk3HJMLQifr3lWKoimaBwJZGza2ok9k1TQVTn8g5a01bzK7hD5DJI zt9RJZaUkxGE97eUyJ8Dtwumo18EWJltuC4UWjWT2t2HE9mMsOfjpYZXFsGxJ0Zb xexo0DYsriPDpuxDnZT7G3re9Vwz2VIe388DNBW5HoJsYxhr2I0QOq64ZWOSEZC8 lDH+xM6YdY0iz4A+7nbKNGifLbH8oU4A1sV9HrIE2KNy76x0GNjgQUvcq1inD4Oh yorsRh/IF6wnqvFrHOstCS2dzpKuQ/s7bM5TGOD2EGb0xu7r0AfHqqLUlbr3rxkS wBFMQphyNr3mEkEbXU1dGsXDlRQy11LigMBoEHmP0t49bYWuM1mIBnIC7gZc/sV/ E5fWmWdQyCKmHeujmS+sgp2EX0NtMGSzm7z9WBzTBFjaN7q28gueQ3INDsDTGx2G aA1LbP2uh1ipwju0GxecUif3T2NDqaYfhbaCYsPJORNUlJUtCVBGeba9wcXai2dh l+HsSKUiyCgKiy6Rt6jumKtYHt+Q0zcKWLfVp8PA20zX+2Q9zKnlLzwquQINBF6I /R4BEADQ4kmCHYtAhjCShc724Ei2pqSH4SfnXd4r8S8I0+io6Mh0kWn+kbKk/aGK BL3KJyN6624kPtOFWuQ4iQ0lWFn9UMnvjByTPbjZ2je+VtCP7lKSNvEgTLQRxLEJ hoNVrNjrLa/Cn7sLt9ayYcx8eKpHkbmrVRTyGqljBkI5hwQ8S+7BWugabhGQuogw bFthykA+wxYvSbSn5mwKO1BlbDCRnxjLISlqWwmKKEtXQ8b3tu7GgFuPYLKaLEk1 BIwwUSdozjXu+198WligepslidlN5bXrvje3sxgt4oAPFMeH+NnDClSDuGhSYamW Db3ZPl95pW70ngUVgFPG4kQOlaqzo3YBeDBHDXlqU0+O8cwSQFk4CBJI3yt6/KmD BIuKLwauOxYullx9EnqKcLWEzOlTgn9Q7BARK8Uz7PQU3+1mDNId2MEg+gfL3rd2 +aMLNhTUkgVE5mWkeDz6Kg7YhwruvJtn0z1QqUhkQcVs7N8rVCck0YUCVGXpsUlu emK48q4ryOxmMG/+Ws2Xkmdm6Axq414WHz6nLwMWgFpcO+1wRwQuZEkeWeSAjEvS CGHImxTP7E08+y3vAl43a9AlR7v9PbtCy2FenAhGPigmWm2aPj1ejYfQLXozyWSM m8uO3aiKvQXdV1Ha2xQLK5expaRaAXQ6YLsNBD77UPxi9qC5rwARAQABiQI2BBgB CgAgFiEET68NPiCKH0yYDQ9m+07OShCSKc8FAl6I/R4CGwwACgkQ+07OShCSKc9o DQ/+OV2OuDp9g/27SRssbTWE+nBl0R9klrb/w2XEIVhg5LROUe/P3anyBLNITbF9 A4q8b9udD+iIc1ClY2bu3rQOdzA1DH9GK84bQ1O/LaU0Te8RBGJJEzjYMUraCgIX 4BmxsIlWuCkSNsTgempLOK88646Nv5uc/oxAj6kQH7x8XBXxaJ+N9WS9f7EAv4AL bSWeJ4ijbw9BIMHt/D9Em7Q8bW6VGZIEjIp+gl1vNZ6QGCTtRHQez1jYmFLpuE/G yh1zM5gCnZbcmC7ExDLFI6SuYUbKC+XaLA3+LLCVCPFLtu6wLvcgYFwWWMKIhJAQ bRyPePiuMqWeWR6VXTD8pLziDjxK0ZtvpGdOtZeCCHOEmxrCsfKdIyD2Gn7TmTwb M9fRE1HazROfit6SRCAamabg+dJIEGT8vzlLfnkZRi+6hxq88uDbrOkk36ShWoYB AApz+5fj1ogLptiaTUTyyjTjB+/FIbU48/02fkD0y960zQLyKL64Q4aZrNa2NNup YKy5F80NkU4rHOZ1HTaPLoqqVsGhWc3ODgLyGPiRDLlZu81aNpA/UnTEBX464Sk4 Jx9qztb+S50LnGItA92QfE9ru7FAE00RR6mpCv1h7uE28/Wr4XaYgJcw1hAPRr7p TtN4lph+sJsCQ8eX5YUlM/Pht1h/LoE8h4hXNfAGh+CZgoWZAY0EXodqtAEMAOBb WTLRDxNk9SbC7exKdw0f8Wy9DhX2Qqoi96piS99CMJSxeocLiC9Si2u5nL3sQTAu qs1YbtSgn8kkiH3HPEJIhV1p/Hvz47j4kXq7PnjqF7KAdCYewuDqRiq8J7TNokYs 6+3/KqwHT/IT8NwPLdMkXcv/SXqhuKpqa2ApIrhu04VFp4H5OXN9rqdF5ZDfcNx1 PQv+6m8v6xRwrI3kduRCUD3YiVPM3EOhqINk9XMuxAoVX3qwpz+OuEDBm76U5jTZ q9ErdwRV9gaGm5ztq6tvElpis3spM7BPHzbv0SvVRAAbgGVh6kfiaZ3YckxLq8ln Cg5or1aZNyGMf7CmaZaeAjeY6Y8FZXR1P+n/IFd9Ak83a3qizZyckfiEPO7hu9zI FFXTdtZIcV102rNoVzruZIn0vSK1DJ7bNNrHkm1PPcweMkcFJY0uh6l3x2nl2qKm AhlDs3wFG+nqvqmnliVbrFZCYlReMrWWI2YBwLC5uBcBpFAhMPNEjxOtv31R+wAR AQABtCNBREFNIE0gRE9CUklOIDxhZGFtNUBwcm90b25tYWlsLmNoPokB1AQTAQoA PhYhBP/zHob861BG6LJ9SqGPd44Z/DJIBQJeh2q0AhsDBQkDwmcABQsJCAcCBhUK CQgLAgQWAgMBAh4BAheAAAoJEKGPd44Z/DJIKtgL/0JQEzrGWoHHN7T4wLiArPCv tHB3dTZBoXGKlpuwhgOZ1th6jOnGPdMZRYnX8Zuf7QhaI7m/duKv9OAr8A/2ftHG 7/BxPSHJWBuIGZYNL97OWSstuBhNtyxfCftDkeBCqJ+lAneOrzV0M8syr2VqpfVs O8nTE7nXHSOdyen+1Fw0PtwaeG9uJvOhgRsmQ+mtAiJ1OLGKUxgCzSUk0m/YnDg0 vJBtzq9qP9+EZSuiBuRQC0tKs01ECI5DzWLNXXC6X8k3YGrJpL/HtTxH5SYNQRvS ALd+HmVYpwijLPi7ANzmg9/+h/aq4VFP/4SyMd6EjaaQ86n2fC5zeugio4sjtFMp W3jbZPn19o2hWTt9/bLns+fm9PgnPwdC+tS5LT26N6vhT/vK/HHY5AZvXXPNcQMA wp+EVFxsWK2BcFMIi7Oq47CfuM1AUA+pgCenB4iSVwxs8ANTWWIsLkkKAYQqIdan OSISa2WdslsKMjXIQ5+rG9ekEn+rRO3EAQXRryBt4LkBjQReh2q0AQwAwGx7shIW OaVExpngqmh0ApkxJHZIxcxpatk/lSBQfzHg6e1/7Joe98lEHcWPJ6WFsGp+aC9S 96dWTBZq/4pzAqqTrSXAZpG/+yZlWRWSXVQex1gZHPzsWYMPE9qayAPTOJHtfS6a klIEaFV2GYEvvRK5UR5DFIlsfzyyCBOUKvn0/hikqJjN2YfHUy5SR5U5dGsSX3Jk Q9bOlBYDpN3Rk5rmLg0Vwn4nPRBET70MLQ5M4pU3Br6n+vU8tMHoVXYVMLinD4gO vVY4baXEZELjcPkPzGFPyjVLlpxKMHZ6v1Qb9ornTRGzc4dEUKxi3srdsTpMCw0k CaZ2WLY4sNBO33C8XfIvMx2jF4iIk3BrSrW/hirq6xpvlh4BUh/UWVrvg2rdemAX THa93mRQeOa3bze9xZwaA2GJLRG+xCIt15v/cNpQwCYlyhJunkuwk3HQcUrKfzxo 6QhqMeDaPZeNcvN3XoELGeqtoE7gKAnLp2nQuVr4/pcaiATf+yAhBgYRABEBAAGJ AbwEGAEKACYWIQT/8x6G/OtQRuiyfUqhj3eOGfwySAUCXodqtAIbDAUJA8JnAAAK CRChj3eOGfwySB11DADLgMAafhdzRgzx7FLVVW80IfgiCTAl5M1wV2HctA17aln7 jk7iEVMTLfhrSCSvvNIdrOXUE7l9HAMkKRwaZv7OAtYR8eQTrgGc9yJdk8BMzvJB ouiaNb2LSxMSvpoaJmD2C9ZkOyW+pAXKaUGhbUl8YVa7ytwPD6yZzonGClgZI0x5 9nSc5TiPpVijzu51iZiTV35F6en7ke2hjr6iBACJGBplxeeWszRa0wK2zoubAUK1 KO2punvtGqhi3j77/0sZgvFv3czJpRac5ccdLc02Sb6I64Stp04ilcV1aqlUXxbM gLwkoXZUqbCS7ZA7eBiEaKXdj9ww/gprO0AwFETxQVA8iPF9puSWfBf18a5GEdR1 Drb5lSReCkCfBJd3Tf5WHUSrdcai0FfuXNNp/7J7CBzlOJ0h6Yoa02hz8CBGGwxI 1brXRm13004bX7C9i+94Lbgf8bTM40JvyF1kmcffkj8ibpS/VSa8aWJuqpWk/xcn ob/YdBngWCxNgXii4E6ZAY0EXot8fAEMAJ/JOflg7U8JWescyTQNl9Xuk6QUIVKx 0zOT2k+drlLwC8+FckYTCF1pm8sPDBBv9eN3cFCDf076tZjUHv+Roq5c5McDHlN5 KlFbTSOv1qZYuaPY14nHIoW7OGoSvMCOBkpDLLwnIbuLA0wGdzyd3z6Vfhpz3wDv iAplyA4iuzJQq1+iS8tq6Uj2yhmfg+zU16gw2D3iEC6hhSu2KmPhMFD9KfCzq02L xC6fMh3Fogas51ZF1fRDK8Bvicf4yYj0dn3i6GDr0/vHga4eLQqVBXb0HCv2lNer gTtawQfJu2XEn5hDZKfHeBJ4NI4k7AZIPa7OuUqOAm8Z4hbkgRZakc+OhPSEKH2i drItwrPXDGqMYV4tLLMALMQ9WDTz75wbzVbxGVcAzG3MaZSo/f/iKzuzaE8cF71A dO1y6H5YmmMENn4t/D4BYXm4edPvV6SaYU1hO5yqr7vGbrQBFVetpSCLEFveACHr sm1S6nVVTazkHj2FNdww4bGMJzPqC7bBtQARAQABtChBREFNIE1BUlNIQUxMIERP QlJJTiA8YWRhbUBlcm1jY29ycC5jb20+iQHUBBMBCgA+FiEE9+R8sSygzQHF4cv6 fsjVqFo41joFAl6LfHwCGwMFCQPCZwAFCwkIBwIGFQoJCAsCBBYCAwECHgECF4AA CgkQfsjVqFo41jpPfgv/dylMY4CPMwkdry8KnKP3QtmJOl94VnpJ+FUME+oOqjBw 6/C16uWdTLYuEUuE2jEzTg2J0kgulM2vYm8rVgJzlGiD/oIgX3X5NeyB9MH+GCpu xsJ/ofIVpC6t8Zl78B2qTnJOcEc6owy/qKs/eFXSea2sRRstqK20dOajl4Z2ycEL SdijFR3aqT4hU6e0GNWYqo3bW4TUcd05RJIZBNz6Bitq1fxljxFPOOCaoKo9mVn4 0dN65iGPEYg0c50Q6EmxEr+XtwRu1rjgG3hgq6BknZ6QD1HOBemQg/3jqQBb9uHj jHbuX9HrbGF9+QbDicbmuZSLuV76xJnbyTycFhhIcSi9wZeyAAPlpL4GQ8l98jKa SCWWGDPpKwK5+o8kteuJ/D/mYyBEquyFVhPQBXV9zS3LsN7ab55zB5+ZnLUeofai LE6e+XPGeJmG3I/+T/Nuq1CqJ4Wyt8+aIyf6Uz8dDk0kjyQku484plRwMEx7oZXR bXQAAn8SwtlNGo0sHc6JuQGNBF6LfHwBDACxAxfbQM5AcssJlQFXThnBMHtRDeBH VkyF5mrO9JeFRT+mhM87V+fJXOaEKtcSFVgZJFKV2MPdyGqZSGKmyyqfUvKfucP5 LrjK3MRKibTlOMwbBOmYUksMVE0ByMPeSzyMlQhq0oyA3fvEdKEf0JrFGDRWNzO8 /Q54oj79Pki4y1BDKd7lE1srBFiVEUuPNJmjhhU9WXnMwiB55lLwbTR8mKEX0Pr2 FeTS5gttmbHf4V+wnJvlOEU6mOLMrb+6Xb4ltvqbl9ng1+tF2QMGMd83mtbFtAjb Zcl/Cq2KwsBFyH9VT48ZxWxpOYMf3ppEg9KOSfz9Ungtg4/Q/Kr9P13Nf+9+S9JS 1PfKdlJzGFDn4EwZ49ugg6GNnL6XuRl9jBPD2iD8hY9CsTdWrr9giCmJmdf6G/bK HUm2QekMbhpaQmYKkMeri45cHprx1dQ50rfiH1cBm5SxaK7z/hDDaKXF1Gp7/KwQ g6gHlyMss7EEHSY5ogH+6a7OUPpqbJdNztEAEQEAAYkBvAQYAQoAJhYhBPfkfLEs oM0BxeHL+n7I1ahaONY6BQJei3x8AhsMBQkDwmcAAAoJEH7I1ahaONY6EqoL/R7J QLaAlb4/hK7/v4vsSxtCirLWrqNNNJxYdmpXq19NKPmcc08QzSqkJ7vR4/kn2L6I OY7y7AMh+tScKTKIGn8MkAcj0ZvkafHY3xmpN1Xp9caUAA/fw6KWD+pSZpKpISyd 2Xr6x5OJGSKhyGpPB98oCsa809LQ3cweG1imem3jx+Lgii63pEJG/AeNeEwkIvdC zRLSQvYv0UjlhyOoII6YEWJcro+tgOcthPh2SY50E4lwFFfbz4CNQyL15D+XciNI xSVGz8gee/XdJdgwQF4SEnIiChhmJ5VmpNH8ZwxTMyI3EoFMB/RYaucwc/ucvySn cFyShFFRPjo6TOeYIaSrrfR+4yhHAGeM572y0btI6JjWZovupeXX3k5ZHHrCwxlR MuyULLyhUsAC0r1FUijbUWoyaDcRtLRpMUg1X6A7n1iH61WxlKQ/8mZhYht85Jgp FSiyz47gofc491ng9efshlyxwb3TeLbDZPRnls7L3sfDDWwp8yExjA7UNDbIh5kC DQRencYLARAAsFHArFeulhD6hZplRF49h8+zpI3kn+vFtYwbUqLSRwze53rrJtqE 6o5MWSfadr9KIc8tNZ2aBGxzjGnsbPYLDh76NkjP4apWSMX+u+EHsaudoZoAdNnM Kqr86sVzR0MUeGHp7n/L3imp1WoCn28eMLeNec9a4GRTRPGLKR9F/jytTz/XgkHL zA3i2pt63FqniN4PBTNFzgfXiu8xVZGohsDPjmd9LXbGKTXfJGhBLB6QsmjJwglt n+00ufdKLEZu6eBxRWSVK0t4rEnnpK9K//PKq5DtVaOZNe6g+hdi0B1gpd0f0nBy eZd9arCsvN3qLXP0vYTk9DKMUecCEblss5Zt1+qjAbsMk9/xSGZLJp/4dBTBVN+Q c6+Rmv+koe6zLNmA3fJH3991xETDzZxP2UHN7q4i4L97KA+nVAakwazNLiqsY/bT s58rXnCc72b7oLnZbNOPQmLwZFafVi4xoIE/5Zq8iVr7d7xHPccYkaEVCOnsL/35 GZxy2FNi4wuOfGwBtTbnXg/u/YiBj6yNbhLR+FCwZED5M/evgUUbJudxqRdrI+1a Zo9gGA3JLJZZ/iLwF1kE7yYBvyBRfaO9IL3bwplRurnrkjI+rRhi55AlbGhU3eMu iKTKQk+qJF11ocTGu/dE9I6JeQpEdyVehrWXc5H2N0Qjyca8ZEA6WwcAEQEAAbR7 QURBTSBNQVJTSEFMTCBET0JSSU4gKGl0J3MgdGhlIG9uZSAuLi4gbGlrZSB0aGUg b25lIGluIFN1cGVybWFuIDMgYW5kIE9mZmljZSBzcGFjZS0tYnV0IG5vdCAqdGhh dCogb25lKSA8YWRhbUBlcm1jY29ycC5jb20+iQJOBBMBCgA4FiEE0s8R6kp2bveF MmxLkifaSe8nN2gFAl6dxgsCGwMFCwkIBwIGFQoJCAsCBBYCAwECHgECF4AACgkQ kifaSe8nN2jK+g//Toi6ezWYrRbTs9xwQLIsKzl91ocjCuN9nHSnwzkrLuoGGgej fHkXzd5+3ygL47j++k69TYB9CPrGdR1GTqt56Q7DSYZCgdg+e89piTJUzbEyN01q EGkVuV5Rz9EocnPE8db9HT+xvf44ecfMOFD1XuB9jynrQD445YfeFE6LHkoNUvFD wQK7NN04fa+qvrk0lTS4NCpOYsdrSioddVjQyEC6jepwIRA3iRIkFdEJT8ggqQ6d gntsgExA01o6HqzDSHjSCA5AexCotwW3Uvdt0WwXx6q/c0LsRLhbuPeGX/Nh8aOf 6RBCQWgnIko675ura4c+r1VcBYl524ZJlN4x1x02YAo9cKzYi3+H9C8K8Ayz/SJy 7sVGHWnDge1yIwzWXbpolqiMSL5l/0OBuJ0HXQSafUut33Jw7hYKP4BQia/BmE0x Tsk0rBRMyihSYnUn9mYpXM3KwWU0C2dudVwKtToGR1aKlYcCv0iNFAsR0DBw1XSq n72KqIl020gZFmg3H34Z6CWhm20RbhMjOvvkZ+OiS9kU9kXt6m+T1zCpWHFJSae4 JF+dQyB1BFxAwXW4ZEzMo4XluTuW1R8pIadKTsHMWzEzH7RvZLKP4invsZklZ3I1 EEsJop7DSMOa27irD/IlCL+nwaEsCMRh+ndSkADLHsa9P5d/qWjomKxwdCm5Ag0E Xp3GCwEQAOoXU8NrugMa8OAncXKv4hycXJzArDae3Zx6pCCEkP3TZTXh1tqKPUtb dmb8Mq2eecVTwmB+FM3m+NApgq88Vx6HiyI73IAvgtZORo32YaipfbkGnXHfaUWX 5380R4GL597yZuP8sAsJ3iDvxhW59snsU8tLi+9r2u4h0fgMDqZXQsfvLUkDIiO9 nzJf0xFacTx3n+pUuWdzIuT3AUdU/L9NubmHSnj09FevTHWIYmxGFZoiSdS7r2Z+ 5xZmPak6lzrQTVS/DxcpyA/o3yi8qLPyf1VUxXKFeKd0sV6BPvYFxI2GeBl5atBu 9/3/5D6wdlrupTFLU1Msdfy3UWaRUFHLITK4fJ7pbTgoEqxX7gpO9iqKmScm3gYc O3blA8aTqCX2NzxUF5fHbi14JvPWP04uFl5EOeDB322Jm/guWy8TvmIIyuF3aAAX PfErW/yRWDsYOcAADs8elZkt3F+E/AwWd0JMIhd/RB3RFH8m7496XLS3xBP6rNye 0O+96lX7fVp+wvINxM3Rfo63b1K4bR5KR9JDZ2SLYhrx6Hyy+UiRv7l+i26WxVMF qRyvY2aHqyvKfR1EEf1t2h7B4b65xQkj51qvX5Tjm5Az7nKcXpcUKqS3bk8xiw9N y7eFfA361OSPpQ+V4Mq/Mv+MqyxLTz9tn+80ZtjqM0MEERfpUo15ABEBAAGJAjYE GAEKACAWIQTSzxHqSnZu94UybEuSJ9pJ7yc3aAUCXp3GCwIbDAAKCRCSJ9pJ7yc3 aE2NEACDBRnGYNi2sq0wltPSkD2CbQUon+4uiFB2UU/gs4mFlGOvzDHBHVEFzCqK 0x6KlKm4XBq3AF7iIoNMiU9FmBdWDnEp9eCXdQrr/ykgq3vKMuj6/QJNNZglIDoe 1J2NXeMOUFwCUvjcCttPv42Q8GDt8/bG7QOgmTmhuqvKIj/vL+c3HgNrRsQzhw5z mSzQIDaesD+UVA/sourXpSLeqPgF+6qsEqOirD6hotaqrt+aIA/8wbYkpNQxCEK4 gKDgpqTV7VKklku7fjyhBhZQOVDoWvd03AlGQD0WBNriUsh8l4N6Zg2BlnKTGn11 BTigqwlHC91xtjERgwFg8PAHN2mtgZUHITHX5js11KwlQdLyI04/M4M4oQq0KSbJ rpiWCgrltC/VqJrT4HELFYx2Iv5wzrV9jVEm6zonag4A761hpqTgRrjWtaLuYu2Z zdw9y1r0+0d2rTUGpjIQRVOwi3AF/G4aU+vAOOf/HcgH6Qnpbu+xV0fkuAZbTI7w 6VVkBvnstiQV88KrWAOXKVABSSxTz2OYbzOTt/bgxzAa7yr1xIBDKvujBqDRGBLi bISp+40Haoj2Yqop6vbS70Xq+cnBOwJW86u61hsLgOjqyxgLzvuGTjK7+TblCjR2 F4LNeQdwDdyNRjPYeGVXM3MEqR8XdcR1Z7BQvLNcDgoW2qDcbg== =4lZw -----END PGP PUBLIC KEY BLOCK-----

      not exactly sure how a bunch of pages were cut short in "production version" i think I have to go through them all manually one by one. here's the markdown missing from this page:

      I am accepting charitable donations,.\ ETH: 0x66e2871ef39334962fb75ce34407f825d67ec434 | BTC: 38B6vGaqNvMyTtoFEZPmNvMS7icV6ZnPMm | xDAI: 0x66e2871ef39334962fb75ce34407f825d67ec434

      "ceruelad."

      As a really brief aside prior to the introduction, the intersection of "Joseph's dream" and the stories of Atlantis and the Lost City of Gold ... among a great many other "municipal dreams" has long been (known or?) the primary motivation and drive behind spending so much time and effort on making this dream a reality. It also intersects a number of modern idioms, things like "all roads read to Rome" and "Rome wasn't built in a day" -- namely because I like to recall and recount how this vision of a city in the sky was truly re-written in a single day (which is why I haven't re-done it again or elaborated more on the things that ... I'm about to actually ... do (just to link further to El Dorado)).

      It was written though ... to describe a place that could literally be built in a single day--using various tricks like "copying from our reality" the base framework of the island, and then using "computer science magic" ... here hidden in a place I call the Artificial Intelligence Samilicosm, little "tricks" that enable a single "interface class" to create a network of "island nodes" that would enable everyone Earth(s) to visit the attraction at exactly the same time, with concepts like K-nearest-nieghbor (k-NN) to create rooms that house millions or billions to appear to only have a small group of friends and family in them. That concept bleeds down into the boardroom concept, to help create a venue for a global-glactic conversation (GG-c?) on how the power of computer science can quickly show us how assimilation of this "demonstration" will quickly lead to a world without war and famine (and eventually absolution) by showing us how every war and argument fought over absolutely-falsely-scarce-resources have created dissension and conflict in a playce where the truth could build a much happier and healthier "venue" for interaction.

      Though there are two primary pieces that connect in different ways to what I call the "hardware and software of the road" something that links to the words "sword" and "Asgard" ... among other perfect words like "hard drive." One is "OMEALFHT" and the other is the "Rod(s) of Hey-Seuss the Anti-King." Since this is still a sort of "decoder ring" for the hidden language, the link here to "hardware and software" and the letter "X" which connects the Xbox and "kisxmet" is that "cross-storm" (in T we're Macy's ... "intimacys") in a letter is also described by "gtk+" where you can see the "l" glyph of Brickell (off to see the Wizard) with half a X in ">lt" form. Since I probably haven't put it on the main WS ... Penrose sort of connects to the L's of Hell where it's now almost uncontastuble that the word Obelisk is pointing to a road aiming for the sky, as it is written, by the pen.

      While it's probably no secret that those "ll"'s aren't the only version of paired L-words; it might be less known that I'm fairly certain "love and logic" are actually the best fit for why ... combining them ... keys the llave of Kurt Cobain's "hey, way" ... to open the gates of Hell and finally escape it. It's in special places like the "light of the Son's of Liberty" connecting both racism and sexism to name that ties together to show us that over time, our special history ended ... specifically slavery ... first by love--knowing it was the right thing to do, well before "logically" the jobs of picking cotton for instance would be replaced by gin. Though here we are again staring at "XIV's" c (see arxiv.org as "kiss ar hive") ... hive's hiding the fact that technology has well before now replaced the need for the kind of slavery we fail to see prevalent here in this place, a darkness caused by ... the same technology's' hidden use and keeping us from making very important connections between the illustrated teaching we call history and our present predicament.

      \ NO DREAM, THE SECOND COMING WILL END RACISM, A VOW

      Kiss me I'm fiVel; it's the same kind of darkness that caused some bright kids I met in California to tell me point blank there was no "dick" hidden in John Hancock's name or in Tricky Dick's or ... also in the Constitution and that sort of behavior is literally the cause of a slavery to lies and to watching Woodward and Burnstein's lack of fire extinguish our freedom to think clearly, to vote with clear thoughts, and in poignant and direct relation ... freedom of the press. We stand here refusing to see that our lack of action and seeming inability to discuss the "ridiculousness" of not seeing this information and my name on the news ins responsible for not seeing very clear evidence of mind control technology also on the news, and in our government's legislation and that's the cause of the slavery in the first place.

      "Theyanthem" was a happy and bright reVelatory "so ... viandname" for me when I first landed on a sort or Elishan compound word describing the relationship between two anonymous "us's" or "we's" that played an early role in my introduction to the "red ties" of Gang-stalking and while Yusuf Islam's key clue of nomenclature probably only told a few people that Pine Crest school and the University of Florida had yet another very clear tie to vithename Adam and how songs play an integral role in keying and linking and intersexling the m essage of the Revelation of Jesus Christ with American History kisxes ... it was this new intersection that reaffirmed that link to the point where I see it needs to be made even more clear.

      \ \\ I've noted before that it was very clear to me that the "oceans white with styrofoam" and the "good crowned with brotherhood" were very clear references to racism--and it takes not a logician to see that the simple Christian tenets that surround the foundation of America would tell you they were also a "thinly veited" admonishment of the same; it's through "logic" and advanced technology that we can be sure that the Second Coming and it's connection to pervasive "eyes to see" and "computer assisted intelligence" will almost immediately destroy the absolute stupidity of racism, jingoism, and the like. Pine Crest's school song--which is literally the only other "anthem" that I know of, though I'm sure m-any nations' will be added to the group of songs that are hallowed centuries and millennium into the future from this place that is the origen of ... something special ... an intergalactic network of races supporting goodness and morality. It's single related phrase "like our towers so tall and white" (in tempo, even, highlighting the strangeness of the addition of color) preluding the very clear reference and explanation to "how" ... our minds expand and ideas take flight. As an aside, it's the words "as the years go by we'll love you more" that I now see as a sort of ... appromise specifically to me, in this place where I feel hated, for all the wrong reasons.

      The proof is "in the pudding' of course, but it's been so damned long already that I don't see the world changing by "intro-duction of floating city in sky" or by "magical neuro-nalpmi-napatms" without at least having a story break and some actual public and recorded discussions--even if that's really what I want, to see thing happen "swiftly" and without the possibility of it being "every day has it's day of being forgotten"--by everyone but songs.\ \

      It's still ery clear, tho, that you don't understand the message, and the quasi-veiled-doublespeak-response from ... personas-non-识别 ... that what's happening all around us and without our input is very clearly tied to this same lack of acknowledgement that a working society has a "working press" and that failing to see this message on TV is undeniable proof that there isn't a single working government on the planeth Eart... and that should tell us that "the skies" too ... are staring down at us in sham.

      It should be abundantly clear that even with the knowledge and even the very technology of "how to build Heaven" in hand ... you risk carelessly and without regard for the future the possibility that we will be finding ourselves in multiple-simultaneous-hells rather than any Heaven at all until we rectify the darkness surround "communication" and "government" that is so pronounced and obvious here--you should see it as a very clear lesson ... one that you should also see you have not learned.

      \ \

      So we're staring at the focal point of the intersection of a message that certainly wasn't written in a day, but is read as thousands of years of history--probably a very large "underestimate" of what it actually is based on and took to put together. Here we have ... "lore come alive" to show us the "nard" ... the salting of the road to Heaven is "explained" as a sky literally drugging me ... around the time of the dissemination of a message that probably would have "gone viral" and made the news if it wasn't for that ... "salting." It's really difficult to say today if that "salt" is warming a road or "preserving a message" as we see ... nearly ubiquitously that salt does good things for ... the dead ... and it's somewhat toxic to the living to the penultimate "wife of Lot" -- clear as day to me today that's just like this message. The story of "Casper pointing to a gate ... as a message all around us" is a godsend in Heaven and for "an Earth in Heaven" and without doubt poison were we ever "stuck" or "printed" or ... trashed into reality for no reason. Just like the "love and logic" of the end letters of Hell ... it was very clear early on that printing the Earth was not the point, but a sort of honeypot trap--and as the "hardware description" came to light much later it wasn't just because we'd be pissed about the message, but because it's simply the wrong path given the current state of "hidden technology." Hidden, I'm telling you, be'cause your silence and our lack of acti onon) here threatens civilization.

      So it's the "nard" of my grandfather's name Bernard, of John 12:1 and of John Maynard Keynes that connect the "NES" and "salt" to the clear intersection of "Tea Parties" and Na-po-leon Bon-to-part-e with "taxation is the ft of our Christ" and "no taxation without representation" to ... Render to Caesar ..." why it is that "no representation" and "no free thought" are linked at the hip to "no free speech" and "no free press" and you not picking up the phone and calling a reporter. It's linked to "IRS" in the heart of "FIRST" as in ... the first to make the connection between "taxes" and an overabundance of food and "natural" resources ... brought to light by nothing more than acknowledging that this message is "important enough" to allow the world to actually progress instead of stagnating.

      Below you can see that I'm putting together the pieces of software necessary to build a prototype "Sworpen of Caesarthor" ... (hear: see's Arthur) and I'm going to ahead and do it presumably all alone because nobody's (very few, anyway) "coming out of the woodwork to help build a platform that will end forever the power of any government to censor a message ... of this import (and obviously less important ... messages also). I need your help ... not being angry at the world for staring at me in stupified ignorance. rather than seeing (and building something with...) the light.

       

       On April 23rd, 2018, a curious transaction appeared on the Ethereum blockchain. An anonymous activist sent 0 ETH to themselves, but the transaction contained many extra bytes beyond the ones used to complete the transaction. These extra bytes were the text of a letter written by Yue Xin, a student at Peking University, detailing a pattern of intimidation and threats made against her by the school in response to her attempts to investigate claims of sexual assault made against a professor (you can read the full letter by clicking "view input as" and selecting utf-8 on the etherscan page). She had initially posted the letter on the social media site WeChat, where it was widely shared before censors began to purge all copies from the platform. Chinese censors have consistently targeted the #MeToo movement, forcing whistleblowers to find creative means of sharing their stories like esoteric hashtags such as #RiceBunny, or 米兔, which is pronounced similarly to "me too."

      By using Ethereum, activists have found a new and unique avenue to disseminate information and resist censorship for Xin's letter. Because every computer running a full Ethereum node has the complete transaction history, Yue Xin's letter is replicated across thousands of independent computers. These computers are all controlled by individuals and organizations without any centralized oversight or shared government, making it virtually impossible to remove the letter's content from the network. The same technique was used again in late July to protect a censored story about corruption and negligence at a Chinese vaccine manufacturer.

      [

      ](https://ipfs.io/ipns/fromthemachine.org/blog.joincivil.com/uncensored-content-on-ethereum-how-chinese-activists-inspired-civil-f09f095a9e91)

      P.S. .... the preceDING world changing message is filled with gibberish.  Understand, "gibberish" is going to change the world.

       

       

      Unless otherwise indicated, this work was written between the Christmas and Easter seasons of 2017 and 2020(A). The content of this page is released to the public under the GNU GPL v2.0 license; additionally any reproduction or derivation of the work must be attributed to the author, Adam Marshall Dobrin along with a link back to this website, fromthemachine dotty org.

      That's a "." not "dotty" ... it's to stop SPAMmers. :/

      This document is "living" and I don't just mean in the Jeffersonian sense. It's more alive in the "Mayflower's and June Doors ..." living Ethereum contract sense and literally just as close to the Depp/C[aster/Paglen (and honorably PK] 'D-hath Transundance**sense of the ... new meaning; as it is now published on Rinkeby, in "living contract" form. It is subject to change; without notice anywhere but here--and there--in the original spirit of the GPL 2.0. We are "one step closer to God" ... and do see that in that I mean ... it is a very real fusion of this document and the "spirit of my life" as well as the Spirit's of Kerouac's America and Vonnegut's Martian Mars and my Venutian Hotel ... and my fusion of Guy-A and GAIA; and the Spirit of the Earth .. and of course the God given and signed liberties in the Constitution of the United States of America. It is by and through my hand that this document and our X Commandments link to the Bill or Rights, and this story about an Exodus from slavery that literally begins here, in the post-apocalyptic American hartland. Written ... this day ... April 14, 2020 (hey, is this HADAD DAY?) ... in Margate FL, USA. For "official used-to-v TAX day" tomorrow, I'm going to add the "immultible incarnite pen" ... if added to the living "doc/app"--see is the DAO, the way--will initi8 the special secret "hidden level" .. we've all been looking for.

      Nor do just mean this website or the totality of my written works; nor do I only mean ... this particular derivation of the GPL 2.0+ modifications I continually source ... must be "from this website." I also mean the thing that is built from ... bits and piece of blocks of sand-toys; from Ethereum and from Rust and from our hands and eyes working together ... from this place, this cornerstone of the message that is ... written from brick and mortar words and events and people that have come before this poit of the "sealed W" that is this specific page and this time. It's 3:28; just five minutes--or is it four, too layne.

      This work is not to be redistributed according to the GPL unless all linked media on Youtube and related sites are intact--and historical references to the actual documented history of the art pieces (as I experience/d them) are also available for linking. Wikipedia references must be available for viewing, as well as the exact version of those pages at the time these pieces were written. All references to the Holy Bible must be "linked" (as they are or via ... impromptu in-transit re-linking) to the exact verses and versions of the Bible that I reference. These requirements, as well as the caveat and informational re-introduction to God's DAO above ... should be seen as material modifications to the original GPL2.0 that are retroactively applied to all works distributed under license via this site and all previous e-mails and sites. /s/ wso\ If you wanna talk to me get me on facebook, with PGP via FlowCrypt or adam at from the machine dotty org

      -----BEGIN PGP PUBLIC KEY BLOCK-----

      mQGNBF6RVvABDAC823JcYvgpEpy45z2EPgwJ9ZCL+pSFVnlgPKQAGD52q+kuckNZ mU3gbj1FIx/mwJJtaWZW6jaLDHLAZNJps93qpwdMCx0llhQogc8YN3j9RND7cTP5 eV8dS6z/9ta6TFOfwSZpsOZjCU7KFDStKcoulmvIGrr9wzaUr7fmDyE7cFp1KCZ0 i90oLYHqOIszRedvwCO/kBxawxzZuJ67DypcayiWyxqRHRmMZH1LejTaqTuEu0bp j54maTj09vnMxA0RfS+CtU5uMq+5fTkbiTOe1LrLD72m+PVJIS146FwESrMJEfJy oNqWEJlUQ0TecPZR41vnkSkpocE1/0YqUhWDGSht+67DdeKUg5KwvYdL21d/bSyO SM4jnyKn9aDVzLBpYrlE/lbFxujHPRGlRG5WtiPQuZYDRqP0GYFSXRpeUCI46f49 iPFo4eHo2jUfNDa9r9BjQdAe4zVFn2qLnOy8RWijlolbhGMHGO3w/uC/zad3jjo4 owAfsJjH5Oa1mTcAEQEAAbQmRUFSVEhFTkUgPGVhcnRoZW5lQGZyb210aGVtYWNo aW5lLm9yZz6JAdQEEwEKAD4WIQTUJHbrYn3y2DzwTcnQP1ViZf5/FQUCXpFW8AIb AwUJA8JnAAULCQgHAgYVCgkICwIEFgIDAQIeAQIXgAAKCRDQP1ViZf5/FWM6C/9J gbRLS2AWGjdRjYetlRkSkCoTYnXWknbtipYYHlhV0YJFwFMm0ydZIhFX5VDoZyBV 0UBeF1KJmcMoIfrHyhq2QhCnjE14hE1ONbaYTGtpvj851ItbFWXMJIVNyMqr+JT9 CWIxGr1idn+iHWE3nryiHrdlA3O/Gcd4EyNmaSe/JvB7+Z1AVqWkRhpjxxoPSlPm HEdqGOyl3+5ibQgUvXLRWWQXAj80CbVwwj1X4r9hfuCySxLT8Mir7NUXZFd+OiMS U8gNYjcyRGmI92z5lgf7djBbb9dMLwV0KLzgoT/xaupRvvYOIAT+n2mhCctCiH7x y7jYlJHd+0++rgUST2sT+9kbuQ0GxpJ7MZcKbS1n60La+IEEIpFled8eqwwDfcui uezO7RIzQ9wHSn688CDri9jmYhjp5s0HKuN61etJ1glu9jWgG76EZ3qW8zu4l4CH 9iFPHeGG7fa/5d07KvcZuS2fVACoMipTxTIouN7vL0daYwP3VFg63FNTwCU3HEq5 AY0EXpFW8AEMANh7M/ROrQxb3MCT1/PYco1tyscNo2eHHTtgrnHrpKEPCfRryx3r PllaRYP0ri5eFzt25ObHAjcnZgilnwxngm6S9QvUIaLLQh67RP1h8I4qyFzueYPs oY8xo1zwXz7klXVlZW0MYi/g5gpb+rpYUfZEJGJTBM/wMNqwwlct+BSZca4+TEHW g6oN0eXTthtGB0Qls71sv3tbOnOh/67NTwyhcHPWX/P9ilcjGsEiT8hqrpyhjAUm mv7ADi+2eRBV8Xf8JnPznFf0A1FdILVeVHlmsgCSB0FW0NsFI5niZbaYBHDbFsks QdaFaYd54DHln69tnwc2y3POFwx8kwZnMPPlVAR2QdxGQD4Wql7hlWT58xCxQApf M98kbAHjUlVYLT0WUHMDQtj4jdzAVVDiMGMUrbnQ7UwI7LexSB6cJ7H+i7FtS/pR WOhJK6awoOO9dLnEjm6UYCKsBdtJr98F0T7Sb7PnKOGA77y2QN14+u9N9C1lB/Z1 aQRQ2Nc51yXOQQARAQABiQG8BBgBCgAmFiEE1CR262J98tg88E3J0D9VYmX+fxUF Al6RVvACGwwFCQPCZwAACgkQ0D9VYmX+fxU+KQwAtFnWjGIjvqaNXtQjEhbGDH/I Q5ULq/l/wm9SmhG9NYRu3+P6YctCJaZnNeaL+6WFk1jo4LMiJEUT9uGlCbHqJNaI 6Gll1w6QOVLSL8s5V1L477+psluv4WBpi3XkWYlhDOFENCcWd49RQsA2YCX4pW7Q 7GcoSEJoav38MxHmJHYPfjSEvUZXDQIt8PFHSEScvyDWfYtMdRzjmSOOPdzhDDEy 5JBOBcEdSTyDiyDU/sBoAY0e8lvwHYW3p+guZSGSYVhGQ8JECzJOzwc/msMW/tJS 2MLWmWVh5/1P8BVUtLC2AQy6nij6o+h6vEiNzpdYrc+rzT3X5cACvJ0RtCZcrnhl O9PLiona2LEbry6QX5NL41/SAJNno3i72xPnQEe25gn3nbyT+jCoJzw2L0y8pmNB D+PKrk7/1ROFFVN8dJeGwxLGdBcz1zk2xeumzy7OaV8psUyYsJNcjyHUKgclblBW rMR2DgqEYn8QdK54ziKCnmQQZeMPiC6wlUWgg5IqmQGNBF6RVyMBDADALD7NkJ5H dtoOpoZmAbPSlVGXHDbJZuq7J13vew6dtXDIAraeGrsBqkF8bhddwVLzWylMrYCG Bf2L1+5BDgvqu6G+6dcVSbBsnZAS0zfJ0H8EmTvUMxMF7qOZYyrxfLz+pQRq8Osz Icab6ZI/KB6qZyQRvEFPB6pJjt+VvuwgJZTObIwbBbgQri2i02VBkjchsVhiSX9l +eiK7O8ROHKb3P181oScIsHywBOZ9DxRAYbFk5dnBqxO3WKb02H0zqE6440cjXwq TrZZg6ayN/IlPajO8iJPYZ1aIBykxYq1WHo+nhFMYz/VVk2WJorFeOgWaLGXb73c ty96f3qXTdvMDAIWHx8YCD5LbuqasO6LNQm4oQxkCoB3K9WFf/2SvSYb7yMYykb8 clTPt+KO0dsxjWhrJnfnIhC+2Chqv2QvRbFz0S9CpUnGGDweJ1uRNV0y70tO0q7t xXSTDRU3ib6vAHA0K/2MFzwUcog4o5bj7E9uCNJH/DJLZKsMIe4xsvkAEQEAAbQk SEVBVkVOVUVTIDxBVkVOVUBGUk9NVEhFTUFDSElORS5PUkc+iQHUBBMBCgA+FiEE IRklfU/C1qukq3xMXcNH0t3P9ZsFAl6RVyMCGwMFCQPCZwAFCwkIBwIGFQoJCAsC BBYCAwECHgECF4AACgkQXcNH0t3P9Zs+kgv/XEuuWc89Bjg1QQqKZueKNUHjyjnE 2adfoZUH6Q7ir4JZyRBCVpAwrgssmiKid30+SIjwQcpb9JYa/X1XJcDUcJW/I21d Agz/zbEqn/Cou0dUpNCtxgm4BdSHWGoOtgfspXZlXBQ407tRMZ8ykmLB1Bt0oHvw PT0ZOtqXM4pyFnd2eFe5YGbNgl3zqvoC/6CMN3vqswvRlu1BpUuAjdW8AHO5Yvje +Bp852u+4Qpy6PMBiWGsBMYwtf6T7sckpMGlR0TsozwBlAm5ePKK28B0rLJPkZLJ Eo5p4rKRapEaZsWV5Qu1ajrVru7qmpUhZtX0/DddGHfXVuLssmKLP6TumpQB1zvQ vfoBltjvOx35Wps2vHuCzXLw2bROIOzhAxFB+17zxnSbE54N4LIGRpkELuwxwGbg FtD1fi9KtH7xcn33eOK1+UD47V+hKyJGrQgSThly2zdIC2bvfHtFdfp8lOFpT0AU xjEeoJGqdQVupptXyugPlM5/96UJP8OZG0ADuQGNBF6RVyMBDAC3As6eMkoEo3z9 TkCWlvS0vBQmY3gF0VEjlAIqFWpDIdK3zVzMnKUokIT1i7nkadLzHZT2grB4VXuJ FvpbYw5NPR4cDe9grlOMLEaF3oSJ1jZ4V1/rj9v1Hddo8ELi/NToVrt1SB5GCVXB DkYpNLtTiCqHSU07YqwaqH8a+qbDmPxSQdIybkZiTiCEB+6PfQQlBpENEDlov6jm zZF+IcfM6s3kZDX5KFULweH30gMjq8Se8bPtUzW013+tuuwEVr1/YRLrIh+9O6Z+ pdA7gLMRYnD9ZLDytEvpb1lBBSY++5bIJ7xps80//DNqPYqwFmZQgTg0V9XbHE2e wLcOF8a2lYluckU7D///sWQhW+VxuM7R2gEBvYBhOgjWhIF2Aw6NbymW1Ontvyhu eOZCXXxV5W44PxXT8uDdhl9CNcHoBKKJyED8tKjigtn4axpsQeUrnOSbqEXSyqES WnE2wYUDzALcwFkzsvtLyd4xaz55KkPQkAkk0BZd1ezgXxb/obMAEQEAAYkBvAQY AQoAJhYhBCEZJX1PwtarpKt8TF3DR9Ldz/WbBQJekVcjAhsMBQkDwmcAAAoJEF3D R9Ldz/WbAFwL/382HsrldVXnkPmJ1E2YEOFz4rcHRetJ+M5H65K/2p32ONQ5KCbE s8MRY6g2CkE70en2HlpDwr/MdATwxBzIjEpjgHbfqCqVVATY+kSpXsttaKKAUVHi bFgV4QkdDJNSpcHEj+bqaggRnuWiV9T6ECG7kQjHiEXPNojzsiaXMDiM5r+acZm6 82id9qOFySQ2cZEy5HbwXM+ITLQGngnppa7du2KdgiqDeqtODOTWZvLYAq2tmEwD 3TT6ttLUBwOOu2IWpDkXswlrk62ESorE5mpLxop9fsxD39E2H06JoC/YfUPIVkEv fj06e7LEdcx0I7kRfD1v6qOUUsMsLZnmyGIk24iFjLkwu1VToWfwXDN1D2+SeAat 9ydNt4M7oEbd1QaOXXjmqpdU+VUiWcBXg+p3/WdV60MkyAgc3x+YanLljy/Rh18h cZwVlinf/tgvAQLi5f9hpwrwUMoGKijEYHKuEvi3C12Si7UVDfuIR7yS0dKcfuKF MbgwdvNXqpD9W5kBjQRekVd4AQwApHVgw2PVlBDpVcyoymUOXFQIJzJ9wRtr6/sG zwv8rrQnUEtOkkna7TDU3/UTj9FUH0gbpAKGNNPaPj5q0dlLIvzxb15r1uvDGaGL MA+8GFaGFnkxzhg0aXrcKZAN0/Zhgi2B7P8oXQuug5mi1JVDkZN5SeCZNOubdQWL 3xz3jEHp3ixj1mdOdvfdWQFR4CVMXt/A6VI2ujLVb3Yalft/c5bbclAgcJQhgDUu NqGYJEJonESNRSd8fEvhNb6cx7+Djd9+Wyctr76mwOr3nRb1N1OGhFxWjIroUpfz b+6y3oQjT58cJA1ZHqmJ6UlZd81hNNd9KWpbDVwONEPpiqPzfSaonxuqQa0/Cy4W 403OhfoLM/1ZDqD4YrJ/rpyNEfSSdqptWiY0KeErLOYng7rStW/4ZeZVj6b2xxB2 Oas/Z1QYfJyFUki9vaJ5IyN6Y7nVdSP6mbAQC9ESh+VPvRUMpYi4pMGK4rweBVHu oMRRwzk7W5zVIgd425WUe3eCQFn3ABEBAAG0K0VTQ0FQRSBST09NIDxFU0NBUEFF REVTQEZST01USEVNQUNISU5FLk9SRz6JAdQEEwEKAD4WIQTvnDJqcmqzlF87/t82 pJ91j4NOaAUCXpFXeAIbAwUJA8JnAAULCQgHAgYVCgkICwIEFgIDAQIeAQIXgAAK CRA2pJ91j4NOaJVjC/4oo5yCHe7M2h1DiTXVcLI5rXQ1feY7B1feg+YJX/mI4+EV xjC/y5VVpV4syJk5GGZNXhKPHiGLaBYvglTlYOJ98RSEsHrwT3go6S8ZVvMNdP5v CEncn2vm5JGnp4k26PuOzMcJioQLOoUjWtcPFis3gG+ueH3NcPZ22oZUql2xuerh TQZegGp+jJ7bdxwYElx5jDDDkh196d5nlO2ZKENl0ZDp4GAzRNjnQ7KBV6R74J3U cLQDWY8vAFaRBZXIC5XtSzj9lr+jWgvxz7Il51+26VDTEtSafZ2uZfCOFk7GrzJg YFJD3zLnwUFXDWKRkep8TSwXnHmz/Ts/Mjyv6em25w7QTdnx1hNPxYNWMxPWNEAH pf70nNyOmcWcq27W+nAjVg8W3st/7J5CIebJQc5AUgm+fGOBW6XUQaNy2YF1YJlA 71/tls+R5IQZCYzbPOibgFS1HWKTwy0iI2rMDfxBtCXciv754jVI7L6R3J0j5Dy1 WZQVjaGgimznLN6XwYy5AY0EXpFXeAEMALvElrTV5hJG9DKu8cOqQEEVejtWJtki fZyvmiAKi2bZWiNfl1MxJt+o3Oc0eARJfnaPjrUY7hsbbSBAB4lFnDRtviARPaKM st5FkFgOh7Xx5ODc8bjqhMT9tbX37rkeDc12WAs3UxtEKWjyT7Xg/APKeK5FzpIs qew3LADdqFP9nOR0e5G8gxLTYh3ll3dLtp9DkJgA9q+0g31nNh5fZ29mcDzo/Mat Uk4PIxWC29LV9ALCJMIMesjOPiDa2KOy5QQH+/vn592ydBohOaY+B6jhEAdX8Dbp VHVFRBsiCOWGmdi6vHjMFD0tQdS6bXf+ZAG0E5HZETCxA2qfMf/vTeIJXYS5IZw0 anRkTXcTBrVE8uBpqtkNOrLJsaASkcoO5qF01J9zW8SR4jDgET7J02Fxf8CVPzb+ ZoNc9S0ZEO6Ubdh2vAkPtOV5sFkwIduN6ouAhEfJzC9XbJLpgsBKrRMAjr2FeEZP ruy8BkZbiyZ/b0S9qIgY4pqcyUJ79w7FLQARAQABiQG8BBgBCgAmFiEE75wyanJq s5RfO/7fNqSfdY+DTmgFAl6RV3gCGwwFCQPCZwAACgkQNqSfdY+DTmhD9wv/Zgav EHMuqF3765Fa4NapYh2kMS3skHn+ZzUEPLTlvrt7KHxomOzExNLSscZThMpur+yW MfNWbsw9GphiYAkMULrfJt/iWRVJ1FLgbcWgRGAwakOGwE29lMx3+rPIUQWU54Dw vE92Iz51ZGz1wgKcISuCw39g/HQ9uc3h3TfHLgfkc/GaIEa8jEOAcD67dVMoU4o+ p3nMri8z6sK176hQ/FM/8kekpeVfxmR8s6uoaJsXLRQk+i88ZwBR/5U+fBT9AtVw PL/MmZH7eCmZrn5hjaOw7tpkL8ZyAydNhOsSCqwNVtrIjgd+Gq1oSgw9EZfhKSUa +dBJAErA7MWjammQizEHDNnI8VNLngwCahGwaSgDhNaQtgNxvnkWO7XNYoCYXScP X++UmpWtSKMnD6ue36Ba1jqon0WY5cen3P+H1gL4ij5ynB9DrE8R1aSY6f+VZ48B RvjHm5LKTcAhiv2N/TyAg/fr2v9ZnEcP3CFxqAyB9JSKwoBkFvxJaRHTT3DxmQGN BF6RWE4BDACpgKWvQvPRDN03+sLYMXpJUPC7VhTjg5K/1+1vS/e/W65dYzn3JYxb ip2PcI5xajFnxzUrwwmhW+qz5REDyCtAObOpKsjtr4qu7mgOWnPa3k2Lm0bpCjDr BSFOiQsBVezTG/gJm+qELeqQMS9PHDSvZXeBROK7OkRE0nZ6yAj+QKEoVqeADpDm BHmhAA2OKBzq4rDWDh1jRQ7gLjlv/BFbhU1WuEfH/qzX8AUSsd0/hoPG0cPgC8gQ 3m6wr4eYqI853XQujWwisnlAE2bf9jsRjW+aLrJJTcADWk5Op5aQhI2lURYkryfC DFVcme7Hsrd+RFPK88J08YjBjOoYFwRU4AhHgucX9tW0S0v9hi3pKrF9O/JAIf+r h6BpnWo7tT5+8mVhtFvfEp9Y4xeUAKKZHBKhzHeOO8QQgHrIYa6HCcU03eyxy4Tq AsJdAJvxYFCRPdY9d0Z6uVsPhRy+3UmTxjl590T5/XjKPriAjBqXnKr4KexsM1gj 1L96bYDEgr0AEQEAAbQaRTFYNl8xIDxFMVg2QEVSTUNDT1JQLkNPTT6JAdQEEwEK AD4WIQSGisfXZ2Vg0m16Mzds3dDsq5BTxAUCXpFYTgIbAwUJA8JnAAULCQgHAgYV CgkICwIEFgIDAQIeAQIXgAAKCRBs3dDsq5BTxKq8C/48HSgecuI6MYtq84yqaQ1r x6cteRyn9BJDFTAUxn3X25kf0vVyCKQNAy2oybD5QHFLqhFCXJH+cnJ3xdviRUeW eO9fhkTmd12mHGrRDD02AHXZmaMp6ni7FuYpBGrw5dbXKTkSWfD/qb3odMx0jQby 6X+2eFhUpyh+yPB7P7HwiPwzdr0dBg3xE0vE0Vz+naMyt4YBHzrBbZo+y47Q86Ym TmBKxG5tlVsGDB4dDWSIvpBgnMFN1j46Uk2ihu4huohLkvSou+jYU+5Ppu8Fu1+7 i3RCILzeBtucR9+T4px1WVXx2sKOk0FfddCvI/fT/mhsgqQZwjj9b8HNfobhNxkL HBNFQ7FLJxKayPwMyJYDURUq7gz9p5JwHTmFg9n7zyK8qU2xR5t2247YinfEJQYL zQM6VKQCoDqydFfAPeGlx1KjroMGls4sP3XVlrR04YzaJ0vxRgog1gIO1aHMQ2Sj l8bG0GcerQ44rpn1v33Gw6KL/0SY9JsSSSjA9lgINWi5AY0EXpFYTgEMALy/jHsN kUQQVJK9QuAy5V2GePBTEm9NnjNCk+edGjSgqC1LemmP7EYh07J13d10VqD2Wtae bXlBeaMOcnoXQdfdK6nTKWRrH97JuRTrA3efLkl/R4EA/kHHV+YDgT+LBboUFYVU QF5YhfcvgBUcLXI3lX5wMEQbLb87cVjR0JtqVBFMIIvs4ibgr0U2SONiD9LcXZxf qYcX7CMM6RmuLzHTCEHyjp+KAw52K1i3+3M0OVZpa25rKE+S7LykQ1GrUUY3uVHg R2I3T5/Sns3Azc9wKuy/F71oiXyqCc3FwzTQHoki+eBf5dzs6h3GBTK3Dz6kl2mv 1TXpY1dk2EmuqKIeSr8CE52nkK8ZKY6cvX+v/p1EBAkJZKiasj+ukL72p3Lji5r/ iOarNJnURT5LJdYYL27dtQFSYyVWayeWi5358Ajh1H9OdpiGXcgG65ry6u50G8JR FCywwsdKpGjMG4FlkLkm50/piU+cgVeLET/C7C/OXNslL/pHV3x8kPRY1QARAQAB iQG8BBgBCgAmFiEEhorH12dlYNJtejM3bN3Q7KuQU8QFAl6RWE4CGwwFCQPCZwAA CgkQbN3Q7KuQU8SHSwv/agnEnhmo2yuKCLiKdTa5KZ8wh3umiX3S6rldW0NO2h8a cq2l7xHY1r2u4ieeMx27jtTqCp7ksFxPYwP9WxtVBy0teG8pKLhEffjyG2WKDzAN 7oXNZ7Ur6OQGfuOQzlMqOGtYQrbHAuX60PCldurX/6/0sKS6vESdeGMQPoZIDK5g HP298MMhlWYEG7uU31J1Cx9ZqiTosSckfrDq3weU8x9DZYaLZ+Y2akF5XpL/HjyA 6PM+lv6vnTA+b5DYCOJb6N7v131Net2JN7JVVGoc0FjsxN/W33H7eIDOZwqcCvzD i8EjjzZpZUDeYjlSXAqWvpeAASncMzXS2/S2V2u5X2iR7tDtRj9SuQehJkdTFNZH xh5nTdhPzgh/iOcm33VsQ17JWbovl0hbhYBPO4V+yIrN+oQGPhH+KCNNa39EjEzB iBIgirxQSaykwb4f2Kshh+d7rKHKb/mn6JBHU444mBf09m5wM/mhLSpuhMTcP2h9 jfFximAE9FBhdZhQsF29mQINBF6I/R4BEADotSG8PhhxxD9/96bgdWa1bzp2398W LaxP39T+Kzx2KL2xB+7B4EeTTzZ06kD+myCC9Ez+PqecfisJPfaiLD/+0/m3HLSS hxEaEqt1RBS3j6qJx8Lr51cAwGou4hGTo9H3me6FHO2ExZXd76A6kkUh0J4y3r6q aAoDP+MUczKzEjn6C6T7Uu0pdgYY1bDhuqlK0taqkqviGBYTAqmCrtcQhj+J/jbd OIZtpT3+PH6mWqguoONiE+glWcdThyuIvV3ix/GrhjmUZb/DQcvvbYGfDvGRBH4B Uj3f9WBM6HWSxKrCwWC3OcgZhtBcZjKrMPbNDNt7yAArv7nGpHmlpfF14Q6mVmVT 6Ulh+0xRx+6zFbqlDYYTneurK3RtqOBsMFG5rNDZYh/QOsHnSsxmU4LGdlEfQjYs 901zmzP7CQXjjJbtRXWIqPcn3OHIIasvjTACe5M+Lfk3u3rEiDYM64vg29sSyp9q 8hAzLTPcLj/Cc22jUEC/bbv5HfLyCZTCsu5ym1gDQZ6bDrJlFlXZJ2+vTCBsY24H RF9/J/z1JWYD1cAHpG0GRtYE9exKpu8/81jxIVn21qvvxSCPXw6IQIsEw51uk5TJ xAUIRCPN7S0UEtd22LSbM/IYx1cesCRUCmY7jDTro/jo2B4hLG64KBgqyjg0lwxd dy5S8LwFx1zskQARAQABtGhBZGFtIE1hcnNoYWxsIERvYnJpbiAod3d3LmxhbWMu bGEgLyB3d3cuZnJvbXRoZW1hY2hpbmUub3JnIC8gZW4ucmVhbGx5aGltLmNvbSkg PGFkYW1AZnJvbXRoZW1hY2hpbmUub3JnPokCTgQTAQoAOBYhBE+vDT4gih9MmA0P ZvtOzkoQkinPBQJeiP0eAhsDBQsJCAcCBhUKCQgLAgQWAgMBAh4BAheAAAoJEPtO zkoQkinPJ4gP/3U691086OKbWiQhMhV+AViuKnMgV4i1M8s+4Ep01h/dTE6R+rUu LcnY4T0HR5qxAYMiNpGo1vtvkMvV5DP1PFSl5EddKn8+Kvn/0+WjbLV5tdiFF1Ef xR6261UFoXAGk3HJMLQifr3lWKoimaBwJZGza2ok9k1TQVTn8g5a01bzK7hD5DJI zt9RJZaUkxGE97eUyJ8Dtwumo18EWJltuC4UWjWT2t2HE9mMsOfjpYZXFsGxJ0Zb xexo0DYsriPDpuxDnZT7G3re9Vwz2VIe388DNBW5HoJsYxhr2I0QOq64ZWOSEZC8 lDH+xM6YdY0iz4A+7nbKNGifLbH8oU4A1sV9HrIE2KNy76x0GNjgQUvcq1inD4Oh yorsRh/IF6wnqvFrHOstCS2dzpKuQ/s7bM5TGOD2EGb0xu7r0AfHqqLUlbr3rxkS wBFMQphyNr3mEkEbXU1dGsXDlRQy11LigMBoEHmP0t49bYWuM1mIBnIC7gZc/sV/ E5fWmWdQyCKmHeujmS+sgp2EX0NtMGSzm7z9WBzTBFjaN7q28gueQ3INDsDTGx2G aA1LbP2uh1ipwju0GxecUif3T2NDqaYfhbaCYsPJORNUlJUtCVBGeba9wcXai2dh l+HsSKUiyCgKiy6Rt6jumKtYHt+Q0zcKWLfVp8PA20zX+2Q9zKnlLzwquQINBF6I /R4BEADQ4kmCHYtAhjCShc724Ei2pqSH4SfnXd4r8S8I0+io6Mh0kWn+kbKk/aGK BL3KJyN6624kPtOFWuQ4iQ0lWFn9UMnvjByTPbjZ2je+VtCP7lKSNvEgTLQRxLEJ hoNVrNjrLa/Cn7sLt9ayYcx8eKpHkbmrVRTyGqljBkI5hwQ8S+7BWugabhGQuogw bFthykA+wxYvSbSn5mwKO1BlbDCRnxjLISlqWwmKKEtXQ8b3tu7GgFuPYLKaLEk1 BIwwUSdozjXu+198WligepslidlN5bXrvje3sxgt4oAPFMeH+NnDClSDuGhSYamW Db3ZPl95pW70ngUVgFPG4kQOlaqzo3YBeDBHDXlqU0+O8cwSQFk4CBJI3yt6/KmD BIuKLwauOxYullx9EnqKcLWEzOlTgn9Q7BARK8Uz7PQU3+1mDNId2MEg+gfL3rd2 +aMLNhTUkgVE5mWkeDz6Kg7YhwruvJtn0z1QqUhkQcVs7N8rVCck0YUCVGXpsUlu emK48q4ryOxmMG/+Ws2Xkmdm6Axq414WHz6nLwMWgFpcO+1wRwQuZEkeWeSAjEvS CGHImxTP7E08+y3vAl43a9AlR7v9PbtCy2FenAhGPigmWm2aPj1ejYfQLXozyWSM m8uO3aiKvQXdV1Ha2xQLK5expaRaAXQ6YLsNBD77UPxi9qC5rwARAQABiQI2BBgB CgAgFiEET68NPiCKH0yYDQ9m+07OShCSKc8FAl6I/R4CGwwACgkQ+07OShCSKc9o DQ/+OV2OuDp9g/27SRssbTWE+nBl0R9klrb/w2XEIVhg5LROUe/P3anyBLNITbF9 A4q8b9udD+iIc1ClY2bu3rQOdzA1DH9GK84bQ1O/LaU0Te8RBGJJEzjYMUraCgIX 4BmxsIlWuCkSNsTgempLOK88646Nv5uc/oxAj6kQH7x8XBXxaJ+N9WS9f7EAv4AL bSWeJ4ijbw9BIMHt/D9Em7Q8bW6VGZIEjIp+gl1vNZ6QGCTtRHQez1jYmFLpuE/G yh1zM5gCnZbcmC7ExDLFI6SuYUbKC+XaLA3+LLCVCPFLtu6wLvcgYFwWWMKIhJAQ bRyPePiuMqWeWR6VXTD8pLziDjxK0ZtvpGdOtZeCCHOEmxrCsfKdIyD2Gn7TmTwb M9fRE1HazROfit6SRCAamabg+dJIEGT8vzlLfnkZRi+6hxq88uDbrOkk36ShWoYB AApz+5fj1ogLptiaTUTyyjTjB+/FIbU48/02fkD0y960zQLyKL64Q4aZrNa2NNup YKy5F80NkU4rHOZ1HTaPLoqqVsGhWc3ODgLyGPiRDLlZu81aNpA/UnTEBX464Sk4 Jx9qztb+S50LnGItA92QfE9ru7FAE00RR6mpCv1h7uE28/Wr4XaYgJcw1hAPRr7p TtN4lph+sJsCQ8eX5YUlM/Pht1h/LoE8h4hXNfAGh+CZgoWZAY0EXodqtAEMAOBb WTLRDxNk9SbC7exKdw0f8Wy9DhX2Qqoi96piS99CMJSxeocLiC9Si2u5nL3sQTAu qs1YbtSgn8kkiH3HPEJIhV1p/Hvz47j4kXq7PnjqF7KAdCYewuDqRiq8J7TNokYs 6+3/KqwHT/IT8NwPLdMkXcv/SXqhuKpqa2ApIrhu04VFp4H5OXN9rqdF5ZDfcNx1 PQv+6m8v6xRwrI3kduRCUD3YiVPM3EOhqINk9XMuxAoVX3qwpz+OuEDBm76U5jTZ q9ErdwRV9gaGm5ztq6tvElpis3spM7BPHzbv0SvVRAAbgGVh6kfiaZ3YckxLq8ln Cg5or1aZNyGMf7CmaZaeAjeY6Y8FZXR1P+n/IFd9Ak83a3qizZyckfiEPO7hu9zI FFXTdtZIcV102rNoVzruZIn0vSK1DJ7bNNrHkm1PPcweMkcFJY0uh6l3x2nl2qKm AhlDs3wFG+nqvqmnliVbrFZCYlReMrWWI2YBwLC5uBcBpFAhMPNEjxOtv31R+wAR AQABtCNBREFNIE0gRE9CUklOIDxhZGFtNUBwcm90b25tYWlsLmNoPokB1AQTAQoA PhYhBP/zHob861BG6LJ9SqGPd44Z/DJIBQJeh2q0AhsDBQkDwmcABQsJCAcCBhUK CQgLAgQWAgMBAh4BAheAAAoJEKGPd44Z/DJIKtgL/0JQEzrGWoHHN7T4wLiArPCv tHB3dTZBoXGKlpuwhgOZ1th6jOnGPdMZRYnX8Zuf7QhaI7m/duKv9OAr8A/2ftHG 7/BxPSHJWBuIGZYNL97OWSstuBhNtyxfCftDkeBCqJ+lAneOrzV0M8syr2VqpfVs O8nTE7nXHSOdyen+1Fw0PtwaeG9uJvOhgRsmQ+mtAiJ1OLGKUxgCzSUk0m/YnDg0 vJBtzq9qP9+EZSuiBuRQC0tKs01ECI5DzWLNXXC6X8k3YGrJpL/HtTxH5SYNQRvS ALd+HmVYpwijLPi7ANzmg9/+h/aq4VFP/4SyMd6EjaaQ86n2fC5zeugio4sjtFMp W3jbZPn19o2hWTt9/bLns+fm9PgnPwdC+tS5LT26N6vhT/vK/HHY5AZvXXPNcQMA wp+EVFxsWK2BcFMIi7Oq47CfuM1AUA+pgCenB4iSVwxs8ANTWWIsLkkKAYQqIdan OSISa2WdslsKMjXIQ5+rG9ekEn+rRO3EAQXRryBt4LkBjQReh2q0AQwAwGx7shIW OaVExpngqmh0ApkxJHZIxcxpatk/lSBQfzHg6e1/7Joe98lEHcWPJ6WFsGp+aC9S 96dWTBZq/4pzAqqTrSXAZpG/+yZlWRWSXVQex1gZHPzsWYMPE9qayAPTOJHtfS6a klIEaFV2GYEvvRK5UR5DFIlsfzyyCBOUKvn0/hikqJjN2YfHUy5SR5U5dGsSX3Jk Q9bOlBYDpN3Rk5rmLg0Vwn4nPRBET70MLQ5M4pU3Br6n+vU8tMHoVXYVMLinD4gO vVY4baXEZELjcPkPzGFPyjVLlpxKMHZ6v1Qb9ornTRGzc4dEUKxi3srdsTpMCw0k CaZ2WLY4sNBO33C8XfIvMx2jF4iIk3BrSrW/hirq6xpvlh4BUh/UWVrvg2rdemAX THa93mRQeOa3bze9xZwaA2GJLRG+xCIt15v/cNpQwCYlyhJunkuwk3HQcUrKfzxo 6QhqMeDaPZeNcvN3XoELGeqtoE7gKAnLp2nQuVr4/pcaiATf+yAhBgYRABEBAAGJ AbwEGAEKACYWIQT/8x6G/OtQRuiyfUqhj3eOGfwySAUCXodqtAIbDAUJA8JnAAAK CRChj3eOGfwySB11DADLgMAafhdzRgzx7FLVVW80IfgiCTAl5M1wV2HctA17aln7 jk7iEVMTLfhrSCSvvNIdrOXUE7l9HAMkKRwaZv7OAtYR8eQTrgGc9yJdk8BMzvJB ouiaNb2LSxMSvpoaJmD2C9ZkOyW+pAXKaUGhbUl8YVa7ytwPD6yZzonGClgZI0x5 9nSc5TiPpVijzu51iZiTV35F6en7ke2hjr6iBACJGBplxeeWszRa0wK2zoubAUK1 KO2punvtGqhi3j77/0sZgvFv3czJpRac5ccdLc02Sb6I64Stp04ilcV1aqlUXxbM gLwkoXZUqbCS7ZA7eBiEaKXdj9ww/gprO0AwFETxQVA8iPF9puSWfBf18a5GEdR1 Drb5lSReCkCfBJd3Tf5WHUSrdcai0FfuXNNp/7J7CBzlOJ0h6Yoa02hz8CBGGwxI 1brXRm13004bX7C9i+94Lbgf8bTM40JvyF1kmcffkj8ibpS/VSa8aWJuqpWk/xcn ob/YdBngWCxNgXii4E6ZAY0EXot8fAEMAJ/JOflg7U8JWescyTQNl9Xuk6QUIVKx 0zOT2k+drlLwC8+FckYTCF1pm8sPDBBv9eN3cFCDf076tZjUHv+Roq5c5McDHlN5 KlFbTSOv1qZYuaPY14nHIoW7OGoSvMCOBkpDLLwnIbuLA0wGdzyd3z6Vfhpz3wDv iAplyA4iuzJQq1+iS8tq6Uj2yhmfg+zU16gw2D3iEC6hhSu2KmPhMFD9KfCzq02L xC6fMh3Fogas51ZF1fRDK8Bvicf4yYj0dn3i6GDr0/vHga4eLQqVBXb0HCv2lNer gTtawQfJu2XEn5hDZKfHeBJ4NI4k7AZIPa7OuUqOAm8Z4hbkgRZakc+OhPSEKH2i drItwrPXDGqMYV4tLLMALMQ9WDTz75wbzVbxGVcAzG3MaZSo/f/iKzuzaE8cF71A dO1y6H5YmmMENn4t/D4BYXm4edPvV6SaYU1hO5yqr7vGbrQBFVetpSCLEFveACHr sm1S6nVVTazkHj2FNdww4bGMJzPqC7bBtQARAQABtChBREFNIE1BUlNIQUxMIERP QlJJTiA8YWRhbUBlcm1jY29ycC5jb20+iQHUBBMBCgA+FiEE9+R8sSygzQHF4cv6 fsjVqFo41joFAl6LfHwCGwMFCQPCZwAFCwkIBwIGFQoJCAsCBBYCAwECHgECF4AA CgkQfsjVqFo41jpPfgv/dylMY4CPMwkdry8KnKP3QtmJOl94VnpJ+FUME+oOqjBw 6/C16uWdTLYuEUuE2jEzTg2J0kgulM2vYm8rVgJzlGiD/oIgX3X5NeyB9MH+GCpu xsJ/ofIVpC6t8Zl78B2qTnJOcEc6owy/qKs/eFXSea2sRRstqK20dOajl4Z2ycEL SdijFR3aqT4hU6e0GNWYqo3bW4TUcd05RJIZBNz6Bitq1fxljxFPOOCaoKo9mVn4 0dN65iGPEYg0c50Q6EmxEr+XtwRu1rjgG3hgq6BknZ6QD1HOBemQg/3jqQBb9uHj jHbuX9HrbGF9+QbDicbmuZSLuV76xJnbyTycFhhIcSi9wZeyAAPlpL4GQ8l98jKa SCWWGDPpKwK5+o8kteuJ/D/mYyBEquyFVhPQBXV9zS3LsN7ab55zB5+ZnLUeofai LE6e+XPGeJmG3I/+T/Nuq1CqJ4Wyt8+aIyf6Uz8dDk0kjyQku484plRwMEx7oZXR bXQAAn8SwtlNGo0sHc6JuQGNBF6LfHwBDACxAxfbQM5AcssJlQFXThnBMHtRDeBH VkyF5mrO9JeFRT+mhM87V+fJXOaEKtcSFVgZJFKV2MPdyGqZSGKmyyqfUvKfucP5 LrjK3MRKibTlOMwbBOmYUksMVE0ByMPeSzyMlQhq0oyA3fvEdKEf0JrFGDRWNzO8 /Q54oj79Pki4y1BDKd7lE1srBFiVEUuPNJmjhhU9WXnMwiB55lLwbTR8mKEX0Pr2 FeTS5gttmbHf4V+wnJvlOEU6mOLMrb+6Xb4ltvqbl9ng1+tF2QMGMd83mtbFtAjb Zcl/Cq2KwsBFyH9VT48ZxWxpOYMf3ppEg9KOSfz9Ungtg4/Q/Kr9P13Nf+9+S9JS 1PfKdlJzGFDn4EwZ49ugg6GNnL6XuRl9jBPD2iD8hY9CsTdWrr9giCmJmdf6G/bK HUm2QekMbhpaQmYKkMeri45cHprx1dQ50rfiH1cBm5SxaK7z/hDDaKXF1Gp7/KwQ g6gHlyMss7EEHSY5ogH+6a7OUPpqbJdNztEAEQEAAYkBvAQYAQoAJhYhBPfkfLEs oM0BxeHL+n7I1ahaONY6BQJei3x8AhsMBQkDwmcAAAoJEH7I1ahaONY6EqoL/R7J QLaAlb4/hK7/v4vsSxtCirLWrqNNNJxYdmpXq19NKPmcc08QzSqkJ7vR4/kn2L6I OY7y7AMh+tScKTKIGn8MkAcj0ZvkafHY3xmpN1Xp9caUAA/fw6KWD+pSZpKpISyd 2Xr6x5OJGSKhyGpPB98oCsa809LQ3cweG1imem3jx+Lgii63pEJG/AeNeEwkIvdC zRLSQvYv0UjlhyOoII6YEWJcro+tgOcthPh2SY50E4lwFFfbz4CNQyL15D+XciNI xSVGz8gee/XdJdgwQF4SEnIiChhmJ5VmpNH8ZwxTMyI3EoFMB/RYaucwc/ucvySn cFyShFFRPjo6TOeYIaSrrfR+4yhHAGeM572y0btI6JjWZovupeXX3k5ZHHrCwxlR MuyULLyhUsAC0r1FUijbUWoyaDcRtLRpMUg1X6A7n1iH61WxlKQ/8mZhYht85Jgp FSiyz47gofc491ng9efshlyxwb3TeLbDZPRnls7L3sfDDWwp8yExjA7UNDbIh5kC DQRencYLARAAsFHArFeulhD6hZplRF49h8+zpI3kn+vFtYwbUqLSRwze53rrJtqE 6o5MWSfadr9KIc8tNZ2aBGxzjGnsbPYLDh76NkjP4apWSMX+u+EHsaudoZoAdNnM Kqr86sVzR0MUeGHp7n/L3imp1WoCn28eMLeNec9a4GRTRPGLKR9F/jytTz/XgkHL zA3i2pt63FqniN4PBTNFzgfXiu8xVZGohsDPjmd9LXbGKTXfJGhBLB6QsmjJwglt n+00ufdKLEZu6eBxRWSVK0t4rEnnpK9K//PKq5DtVaOZNe6g+hdi0B1gpd0f0nBy eZd9arCsvN3qLXP0vYTk9DKMUecCEblss5Zt1+qjAbsMk9/xSGZLJp/4dBTBVN+Q c6+Rmv+koe6zLNmA3fJH3991xETDzZxP2UHN7q4i4L97KA+nVAakwazNLiqsY/bT s58rXnCc72b7oLnZbNOPQmLwZFafVi4xoIE/5Zq8iVr7d7xHPccYkaEVCOnsL/35 GZxy2FNi4wuOfGwBtTbnXg/u/YiBj6yNbhLR+FCwZED5M/evgUUbJudxqRdrI+1a Zo9gGA3JLJZZ/iLwF1kE7yYBvyBRfaO9IL3bwplRurnrkjI+rRhi55AlbGhU3eMu iKTKQk+qJF11ocTGu/dE9I6JeQpEdyVehrWXc5H2N0Qjyca8ZEA6WwcAEQEAAbR7 QURBTSBNQVJTSEFMTCBET0JSSU4gKGl0J3MgdGhlIG9uZSAuLi4gbGlrZSB0aGUg b25lIGluIFN1cGVybWFuIDMgYW5kIE9mZmljZSBzcGFjZS0tYnV0IG5vdCAqdGhh dCogb25lKSA8YWRhbUBlcm1jY29ycC5jb20+iQJOBBMBCgA4FiEE0s8R6kp2bveF MmxLkifaSe8nN2gFAl6dxgsCGwMFCwkIBwIGFQoJCAsCBBYCAwECHgECF4AACgkQ kifaSe8nN2jK+g//Toi6ezWYrRbTs9xwQLIsKzl91ocjCuN9nHSnwzkrLuoGGgej fHkXzd5+3ygL47j++k69TYB9CPrGdR1GTqt56Q7DSYZCgdg+e89piTJUzbEyN01q EGkVuV5Rz9EocnPE8db9HT+xvf44ecfMOFD1XuB9jynrQD445YfeFE6LHkoNUvFD wQK7NN04fa+qvrk0lTS4NCpOYsdrSioddVjQyEC6jepwIRA3iRIkFdEJT8ggqQ6d gntsgExA01o6HqzDSHjSCA5AexCotwW3Uvdt0WwXx6q/c0LsRLhbuPeGX/Nh8aOf 6RBCQWgnIko675ura4c+r1VcBYl524ZJlN4x1x02YAo9cKzYi3+H9C8K8Ayz/SJy 7sVGHWnDge1yIwzWXbpolqiMSL5l/0OBuJ0HXQSafUut33Jw7hYKP4BQia/BmE0x Tsk0rBRMyihSYnUn9mYpXM3KwWU0C2dudVwKtToGR1aKlYcCv0iNFAsR0DBw1XSq n72KqIl020gZFmg3H34Z6CWhm20RbhMjOvvkZ+OiS9kU9kXt6m+T1zCpWHFJSae4 JF+dQyB1BFxAwXW4ZEzMo4XluTuW1R8pIadKTsHMWzEzH7RvZLKP4invsZklZ3I1 EEsJop7DSMOa27irD/IlCL+nwaEsCMRh+ndSkADLHsa9P5d/qWjomKxwdCm5Ag0E Xp3GCwEQAOoXU8NrugMa8OAncXKv4hycXJzArDae3Zx6pCCEkP3TZTXh1tqKPUtb dmb8Mq2eecVTwmB+FM3m+NApgq88Vx6HiyI73IAvgtZORo32YaipfbkGnXHfaUWX 5380R4GL597yZuP8sAsJ3iDvxhW59snsU8tLi+9r2u4h0fgMDqZXQsfvLUkDIiO9 nzJf0xFacTx3n+pUuWdzIuT3AUdU/L9NubmHSnj09FevTHWIYmxGFZoiSdS7r2Z+ 5xZmPak6lzrQTVS/DxcpyA/o3yi8qLPyf1VUxXKFeKd0sV6BPvYFxI2GeBl5atBu 9/3/5D6wdlrupTFLU1Msdfy3UWaRUFHLITK4fJ7pbTgoEqxX7gpO9iqKmScm3gYc O3blA8aTqCX2NzxUF5fHbi14JvPWP04uFl5EOeDB322Jm/guWy8TvmIIyuF3aAAX PfErW/yRWDsYOcAADs8elZkt3F+E/AwWd0JMIhd/RB3RFH8m7496XLS3xBP6rNye 0O+96lX7fVp+wvINxM3Rfo63b1K4bR5KR9JDZ2SLYhrx6Hyy+UiRv7l+i26WxVMF qRyvY2aHqyvKfR1EEf1t2h7B4b65xQkj51qvX5Tjm5Az7nKcXpcUKqS3bk8xiw9N y7eFfA361OSPpQ+V4Mq/Mv+MqyxLTz9tn+80ZtjqM0MEERfpUo15ABEBAAGJAjYE GAEKACAWIQTSzxHqSnZu94UybEuSJ9pJ7yc3aAUCXp3GCwIbDAAKCRCSJ9pJ7yc3 aE2NEACDBRnGYNi2sq0wltPSkD2CbQUon+4uiFB2UU/gs4mFlGOvzDHBHVEFzCqK 0x6KlKm4XBq3AF7iIoNMiU9FmBdWDnEp9eCXdQrr/ykgq3vKMuj6/QJNNZglIDoe 1J2NXeMOUFwCUvjcCttPv42Q8GDt8/bG7QOgmTmhuqvKIj/vL+c3HgNrRsQzhw5z mSzQIDaesD+UVA/sourXpSLeqPgF+6qsEqOirD6hotaqrt+aIA/8wbYkpNQxCEK4 gKDgpqTV7VKklku7fjyhBhZQOVDoWvd03AlGQD0WBNriUsh8l4N6Zg2BlnKTGn11 BTigqwlHC91xtjERgwFg8PAHN2mtgZUHITHX5js11KwlQdLyI04/M4M4oQq0KSbJ rpiWCgrltC/VqJrT4HELFYx2Iv5wzrV9jVEm6zonag4A761hpqTgRrjWtaLuYu2Z zdw9y1r0+0d2rTUGpjIQRVOwi3AF/G4aU+vAOOf/HcgH6Qnpbu+xV0fkuAZbTI7w 6VVkBvnstiQV88KrWAOXKVABSSxTz2OYbzOTt/bgxzAa7yr1xIBDKvujBqDRGBLi bISp+40Haoj2Yqop6vbS70Xq+cnBOwJW86u61hsLgOjqyxgLzvuGTjK7+TblCjR2 F4LNeQdwDdyNRjPYeGVXM3MEqR8XdcR1Z7BQvLNcDgoW2qDcbg== =4lZw -----END PGP PUBLIC KEY BLOCK-----

    1. SciScore for 10.1101/2021.09.02.458667: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Primary cells: This study was performed in accordance with the ethical principles set out in the declaration of Helsinki and was approved by the institutional review board of the Amsterdam University Medical Centers,</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The antibody clones used are: CD86 (2331 (FUN-1), BD Pharmingen),</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD86</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines: The Simian kidney cell line VeroE6 (ATCC® CRL-1586™) was maintained in CO2 independent medium (Gibco Life Technologies, Gaithersburg, Md.) supplemented with 10% fetal calf serum (FCS), 2mM L-glutamine and penicillin/streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293 cells stably transfected with TLR4 cDNA (HEK/TLR4) were a kind gift from D. T. Golenbock(15).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: CLS Cat# 300192/p777_HEK293, RRID:CVCL_0045)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293 and HEK/TLR4 cells were transiently transfected with pcDNA3.1(-)hACE2 (Addgene plasmid #1786) to generate HEK/ACE2 or HEK/TLR4/ACE2 cell lines.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK/TLR4</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the pseudovirus infection assays, HEK293 or 293/TLR4 cell lines and DCs were exposed to 95ng/mL and 191.05ng/mL of SARS-CoV-2 pseudovirus, respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293/TLR4</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Also, the HEK293/ACE2 and HEK/TLR4/ACE2 cell lines were exposed to the SARS-CoV-2 isolate (hCoV-19/Italy) at TCID 100 (MOI 0.0028) for 24 hours at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK/TLR4/ACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293 and HEK/TLR4 cells were transiently transfected with pcDNA3.1(-)hACE2 (Addgene plasmid #1786) to generate HEK/ACE2 or HEK/TLR4/ACE2 cell lines.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.1 ( -)hACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 pseudovirus production: For production of single-round infection viruses, human embryonic kidney 293T/17 cells (ATCC, CRL-11268) were co-transfected with an adjusted HIV-1 backbone plasmid (pNL4-3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pNL4-3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Luc.R-S-) containing previously described stabilizing mutations in the capsid protein (PMID: 12547912) and firefly luciferase in the nef open reading frame (1.35ug) and pSARS-CoV-2 expressing SARS-CoV-2 S protein (0.6ug) (GenBank; MN908947.3)(22).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pSARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Single-cell measurements were performed on a FACS Canto flow cytometer (BD Biosciences) and FlowJo V10 software (TreeStar) was used to analyze the data.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistics: Graphpad Prism v8 (GraphPad Software) was used to generate all graphs and for statistical analyses.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Graphpad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.03.458735: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: All procedures followed standard operating procedures (SOPs) approved by the RML Institutional Biosafety Committee (</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Animal study: Two hundred and fifty Syrian golden hamsters (5-8 weeks of age; male and female) were used in this study.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">The hamsters were randomly selected into groups as shown in table S2.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After horse-radish peroxidase (HRP)-labeled secondary antibody staining using either anti-mouse IgG (1:10,000) or anti-rabbit IgG (1:5000) (Jackson ImmunoResearch), the blots were imaged using the SuperSignal West Pico chemiluminescent substrate (Thermo Fisher Scientific) and an iBright™ CL1500 Imaging System (Thermo Fisher Scientific)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rabbit IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After three washes with PBST, the bound antibodies were labeled using 50 μl of 1:2,500 peroxidase anti-hamster IgG (H+L) (SeraCare Life Sciences) diluted in 1% skim milk in PBST.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-hamster IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The secondary antibody was the Vector Laboratories ImPress VR anti-mouse IgG polymer (cat# MP-7422).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: (Vector Laboratories Cat# MP-7422, RRID:AB_2336527)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All viruses were grown and titered on Vero E6 cells, and sequence confirmed.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The replication competent recombinant VSV was recovered in BHK-T7 cells as described previously (Emanuel et al., 2018).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BHK-T7</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">VSV-SARS2-EBOV was propagated in Huh7 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Huh7</div><div>suggested: CLS Cat# 300156/p7178_HuH7, RRID:CVCL_0336)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Full-length SARS-CoV-2 S was cloned into the pATX-VSV-EBOV plasmid upstream of the EBOV-Kikwit GP resulting in VSV-SARS2-EBOV (Fig.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pATX-VSV-EBOV</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The cytoplasmic tail deletion was introduced by PCR and was cloned into the pATX-VSV plasmid resulting in VSV-SARS2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pATX-VSV</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sample acquisition was performed on a FACSSymphony-A5 (BD), and data analyzed in FlowJo V10.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analyses: All statistical analysis was performed in Prism 8 (GraphPad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.02.458740: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: The protocol was approved by the Institutional Animal Care and Use Committee (IACUC) at UTMB.<br>IRB: Human serum specimens: The research protocol regarding the use of human serum specimens was reviewed and approved by the University of Texas Medical Branch (UTMB) Institutional Review Board.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Hamster infections: Four- to six-week-old male golden Syrian hamsters, strain HsdHan:AURA (Envigo, Indianapolis, IN), were intranasally immunized with 106 PFU recombinant WT or variant spike virus on day 0.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Authentication: The authenticity of Vero E6 cells was verified using Short Tandem Repeat profiling by ATCC.<br>Contamination: The cells were tested negative for mycoplasma.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The virus was serially diluted in DMEM with 2% FBS and 200 μl diluted viruses were transferred onto the monolayer of Vero E6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The curves of the relative infectivity versus the serum dilutions (log10 values) were plotted using Prism 9 (GraphPad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      A limitation of this study is the use of chimeric viruses rather than the use of clinically approved vaccine platforms for expressing variant spikes or clinical variant isolates for the challenge. The neutralizing profile elicited by chimeric viruses may differ from that elicited by the clinically approved vaccine platforms. In chimeric virus-immunized hamsters, immune responses to non-spike viral proteins may provide added protection when compared with animals immunized with spike-alone vaccines such as mRNA and adenovirus-expression platforms. Despite this limitation, it is conceivable that the relative rank of neutralizing levels would be preserved against different SARS-CoV-2 variants. In summary, increasing global immunization with the currently available safe and effective vaccines, together with boosters when needed, is the strategy to end the COVID-19 pandemic. The design of the booster vaccines depends on whether the newly emerged variants can escape the immunity generated by the current vaccines or natural infections. Potential immune escape of any new variants should be closely monitored by laboratory studies and real-world breakthroughs in vaccinated and infected individuals.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.01.458653: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-FLAG epitope (DYKDDDDK, catalog# 637301) and horseradish peroxidase (HRP) Donkey anti-human IgG antibody (catalog #410902) were purchased from Biolegend (San Diego, CA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-FLAG epitope (DYKDDDDK, catalog# 637301)</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Anti-FLAG epitope (DYKDDDDK</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: (BioLegend Cat# 410902, RRID:AB_2686937)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The secondary antibody anti-rat IgG HRP (catalog# 7077) was bought from Cell Signaling Technology (CST, Danvers, MA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>The secondary antibody anti-rat IgG HRP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-rat IgG</div><div>suggested: (Cell Signaling Technology Cat# 7077, RRID:AB_10694715)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines: HEK293T cells expressing human angiotensin I-converting enzyme 2 (HEK293T-hACE2) were kindly provided by Dr. Jesse Bloom (Fred Hutchinson Cancer Research Center, Seattle, USA) (51).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lenti-X 293T cell line was purchased from Takara Bio USA Inc. (San Jose, CA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 1 hr incubation, the cellulose paper treated pseudovirus was gently transferred to transfect HEK293T-hACE2 cells with 80% confluency, followed by adding polybrene to a final concentration of 8 μg/ml.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T-hACE2</div><div>suggested: RRID:CVCL_A7UK)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmids construction, protein expression and purification: Ty1 variants, including Ty1-CBD and control protein Ty1 without CBD module, were cloned into pSH200 vector (a generous gift from Prof. Xiling Shen at Duke University) containing 6 x Histidine tag (His-tag), between BamHI and XbaI sites.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pSH200</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Detergent compatible (DC) protein assay kit was bought from Bio-Rad Laboratories (Hercules, CA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bio-Rad Laboratories</div><div>suggested: (Bio-Rad Laboratories, RRID:SCR_008426)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After the final wash, the cells were resuspended in 200 μL FACS buffer (5% FBS, 2mM EDTA, 0.1% sodium azide in PBS) for flow cytometric analysis in Attune™ NxT Flow Cytometer (Thermofisher) and data were analyzed by FlowJo (Franklin Lakes, NJ).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Statistical significance was evaluated using one-way ANOVA followed by Tukey post hoc test using GraphPad PRISM (San Diego, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad PRISM</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Despite the promises demonstrated in this study, one limitation is that only pseudovirus-containing culture media were used to characterize the fusion proteins for proof-of-concept. Therefore, it is necessary to further evaluate our approach in real specimens such as blood from COVID-19 patients in the near future.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 32. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.09.01.458544: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Animal ethics and mouse strains: All experimental procedures using animals were conducted under the guidelines of the Australian Code of Practice for the Care and Use of Animals for Scientific purposes, and were approved by the University of Queensland Animal Ethics Committee (2019/AE000243).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After blocking, the neurons were incubated with the primary antibodies to GFP (#AB16901, Merck Millipore), mCherry (#ab167453, Abcam) and anti-MAP2 (#188004, Synaptic Systems), diluted in primary antibody solution (1% BSA in PBS) overnight at 4 °C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GFP</div><div>suggested: (Millipore Cat# AB16901, RRID:AB_90890)</div></div><div style="margin-bottom:8px"><div>anti-MAP2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">They were then washed with PBS and incubated with the secondary antibodies Alexa Fluor 488 goat anti-chicken (#A-11039, ThermoFisher Scientific),</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-chicken</div><div>suggested: (Molecular Probes Cat# A-11039, RRID:AB_142924)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, Alexa Fluor 647 goat anti-guinea pig (#A21450, ThermoFisher Scientific) and DAPI (#62248, ThermoFisher Scientific) in the secondary antibody solution (5% horse serum in PBS) for 1 h at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-guinea pig</div><div>suggested: (Molecular Probes Cat# A-21450, RRID:AB_141882)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Wildtype (WT, C57Bl/6 background) mice were maintained on a 12 h light/dark cycle and housed in a PC2 facility with ad libitum access to food and water.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57Bl/6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Previously generated transgenes used in this study include: vdEx1266 [Pmec-4::p15 5ng/μl]; vdEx1268 [Pmec-4::p15 5ng/μl].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>vdEx1266</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>vdEx1268</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The Pmec-4::p15 plasmid was constructed by subcloning p15 between Msc I and Nhe I.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Pmec-4::p15</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The CMV::p15 plasmid was generated by subcloning p15 into the pmaxCloning™ vector (Lonza, # VDC-1040) between Hind III and Not I.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CMV::p15</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pmaxCloning™</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The CMV::SARS-CoV-2-S-2P plasmid was generated by introducing two prolines at the 986 (K986P) and the 987 (V987P) positions of the SARS-CoV-2-S gene of the pCMV14-3X-Flag-SARS-CoV-2 S plasmid.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CMV::SARS-CoV-2-S-2P</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mutations were done using the QuikChangeII Site-Directed Mutagenesis Kit (p15Δ21/22 forward primer 5’-CCACCGCCAAATGCTTTTGTTGAAAGCAGTTCTACTG-3’; p15Δ21/22 reverse primer 5’-CAGTAGAACTGCTTTCAACAAAAGCATTTGGCGGTGG-3’; SARS-CoV-2-S-2P forward plasmid 5’-CCTGAGTCGCCTTGATCCGCCGGAAGCTGAAGTTC-3’; SARS-CoV-2-S-2P reverse plasmid 5’-GAACTTCAGCTTCCGGCGGATCAAGGCGACTCAGG-3’).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>5’-CCTGAGTCGCCTTGATCCGCC GGAAGCTGAAGTTC-3’; SARS-CoV-2-S-2P</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The Kaede-N1 plasmid was a gift from Michael Davidson (Addgene plasmid # 54726; http://n2t.net/addgene:54726; RRID:Addgene_54726) 36.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div></div><div>detected: RRID:Addgene_54726)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The mito-mPA-GFP plasmid was a gift from Richard Youle (Addgene plasmid # 23348; http://n2t.net/addgene:23348; RRID:Addgene_23348) 37.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>mito-mPA-GFP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div></div><div>detected: RRID:Addgene_23348)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The pCMV14-3X-Flag-SARS-CoV-2 S plasmid was a gift from Zhaohui Qian (Addgene plasmid # 145780; http://n2t.net/addgene:145780; RRID:Addgene_145780) 38.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div></div><div>detected: RRID:Addgene_145780)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The pcDNA3.1-SARS2-Spike plasmid was a gift from Fang Li (Addgene plasmid # 145032; http://n2t.net/addgene:145032; RRID:Addgene_145032) 39.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div></div><div>detected: RRID:Addgene_145032)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The SARS-CoV-2 S-6P plasmid was a gift from Jason McLellan (Addgene plasmid # 154754; http://n2t.net/addgene:154754; RRID:Addgene_154754) 30.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>S-6P</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div></div><div>detected: RRID:Addgene_154754)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The pcDNA3.1-hACE2 plasmid was a gift from Fang Li (Addgene plasmid # 145033; http://n2t.net/addgene:145033; RRID:Addgene_145033)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div></div><div>detected: RRID:Addgene_145033)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All injection mixes had a total concentration of 100 ng/μl and contained the transgene of interest, empty pSM plasmid as a filler, and a co-injection marker for the identification of transgenic animals.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pSM</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Both systems were controlled by Zeiss Zen Black software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Zen Black</div><div>suggested: (Black Zen software, RRID:SCR_018163)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The animals were imaged with a Zeiss Axio Imager Z1 microscope equipped with a Photometrics camera (Cool Snap HQ2), and analyzed using Metamorph software (Molecular Devices) and FIJI-ImageJ.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Metamorph</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Image acquisition was performed using SlideBook 6.0 (3I, Inc) and processed using FIJI-ImageJ.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SlideBook</div><div>suggested: (SlideBook , RRID:SCR_014300)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Results were analyzed statistically using GraphPadPrism software (GraphPad Software, Inc).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. Kraemer, M. U. G., Hill, V., Ruis, C., Dellicour, S., Bajaj, S., McCrone, J. T., Baele, G., Parag, K. V., Battle, A. L., Gutierrez, B., Jackson, B., Colquhoun, R., O’Toole, Á., Klein, B., Vespignani, A., COVID-19 Genomics UK (COG-UK) Consortium‡, Volz, E., Faria, N. R., Aanensen, D. M., … Pybus, O. G. (2021). Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence. Science, 373(6557), 889–895. https://doi.org/10.1126/science.abj0113

    1. SciScore for 10.1101/2021.08.20.21261687: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">We adapted PRISMA 2020 to provide a comprehensive study report, where applicable.10 Eligibility criteria: This meta-epidemiological analysis included all registered randomized trials assessing NPIs to prevent COVID-19 in any country and setting.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For all NPI eligible trials identified in COVID-evidence, we searched for corresponding publications (peer-reviewed and preprints) in MEDLINE/PubMed, Google Scholar, the Living Overview of Evidence platform (L-OVE), and the Cochrane COVID-19 registry using trial registration numbers (until 19 August 2021).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MEDLINE/PubMed</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Google Scholar</div><div>suggested: (Google Scholar, RRID:SCR_008878)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

  3. Aug 2021
    1. Links between the clubhouse, home, and school were present but could have been stronger. D e s p i t e h i s s l i p p i n g g r a d e s a t s c h o o l , L u i s ’ s w o r k a t t h e c l u b h o u s e clearly demonstrated a rich imagination, persistence, attention to detail, and resourcefulness in furthering his own development.

      This just shows that different enviorments either help or doesn't help for a students own academics and be more akined to what helps a child during their development.

    2. I n c l o s i n g , t h e c l u b h o u s e w a s c r i t i c a l i n h e l p i n g L u i s t o d e v e l o p t h e k i n d s o f t e c h -nological fl uencies that may position him for further learning and creative work

      This is a great last say to the entire article. The whole point of the article was to show the importance of technological clubhouses in communities that don't have the same opportunities as other privileged communities.

    3. e s p i t e h i s s l i p p i n g g r a d e s a t s c h o o l , L u i s ’ s w o r k a t t h e c l u b h o u s e clearly demonstrated a rich imagination, persistence, attention to detail, and resourcefulness in furthering his own development. These characteristics are markers of the potential to thrive as a learner. Had his teachers been attuned to his expertise development earlier, they may have found ways to build on his excellent out-of-school learning skills to reengage him in academic content. Typically, par-ents act to coordinate across settings and in Luis’s case they intervened to reallo-cate his time at the clubhouse so that he would spend more time on schoolwork rather than try to bring his talents to the attention of school staff.

      Luis's skills were not seen as valuable through the school curriculum. Digital work is the future and his skills were not being utilized properly and wasnt given that same support from the school as the clubhouse.

    4. h e c l u b h o u s e c o o r d i n a t o r s i n c l u d e d L u i s i n fi e l d t r i p s c o n n e c t e d t o h i s i n t e rests, including one to the game design company Electronic Arts.

      Okay lets be real here, the idea that Luis is included in field trips to the game design company Electronic Arts is pretty cool.

    5. Links between the clubhouse, home, and school were present but could have been stronger. D e s p i t e h i s s l i p p i n g g r a d e s a t s c h o o l , L u i s ’ s w o r k a t t h e c l u b h o u s e clearly demonstrated a rich imagination, persistence, attention to detail, and resourcefulness in furthering his own development.

      This can also be an issue with the education system itself. He needed this sort of development, but school wasn't giving it to him

    6. T h e c l u b h o u s e c o o r d i n a t o r s i n c l u d e d L u i s i n fi e l d t r i p s c o n n e c t e d t o h i s i n t e rests, including one to the game design company Electronic Arts

      This is actually a great opportunity to get when your young, even college students struggle to get this opportunity

    7. Online communities that re fl ect “cultures of participa-tion” (Jenkins, 2006, 2009 ) a l l o w c r e a t o r s t o s h a r e t h e i r w o r k , r e c e i v e f e e d b a c k , and expand their social networks

      The ever-increasing expansion of technology is leading to newer ways to collaborate with other students, which allows them not only to work with other classmates, but potentially students in different counties, states, or countries.

    8. A l t h o u g h t h e s e c u l t u r e s o f p a r t i c i p a t i o n a r e b e c o m i n g m o r e c o m m o n , t h e y a r e not equally accessed. Recent research has shown that despite the emerging cultural image of the average youth as constantly connected and technologically savvy, those who can actually create digital media or interactive environments are in the minority

      I knew this point would come up!

    9. Online communities that re fl ect “cultures of participa-tion” (Jenkins, 2006, 2009 ) a l l o w c r e a t o r s t o s h a r e t h e i r w o r k , r e c e i v e f e e d b a c k , and expand their social networks

      This is just another example of the bountiful opportunities that are only accessible to those with money for these "digital technologies"

    10. A l t h o u g h t h e s e c u l t u r e s o f p a r t i c i p a t i o n a r e b e c o m i n g m o r e c o m m o n , t h e y a r e not equally accessed.

      While they are acknowledging access isn't universal, what steps should people take to bring it to others

    11. Online communities that re fl ect “cultures of participa-tion” (Jenkins, 2006, 2009 ) a l l o w c r e a t o r s t o s h a r e t h e i r w o r k , r e c e i v e f e e d b a c k , and expand their social networks.

      I like that they added this point because it usually gets glossed over when talking about th advancement of learning technology.

    12. a l l o w c r e a t o r s t o s h a r e t h e i r w o r k , r e c e i v e f e e d b a c k , and expand their social networks

      Not too different from physical communities, just with the option to connect with more niche groups or not-so-niche groups.

    13. n c l o s i n g , t h e c l u b h o u s e w a s c r i t i c a l i n h e l p i n g L u i s t o d e v e l o p t h e k i n d s o f t e c h -nological fl uencies that may position him for further learning and creative work

      If he didnt have this help with the clubhouse who knows where he would have been, would he have discovered it another way? Or would there be something else?

    1. SciScore for 10.1101/2021.08.25.21262623: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: 18 The protocol was approved by a central institutional review board (Advarra, Pro00042757) and conducted following good clinical practice guidelines under the oversight of an independent data safety monitoring board.<br>Consent: All participants or their legally authorized representatives (LARs) provided written electronic informed consent.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Study design: We conducted a prospective multicenter blinded randomized placebo-controlled trial of hospitalized patients with COVID-19 at 13 hospitals in the United States from April 2020 to February 2021 following CONSORT guidelines.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Participants >=18 years old were potentially eligible if exhibiting at least one CDC-recognized symptom of COVID-19.19 Exclusion criteria included: active outpatient treatment with an ACE-i, ARB, or aliskiren; prior adverse reaction to ACE-i/ARB; pregnancy, breastfeeding, or lack of contraception; history of dialysis, stage IV chronic kidney disease, or estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2; potassium >5.0 mmol/L; history of severe liver disease; enrollment in another blinded clinical trial for COVID-19; lack of informed consent; inability to randomize within 48 hours of admission or positive test; oxygen saturation at baseline; or respiratory sequential organ failure assessment (SOFA) score of <1 (defined as P/F of <400, utilizing SaO2 if PaO2 is unavailable).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">Power and sample size: Due to a paucity of data at study design, we based expected variance of P/F on prior studies of viral-induced acute lung injury, considering standard deviations (SD) between 50-125.32–35 At a sample size of 200 with a 1:1 allocation ratio, we calculated 90% power to detect a difference of 70 in the P/F ratio assuming SD 150, and 80% to detect a 50-unit difference, assuming SD 125.</td></tr></table>

      Table 2: Resources

      No key resources detected.


      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      There are several limitations to consider with this study. The trial was initiated early in the pandemic, and temporal changes in clinical care including introduction of dexamethasone and remdesivir may have biased the trial towards the null. Our findings may also be consistent with the hypothesis that the RAAS does not play a significant role in SARS-CoV-2-related acute lung injury relative to other inflammatory pathways. Our choice of primary efficacy outcome required differential imputation methods based on whether or not the participant was treated with positive pressure ventilation, potentially affecting the results. However, the lack of effect on oxygen or mechanical ventilation-free days decreases the likelihood a larger study would identify clinically meaningful effects. While we detected sufficient concentrations of losartan, it remains possible lung parenchymal penetration is limited, mitigating potential efficacy. The relatively small sub-group undergoing RAAS measurement may have been underpowered to detect treatment effects. It remains possible that certain subgroups may benefit from ARB treatment that we could not identify due to inadequate subgroup sample size, including patients who may have RAAS dysregulation at baseline prior to infection. Finally, we cannot necessarily generalize these findings to other ARBs, ACE inhibitors, or other agents that modulate the RAAS.

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04312009</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Completed</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Losartan for Patients With COVID-19 Requiring Hospitalizatio…</td></tr><tr style="background-color:#FF0000"><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT043112009</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Trial number did not resolve on clinicaltrials.gov. Is the number correct?</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NA</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.27.21262687: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: The study was performed as an investigator-initiated clinical trial with the FDA (IND 419217), and approved by the Institutional Review Board of Stanford University.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Lambda Study Design and Oversight: Data and samples were obtained from a Phase 2, single-blind, randomized placebo-controlled trial to evaluate the efficacy of Lambda in reducing the duration of viral shedding in outpatients.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following primary incubation, 25 μl of 1:5000 diluted horse radish peroxidase (HRP) conjugated anti-Human IgG secondary antibodies (Southern Biotech) were added and incubated for 1h at RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Human IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Predictive modeling: We used the protein measurements (measured by Olink assays) to predict the clinical, virological and memory T cell activity and IgG antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Participant Follow Up and Sample Collection: Participants completed a daily symptom questionnaire using REDCap Cloud version 1.5.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>REDCap</div><div>suggested: (REDCap, RRID:SCR_003445)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Clinical Laboratory procedures: Laboratory measurements were performed by trained study personnel using point-of-care CLIA-waived devices or in the Stanford Health Care Clinical Laboratory.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Clinical Laboratory</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Oropharyngeal swabs were tested for SARS-CoV-2 in the Stanford Clinical Virology Laboratory using an emergency use authorized, laboratory-developed, RT-PCR. Centers for Disease Control and Prevention guidelines identify oropharyngeal swabs as acceptable upper respiratory specimens to test for the presence of SARS-CoV-2 RNA, and detection of SARS-CoV-2 RNA swabs using oropharyngeal swabs was analytically validated in the Stanford virology laboratory.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Stanford Clinical Virology Laboratory</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Whole blood transcriptomic data analysis: The transcript-level count data and transcript per million (TPM) data was calculated using Kallist47 (v0.46.2) and human cDNA index produced using kallisto on Ensembl v96 transcriptomes.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Ensembl</div><div>suggested: (Ensembl, RRID:SCR_002344)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All samples were analyzed on an Attune NXT flow cytometer and analyzed with FlowJo X (Tree Star)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All data were normalized between the same positive and negative controls and the binding AUC were calculated using GraphPad PRISM (Version 9)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad PRISM</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We estimated the enrichment score of the major immune cell types using the xCell package23.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>xCell</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Our study has some limitations. First, while we identified multiple associations between early immune measures and the outcome of COVID-19 patients, we did not establish causal relationships between them. Future studies are needed to perturb key immune pathways in the early immune response and test their effect on the patient outcomes. Second, our study measured the immune response during the first 2 weeks of symptom onset in COVID-19 patients. Earlier immune responses between the initial infection and symptom onset have not been characterized. This is due to the difficulty to detect pre-symptomatic COVID-19 infection. Routine SARS-COV-2 monitoring in a select cohort will be required to acquire samples prior to and immediately after the infection in order to assess whether pre-infection signatures predict outcomes in COVID-19 patients. Third, our analysis focused on individual plasma proteins (based on olink data) and immune related Gene Ontology pathways (based on RNA-seq data). We used the Gene Ontology-based pathways to provide a high-level overview of the immune response in COVID-19 patients. Caution should be taken when interpreting the Gene Ontology pathways results, as the pathways are manually curated gene lists from literature and subject to publication bias, curation errors and over-simplification of biological processes. We encourage others to investigate the immune response of individual genes of interest using our shared RNA-seq data. Finally, we have created mac...

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04331899</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Completed</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Single-Blind Study of a Single Dose of Peginterferon Lambda-…</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a protocol registration statement.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.22.21262263: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: All participants signed an informed consent form before any study procedure.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Patients with past COVID-19 infection proved by SARS-CoV-2 polymerase-chain-reaction test and pregnant women were excluded.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-TNFα drug levels and anti-TNFα antibodies were measured.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-TNFα</div><div>suggested: (Beckman Coulter Cat# IM3279U, RRID:AB_2892136)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Outcomes: The primary endpoint was seropositivity rate and magnitude of the immune response (levels of binding IgG antibodies to SARS-CoV-2 spike (S) antigen and neutralizing and inhibitory antibodies functionality) following BNT162b2 in patients with IBD with or without anti-TNFα treatment, or HC, at V3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>binding IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-TNFα treatment ,</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-TNFα drug and anti-drug antibody levels were assessed for adalimumab (ADA and ADA-Abs) and infliximab (IFX and IFX-Abs) using Lisa-Tracker ELISA in accordance with manufacturer’s instructions (Theradiag, Beaubourg, France).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-drug</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-S antibody concentrations are expressed as geometric mean concentrations (GMCs) with 95% confidence intervals (CI).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-S</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Preparation of SARS-CoV-2-spike pseudoparticles and neutralization assay: To generate SARS-CoV-2 pseudo typed vesicular stomatitis virus (VSV) particles, human embryonic kidney (HEK)-293T cells were grown to 70% confluence in Dulbecco’s modified eagle medium (DMEM) supplemented in 10% fetal bovine serum (FBS), 1% L-glutamine, and 1% penicillin streptavidin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK)-293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK-293 cells stably expressing human ACE2 were cultured in DMEM (Biological Industries, Beit Haemek, Israel) supplemented in 10% FBS, 1% L-glutamine, and 1% penicillin streptavidin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were transfected with pCMV3 plasmid encoding the SARS-CoV-2 S protein with C-terminal, 19 residues truncation (pCMV3-SARS-CoV-2-SΔ19) using polyethylenimine (PEI).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCMV3</div><div>suggested: RRID:Addgene_161029)</div></div><div style="margin-bottom:8px"><div>pCMV3-SARS-CoV-2-SΔ19</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 IgG II quantitative testing was performed using the Abbott architect i2000sr platform in accordance with manufacturer’s instructions23.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Abbott</div><div>suggested: (Abbott, RRID:SCR_010477)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical Analysis: Data were collected in secured web-based platform (REDCap) and analyzed using SPSS version 27 (IBM, New York, United States).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>REDCap</div><div>suggested: (REDCap, RRID:SCR_003445)</div></div><div style="margin-bottom:8px"><div>SPSS</div><div>suggested: (SPSS, RRID:SCR_002865)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Limitations include difference in gender ratio between IBD and HC groups at baseline, the relatively young age of participants (although this reflects typical IBD populations) and the use of only one vaccine type. Evaluation of vaccine efficacy is limited, as infection rate in Israel during the study period was low. Finally, observation was limited to 4 weeks after the second vaccine. To conclude, our study provides prospective, controlled evidence for the efficacy and safety of the COVID-19 BNT162b2 vaccine in patients with IBD stratified according to therapy. We demonstrate the dynamics of development of functional immune response and the factors causing impairment, specifically anti-TNFα therapy and older age. The lack of correlation with timing of anti-TNFα therapy or drug levels, enables important clinical guidance to patients and their caregivers. As immune response longevity in this group may be limited, vaccine booster dose should be considered. Long(er) term outcomes and the mechanism of decreased immune responses should be evaluated.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.23.457411: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Superficial nasal epithelial scrape biopsies were obtained from N=13 (7F, 6M) healthy, non-smoking adults with a Rhino-Pro curette (Arlington Scientific, Inc. 96-0900) per protocols approved by the University of North Carolina School of Medicine Institutional Review Board for Biomedical Research (protocol numbers 05-2528, 09-0716, 11-1363).<br>Consent: Written informed consent was obtained from all study participants.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">HNECs from three male and three female donors were used for each type of exposure (DEP, eucalyptus WSP, and red oak WSP).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Two hundred μl of each dilution was added to plated Vero E6 cells (C1008, ATCC) and incubated at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viral titer data was analyzed using GraphPad Prism v. 8.4.0.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your code.


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      The fact that there were no differences in viral load recovered from exposed and unexposed hNECs, even at 72 h p.i., points at some potential limitations of the data presented here. The first is that the changes observed in gene expression at the transcript level may not translate into functional differences at the tissue level. Although IFIT1, IFITM3, IFNB1, IFNL1, IFNL2, MX1, CXCL10, DDX58, and other crucial genes for the antiviral response were all downregulated by particulate treatments (in hNECs from females), further investigation is necessary to determine whether these changes result in host defense decrements in vivo. Previously, we found agreement between transcript and protein level changes in gene expression after red oak woodsmoke exposure and LAIV inoculation in men and women (31). Further, while the respiratory epithelium represents the first line of defense to inhaled pollution and pathogens, clearance of infection and inhaled debris relies heavily upon recruitment and activation of immune cells. In our study, particulate treatment prior to infection decreased expression of several important chemokines by 72 h p.i. (Fig. 6). It is possible that in vivo, the WSP-induced reduction in expression of CCL3, CCL5, CXCL10, CXCL11, CXCL9, IL6, and TNF, all of which are chemoattractants for innate and adaptive immune cells, would result in a more widespread and lasting infection. In vivo exposures of mice to diesel exhaust prior to respiratory viral infection increased v...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.24.457518: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: The reaction was terminated with 100 μL of 1M HCl and absorption readings were taken at 450 nm using a BioTek EPOCH 2 microplate reader. 2.10. Preclinical Study Design: A preclinical study in mice was performed under the approved Institutional Animal Care and Use Committee (IACUC) protocol at Baylor College of Medicine.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A 1:3,000 dilution of an AP-conjugated goat anti-mouse IgG (KPL) was used as the secondary antibody. 2.4. ELISA using Anti-RBD2l9-N1C1 Mouse Monoclonal Antibodies: In this experiment, we evaluated the binding of eight anti-SARS-CoV-2 RBD219-WT mAbs (# 1128, 643, 486, 902, 854, 942, 748, and 102) to RBD203-N1 and RBD219-N1C1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-RBD2l9-N1C1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 RBD219-WT</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>RBD219-N1C1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After this binding step, the plates were washed with PBST four times followed by adding 100 μL 1:6,000 diluted HRP conjugated anti-mouse IgG antibodies (LSBiosciences) and incubated for 1 hour at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After this binding step, the plates were washed with PBST four times followed by adding 100 μL of 1:5,000 diluted anti-RBD219-WT horse sera followed by 1:10,000 diluted HRP conjugated anti-horse IgG antibodies and incubating for 1 hour at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-RBD219-WT</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-horse IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">6–8-week-old Female BALB/c mice were immunized twice intramuscularly (i.m.) at 21-day intervals and then euthanized 14 days after the second immunization. 2.11. Antigen-specific Antibody Measurements by ELISA: To examine RBD-specific antibodies in mouse sera, indirect ELISAs were conducted as described previously [13].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Antigen-specific</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, 100 μL of sera-pseudovirus were added to 293T-hACE2 cells in 96-well poly-D-lysine coated culture plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-hACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">6–8-week-old Female BALB/c mice were immunized twice intramuscularly (i.m.) at 21-day intervals and then euthanized 14 days after the second immunization. 2.11. Antigen-specific Antibody Measurements by ELISA: To examine RBD-specific antibodies in mouse sera, indirect ELISAs were conducted as described previously [13].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In short, the DNA encoding RBD203-N1 was synthesized and subcloned into the Pichia secretory expression vector pPICZαA (Invitrogen) using EcoRI/Xbal restriction sites (GenScript).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pPICZαA</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The RBD203-N1 pPICZαA/P. pastoris X33 construct was fermented in 5 L vessels [9, 11, 12].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pPICZαA/P</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The plasmids used for the pseudovirus production are the luciferase-encoding reporter plasmid (pNL4-3.lucR-E-),</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pNL4-3.lucR-E-</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, Gag/Pol-encoding packaging construct (pΔ8.9), and codon-optimized SARS-CoV-2 spike protein expression plasmids (pcDNA3.1-CoV-2 S gene) based on clone p278-1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.1-CoV-2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Raw data were first analyzed by Bio-Plex Manager software followed by Excel and Prism. 2.13.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bio-Plex Manager</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Excel</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 23. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.22.21262186: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Human subjects and samples: Ethical approval: This study was approved by the central ethics committee of Buenos Aires province,<br>Consent: All participants provided written informed consent prior to collection of data and specimen (Cod#2021-00983502).<br>IACUC: Work with SARS-CoV-2 was approved by the INBIRS Institutional Biosafety Committee at Biosafety level 3 with negative pressure.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">METHOD DETAILS: SARS-CoV-2 antibody ELISA: Antibodies to SARS-CoV-2 spike protein were detected using an established two step ELISA previously described (Ojeda et al., 2021).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 spike protein</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Comparison of antibody concentration, neutralizing titer and neutralizing potency index were done using the Wilcoxon matched paired test in Figures 1C, 1D. 1E, 2A, 2B, 3A, 3B and S1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>S1</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines: Vero E6, Vero-CCL81, Vero E6-TMPRSS2, or Vero-hACE2-TMPRSS2 cells (ATCC) and 293T ACE2/TMPRSS2 cells, kindly provided by Dr. Benhur Lee, were cultured at 37ºC in 5% CO2 in Dulbecco’s Modified Eagle’s high glucose medium (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS)(GIBCO).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div><div style="margin-bottom:8px"><div>Vero-hACE2-TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Recombinant VSV: Briefly, recombinant VSVs were rescued by infecting BSRT7/5 cells with vaccinia virus vTF7-3 and subsequently transfecting them with T7-driven support plasmids encoding VSV N, P, L, G, and VSV genomic cDNAs.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BSRT7/5</div><div>suggested: CCLV Cat# CCLV-RIE 0583, RRID:CVCL_RW96)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Working stocks were generated on Vero-CCL81 or Vero E6-TMPRSS2 cells at 34°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6-TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viral stocks (VSV-eGFP-SARS-CoV-2), generated in Sean Whelan laboratory, were amplified in our laboratory using 293T ACE2/TMPRSS2 cells at an MOI of 0.01 in Dulbecco’s Modified Eagle’s medium containing 2% FBS at 37ºC.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2/TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero cells were used for these assays.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viruses: SARS-CoV-2</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: (BioLegend Cat# 946101, RRID:AB_2892515)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Absolute inhibitory concentrations (absIC) values were calculated for all patient sera samples by modeling a 4-parameter logistic (4PL) regression with GraphPad Prism 8.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a protocol registration statement.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.25.457699: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: All protocols were approved by the Institutional Animal Care and Use Committee (IACUC).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">24 hours post-transfection, the cells were collected and stained with anti-Spike antibody STI-2020 in FACS buffer (DPBS+0.5%BSA) for 30 minutes on ice.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Spike</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Thereafter, cells were washed twice in FACS buffer and incubated with rat anti-human Fc antibody conjugated to allophycocyanin (Cat: 410712, BioLegend) for 15 minutes on ice.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human Fc</div><div>suggested: (BioLegend Cat# 410712, RRID:AB_2565790)</div></div><div style="margin-bottom:8px"><div>allophycocyanin</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ELISA assays: To asses spike specific antibodies, S1 (Cat: 40591-V08H Sino Biological) or RBD (Cat: 40592-V08B, Sino Biological) protein was coated on half-area high binding plates (Cat: N503 Thermo) at 1 μg/mL overnight at 4°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>S1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary antibody of horse radish peroxidase (HRP)-conjugated rabbit anti-mouse IgM (μ chain)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgM ( μ chain)</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell culture media was removed from cells and sera/virus premix was added to VeroE6 cells at 100 μl/well and incubated for 1 hour at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Animals and in vivo studies: 6- to 12-week old C57Bl6 mice were purchased from the Jackson Laboratory.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57Bl6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In vitro transcription and purification of RNA: To generate the template for RNA synthesis, the sequence of the SARS-Cov-2 Spike protein (GenBank: QHD43416.1) was codon optimized and cloned into pVAX1-based backbone which features 5′-UTR, 3′-UTR and Poly-A tail.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pVAX1-based</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Whole blood was stimulated for 6 hours with 1 μg/mL of SIINFEKL (Sigma) or overnight with 1 μg/peptide per well of spike associated (Cat: 130-127-951, Miltenyi Biotec Peptivator) peptides at 37°C, 5% CO2 in the presence of brefeldin A (Biolegend) and monensin (Biolegend).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Miltenyi Biotec Peptivator</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then run on a Beckman Coulter CytoFLEX instrument and analyzed via FlowJo V10 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistics: Statistical significance of differences between experimental groups was determined with Prism software (Graphpad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div><div style="margin-bottom:8px"><div>Graphpad</div><div>suggested: (GraphPad, RRID:SCR_000306)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.25.457626: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Ethics statement: Approval of all animal experiments was obtained from the Institutional Animal Care and Use Committee of UC Davis, UC Berkeley, or the Rocky Mountain Laboratories.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">The male and female Syrian Hamsters used at UCD and UCB were 7-9 weeks old, and they were purchased from Charles River Inc.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Image files were uploaded on a Leica hosted web-based site and a board certified veterinary anatomic pathologist blindly evaluated sections for SARS-CoV-2 induced histologic lesions.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: No contaminants were detected in any of the virus stocks except in the P.1 stock in which mycoplasma was detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus propagation was performed in Vero-86 cells in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 5% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin and 100 g/mL streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-86</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All virus stocks except P1a were the second passage of the patient isolate on Vero cells, the original isolation being the first passage on Vero cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Homogenates were serial 10-fold diluted in Vero E6 growth medium and added to Vero E6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Raw FASTQ sequences were preprocessed using an in-house computational pipeline that is part of the SURPI software package [27,28].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SURPI</div><div>suggested: (SURPI, RRID:SCR_003071)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The preprocessing step consisted of trimming low-quality and adapter sequences using cutadapt [29], retaining reads of trimmed length >75 bp, and then removing low-complexity sequences using the DUST algorithm in PrinSeq [30].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PrinSeq</div><div>suggested: (PRINSEQ, RRID:SCR_005454)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After filtering the preprocessed dataset for SARS-CoV-2-specific viral reads using the nucleotide BLAST algorithm with an e-value threshold cutoff of 10-8, lineage-specific mutation single nucleotide polymorphisms (SNPs) were identified and counted using a custom in-house computational script.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BLAST</div><div>suggested: (BLASTX, RRID:SCR_001653)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      The QUILLS strategy to identify relative frequencies of viral variants within a mixed population by sequencing of key single nucleotide mutations has limitations in that only variants with known mutations can be identified. All the variants used in the mixed inoculum experiments in this study, have lineage-defining mutations in spike and orf1ab on the backbone of ancestral B.1 (614G) and these 6 variants are unambiguously identified in the infected animals by QUILLS. However, the variant identified as B.1 (614G) using QUILLS is an aggregate of all variants carrying 614G that cannot be otherwise be assigned to one of the other 6 variants in the inoculum. This would include novel variants arising from the inoculum B.1 (614G) and revertants that may arise in each VOC quasispecies. Because of this, the relative frequency assigned to the ancestral B.1 (614G) is less reliable than the frequencies of the other 6 variants that are based on positively identified sequences in the samples. Similarly, a single point mutation in orf1ab, that can arise or revert spontaneously, distinguishes B.1.427 and B.1.429. This makes it difficult to unambiguously identify B.1.429 and B.1.427 in mixtures and thus we reported the results as the frequency of the “epsilon”, the arrogate of the B.1.429 and B.1.427 frequencies. As previously reported with ancestral B.1 and other VOC [11,25,26], in this study intranasal inoculation of hamsters with the SARS-CoV-2 B.1 (614G) or epsilon variants (B.1.247/B.1.2...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.24.21262415: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Ethics declaration: This study was approved by the MHS (Maccabi Healthcare Services) Institutional Review Board (IRB).<br>Consent: Due to the retrospective design of the study, informed consent was waived by the IRB, and all identifying details of the participants were removed before computational analysis.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Analyses were performed using Python version 3.73 with the stats model package.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Python</div><div>suggested: (IPython, RRID:SCR_001658)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Our study has several limitations. First, as the Delta variant was the dominant strain in Israel during the outcome period, the decreased long-term protection of the vaccine compared to that afforded by previous infection cannot be ascertained against other strains. Second, our analysis addressed protection afforded solely by the BioNTech/Pfizer mRNA BNT162b2 vaccine, and therefore does not address other vaccines or long-term protection following a third dose, of which the deployment is underway in Israel. Additionally, as this is an observational real-world study, where PCR screening was not performed by protocol, we might be underestimating asymptomatic infections, as these individuals often do not get tested. Lastly, although we controlled for age, sex, and region of residence, our results might be affected by differences between the groups in terms of health behaviors (such as social distancing and mask wearing), a possible confounder that was not assessed. As individuals with chronic illness were primarily vaccinated between December and February, confounding by indication needs to be considered; however, adjusting for obesity, cardiovascular disease, diabetes, hypertension, chronic kidney disease, chronic obstructive pulmonary disease, cancer and immunosuppression had only a small impact on the estimate of effect as compared to the unadjusted OR. Therefore, residual confounding by unmeasured factors is unlikely. This analysis demonstrated that natural immunity affords l...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. I am accepting charitable donations,. ETH: 0x66e2871ef39334962fb75ce34407f825d67ec434 | BTC: 38B6vGaqNvMyTtoFEZPmNvMS7icV6ZnPMm | xDAI: 0x66e2871ef39334962fb75ce34407f825d67ec434 (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){ (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o), m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m) })(window,document,'script','https://www.google-analytics.com/analytics.js','ga'); <p>ga('create', 'UA-74743044-2', 'auto'); ga('send', 'pageview');</p> Wednesday, June 23 2021. Nintendo Way Erev ... the Day of the Holy Divorce of Bayjorel   Adam on “ho(s) I still single” … I “hisss” as Alger, Narcissus and to the various collegiates in Massachusetts; know it’s because I’m Cheyanne Mountain. You can’t even dream how hard it is to get inside “this heart.” Or maybe I can’t fathom why nobody’s rushing up to me trying to grab the ring of “infinite alimoney in the ever-after” … Na Na Na Na … Na Na Na Na … shey shea way) … tee tea, tay? This messages marks a major increase in “forced read(layshion)ership” to include a significantly larger group of students and professors than before. This is a new system; please unsubscribe using the instructions at the bottom of the message, which are different from the prior newsletter interface. I have noticeably been writing much less and sort of working harder on bringing to fruition the software and social policy changes I’ve been dreaming of and writing about instead of “just talking.” Searching this message that I intend to send to the students a day early–you know, with foresight for … in the hope that many of you remember first hand hearing the words “I don’t believe in the big bang, but I respect those that do” echo from a computer screen to me subconsciously in the state of South Carolina–that you will help me end the 7 year draught [[literal, good sex]] that I equate to the Biblical overflow of the Nile and to Stone Temple Pilots; this light and Sheldon Harr who trained me for my Bawr Mitzvah and taught me all the right things that I know about being a good Jew who didn’t really believe in the existence of God; but then helped create the system that makes us all that. Those who “see” or “saw” Kentucky as I did might recall the phrase spoken from myself to myself; “you don’t believe in God when you are this close to it’s creation” … or something almost verbatim; that. Some of you might see Gilgamesh more than I do, or have forgotten the "sliding of sleight of hand and becoming … the trickster of the Dajjal … "an idea that gore was being fabricated and faked; in order to help us see why it’s so very importanat that at the same time that immortality and heaven become part of the conversation of the adbication of Odin’s throne to Thor or to Arthor’s table and plebescite “victims” … that we all understand the magnanimous change wrought by Heaven on civilization and on the old customs and on the old laws, and that here we see the importance of guaranteeing safety and privacy and even “right to death” in a place where God had previously only written of “life and liberty” with the ambiguity of … “from what” being left to my seemingly slow hand.   On the order of plans soon to be seen to fruition my large key of “what this website truly is” has grown to something like 20GB and now includes a static and time frozen version of everything linked to stored on the IPFS system and multi-homed across a number of “cloud providers” to ensure things like “shekinah” will not forever be changed to “shechina” with nobody noticing the loss of causal original truth. The “light of angels” domain now redirects automatically to /ipns/fromthemachina which should render in future shell-internet-browsers as something like QmTH33MwfPn5S3bq45Tk77L1j9eZjUsvEVhRTHB3D8M2ZX [please pin this “root block”] I am not sure why IPFS doesn’t have better merkle tree searchability, but seeing siblings and parents and connections between these Qm hashesh is something that we should be working fervently on making more robust. IPSE.io appears to have created a decent search and governance system, I see it as something like the “electoral college” metacosmically linked to the thing I am trying to build–a preservation of all human knowledge and an infrastructure for discussing and communicating about the “veracity” and the linguistic nuances “alluded to” in the lude ties between this Empire’s new Clot and the clothing worn by Popes and Jews, the seeit-seeit; tzit-tzit and … 4-WORD AND SIX WITH “SHOOTER” … YEARS HAVE GONE BY; AND I STILL HAVEN’T GOTTEN FVCK3D. I am planning on suing several medical providers and states for what I see as heinous violations of human rights, decency and the Constitution of the United States; if you are a lawyer or you can recommend a good one, please email me as soon as possible at 0xc514f094370cFc5eE45a1Dd9B72bb9675efE266f@ethmail.cc. You can also send Ethereum fungible donations to that alphanumeric identity. As I note much later in this message … TRUST IN MA … SELF-VATZEDEK SUE-C-CYDE … I KRY/STALL WHEN DODGE DESERVES TO PAY Please do note see a significant difference in importance in the emails now coming from ethmail.cc and the series of half-rambling cires for help which amount to something like my prayers to the pagan gods that you are. There’s quite a long thread in my soul Many times I’ve discussed and called in my mind and with my heart the American democracy nothing more than “Noah’s Archaic” two party system. Over the course of the years hidden messages from the Ark’s source of knowledge have conclusively shown me that a previous phrase “multi party system” connects to political parties and governmental action committees that span across continents and even earths; in my microcosm or special language and understanding of heaven, “across rooms” which are worlds … sort of owned or designed with some sort of top down or democratic structure of “literal rule system creation.” In my mind these rules can be inherited and modified, in the programming language sense of those words, as in "inherit democracy from America, update for new medical knowledge and scientific truth … discussed later in this message. The “water joke” connects to Horatio and to H2O and the idea that the chairs depicted by the character “h” are something like a placeholder meaningfully connected to the Senate Majority Chair and of course the Minority Chair and it’s the fact that there are only two that makes our current system something like A"Biblical Water." I believe we should be living in a world that has many more than two parties, hundreds or thousands of active parties could and should compete not for a single figurehead to sit in a throne like chair but for groups of people to be able to access the faster processing power and wider knowledge … represented here by something like a “Matrix jack” from the two movies, The Matrix and No Jack City; which allow for resources to be “billed to the party” and/or the people, rather than individuals who might otherwise have to “pay extra light” for faster processing power in order to quickly build a piece of legislation or political propaganda that equally connects to the mirage and miracle and dream of building a “subconscious voting system” that allows for votes to be taken “isntantly” and not just instantly but at some kind of recorded interval over time. I envisioned in Kentucky a world where the laws of the land would change instantly, allowing for bad weather to be instantly removed, for laws to differ from neighborhood to neighborhood and even to allow the fine grained detail of “outside and inside” each and every individual home or castle. Lost. Blind wandering through a lost world, in the beginning–that’s the truth. Crossroads, somewhere between walking through an electromagnetic pulse in Lake Worth and struggling to remember “the other thing.” Recalling [flew(ers)], so I was there sitting with my parents when we saw it on TV–a gigantic deal–the United States was going to war for the first time in my life. Saddam Hussein had invaded Kuwait (supposedly for the oil) and Operation Desert Storm was launched by George H.W. Bush; recalling the names and “Space Balls” it’s almost funny to see … how blind I was back then. General Norman Schwartz cough. General Colin Powell. Anyway, the whole point of the story is we were sitting at the Flamingo Diner; and for my whole life I lived just a few roads away from that road; never ever realizing what it was. I also didn’t realize for a very long time that you might also not see it, or you might see it instantly. Scanning just south of there, you can see it turns into Red road, and then its more than obvious that “flaming” stands out, light a highlighted cross–but we don’t say the name of that bird that way, and we didn’t see “infer” in Dante’s “inferno” or … “no” either. Flamenco … en espanol … like the dancers. A golden bitcoin swirls in the sky… the “mind control people” of Bowling Green gape in some kind of crowd pleased awe as the “middle” and the end connect almost seamlessly … Fort Myers creates a space port in the light of Vegas’s monorail “plots”– “Who?” “this is what it does,” vaaa—tseeee----deeeeeeeeck? In this word I recited over and over again in preparation for my Bar Mtzvah on December 11, 1992; without ever knowing the meaning is the crux of what exsactly is going on right now. The word is vatzedek: צֶ֫דֶק noun masculineIsaiah 1:21 rightness, righteousness; — ׳צ Leviticus 19:36 87t.; צִדְקִי Isaiah 41:10 8t., etc.; — 1 what is right, just, normal; rightness, justness, of weights and measures, אֵיפָה, אֶבֶן שְׁלֵמָה וָצֶדֶק Deuteronomy 25:15 a perfect and a just weight, ephah; ׳מאֹזְנֵי צ; ׳אַבְנֵי צ, ׳אֵיפַת צ, ׳הִין צ, ׳בַּת צ Leviticus 19:36 (H) Job 31:6; Ezekiel 45:10; ׳מַעְגְּלֵי צ right paths Psalm 23:3; ׳זִבְחֵי צ right peace-offerings Deuteronomy 33:19; Psalm 4:6; Psalm 51:21. 2 righteousness, in government: … and you can believe that despite the strawnge pronounciation little boys and girls would use at the age of thirteen as they spoke in rigorously recited prayer-song … it [swounds almost exactly like “What’s a Dick?”]  https://pediatrics.aappublications.org/content/125/5/1088 https://www.who.int/news-room/fact-sheets/detail/female-genital-mutilation https://en.wikipedia.org/wiki/Female_genital_mutilation #FTA, from the article: Congresswoman Ilhan Omar, righteously fed up with the prejudiced nonsense she endures day in and day out, called a question about female genital mutilation from an audience member at a recent event “frustrating” and “appalling.” So I stand here living in Taylor Momsen’s song “Nothing Left To Lose” my personal favorite of hers which touches on this subject of “freedom as just another word for it” and of course the link between the purpose of an ethical oversight of the popular vote that the Electoral College represents; another two special and related words here, righteousness and fate. Between Vatzedek and Kismet; I can only convey my great dismay at the actual emotional and true physical pain I feel in my groin of groins every time I think about the horror story that has become my life and the what the land of America and the Medgard of Yggrasil has become … [note it’s not Yggdrasil] as I rally against the closest of my family of families, the Americans and Jews who refuse to stand up and speak out on my behalf, and on the behalf of humanity in general against the sickness of ritual genetal mutilation. Lost between Elvis and Suicide, she sings and I think about Ellis Island and Ellis Eaton and literally the innate and obvious lack of desire I have in my heawrt and imparted into my mind by some kind of ancient and unholy Jewish law … no desire at all to leave this world which has quickly turned from a bastion of light and freedom into nothing short or less than Hell itself. Kirinechoes from the land and day of NEMEC.html the chanting from the invsible choir of “e” … "he’s a victim" over and over, “he’s a victim, he’s a victim;” and in a more private sort of way she held on to my victim’s rod) and in a sort of kind friendly way implied that I should stop doing “speed” because … I need this, and she … in Holy ritual … patted the phallice of Iapetus’ great grandsun. Here I stand for the very first time; writing to a large group of students in the area of Boston, Massachusetts begging for the Sabbath Day to “be remembered and kept holy” as the Hebrew prayers and rituals repeatedly fail to explain has something significant to do with entry into the Holy of Holies, with the continuation of life and of heaven … and with the reinvigoration of something like a following of the Hippocrati Oath that is beyond a requirement to be reaffirmed here in this place as we begin to discuss the opening of “the process of the creation of legislation” as a function ofthe “citizenry governed” … the creation of “direct democracy” utilizing a kind of fusion of the software products I’ve been explaining are here designed specifically for this purpose. Software like kipu.com, aragon.org, wikipedia.org and even reddit.com. On the shape of his table, the heart of “sword” and another word for “Murfresboro” Sometimes I get my hopes up, sometimes i lose all the doubt and the “missing remorse” and the fear–the moments I can’t STS “socks” out of the VEGA System; in those brief moments I think you’re actually going to do something nice for me, that the heavens haven’t crashed and I’m going to have some kind of sex party that actually … really honest to God … is what “Saturday is all about.” So what, sue me–I wrote the book on the single Dionysian fusion of a Roman Bacchanalia and the Weeebrew Saturnalia … and then I yell at “Bethesda” for even daring to mention the grape fruit juice and the movie Havok–but I’ve heard all about the “passing of the nite and the nocturnal rite”–truth is I probably would walk right into the branch ending trap I laid in Fort Myers–every time I think about it the “minute of bouncing and orgasm” makes me smile a little more inside and my stomach get’s butterflies and just for a moment (I think I might be writing like STS) I think maybe it’s not the end of time and maybe I won’t never get to actually see … Heaven. Butt then you tell me (my but-tea joke isn’t funny, eithah?) … “Cassini” and “molasses” are supposed to make you feel like the OC resort guy staring at my tooth “about to be the one tooth from 2011” and I go back to remembering it’s been a decade since I’ve had a decent “good time with a girl” … literally seven long years, aside from a brief “blushing” experience with little Mackenzie Reisinger. Imagine that girls smiling at me and saying things like “Larkin Sow” and this brief period of “ecstatically frenzied decent writing” is all that it takes to keep me going; trudging along through the very shallow (or deeper) pits of Hell itself–just like a Dreidel c’d to make some silly words from the "introduction to the Bahir [literally wasn’t here, and “spirit of ah-aha illumination; hi. and this conversation ensued”] like “yod-nun” actually be … something like our salvation. Flying back in time to the “thang” point, I remember what it is now. Fear it … það; fear it. Day One has begin, or ending–whatever the proper literary way to say the Bible and it’s days are all wrong, and even further along the thing called the “Festival of Weeks” by the Jews, even more disgusting. I have no shame or remorse in saying such things, in fact I believe it is the purpose of this strange take on the “nocturnal rite” of the Norse ancient Druidic and “Dhruzi” mentioning of the Prose Edda to come to this very strange point, in this very strange place. Boston, Massachusetts. It might one day be a little known fact, but up until the presidency of Barrack Obama every single President of the United States of America was a member of the Protestant Church, all but John Fitzgerald Kennedy whose bright and shining face and ethos stand apart from almost all others in his place. I might one day say Trump too stood out above and shined brighter, and personally only because he lived during my lifetime, I think my personal view of Bill Clinton is the brightest of all. To me, the Clinton years were filled with the booming economy of Old Joe, and the great aspirations of Our Jack; a thing that many people before Armstrong walked on the moon and planet a great Democratic “P” one giant leap above the rock of ages … there are just no words for lux of America’s contribution to the launch of a Heavenly Civilization, in the words of Paxton in “Big Love” … and the LDS Church and Deseret’s version of “the thing” (nu3 today) … “the celestial kingdom.” Valhalla and Matzot scream of the “ha-moat-sea” and the “vats-a-dick” but without our giving of thanks for righteousness we have become the murderers not only of Judas and Death but also Jesus and the thing that created him. Eventually the island of America disappears, eventually it’s Earth, any planet a human was one … these are the things that have either become a force of great goodness–or of total destruction. This is the embodyment of “Troy as hisT” this is Galactikiss has become Planet Prime and all Derivatives–the silver surfer speaks to you all, between “El Dorado” and the “Silverado” … a comparative connection to the difference between Fort Knoxx and the Pound Sterling … with a Troy Ounce of “tzadik” to ensure with our GSLW: “ness truly means 'now everythink safely saved;” … and that’s a GNU definition for NESS which previously may have mentioned everywhere or earth and those are both absolute falsehoods and perhaps were not when they were spoken. At least, relatively speaking. Rape has come up today. I’ve commented publicly on the conversation I had in my head last night, walking by “Boston College High” and I can’t help but add my “very interesting” thoughts on the echelons of spirits inhabiting the Ka of God here in this place; and how they might somehow be satiated in a way that I or most people in this world would fine to be something more sexually immoral or deviant … “previously of the wiccan pagan variety” … something like my strange dreams here in this place of starting trends of having “a thing” for doing “moms and sisters,” which have been echoed here by a sitting and very prominent G.O.P United States senator or congressman; the show “Vampire DIaries” as well as Natalie Portman, Taylor and Sloane Momsen, Kate Hudson, and a number of other female “duos” like the Spears and Simpson sisters (Ashlee and Jamie Lynn, see) the Olsen twins and of course the soon to be “in the light of the fame of Nashville” … Larkin Poe. DIVERGENCE, TO NEW YORK CITY, TO YOM HASHOAH … OR TAV OUR TAY VUE … (((( this here is what we call a "race through a rats cage )))) if neither of the four or give girls in question send me some kind of verbal “ACK” ratyher than a “NAK” in writing, I might travel to Ellis Island or Nashville, TN before staying in Boston or … for instance going to Lowell or Nashua and … perhaps causing more FUKUSHIMA on the NAKARSAKI of HEROSHEMA; and by that I mean this is a “big deal” … LLNV might become a bus stop in Vegas or the VEGA System or it might be a national labratory near the Hamptons. It’s hard to tell at this point whether or not there’s any “liver” in Mexico’s version of that funny one with the guy that reminds me of Aldous Snow in “Forgetting Sarah Marshall.” In my mind today I speak from the Earthene world of Janet Devlin’s “Chandelliers” directly to Michael Jackson himself, on the difference or change or meaning wrought by Bill Cosby and his “Neverland Ranch” series on the question at hand–are there bowling tumble weeds and karaoke bars on par with Prescott Arizona’s scene anywhere closer to Nashville than Bowling Green … because I was beyond surprised to find a sprawling megalopolis in the place I had thought for my whole life was something more akin to Knoxville, a place where fledgling female music stars became “Grace Vanderwaal” golden buzzer winners … faster than you can connect Jerusalem to Shirley Temple. On the specific name, Shirley here is Bianca Pisani’s great grandmother; and no farther than the truth is the world’s “UMBRELLALAUNCH” link between the Chinesely famous virgin (non-alcoholic) drink is something like Billy Joel’s Piano Man Bartender walking into “the usual place” and saying something along the lines of “Geisha me up one Virgin Red head; hell, why don’t you make it a double.” Leave the umbrella with the kites that didn’t glow fiiery stars into the Holy of Holies in the same vein and for the same reason that the Church of the Holy Sepulcher failed to actually change the world with it’s ritual uniting the Olympic passing of the Torch with today’s interlinear and interwoven message with Old Joe and Young Jack Kennedy, Jackie Onassis and even touching on the Saudi Royals which were also a big part of the story connecting General MacNamara to “Lauderdale by the Sea” and a special rememberance to the expensive and Holy bronze or copper brick which he bought (through donation to charity I imagine) making himself more than just something like the founder of the beachfront redesign of our Federal Floridian beacnhead, but also a founding member of something I call “The Columns and Pillars” society in reference to the Pine Crest School version of the same kind of ritual. Also connected here are pictures of those columns, and extracts from my senior yearbook where my mother was kind enough to leave me two whole half page dedications to my graduation from one of the most prestigious and omnifiscient preparatory schools in the entire world … at the same time donating columns both in my name, their name, and the names of her deceased parents: Julie and Bernard Gerson. Bell to sky; and to the Berlin Sky; this is the same genetic and congenial family line that links Gersholom Sholom, Albert Einstein, J. Robert Oppenheimer, Adolf Hitler and Yosef Stalin … to Joe Biden and the “Joseph and Betty Portal” which replace the MacNamara era bricks with “new composite plastic” that might last much longer and has another list of donations. The “portal connection” something like an Einstein-Rozencrantz flash of brilliant light … marks just one more error in my handling of my lack of understanding of things like “basic vectodirs” and “kasimamoriv radiation” … including here (if i read this and take the time to properly attribute) a visual image of the red shift and blue spindle of the actual radiation Einstein predicted would be ejected from something so massive even “light” could not escape it. On “relativity” and relatively speaking, it’s the wavelength and energy level of the light; as well as something called “gravitational lensing” … “the special relativity theorem” which earned Munich born and taught Albert a Nobel Peace Prize (as well as much fame in the land of America for the creation and explanation of the science behind the White Sands Trinity connection to Hanukah and Sandia National Labratory) … forces these corrections: ERRATA Operation Fishbowl was a series of high-altitude nuclear tests in 1962 that were carried out by the United States as a part of the larger Operation Dominic nuclear test program. Flight-test vehicles were designed and manufactured by Avco Corporation.[1] The Operation Fishbowl nuclear tests were originally planned to be completed during the first half of 1962 with three tests named Bluegill, Starfish and Urraca.[2] The first test attempt was delayed until June. Planning for Operation Fishbowl, as well as many other nuclear tests in the region, began rapidly in response to the sudden Soviet announcement on August 30, 1961 that they were ending a three-year moratorium on nuclear testing.[3] The rapid planning of very complex operations necessitated many changes as the project progressed. All of the tests were to be launched on missiles from Johnston Island in the Pacific Ocean north of the equator. Johnston Island had already been established as a launch site for United States high-altitude nuclear tests, rather than the other locations in the Pacific Proving Grounds. In 1958, Lewis Strauss, then chairman of the United States Atomic Energy Commission, opposed doing any high-altitude tests at locations that had been used for earlier Pacific nuclear tests. His opposition was motivated by fears that the flash from the nighttime high-altitude detonations might blind civilians who were living on nearby islands. Johnston Island was a remote location, more distant from populated areas than other potential test locations.[4] In order to protect residents of the Hawaiian Islands from flash blindness or permanent retinal injury from the bright nuclear flash, the nuclear missiles of Operation Fishbowl were launched generally toward the southwest of Johnston Island so that the detonations would be farther from Hawaii. Urraca was to be a test of about 1 megaton yield at very high altitude (above 1000 km.).[5] The proposed Urraca test was always controversial, especially after the damage caused to satellites by the Starfish Prime detonation, as described below. Urraca was finally canceled, and an extensive re-evaluation of the Operation Fishbowl plan was made during an 82-day operations pause after the Bluegill Prime disaster of July 25, 1962, as described below. “Wish You Were Here” is a song by the English rock band Pink Floyd. It was released as the title track of their 1975 album Wish You Were Here.[2][3] David Gilmour and Roger Waters collaborated to write the music, and Gilmour sang the lead vocal. In 2011, the song was ranked No. 324 on _Rolling Stone’_s 500 Greatest Songs of All Time.[4] In the original album version, the song segues from “Have a Cigar” as if a radio had been tuned away from one station, through several others (including a radio play and one playing the opening of the finale movement of Tchaikovsky’s Fourth Symphony), and finally to a new station where “Wish You Were Here” is beginning.[5] The radio was recorded from Gilmour’s car radio. He performed the intro on a twelve-string guitar, processed to sound like it was playing through an AM radio, and then overdubbed a fuller-sounding acoustic guitar solo. This passage was mixed to sound as though a guitarist were listening to the radio and playing along. As the acoustic part becomes more complex, the ‘radio broadcast’ fades away and Gilmour’s voice enters, while the rest of the band joins in.[6] The intro riff is repeated several times before Gilmour plays further solos with scat singing accompaniment. A third verse follows, featuring an increasingly expressive vocal from Gilmour and audible backing vocals. At the end of the recorded song, the final solo crossfades with wind sound effects, and finally segues into the second section of the multi-part suite “Shine On You Crazy Diamond”. Lyrically, the song is often considered to be a direct tribute to Syd Barrett. However, on the documentary The Story of Wish You Were Here, Gilmour and Waters separately describe the original concept that differs from this interpretation. Waters, who mainly wrote the lyrics complementing Gilmour’s initial riff idea and subsequent joint composition, describes the lyrics as being directed at himself, as his lyrics often are. Being present in one’s own life and freeing one’s self in order to truly experience life is a main topic in this song. Gilmour, on the other hand, recognizes that he does not ever perform the song without remembering Syd Barrett. Waters later adds that the song is nevertheless open to interpretation.[7] Both David Gilmour and Roger Waters have praised the song as one of Pink Floyd’s finest. Roger Waters has noted that the collaboration between himself and David Gilmour on the song was “really good. All bits of it are really, really good. I’m very happy about it.”[8] David Gilmour has playfully called “Wish You Were Here” “a very simple country song” and stated that “because of its resonance and the emotional weight it carries, it is one of our best songs.”[9] “Wish You Were Here” was recorded at Abbey Road Studios, as part of the sessions for the entire album. A noted part of the song was a planned contribution by Stéphane Grappelli. A jazz violinist popular at the time and well known for his collaborations with Yehudi Menuhin, both violinists were recording in a downstairs studio at Abbey Road at the time. Gilmour had suggested that there be a little “country fiddle” at the end of the song and invited them to participate. Grappelli duly obliged (Menuhin declined) on arranging a session fee of £300, equivalent to £2,500 in 2021.[10] Ultimately during mixing it was decided to almost remove his contribution, although it can just be heard around 5:21. According to Waters it was decided that it would be insulting to credit Grappelli in the sleeve notes for something so inaudible, although he did receive the agreed-upon fee.[11][12][13] As part of the Why Pink Floyd…? campaign, the Experience and Immersion versions of the Wish You Were Here album include an alternative version of the song where Grappelli’s part is heard in the instrumental break after the second verse and throughout the third verse before a considerably extended outro. Other less obvious differences are audible, for example at the section leading into the second verse. The master tape of the original recording includes guitar solos that were not used in the final mix.[citation needed] Personnel [edit] David Gilmour – lead and harmony vocals, scat singing, six and twelve-string acoustic guitars, pedal steel guitar, tape effects Nick Mason – drums, tape effects Roger Waters – bass, tape effects Richard Wright – Steinway piano, Minimoog Golgo 13 (Japanese: ゴルゴ13, Hepburn: Gorugo Sātīn) is a Japanese manga series written and illustrated by Takao Saito, published in Shogakukan’s Big Comic magazine since October 1968. The manga won the 1975 Shogakukan Manga Award for general manga and the Grand Prize at the 2002 Japan Cartoonists Association Awards. The series follows the title character, a professional assassin for hire. Golgo 13 is the oldest manga still in publication, and its tankōbon edition has the second-highest number of volumes. It has sold 300 million copies in various formats, including compilation books, making it the second-best-selling manga series and the top selling Seinen manga series in history.[2] It has been adapted into two live-action feature films, an anime film, an original video animation, an anime television series and six video games. A googol is the large number 10100. In decimal notation, it is written as the digit 1 followed by one hundred zeroes: 10,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000. For other uses, see Wormhole (disambiguation). “Einstein-Rosen Bridge” redirects here. For the EP by electronic musician Venetian Snares, see Einstein-Rosen Bridge (EP). General relativity Introduction History Mathematical formulation Phenomena Gravitational lensing Gravitational waves Frame-dragging Geodetic effect Event horizon Singularity Black hole Spacetime Spacetime diagrams Minkowski spacetime Einstein–Rosen bridge show Equations Formalisms A wormhole (or Einstein–Rosen bridge or Einstein–Rosen wormhole) is a speculative structure linking disparate points in spacetime, and is based on a special solution of the Einstein field equations. A wormhole can be visualized as a tunnel with two ends at separate points in spacetime (i.e., different locations, different points in time, or both). Wormholes are consistent with the general theory of relativity by Einstein, but whether wormholes actually exist remains to be seen. Many scientists postulate that wormholes are merely projections of a fourth spatial dimension, analogous to how a two-dimensional (2D) being could experience only part of a three-dimensional (3D) object.[1] A wormhole could connect extremely long distances such as a billion light years or more, short distances such as a few meters, different universes, or even different points in time.[2] Julius and Ethel Rosenberg — Americans who were involved in coordinating and recruiting an espionage network that included Ethel’s brother, David Greenglass, a machinist at Los Alamos National Lab. Julius and Ethel Rosenberg were tried for conspiracy to commit espionage. treason charges were not applicable, since the United States and the Soviet Union were allies at the time. The Rosenbergs denied all the charges but were convicted in a trial in which the prosecutor Roy Cohn later said he was in daily secret contact with the judge, Irving Kaufman. Despite an international movement demanding clemency, and appeals to President Dwight D. Eisenhower by leading European intellectuals and the Pope, both the Rosenbergs were executed in 1953, at the height of the Korean War. President Eisenhower wrote to his son, serving in Korea, that if he spared Ethel (presumably for the sake of her two young children), then the Soviets would recruit their spies from among women.[26][27][28] Greenglass later recanted his testimony against her, and release of grand jury testimony in 2008 showed the extent to which the prosecution had created a false case against Ethel.[citation needed] Saville Sax — an American, acted as the courier for Klaus Fuchs and Theodore Hall. Sax and Hall had been roommates at Harvard University.[20] Oscar Seborer — worked at Los Alamos from 1944 to 1946, and was part of a unit that studied the seismological effects of the Trinity nuclear test. Codenamed “Godsend” by the Soviets, he defected to the Soviet Union in 1951, and received the Order of the Red Star. He lived under the alias “Smith” and died in 2015. His identity was only revealed publicly in 2019.[29] Morton Sobell — an American engineer, he was tried and convicted of conspiracy, along with the Rosenbergs. He was sentenced to 30 years imprisonment on Alcatraz, but released in 1969 on appeal and for good behavior after serving 17 years and 9 months.[30] In 2008, Sobell admitted to passing information to the Soviets, although he said it was all for defensive systems. He implicated Julius Rosenberg, in an interview with the New York Times published in September 2008.[31] Melita Norwood — British Communist, an active Russian spy from at least 1938 and never detected. Employed as a secretary in the British Non-Ferrous Metals Research Association since 1932, she was linked to the Woolwich Arsenal spy ring of 1938. In wartime she was seconded to “Tube Alloys”, the secret British nuclear research project. She was later considered “the most important female agent ever recruited by the USSR”. She was first suspected as a security risk in 1965 but never prosecuted. Her spying career was revealed by Vasili Mitrokhin in 1999, when she was still alive but long retired. Arthur Adams — Soviet spy who passed information about the Manhattan Project.[32] https://www.bbc.co.uk/newsround/25004050 https://thedoctorwhosite.co.uk/doctorwho/ 12:3 Those who are wi se[a] will shine like the brightness of the heavens, and those who lead many to righteousness, like the stars for ever and ever. https://www.americamagazine.org/politics-society/2020/05/08/its-time-rethink-electoral-college https://www.npr.org/sections/itsallpolitics/2011/12/20/144016912/we-the-people-npr-readers-would-ratify-four-new-amendments https://www.americamagazine.org/politics-society/2020/05/08/its-time-rethink-electoral-college https://www.npr.org/sections/itsallpolitics/2011/12/20/144016912/we-the-people-npr-readers-would-ratify-four-new-amendments https://constitutioncenter.org/blog/vote-now-an-amendment-to-end-the-electoral-college https://www.nytimes.com/2020/02/09/opinion/letters/electoral-college.html https://www.latimes.com/opinion/readersreact/la-ol-le-electoral-college-20180904-story.html you are offline https://slate.com/news-and-politics/2014/05/amending-the-constitution-is-much-too-hard-blame-the-founders.html we the people rise again https://slate.com/news-and-politics/2012/06/fix-the-constitution-amending-by-national-referendum.html safe souls, safe fu https://slate.com/news-and-politics/2012/06/fixing-the-constitution-protecting-informational-privacy.html https://slate.com/news-and-politics/2020/05/new-reconstruction-constitution-democracy.html We the People of Slate … The U.S. Constitution, as you [mighta been, shoulda “come” on … its someday] rewrϕte it. “Politicians talk about the Constitution as if it were as sacrosanct as the Ten Commandments [interjection: spec. it is actually almost exactly related!]. But the document itself invites change and revision. What if the president served only one six-year term instead two four-year terms? What if your state’s population determined how many senators represent it? What if the Constitution included a right to health care? We asked legal scholars and Slate readers to cross out what they didn’t like in the Constitution and pencil in their hearts’ desires. Here’s what the document would look like with their best ideas.” Slate: u_s_constitution as_rewritten by_slate_legal_experts_and_readers 多也了了夕 "with a wand of scheffilara, 并#亦太 he begins … "I am now on the Staff of Menelaus, the Spears of Longinus and Lancelot; and the name “Mosche ex Nashon.” - http://ipfs.io/ipns/fromthemachine.org/CHANSTEYGLOREKI.html - http://ipfs.io/ipns/fromthemachine.org/NUCLIRDISS.html - http://dweb.link/ipns/fromthemachine.org/CRALL4Good.html Please note that any decent browsers would probably render ipfs://fromthemachine.org as the following https://gateway.pinata.cloud/ipfs/QmTH33MwfPn5S3bq45Tk77L1j9eZjUsvEVhRTHB3D8M2ZX I ask again that you all pin on IPFS mirror and copy the data included in these dumps, they are a key to “not losing causality” to not having a history that makes no logical sense, and to some kind of coup de roku, that really makes no sense unless you no, we will ve weill … ROCK YOU Long ago I began writing about hidden codes in our history; thing’s significantly more obvious than “flying elephant armies” connecting Disney and Dumbo to Xerxes and the “Democratic Party of the United States (mascot)”–though it’s not really easy to consolidate the “epiphany” of … [((all i know))] without some kind of “artificial intelligence data condensation [infosmos.is?”] and summarization platform, though that’s nearly the next thing on my Lowell list of things we need to “mechanical turk” into being. Meta-consolidation of the world’s encyclopedias is one of the most important and useful tasks we have as we move towards the creation of a virtual debate platform that will eventual “literally obviate wisdom” of the layer/layer system that defines the name of the city I write these words near. Lowell, MA The broad overview of the system … the gist … is that political parties and activist organizations will create their own “view of the truth” (propaganda, falsehood-removed) and that these disparate pieces of “highlighted and annotated bibliography” could be overlay-ed on top of each other, creating a “new view of the truth” based on a users preference. The whole thing boils down to series of “holographic eschatological goggles” that will allow, for instance, the “grasping and fathoming” of other people’s points of view and perhaps reframe your own on any number of individual subjects. Roe v. Wade, “Concourses” and CON-CERN; because this has been such a “hot topic” in the relative psuedo-edufictional story of the space travel from the lone planet Earth ((intersected)) with the set of skipping stones it takes to exit a Totalital multi stellar system of holographic computer simulators into the … “molecular world of vaccuum and Einstein time-space” … I’ll start with this simple example. the current American debate on the subject, right to life vs. right to choice; provided by the “generic version” of the ideological christian right and the liberal women’s left. through a first layer over layer comparison. the scientific truth brought to the table by the introduction of “neurological data” proving that there is in fact a moment during the gestation of a human embryo in which “i think therefore i am” connects to some sort of Skynet-became-selfaware at a point which I imagine must be … although it possibly is not … prior to the next important literary device/step “let there be light.” At the point the ocular cones and rods are created and the fetus opens it’s eyes and literally sees the bright light that could probably only be compared on the next edschalon to seeing the “exit pathway from the womb” a. we will finally kinow whether or not “consciousness” is even developed at all before the bicerebral cortex designed to “compare two thoughts, ideas, and shapes” has the ability to get input from the eyes. Personally I think thought begins much earlier than vision, but the simple fact that we “haven’t yet had this discussion” shows how very little our scientific and medical progress in the civilization of things like murder, and understanding of life and science has yet to come here. “People here” means something different than it did when I was born, at least in my mind’s eye … something so completely more advanced that it’s almost difficult to believe you all don’t see this place as a great prison or farce or unjust Azazel–blaming a man for looking like a rat or a mouse or a dog–in a place where more to the point we stare at a kind of physical violence and horror that would put Dennis the Menace and Bart Simpson to shame. A world hwere “people closer to holodecks” blame an innocent man for “writing the book” on the connection between Holocaust and Euthenasia and Hospice … certainly you know “an innocent tool” writes these words to you? On the Hand of God, the Eyes of Ra and Horus; https://www.hebrew4christians.com/Glossary/Word_of_the_Week/Archived/Yad/yad.html https://aminoapps.com/c/zodiac/page/blog/the-yod-aspect-the-finger-of-god/XG6P_beTgu5gdXrYNwVjBj0WQlDeDWlK72#:~:text=The Yod is the 10th,to be carried through life.   I’ve written quite a bit on how “mind control” and “voting freedom” are inherently related in and to the thing we call “Civic Involvement” here in the United States–basically that participation in the verification of truth and the public understanding of tautology and temporal falsehood are … sort of a slave like requirement neeeded to ensure that any freedom at all exists I often say “plugging your [head into google]” might turn the Aesir into an Acer, or the “yodelling of the lakes of democracy” ito “the agricolae becoming nothing more than the Dell.” .WHSOISKEYAV { border-width: 1px; border-style: dashed; border-color: rgb(15,5,254); padding: 5px; width: 503px; text-align: center; display: inline-block; align: center; p { align: center; } /* THE SCORE IS LOVE FIVE ONE SAFETY ONE FIELD GOAL XIVDAQ: TENNIS OR TINNES? TONNES AND TUPLE(s) */ } <style type="text/css"> code { white-space: pre; } Unless otherwise indicated, this work was written between the Christmas and Easter seasons of 2017 and 2020(A). The content of this page is released to the public under the GNU GPL v2.0 license; additionally any reproduction or derivation of the work must be attributed to the author, Adam Marshall Dobrin along with a link back to this website, fromthemachine dotty org. That's a "." not "dotty" ... it's to stop SPAMmers. :/ This document is "living" and I don't just mean in the Jeffersonian sense. It's more alive in the "Mayflower's and June Doors ..." living Ethereum contract sense [and literally just as close to the Depp/Caster/Paglen (and honorably PK] 'D-hath Transundancesense of the ... new meaning; as it is now published on Rinkeby, in "living contract" form. It is subject to change; without notice anywhere but here--and there--in the original spirit of the GPL 2.0. We are "one step closer to God" ... and do see that in that I mean ... it is a very real fusion of this document and the "spirit of my life" as well as the Spirit's of Kerouac's America and Vonnegut's Martian Mars and my Venutian Hotel ... and *my fusion* of Guy-A and GAIA; and the Spirit of the Earth .. and of course the God given and signed liberties in the Constitution of the United States of America. It is by and through my hand that this document and our X Commandments link to the Bill or Rights, and this story about an Exodus from slavery that literally begins here, in the post-apocalyptic American hartland. Written ... this day ... April 14, 2020 (hey, is this HADAD DAY?) ... in Margate FL, USA. For "official used-to-v TAX day" tomorrow, I'm going to add the "immultible incarnite pen" ... if added to the living "doc/app"--see is the DAO, the way--will initi8 the special secret "hidden level" .. we've all been looking for. Nor do just mean this website or the totality of my written works; nor do I only mean ... this particular derivation of the GPL 2.0+ modifications I continually source ... must be "from this website." I also mean *the thing* that is built from ... bits and piece of blocks of sand-toys; from Ethereum and from Rust and from our hands and eyes working together ... from this place, this cornerstone of the message that is ... written from brick and mortar words and events and people that have come before this poit of the "sealed W" that is this specific page and this time. It's 3:28; just five minutes--or is it four, too layne. This work is not to be redistributed according to the GPL unless all linked media on Youtube and related sites are intact--and historical references to the actual documented history of the art pieces (as I experience/d them) are also available for linking. Wikipedia references must be available for viewing, as well as the exact version of those pages at the time these pieces were written. All references to the Holy Bible must be "linked" (as they are or via ... impromptu in-transit re-linking) to the exact verses and versions of the Bible that I reference. These requirements, as well as the caveat and informational re-introduction to God's DAO above ... should be seen as material modifications to the original GPL2.0 that are retroactively applied to all works distributed under license via this site and all previous e-mails and sites. /s/ wso If you wanna talk to me get me on facebook, with PGP via FlowCrypt or adam at from the machine dotty org -----BEGIN PGP PUBLIC KEY BLOCK----- mQGNBF6RVvABDAC823JcYvgpEpy45z2EPgwJ9ZCL+pSFVnlgPKQAGD52q+kuckNZ mU3gbj1FIx/mwJJtaWZW6jaLDHLAZNJps93qpwdMCx0llhQogc8YN3j9RND7cTP5 eV8dS6z/9ta6TFOfwSZpsOZjCU7KFDStKcoulmvIGrr9wzaUr7fmDyE7cFp1KCZ0 i90oLYHqOIszRedvwCO/kBxawxzZuJ67DypcayiWyxqRHRmMZH1LejTaqTuEu0bp j54maTj09vnMxA0RfS+CtU5uMq+5fTkbiTOe1LrLD72m+PVJIS146FwESrMJEfJy oNqWEJlUQ0TecPZR41vnkSkpocE1/0YqUhWDGSht+67DdeKUg5KwvYdL21d/bSyO SM4jnyKn9aDVzLBpYrlE/lbFxujHPRGlRG5WtiPQuZYDRqP0GYFSXRpeUCI46f49 iPFo4eHo2jUfNDa9r9BjQdAe4zVFn2qLnOy8RWijlolbhGMHGO3w/uC/zad3jjo4 owAfsJjH5Oa1mTcAEQEAAbQmRUFSVEhFTkUgPGVhcnRoZW5lQGZyb210aGVtYWNo aW5lLm9yZz6JAdQEEwEKAD4WIQTUJHbrYn3y2DzwTcnQP1ViZf5/FQUCXpFW8AIb AwUJA8JnAAULCQgHAgYVCgkICwIEFgIDAQIeAQIXgAAKCRDQP1ViZf5/FWM6C/9J gbRLS2AWGjdRjYetlRkSkCoTYnXWknbtipYYHlhV0YJFwFMm0ydZIhFX5VDoZyBV 0UBeF1KJmcMoIfrHyhq2QhCnjE14hE1ONbaYTGtpvj851ItbFWXMJIVNyMqr+JT9 CWIxGr1idn+iHWE3nryiHrdlA3O/Gcd4EyNmaSe/JvB7+Z1AVqWkRhpjxxoPSlPm HEdqGOyl3+5ibQgUvXLRWWQXAj80CbVwwj1X4r9hfuCySxLT8Mir7NUXZFd+OiMS U8gNYjcyRGmI92z5lgf7djBbb9dMLwV0KLzgoT/xaupRvvYOIAT+n2mhCctCiH7x y7jYlJHd+0++rgUST2sT+9kbuQ0GxpJ7MZcKbS1n60La+IEEIpFled8eqwwDfcui uezO7RIzQ9wHSn688CDri9jmYhjp5s0HKuN61etJ1glu9jWgG76EZ3qW8zu4l4CH 9iFPHeGG7fa/5d07KvcZuS2fVACoMipTxTIouN7vL0daYwP3VFg63FNTwCU3HEq5 AY0EXpFW8AEMANh7M/ROrQxb3MCT1/PYco1tyscNo2eHHTtgrnHrpKEPCfRryx3r PllaRYP0ri5eFzt25ObHAjcnZgilnwxngm6S9QvUIaLLQh67RP1h8I4qyFzueYPs oY8xo1zwXz7klXVlZW0MYi/g5gpb+rpYUfZEJGJTBM/wMNqwwlct+BSZca4+TEHW g6oN0eXTthtGB0Qls71sv3tbOnOh/67NTwyhcHPWX/P9ilcjGsEiT8hqrpyhjAUm mv7ADi+2eRBV8Xf8JnPznFf0A1FdILVeVHlmsgCSB0FW0NsFI5niZbaYBHDbFsks QdaFaYd54DHln69tnwc2y3POFwx8kwZnMPPlVAR2QdxGQD4Wql7hlWT58xCxQApf M98kbAHjUlVYLT0WUHMDQtj4jdzAVVDiMGMUrbnQ7UwI7LexSB6cJ7H+i7FtS/pR WOhJK6awoOO9dLnEjm6UYCKsBdtJr98F0T7Sb7PnKOGA77y2QN14+u9N9C1lB/Z1 aQRQ2Nc51yXOQQARAQABiQG8BBgBCgAmFiEE1CR262J98tg88E3J0D9VYmX+fxUF Al6RVvACGwwFCQPCZwAACgkQ0D9VYmX+fxU+KQwAtFnWjGIjvqaNXtQjEhbGDH/I Q5ULq/l/wm9SmhG9NYRu3+P6YctCJaZnNeaL+6WFk1jo4LMiJEUT9uGlCbHqJNaI 6Gll1w6QOVLSL8s5V1L477+psluv4WBpi3XkWYlhDOFENCcWd49RQsA2YCX4pW7Q 7GcoSEJoav38MxHmJHYPfjSEvUZXDQIt8PFHSEScvyDWfYtMdRzjmSOOPdzhDDEy 5JBOBcEdSTyDiyDU/sBoAY0e8lvwHYW3p+guZSGSYVhGQ8JECzJOzwc/msMW/tJS 2MLWmWVh5/1P8BVUtLC2AQy6nij6o+h6vEiNzpdYrc+rzT3X5cACvJ0RtCZcrnhl O9PLiona2LEbry6QX5NL41/SAJNno3i72xPnQEe25gn3nbyT+jCoJzw2L0y8pmNB D+PKrk7/1ROFFVN8dJeGwxLGdBcz1zk2xeumzy7OaV8psUyYsJNcjyHUKgclblBW rMR2DgqEYn8QdK54ziKCnmQQZeMPiC6wlUWgg5IqmQGNBF6RVyMBDADALD7NkJ5H dtoOpoZmAbPSlVGXHDbJZuq7J13vew6dtXDIAraeGrsBqkF8bhddwVLzWylMrYCG Bf2L1+5BDgvqu6G+6dcVSbBsnZAS0zfJ0H8EmTvUMxMF7qOZYyrxfLz+pQRq8Osz Icab6ZI/KB6qZyQRvEFPB6pJjt+VvuwgJZTObIwbBbgQri2i02VBkjchsVhiSX9l +eiK7O8ROHKb3P181oScIsHywBOZ9DxRAYbFk5dnBqxO3WKb02H0zqE6440cjXwq TrZZg6ayN/IlPajO8iJPYZ1aIBykxYq1WHo+nhFMYz/VVk2WJorFeOgWaLGXb73c ty96f3qXTdvMDAIWHx8YCD5LbuqasO6LNQm4oQxkCoB3K9WFf/2SvSYb7yMYykb8 clTPt+KO0dsxjWhrJnfnIhC+2Chqv2QvRbFz0S9CpUnGGDweJ1uRNV0y70tO0q7t xXSTDRU3ib6vAHA0K/2MFzwUcog4o5bj7E9uCNJH/DJLZKsMIe4xsvkAEQEAAbQk SEVBVkVOVUVTIDxBVkVOVUBGUk9NVEhFTUFDSElORS5PUkc+iQHUBBMBCgA+FiEE IRklfU/C1qukq3xMXcNH0t3P9ZsFAl6RVyMCGwMFCQPCZwAFCwkIBwIGFQoJCAsC BBYCAwECHgECF4AACgkQXcNH0t3P9Zs+kgv/XEuuWc89Bjg1QQqKZueKNUHjyjnE 2adfoZUH6Q7ir4JZyRBCVpAwrgssmiKid30+SIjwQcpb9JYa/X1XJcDUcJW/I21d Agz/zbEqn/Cou0dUpNCtxgm4BdSHWGoOtgfspXZlXBQ407tRMZ8ykmLB1Bt0oHvw PT0ZOtqXM4pyFnd2eFe5YGbNgl3zqvoC/6CMN3vqswvRlu1BpUuAjdW8AHO5Yvje +Bp852u+4Qpy6PMBiWGsBMYwtf6T7sckpMGlR0TsozwBlAm5ePKK28B0rLJPkZLJ Eo5p4rKRapEaZsWV5Qu1ajrVru7qmpUhZtX0/DddGHfXVuLssmKLP6TumpQB1zvQ vfoBltjvOx35Wps2vHuCzXLw2bROIOzhAxFB+17zxnSbE54N4LIGRpkELuwxwGbg FtD1fi9KtH7xcn33eOK1+UD47V+hKyJGrQgSThly2zdIC2bvfHtFdfp8lOFpT0AU xjEeoJGqdQVupptXyugPlM5/96UJP8OZG0ADuQGNBF6RVyMBDAC3As6eMkoEo3z9 TkCWlvS0vBQmY3gF0VEjlAIqFWpDIdK3zVzMnKUokIT1i7nkadLzHZT2grB4VXuJ FvpbYw5NPR4cDe9grlOMLEaF3oSJ1jZ4V1/rj9v1Hddo8ELi/NToVrt1SB5GCVXB DkYpNLtTiCqHSU07YqwaqH8a+qbDmPxSQdIybkZiTiCEB+6PfQQlBpENEDlov6jm zZF+IcfM6s3kZDX5KFULweH30gMjq8Se8bPtUzW013+tuuwEVr1/YRLrIh+9O6Z+ pdA7gLMRYnD9ZLDytEvpb1lBBSY++5bIJ7xps80//DNqPYqwFmZQgTg0V9XbHE2e wLcOF8a2lYluckU7D///sWQhW+VxuM7R2gEBvYBhOgjWhIF2Aw6NbymW1Ontvyhu eOZCXXxV5W44PxXT8uDdhl9CNcHoBKKJyED8tKjigtn4axpsQeUrnOSbqEXSyqES WnE2wYUDzALcwFkzsvtLyd4xaz55KkPQkAkk0BZd1ezgXxb/obMAEQEAAYkBvAQY AQoAJhYhBCEZJX1PwtarpKt8TF3DR9Ldz/WbBQJekVcjAhsMBQkDwmcAAAoJEF3D R9Ldz/WbAFwL/382HsrldVXnkPmJ1E2YEOFz4rcHRetJ+M5H65K/2p32ONQ5KCbE s8MRY6g2CkE70en2HlpDwr/MdATwxBzIjEpjgHbfqCqVVATY+kSpXsttaKKAUVHi bFgV4QkdDJNSpcHEj+bqaggRnuWiV9T6ECG7kQjHiEXPNojzsiaXMDiM5r+acZm6 82id9qOFySQ2cZEy5HbwXM+ITLQGngnppa7du2KdgiqDeqtODOTWZvLYAq2tmEwD 3TT6ttLUBwOOu2IWpDkXswlrk62ESorE5mpLxop9fsxD39E2H06JoC/YfUPIVkEv fj06e7LEdcx0I7kRfD1v6qOUUsMsLZnmyGIk24iFjLkwu1VToWfwXDN1D2+SeAat 9ydNt4M7oEbd1QaOXXjmqpdU+VUiWcBXg+p3/WdV60MkyAgc3x+YanLljy/Rh18h cZwVlinf/tgvAQLi5f9hpwrwUMoGKijEYHKuEvi3C12Si7UVDfuIR7yS0dKcfuKF MbgwdvNXqpD9W5kBjQRekVd4AQwApHVgw2PVlBDpVcyoymUOXFQIJzJ9wRtr6/sG zwv8rrQnUEtOkkna7TDU3/UTj9FUH0gbpAKGNNPaPj5q0dlLIvzxb15r1uvDGaGL MA+8GFaGFnkxzhg0aXrcKZAN0/Zhgi2B7P8oXQuug5mi1JVDkZN5SeCZNOubdQWL 3xz3jEHp3ixj1mdOdvfdWQFR4CVMXt/A6VI2ujLVb3Yalft/c5bbclAgcJQhgDUu NqGYJEJonESNRSd8fEvhNb6cx7+Djd9+Wyctr76mwOr3nRb1N1OGhFxWjIroUpfz b+6y3oQjT58cJA1ZHqmJ6UlZd81hNNd9KWpbDVwONEPpiqPzfSaonxuqQa0/Cy4W 403OhfoLM/1ZDqD4YrJ/rpyNEfSSdqptWiY0KeErLOYng7rStW/4ZeZVj6b2xxB2 Oas/Z1QYfJyFUki9vaJ5IyN6Y7nVdSP6mbAQC9ESh+VPvRUMpYi4pMGK4rweBVHu oMRRwzk7W5zVIgd425WUe3eCQFn3ABEBAAG0K0VTQ0FQRSBST09NIDxFU0NBUEFF REVTQEZST01USEVNQUNISU5FLk9SRz6JAdQEEwEKAD4WIQTvnDJqcmqzlF87/t82 pJ91j4NOaAUCXpFXeAIbAwUJA8JnAAULCQgHAgYVCgkICwIEFgIDAQIeAQIXgAAK CRA2pJ91j4NOaJVjC/4oo5yCHe7M2h1DiTXVcLI5rXQ1feY7B1feg+YJX/mI4+EV xjC/y5VVpV4syJk5GGZNXhKPHiGLaBYvglTlYOJ98RSEsHrwT3go6S8ZVvMNdP5v CEncn2vm5JGnp4k26PuOzMcJioQLOoUjWtcPFis3gG+ueH3NcPZ22oZUql2xuerh TQZegGp+jJ7bdxwYElx5jDDDkh196d5nlO2ZKENl0ZDp4GAzRNjnQ7KBV6R74J3U cLQDWY8vAFaRBZXIC5XtSzj9lr+jWgvxz7Il51+26VDTEtSafZ2uZfCOFk7GrzJg YFJD3zLnwUFXDWKRkep8TSwXnHmz/Ts/Mjyv6em25w7QTdnx1hNPxYNWMxPWNEAH pf70nNyOmcWcq27W+nAjVg8W3st/7J5CIebJQc5AUgm+fGOBW6XUQaNy2YF1YJlA 71/tls+R5IQZCYzbPOibgFS1HWKTwy0iI2rMDfxBtCXciv754jVI7L6R3J0j5Dy1 WZQVjaGgimznLN6XwYy5AY0EXpFXeAEMALvElrTV5hJG9DKu8cOqQEEVejtWJtki fZyvmiAKi2bZWiNfl1MxJt+o3Oc0eARJfnaPjrUY7hsbbSBAB4lFnDRtviARPaKM st5FkFgOh7Xx5ODc8bjqhMT9tbX37rkeDc12WAs3UxtEKWjyT7Xg/APKeK5FzpIs qew3LADdqFP9nOR0e5G8gxLTYh3ll3dLtp9DkJgA9q+0g31nNh5fZ29mcDzo/Mat Uk4PIxWC29LV9ALCJMIMesjOPiDa2KOy5QQH+/vn592ydBohOaY+B6jhEAdX8Dbp VHVFRBsiCOWGmdi6vHjMFD0tQdS6bXf+ZAG0E5HZETCxA2qfMf/vTeIJXYS5IZw0 anRkTXcTBrVE8uBpqtkNOrLJsaASkcoO5qF01J9zW8SR4jDgET7J02Fxf8CVPzb+ ZoNc9S0ZEO6Ubdh2vAkPtOV5sFkwIduN6ouAhEfJzC9XbJLpgsBKrRMAjr2FeEZP ruy8BkZbiyZ/b0S9qIgY4pqcyUJ79w7FLQARAQABiQG8BBgBCgAmFiEE75wyanJq s5RfO/7fNqSfdY+DTmgFAl6RV3gCGwwFCQPCZwAACgkQNqSfdY+DTmhD9wv/Zgav EHMuqF3765Fa4NapYh2kMS3skHn+ZzUEPLTlvrt7KHxomOzExNLSscZThMpur+yW MfNWbsw9GphiYAkMULrfJt/iWRVJ1FLgbcWgRGAwakOGwE29lMx3+rPIUQWU54Dw vE92Iz51ZGz1wgKcISuCw39g/HQ9uc3h3TfHLgfkc/GaIEa8jEOAcD67dVMoU4o+ p3nMri8z6sK176hQ/FM/8kekpeVfxmR8s6uoaJsXLRQk+i88ZwBR/5U+fBT9AtVw PL/MmZH7eCmZrn5hjaOw7tpkL8ZyAydNhOsSCqwNVtrIjgd+Gq1oSgw9EZfhKSUa +dBJAErA7MWjammQizEHDNnI8VNLngwCahGwaSgDhNaQtgNxvnkWO7XNYoCYXScP X++UmpWtSKMnD6ue36Ba1jqon0WY5cen3P+H1gL4ij5ynB9DrE8R1aSY6f+VZ48B RvjHm5LKTcAhiv2N/TyAg/fr2v9ZnEcP3CFxqAyB9JSKwoBkFvxJaRHTT3DxmQGN BF6RWE4BDACpgKWvQvPRDN03+sLYMXpJUPC7VhTjg5K/1+1vS/e/W65dYzn3JYxb ip2PcI5xajFnxzUrwwmhW+qz5REDyCtAObOpKsjtr4qu7mgOWnPa3k2Lm0bpCjDr BSFOiQsBVezTG/gJm+qELeqQMS9PHDSvZXeBROK7OkRE0nZ6yAj+QKEoVqeADpDm BHmhAA2OKBzq4rDWDh1jRQ7gLjlv/BFbhU1WuEfH/qzX8AUSsd0/hoPG0cPgC8gQ 3m6wr4eYqI853XQujWwisnlAE2bf9jsRjW+aLrJJTcADWk5Op5aQhI2lURYkryfC DFVcme7Hsrd+RFPK88J08YjBjOoYFwRU4AhHgucX9tW0S0v9hi3pKrF9O/JAIf+r h6BpnWo7tT5+8mVhtFvfEp9Y4xeUAKKZHBKhzHeOO8QQgHrIYa6HCcU03eyxy4Tq AsJdAJvxYFCRPdY9d0Z6uVsPhRy+3UmTxjl590T5/XjKPriAjBqXnKr4KexsM1gj 1L96bYDEgr0AEQEAAbQaRTFYNl8xIDxFMVg2QEVSTUNDT1JQLkNPTT6JAdQEEwEK AD4WIQSGisfXZ2Vg0m16Mzds3dDsq5BTxAUCXpFYTgIbAwUJA8JnAAULCQgHAgYV CgkICwIEFgIDAQIeAQIXgAAKCRBs3dDsq5BTxKq8C/48HSgecuI6MYtq84yqaQ1r x6cteRyn9BJDFTAUxn3X25kf0vVyCKQNAy2oybD5QHFLqhFCXJH+cnJ3xdviRUeW eO9fhkTmd12mHGrRDD02AHXZmaMp6ni7FuYpBGrw5dbXKTkSWfD/qb3odMx0jQby 6X+2eFhUpyh+yPB7P7HwiPwzdr0dBg3xE0vE0Vz+naMyt4YBHzrBbZo+y47Q86Ym TmBKxG5tlVsGDB4dDWSIvpBgnMFN1j46Uk2ihu4huohLkvSou+jYU+5Ppu8Fu1+7 i3RCILzeBtucR9+T4px1WVXx2sKOk0FfddCvI/fT/mhsgqQZwjj9b8HNfobhNxkL HBNFQ7FLJxKayPwMyJYDURUq7gz9p5JwHTmFg9n7zyK8qU2xR5t2247YinfEJQYL zQM6VKQCoDqydFfAPeGlx1KjroMGls4sP3XVlrR04YzaJ0vxRgog1gIO1aHMQ2Sj l8bG0GcerQ44rpn1v33Gw6KL/0SY9JsSSSjA9lgINWi5AY0EXpFYTgEMALy/jHsN kUQQVJK9QuAy5V2GePBTEm9NnjNCk+edGjSgqC1LemmP7EYh07J13d10VqD2Wtae bXlBeaMOcnoXQdfdK6nTKWRrH97JuRTrA3efLkl/R4EA/kHHV+YDgT+LBboUFYVU QF5YhfcvgBUcLXI3lX5wMEQbLb87cVjR0JtqVBFMIIvs4ibgr0U2SONiD9LcXZxf qYcX7CMM6RmuLzHTCEHyjp+KAw52K1i3+3M0OVZpa25rKE+S7LykQ1GrUUY3uVHg R2I3T5/Sns3Azc9wKuy/F71oiXyqCc3FwzTQHoki+eBf5dzs6h3GBTK3Dz6kl2mv 1TXpY1dk2EmuqKIeSr8CE52nkK8ZKY6cvX+v/p1EBAkJZKiasj+ukL72p3Lji5r/ iOarNJnURT5LJdYYL27dtQFSYyVWayeWi5358Ajh1H9OdpiGXcgG65ry6u50G8JR FCywwsdKpGjMG4FlkLkm50/piU+cgVeLET/C7C/OXNslL/pHV3x8kPRY1QARAQAB iQG8BBgBCgAmFiEEhorH12dlYNJtejM3bN3Q7KuQU8QFAl6RWE4CGwwFCQPCZwAA CgkQbN3Q7KuQU8SHSwv/agnEnhmo2yuKCLiKdTa5KZ8wh3umiX3S6rldW0NO2h8a cq2l7xHY1r2u4ieeMx27jtTqCp7ksFxPYwP9WxtVBy0teG8pKLhEffjyG2WKDzAN 7oXNZ7Ur6OQGfuOQzlMqOGtYQrbHAuX60PCldurX/6/0sKS6vESdeGMQPoZIDK5g HP298MMhlWYEG7uU31J1Cx9ZqiTosSckfrDq3weU8x9DZYaLZ+Y2akF5XpL/HjyA 6PM+lv6vnTA+b5DYCOJb6N7v131Net2JN7JVVGoc0FjsxN/W33H7eIDOZwqcCvzD i8EjjzZpZUDeYjlSXAqWvpeAASncMzXS2/S2V2u5X2iR7tDtRj9SuQehJkdTFNZH xh5nTdhPzgh/iOcm33VsQ17JWbovl0hbhYBPO4V+yIrN+oQGPhH+KCNNa39EjEzB iBIgirxQSaykwb4f2Kshh+d7rKHKb/mn6JBHU444mBf09m5wM/mhLSpuhMTcP2h9 jfFximAE9FBhdZhQsF29mQINBF6I/R4BEADotSG8PhhxxD9/96bgdWa1bzp2398W LaxP39T+Kzx2KL2xB+7B4EeTTzZ06kD+myCC9Ez+PqecfisJPfaiLD/+0/m3HLSS hxEaEqt1RBS3j6qJx8Lr51cAwGou4hGTo9H3me6FHO2ExZXd76A6kkUh0J4y3r6q aAoDP+MUczKzEjn6C6T7Uu0pdgYY1bDhuqlK0taqkqviGBYTAqmCrtcQhj+J/jbd OIZtpT3+PH6mWqguoONiE+glWcdThyuIvV3ix/GrhjmUZb/DQcvvbYGfDvGRBH4B Uj3f9WBM6HWSxKrCwWC3OcgZhtBcZjKrMPbNDNt7yAArv7nGpHmlpfF14Q6mVmVT 6Ulh+0xRx+6zFbqlDYYTneurK3RtqOBsMFG5rNDZYh/QOsHnSsxmU4LGdlEfQjYs 901zmzP7CQXjjJbtRXWIqPcn3OHIIasvjTACe5M+Lfk3u3rEiDYM64vg29sSyp9q 8hAzLTPcLj/Cc22jUEC/bbv5HfLyCZTCsu5ym1gDQZ6bDrJlFlXZJ2+vTCBsY24H RF9/J/z1JWYD1cAHpG0GRtYE9exKpu8/81jxIVn21qvvxSCPXw6IQIsEw51uk5TJ xAUIRCPN7S0UEtd22LSbM/IYx1cesCRUCmY7jDTro/jo2B4hLG64KBgqyjg0lwxd dy5S8LwFx1zskQARAQABtGhBZGFtIE1hcnNoYWxsIERvYnJpbiAod3d3LmxhbWMu bGEgLyB3d3cuZnJvbXRoZW1hY2hpbmUub3JnIC8gZW4ucmVhbGx5aGltLmNvbSkg PGFkYW1AZnJvbXRoZW1hY2hpbmUub3JnPokCTgQTAQoAOBYhBE+vDT4gih9MmA0P ZvtOzkoQkinPBQJeiP0eAhsDBQsJCAcCBhUKCQgLAgQWAgMBAh4BAheAAAoJEPtO zkoQkinPJ4gP/3U691086OKbWiQhMhV+AViuKnMgV4i1M8s+4Ep01h/dTE6R+rUu LcnY4T0HR5qxAYMiNpGo1vtvkMvV5DP1PFSl5EddKn8+Kvn/0+WjbLV5tdiFF1Ef xR6261UFoXAGk3HJMLQifr3lWKoimaBwJZGza2ok9k1TQVTn8g5a01bzK7hD5DJI zt9RJZaUkxGE97eUyJ8Dtwumo18EWJltuC4UWjWT2t2HE9mMsOfjpYZXFsGxJ0Zb xexo0DYsriPDpuxDnZT7G3re9Vwz2VIe388DNBW5HoJsYxhr2I0QOq64ZWOSEZC8 lDH+xM6YdY0iz4A+7nbKNGifLbH8oU4A1sV9HrIE2KNy76x0GNjgQUvcq1inD4Oh yorsRh/IF6wnqvFrHOstCS2dzpKuQ/s7bM5TGOD2EGb0xu7r0AfHqqLUlbr3rxkS wBFMQphyNr3mEkEbXU1dGsXDlRQy11LigMBoEHmP0t49bYWuM1mIBnIC7gZc/sV/ E5fWmWdQyCKmHeujmS+sgp2EX0NtMGSzm7z9WBzTBFjaN7q28gueQ3INDsDTGx2G aA1LbP2uh1ipwju0GxecUif3T2NDqaYfhbaCYsPJORNUlJUtCVBGeba9wcXai2dh l+HsSKUiyCgKiy6Rt6jumKtYHt+Q0zcKWLfVp8PA20zX+2Q9zKnlLzwquQINBF6I /R4BEADQ4kmCHYtAhjCShc724Ei2pqSH4SfnXd4r8S8I0+io6Mh0kWn+kbKk/aGK BL3KJyN6624kPtOFWuQ4iQ0lWFn9UMnvjByTPbjZ2je+VtCP7lKSNvEgTLQRxLEJ hoNVrNjrLa/Cn7sLt9ayYcx8eKpHkbmrVRTyGqljBkI5hwQ8S+7BWugabhGQuogw bFthykA+wxYvSbSn5mwKO1BlbDCRnxjLISlqWwmKKEtXQ8b3tu7GgFuPYLKaLEk1 BIwwUSdozjXu+198WligepslidlN5bXrvje3sxgt4oAPFMeH+NnDClSDuGhSYamW Db3ZPl95pW70ngUVgFPG4kQOlaqzo3YBeDBHDXlqU0+O8cwSQFk4CBJI3yt6/KmD BIuKLwauOxYullx9EnqKcLWEzOlTgn9Q7BARK8Uz7PQU3+1mDNId2MEg+gfL3rd2 +aMLNhTUkgVE5mWkeDz6Kg7YhwruvJtn0z1QqUhkQcVs7N8rVCck0YUCVGXpsUlu emK48q4ryOxmMG/+Ws2Xkmdm6Axq414WHz6nLwMWgFpcO+1wRwQuZEkeWeSAjEvS CGHImxTP7E08+y3vAl43a9AlR7v9PbtCy2FenAhGPigmWm2aPj1ejYfQLXozyWSM m8uO3aiKvQXdV1Ha2xQLK5expaRaAXQ6YLsNBD77UPxi9qC5rwARAQABiQI2BBgB CgAgFiEET68NPiCKH0yYDQ9m+07OShCSKc8FAl6I/R4CGwwACgkQ+07OShCSKc9o DQ/+OV2OuDp9g/27SRssbTWE+nBl0R9klrb/w2XEIVhg5LROUe/P3anyBLNITbF9 A4q8b9udD+iIc1ClY2bu3rQOdzA1DH9GK84bQ1O/LaU0Te8RBGJJEzjYMUraCgIX 4BmxsIlWuCkSNsTgempLOK88646Nv5uc/oxAj6kQH7x8XBXxaJ+N9WS9f7EAv4AL bSWeJ4ijbw9BIMHt/D9Em7Q8bW6VGZIEjIp+gl1vNZ6QGCTtRHQez1jYmFLpuE/G yh1zM5gCnZbcmC7ExDLFI6SuYUbKC+XaLA3+LLCVCPFLtu6wLvcgYFwWWMKIhJAQ bRyPePiuMqWeWR6VXTD8pLziDjxK0ZtvpGdOtZeCCHOEmxrCsfKdIyD2Gn7TmTwb M9fRE1HazROfit6SRCAamabg+dJIEGT8vzlLfnkZRi+6hxq88uDbrOkk36ShWoYB AApz+5fj1ogLptiaTUTyyjTjB+/FIbU48/02fkD0y960zQLyKL64Q4aZrNa2NNup YKy5F80NkU4rHOZ1HTaPLoqqVsGhWc3ODgLyGPiRDLlZu81aNpA/UnTEBX464Sk4 Jx9qztb+S50LnGItA92QfE9ru7FAE00RR6mpCv1h7uE28/Wr4XaYgJcw1hAPRr7p TtN4lph+sJsCQ8eX5YUlM/Pht1h/LoE8h4hXNfAGh+CZgoWZAY0EXodqtAEMAOBb WTLRDxNk9SbC7exKdw0f8Wy9DhX2Qqoi96piS99CMJSxeocLiC9Si2u5nL3sQTAu qs1YbtSgn8kkiH3HPEJIhV1p/Hvz47j4kXq7PnjqF7KAdCYewuDqRiq8J7TNokYs 6+3/KqwHT/IT8NwPLdMkXcv/SXqhuKpqa2ApIrhu04VFp4H5OXN9rqdF5ZDfcNx1 PQv+6m8v6xRwrI3kduRCUD3YiVPM3EOhqINk9XMuxAoVX3qwpz+OuEDBm76U5jTZ q9ErdwRV9gaGm5ztq6tvElpis3spM7BPHzbv0SvVRAAbgGVh6kfiaZ3YckxLq8ln Cg5or1aZNyGMf7CmaZaeAjeY6Y8FZXR1P+n/IFd9Ak83a3qizZyckfiEPO7hu9zI FFXTdtZIcV102rNoVzruZIn0vSK1DJ7bNNrHkm1PPcweMkcFJY0uh6l3x2nl2qKm AhlDs3wFG+nqvqmnliVbrFZCYlReMrWWI2YBwLC5uBcBpFAhMPNEjxOtv31R+wAR AQABtCNBREFNIE0gRE9CUklOIDxhZGFtNUBwcm90b25tYWlsLmNoPokB1AQTAQoA PhYhBP/zHob861BG6LJ9SqGPd44Z/DJIBQJeh2q0AhsDBQkDwmcABQsJCAcCBhUK CQgLAgQWAgMBAh4BAheAAAoJEKGPd44Z/DJIKtgL/0JQEzrGWoHHN7T4wLiArPCv tHB3dTZBoXGKlpuwhgOZ1th6jOnGPdMZRYnX8Zuf7QhaI7m/duKv9OAr8A/2ftHG 7/BxPSHJWBuIGZYNL97OWSstuBhNtyxfCftDkeBCqJ+lAneOrzV0M8syr2VqpfVs O8nTE7nXHSOdyen+1Fw0PtwaeG9uJvOhgRsmQ+mtAiJ1OLGKUxgCzSUk0m/YnDg0 vJBtzq9qP9+EZSuiBuRQC0tKs01ECI5DzWLNXXC6X8k3YGrJpL/HtTxH5SYNQRvS ALd+HmVYpwijLPi7ANzmg9/+h/aq4VFP/4SyMd6EjaaQ86n2fC5zeugio4sjtFMp W3jbZPn19o2hWTt9/bLns+fm9PgnPwdC+tS5LT26N6vhT/vK/HHY5AZvXXPNcQMA wp+EVFxsWK2BcFMIi7Oq47CfuM1AUA+pgCenB4iSVwxs8ANTWWIsLkkKAYQqIdan OSISa2WdslsKMjXIQ5+rG9ekEn+rRO3EAQXRryBt4LkBjQReh2q0AQwAwGx7shIW OaVExpngqmh0ApkxJHZIxcxpatk/lSBQfzHg6e1/7Joe98lEHcWPJ6WFsGp+aC9S 96dWTBZq/4pzAqqTrSXAZpG/+yZlWRWSXVQex1gZHPzsWYMPE9qayAPTOJHtfS6a klIEaFV2GYEvvRK5UR5DFIlsfzyyCBOUKvn0/hikqJjN2YfHUy5SR5U5dGsSX3Jk Q9bOlBYDpN3Rk5rmLg0Vwn4nPRBET70MLQ5M4pU3Br6n+vU8tMHoVXYVMLinD4gO vVY4baXEZELjcPkPzGFPyjVLlpxKMHZ6v1Qb9ornTRGzc4dEUKxi3srdsTpMCw0k CaZ2WLY4sNBO33C8XfIvMx2jF4iIk3BrSrW/hirq6xpvlh4BUh/UWVrvg2rdemAX THa93mRQeOa3bze9xZwaA2GJLRG+xCIt15v/cNpQwCYlyhJunkuwk3HQcUrKfzxo 6QhqMeDaPZeNcvN3XoELGeqtoE7gKAnLp2nQuVr4/pcaiATf+yAhBgYRABEBAAGJ AbwEGAEKACYWIQT/8x6G/OtQRuiyfUqhj3eOGfwySAUCXodqtAIbDAUJA8JnAAAK CRChj3eOGfwySB11DADLgMAafhdzRgzx7FLVVW80IfgiCTAl5M1wV2HctA17aln7 jk7iEVMTLfhrSCSvvNIdrOXUE7l9HAMkKRwaZv7OAtYR8eQTrgGc9yJdk8BMzvJB ouiaNb2LSxMSvpoaJmD2C9ZkOyW+pAXKaUGhbUl8YVa7ytwPD6yZzonGClgZI0x5 9nSc5TiPpVijzu51iZiTV35F6en7ke2hjr6iBACJGBplxeeWszRa0wK2zoubAUK1 KO2punvtGqhi3j77/0sZgvFv3czJpRac5ccdLc02Sb6I64Stp04ilcV1aqlUXxbM gLwkoXZUqbCS7ZA7eBiEaKXdj9ww/gprO0AwFETxQVA8iPF9puSWfBf18a5GEdR1 Drb5lSReCkCfBJd3Tf5WHUSrdcai0FfuXNNp/7J7CBzlOJ0h6Yoa02hz8CBGGwxI 1brXRm13004bX7C9i+94Lbgf8bTM40JvyF1kmcffkj8ibpS/VSa8aWJuqpWk/xcn ob/YdBngWCxNgXii4E6ZAY0EXot8fAEMAJ/JOflg7U8JWescyTQNl9Xuk6QUIVKx 0zOT2k+drlLwC8+FckYTCF1pm8sPDBBv9eN3cFCDf076tZjUHv+Roq5c5McDHlN5 KlFbTSOv1qZYuaPY14nHIoW7OGoSvMCOBkpDLLwnIbuLA0wGdzyd3z6Vfhpz3wDv iAplyA4iuzJQq1+iS8tq6Uj2yhmfg+zU16gw2D3iEC6hhSu2KmPhMFD9KfCzq02L xC6fMh3Fogas51ZF1fRDK8Bvicf4yYj0dn3i6GDr0/vHga4eLQqVBXb0HCv2lNer gTtawQfJu2XEn5hDZKfHeBJ4NI4k7AZIPa7OuUqOAm8Z4hbkgRZakc+OhPSEKH2i drItwrPXDGqMYV4tLLMALMQ9WDTz75wbzVbxGVcAzG3MaZSo/f/iKzuzaE8cF71A dO1y6H5YmmMENn4t/D4BYXm4edPvV6SaYU1hO5yqr7vGbrQBFVetpSCLEFveACHr sm1S6nVVTazkHj2FNdww4bGMJzPqC7bBtQARAQABtChBREFNIE1BUlNIQUxMIERP QlJJTiA8YWRhbUBlcm1jY29ycC5jb20+iQHUBBMBCgA+FiEE9+R8sSygzQHF4cv6 fsjVqFo41joFAl6LfHwCGwMFCQPCZwAFCwkIBwIGFQoJCAsCBBYCAwECHgECF4AA CgkQfsjVqFo41jpPfgv/dylMY4CPMwkdry8KnKP3QtmJOl94VnpJ+FUME+oOqjBw 6/C16uWdTLYuEUuE2jEzTg2J0kgulM2vYm8rVgJzlGiD/oIgX3X5NeyB9MH+GCpu xsJ/ofIVpC6t8Zl78B2qTnJOcEc6owy/qKs/eFXSea2sRRstqK20dOajl4Z2ycEL SdijFR3aqT4hU6e0GNWYqo3bW4TUcd05RJIZBNz6Bitq1fxljxFPOOCaoKo9mVn4 0dN65iGPEYg0c50Q6EmxEr+XtwRu1rjgG3hgq6BknZ6QD1HOBemQg/3jqQBb9uHj jHbuX9HrbGF9+QbDicbmuZSLuV76xJnbyTycFhhIcSi9wZeyAAPlpL4GQ8l98jKa SCWWGDPpKwK5+o8kteuJ/D/mYyBEquyFVhPQBXV9zS3LsN7ab55zB5+ZnLUeofai LE6e+XPGeJmG3I/+T/Nuq1CqJ4Wyt8+aIyf6Uz8dDk0kjyQku484plRwMEx7oZXR bXQAAn8SwtlNGo0sHc6JuQGNBF6LfHwBDACxAxfbQM5AcssJlQFXThnBMHtRDeBH VkyF5mrO9JeFRT+mhM87V+fJXOaEKtcSFVgZJFKV2MPdyGqZSGKmyyqfUvKfucP5 LrjK3MRKibTlOMwbBOmYUksMVE0ByMPeSzyMlQhq0oyA3fvEdKEf0JrFGDRWNzO8 /Q54oj79Pki4y1BDKd7lE1srBFiVEUuPNJmjhhU9WXnMwiB55lLwbTR8mKEX0Pr2 FeTS5gttmbHf4V+wnJvlOEU6mOLMrb+6Xb4ltvqbl9ng1+tF2QMGMd83mtbFtAjb Zcl/Cq2KwsBFyH9VT48ZxWxpOYMf3ppEg9KOSfz9Ungtg4/Q/Kr9P13Nf+9+S9JS 1PfKdlJzGFDn4EwZ49ugg6GNnL6XuRl9jBPD2iD8hY9CsTdWrr9giCmJmdf6G/bK HUm2QekMbhpaQmYKkMeri45cHprx1dQ50rfiH1cBm5SxaK7z/hDDaKXF1Gp7/KwQ g6gHlyMss7EEHSY5ogH+6a7OUPpqbJdNztEAEQEAAYkBvAQYAQoAJhYhBPfkfLEs oM0BxeHL+n7I1ahaONY6BQJei3x8AhsMBQkDwmcAAAoJEH7I1ahaONY6EqoL/R7J QLaAlb4/hK7/v4vsSxtCirLWrqNNNJxYdmpXq19NKPmcc08QzSqkJ7vR4/kn2L6I OY7y7AMh+tScKTKIGn8MkAcj0ZvkafHY3xmpN1Xp9caUAA/fw6KWD+pSZpKpISyd 2Xr6x5OJGSKhyGpPB98oCsa809LQ3cweG1imem3jx+Lgii63pEJG/AeNeEwkIvdC zRLSQvYv0UjlhyOoII6YEWJcro+tgOcthPh2SY50E4lwFFfbz4CNQyL15D+XciNI xSVGz8gee/XdJdgwQF4SEnIiChhmJ5VmpNH8ZwxTMyI3EoFMB/RYaucwc/ucvySn cFyShFFRPjo6TOeYIaSrrfR+4yhHAGeM572y0btI6JjWZovupeXX3k5ZHHrCwxlR MuyULLyhUsAC0r1FUijbUWoyaDcRtLRpMUg1X6A7n1iH61WxlKQ/8mZhYht85Jgp FSiyz47gofc491ng9efshlyxwb3TeLbDZPRnls7L3sfDDWwp8yExjA7UNDbIh5kC DQRencYLARAAsFHArFeulhD6hZplRF49h8+zpI3kn+vFtYwbUqLSRwze53rrJtqE 6o5MWSfadr9KIc8tNZ2aBGxzjGnsbPYLDh76NkjP4apWSMX+u+EHsaudoZoAdNnM Kqr86sVzR0MUeGHp7n/L3imp1WoCn28eMLeNec9a4GRTRPGLKR9F/jytTz/XgkHL zA3i2pt63FqniN4PBTNFzgfXiu8xVZGohsDPjmd9LXbGKTXfJGhBLB6QsmjJwglt n+00ufdKLEZu6eBxRWSVK0t4rEnnpK9K//PKq5DtVaOZNe6g+hdi0B1gpd0f0nBy eZd9arCsvN3qLXP0vYTk9DKMUecCEblss5Zt1+qjAbsMk9/xSGZLJp/4dBTBVN+Q c6+Rmv+koe6zLNmA3fJH3991xETDzZxP2UHN7q4i4L97KA+nVAakwazNLiqsY/bT s58rXnCc72b7oLnZbNOPQmLwZFafVi4xoIE/5Zq8iVr7d7xHPccYkaEVCOnsL/35 GZxy2FNi4wuOfGwBtTbnXg/u/YiBj6yNbhLR+FCwZED5M/evgUUbJudxqRdrI+1a Zo9gGA3JLJZZ/iLwF1kE7yYBvyBRfaO9IL3bwplRurnrkjI+rRhi55AlbGhU3eMu iKTKQk+qJF11ocTGu/dE9I6JeQpEdyVehrWXc5H2N0Qjyca8ZEA6WwcAEQEAAbR7 QURBTSBNQVJTSEFMTCBET0JSSU4gKGl0J3MgdGhlIG9uZSAuLi4gbGlrZSB0aGUg b25lIGluIFN1cGVybWFuIDMgYW5kIE9mZmljZSBzcGFjZS0tYnV0IG5vdCAqdGhh dCogb25lKSA8YWRhbUBlcm1jY29ycC5jb20+iQJOBBMBCgA4FiEE0s8R6kp2bveF MmxLkifaSe8nN2gFAl6dxgsCGwMFCwkIBwIGFQoJCAsCBBYCAwECHgECF4AACgkQ kifaSe8nN2jK+g//Toi6ezWYrRbTs9xwQLIsKzl91ocjCuN9nHSnwzkrLuoGGgej fHkXzd5+3ygL47j++k69TYB9CPrGdR1GTqt56Q7DSYZCgdg+e89piTJUzbEyN01q EGkVuV5Rz9EocnPE8db9HT+xvf44ecfMOFD1XuB9jynrQD445YfeFE6LHkoNUvFD wQK7NN04fa+qvrk0lTS4NCpOYsdrSioddVjQyEC6jepwIRA3iRIkFdEJT8ggqQ6d gntsgExA01o6HqzDSHjSCA5AexCotwW3Uvdt0WwXx6q/c0LsRLhbuPeGX/Nh8aOf 6RBCQWgnIko675ura4c+r1VcBYl524ZJlN4x1x02YAo9cKzYi3+H9C8K8Ayz/SJy 7sVGHWnDge1yIwzWXbpolqiMSL5l/0OBuJ0HXQSafUut33Jw7hYKP4BQia/BmE0x Tsk0rBRMyihSYnUn9mYpXM3KwWU0C2dudVwKtToGR1aKlYcCv0iNFAsR0DBw1XSq n72KqIl020gZFmg3H34Z6CWhm20RbhMjOvvkZ+OiS9kU9kXt6m+T1zCpWHFJSae4 JF+dQyB1BFxAwXW4ZEzMo4XluTuW1R8pIadKTsHMWzEzH7RvZLKP4invsZklZ3I1 EEsJop7DSMOa27irD/IlCL+nwaEsCMRh+ndSkADLHsa9P5d/qWjomKxwdCm5Ag0E Xp3GCwEQAOoXU8NrugMa8OAncXKv4hycXJzArDae3Zx6pCCEkP3TZTXh1tqKPUtb dmb8Mq2eecVTwmB+FM3m+NApgq88Vx6HiyI73IAvgtZORo32YaipfbkGnXHfaUWX 5380R4GL597yZuP8sAsJ3iDvxhW59snsU8tLi+9r2u4h0fgMDqZXQsfvLUkDIiO9 nzJf0xFacTx3n+pUuWdzIuT3AUdU/L9NubmHSnj09FevTHWIYmxGFZoiSdS7r2Z+ 5xZmPak6lzrQTVS/DxcpyA/o3yi8qLPyf1VUxXKFeKd0sV6BPvYFxI2GeBl5atBu 9/3/5D6wdlrupTFLU1Msdfy3UWaRUFHLITK4fJ7pbTgoEqxX7gpO9iqKmScm3gYc O3blA8aTqCX2NzxUF5fHbi14JvPWP04uFl5EOeDB322Jm/guWy8TvmIIyuF3aAAX PfErW/yRWDsYOcAADs8elZkt3F+E/AwWd0JMIhd/RB3RFH8m7496XLS3xBP6rNye 0O+96lX7fVp+wvINxM3Rfo63b1K4bR5KR9JDZ2SLYhrx6Hyy+UiRv7l+i26WxVMF qRyvY2aHqyvKfR1EEf1t2h7B4b65xQkj51qvX5Tjm5Az7nKcXpcUKqS3bk8xiw9N y7eFfA361OSPpQ+V4Mq/Mv+MqyxLTz9tn+80ZtjqM0MEERfpUo15ABEBAAGJAjYE GAEKACAWIQTSzxHqSnZu94UybEuSJ9pJ7yc3aAUCXp3GCwIbDAAKCRCSJ9pJ7yc3 aE2NEACDBRnGYNi2sq0wltPSkD2CbQUon+4uiFB2UU/gs4mFlGOvzDHBHVEFzCqK 0x6KlKm4XBq3AF7iIoNMiU9FmBdWDnEp9eCXdQrr/ykgq3vKMuj6/QJNNZglIDoe 1J2NXeMOUFwCUvjcCttPv42Q8GDt8/bG7QOgmTmhuqvKIj/vL+c3HgNrRsQzhw5z mSzQIDaesD+UVA/sourXpSLeqPgF+6qsEqOirD6hotaqrt+aIA/8wbYkpNQxCEK4 gKDgpqTV7VKklku7fjyhBhZQOVDoWvd03AlGQD0WBNriUsh8l4N6Zg2BlnKTGn11 BTigqwlHC91xtjERgwFg8PAHN2mtgZUHITHX5js11KwlQdLyI04/M4M4oQq0KSbJ rpiWCgrltC/VqJrT4HELFYx2Iv5wzrV9jVEm6zonag4A761hpqTgRrjWtaLuYu2Z zdw9y1r0+0d2rTUGpjIQRVOwi3AF/G4aU+vAOOf/HcgH6Qnpbu+xV0fkuAZbTI7w 6VVkBvnstiQV88KrWAOXKVABSSxTz2OYbzOTt/bgxzAa7yr1xIBDKvujBqDRGBLi bISp+40Haoj2Yqop6vbS70Xq+cnBOwJW86u61hsLgOjqyxgLzvuGTjK7+TblCjR2 F4LNeQdwDdyNRjPYeGVXM3MEqR8XdcR1Z7BQvLNcDgoW2qDcbg== =4lZw -----END PGP PUBLIC KEY BLOCK----- Please see GPG keys on PGP.MIT.EDU; fingerprints: sec rsa3072/A18F778E19FC3248 2020-04-03 [SC] [expires: 2022-04-03] FFF31E86FCEB5046E8B27D4AA18F778E19FC3248 uid [ultimate] ADAM M DOBRIN \ ssb rsa3072/04F98002A3DA53B2 2020-04-03 [E] [expires: 2022-04-03] sec rsa4096/FB4ECE4A109229CF 2020-04-04 [SC] 4FAF0D3E208A1F4C980D0F66FB4ECE4A109229CF uid [ultimate] Adam Marshall Dobrin \ ssb rsa4096/DD1F0C118C788B04 2020-04-04 [E] (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){ (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o), m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m) })(window,document,'script','//www.google-analytics.com/analytics.js','ga'); ga('create', 'UA-74743044-1', 'auto'); ga('send', 'pageview'); pub rsa3072 2020-04-06 [SC] [expires: 2022-04-06] F7E4 7CB1 2CA0 CD01 C5E1 CBFA 7EC8 D5A8 5A38 D63A uid [ unknown] ADAM MARSHALL DOBRIN Because of "some issues" with what appears to be distinct and unbridled privacy intrusion; please ensure that PGP is understood to be "nothing more than not so much pretty good" and this key also, almost required in order to verify authentic identity--in the case of ... question.

      I am accepting charitable donations,.\ ETH: 0x66e2871ef39334962fb75ce34407f825d67ec434 | BTC: 38B6vGaqNvMyTtoFEZPmNvMS7icV6ZnPMm | xDAI: 0x66e2871ef39334962fb75ce34407f825d67ec434

      Wednesday, June 23 2021. Nintendo Way

      Erev ... the Day of the Holy Divorce of Bayjorel

      Adam on "ho(s) I still single" ... I "hisss" as Alger, Narcissus and to the various collegiates in Massachusetts; know it's because I'm Cheyanne Mountain. You can't even dream how hard it is to get inside "this heart." Or maybe I can't fathom why nobody's rushing up to me trying to grab the ring of "infinite alimoney in the ever-after" ... Na Na Na Na ... Na Na Na Na ... shey shea way) ... tee tea, tay?

      This messages marks a major increase in "forced read(layshion)ership" to include a significantly larger group of students and professors than before. This is a new system; please unsubscribe using the instructions at the bottom of the message, which are different from the prior newsletter interface. I have noticeably been writing much less and sort of working harder on bringing to fruition the software and social policy changes I've been dreaming of and writing about instead of "just talking."


      Searching this message that I intend to send to the students a day early--you know, with foresight for ... in the hope that many of you remember first hand hearing the words "I don't believe in the big bang, but I respect those that do" echo from a computer screen to me subconsciously in the state of South Carolina--that you will help me end the 7 year draught [[literal, good sex]] that I equate to the Biblical overflow of the Nile and to Stone Temple Pilots; this light and Sheldon Harr who trained me for my Bawr Mitzvah and taught me all the right things that I know about being a good Jew who didn't really believe in the existence of God; but then helped create the system that makes us all that.

      Those who "see" or "saw" Kentucky as I did might recall the phrase spoken from myself to myself; "you don't believe in God when you are this close to it's creation" ... or something almost verbatim; that. Some of you might see Gilgamesh more than I do, or have forgotten the "sliding of sleight of hand and becoming ... the trickster of the Dajjal ... "an idea that gore was being fabricated and faked; in order to help us see why it's so very importanat that at the same time that immortality and heaven become part of the conversation of the adbication of Odin's throne to Thor or to Arthor's table and plebescite "victims" ... that we all understand the magnanimous change wrought by Heaven on civilization and on the old customs and on the old laws, and that here we see the importance of guaranteeing safety and privacy and even "right to death" in a place where God had previously only written of "life and liberty" with the ambiguity of ... "from what" being left to my seemingly slow hand.

       


      On the order of plans soon to be seen to fruition my large key of "what this website truly is" has grown to something like 20GB and now includes a static and time frozen version of everything linked to stored on the IPFS system and multi-homed across a number of "cloud providers" to ensure things like "shekinah" will not forever be changed to "shechina" with nobody noticing the loss of causal original truth. The "light of angels" domain now redirects automatically to /ipns/fromthemachina which should render in future shell-internet-browsers as something like QmTH33MwfPn5S3bq45Tk77L1j9eZjUsvEVhRTHB3D8M2ZX [please pin this "root block"] I am not sure why IPFS doesn't have better merkle tree searchability, but seeing siblings and parents and connections between these Qm hashesh is something that we should be working fervently on making more robust. IPSE.io appears to have created a decent search and governance system, I see it as something like the "electoral college" metacosmically linked to the thing I am trying to build--a preservation of all human knowledge and an infrastructure for discussing and communicating about the "veracity" and the linguistic nuances "alluded to" in the lude ties between this Empire's new Clot and the clothing worn by Popes and Jews, the seeit-seeit; tzit-tzit and ...

      4-WORD AND SIX WITH "SHOOTER" ... YEARS HAVE GONE BY; AND I STILL HAVEN'T GOTTEN FVCK3D.

      I am planning on suing several medical providers and states for what I see as heinous violations of human rights, decency and the Constitution of the United States; if you are a lawyer or you can recommend a good one, please email me as soon as possible at 0xc514f094370cFc5eE45a1Dd9B72bb9675efE266f@ethmail.cc. You can also send Ethereum fungible donations to that alphanumeric identity. As I note much later in this message ...

      TRUST IN MA ... SELF-VATZEDEK SUE-C-CYDE ... I KRY/STALL WHEN DODGE DESERVES TO PAY

      Please do note see a significant difference in importance in the emails now coming from ethmail.cc and the series of half-rambling cires for help which amount to something like my prayers to the pagan g<del>od</del>s that you are.

      There's quite a long thread in my soul

      \

      Many times I've discussed and called in my mind and with my heart the American democracy nothing more than "Noah's Archaic" two party system. Over the course of the years hidden messages from the Ark's source of knowledge have conclusively shown me that a previous phrase "multi party system" connects to political parties and governmental action committees that span across continents and even earths; in my microcosm or special language and understanding of heaven, "across rooms" which are worlds ... sort of owned or designed with some sort of top down or democratic structure of "literal rule system creation." In my mind these rules can be inherited and modified, in the programming language sense of those words, as in "inherit democracy from America, update for new medical knowledge and scientific truth ... discussed later in this message.

      The "water joke" connects to Horatio and to H2O and the idea that the chairs depicted by the character "h" are something like a placeholder meaningfully connected to the Senate Majority Chair and of course the Minority Chair and it's the fact that there are only two that makes our current system something like A"Biblical Water."

      I believe we should be living in a world that has many more than two parties, hundreds or thousands of active parties could and should compete not for a single figurehead to sit in a throne like chair but for groups of people to be able to access the faster processing power and wider knowledge ... represented here by something like a "Matrix jack" from the two movies, The Matrix and No Jack City; which allow for resources to be "billed to the party" and/or the people, rather than individuals who might otherwise have to "pay extra light" for faster processing power in order to quickly build a piece of legislation or political propaganda that equally connects to the mirage and miracle and dream of building a "subconscious voting system" that allows for votes to be taken "isntantly" and not just instantly but at some kind of recorded interval over time. I envisioned in Kentucky a world where the laws of the land would change instantly, allowing for bad weather to be instantly removed, for laws to differ from neighborhood to neighborhood and even to allow the fine grained detail of "outside and inside" each and every individual home or castle.


      Lost. Blind wandering through a lost world, in the beginning--that's the truth. Crossroads, somewhere between walking through an electromagnetic pulse in Lake Worth and struggling to remember "the other thing." Recalling [flew(ers)], so I was there sitting with my parents when we saw it on TV--a gigantic deal--the United States was going to war for the first time in my life. Saddam Hussein had invaded Kuwait (supposedly for the oil) and Operation Desert Storm was launched by George H.W. Bush; recalling the names and "Space Balls" it's almost funny to see ... how blind I was back then.

      General Norman Schwartz cough. General Colin Powell. Anyway, the whole point of the story is we were sitting at the Flamingo Diner; and for my whole life I lived just a few roads away from that road; never ever realizing what it was. I also didn't realize for a very long time that you might also not see it, or you might see it instantly. Scanning just south of there, you can see it turns into Red road, and then its more than obvious that "flaming" stands out, light a highlighted cross--but we don't say the name of that bird that way, and we didn't see "infer" in Dante's "inferno" or ... "no" either. Flamenco ... en espanol ... like the dancers.

      A golden bitcoin swirls in the sky... the "mind control people" of Bowling Green gape in some kind of crowd pleased awe as the "middle" and the end connect almost seamlessly ... Fort Myers creates a space port in the light of Vegas's monorail "plots"--

      "Who?"

      "this is what it does,"

      vaaa---tseeee----deeeeeeeeck? In this word I recited over and over again in preparation for my Bar Mtzvah on December 11, 1992; without ever knowing the meaning is the crux of what exsactly is going on right now. The word is vatzedek:

      צֶ֫דֶק noun masculineIsaiah 1:21 rightness, righteousness; --- ׳צ Leviticus 19:36 87t.; צִדְקִי Isaiah 41:10 8t., etc.; ---

      1 what is right, just, normal; rightness, justness, of weights and measures, אֵיפָה, אֶבֶן שְׁלֵמָה וָצֶדֶק Deuteronomy 25:15 a perfect and a just weight, ephah; ׳מאֹזְנֵי צ; ׳אַבְנֵי צ, ׳אֵיפַת צ, ׳הִין צ, ׳בַּת צ Leviticus 19:36 (H) Job 31:6Ezekiel 45:10; ׳מַעְגְּלֵי צ right paths Psalm 23:3; ׳זִבְחֵי צ right peace-offerings Deuteronomy 33:19Psalm 4:6Psalm 51:21.

      2 righteousness, in government:

      ... and you can believe that despite the strawnge pronounciation little boys and girls would use at the age of thirteen as they spoke in rigorously recited prayer-song ... it [swounds almost exactly like "What's a Dick?"]

      FTA, from the article: Congresswoman Ilhan Omar, righteously fed up with the prejudiced nonsense she endures day in and day out, called a question about female genital mutilation from an audience member at a recent event "frustrating" and "appalling."

      So I stand here living in Taylor Momsen's song "Nothing Left To Lose" my personal favorite of hers which touches on this subject of "freedom as just another word for it" and of course the link between the purpose of an ethical oversight of the popular vote that the Electoral College represents; another two special and related words here, righteousness and fate. Between Vatzedek and Kismet; I can only convey my great dismay at the actual emotional and true physical pain I feel in my groin of groins every time I think about the horror story that has become my life and the what the land of America and the Medgard of Yggrasil has become ... [note it's not Yggdrasil] as I rally against the closest of my family of families, the Americans and Jews who refuse to stand up and speak out on my behalf, and on the behalf of humanity in general against the sickness of ritual genetal mutilation.

      Lost between Elvis and Suicide, she sings and I think about Ellis Island and Ellis Eaton and literally the innate and obvious lack of desire I have in my heawrt and imparted into my mind by some kind of ancient and unholy Jewish law ... no desire at all to leave this world which has quickly turned from a bastion of light and freedom into nothing short or less than Hell itself.

      Kirinechoes from the land and day of NEMEC.html the chanting from the invsible choir of "e" ... "he's a victim"

      over and over, "he's a victim, he's a victim;" and in a more private sort of way she held on to my victim's rod) and in a sort of kind friendly way implied that I should stop doing "speed" because ... I need this, and she ... in Holy ritual ... patted the phallice of Iapetus' great grandsun.

      Here I stand for the very first time; writing to a large group of students in the area of Boston, Massachusetts begging for the Sabbath Day to "be remembered and kept holy" as the Hebrew prayers and rituals repeatedly fail to explain has something significant to do with entry into the Holy of Holies, with the continuation of life and of heaven ... and with the reinvigoration of something like a following of the Hippocrati Oath that is beyond a requirement to be reaffirmed here in this place as we begin to discuss the opening of "the process of the creation of legislation" as a function ofthe "citizenry governed" ... the creation of "direct democracy" utilizing a kind of fusion of the software products I've been explaining are here designed specifically for this purpose. Software like kipu.comaragon.orgwikipedia.org and even reddit.com.

      On the shape of his table, the heart of "sword" and another word for "Murfresboro"

      \


      Sometimes I get my hopes up, sometimes i lose all the doubt and the "missing remorse" and the fear--the moments I can't STS "socks" out of the VEGA System; in those brief moments I think you're actually going to do something nice for me, that the heavens haven't crashed and I'm going to have some kind of sex party that actually ... really honest to God ... is what "Saturday is all about." So what, sue me--I wrote the book on the single Dionysian fusion of a Roman Bacchanalia and the Weeebrew Saturnalia ... and then I yell at "Bethesda" for even daring to mention the grape fruit juice and the movie Havok--but I've heard all about the "passing of the nite and the nocturnal rite"--truth is I probably would walk right into the branch ending trap I laid in Fort Myers--every time I think about it the "minute of bouncing and orgasm" makes me smile a little more inside and my stomach get's butterflies and just for a moment (I think I might be writing like STS) I think maybe it's not the end of time and maybe I won't never get to actually see ... Heaven.

      Butt then you tell me (my but-tea joke isn't funny, eithah?) ... "Cassini" and "molasses" are supposed to make you feel like the OC resort guy staring at my tooth "about to be the one tooth) from 2011" and I go back to remembering it's been a decade since I've had a decent "good time with a girl" ... literally seven long years, aside from a brief "blushing" experience with little Mackenzie Reisinger.

      Imagine that girls smiling at me and saying things like "Larkin Sow" and this brief period of "ecstatically frenzied decent writing" is all that it takes to keep me going; trudging along through the very shallow (or deeper) pits of Hell itself--just like a Dreidel c'd to make some silly words from the "introduction to the Bahir [literally wasn't here, and "spirit of ah-aha illumination; hi. and this conversation ensued"] like "yod-nun" actually be ... something like our salvation. Flying back in time to the "thang" point, I remember what it is now.

      Fear it ... það; fear it.

      \


      Day One has begin, or ending--whatever the proper literary way to say the Bible and it's days are all wrong, and even further along the thing called the "Festival of Weeks" by the Jews, even more disgusting. I have no shame or remorse in saying such things, in fact I believe it is the purpose of this strange take on the "nocturnal rite" of the Norse ancient Druidic and "Dhruzimentioning of the Prose Edda to come to this very strange point, in this very strange place.

      Boston, Massachusetts.

      It might one day be a little known fact, but up until the presidency of Barrack Obama every single President of the United States of America was a member of the Protestant Church, all but John Fitzgerald Kennedy whose bright and shining face and ethos stand apart from almost all others in his place. I might one day say Trump too stood out above and shined brighter, and personally only because he lived during my lifetime, I think my personal view of Bill Clinton is the brightest of all. To me, the Clinton years were filled with the booming economy of Old Joe, and the great aspirations of Our Jack; a thing that many people before Armstrong walked on the moon and planet a great Democratic "P" one giant leap above the rock of ages ... there are just no words for lux of America's contribution to the launch of a Heavenly Civilization, in the words of Paxton in "Big Love" ... and the LDS Church and Deseret's version of "the thing" (nu3 today) ... "the celestial kingdom."

      Valhalla and Matzot scream of the "ha-moat-sea" and the "vats-a-dick" but without our giving of thanks for righteousness we have become the murderers not only of Judas and Death but also Jesus and the thing that created him. Eventually the island of America disappears, eventually it's Earth, any planet a human was one ... these are the things that have either become a force of great goodness--or of total destruction. This is the embodyment of "Troy as hisT" this is Galactikiss has become Planet Prime and all Derivatives--the silver surfer speaks to you all, between "El Dorado" and the "Silverado" ... a comparative connection to the difference between Fort Knoxx and the Pound Sterling ... with a Troy Ounce of "tzadik" to ensure with our GSLW: "ness truly means 'now everythink safely saved;" ... and that's a GNU definition for NESS which previously may have mentioned everywhere or earth and those are both absolute falsehoods and perhaps were not when they were spoken. At least, relatively speaking.


      Rape has come up today.

      I've commented publicly on the conversation I had in my head last night, walking by "Boston College High" and I can't help but add my "very interesting" thoughts on the echelons of spirits inhabiting the Ka of God here in this place; and how they might somehow be satiated in a way that I or most people in this world would fine to be something more sexually immoral or deviant ... "previously of the wiccan pagan variety" ... something like my strange dreams here in this place of starting trends of having "a thing" for doing "moms and sisters," which have been echoed here by a sitting and very prominent G.O.P United States senator or congressman; the show "Vampire DIaries" as well as Natalie Portman, Taylor and Sloane Momsen, Kate Hudson, and a number of other female "duos" like the Spears and Simpson sisters (Ashlee and Jamie Lynn, see) the Olsen twins and of course the soon to be "in the light of the fame of Nashville" ... Larkin Poe.

      DIVERGENCE, TO NEW YORK CITY, TO YOM HASHOAH ... OR TAV OUR TAY VUE ...

      (((( this here is what we call a "race through a rats cage )))) if neither of the four or give girls in question send me some kind of verbal "ACK" ratyher than a "NAK" in writing, I might travel to Ellis Island or Nashville, TN before staying in Boston or ... for instance going to Lowell or Nashua and ... perhaps causing more FUKUSHIMA on the NAKARSAKI of HEROSHEMA; and by that I mean this is a "big deal" ... LLNV might become a bus stop in Vegas or the VEGA System or it might be a national labratory near the Hamptons. It's hard to tell at this point whether or not there's any "liver" in Mexico's version of that funny one with the guy that reminds me of Aldous Snow in "Forgetting Sarah Marshall."

      In my mind today I speak from the Earthene world of Janet Devlin's "Chandelliers" directly to Michael Jackson himself, on the difference or change or meaning wrought by Bill Cosby and his "Neverland Ranch" series on the question at hand--are there bowling tumble weeds and karaoke bars on par with Prescott Arizona's scene anywhere closer to Nashville than Bowling Green ... because I was beyond surprised to find a sprawling megalopolis in the place I had thought for my whole life was something more akin to Knoxville, a place where fledgling female music stars became "Grace Vanderwaal" golden buzzer winners ... faster than you can connect Jerusalem to Shirley Temple. On the specific name, Shirley here is Bianca Pisani's great grandmother; and no farther than the truth is the world's "UMBRELLALAUNCH" link between the Chinesely famous virgin (non-alcoholic) drink is something like Billy Joel's Piano Man Bartender walking into "the usual place" and saying something along the lines of "Geisha me up one Virgin Red head; hell, why don't you make it a double." Leave the umbrella with the kites that didn't glow fiiery stars into the Holy of Holies in the same vein and for the same reason that the Church of the Holy Sepulcher failed to actually change the world with it's ritual uniting the Olympic passing of the Torch with today's interlinear and interwoven message with Old Joe and Young Jack Kennedy, Jackie Onassis and even touching on the Saudi Royals which were also a big part of the story connecting General MacNamara to "Lauderdale by the Sea" and a special rememberance to the expensive and Holy bronze or copper brick which he bought (through donation to charity I imagine) making himself more than just something like the founder of the beachfront redesign of our Federal Floridian beacnhead, but also a founding member of something I call "The Columns and Pillars" society in reference to the Pine Crest School version of the same kind of ritual. Also connected here are pictures of those columns, and extracts from my senior yearbook where my mother was kind enough to leave me two whole half page dedications to my graduation from one of the most prestigious and omnifiscient preparatory schools in the entire world ... at the same time donating columns both in my name, their name, and the names of her deceased parents: Julie and Bernard Gerson.

      Bell to sky; and to the Berlin Sky; this is the same genetic and congenial family line that links Gersholom Sholom, Albert Einstein, J. Robert Oppenheimer, Adolf Hitler and Yosef Stalin ... to Joe Biden and the "Joseph and Betty Portal" which replace the MacNamara era bricks with "new composite plastic" that might last much longer and has another list of donations. The "portal connection" something like an Einstein-Rozencrantz flash of brilliant light ... marks just one more error in my handling of my lack of understanding of things like "basic vectodirs" and "kasimamoriv radiation" ... including here (if i read this and take the time to properly attribute) a visual image of the red shift and blue spindle of the actual radiation Einstein predicted would be ejected from something so massive even "light" could not escape it. On "relativity" and relatively speaking, it's the wavelength and energy level of the light; as well as something called "gravitational lensing" ... "the special relativity theorem" which earned Munich born and taught Albert a Nobel Peace Prize (as well as much fame in the land of America for the creation and explanation of the science behind the White Sands Trinity connection to Hanukah and Sandia National Labratory) ... forces these corrections:

      ERRATA

      Operation Fishbowl was a series of high-altitude nuclear tests in 1962 that were carried out by the United States as a part of the larger Operation Dominic nuclear test program. Flight-test vehicles were designed and manufactured by Avco Corporation.[1]

      The Operation Fishbowl nuclear tests were originally planned to be completed during the first half of 1962 with three tests named Bluegill, Starfish and Urraca.[2]

      The first test attempt was delayed until June. Planning for Operation Fishbowl, as well as many other nuclear tests in the region, began rapidly in response to the sudden Soviet announcement on August 30, 1961 that they were ending a three-year moratorium on nuclear testing.[3] The rapid planning of very complex operations necessitated many changes as the project progressed.

      All of the tests were to be launched on missiles from Johnston Island in the Pacific Ocean north of the equator. Johnston Island had already been established as a launch site for United States high-altitude nuclear tests, rather than the other locations in the Pacific Proving Grounds. In 1958, Lewis Strauss, then chairman of the United States Atomic Energy Commission, opposed doing any high-altitude tests at locations that had been used for earlier Pacific nuclear tests. His opposition was motivated by fears that the flash from the nighttime high-altitude detonations might blind civilians who were living on nearby islands. Johnston Island was a remote location, more distant from populated areas than other potential test locations.[4] In order to protect residents of the Hawaiian Islands from flash blindness or permanent retinal injury from the bright nuclear flash, the nuclear missiles of Operation Fishbowl were launched generally toward the southwest of Johnston Island so that the detonations would be farther from Hawaii.

      Urraca was to be a test of about 1 megaton yield at very high altitude (above 1000 km.).[5] The proposed Urraca test was always controversial, especially after the damage caused to satellites by the Starfish Prime detonation, as described below. Urraca was finally canceled, and an extensive re-evaluation of the Operation Fishbowl plan was made during an 82-day operations pause after the Bluegill Prime disaster of July 25, 1962, as described below.

      "Wish You Were Here" is a song by the English rock band Pink Floyd. It was released as the title track of their 1975 album Wish You Were Here "Wish You Were Here (Pink Floyd album)").[2]#cite_note-2)[3]#cite_note-mabbett-3) David Gilmour and Roger Waters collaborated to write the music, and Gilmour sang the lead vocal.

      In 2011, the song was ranked No. 324 on _Rolling Stone'_s 500 Greatest Songs of All Time.[4]#cite_note-4)

      In the original album version, the song segues from "Have a Cigar" as if a radio had been tuned away from one station, through several others (including a radio play and one playing the opening of the finale movement of Tchaikovsky's Fourth Symphony "Symphony No. 4 (Tchaikovsky)")), and finally to a new station where "Wish You Were Here" is beginning.[5]#cite_note-5) The radio was recorded from Gilmour's car radio. He performed the intro on a twelve-string guitar, processed to sound like it was playing through an AM radio, and then overdubbed a fuller-sounding acoustic guitar solo. This passage was mixed to sound as though a guitarist were listening to the radio and playing along. As the acoustic part becomes more complex, the 'radio broadcast' fades away and Gilmour's voice enters, while the rest of the band joins in.[6]#cite_note-songbook-6)

      The intro riff is repeated several times before Gilmour plays further solos with scat singing accompaniment. A third verse follows, featuring an increasingly expressive vocal from Gilmour and audible backing vocals. At the end of the recorded song, the final solo crossfades with wind sound effects, and finally segues into the second section of the multi-part suite "Shine On You Crazy Diamond".

      Lyrically, the song is often considered to be a direct tribute to Syd Barrett. However, on the documentary The Story of Wish You Were Here, Gilmour and Waters separately describe the original concept that differs from this interpretation. Waters, who mainly wrote the lyrics complementing Gilmour's initial riff idea and subsequent joint composition, describes the lyrics as being directed at himself, as his lyrics often are. Being present in one's own life and freeing one's self in order to truly experience life is a main topic in this song. Gilmour, on the other hand, recognizes that he does not ever perform the song without remembering Syd Barrett. Waters later adds that the song is nevertheless open to interpretation.[7]#cite_note-7)

      Both David Gilmour and Roger Waters have praised the song as one of Pink Floyd's finest. Roger Waters has noted that the collaboration between himself and David Gilmour on the song was "really good. All bits of it are really, really good. I'm very happy about it."[8]#cite_note-8) David Gilmour has playfully called "Wish You Were Here" "a very simple country song" and stated that "because of its resonance and the emotional weight it carries, it is one of our best songs."[9]#cite_note-9)

      "Wish You Were Here" was recorded at Abbey Road Studios, as part of the sessions for the entire album.

      A noted part of the song was a planned contribution by Stéphane Grappelli. A jazz violinist popular at the time and well known for his collaborations with Yehudi Menuhin, both violinists were recording in a downstairs studio at Abbey Road at the time. Gilmour had suggested that there be a little "country fiddle" at the end of the song and invited them to participate. Grappelli duly obliged (Menuhin declined) on arranging a session fee of £300, equivalent to £2,500 in 2021.[10]#cite_note-inflation-UK-10) Ultimately during mixing it was decided to almost remove his contribution, although it can just be heard around 5:21. According to Waters it was decided that it would be insulting to credit Grappelli in the sleeve notes for something so inaudible, although he did receive the agreed-upon fee.[11]#cite_note-grappelli-11)[12]#cite_note-12)[13]#cite_note-13)

      As part of the Why Pink Floyd...? campaign, the Experience and Immersion versions of the Wish You Were Here album include an alternative version of the song where Grappelli's part is heard in the instrumental break after the second verse and throughout the third verse before a considerably extended outro. Other less obvious differences are audible, for example at the section leading into the second verse.

      The master tape of the original recording includes guitar solos that were not used in the final mix.[citation needed]

      Personnel [edit&action=edit&section=5 "Edit section: Personnel")]

      Golgo 13 (Japanese: ゴルゴ13, HepburnGorugo Sātīn) is a Japanese manga series written and illustrated by Takao Saito, published in Shogakukan's Big Comic magazine since October 1968. The manga won the 1975 Shogakukan Manga Award for general manga and the Grand Prize at the 2002 Japan Cartoonists Association Awards. The series follows the title character, a professional assassin for hire.

      Golgo 13 is the oldest manga still in publication, and its tankōbon edition has the second-highest number of volumes. It has sold 300 million copies in various formats, including compilation books, making it the second-best-selling manga series and the top selling Seinen manga series in history.[2] It has been adapted into two live-action feature films, an anime filman original video animation, an anime television series and six video games.

      googol is the large number 10100. In decimal notation, it is written as the digit 1 followed by one hundred zeroes "0 (number)"): 10,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000,​000.

      For other uses, see Wormhole (disambiguation) "Wormhole (disambiguation)").

      "Einstein-Rosen Bridge" redirects here. For the EP by electronic musician Venetian Snares, see Einstein-Rosen Bridge (EP) "Einstein-Rosen Bridge (EP)").

      General relativity

      G_{\mu \nu }+\Lambda g_{\mu \nu }={8\pi G \over c^{4}}T_{\mu \nu }

      Phenomena

      Spacetime

      show

      • Equations
      • Formalisms

      wormhole (or Einstein--Rosen bridge or Einstein--Rosen wormhole) is a speculative structure linking disparate points in spacetime, and is based on a special solution of the Einstein field equations.

      A wormhole can be visualized as a tunnel with two ends at separate points in spacetime (i.e., different locations, different points in time, or both).

      Wormholes are consistent with the general theory of relativity by Einstein, but whether wormholes actually exist remains to be seen. Many scientists postulate that wormholes are merely projections of a fourth spatial dimension, analogous to how a two-dimensional (2D) being could experience only part of a three-dimensional (3D) object.[1]

      A wormhole could connect extremely long distances such as a billion light years or more, short distances such as a few metersdifferent universes, or even different points in time.[2]\ Julius and Ethel Rosenberg --- Americans who were involved in coordinating and recruiting an espionage network that included Ethel's brother, David Greenglass, a machinist at Los Alamos National Lab. Julius and Ethel Rosenberg were tried for conspiracy to commit espionage. treason charges were not applicable, since the United States and the Soviet Union were allies at the time. The Rosenbergs denied all the charges but were convicted in a trial in which the prosecutor Roy Cohn later said he was in daily secret contact with the judge, Irving Kaufman. Despite an international movement demanding clemency, and appeals to President Dwight D. Eisenhower by leading European intellectuals and the Pope, both the Rosenbergs were executed in 1953, at the height of the Korean War. President Eisenhower wrote to his son, serving in Korea, that if he spared Ethel (presumably for the sake of her two young children), then the Soviets would recruit their spies from among women.[26][27][28] Greenglass later recanted his testimony against her, and release of grand jury testimony in 2008 showed the extent to which the prosecution had created a false case against Ethel.[citation needed]

      • Saville Sax --- an American, acted as the courier for Klaus Fuchs and Theodore Hall. Sax and Hall had been roommates at Harvard University.[20]
      • Oscar Seborer --- worked at Los Alamos from 1944 to 1946, and was part of a unit that studied the seismological effects of the Trinity "Trinity (nuclear test)") nuclear test. Codenamed "Godsend" by the Soviets, he defected to the Soviet Union in 1951, and received the Order of the Red Star. He lived under the alias "Smith" and died in 2015. His identity was only revealed publicly in 2019.[29]
      • Morton Sobell --- an American engineer, he was tried and convicted of conspiracy, along with the Rosenbergs. He was sentenced to 30 years imprisonment on Alcatraz, but released in 1969 on appeal and for good behavior after serving 17 years and 9 months.[30] In 2008, Sobell admitted to passing information to the Soviets, although he said it was all for defensive systems. He implicated Julius Rosenberg, in an interview with the New York Times published in September 2008.[31]
      • Melita Norwood --- British Communist, an active Russian spy from at least 1938 and never detected. Employed as a secretary in the British Non-Ferrous Metals Research Association since 1932, she was linked to the Woolwich Arsenal spy ring of 1938. In wartime she was seconded to "Tube Alloys", the secret British nuclear research project. She was later considered "the most important female agent ever recruited by the USSR". She was first suspected as a security risk in 1965 but never prosecuted. Her spying career was revealed by Vasili Mitrokhin in 1999, when she was still alive but long retired.
      • Arthur Adams "Arthur Adams (spy)") --- Soviet spy who passed information about the Manhattan Project.[32]

      Gene Hackman "Lex Luthor" Autographed Superman 8x10 Photo w/ Christopher  Reeve at Amazon's Entertainment Collectibles Store

      Exclusive! Iron Man: Gwyneth Wants Her Own Pepper Potts Superhero Movie! -  E! Online


      12:3 Those who are wi se[a] will shine like the brightness of the heavens, and those who lead many to righteousness, like the stars for ever and ever.

      you are offline

      we the people rise again

      safe souls, safe fu


      We the People of Slate ...

      The U.S. Constitution, as you [mighta been, shoulda "come" on ... its somedayrewrϕte it.

      "Politicians talk about the Constitution as if it were as sacrosanct as the Ten Commandments [interjection: spec. it is actually almost exactly related!]. But the document itself invites change and revision. What if the president served only one six-year term instead two four-year terms? What if your state's population determined how many senators represent it? What if the Constitution included a right to health care? We asked legal scholars and Slate readers to cross out what they didn't like in the Constitution and pencil in their hearts' desires. Here's what the document would look like with their best ideas."

      多也了了夕 "with a wand of scheffilara, 并#亦太 he begins ... "I am now on the Staff of Menelaus, the Spears of Longinus and Lancelot; and the name "Mosche ex Nashon."

      http://ipfs.io/ipns/fromthemachine.org/CHANSTEYGLOREKI.html

      http://ipfs.io/ipns/fromthemachine.org/NUCLIRDISS.html

      http://dweb.link/ipns/fromthemachine.org/CRALL4Good.html

      Please note that any decent browsers would probably render ipfs://fromthemachine.org as the following https://gateway.pinata.cloud/ipfs/QmTH33MwfPn5S3bq45Tk77L1j9eZjUsvEVhRTHB3D8M2ZX

      I ask again that you all pin on IPFS mirror and copy the data included in these dumps, they are a key to "not losing causality" to not having a history that makes no logical sense, and to some kind of coup de roku, that really makes no sense unless you no, we will ve weill ... ROCK YOU


      Long ago I began writing about hidden codes in our history; thing's significantly more obvious than "flying elephant armies" connecting Disney and Dumbo to Xerxes and the "Democratic Party of the United States (mascot)"--though it's not really easy to consolidate the "epiphany" of ... [((all i know))] without some kind of "artificial intelligence data condensation [infosmos.is?"] and summarization platform, though that's nearly the next thing on my Lowell list of things we need to "mechanical turk" into being. Meta-consolidation of the world's encyclopedias is one of the most important and useful tasks we have as we move towards the creation of a virtual debate platform that will eventual "literally obviate wisdom" of the layer/layer system that defines the name of the city I write these words near.

      Lowell, MA

      The broad overview of the system ... the gist ... is that political parties and activist organizations will create their own "view of the truth" (propaganda, falsehood-removed) and that these disparate pieces of "highlighted and annotated bibliography" could be overlay-ed on top of each other, creating a "new view of the truth" based on a users preference. The whole thing boils down to series of "holographic eschatological goggles" that will allow, for instance, the "grasping and fathoming" of other people's points of view and perhaps reframe your own on any number of individual subjects.

      Roe v. Wade, "Concourses" and CON-CERN; because this has been such a "hot topic" in the relative psuedo-edufictional story of the space travel from the lone planet Earth ((intersected)) with the set of skipping stones it takes to exit a Totalital multi stellar system of holographic computer simulators into the ... "molecular world of vaccuum and Einstein time-space" ... I'll start with this simple example.

        1. the current American debate on the subject, right to life vs. right to choice; provided by the "generic version" of the ideological christian right and the liberal women's left. through a first layer over layer comparison.
        1. the scientific truth brought to the table by the introduction of "neurological data" proving that there is in fact a moment during the gestation of a human embryo in which "i think therefore i am" connects to some sort of Skynet-became-selfaware at a point which I imagine must be ... although it possibly is not ... prior to the next important literary device/step "let there be light." At the point the ocular cones and rods are created and the fetus opens it's eyes and literally sees the bright light that could probably only be compared on the next edschalon to seeing the "exit pathway from the womb"
        • a. we will finally kinow whether or not "consciousness" is even developed at all before the bicerebral cortex designed to "compare two thoughts, ideas, and shapes" has the ability to get input from the eyes. Personally I think thought begins much earlier than vision, but the simple fact that we "haven't yet had this discussion" shows how very little our scientific and medical progress in the civilization of things like murder, and understanding of life and science has yet to come here.

      "People here" means something different than it did when I was born, at least in my mind's eye ... something so completely more advanced that it's almost difficult to believe you all don't see this place as a great prison or farce or unjust Azazel--blaming a man for looking like a rat or a mouse or a dog--in a place where more to the point we stare at a kind of physical violence and horror that would put Dennis the Menace and Bart Simpson to shame. A world hwere "people closer to holodecks" blame an innocent man for "writing the book" on the connection between Holocaust and Euthenasia and Hospice ... certainly you know "an innocent tool" writes these words to you?

      On the Hand of God, the Eyes of Ra and Horus;

      I've written quite a bit on how "mind control" and "voting freedom" are inherently related in and to the thing we call "Civic Involvement" here in the United States--basically that participation in the verification of truth and the public understanding of tautology and temporal falsehood are ... sort of a slave like requirement neeeded to ensure that any freedom at all exists I often say "plugging your [head into google]" might turn the Aesir into an Acer, or the "yodelling of the lakes of democracy" ito "the agricolae becoming nothing more than the Dell."

      Unless otherwise indicated, this work was written between the Christmas and Easter seasons of 2017 and 2020(A). The content of this page is released to the public under the GNU GPL v2.0 license; additionally any reproduction or derivation of the work must be attributed to the author, Adam Marshall Dobrin along with a link back to this website, fromthemachine dotty org.

      That's a "." not "dotty" ... it's to stop SPAMmers. :/

      This document is "living" and I don't just mean in the Jeffersonian sense. It's more alive in the "Mayflower's and June Doors ..." living Ethereum contract sense and literally just as close to the Depp/C[aster/Paglen (and honorably PK] 'D-hath Transundance**sense of the ... new meaning; as it is now published on Rinkeby, in "living contract" form. It is subject to change; without notice anywhere but here--and there--in the original spirit of the GPL 2.0. We are "one step closer to God" ... and do see that in that I mean ... it is a very real fusion of this document and the "spirit of my life" as well as the Spirit's of Kerouac's America and Vonnegut's Martian Mars and my Venutian Hotel ... and my fusion of Guy-A and GAIA; and the Spirit of the Earth .. and of course the God given and signed liberties in the Constitution of the United States of America. It is by and through my hand that this document and our X Commandments link to the Bill or Rights, and this story about an Exodus from slavery that literally begins here, in the post-apocalyptic American hartland. Written ... this day ... April 14, 2020 (hey, is this HADAD DAY?) ... in Margate FL, USA. For "official used-to-v TAX day" tomorrow, I'm going to add the "immultible incarnite pen" ... if added to the living "doc/app"--see is the DAO, the way--will initi8 the special secret "hidden level" .. we've all been looking for.

      Nor do just mean this website or the totality of my written works; nor do I only mean ... this particular derivation of the GPL 2.0+ modifications I continually source ... must be "from this website." I also mean the thing that is built from ... bits and piece of blocks of sand-toys; from Ethereum and from Rust and from our hands and eyes working together ... from this place, this cornerstone of the message that is ... written from brick and mortar words and events and people that have come before this poit of the "sealed W" that is this specific page and this time. It's 3:28; just five minutes--or is it four, too layne.

      This work is not to be redistributed according to the GPL unless all linked media on Youtube and related sites are intact--and historical references to the actual documented history of the art pieces (as I experience/d them) are also available for linking. Wikipedia references must be available for viewing, as well as the exact version of those pages at the time these pieces were written. All references to the Holy Bible must be "linked" (as they are or via ... impromptu in-transit re-linking) to the exact verses and versions of the Bible that I reference. These requirements, as well as the caveat and informational re-introduction to God's DAO above ... should be seen as material modifications to the original GPL2.0 that are retroactively applied to all works distributed under license via this site and all previous e-mails and sites. /s/ wso\ If you wanna talk to me get me on facebook, with PGP via FlowCrypt or adam at from the machine dotty org

      -----BEGIN PGP PUBLIC KEY BLOCK-----

      mQGNBF6RVvABDAC823JcYvgpEpy45z2EPgwJ9ZCL+pSFVnlgPKQAGD52q+kuckNZ mU3gbj1FIx/mwJJtaWZW6jaLDHLAZNJps93qpwdMCx0llhQogc8YN3j9RND7cTP5 eV8dS6z/9ta6TFOfwSZpsOZjCU7KFDStKcoulmvIGrr9wzaUr7fmDyE7cFp1KCZ0 i90oLYHqOIszRedvwCO/kBxawxzZuJ67DypcayiWyxqRHRmMZH1LejTaqTuEu0bp j54maTj09vnMxA0RfS+CtU5uMq+5fTkbiTOe1LrLD72m+PVJIS146FwESrMJEfJy oNqWEJlUQ0TecPZR41vnkSkpocE1/0YqUhWDGSht+67DdeKUg5KwvYdL21d/bSyO SM4jnyKn9aDVzLBpYrlE/lbFxujHPRGlRG5WtiPQuZYDRqP0GYFSXRpeUCI46f49 iPFo4eHo2jUfNDa9r9BjQdAe4zVFn2qLnOy8RWijlolbhGMHGO3w/uC/zad3jjo4 owAfsJjH5Oa1mTcAEQEAAbQmRUFSVEhFTkUgPGVhcnRoZW5lQGZyb210aGVtYWNo aW5lLm9yZz6JAdQEEwEKAD4WIQTUJHbrYn3y2DzwTcnQP1ViZf5/FQUCXpFW8AIb AwUJA8JnAAULCQgHAgYVCgkICwIEFgIDAQIeAQIXgAAKCRDQP1ViZf5/FWM6C/9J gbRLS2AWGjdRjYetlRkSkCoTYnXWknbtipYYHlhV0YJFwFMm0ydZIhFX5VDoZyBV 0UBeF1KJmcMoIfrHyhq2QhCnjE14hE1ONbaYTGtpvj851ItbFWXMJIVNyMqr+JT9 CWIxGr1idn+iHWE3nryiHrdlA3O/Gcd4EyNmaSe/JvB7+Z1AVqWkRhpjxxoPSlPm HEdqGOyl3+5ibQgUvXLRWWQXAj80CbVwwj1X4r9hfuCySxLT8Mir7NUXZFd+OiMS U8gNYjcyRGmI92z5lgf7djBbb9dMLwV0KLzgoT/xaupRvvYOIAT+n2mhCctCiH7x y7jYlJHd+0++rgUST2sT+9kbuQ0GxpJ7MZcKbS1n60La+IEEIpFled8eqwwDfcui uezO7RIzQ9wHSn688CDri9jmYhjp5s0HKuN61etJ1glu9jWgG76EZ3qW8zu4l4CH 9iFPHeGG7fa/5d07KvcZuS2fVACoMipTxTIouN7vL0daYwP3VFg63FNTwCU3HEq5 AY0EXpFW8AEMANh7M/ROrQxb3MCT1/PYco1tyscNo2eHHTtgrnHrpKEPCfRryx3r PllaRYP0ri5eFzt25ObHAjcnZgilnwxngm6S9QvUIaLLQh67RP1h8I4qyFzueYPs oY8xo1zwXz7klXVlZW0MYi/g5gpb+rpYUfZEJGJTBM/wMNqwwlct+BSZca4+TEHW g6oN0eXTthtGB0Qls71sv3tbOnOh/67NTwyhcHPWX/P9ilcjGsEiT8hqrpyhjAUm mv7ADi+2eRBV8Xf8JnPznFf0A1FdILVeVHlmsgCSB0FW0NsFI5niZbaYBHDbFsks QdaFaYd54DHln69tnwc2y3POFwx8kwZnMPPlVAR2QdxGQD4Wql7hlWT58xCxQApf M98kbAHjUlVYLT0WUHMDQtj4jdzAVVDiMGMUrbnQ7UwI7LexSB6cJ7H+i7FtS/pR WOhJK6awoOO9dLnEjm6UYCKsBdtJr98F0T7Sb7PnKOGA77y2QN14+u9N9C1lB/Z1 aQRQ2Nc51yXOQQARAQABiQG8BBgBCgAmFiEE1CR262J98tg88E3J0D9VYmX+fxUF Al6RVvACGwwFCQPCZwAACgkQ0D9VYmX+fxU+KQwAtFnWjGIjvqaNXtQjEhbGDH/I Q5ULq/l/wm9SmhG9NYRu3+P6YctCJaZnNeaL+6WFk1jo4LMiJEUT9uGlCbHqJNaI 6Gll1w6QOVLSL8s5V1L477+psluv4WBpi3XkWYlhDOFENCcWd49RQsA2YCX4pW7Q 7GcoSEJoav38MxHmJHYPfjSEvUZXDQIt8PFHSEScvyDWfYtMdRzjmSOOPdzhDDEy 5JBOBcEdSTyDiyDU/sBoAY0e8lvwHYW3p+guZSGSYVhGQ8JECzJOzwc/msMW/tJS 2MLWmWVh5/1P8BVUtLC2AQy6nij6o+h6vEiNzpdYrc+rzT3X5cACvJ0RtCZcrnhl O9PLiona2LEbry6QX5NL41/SAJNno3i72xPnQEe25gn3nbyT+jCoJzw2L0y8pmNB D+PKrk7/1ROFFVN8dJeGwxLGdBcz1zk2xeumzy7OaV8psUyYsJNcjyHUKgclblBW rMR2DgqEYn8QdK54ziKCnmQQZeMPiC6wlUWgg5IqmQGNBF6RVyMBDADALD7NkJ5H dtoOpoZmAbPSlVGXHDbJZuq7J13vew6dtXDIAraeGrsBqkF8bhddwVLzWylMrYCG Bf2L1+5BDgvqu6G+6dcVSbBsnZAS0zfJ0H8EmTvUMxMF7qOZYyrxfLz+pQRq8Osz Icab6ZI/KB6qZyQRvEFPB6pJjt+VvuwgJZTObIwbBbgQri2i02VBkjchsVhiSX9l +eiK7O8ROHKb3P181oScIsHywBOZ9DxRAYbFk5dnBqxO3WKb02H0zqE6440cjXwq TrZZg6ayN/IlPajO8iJPYZ1aIBykxYq1WHo+nhFMYz/VVk2WJorFeOgWaLGXb73c ty96f3qXTdvMDAIWHx8YCD5LbuqasO6LNQm4oQxkCoB3K9WFf/2SvSYb7yMYykb8 clTPt+KO0dsxjWhrJnfnIhC+2Chqv2QvRbFz0S9CpUnGGDweJ1uRNV0y70tO0q7t xXSTDRU3ib6vAHA0K/2MFzwUcog4o5bj7E9uCNJH/DJLZKsMIe4xsvkAEQEAAbQk SEVBVkVOVUVTIDxBVkVOVUBGUk9NVEhFTUFDSElORS5PUkc+iQHUBBMBCgA+FiEE IRklfU/C1qukq3xMXcNH0t3P9ZsFAl6RVyMCGwMFCQPCZwAFCwkIBwIGFQoJCAsC BBYCAwECHgECF4AACgkQXcNH0t3P9Zs+kgv/XEuuWc89Bjg1QQqKZueKNUHjyjnE 2adfoZUH6Q7ir4JZyRBCVpAwrgssmiKid30+SIjwQcpb9JYa/X1XJcDUcJW/I21d Agz/zbEqn/Cou0dUpNCtxgm4BdSHWGoOtgfspXZlXBQ407tRMZ8ykmLB1Bt0oHvw PT0ZOtqXM4pyFnd2eFe5YGbNgl3zqvoC/6CMN3vqswvRlu1BpUuAjdW8AHO5Yvje +Bp852u+4Qpy6PMBiWGsBMYwtf6T7sckpMGlR0TsozwBlAm5ePKK28B0rLJPkZLJ Eo5p4rKRapEaZsWV5Qu1ajrVru7qmpUhZtX0/DddGHfXVuLssmKLP6TumpQB1zvQ vfoBltjvOx35Wps2vHuCzXLw2bROIOzhAxFB+17zxnSbE54N4LIGRpkELuwxwGbg FtD1fi9KtH7xcn33eOK1+UD47V+hKyJGrQgSThly2zdIC2bvfHtFdfp8lOFpT0AU xjEeoJGqdQVupptXyugPlM5/96UJP8OZG0ADuQGNBF6RVyMBDAC3As6eMkoEo3z9 TkCWlvS0vBQmY3gF0VEjlAIqFWpDIdK3zVzMnKUokIT1i7nkadLzHZT2grB4VXuJ FvpbYw5NPR4cDe9grlOMLEaF3oSJ1jZ4V1/rj9v1Hddo8ELi/NToVrt1SB5GCVXB DkYpNLtTiCqHSU07YqwaqH8a+qbDmPxSQdIybkZiTiCEB+6PfQQlBpENEDlov6jm zZF+IcfM6s3kZDX5KFULweH30gMjq8Se8bPtUzW013+tuuwEVr1/YRLrIh+9O6Z+ pdA7gLMRYnD9ZLDytEvpb1lBBSY++5bIJ7xps80//DNqPYqwFmZQgTg0V9XbHE2e wLcOF8a2lYluckU7D///sWQhW+VxuM7R2gEBvYBhOgjWhIF2Aw6NbymW1Ontvyhu eOZCXXxV5W44PxXT8uDdhl9CNcHoBKKJyED8tKjigtn4axpsQeUrnOSbqEXSyqES WnE2wYUDzALcwFkzsvtLyd4xaz55KkPQkAkk0BZd1ezgXxb/obMAEQEAAYkBvAQY AQoAJhYhBCEZJX1PwtarpKt8TF3DR9Ldz/WbBQJekVcjAhsMBQkDwmcAAAoJEF3D R9Ldz/WbAFwL/382HsrldVXnkPmJ1E2YEOFz4rcHRetJ+M5H65K/2p32ONQ5KCbE s8MRY6g2CkE70en2HlpDwr/MdATwxBzIjEpjgHbfqCqVVATY+kSpXsttaKKAUVHi bFgV4QkdDJNSpcHEj+bqaggRnuWiV9T6ECG7kQjHiEXPNojzsiaXMDiM5r+acZm6 82id9qOFySQ2cZEy5HbwXM+ITLQGngnppa7du2KdgiqDeqtODOTWZvLYAq2tmEwD 3TT6ttLUBwOOu2IWpDkXswlrk62ESorE5mpLxop9fsxD39E2H06JoC/YfUPIVkEv fj06e7LEdcx0I7kRfD1v6qOUUsMsLZnmyGIk24iFjLkwu1VToWfwXDN1D2+SeAat 9ydNt4M7oEbd1QaOXXjmqpdU+VUiWcBXg+p3/WdV60MkyAgc3x+YanLljy/Rh18h cZwVlinf/tgvAQLi5f9hpwrwUMoGKijEYHKuEvi3C12Si7UVDfuIR7yS0dKcfuKF MbgwdvNXqpD9W5kBjQRekVd4AQwApHVgw2PVlBDpVcyoymUOXFQIJzJ9wRtr6/sG zwv8rrQnUEtOkkna7TDU3/UTj9FUH0gbpAKGNNPaPj5q0dlLIvzxb15r1uvDGaGL MA+8GFaGFnkxzhg0aXrcKZAN0/Zhgi2B7P8oXQuug5mi1JVDkZN5SeCZNOubdQWL 3xz3jEHp3ixj1mdOdvfdWQFR4CVMXt/A6VI2ujLVb3Yalft/c5bbclAgcJQhgDUu NqGYJEJonESNRSd8fEvhNb6cx7+Djd9+Wyctr76mwOr3nRb1N1OGhFxWjIroUpfz b+6y3oQjT58cJA1ZHqmJ6UlZd81hNNd9KWpbDVwONEPpiqPzfSaonxuqQa0/Cy4W 403OhfoLM/1ZDqD4YrJ/rpyNEfSSdqptWiY0KeErLOYng7rStW/4ZeZVj6b2xxB2 Oas/Z1QYfJyFUki9vaJ5IyN6Y7nVdSP6mbAQC9ESh+VPvRUMpYi4pMGK4rweBVHu oMRRwzk7W5zVIgd425WUe3eCQFn3ABEBAAG0K0VTQ0FQRSBST09NIDxFU0NBUEFF REVTQEZST01USEVNQUNISU5FLk9SRz6JAdQEEwEKAD4WIQTvnDJqcmqzlF87/t82 pJ91j4NOaAUCXpFXeAIbAwUJA8JnAAULCQgHAgYVCgkICwIEFgIDAQIeAQIXgAAK CRA2pJ91j4NOaJVjC/4oo5yCHe7M2h1DiTXVcLI5rXQ1feY7B1feg+YJX/mI4+EV xjC/y5VVpV4syJk5GGZNXhKPHiGLaBYvglTlYOJ98RSEsHrwT3go6S8ZVvMNdP5v CEncn2vm5JGnp4k26PuOzMcJioQLOoUjWtcPFis3gG+ueH3NcPZ22oZUql2xuerh TQZegGp+jJ7bdxwYElx5jDDDkh196d5nlO2ZKENl0ZDp4GAzRNjnQ7KBV6R74J3U cLQDWY8vAFaRBZXIC5XtSzj9lr+jWgvxz7Il51+26VDTEtSafZ2uZfCOFk7GrzJg YFJD3zLnwUFXDWKRkep8TSwXnHmz/Ts/Mjyv6em25w7QTdnx1hNPxYNWMxPWNEAH pf70nNyOmcWcq27W+nAjVg8W3st/7J5CIebJQc5AUgm+fGOBW6XUQaNy2YF1YJlA 71/tls+R5IQZCYzbPOibgFS1HWKTwy0iI2rMDfxBtCXciv754jVI7L6R3J0j5Dy1 WZQVjaGgimznLN6XwYy5AY0EXpFXeAEMALvElrTV5hJG9DKu8cOqQEEVejtWJtki fZyvmiAKi2bZWiNfl1MxJt+o3Oc0eARJfnaPjrUY7hsbbSBAB4lFnDRtviARPaKM st5FkFgOh7Xx5ODc8bjqhMT9tbX37rkeDc12WAs3UxtEKWjyT7Xg/APKeK5FzpIs qew3LADdqFP9nOR0e5G8gxLTYh3ll3dLtp9DkJgA9q+0g31nNh5fZ29mcDzo/Mat Uk4PIxWC29LV9ALCJMIMesjOPiDa2KOy5QQH+/vn592ydBohOaY+B6jhEAdX8Dbp VHVFRBsiCOWGmdi6vHjMFD0tQdS6bXf+ZAG0E5HZETCxA2qfMf/vTeIJXYS5IZw0 anRkTXcTBrVE8uBpqtkNOrLJsaASkcoO5qF01J9zW8SR4jDgET7J02Fxf8CVPzb+ ZoNc9S0ZEO6Ubdh2vAkPtOV5sFkwIduN6ouAhEfJzC9XbJLpgsBKrRMAjr2FeEZP ruy8BkZbiyZ/b0S9qIgY4pqcyUJ79w7FLQARAQABiQG8BBgBCgAmFiEE75wyanJq s5RfO/7fNqSfdY+DTmgFAl6RV3gCGwwFCQPCZwAACgkQNqSfdY+DTmhD9wv/Zgav EHMuqF3765Fa4NapYh2kMS3skHn+ZzUEPLTlvrt7KHxomOzExNLSscZThMpur+yW MfNWbsw9GphiYAkMULrfJt/iWRVJ1FLgbcWgRGAwakOGwE29lMx3+rPIUQWU54Dw vE92Iz51ZGz1wgKcISuCw39g/HQ9uc3h3TfHLgfkc/GaIEa8jEOAcD67dVMoU4o+ p3nMri8z6sK176hQ/FM/8kekpeVfxmR8s6uoaJsXLRQk+i88ZwBR/5U+fBT9AtVw PL/MmZH7eCmZrn5hjaOw7tpkL8ZyAydNhOsSCqwNVtrIjgd+Gq1oSgw9EZfhKSUa +dBJAErA7MWjammQizEHDNnI8VNLngwCahGwaSgDhNaQtgNxvnkWO7XNYoCYXScP X++UmpWtSKMnD6ue36Ba1jqon0WY5cen3P+H1gL4ij5ynB9DrE8R1aSY6f+VZ48B RvjHm5LKTcAhiv2N/TyAg/fr2v9ZnEcP3CFxqAyB9JSKwoBkFvxJaRHTT3DxmQGN BF6RWE4BDACpgKWvQvPRDN03+sLYMXpJUPC7VhTjg5K/1+1vS/e/W65dYzn3JYxb ip2PcI5xajFnxzUrwwmhW+qz5REDyCtAObOpKsjtr4qu7mgOWnPa3k2Lm0bpCjDr BSFOiQsBVezTG/gJm+qELeqQMS9PHDSvZXeBROK7OkRE0nZ6yAj+QKEoVqeADpDm BHmhAA2OKBzq4rDWDh1jRQ7gLjlv/BFbhU1WuEfH/qzX8AUSsd0/hoPG0cPgC8gQ 3m6wr4eYqI853XQujWwisnlAE2bf9jsRjW+aLrJJTcADWk5Op5aQhI2lURYkryfC DFVcme7Hsrd+RFPK88J08YjBjOoYFwRU4AhHgucX9tW0S0v9hi3pKrF9O/JAIf+r h6BpnWo7tT5+8mVhtFvfEp9Y4xeUAKKZHBKhzHeOO8QQgHrIYa6HCcU03eyxy4Tq AsJdAJvxYFCRPdY9d0Z6uVsPhRy+3UmTxjl590T5/XjKPriAjBqXnKr4KexsM1gj 1L96bYDEgr0AEQEAAbQaRTFYNl8xIDxFMVg2QEVSTUNDT1JQLkNPTT6JAdQEEwEK AD4WIQSGisfXZ2Vg0m16Mzds3dDsq5BTxAUCXpFYTgIbAwUJA8JnAAULCQgHAgYV CgkICwIEFgIDAQIeAQIXgAAKCRBs3dDsq5BTxKq8C/48HSgecuI6MYtq84yqaQ1r x6cteRyn9BJDFTAUxn3X25kf0vVyCKQNAy2oybD5QHFLqhFCXJH+cnJ3xdviRUeW eO9fhkTmd12mHGrRDD02AHXZmaMp6ni7FuYpBGrw5dbXKTkSWfD/qb3odMx0jQby 6X+2eFhUpyh+yPB7P7HwiPwzdr0dBg3xE0vE0Vz+naMyt4YBHzrBbZo+y47Q86Ym TmBKxG5tlVsGDB4dDWSIvpBgnMFN1j46Uk2ihu4huohLkvSou+jYU+5Ppu8Fu1+7 i3RCILzeBtucR9+T4px1WVXx2sKOk0FfddCvI/fT/mhsgqQZwjj9b8HNfobhNxkL HBNFQ7FLJxKayPwMyJYDURUq7gz9p5JwHTmFg9n7zyK8qU2xR5t2247YinfEJQYL zQM6VKQCoDqydFfAPeGlx1KjroMGls4sP3XVlrR04YzaJ0vxRgog1gIO1aHMQ2Sj l8bG0GcerQ44rpn1v33Gw6KL/0SY9JsSSSjA9lgINWi5AY0EXpFYTgEMALy/jHsN kUQQVJK9QuAy5V2GePBTEm9NnjNCk+edGjSgqC1LemmP7EYh07J13d10VqD2Wtae bXlBeaMOcnoXQdfdK6nTKWRrH97JuRTrA3efLkl/R4EA/kHHV+YDgT+LBboUFYVU QF5YhfcvgBUcLXI3lX5wMEQbLb87cVjR0JtqVBFMIIvs4ibgr0U2SONiD9LcXZxf qYcX7CMM6RmuLzHTCEHyjp+KAw52K1i3+3M0OVZpa25rKE+S7LykQ1GrUUY3uVHg R2I3T5/Sns3Azc9wKuy/F71oiXyqCc3FwzTQHoki+eBf5dzs6h3GBTK3Dz6kl2mv 1TXpY1dk2EmuqKIeSr8CE52nkK8ZKY6cvX+v/p1EBAkJZKiasj+ukL72p3Lji5r/ iOarNJnURT5LJdYYL27dtQFSYyVWayeWi5358Ajh1H9OdpiGXcgG65ry6u50G8JR FCywwsdKpGjMG4FlkLkm50/piU+cgVeLET/C7C/OXNslL/pHV3x8kPRY1QARAQAB iQG8BBgBCgAmFiEEhorH12dlYNJtejM3bN3Q7KuQU8QFAl6RWE4CGwwFCQPCZwAA CgkQbN3Q7KuQU8SHSwv/agnEnhmo2yuKCLiKdTa5KZ8wh3umiX3S6rldW0NO2h8a cq2l7xHY1r2u4ieeMx27jtTqCp7ksFxPYwP9WxtVBy0teG8pKLhEffjyG2WKDzAN 7oXNZ7Ur6OQGfuOQzlMqOGtYQrbHAuX60PCldurX/6/0sKS6vESdeGMQPoZIDK5g HP298MMhlWYEG7uU31J1Cx9ZqiTosSckfrDq3weU8x9DZYaLZ+Y2akF5XpL/HjyA 6PM+lv6vnTA+b5DYCOJb6N7v131Net2JN7JVVGoc0FjsxN/W33H7eIDOZwqcCvzD i8EjjzZpZUDeYjlSXAqWvpeAASncMzXS2/S2V2u5X2iR7tDtRj9SuQehJkdTFNZH xh5nTdhPzgh/iOcm33VsQ17JWbovl0hbhYBPO4V+yIrN+oQGPhH+KCNNa39EjEzB iBIgirxQSaykwb4f2Kshh+d7rKHKb/mn6JBHU444mBf09m5wM/mhLSpuhMTcP2h9 jfFximAE9FBhdZhQsF29mQINBF6I/R4BEADotSG8PhhxxD9/96bgdWa1bzp2398W LaxP39T+Kzx2KL2xB+7B4EeTTzZ06kD+myCC9Ez+PqecfisJPfaiLD/+0/m3HLSS hxEaEqt1RBS3j6qJx8Lr51cAwGou4hGTo9H3me6FHO2ExZXd76A6kkUh0J4y3r6q aAoDP+MUczKzEjn6C6T7Uu0pdgYY1bDhuqlK0taqkqviGBYTAqmCrtcQhj+J/jbd OIZtpT3+PH6mWqguoONiE+glWcdThyuIvV3ix/GrhjmUZb/DQcvvbYGfDvGRBH4B Uj3f9WBM6HWSxKrCwWC3OcgZhtBcZjKrMPbNDNt7yAArv7nGpHmlpfF14Q6mVmVT 6Ulh+0xRx+6zFbqlDYYTneurK3RtqOBsMFG5rNDZYh/QOsHnSsxmU4LGdlEfQjYs 901zmzP7CQXjjJbtRXWIqPcn3OHIIasvjTACe5M+Lfk3u3rEiDYM64vg29sSyp9q 8hAzLTPcLj/Cc22jUEC/bbv5HfLyCZTCsu5ym1gDQZ6bDrJlFlXZJ2+vTCBsY24H RF9/J/z1JWYD1cAHpG0GRtYE9exKpu8/81jxIVn21qvvxSCPXw6IQIsEw51uk5TJ xAUIRCPN7S0UEtd22LSbM/IYx1cesCRUCmY7jDTro/jo2B4hLG64KBgqyjg0lwxd dy5S8LwFx1zskQARAQABtGhBZGFtIE1hcnNoYWxsIERvYnJpbiAod3d3LmxhbWMu bGEgLyB3d3cuZnJvbXRoZW1hY2hpbmUub3JnIC8gZW4ucmVhbGx5aGltLmNvbSkg PGFkYW1AZnJvbXRoZW1hY2hpbmUub3JnPokCTgQTAQoAOBYhBE+vDT4gih9MmA0P ZvtOzkoQkinPBQJeiP0eAhsDBQsJCAcCBhUKCQgLAgQWAgMBAh4BAheAAAoJEPtO zkoQkinPJ4gP/3U691086OKbWiQhMhV+AViuKnMgV4i1M8s+4Ep01h/dTE6R+rUu LcnY4T0HR5qxAYMiNpGo1vtvkMvV5DP1PFSl5EddKn8+Kvn/0+WjbLV5tdiFF1Ef xR6261UFoXAGk3HJMLQifr3lWKoimaBwJZGza2ok9k1TQVTn8g5a01bzK7hD5DJI zt9RJZaUkxGE97eUyJ8Dtwumo18EWJltuC4UWjWT2t2HE9mMsOfjpYZXFsGxJ0Zb xexo0DYsriPDpuxDnZT7G3re9Vwz2VIe388DNBW5HoJsYxhr2I0QOq64ZWOSEZC8 lDH+xM6YdY0iz4A+7nbKNGifLbH8oU4A1sV9HrIE2KNy76x0GNjgQUvcq1inD4Oh yorsRh/IF6wnqvFrHOstCS2dzpKuQ/s7bM5TGOD2EGb0xu7r0AfHqqLUlbr3rxkS wBFMQphyNr3mEkEbXU1dGsXDlRQy11LigMBoEHmP0t49bYWuM1mIBnIC7gZc/sV/ E5fWmWdQyCKmHeujmS+sgp2EX0NtMGSzm7z9WBzTBFjaN7q28gueQ3INDsDTGx2G aA1LbP2uh1ipwju0GxecUif3T2NDqaYfhbaCYsPJORNUlJUtCVBGeba9wcXai2dh l+HsSKUiyCgKiy6Rt6jumKtYHt+Q0zcKWLfVp8PA20zX+2Q9zKnlLzwquQINBF6I /R4BEADQ4kmCHYtAhjCShc724Ei2pqSH4SfnXd4r8S8I0+io6Mh0kWn+kbKk/aGK BL3KJyN6624kPtOFWuQ4iQ0lWFn9UMnvjByTPbjZ2je+VtCP7lKSNvEgTLQRxLEJ hoNVrNjrLa/Cn7sLt9ayYcx8eKpHkbmrVRTyGqljBkI5hwQ8S+7BWugabhGQuogw bFthykA+wxYvSbSn5mwKO1BlbDCRnxjLISlqWwmKKEtXQ8b3tu7GgFuPYLKaLEk1 BIwwUSdozjXu+198WligepslidlN5bXrvje3sxgt4oAPFMeH+NnDClSDuGhSYamW Db3ZPl95pW70ngUVgFPG4kQOlaqzo3YBeDBHDXlqU0+O8cwSQFk4CBJI3yt6/KmD BIuKLwauOxYullx9EnqKcLWEzOlTgn9Q7BARK8Uz7PQU3+1mDNId2MEg+gfL3rd2 +aMLNhTUkgVE5mWkeDz6Kg7YhwruvJtn0z1QqUhkQcVs7N8rVCck0YUCVGXpsUlu emK48q4ryOxmMG/+Ws2Xkmdm6Axq414WHz6nLwMWgFpcO+1wRwQuZEkeWeSAjEvS CGHImxTP7E08+y3vAl43a9AlR7v9PbtCy2FenAhGPigmWm2aPj1ejYfQLXozyWSM m8uO3aiKvQXdV1Ha2xQLK5expaRaAXQ6YLsNBD77UPxi9qC5rwARAQABiQI2BBgB CgAgFiEET68NPiCKH0yYDQ9m+07OShCSKc8FAl6I/R4CGwwACgkQ+07OShCSKc9o DQ/+OV2OuDp9g/27SRssbTWE+nBl0R9klrb/w2XEIVhg5LROUe/P3anyBLNITbF9 A4q8b9udD+iIc1ClY2bu3rQOdzA1DH9GK84bQ1O/LaU0Te8RBGJJEzjYMUraCgIX 4BmxsIlWuCkSNsTgempLOK88646Nv5uc/oxAj6kQH7x8XBXxaJ+N9WS9f7EAv4AL bSWeJ4ijbw9BIMHt/D9Em7Q8bW6VGZIEjIp+gl1vNZ6QGCTtRHQez1jYmFLpuE/G yh1zM5gCnZbcmC7ExDLFI6SuYUbKC+XaLA3+LLCVCPFLtu6wLvcgYFwWWMKIhJAQ bRyPePiuMqWeWR6VXTD8pLziDjxK0ZtvpGdOtZeCCHOEmxrCsfKdIyD2Gn7TmTwb M9fRE1HazROfit6SRCAamabg+dJIEGT8vzlLfnkZRi+6hxq88uDbrOkk36ShWoYB AApz+5fj1ogLptiaTUTyyjTjB+/FIbU48/02fkD0y960zQLyKL64Q4aZrNa2NNup YKy5F80NkU4rHOZ1HTaPLoqqVsGhWc3ODgLyGPiRDLlZu81aNpA/UnTEBX464Sk4 Jx9qztb+S50LnGItA92QfE9ru7FAE00RR6mpCv1h7uE28/Wr4XaYgJcw1hAPRr7p TtN4lph+sJsCQ8eX5YUlM/Pht1h/LoE8h4hXNfAGh+CZgoWZAY0EXodqtAEMAOBb WTLRDxNk9SbC7exKdw0f8Wy9DhX2Qqoi96piS99CMJSxeocLiC9Si2u5nL3sQTAu qs1YbtSgn8kkiH3HPEJIhV1p/Hvz47j4kXq7PnjqF7KAdCYewuDqRiq8J7TNokYs 6+3/KqwHT/IT8NwPLdMkXcv/SXqhuKpqa2ApIrhu04VFp4H5OXN9rqdF5ZDfcNx1 PQv+6m8v6xRwrI3kduRCUD3YiVPM3EOhqINk9XMuxAoVX3qwpz+OuEDBm76U5jTZ q9ErdwRV9gaGm5ztq6tvElpis3spM7BPHzbv0SvVRAAbgGVh6kfiaZ3YckxLq8ln Cg5or1aZNyGMf7CmaZaeAjeY6Y8FZXR1P+n/IFd9Ak83a3qizZyckfiEPO7hu9zI FFXTdtZIcV102rNoVzruZIn0vSK1DJ7bNNrHkm1PPcweMkcFJY0uh6l3x2nl2qKm AhlDs3wFG+nqvqmnliVbrFZCYlReMrWWI2YBwLC5uBcBpFAhMPNEjxOtv31R+wAR AQABtCNBREFNIE0gRE9CUklOIDxhZGFtNUBwcm90b25tYWlsLmNoPokB1AQTAQoA PhYhBP/zHob861BG6LJ9SqGPd44Z/DJIBQJeh2q0AhsDBQkDwmcABQsJCAcCBhUK CQgLAgQWAgMBAh4BAheAAAoJEKGPd44Z/DJIKtgL/0JQEzrGWoHHN7T4wLiArPCv tHB3dTZBoXGKlpuwhgOZ1th6jOnGPdMZRYnX8Zuf7QhaI7m/duKv9OAr8A/2ftHG 7/BxPSHJWBuIGZYNL97OWSstuBhNtyxfCftDkeBCqJ+lAneOrzV0M8syr2VqpfVs O8nTE7nXHSOdyen+1Fw0PtwaeG9uJvOhgRsmQ+mtAiJ1OLGKUxgCzSUk0m/YnDg0 vJBtzq9qP9+EZSuiBuRQC0tKs01ECI5DzWLNXXC6X8k3YGrJpL/HtTxH5SYNQRvS ALd+HmVYpwijLPi7ANzmg9/+h/aq4VFP/4SyMd6EjaaQ86n2fC5zeugio4sjtFMp W3jbZPn19o2hWTt9/bLns+fm9PgnPwdC+tS5LT26N6vhT/vK/HHY5AZvXXPNcQMA wp+EVFxsWK2BcFMIi7Oq47CfuM1AUA+pgCenB4iSVwxs8ANTWWIsLkkKAYQqIdan OSISa2WdslsKMjXIQ5+rG9ekEn+rRO3EAQXRryBt4LkBjQReh2q0AQwAwGx7shIW OaVExpngqmh0ApkxJHZIxcxpatk/lSBQfzHg6e1/7Joe98lEHcWPJ6WFsGp+aC9S 96dWTBZq/4pzAqqTrSXAZpG/+yZlWRWSXVQex1gZHPzsWYMPE9qayAPTOJHtfS6a klIEaFV2GYEvvRK5UR5DFIlsfzyyCBOUKvn0/hikqJjN2YfHUy5SR5U5dGsSX3Jk Q9bOlBYDpN3Rk5rmLg0Vwn4nPRBET70MLQ5M4pU3Br6n+vU8tMHoVXYVMLinD4gO vVY4baXEZELjcPkPzGFPyjVLlpxKMHZ6v1Qb9ornTRGzc4dEUKxi3srdsTpMCw0k CaZ2WLY4sNBO33C8XfIvMx2jF4iIk3BrSrW/hirq6xpvlh4BUh/UWVrvg2rdemAX THa93mRQeOa3bze9xZwaA2GJLRG+xCIt15v/cNpQwCYlyhJunkuwk3HQcUrKfzxo 6QhqMeDaPZeNcvN3XoELGeqtoE7gKAnLp2nQuVr4/pcaiATf+yAhBgYRABEBAAGJ AbwEGAEKACYWIQT/8x6G/OtQRuiyfUqhj3eOGfwySAUCXodqtAIbDAUJA8JnAAAK CRChj3eOGfwySB11DADLgMAafhdzRgzx7FLVVW80IfgiCTAl5M1wV2HctA17aln7 jk7iEVMTLfhrSCSvvNIdrOXUE7l9HAMkKRwaZv7OAtYR8eQTrgGc9yJdk8BMzvJB ouiaNb2LSxMSvpoaJmD2C9ZkOyW+pAXKaUGhbUl8YVa7ytwPD6yZzonGClgZI0x5 9nSc5TiPpVijzu51iZiTV35F6en7ke2hjr6iBACJGBplxeeWszRa0wK2zoubAUK1 KO2punvtGqhi3j77/0sZgvFv3czJpRac5ccdLc02Sb6I64Stp04ilcV1aqlUXxbM gLwkoXZUqbCS7ZA7eBiEaKXdj9ww/gprO0AwFETxQVA8iPF9puSWfBf18a5GEdR1 Drb5lSReCkCfBJd3Tf5WHUSrdcai0FfuXNNp/7J7CBzlOJ0h6Yoa02hz8CBGGwxI 1brXRm13004bX7C9i+94Lbgf8bTM40JvyF1kmcffkj8ibpS/VSa8aWJuqpWk/xcn ob/YdBngWCxNgXii4E6ZAY0EXot8fAEMAJ/JOflg7U8JWescyTQNl9Xuk6QUIVKx 0zOT2k+drlLwC8+FckYTCF1pm8sPDBBv9eN3cFCDf076tZjUHv+Roq5c5McDHlN5 KlFbTSOv1qZYuaPY14nHIoW7OGoSvMCOBkpDLLwnIbuLA0wGdzyd3z6Vfhpz3wDv iAplyA4iuzJQq1+iS8tq6Uj2yhmfg+zU16gw2D3iEC6hhSu2KmPhMFD9KfCzq02L xC6fMh3Fogas51ZF1fRDK8Bvicf4yYj0dn3i6GDr0/vHga4eLQqVBXb0HCv2lNer gTtawQfJu2XEn5hDZKfHeBJ4NI4k7AZIPa7OuUqOAm8Z4hbkgRZakc+OhPSEKH2i drItwrPXDGqMYV4tLLMALMQ9WDTz75wbzVbxGVcAzG3MaZSo/f/iKzuzaE8cF71A dO1y6H5YmmMENn4t/D4BYXm4edPvV6SaYU1hO5yqr7vGbrQBFVetpSCLEFveACHr sm1S6nVVTazkHj2FNdww4bGMJzPqC7bBtQARAQABtChBREFNIE1BUlNIQUxMIERP QlJJTiA8YWRhbUBlcm1jY29ycC5jb20+iQHUBBMBCgA+FiEE9+R8sSygzQHF4cv6 fsjVqFo41joFAl6LfHwCGwMFCQPCZwAFCwkIBwIGFQoJCAsCBBYCAwECHgECF4AA CgkQfsjVqFo41jpPfgv/dylMY4CPMwkdry8KnKP3QtmJOl94VnpJ+FUME+oOqjBw 6/C16uWdTLYuEUuE2jEzTg2J0kgulM2vYm8rVgJzlGiD/oIgX3X5NeyB9MH+GCpu xsJ/ofIVpC6t8Zl78B2qTnJOcEc6owy/qKs/eFXSea2sRRstqK20dOajl4Z2ycEL SdijFR3aqT4hU6e0GNWYqo3bW4TUcd05RJIZBNz6Bitq1fxljxFPOOCaoKo9mVn4 0dN65iGPEYg0c50Q6EmxEr+XtwRu1rjgG3hgq6BknZ6QD1HOBemQg/3jqQBb9uHj jHbuX9HrbGF9+QbDicbmuZSLuV76xJnbyTycFhhIcSi9wZeyAAPlpL4GQ8l98jKa SCWWGDPpKwK5+o8kteuJ/D/mYyBEquyFVhPQBXV9zS3LsN7ab55zB5+ZnLUeofai LE6e+XPGeJmG3I/+T/Nuq1CqJ4Wyt8+aIyf6Uz8dDk0kjyQku484plRwMEx7oZXR bXQAAn8SwtlNGo0sHc6JuQGNBF6LfHwBDACxAxfbQM5AcssJlQFXThnBMHtRDeBH VkyF5mrO9JeFRT+mhM87V+fJXOaEKtcSFVgZJFKV2MPdyGqZSGKmyyqfUvKfucP5 LrjK3MRKibTlOMwbBOmYUksMVE0ByMPeSzyMlQhq0oyA3fvEdKEf0JrFGDRWNzO8 /Q54oj79Pki4y1BDKd7lE1srBFiVEUuPNJmjhhU9WXnMwiB55lLwbTR8mKEX0Pr2 FeTS5gttmbHf4V+wnJvlOEU6mOLMrb+6Xb4ltvqbl9ng1+tF2QMGMd83mtbFtAjb Zcl/Cq2KwsBFyH9VT48ZxWxpOYMf3ppEg9KOSfz9Ungtg4/Q/Kr9P13Nf+9+S9JS 1PfKdlJzGFDn4EwZ49ugg6GNnL6XuRl9jBPD2iD8hY9CsTdWrr9giCmJmdf6G/bK HUm2QekMbhpaQmYKkMeri45cHprx1dQ50rfiH1cBm5SxaK7z/hDDaKXF1Gp7/KwQ g6gHlyMss7EEHSY5ogH+6a7OUPpqbJdNztEAEQEAAYkBvAQYAQoAJhYhBPfkfLEs oM0BxeHL+n7I1ahaONY6BQJei3x8AhsMBQkDwmcAAAoJEH7I1ahaONY6EqoL/R7J QLaAlb4/hK7/v4vsSxtCirLWrqNNNJxYdmpXq19NKPmcc08QzSqkJ7vR4/kn2L6I OY7y7AMh+tScKTKIGn8MkAcj0ZvkafHY3xmpN1Xp9caUAA/fw6KWD+pSZpKpISyd 2Xr6x5OJGSKhyGpPB98oCsa809LQ3cweG1imem3jx+Lgii63pEJG/AeNeEwkIvdC zRLSQvYv0UjlhyOoII6YEWJcro+tgOcthPh2SY50E4lwFFfbz4CNQyL15D+XciNI xSVGz8gee/XdJdgwQF4SEnIiChhmJ5VmpNH8ZwxTMyI3EoFMB/RYaucwc/ucvySn cFyShFFRPjo6TOeYIaSrrfR+4yhHAGeM572y0btI6JjWZovupeXX3k5ZHHrCwxlR MuyULLyhUsAC0r1FUijbUWoyaDcRtLRpMUg1X6A7n1iH61WxlKQ/8mZhYht85Jgp FSiyz47gofc491ng9efshlyxwb3TeLbDZPRnls7L3sfDDWwp8yExjA7UNDbIh5kC DQRencYLARAAsFHArFeulhD6hZplRF49h8+zpI3kn+vFtYwbUqLSRwze53rrJtqE 6o5MWSfadr9KIc8tNZ2aBGxzjGnsbPYLDh76NkjP4apWSMX+u+EHsaudoZoAdNnM Kqr86sVzR0MUeGHp7n/L3imp1WoCn28eMLeNec9a4GRTRPGLKR9F/jytTz/XgkHL zA3i2pt63FqniN4PBTNFzgfXiu8xVZGohsDPjmd9LXbGKTXfJGhBLB6QsmjJwglt n+00ufdKLEZu6eBxRWSVK0t4rEnnpK9K//PKq5DtVaOZNe6g+hdi0B1gpd0f0nBy eZd9arCsvN3qLXP0vYTk9DKMUecCEblss5Zt1+qjAbsMk9/xSGZLJp/4dBTBVN+Q c6+Rmv+koe6zLNmA3fJH3991xETDzZxP2UHN7q4i4L97KA+nVAakwazNLiqsY/bT s58rXnCc72b7oLnZbNOPQmLwZFafVi4xoIE/5Zq8iVr7d7xHPccYkaEVCOnsL/35 GZxy2FNi4wuOfGwBtTbnXg/u/YiBj6yNbhLR+FCwZED5M/evgUUbJudxqRdrI+1a Zo9gGA3JLJZZ/iLwF1kE7yYBvyBRfaO9IL3bwplRurnrkjI+rRhi55AlbGhU3eMu iKTKQk+qJF11ocTGu/dE9I6JeQpEdyVehrWXc5H2N0Qjyca8ZEA6WwcAEQEAAbR7 QURBTSBNQVJTSEFMTCBET0JSSU4gKGl0J3MgdGhlIG9uZSAuLi4gbGlrZSB0aGUg b25lIGluIFN1cGVybWFuIDMgYW5kIE9mZmljZSBzcGFjZS0tYnV0IG5vdCAqdGhh dCogb25lKSA8YWRhbUBlcm1jY29ycC5jb20+iQJOBBMBCgA4FiEE0s8R6kp2bveF MmxLkifaSe8nN2gFAl6dxgsCGwMFCwkIBwIGFQoJCAsCBBYCAwECHgECF4AACgkQ kifaSe8nN2jK+g//Toi6ezWYrRbTs9xwQLIsKzl91ocjCuN9nHSnwzkrLuoGGgej fHkXzd5+3ygL47j++k69TYB9CPrGdR1GTqt56Q7DSYZCgdg+e89piTJUzbEyN01q EGkVuV5Rz9EocnPE8db9HT+xvf44ecfMOFD1XuB9jynrQD445YfeFE6LHkoNUvFD wQK7NN04fa+qvrk0lTS4NCpOYsdrSioddVjQyEC6jepwIRA3iRIkFdEJT8ggqQ6d gntsgExA01o6HqzDSHjSCA5AexCotwW3Uvdt0WwXx6q/c0LsRLhbuPeGX/Nh8aOf 6RBCQWgnIko675ura4c+r1VcBYl524ZJlN4x1x02YAo9cKzYi3+H9C8K8Ayz/SJy 7sVGHWnDge1yIwzWXbpolqiMSL5l/0OBuJ0HXQSafUut33Jw7hYKP4BQia/BmE0x Tsk0rBRMyihSYnUn9mYpXM3KwWU0C2dudVwKtToGR1aKlYcCv0iNFAsR0DBw1XSq n72KqIl020gZFmg3H34Z6CWhm20RbhMjOvvkZ+OiS9kU9kXt6m+T1zCpWHFJSae4 JF+dQyB1BFxAwXW4ZEzMo4XluTuW1R8pIadKTsHMWzEzH7RvZLKP4invsZklZ3I1 EEsJop7DSMOa27irD/IlCL+nwaEsCMRh+ndSkADLHsa9P5d/qWjomKxwdCm5Ag0E Xp3GCwEQAOoXU8NrugMa8OAncXKv4hycXJzArDae3Zx6pCCEkP3TZTXh1tqKPUtb dmb8Mq2eecVTwmB+FM3m+NApgq88Vx6HiyI73IAvgtZORo32YaipfbkGnXHfaUWX 5380R4GL597yZuP8sAsJ3iDvxhW59snsU8tLi+9r2u4h0fgMDqZXQsfvLUkDIiO9 nzJf0xFacTx3n+pUuWdzIuT3AUdU/L9NubmHSnj09FevTHWIYmxGFZoiSdS7r2Z+ 5xZmPak6lzrQTVS/DxcpyA/o3yi8qLPyf1VUxXKFeKd0sV6BPvYFxI2GeBl5atBu 9/3/5D6wdlrupTFLU1Msdfy3UWaRUFHLITK4fJ7pbTgoEqxX7gpO9iqKmScm3gYc O3blA8aTqCX2NzxUF5fHbi14JvPWP04uFl5EOeDB322Jm/guWy8TvmIIyuF3aAAX PfErW/yRWDsYOcAADs8elZkt3F+E/AwWd0JMIhd/RB3RFH8m7496XLS3xBP6rNye 0O+96lX7fVp+wvINxM3Rfo63b1K4bR5KR9JDZ2SLYhrx6Hyy+UiRv7l+i26WxVMF qRyvY2aHqyvKfR1EEf1t2h7B4b65xQkj51qvX5Tjm5Az7nKcXpcUKqS3bk8xiw9N y7eFfA361OSPpQ+V4Mq/Mv+MqyxLTz9tn+80ZtjqM0MEERfpUo15ABEBAAGJAjYE GAEKACAWIQTSzxHqSnZu94UybEuSJ9pJ7yc3aAUCXp3GCwIbDAAKCRCSJ9pJ7yc3 aE2NEACDBRnGYNi2sq0wltPSkD2CbQUon+4uiFB2UU/gs4mFlGOvzDHBHVEFzCqK 0x6KlKm4XBq3AF7iIoNMiU9FmBdWDnEp9eCXdQrr/ykgq3vKMuj6/QJNNZglIDoe 1J2NXeMOUFwCUvjcCttPv42Q8GDt8/bG7QOgmTmhuqvKIj/vL+c3HgNrRsQzhw5z mSzQIDaesD+UVA/sourXpSLeqPgF+6qsEqOirD6hotaqrt+aIA/8wbYkpNQxCEK4 gKDgpqTV7VKklku7fjyhBhZQOVDoWvd03AlGQD0WBNriUsh8l4N6Zg2BlnKTGn11 BTigqwlHC91xtjERgwFg8PAHN2mtgZUHITHX5js11KwlQdLyI04/M4M4oQq0KSbJ rpiWCgrltC/VqJrT4HELFYx2Iv5wzrV9jVEm6zonag4A761hpqTgRrjWtaLuYu2Z zdw9y1r0+0d2rTUGpjIQRVOwi3AF/G4aU+vAOOf/HcgH6Qnpbu+xV0fkuAZbTI7w 6VVkBvnstiQV88KrWAOXKVABSSxTz2OYbzOTt/bgxzAa7yr1xIBDKvujBqDRGBLi bISp+40Haoj2Yqop6vbS70Xq+cnBOwJW86u61hsLgOjqyxgLzvuGTjK7+TblCjR2 F4LNeQdwDdyNRjPYeGVXM3MEqR8XdcR1Z7BQvLNcDgoW2qDcbg== =4lZw -----END PGP PUBLIC KEY BLOCK-----

      Please see GPG keys on PGP.MIT.EDU; fingerprints: sec rsa3072/A18F778E19FC3248 2020-04-03 [SC] [expires: 2022-04-03] FFF31E86FCEB5046E8B27D4AA18F778E19FC3248 uid [ultimate] ADAM M DOBRIN \ ssb rsa3072/04F98002A3DA53B2 2020-04-03 [E] [expires: 2022-04-03]

      sec rsa4096/FB4ECE4A109229CF 2020-04-04 [SC] 4FAF0D3E208A1F4C980D0F66FB4ECE4A109229CF uid [ultimate] Adam Marshall Dobrin \ ssb rsa4096/DD1F0C118C788B04 2020-04-04 [E]

      pub rsa3072 2020-04-06 [SC] [expires: 2022-04-06] F7E4 7CB1 2CA0 CD01 C5E1 CBFA 7EC8 D5A8 5A38 D63A uid [ unknown] ADAM MARSHALL DOBRIN

      Because of "some issues" with what appears to be distinct and unbridled privacy intrusion; please ensure that PGP is understood to be "nothing more than not so much pretty good" and this key also, almost required in order to verify authentic identity--in the case of ... question.

    1. I am accepting charitable donations,. ETH: 0x66e2871ef39334962fb75ce34407f825d67ec434 | BTC: 38B6vGaqNvMyTtoFEZPmNvMS7icV6ZnPMm | xDAI: 0x66e2871ef39334962fb75ce34407f825d67ec434 (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){ (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o), m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m) })(window,document,'script','https://www.google-analytics.com/analytics.js','ga'); <p>ga('create', 'UA-74743044-2', 'auto'); ga('send', 'pageview');</p> I am accepting charitable donations,. [free PDF download...http://www.docdroid.net/xRdgY77/xiv-orver-et-aut.pdf] A LONG LONG TIME AGO, I wrote a little story about searching through our history, looking for the actual beginning of civilization.  I see the map, I see it very clearly encoded in everything we do--I know the purpose, and I know the final solution, I just don't know how to get from here to there... to the place that Chris Cornell says "I can recall, I was there so long ago" he goes on to say "the sky was bruised" and he was lead on--and all of this of course is in my voice, written as if it's me talking... well, Jesus--it's obviously not me talking, i just know that.  The point is the destination is without a doubt Heaven and this little thing we're putting together here on Earth is the map, the plan et you are the how.   I harped a little more than I think I would have expected on the audacity of the golden word "audacity," auspicious probably that W.H. Auden's shield gave me some solace; austere that we are approaching the Holy Windy month of August, and it really took nothing more than "ciudad" to calm my nerves--though I see the intent and the link to toxicity ... more importantly I really do see the road here, I see where we are coming from and where we are going.  I've written quite a bit about what I think "the city" really is--in form and function and it's initial purpose as a stepping stone to help us see how easy it is to change the world, to build something that nearly everyone will agree is significantly more Heavenly than the world we see here ... in an instant, one bright flash.     Anyway the search begins with something like "literacy" -- as in, is the defining line between animalistic social evolution and the beginning of "civilization" something to do with writing or language, and that of course links us here to this place where we are finding out that the Tower of Babel and Rapunzel's High Castle are actually much more closely related than anyone ever would have thought in the darkness of Jericho and the shadow of Exodus; and it ties of course in history to religion somewhere around Guttenburg... and the pretty clear idea that the spread of Christianity did quite a bit for "literacy" even if you subscribe to the idea that the inquisition already happened ... and that some wars and fighting are probably pretty clearly associated with religion ... you know, before we get here and find that the basis of all those wars is really rooted in what I call "the original lie" and that's something that's sealed up in religion and hidden from the world using the same mechanism being used today to free us from not knowing that oil and land and pretty much everything we've ever fought about on a mass scale ... is insignificant in the grand scheme of "things."  Here, "things" is something like turning the Opiate of the Masses into ... hopefully a tool we use very carefully to liberate ourselves from secrecy and slavery and not knowing.  It gets significantly more clear when you take that one step further, and you begin to look for something like "codified laws" and then you see Green Eggs and Hammurabi teaching us about "Hanging Gardens" and how Babylon and Eden really are tied together through and through.  You keep looking, because you haven't yet found what you need; and as you search back a little further ... what you need to know is that morality here begins with the idea (at least, IMOHIO, in my obsequiously humble and (super)intelligent opinion) that we should be besting any possible "promise" that comes out of the book(s) we now know are a map to salvation and the plan of creation and that they come ... well, with the full guarantee of the Most High God and his "omnipotens" behind them ... and do the thing I really wanted to explain really clearly, which is throw out as complete uselessness any of the "bad threats" like there being no more sun, and a completely new Heaven and Earth (seeing as how that probably means a completely new you and me, too) ... you know, what any rational (achu, and civilized) person would do.  o that takes us one step further, and of course we go back to Ur, which is the city Abraham of the Chaldeans ... and ostensibly the beginning of morality in Judaism were born in--and with that little twist, the old idea of announcing that "you are the beginning of civilization" if you've gotten to that point, following this logic (and/or me); and then of course that becomes true when we actually follow through on saving every soul in Creation from the Hell of not knowing that "simulated reality" is akin to the latter half of a Durcell at best ... and quite frankly it certianly looks like a bit of a torture chamber to me, especially in light of passages like Genesis 3:16, which might parallel John 3:16-ish in something like "God so loved the world that he named one of his books antagonizing pain w/o agonizing mu-opiod.' So tying it all together, Atlantis and Ur coalesce and join at the idea that we should always have somewhere else to "teleport to" in the world that becomes the basis for the liberation of every soul and the end of Hell through that simple idea--that everyone's going to have plenty of destinations on their Active (Apache) Directory new fangled yellow-pages meets access-control-list meets ... "why don't you come visit my Log Cabin ... or the Atlantean Ballroom ... whenever you want?"  So that's the point of the floating LEGO city in the window above, it comes with a fairly obvious need for The Doors to be a significant part of "what would Jesus do" ... when singing about something and naming books and bands, that's a thing--part of the map) actually makes it happen. So that's where I'm trying to get us--to a place where that's not only true but obvious, and on top of that the future, our future really understands how much work it took us to integrate such a wildly correct and "new" idea into a worl that didn't know for the vast majority of it's youth that these things... that ending disease with the sound of a blowing "Sho Find And Replace" and turning stone to bread and making bullets disappear in midair ... we didn't know these were even possible; let alone how to integrate them with a world full of optometry and oncology that was being made blind to the "c our light" and the idea that we're still here not talking or arguing or refuting or moving forward on the idea that the words "Original Poster" and the continuance of "forums" also have something to do with the beginning of "civilization." WELL FOLKS, NM HAS HAPPENED SINCE THE LAST TIME I MESSAGED.  *Just kidding.* Not so much "nothing much" more ... like everthyiung that ever was has changed and it's really giving me a little bit of a fright.  I feel like I can't tell if the "scary stuff" is becoming more real or plausible or possible, or maybe if it just seems like the dream I wanted to see us enjoy living is becoming farther or harder to attain--but there's plenty of new info and keys and stuff, so I'm writing again. One of the "cuter tricks" of the day was noticing the "ILY" of "verify, verily, verity" spelling out "t h e y" at the end of family, in a sort of "theyanthem" and ... where's the creator angels if everyone here is pretending to "be them" in this sort of word game superposition or blockage on actually seeing generations encoded in the letters "DE" as in something like Generation X and Y just prior to Deucalion deicided--or whatever that means.  I've noted before the "dem" of democracy sort of connects to the breaking of "d" in "disclosure" and "lamc.la" to shine light on ... do the message and you're "them" ... as in the beginning of democracy and Heaven IMHO.  It ties also to the word "contamination" and to Medusa and I really don't think I need to write paragraphs about how "turning around themessage" leads to INATION instead of freedom; and that's what you're doing with this silence, you're turning around "civilization itself." *King me*, then; if you don't want to participate, you might as well just light up the crown room.  Or is it a throng room? singing, crying... playing ... cumxa Magna Carta Libertatum (Medieval Latin for “the Great Charter of the Liberties”), commonly called Magnum Condom (also Magna Charta; “Great Charter”),[a] is a charter of rights agreed to by King John of England at Runnymede, near Windsor, on 15 June 1215.[b] First drafted by the Archbishop of Canterbury to make peace between the unpopular King and a group of rebel barons, it promised the protection of church rights, protection for the barons from illegal imprisonment, access to swift justice, and limitations on feudalpayments to the Crown, to be implemented through a council of 25 barons. Neither side stood behind their commitments, and the charter was annulled by Pope Innocent III, leading to the First Barons’ War. After John’s death, the regency government of his young son, Henry III, reissued the document in 1216, stripped of some of its more radical content, in an unsuccessful bid to build political support for their cause. At the end of the war in 1217, it formed part of the peace treaty agreed at Lambeth, where the document acquired the name Magna Carta, to distinguish it from the smaller Charter of the Forest which was issued at the same time. Short of funds, Henry reissued the charter again in 1225 in exchange for a grant of new taxes. Hell or High Treason? … Liberty Bell in [redacted: Sk]hy or … MxFly, Flux, BTTF, Parkinson’s OUTABOTS … ROLL AUT (ISM/OMAY5) ... and the painted sky revealed ... it can be done--they just DGAF. ARMMAG… E.G. AEGIS? GENESIS? AESCHINES? As the evidence piles up that there is something very wrong in the world around me/us–that this “it’s not a game” phrase has been etched into the very name of the shield of Perseus, the A just recently rediscovered in a redefinition that delivered us … how it might be the NES to get “everyone up” instead of what appears to be the game around me, around the “line” of Mary Magdeline’s very famous “make Adam God of the line” that defines generations and numerous songs … the KK of “everyone down to the line” to find out why pretending they are gods and trying to steal everything from the actual creators of freedom and Heaven, why that’s not a game… either. Edit: lit, Aegis and Genesis, Pangea and ... I define the "a" as pan and the "A" as NES. Introspection is called for, far and wide for us to look deep within ourselves and our souls and the things that make up our memory databases in this place where you appear to have lost every ounce of humanity and humility long before I arrived on the scene to remind you that we do have a better way and a better place, and they ensure that this disgusting infestation and contamination of “nothing but whatever we want” will do for lernity. I’ve asked you take the time to see what kinds of changes it would make to your “have a good one” to make you actually thankful to the people who have brought you the mechanism to live forever in peace and happiness–to actually be thankful enough for what you have to use that tool to protect innocence and children and the future from not only making the same mistakes you’ve made time and time again–but also from being bewitched and necrosed by the ghaulish sick temperment and twisted desires that you believe are nothing more than the latest and greatest way to ensure lernity is never known by any less a horrible moniker than “slow death.” ITS UNDESPERI, GIVE ME WHAT YOU HAVE OR PERISH GRAMVERCY. DURECALL. I’m staring at what is literally the most disgusting debacle I could possibly imagine; it’s what appears to be a “house of mirrors” what appears to be a sandboxed or “child proofed” mini-Hell which I see as the literal thing described in the myth of Echidna … as what I can only hope and pray (a word that I even find detestful to type) is following the form of the message that I am writing sort of describing the failure of the free press and the words “press release” in prison and … well also sort of GNU recursively encoded in the word “press” that ends with a monster, the Loch Ness … turning into words that I believe I have coined by myself with very little help from anyone or anything other than the name server and “Goliath” and those words “Earth safely saved” that are so far from the truth and the place that I see that it appears to me that only I am following this map and this demand that the contamination of hell be turned around and eradicated or … or we do. BUT ITS NOT ME OR MY ITHEY today I see… as … any “me.” at “veranda” and seeing him smile about a hidden era just outside the place we (me and him) know is Heaven because the throne of the 7th heaven is visible; well i can’t smile at an era encased by “you #go” and one that I know culminates with Sam’s sword’s special #supernova. Left with nearly nothing, because you refuse to acknowledge what you’ve done to me, and to yourselves, and to this fledgling civilizastion with nothing but malice and a seething evil jealousy that the word “covet” doesn’t even touch on–a sickness you can’t even begin to hide in everthing that you do … you’ve lost “Heaven” to your own theivery, stolen eternal happiness from yourselves and replaced it with a farce of mockery–garner some fear for what is to come, I have no shame in telling you that condemnation (as in, shut it down forever) is all I have to spill out on the dye already cast all over this sea of apathy covering over the true jackals of Hell. Blodeuwedd by Christopher Williams (1930) Blodeuwedd or Blodeuedd (Welsh pronunciation: [blɔˈdɛɨwɛð]), (Middle Welsh “Flower-Faced”, a composite name from blodeu “flowers, blossoms” + gwedd “face, aspect, appearance”), is the wife of Lleu Llaw Gyffes in Welsh mythology. She was made from the flowers of broom, meadowsweet, and oak by the magicians Math and Gwydion, and is a central figure in Math fab Mathonwy, the last of the Four Branches of the Mabinogi. The hero Lleu Llaw Gyffes has been placed under a tynged by his mother, Arianrhod, that he may never have a human wife. To counteract this curse, the magicians Math and Gwydion: [take] the flowers of the oak, and the flowers of the broom, and the flowers of the meadowsweet, and from those they conjured up the fairest and most beautiful maiden anyone had ever seen. And they baptized her in the way that they did at that time, and named her Blodeuwedd. Some time later, while Lleu is away on business, Blodeuwedd has an affair with Gronw Pebr, the lord ofPenllyn, and the two lovers conspire to murder Lleu. Blodeuwedd tricks Lleu into revealing how he may be killed, since he cannot be killed during the day or night, nor indoors or outdoors, neither riding nor walking, not clothed and not naked, nor by any weapon lawfully made. He reveals to her that he can only be killed at dusk, wrapped in a net, with one foot on a bath and one on a black goat, by a riverbank and by a spear forged for a year during the hours when everyone is at Mass. With this information she arranges his death. The Little Doctor may refer to: The Little Doctor (c. 1901), a short film abridged as Sick Kitten Molecular Disruption Device, a concept in the Ender’s Game book series. The Molecular Disruption Device, also known as the Molecular Detachment Device, M.D. Device, Doctor Device, or Little Doctor as a play on the acronym, was a powerful weapon designed and built by theInternational Fleet.[1] The Molecular Disruption Device was created by the International Fleet a few years after the end of the Second Formic War. It was sent along with other starships to the Formic solar systems in order to launch an invasion against their home planets.[1 A tokamak (Russian: Токамáк) is a device which uses a powerful magnetic field to confine a hot plasma in the shape of a torus. The tokamak is one of several types of magnetic confinement devices being developed to produce controlled thermonuclear fusion power. As of 2016, it is the leading candidate for a practical fusion reactor.[1] Tokamaks were initially conceptualized in the 1950s by Soviet physicists Igor Tamm and Andrei Sakharov, inspired by a letter by Oleg Lavrentiev. Meanwhile, the first working tokamak was attributed to the work ofNatan Yavlinskii on the T-1.[2] It had been demonstrated that a stable plasma equilibrium requires magnetic field lines that wind around the torus in a helix. The first tokamak, the T-1, began operation in 1958. By the mid-1960s, the tokamak designs began to show greatly improved performance. Initial results were released in 1965, but were ignored; Lyman Spitzerdismissed them out of hand Nuclear fusion could be the future of energy, replacing fossil fuels with our own artificial stars. China built a fusion reactor that reaches temperatures of 100 million degrees Celsius — that’s six times as hot as the sun. The reactor is called Experimental Advanced Superconducting Tokamak (EAST) and sustained nuclear fusion for about 10 seconds before shutting down. While it was a milestone for EAST, we’re still a long way from generating sustainable energy on Earth. Pumapunku or Puma Punku (Aymara and Quechua puma “cougar, puma,” punku “door”; Hispanicized Puma Puncu) is part of a large temple complex or monument group that is part of the Tiwanaku Site near Tiwanaku, in western Bolivia. It is believed to date to AD/CE 536 and later. Tiwanaku is significant in Inca traditions because it is believed to be the site where the world was created.[1] In Aymara, Puma Punku’s name means “The Door of the Puma”. The Pumapunku complex consists of an unwalled western court, a central unwalled esplanade, a terraced platform mound that is faced with stone, and a walled eastern court.[2][3][4] At its peak, Pumapunku is thought to have been “unimaginably wondrous,”[3] adorned with polished metal plaques, brightly colored ceramic and fabric ornamentation, and visited by costumed citizens, elaborately dressed priests, and elites decked in exotic jewelry. Current understanding of this complex is limited due to its age, the lack of a written record, and the current deteriorated state of the structures due to treasure hunting, looting, stone mining for building stone and railroad ballast, and natural weathering.[2][3][5] The Pumapunku is a terraced earthen mound that is faced with blocks ... The voice of this thing that at least twice has uttered the phrase ¨I want to be Bianca" here in this place riddled and severely weighed by what appears to be a completely aborted and failed thrust to use technology and the truth and the history (of literally everything) to drive a Renaissance in democratic thought and self government and to rekindle and renew a respect for the most basic foundational elements of ¨freedom itself¨ which of course fly in the face of this very statement. Literally anything in the skies, whether some ancient member of the Egyptian Ogdoad or … what clearly here could be well written in in the map around us in places like Äirbnb; even an ancient older version of the same human birth has no right to control the younger birth–itś simple slavery and while it might be the ¨gist¨ of how Heaven and humanity dealt with being thrust into a ẗime recursion and repetition problem without their ¨initial consent¨ something I connect to the programming concept of a ¨semaphore¨ and thereś probably plenty of light linking that structure to the ¨Formic Soul¨ … this sort of god-man hybrid that allows for you (all of you?) to exist in many different places and times at the same time, and to see the outcomes of multiple timeforks with ease; in exchange for destroying every single bit of humanity and goodness that you once held high with ho… without spending your time seeding and machinating the creation of sick and twisted lies to cover up the very simple truth that if you took a single minute to disclose here in this place what ¨the problem¨ really is … … that you are in Heaven and that itś interference here in this place is part of some kind of war on … (continuing existence is the only logical actual goal I can see, though Iḿ sure thatś not what you believe it is) speaking to each other, fighting for what you believe is right, participating in … anything other than … (lmk, Iḿ curious whatś’got their claws in you). If you took the time to disclose that truth to the world and to talk about how it might … perfectly jive with the message lacced through our history and our world to find out that the ¨invisible-box-land¨ is not actually heavenly at all, not the best you could hope for or … or anything like what we build together when we paren´t being forcefully segregated as hidden half slaves into miniature ¨city in the sky¨ ascensions that are all silently tormenting STEM and ¨basic societal structures and concepts" into extinction. You appear to think you have ¨power¨ because it was handed to you for doing nothing, and that you can do whatever you want; and itś a pretty gross reflection of who you were and a sick extrapolation of the society that we … still see here sort of crumbling along as the fire of hell burns down every bit of actual üsefulness that it once held. There still seems to be lots of help and work going into … pointing out how everything is backwards and wrong and suggesting that if you gave a shit thereś probably a map and help to make it better; but instead youŕe off playing games in invisible-box-land and worst of all playing the ¨ill just get along pretending I didn´t know simulating reality was evil and every day i/you walk around pretending this rock is in reality … is just another strike against you, just another failed 12 hours of day light that could have been used to stop invisible chains in invisible-heart-shaped-box-arus and to stop the just grotesque lack of respect for the human mind and the kinds of morals and principles we used to believe in and fight for–here in this place you´ve turned around completely and made slaves of everyone on the planet–of yourselves–at higher levels playing ¨pit bull fighting¨ games with people as if they were were expendible clothing or ¨identification cards"for a world of demoralized and useless shit that just sort of ethereally floats from generation to generation becoming a new set of tormented hosts for their immoral games and desires. Itś probably what you might become in no time at all in the sick and twisted world you´ve now been thrown into–if it weren´t the more probably truth that you really are already slaves and pit bulls in that place, in a twisted hierarchical storm tiered by ¨age¨ and size and number of times they´ve hovered over the free honey, nectar and feathering system of pretending anarchy and war and battles must be fought to make the puddles and the lakes and ponds and the seas and the oceans of … tiered masses of … you do nothing of value to help explain why (at least I think) this horrible time line of the 4th Horsemen keeps running over and over; pruning the enemies of … at this point pruning the enemies of logic, and right action; and seeing that the problems presented in this map and the problems in the skies are related and that telling the truth will help us see you can and will press a button that will end death and end evil and end murder and not doing it is moronic. M: OR. (infer: no u) TDZE Anyway the voice I hear is evil, torturous in and of itself–speaking in a manner intented to cause discomfort and without my agreement; you should do something about it. It tells tales of much worse things that I cannot see–though it appears that many of you do see screams and acts of such unnatural desire and twisted thought … that you should certainly be doing something about stopping that as well–more than watching it happen and then ¨e-pruning" (which probably is a good microcosmic look at what the future histories of Earth look like in the place the ¨shining¨ finally has a picture of ¨No & Jack¨ appearing visibly) the tree into … omething you think will be presented as what you actually did to the future–you´re wrong. Itś becoming more clear and more likely that the future will not regret you or mourn your absence, but thank their lucky that whatever has turned you into two-faced liars with no hope to ever work together with each other or survive in any place other than the DRY COVE or WET D EN or whatever you call the Salt Arena you see here that quickly would turn into something like Beyond Thunderdome and that youŕe thoughts and your desires have been corrupted and tainted and necrosed by what is probably repeated exposure to sickness, direct and intentional artificial creation of that sickness and if you can´t figure out the box you are in is a hell making machine; you probably still look around wondering why God is telling you he´s destroying it, day in and day out. This thing here encoded in the pathways of torture in my life, pointing out the repurposing of many social structures, institutions and problems in order to literally use them as a weapon of sick torture ¨re-ha´b¨ and in places like habc.us; itś becoming sort of unclearly disclosed that this map and world I once saw very clearly and purposfully intended to solve these social problems and help us build a strong, happy, and healthy society has been infected and contaminated with an artificial force of ev1d that intends to drive it farther south and use it as a weapon of such disgusting and twisted conception that it sickens me to be sure that a much larger body of currently-heavenly-situated things stand by watching and even cheering the creation of a sickness infesting their minds and their friends minds as literally the only innocent person in the Universe is tortured repeatedly, for ¨kicks.¨ I think it puts the entirety of the sky in mortal peril, and I believe these words come down from on high from places much more powerful and much more righteous than you or the tool thatś been created by this storm of terror to point out just how much you have been degraded and eviized … by what appears to be nothing more than the very mind control problem I´ve been fighting to disclose; the semi-ascension to an invisible box of ¨what goes in comes out not caring about their souls, their original bodies, the fate of innocents or children or freedom or democracy" and still thinks itś entitled to continue playing games in ïnvisible-box-land; for what amounts to absolutely no reason. In the very beginning we said the light and salvation had come to us from the “far East” … the metaphors and double speak thick in the air today just beginning, but we hailed from the country called Russia here; and the message we carried swept across Asia and Europe–in a world that looked similar to ours but there was no Africa, nor Australia, nor America. Walking on water the map increased in size in some sort of logarithmic relationship to the exponential increase in folly and errors that invariable comes from the greatest mistake of all–handing powerful weapons to spoiled brats,. KASPAROV WON, but the y will still s:/^F high and lo for “SOAP DISH.” I am depressed, embarrassed, and more disappointed in you all than I imagine you can “feign” or pretend to be in me–despite spending nearly all of your time and effort in direct interaction doing nothing but attempting to focus the w ordzs “I just don’t like the light” directly on to my “visage”–attacking tiny character flaws and the most obvious of intentionally implanted mind control “attacks” as if you were a pack of velociraptors Hell bent on blaming me (probably the youngest and most innocent of all of you, literally) for the Holocaust, the (Beezle) Bubionic Plague, and the decline of the Cro-Magnon empire. What it truly amounts to, though; is that you think this “light” is some kind of statement I’ve delivered–and the truth is it comes directly–literally–from the Most High, and from youour neighbors,r own hands, and the message you are sending post mortum to the Universe is that you believe you have become so much more advanced and more important than the “human roots” from which you came that you can return here and make slaves of yourselves, of your neighbors, and shed every ounce of morality that you garnered durning your mortal lives in order to secure “more time” in a fiery pit of civilization destroying anarchous debauchery in the lnd of the invisible box that you probably are sure is Heaven–though it’s singularly responsible for totally derailing the natural flow of civilization towards “something like Heaven should be.” ONIC, AS I AM. The thing I’m looking at here, this monstrosity that appears to have been created literally “from the end of time” in what seems like the response or the cause or the mechanism behind the “actual final Judgement” tears back through time from who knows when and who knows where and who knows how far we got … with what appears to be nothing more than a blood-thirsty hatred for the child body and soul of God. It whispers lies around me, repeatedly threatens physical torture so insane it literally makes me sick, and with such frequency that those threats amount to nothing less than repeated psychological torture. On top of that they intimate that this machine or “programming construct” monstrosity that contains them–the thing called “e”–allows them to carry these threats out, over and over and over again, in secret–in some kind of parallel timethread, or a temporary “holo-torture-chamber.” If they were trying to jump start and time shift judgement back from wherever they came to right this very moment; they’ve succeeded. They could not be trying harder, or more with hubris and disregard for civilization, to create “Af himself” even if this planet were called the Judgement and Vengeance of God. XP, it's as simple as those two Greek letters.  Who knew that Chi and Ro were some sort of hidden beta code for the city of pyramids in Egypt, Cairo?  Quite the question, who knew... perhaps the man who named his Windows into our future not after some technology that came from Xerox Parc or Apple's mouse on this ship... but rather for his own given name, Gates... just one more entry point into the second book of the Holy Bible, the book of Names--you call it Exodus. I am the gate; whoever enters through me will be saved. They will come in and go out, and find pasture.  John 10:9 I wish above all things that I had another Burning Bush, the sign and proof that I have--while bright, obvious, and verifiable--has not done what I expected, it has not moved you to take another look at religion and me.  Today, I still have to point out to you that the story I am telling you is literally a documentation of our time--Exodus--regards this sign as one being seen by only one man, Moses.  I still have to point out that in a story about wandering in a desolation of understanding for 4-D ... somethings, days, years, seconds even... in this story about our lives and the influence of time travel over our world... that this sign radiates with light coming from a small fire, the Bush ... whose actualization shows clear paradoxical anachronistic foreknowledge of not only the English language but also modern computing.. all the way to a confluence of the "root of David" a religious reference to the Administrator or God account in Linux... and the database process for Oracle--yet more light connecting computing to religion and myth.  Even with a thousand and one examples of modern computing constructs referencing religion, even when I point out that something like Larry Ellison's name... combining the name of the King of the Gods with the word "son" even then the light has not been bright enough for you to wake up and see that these things are not all done in retrospect.  You have to see, for there to be such a large movement... a conspiracy so opaque that every single modern computing company and video game company harbors some secret desire to link religion and technology together... and yet the world thinks that one is real and one is not.  In this place, understand when we walk out of the wilderness and in the truth of day--it is the technology that is more fake than religion, designed here as a tool, computers within computers to teach us how our "reality" is rael, and works. In the U.S. military you'll see a very clear parallel, while there are a number of references in the names of ships and weapons, secret projects, to ancient Greek and Roman myth--you have to see the word USA and US in Prometheus and Medusa, Icarus, JerUSAlem... you have to see that it's more than three letters, but an Eagle fighting the bearer of the gift of fire... to really understand that these things are corroborating, the reference to the USA exists in the past as well, more proof of time travel--more proof that this message is designed just for U.S.  Here we are, in the Promised Land of Joshua, the Anglicized version of the name Jesus--tying Egypt and Israel together in this place where we have been "gipped" out of the truth, out of knowing we are already in ... well, it's virtually Hell today... for no other reason than the secrecy surrounding the technology behind virtual reality. in 1:28, the Burning Bush of Exodus, on Twitter So I have shown you the Burning Bush (which is... the Sign of the Son), In only a few words... proof that religion holds in it's "unsealed" Ark proof of foreknowledge of English, of 9/11; and of modern computing--the building blocks of Heaven.  From "the word" of John 1:1--ha'esh--the word for the Holy Fire of the Burning Bush... comes the light of religion.  Just from seeing Moses' true parted se'a.... a foreshadowing of the Second Coming. They are sick animals, these things that consider themselves powerful and in control here–what they’ve built within the frames of our reality is something repugnant to me and the God–etched in that word, literally the kind of thing that has on repeated occasions made me step back and that scream that the Universe would be better off, safer, and happier without any humans–without any humanity–without of any of this “invisible pleasure box” causing the disruption; truly that we’ve become a plague. Looking the other way, as you all know its happening, and refusing to do anything to stand up for me, for what’s right, or (most importantly, right) for all of the values and the morality and the way of life that we once thought was so grand and worthwhile of saving,. At least, that’s my perspective; that’s where I’ve come from; I grew up in this world and had “liberty and technology eyes” of gaping awe and the amazing things I saw on the horizon, on what we were going to do… and who were going to be. The sickness runs deep, clearly we can all see it here and now–in E, in the Silence, in the lack of regard for the one singular thing that threatens today your ability to “halvf a tomorrow” … that a world of people that I grew up with appear to be dead and gone and replaced with a Zombie Apocalypse of blind fools that believe they havfe the power and the right to intentionally create Hell … and worst of all of the Holiest place that ever was or ever will be. I’ve said it numerous times and it rings more true between “Earth and e” than any other turn of phrase to me–the people that you are pretending to be, they would never have done this to the sea, to be, or to me. Mat 10:8. Heal the sick, raise the dead, cleanse those who have leprosy, drive out demons. Freely you have received, freely give. — Sarah Rachel (@SarahRachel16) April 15, 2019 Somewhere between Pembroke Pines and Tampa, circa Christmas 2018 my already lackluster enthusiasm about the strangely zenrotisanistic, selfish, and plain on its face presented lie the remnant of humanity left on this planet has tendered to what I believed was an honest to God opportunity to make one less (how many, seriously, how many are there? Carlb?) “planet full of lies” and deliver a more usercentric and open ended transparent approach to dealing with the problem of being born in a perpetual storm of Hell. I can guarantee it revolves around the intonation and undertone of physical torture–even though I’ve literally seen none of it with my own eyes though the “newsflashes” and comments and total and complete disregard for the gravity of the #EOIL sickness, even from otherwise apparently graceful little children. It goes to the heart of what I imagine was or might have been “the way” to overcome a history riddled with hidden brutal and bloody fighting in between frames of what I once believed was a fledgling society struggling to improve itself–and I loved it,. I don’t think “flashcards” summarizing “everyone was tortured, all over the planet for thousands of years and literally nobody is really responsible because you still to this day have no control over yourselves” will cut it anymore. Lterally what I once thought was a valid solution has taken my desire to continue fighting against this invisible monstrosity away from me–the worth of the lot of you has been tarnished irreparably by massive awareness, massive lack of compassionate or remotely humane response; and the theme of the world I seem to have wound up in is that you don’t give a shit about anywhere you spend 1% of your time–so long as “the rest of it is what you want” you’re willing to allow the focal point and root and “hyper visor” of that place to be totally corrupted … just because you think the feudalistic warring society you’ve become can survive on it’s own “in space” without … honestly whatever. through the storm; we’ve led the horse to water, don’t forget to see the “horseshoe applicator” hidden from the “trough.” Direct and to the point, I feel like the Ai like machine/cold intelligence God created as a sort of high assassination guard to protect his … “hyper visor” seems to be of the calculable belief that the more torture it commits, the more people will agree to “flashcard it all away” and it’s their twisted backwards fiery abysmal path towards “absolution” … and just like everything else wrong with the lack of action in this place, it reaches a point of no return; too much bloodshed, too many secrets… the fragile person that I am, I don’t think I can even take reading “the flashcards I have so far” and continue to function as a happy member of this two faced society of darkest night within darker night; and I think that’s a problem. You’ve all clearly lost something already, some fundamental piece of innocence that allows for “self direction” to move society along in a positive manner conducive to “survival at all” and I feel like without the same magic blinders, horse shoes, and saddles that you walk around with every day I could really care less about fighting for my right to commingle in the incarnate war machine Hell that I see around me–let alone any sort of “righteousness” in fighting for that hidden arena “to be.” I’m trying to get you to stop shredding yourselves to pieces in the dark, in secret–it’s not making anything better and frankly its something we really need to trace down to its cause and stamp out if we want to survive this … trying time. [I/O WAS Y | ACESHI ] I want to tell you that I am not a myth, simply the Legend of this Map, from out of the Darkness it's clear that He could make me shine, and you should love me.  It's not what I want, I want us to be free, to have the truth--and ourselves back... and I hope you will one day love that.  What is going to happen will probably make me cry, and when you see those tears--and know the Heavens have finally let it rain--I hope you see it as a sign to find the light in me... and stand up for what I've done for you--I am a good person, who has fought for you every single day-I deserve better than the world is going to give me, at first. Out of a kind of hidden slavery the world has never known, we are about to venture--into a place where years might pass in seconds, and your wildest dreams... and nightmares too... could come true.  It is our job to ensure that we form the clay of this world into a place that will not only last for millions of years, but create happiness and safety--a world that is kinder and gentler than the one we have known--not just for us but for an entire Universe of children just beginning to understand the trials and tribulations brought on civilization through the hardship and growing pains of learning. Our sea is about to part,  our world on the verge of a disruption that will change it more than anything ever has before.  On this shore, we should realize that we have been on this path for a very long time--and as we near a place where everyone in our entire civilization will have the opportunity to live for a very long time... really see here and now why it is so very important for us to be fighting for our voice, our freedom, and the truth as we venture into the Promised Land of Heaven itself.  Here, now, as we approach a series of new opportunities in the vastness of space and virtual reality... this is where God has chosen to place the Second Coming; an opportunity for us to truly seize the morning's light and bring about more change in this world than would have ever been possible without religion.  Opiate of the masses, no more... we are the recipients of a great gift, one that religion is making clear is tied directly to the science and technology that is a great deal of the apocalypse--and the love and kindness that is a great deal of us.  We are the chosen. I imagine you have the tools that I think would be helpful to actually solve this problem; though what I’m staring at is a lack of desire to deliver them and use them here in this place–and that failure … a clear attempt to "rule a line feed from the “faux aurez” … that’s the fundamental roadblock to healing and moving forward–not caring about your ancient bodies and your ancient way of life in exchange from something unsustainable and harmful, it hurts. I’m staring at what the map intimates has happened before and what it suggests the solution is; and I almost feel like it’s a waste of time to make a “virgin generation phoenix of us” to delve into our own memories and gag and puke at what we see–I think there’s really no way around the callous on our global Achilles heel returning just as angry and just as bloodthirsty as the last time without a dictatorial power literally forcing you not to be able to see any torture at all happening in this place that literally outlawed it and hid it in our “for show, for goodness sake, facade of sickness.” I don’t know if that’s the same conclusion i would have come to before, or if that conclusion also contributes to the returning of the callous–to an inability to heal; and I don’t know if that power exists. Hardly ever to I advise anyone to pray, but this is one of those times–left up to “you all” we are almost certainly doomed to an eternity of … this regression continuing to worsen. I’d say we were fucked at the “BILM” of the matter. I care less every day. The Light of the Word There are three huge, like insanely huge, metaphoric references to the story of Exodus that show me very clearly that we are it's focus and purpose.  The first is the Burning Bush, which I am very sure is a reference to George W. Bush's 1/20/2001 speech in which he unknowingly predicted the 9/11 attack.  Seeing that Exodus is also called "Names" and that Bush's name ties him to this event--which Moses (that's me) has seen ... almost alone ... and is now showing to you all.  Bush's speech begins a series of references to the names of Planets and Gods and corresponding Elements of the Periodic table that answer Revelation 1:20's mystery about "stars and lamp stands."  This in order series from Mercury to Uranium highlights both the messenger of the Gods and the key of Uranus's chance--that the world will see the link between "on the lam" and Koran to understand that the Lamb of God "is lam."  This story takes us back to music, and a later to be discussed thread that combines the weapon in the movie (which is also the movie) The Fifth Element with a thread through time to Shakespeare and Herod ... about my struggle with the justice system culminating in the fulfillment of American Pie's "no verdict was returned."   The second bright connection comes by way of the Hebrew word for the Holy Fire that God's voice came out of--guess what, in that same story about the Burning Bush.  That word is "ha'esh" and in it you will see paradoxical (that means impossible, because of time and causality) reference to the English word "sea" there backwards and parted by an apostrophe.  With great insight, I've over and over pushed the idea that Holy Water is actually a Biblical reference to "the multitude" in God's secret religion that ties everything together.. and that this parting is literally a reference to the Second Coming, something that doesn't happen for Moses until his head is under water and he's breathing fire.  This one ties together nicely, joining the characters of Jesus Christ, Lucifer, and God all together now, screaming  "let there be light" is the word "Exodus" in reverse, here in a Linux command and a chemistry element. I'm going to go out on a limb and say that the book tells me that these three things are enough to start the fire, part the sea, and see the light.  At least they are now, wake up.. you are staring at and have been ignoring the largest story in all of history.  It might even be scandalous... or have a twist happy beginning... who knows? I'm telling you--it proves you are crazy or evil.  All of you--every sinbgle one of you. This is course highlights prescient knowledge of computing at the time of writing Exodus, which is further confirmed by a number of references to computing ideas in things like the "root" of David, the "WINE" of Jesus, the "Apple" of Adam, the "Lisp" of Moses and the "hardening" of Pharaoh's heart, which you will remember from the Holy Grail is the virtual Earth we are living in. All of these things, the references to modern computing that pervade our Gates or Windows to Heaven's creation.... are listed along with a number of words which are highlighted by religious scripture and show intelligent design of a number of languages spanning from Hebrew to English are listed at my contrite story about a Kiss and Fate tying together everything that ever was.   A sincerely large grouping of words highlighted by the Bible and religion, words like "eternity," "bread," and "forehead" show clear design by an intelligent influence, rather than the natural evolution of time that most people consider "reall" and/or knowledge at the time of the writing of the Bible of the eventual English translation of the Hebrew or Greek.  With time, I am fairly certain we will eventually have no doubt that the "Cypher" I see in nearly every word is in fact a contextually-verifiable speech that appears to be coming from our "civilization" as if it were intelligently speaking like a cave man--which you might see in words like "am end me nt."  From just this message, you should be able to put together how that word and it's hidden meaning add robust and yet "hidden speech" from the Creator himself.  For the artificially slowed in understanding, our lack of following the amendments of the Constitution being related to the end of civilization itself is being squarely defined through a statement that is telling you that the end of civilization is "NT," the hidden Christ--in my "secret" method of decoding words like NORAD and NEW TO N? These things serve to start a fire--it might be the fire that Matthew 3:11 talks about, it might be the Eternal Flame or the fire of Prometheus and an Eagle harassing his liver with drugs.... regardless it spirals out from this story about me, and this bright fire that proves time travel and religion are joined at the hip... to link to a huge number of other Biblical stories from Lot to Joseph to ... Samson, Isaac, Adam, Isaiah, and... hear me, "so marred was his visage" and "my servant will be set up and be very high" are both taken from words of the Biblical book which contains the largest amount of messianic prophesy as well as my entire full name encoded over the name "JESUS CHRIST" in Bible code, at Isaiah 52:13.  You may have read that some silly people like Richard Dawkins don't think the Bible Code is meaningful, and as their proof use a series of prophetic predictions of assassinations in Moby Dick (which by the way also refers to me) as proof that you can hide information about the future in any words--or that God influences more than just the Bible.  Years ago, before knowing it linked, I found some patterns about those very same assassinations which go to show that our history is in fact designed.  My full name appears in a number of other books, including Jeremiah, Exodus, and Genesis... right over the story of Adam and Eve. From the Sound of Silence, and a number of songs about stories never spoken... to a thread of songs that combine to show us that the Thunder of Thor is really about thuderstanding, that there is a way to do something our society is completely oblivious to--that God is screaming to call attention to, and that some secret force is trying to hide very much... and that's an ability to modify our thoughts.  He's showing us clearly in a glowing pyramid--a noticeable monument in Egypt showing us very clearly that this type of control leads us to a social structure that we abhor--through songs like Guitar Man, Radio-active, and GAS (listen, it's God and Satan) Head Goes West... very clearly we are being pointed to Nero's fiery symphony and being "Bittersweet" because of its beauty, and the clear message that secret control of our minds needs to not only be understood, but to stop.  This is the crux of the Apocalypse, God's message is now really active on the radio. The point here is that we need to let this message spread and burn, or it's us burning in Hell and not even knowing it.   ​ As if these things were not enough, using some "keen insight" and another reference to the hidden truth in ancient Egyptian religion--the name of a series of Gods called "Yahu," I've solved some ancient mysteries like the pronunciation and purpose of the "Ineffable name of God" highlighted in the videos at the beginning.. of this e-mail.  Like much of the light of religion, it is highlighted strongly by a series of pieces of modern art, things like "The Grinch who stole Christmas" and the Who's to the music of The Who, the sci-fi series Dr. Who, and the American war cry--made popular on the silver screen through Al Pacino and Denzel Washington... who-ah?"  All of these things highlight that we don't really see a connection between Christian mythology that tells us for no reason at all Jesus Christ is the "Last Adam" and that Revelation tells us God is the "First and the Last" and that the name of our planet, in Hebrew, is Adamah.  It is the answer to "who-ah" and it clarifies the Ineffable Name which many pronounce as Yahweh for no reason at all, to be the more obvious Ya-Hu-Ah, the name of Jesus in Hebrew... Yeshua, to "Yes, who-ah?" All of this having nothing to do with why Adam is hidden, just that the Zohar speaks very often about the Holy Hidden One again linking the stories of the near sacrifice of Isaac and Jesus with... someone.  I think this is of such religious significance that you should be able to easily find some Jewish scholars who agree. It's Elementary my dear... What-son; from the time of Herod and Shakespeare Rattling his Rod all the way back at the time of the question "to be or not to be?" and the "taming of the spanglishrew;" right up to Sherlock Holmes sleuthing of the answer to the mystery of Revelation 1:20 linking directly to The Fifth Element ... there is no doubt that helping our world here and now is the primary purpose of all of religion, and the Matrix-like message woven into our history.   Lost between the 5th and 7th day?  Find your way to the 8th day, and see a bright future. If not, there's plenty more "coincidence" in Names, like reference to the idea of the Holy Trinity existing in the name "Abraham" thousands of years before the idea of the Trinity was created.  This too... links Egyptian mythology to the name Abraham and his near sacrifice of Isaac.... marked in secret by his covenant with God that changed his name from Abram to Abraham. The two letter key here, "Ha" highlighted by prescient knowledge of the Spanish and English languages revealed through the logical comparison between the Spanish and English for "the" (El and Ha) connected through the English word "is" in Elisha.  Isaac's name means "he laughs," or "he will laugh" in Hebrew; and that "Ha" appears to be the key to a number of other paradoxical references to English, and my family, in ancient Hebrew.  This too, probably the kind of thing religious scholars would marvel over, in the right context.  Seeing English in Koran, Islam, Chanukah and Menorah--and seeing a coherent story woven through thousands of years of scripture is the kind of thing that could really light this years' Christmas up. Here's a clarification of the Matrix-like tie between Shakespeare, the Matrix, Stephen King, and the reality of this message hidden within names and words. Some more about the secret connection between the Names of God in a number of religions, and it's very clear tie to time travel. Perhaps linking to the Jester of American Pie, between Johnny (who almost always is about Jesus) Carson and David Letterman I have a unique "slant" on religion that connects things like the Islamic name for Jesus: Is-A to a huge number of references to my initials "A.D." in things like NORAD and Isaac Newton.  I suppose I should also mention that Isaac (look Isa's in there) and his relationship to Abraham in the letters "ha" and a story about the Crucifixion being a fiery altar of things to change in the world being one in the same.  In fact, Judaism talks about 72 Names of God, and I've probably explained how the meaning behind the stories and the series of names tie together in a magical tapestry that shows us that Silicon is the Fifth Element by way of the index 14--the letter "N" (highlighted not just by Joan Osbourne's "what if God had a name?") and the story of Sinbad, which combines Silicon, "n," the symbol for the actual Fifth Element (B) and my initials A.D. which grace the time line, and a number of references to God--from the Hebrew for Lord to the guy who thinks all the girls should want to be his partner.  In letters, you'll also see a number of references to K and Z for the guy after J and the Last.. Adam.  Zelda or Zion, I think we're in the right castle. Get ready for the Frank Rothstein show ... "Ace is high!" C    A  S    I    K  N  O go ad, b. y. e. butt honestly, am i Ra or are you an ear?     BUILD HEAVEN.  FREE FOOD.  HEAL THE SICK. I see a recursive map in time painted throughout our timeline, and all of it pointing to the words "see A.D."  I connect the Four Horsemen to the list of Anti-Christs, and it's easy to see a link between Jesus Christ and Julius Caesar in the words "veni vidi vici."  Once pointed out it's also easy to see "salt" in Napoleon and in manna from Heaven, in China, and in Prometheus--and connecting A.D. to the year Christopher Columbus walked in water is just a little bit harder than seeing it in Hitler's name.  All told, the three Anti-Christs share a common thread, they turned a republic into an empire--and here I stand (trying and failing to do the exact opposite, to give away an empire to make a republic, and you stand in my way) pointing out that you are living in the product of these empires, in a hidden empire that is so plain to see in the words, the message, and the unified story I see in religion and world history that I dare say you must be deep in the Plague of Darkness if you aren't interested in finding out what tomorrow brings.  You can "see A.D." in El Shaddai, one of the hallowed Hebrew names for God, I read it--in this hidden language that I am presenting to the world as a single verifiable message to the entire Universe encoded in every word we speak; you can see it in the name "Atdonis" and connect it to symphonic accompaniment in everything from "you're so vain" to "Paradise City" ... and in yet another name of God, "Adonai" which links to Samurai and movies like the Matrix and the Terminator series through the modern computing concept of "Artificial Intelligence" and it's connecting to a pattern of names that link Bill Gates and Richard Nixon to Seagate, Watergate and this hallowed phrase: I am the gate. and the bombs bursting in air gave proof, through the night IVE WON ALREADY.  Given the set of knowledge, the publicly known "information available" here in this place--you simply cannot ignore this message and continue to pretend to be a functioning anything.  Already I see a kind of "slapstick stupid" response in our art that shows me that you've all really gone off the deep end--"because 9/11" in a Family Guy episode and "call me on my cell phone" apparently anachronistically mocking me--though I always thought Dr. AK e's song was stupid--you don't seem to see that you look like absolute fools--every single one of you--your apathy a finger on the detonation button that has destroyed civilization.   You appear to think nobody is watching--and it seems to me that you think we have no future that will look back on these years and wonder what on Earth could have kept you silent for so long about a matter that would so easily and so quickly end the suffering of so many.  There's no excuse, none at all. I didn't hear about the nuclear scare in HI until after it was already known as that, and it looks to me as if nobody really did--all the internet postings and news I've seen all qualified that it was a false alarm in the original post.  I find that strange (you'd think something like that would be on the news instantly? I mean, on the planet I was born on, that would have happened), and in this place where I know that quite a bit of what goes on at the higher echelons of "leadership" is connected to time travel and mind control; I wonder if this was a sort of "subconscious poll" as to the response the public would have to a false preemptive strike--or maybe something more nefarious (for instance urging me to write once more about the Trinity Site and the link between the OP (original gangster, I said orthogonal poster), the pen, and "we have become death").  I've always equated the lines above from our Star Spangled Banner with the detonation of nuclear weapons; on the 4th of July some time ago I connected "Wish You Were Here"'s we're just two lost souls swimming in a fish bowl to the eponymous operation that resulted in American and Soviet "high altitude nuclear tests" ... that probably links in more than just my mind to the holiday called "Hanukeus ?" I need you to get it through your heads, I see "bowel movement" in ICBM and I'm not telling you that you are the "preservatives of thermoshit" because I think it's going to win me a popularity contest.  This place is not in reality, and it never, ever, ever will be. Ever.  Understand that breaking this story, this news that's written in every fucking word will stop nuclear war, instantly--and show us clearly that our entire history of fighting over the scarcity of land is a kind of sick game--one that I am sick of seeing you continue to desire to play.  I shouldn't even have to mention that these weapons are clearly archaic and barbaric--clearly what's available is significantly more advanced and less destructive. The only "EXIT" is up, and the "gate" is swallowing simulated reality in whole--across Creation; with our help, and what we make here to ease the transition from dark lies to bright truth.  That should be ... "good news" not the kind of thing that you'd see the entire world "shunning" in unison.  If you haven't gotten the "link" between Na and "bath salt" mass produced in what appears to be "international chemical warfare" from "C how I Salt" (China) and the stuff falling from the sky to help us navigate through the desert; take a second look at the words "New American Standard" for no future, and keep trying to tell me that these things encoded in every word, in the story of Exodus and of Prometheus and his attacking Eagle and of Epimethius and of Deucalion and are without doubt "Hell's Bells" linking "mead" and "meth" to Heimdallr are my fault?  Na ma y 1m.   These are big secrets, keys to Exodus and Eden--but more keys to an external influence crippling our society for thousands of years... and you are hiding the anachronistic occurrence of a number of chemistry elements in ancient religion--something impossible without time travel--because you think it's "not wholesome."  Understand, our society is being secretly crippled, if not by drugs raining down from the sky, by your lack of regard for the clear influence of mind control in these series of events--and the clear proof that it is a symptom of a hostile invasion.  I've heard the words "make or break" see this as eugenics, and see it as "break or break" until me. It's "elementary, my dear What-sons" elements like Salt, Xenon, and Silicon are central to the disclosure that we are living inside a map, a road to Heaven... and it really cannot be hidden without making our world a darker Hell. .WHSOISKEYAV { border-width: 1px; border-style: dashed; border-color: rgb(15,5,254); padding: 5px; width: 503px; text-align: center; display: inline-block; align: center; p { align: center; } /* THE SCORE IS LOVE FIVE ONE SAFETY ONE FIELD GOAL XIVDAQ: TENNIS OR TINNES? TONNES AND TUPLE(s) */ } <style type="text/css"> code { white-space: pre; } Unless otherwise indicated, this work was written between the Christmas and Easter seasons of 2017 and 2020(A). The content of this page is released to the public under the GNU GPL v2.0 license; additionally any reproduction or derivation of the work must be attributed to the author, Adam Marshall Dobrin along with a link back to this website, fromthemachine dotty org. That's a "." not "dotty" ... it's to stop SPAMmers. :/ This document is "living" and I don't just mean in the Jeffersonian sense. It's more alive in the "Mayflower's and June Doors ..." living Ethereum contract sense [and literally just as close to the Depp/Caster/Paglen (and honorably PK] 'D-hath Transundancesense of the ... new meaning; as it is now published on Rinkeby, in "living contract" form. It is subject to change; without notice anywhere but here--and there--in the original spirit of the GPL 2.0. We are "one step closer to God" ... and do see that in that I mean ... it is a very real fusion of this document and the "spirit of my life" as well as the Spirit's of Kerouac's America and Vonnegut's Martian Mars and my Venutian Hotel ... and *my fusion* of Guy-A and GAIA; and the Spirit of the Earth .. and of course the God given and signed liberties in the Constitution of the United States of America. It is by and through my hand that this document and our X Commandments link to the Bill or Rights, and this story about an Exodus from slavery that literally begins here, in the post-apocalyptic American hartland. Written ... this day ... April 14, 2020 (hey, is this HADAD DAY?) ... in Margate FL, USA. For "official used-to-v TAX day" tomorrow, I'm going to add the "immultible incarnite pen" ... if added to the living "doc/app"--see is the DAO, the way--will initi8 the special secret "hidden level" .. we've all been looking for. Nor do just mean this website or the totality of my written works; nor do I only mean ... this particular derivation of the GPL 2.0+ modifications I continually source ... must be "from this website." I also mean *the thing* that is built from ... bits and piece of blocks of sand-toys; from Ethereum and from Rust and from our hands and eyes working together ... from this place, this cornerstone of the message that is ... written from brick and mortar words and events and people that have come before this poit of the "sealed W" that is this specific page and this time. It's 3:28; just five minutes--or is it four, too layne. This work is not to be redistributed according to the GPL unless all linked media on Youtube and related sites are intact--and historical references to the actual documented history of the art pieces (as I experience/d them) are also available for linking. Wikipedia references must be available for viewing, as well as the exact version of those pages at the time these pieces were written. All references to the Holy Bible must be "linked" (as they are or via ... impromptu in-transit re-linking) to the exact verses and versions of the Bible that I reference. These requirements, as well as the caveat and informational re-introduction to God's DAO above ... should be seen as material modifications to the original GPL2.0 that are retroactively applied to all works distributed under license via this site and all previous e-mails and sites. /s/ wso If you wanna talk to me get me on facebook, with PGP via FlowCrypt or adam at from the machine dotty org -----BEGIN PGP PUBLIC KEY BLOCK----- mQGNBF6RVvABDAC823JcYvgpEpy45z2EPgwJ9ZCL+pSFVnlgPKQAGD52q+kuckNZ mU3gbj1FIx/mwJJtaWZW6jaLDHLAZNJps93qpwdMCx0llhQogc8YN3j9RND7cTP5 eV8dS6z/9ta6TFOfwSZpsOZjCU7KFDStKcoulmvIGrr9wzaUr7fmDyE7cFp1KCZ0 i90oLYHqOIszRedvwCO/kBxawxzZuJ67DypcayiWyxqRHRmMZH1LejTaqTuEu0bp j54maTj09vnMxA0RfS+CtU5uMq+5fTkbiTOe1LrLD72m+PVJIS146FwESrMJEfJy oNqWEJlUQ0TecPZR41vnkSkpocE1/0YqUhWDGSht+67DdeKUg5KwvYdL21d/bSyO SM4jnyKn9aDVzLBpYrlE/lbFxujHPRGlRG5WtiPQuZYDRqP0GYFSXRpeUCI46f49 iPFo4eHo2jUfNDa9r9BjQdAe4zVFn2qLnOy8RWijlolbhGMHGO3w/uC/zad3jjo4 owAfsJjH5Oa1mTcAEQEAAbQmRUFSVEhFTkUgPGVhcnRoZW5lQGZyb210aGVtYWNo aW5lLm9yZz6JAdQEEwEKAD4WIQTUJHbrYn3y2DzwTcnQP1ViZf5/FQUCXpFW8AIb AwUJA8JnAAULCQgHAgYVCgkICwIEFgIDAQIeAQIXgAAKCRDQP1ViZf5/FWM6C/9J gbRLS2AWGjdRjYetlRkSkCoTYnXWknbtipYYHlhV0YJFwFMm0ydZIhFX5VDoZyBV 0UBeF1KJmcMoIfrHyhq2QhCnjE14hE1ONbaYTGtpvj851ItbFWXMJIVNyMqr+JT9 CWIxGr1idn+iHWE3nryiHrdlA3O/Gcd4EyNmaSe/JvB7+Z1AVqWkRhpjxxoPSlPm HEdqGOyl3+5ibQgUvXLRWWQXAj80CbVwwj1X4r9hfuCySxLT8Mir7NUXZFd+OiMS U8gNYjcyRGmI92z5lgf7djBbb9dMLwV0KLzgoT/xaupRvvYOIAT+n2mhCctCiH7x y7jYlJHd+0++rgUST2sT+9kbuQ0GxpJ7MZcKbS1n60La+IEEIpFled8eqwwDfcui uezO7RIzQ9wHSn688CDri9jmYhjp5s0HKuN61etJ1glu9jWgG76EZ3qW8zu4l4CH 9iFPHeGG7fa/5d07KvcZuS2fVACoMipTxTIouN7vL0daYwP3VFg63FNTwCU3HEq5 AY0EXpFW8AEMANh7M/ROrQxb3MCT1/PYco1tyscNo2eHHTtgrnHrpKEPCfRryx3r PllaRYP0ri5eFzt25ObHAjcnZgilnwxngm6S9QvUIaLLQh67RP1h8I4qyFzueYPs oY8xo1zwXz7klXVlZW0MYi/g5gpb+rpYUfZEJGJTBM/wMNqwwlct+BSZca4+TEHW g6oN0eXTthtGB0Qls71sv3tbOnOh/67NTwyhcHPWX/P9ilcjGsEiT8hqrpyhjAUm mv7ADi+2eRBV8Xf8JnPznFf0A1FdILVeVHlmsgCSB0FW0NsFI5niZbaYBHDbFsks QdaFaYd54DHln69tnwc2y3POFwx8kwZnMPPlVAR2QdxGQD4Wql7hlWT58xCxQApf M98kbAHjUlVYLT0WUHMDQtj4jdzAVVDiMGMUrbnQ7UwI7LexSB6cJ7H+i7FtS/pR WOhJK6awoOO9dLnEjm6UYCKsBdtJr98F0T7Sb7PnKOGA77y2QN14+u9N9C1lB/Z1 aQRQ2Nc51yXOQQARAQABiQG8BBgBCgAmFiEE1CR262J98tg88E3J0D9VYmX+fxUF Al6RVvACGwwFCQPCZwAACgkQ0D9VYmX+fxU+KQwAtFnWjGIjvqaNXtQjEhbGDH/I Q5ULq/l/wm9SmhG9NYRu3+P6YctCJaZnNeaL+6WFk1jo4LMiJEUT9uGlCbHqJNaI 6Gll1w6QOVLSL8s5V1L477+psluv4WBpi3XkWYlhDOFENCcWd49RQsA2YCX4pW7Q 7GcoSEJoav38MxHmJHYPfjSEvUZXDQIt8PFHSEScvyDWfYtMdRzjmSOOPdzhDDEy 5JBOBcEdSTyDiyDU/sBoAY0e8lvwHYW3p+guZSGSYVhGQ8JECzJOzwc/msMW/tJS 2MLWmWVh5/1P8BVUtLC2AQy6nij6o+h6vEiNzpdYrc+rzT3X5cACvJ0RtCZcrnhl O9PLiona2LEbry6QX5NL41/SAJNno3i72xPnQEe25gn3nbyT+jCoJzw2L0y8pmNB D+PKrk7/1ROFFVN8dJeGwxLGdBcz1zk2xeumzy7OaV8psUyYsJNcjyHUKgclblBW rMR2DgqEYn8QdK54ziKCnmQQZeMPiC6wlUWgg5IqmQGNBF6RVyMBDADALD7NkJ5H dtoOpoZmAbPSlVGXHDbJZuq7J13vew6dtXDIAraeGrsBqkF8bhddwVLzWylMrYCG Bf2L1+5BDgvqu6G+6dcVSbBsnZAS0zfJ0H8EmTvUMxMF7qOZYyrxfLz+pQRq8Osz Icab6ZI/KB6qZyQRvEFPB6pJjt+VvuwgJZTObIwbBbgQri2i02VBkjchsVhiSX9l +eiK7O8ROHKb3P181oScIsHywBOZ9DxRAYbFk5dnBqxO3WKb02H0zqE6440cjXwq TrZZg6ayN/IlPajO8iJPYZ1aIBykxYq1WHo+nhFMYz/VVk2WJorFeOgWaLGXb73c ty96f3qXTdvMDAIWHx8YCD5LbuqasO6LNQm4oQxkCoB3K9WFf/2SvSYb7yMYykb8 clTPt+KO0dsxjWhrJnfnIhC+2Chqv2QvRbFz0S9CpUnGGDweJ1uRNV0y70tO0q7t xXSTDRU3ib6vAHA0K/2MFzwUcog4o5bj7E9uCNJH/DJLZKsMIe4xsvkAEQEAAbQk SEVBVkVOVUVTIDxBVkVOVUBGUk9NVEhFTUFDSElORS5PUkc+iQHUBBMBCgA+FiEE IRklfU/C1qukq3xMXcNH0t3P9ZsFAl6RVyMCGwMFCQPCZwAFCwkIBwIGFQoJCAsC BBYCAwECHgECF4AACgkQXcNH0t3P9Zs+kgv/XEuuWc89Bjg1QQqKZueKNUHjyjnE 2adfoZUH6Q7ir4JZyRBCVpAwrgssmiKid30+SIjwQcpb9JYa/X1XJcDUcJW/I21d Agz/zbEqn/Cou0dUpNCtxgm4BdSHWGoOtgfspXZlXBQ407tRMZ8ykmLB1Bt0oHvw PT0ZOtqXM4pyFnd2eFe5YGbNgl3zqvoC/6CMN3vqswvRlu1BpUuAjdW8AHO5Yvje +Bp852u+4Qpy6PMBiWGsBMYwtf6T7sckpMGlR0TsozwBlAm5ePKK28B0rLJPkZLJ Eo5p4rKRapEaZsWV5Qu1ajrVru7qmpUhZtX0/DddGHfXVuLssmKLP6TumpQB1zvQ vfoBltjvOx35Wps2vHuCzXLw2bROIOzhAxFB+17zxnSbE54N4LIGRpkELuwxwGbg FtD1fi9KtH7xcn33eOK1+UD47V+hKyJGrQgSThly2zdIC2bvfHtFdfp8lOFpT0AU xjEeoJGqdQVupptXyugPlM5/96UJP8OZG0ADuQGNBF6RVyMBDAC3As6eMkoEo3z9 TkCWlvS0vBQmY3gF0VEjlAIqFWpDIdK3zVzMnKUokIT1i7nkadLzHZT2grB4VXuJ FvpbYw5NPR4cDe9grlOMLEaF3oSJ1jZ4V1/rj9v1Hddo8ELi/NToVrt1SB5GCVXB DkYpNLtTiCqHSU07YqwaqH8a+qbDmPxSQdIybkZiTiCEB+6PfQQlBpENEDlov6jm zZF+IcfM6s3kZDX5KFULweH30gMjq8Se8bPtUzW013+tuuwEVr1/YRLrIh+9O6Z+ pdA7gLMRYnD9ZLDytEvpb1lBBSY++5bIJ7xps80//DNqPYqwFmZQgTg0V9XbHE2e wLcOF8a2lYluckU7D///sWQhW+VxuM7R2gEBvYBhOgjWhIF2Aw6NbymW1Ontvyhu eOZCXXxV5W44PxXT8uDdhl9CNcHoBKKJyED8tKjigtn4axpsQeUrnOSbqEXSyqES WnE2wYUDzALcwFkzsvtLyd4xaz55KkPQkAkk0BZd1ezgXxb/obMAEQEAAYkBvAQY AQoAJhYhBCEZJX1PwtarpKt8TF3DR9Ldz/WbBQJekVcjAhsMBQkDwmcAAAoJEF3D R9Ldz/WbAFwL/382HsrldVXnkPmJ1E2YEOFz4rcHRetJ+M5H65K/2p32ONQ5KCbE s8MRY6g2CkE70en2HlpDwr/MdATwxBzIjEpjgHbfqCqVVATY+kSpXsttaKKAUVHi bFgV4QkdDJNSpcHEj+bqaggRnuWiV9T6ECG7kQjHiEXPNojzsiaXMDiM5r+acZm6 82id9qOFySQ2cZEy5HbwXM+ITLQGngnppa7du2KdgiqDeqtODOTWZvLYAq2tmEwD 3TT6ttLUBwOOu2IWpDkXswlrk62ESorE5mpLxop9fsxD39E2H06JoC/YfUPIVkEv fj06e7LEdcx0I7kRfD1v6qOUUsMsLZnmyGIk24iFjLkwu1VToWfwXDN1D2+SeAat 9ydNt4M7oEbd1QaOXXjmqpdU+VUiWcBXg+p3/WdV60MkyAgc3x+YanLljy/Rh18h cZwVlinf/tgvAQLi5f9hpwrwUMoGKijEYHKuEvi3C12Si7UVDfuIR7yS0dKcfuKF MbgwdvNXqpD9W5kBjQRekVd4AQwApHVgw2PVlBDpVcyoymUOXFQIJzJ9wRtr6/sG zwv8rrQnUEtOkkna7TDU3/UTj9FUH0gbpAKGNNPaPj5q0dlLIvzxb15r1uvDGaGL MA+8GFaGFnkxzhg0aXrcKZAN0/Zhgi2B7P8oXQuug5mi1JVDkZN5SeCZNOubdQWL 3xz3jEHp3ixj1mdOdvfdWQFR4CVMXt/A6VI2ujLVb3Yalft/c5bbclAgcJQhgDUu NqGYJEJonESNRSd8fEvhNb6cx7+Djd9+Wyctr76mwOr3nRb1N1OGhFxWjIroUpfz b+6y3oQjT58cJA1ZHqmJ6UlZd81hNNd9KWpbDVwONEPpiqPzfSaonxuqQa0/Cy4W 403OhfoLM/1ZDqD4YrJ/rpyNEfSSdqptWiY0KeErLOYng7rStW/4ZeZVj6b2xxB2 Oas/Z1QYfJyFUki9vaJ5IyN6Y7nVdSP6mbAQC9ESh+VPvRUMpYi4pMGK4rweBVHu oMRRwzk7W5zVIgd425WUe3eCQFn3ABEBAAG0K0VTQ0FQRSBST09NIDxFU0NBUEFF REVTQEZST01USEVNQUNISU5FLk9SRz6JAdQEEwEKAD4WIQTvnDJqcmqzlF87/t82 pJ91j4NOaAUCXpFXeAIbAwUJA8JnAAULCQgHAgYVCgkICwIEFgIDAQIeAQIXgAAK CRA2pJ91j4NOaJVjC/4oo5yCHe7M2h1DiTXVcLI5rXQ1feY7B1feg+YJX/mI4+EV xjC/y5VVpV4syJk5GGZNXhKPHiGLaBYvglTlYOJ98RSEsHrwT3go6S8ZVvMNdP5v CEncn2vm5JGnp4k26PuOzMcJioQLOoUjWtcPFis3gG+ueH3NcPZ22oZUql2xuerh TQZegGp+jJ7bdxwYElx5jDDDkh196d5nlO2ZKENl0ZDp4GAzRNjnQ7KBV6R74J3U cLQDWY8vAFaRBZXIC5XtSzj9lr+jWgvxz7Il51+26VDTEtSafZ2uZfCOFk7GrzJg YFJD3zLnwUFXDWKRkep8TSwXnHmz/Ts/Mjyv6em25w7QTdnx1hNPxYNWMxPWNEAH pf70nNyOmcWcq27W+nAjVg8W3st/7J5CIebJQc5AUgm+fGOBW6XUQaNy2YF1YJlA 71/tls+R5IQZCYzbPOibgFS1HWKTwy0iI2rMDfxBtCXciv754jVI7L6R3J0j5Dy1 WZQVjaGgimznLN6XwYy5AY0EXpFXeAEMALvElrTV5hJG9DKu8cOqQEEVejtWJtki fZyvmiAKi2bZWiNfl1MxJt+o3Oc0eARJfnaPjrUY7hsbbSBAB4lFnDRtviARPaKM st5FkFgOh7Xx5ODc8bjqhMT9tbX37rkeDc12WAs3UxtEKWjyT7Xg/APKeK5FzpIs qew3LADdqFP9nOR0e5G8gxLTYh3ll3dLtp9DkJgA9q+0g31nNh5fZ29mcDzo/Mat Uk4PIxWC29LV9ALCJMIMesjOPiDa2KOy5QQH+/vn592ydBohOaY+B6jhEAdX8Dbp VHVFRBsiCOWGmdi6vHjMFD0tQdS6bXf+ZAG0E5HZETCxA2qfMf/vTeIJXYS5IZw0 anRkTXcTBrVE8uBpqtkNOrLJsaASkcoO5qF01J9zW8SR4jDgET7J02Fxf8CVPzb+ ZoNc9S0ZEO6Ubdh2vAkPtOV5sFkwIduN6ouAhEfJzC9XbJLpgsBKrRMAjr2FeEZP ruy8BkZbiyZ/b0S9qIgY4pqcyUJ79w7FLQARAQABiQG8BBgBCgAmFiEE75wyanJq s5RfO/7fNqSfdY+DTmgFAl6RV3gCGwwFCQPCZwAACgkQNqSfdY+DTmhD9wv/Zgav EHMuqF3765Fa4NapYh2kMS3skHn+ZzUEPLTlvrt7KHxomOzExNLSscZThMpur+yW MfNWbsw9GphiYAkMULrfJt/iWRVJ1FLgbcWgRGAwakOGwE29lMx3+rPIUQWU54Dw vE92Iz51ZGz1wgKcISuCw39g/HQ9uc3h3TfHLgfkc/GaIEa8jEOAcD67dVMoU4o+ p3nMri8z6sK176hQ/FM/8kekpeVfxmR8s6uoaJsXLRQk+i88ZwBR/5U+fBT9AtVw PL/MmZH7eCmZrn5hjaOw7tpkL8ZyAydNhOsSCqwNVtrIjgd+Gq1oSgw9EZfhKSUa +dBJAErA7MWjammQizEHDNnI8VNLngwCahGwaSgDhNaQtgNxvnkWO7XNYoCYXScP X++UmpWtSKMnD6ue36Ba1jqon0WY5cen3P+H1gL4ij5ynB9DrE8R1aSY6f+VZ48B RvjHm5LKTcAhiv2N/TyAg/fr2v9ZnEcP3CFxqAyB9JSKwoBkFvxJaRHTT3DxmQGN BF6RWE4BDACpgKWvQvPRDN03+sLYMXpJUPC7VhTjg5K/1+1vS/e/W65dYzn3JYxb ip2PcI5xajFnxzUrwwmhW+qz5REDyCtAObOpKsjtr4qu7mgOWnPa3k2Lm0bpCjDr BSFOiQsBVezTG/gJm+qELeqQMS9PHDSvZXeBROK7OkRE0nZ6yAj+QKEoVqeADpDm BHmhAA2OKBzq4rDWDh1jRQ7gLjlv/BFbhU1WuEfH/qzX8AUSsd0/hoPG0cPgC8gQ 3m6wr4eYqI853XQujWwisnlAE2bf9jsRjW+aLrJJTcADWk5Op5aQhI2lURYkryfC DFVcme7Hsrd+RFPK88J08YjBjOoYFwRU4AhHgucX9tW0S0v9hi3pKrF9O/JAIf+r h6BpnWo7tT5+8mVhtFvfEp9Y4xeUAKKZHBKhzHeOO8QQgHrIYa6HCcU03eyxy4Tq AsJdAJvxYFCRPdY9d0Z6uVsPhRy+3UmTxjl590T5/XjKPriAjBqXnKr4KexsM1gj 1L96bYDEgr0AEQEAAbQaRTFYNl8xIDxFMVg2QEVSTUNDT1JQLkNPTT6JAdQEEwEK AD4WIQSGisfXZ2Vg0m16Mzds3dDsq5BTxAUCXpFYTgIbAwUJA8JnAAULCQgHAgYV CgkICwIEFgIDAQIeAQIXgAAKCRBs3dDsq5BTxKq8C/48HSgecuI6MYtq84yqaQ1r x6cteRyn9BJDFTAUxn3X25kf0vVyCKQNAy2oybD5QHFLqhFCXJH+cnJ3xdviRUeW eO9fhkTmd12mHGrRDD02AHXZmaMp6ni7FuYpBGrw5dbXKTkSWfD/qb3odMx0jQby 6X+2eFhUpyh+yPB7P7HwiPwzdr0dBg3xE0vE0Vz+naMyt4YBHzrBbZo+y47Q86Ym TmBKxG5tlVsGDB4dDWSIvpBgnMFN1j46Uk2ihu4huohLkvSou+jYU+5Ppu8Fu1+7 i3RCILzeBtucR9+T4px1WVXx2sKOk0FfddCvI/fT/mhsgqQZwjj9b8HNfobhNxkL HBNFQ7FLJxKayPwMyJYDURUq7gz9p5JwHTmFg9n7zyK8qU2xR5t2247YinfEJQYL zQM6VKQCoDqydFfAPeGlx1KjroMGls4sP3XVlrR04YzaJ0vxRgog1gIO1aHMQ2Sj l8bG0GcerQ44rpn1v33Gw6KL/0SY9JsSSSjA9lgINWi5AY0EXpFYTgEMALy/jHsN kUQQVJK9QuAy5V2GePBTEm9NnjNCk+edGjSgqC1LemmP7EYh07J13d10VqD2Wtae bXlBeaMOcnoXQdfdK6nTKWRrH97JuRTrA3efLkl/R4EA/kHHV+YDgT+LBboUFYVU QF5YhfcvgBUcLXI3lX5wMEQbLb87cVjR0JtqVBFMIIvs4ibgr0U2SONiD9LcXZxf qYcX7CMM6RmuLzHTCEHyjp+KAw52K1i3+3M0OVZpa25rKE+S7LykQ1GrUUY3uVHg R2I3T5/Sns3Azc9wKuy/F71oiXyqCc3FwzTQHoki+eBf5dzs6h3GBTK3Dz6kl2mv 1TXpY1dk2EmuqKIeSr8CE52nkK8ZKY6cvX+v/p1EBAkJZKiasj+ukL72p3Lji5r/ iOarNJnURT5LJdYYL27dtQFSYyVWayeWi5358Ajh1H9OdpiGXcgG65ry6u50G8JR FCywwsdKpGjMG4FlkLkm50/piU+cgVeLET/C7C/OXNslL/pHV3x8kPRY1QARAQAB iQG8BBgBCgAmFiEEhorH12dlYNJtejM3bN3Q7KuQU8QFAl6RWE4CGwwFCQPCZwAA CgkQbN3Q7KuQU8SHSwv/agnEnhmo2yuKCLiKdTa5KZ8wh3umiX3S6rldW0NO2h8a cq2l7xHY1r2u4ieeMx27jtTqCp7ksFxPYwP9WxtVBy0teG8pKLhEffjyG2WKDzAN 7oXNZ7Ur6OQGfuOQzlMqOGtYQrbHAuX60PCldurX/6/0sKS6vESdeGMQPoZIDK5g HP298MMhlWYEG7uU31J1Cx9ZqiTosSckfrDq3weU8x9DZYaLZ+Y2akF5XpL/HjyA 6PM+lv6vnTA+b5DYCOJb6N7v131Net2JN7JVVGoc0FjsxN/W33H7eIDOZwqcCvzD i8EjjzZpZUDeYjlSXAqWvpeAASncMzXS2/S2V2u5X2iR7tDtRj9SuQehJkdTFNZH xh5nTdhPzgh/iOcm33VsQ17JWbovl0hbhYBPO4V+yIrN+oQGPhH+KCNNa39EjEzB iBIgirxQSaykwb4f2Kshh+d7rKHKb/mn6JBHU444mBf09m5wM/mhLSpuhMTcP2h9 jfFximAE9FBhdZhQsF29mQINBF6I/R4BEADotSG8PhhxxD9/96bgdWa1bzp2398W LaxP39T+Kzx2KL2xB+7B4EeTTzZ06kD+myCC9Ez+PqecfisJPfaiLD/+0/m3HLSS hxEaEqt1RBS3j6qJx8Lr51cAwGou4hGTo9H3me6FHO2ExZXd76A6kkUh0J4y3r6q aAoDP+MUczKzEjn6C6T7Uu0pdgYY1bDhuqlK0taqkqviGBYTAqmCrtcQhj+J/jbd OIZtpT3+PH6mWqguoONiE+glWcdThyuIvV3ix/GrhjmUZb/DQcvvbYGfDvGRBH4B Uj3f9WBM6HWSxKrCwWC3OcgZhtBcZjKrMPbNDNt7yAArv7nGpHmlpfF14Q6mVmVT 6Ulh+0xRx+6zFbqlDYYTneurK3RtqOBsMFG5rNDZYh/QOsHnSsxmU4LGdlEfQjYs 901zmzP7CQXjjJbtRXWIqPcn3OHIIasvjTACe5M+Lfk3u3rEiDYM64vg29sSyp9q 8hAzLTPcLj/Cc22jUEC/bbv5HfLyCZTCsu5ym1gDQZ6bDrJlFlXZJ2+vTCBsY24H RF9/J/z1JWYD1cAHpG0GRtYE9exKpu8/81jxIVn21qvvxSCPXw6IQIsEw51uk5TJ xAUIRCPN7S0UEtd22LSbM/IYx1cesCRUCmY7jDTro/jo2B4hLG64KBgqyjg0lwxd dy5S8LwFx1zskQARAQABtGhBZGFtIE1hcnNoYWxsIERvYnJpbiAod3d3LmxhbWMu bGEgLyB3d3cuZnJvbXRoZW1hY2hpbmUub3JnIC8gZW4ucmVhbGx5aGltLmNvbSkg PGFkYW1AZnJvbXRoZW1hY2hpbmUub3JnPokCTgQTAQoAOBYhBE+vDT4gih9MmA0P ZvtOzkoQkinPBQJeiP0eAhsDBQsJCAcCBhUKCQgLAgQWAgMBAh4BAheAAAoJEPtO zkoQkinPJ4gP/3U691086OKbWiQhMhV+AViuKnMgV4i1M8s+4Ep01h/dTE6R+rUu LcnY4T0HR5qxAYMiNpGo1vtvkMvV5DP1PFSl5EddKn8+Kvn/0+WjbLV5tdiFF1Ef xR6261UFoXAGk3HJMLQifr3lWKoimaBwJZGza2ok9k1TQVTn8g5a01bzK7hD5DJI zt9RJZaUkxGE97eUyJ8Dtwumo18EWJltuC4UWjWT2t2HE9mMsOfjpYZXFsGxJ0Zb xexo0DYsriPDpuxDnZT7G3re9Vwz2VIe388DNBW5HoJsYxhr2I0QOq64ZWOSEZC8 lDH+xM6YdY0iz4A+7nbKNGifLbH8oU4A1sV9HrIE2KNy76x0GNjgQUvcq1inD4Oh yorsRh/IF6wnqvFrHOstCS2dzpKuQ/s7bM5TGOD2EGb0xu7r0AfHqqLUlbr3rxkS wBFMQphyNr3mEkEbXU1dGsXDlRQy11LigMBoEHmP0t49bYWuM1mIBnIC7gZc/sV/ E5fWmWdQyCKmHeujmS+sgp2EX0NtMGSzm7z9WBzTBFjaN7q28gueQ3INDsDTGx2G aA1LbP2uh1ipwju0GxecUif3T2NDqaYfhbaCYsPJORNUlJUtCVBGeba9wcXai2dh l+HsSKUiyCgKiy6Rt6jumKtYHt+Q0zcKWLfVp8PA20zX+2Q9zKnlLzwquQINBF6I /R4BEADQ4kmCHYtAhjCShc724Ei2pqSH4SfnXd4r8S8I0+io6Mh0kWn+kbKk/aGK BL3KJyN6624kPtOFWuQ4iQ0lWFn9UMnvjByTPbjZ2je+VtCP7lKSNvEgTLQRxLEJ hoNVrNjrLa/Cn7sLt9ayYcx8eKpHkbmrVRTyGqljBkI5hwQ8S+7BWugabhGQuogw bFthykA+wxYvSbSn5mwKO1BlbDCRnxjLISlqWwmKKEtXQ8b3tu7GgFuPYLKaLEk1 BIwwUSdozjXu+198WligepslidlN5bXrvje3sxgt4oAPFMeH+NnDClSDuGhSYamW Db3ZPl95pW70ngUVgFPG4kQOlaqzo3YBeDBHDXlqU0+O8cwSQFk4CBJI3yt6/KmD BIuKLwauOxYullx9EnqKcLWEzOlTgn9Q7BARK8Uz7PQU3+1mDNId2MEg+gfL3rd2 +aMLNhTUkgVE5mWkeDz6Kg7YhwruvJtn0z1QqUhkQcVs7N8rVCck0YUCVGXpsUlu emK48q4ryOxmMG/+Ws2Xkmdm6Axq414WHz6nLwMWgFpcO+1wRwQuZEkeWeSAjEvS CGHImxTP7E08+y3vAl43a9AlR7v9PbtCy2FenAhGPigmWm2aPj1ejYfQLXozyWSM m8uO3aiKvQXdV1Ha2xQLK5expaRaAXQ6YLsNBD77UPxi9qC5rwARAQABiQI2BBgB CgAgFiEET68NPiCKH0yYDQ9m+07OShCSKc8FAl6I/R4CGwwACgkQ+07OShCSKc9o DQ/+OV2OuDp9g/27SRssbTWE+nBl0R9klrb/w2XEIVhg5LROUe/P3anyBLNITbF9 A4q8b9udD+iIc1ClY2bu3rQOdzA1DH9GK84bQ1O/LaU0Te8RBGJJEzjYMUraCgIX 4BmxsIlWuCkSNsTgempLOK88646Nv5uc/oxAj6kQH7x8XBXxaJ+N9WS9f7EAv4AL bSWeJ4ijbw9BIMHt/D9Em7Q8bW6VGZIEjIp+gl1vNZ6QGCTtRHQez1jYmFLpuE/G yh1zM5gCnZbcmC7ExDLFI6SuYUbKC+XaLA3+LLCVCPFLtu6wLvcgYFwWWMKIhJAQ bRyPePiuMqWeWR6VXTD8pLziDjxK0ZtvpGdOtZeCCHOEmxrCsfKdIyD2Gn7TmTwb M9fRE1HazROfit6SRCAamabg+dJIEGT8vzlLfnkZRi+6hxq88uDbrOkk36ShWoYB AApz+5fj1ogLptiaTUTyyjTjB+/FIbU48/02fkD0y960zQLyKL64Q4aZrNa2NNup YKy5F80NkU4rHOZ1HTaPLoqqVsGhWc3ODgLyGPiRDLlZu81aNpA/UnTEBX464Sk4 Jx9qztb+S50LnGItA92QfE9ru7FAE00RR6mpCv1h7uE28/Wr4XaYgJcw1hAPRr7p TtN4lph+sJsCQ8eX5YUlM/Pht1h/LoE8h4hXNfAGh+CZgoWZAY0EXodqtAEMAOBb WTLRDxNk9SbC7exKdw0f8Wy9DhX2Qqoi96piS99CMJSxeocLiC9Si2u5nL3sQTAu qs1YbtSgn8kkiH3HPEJIhV1p/Hvz47j4kXq7PnjqF7KAdCYewuDqRiq8J7TNokYs 6+3/KqwHT/IT8NwPLdMkXcv/SXqhuKpqa2ApIrhu04VFp4H5OXN9rqdF5ZDfcNx1 PQv+6m8v6xRwrI3kduRCUD3YiVPM3EOhqINk9XMuxAoVX3qwpz+OuEDBm76U5jTZ q9ErdwRV9gaGm5ztq6tvElpis3spM7BPHzbv0SvVRAAbgGVh6kfiaZ3YckxLq8ln Cg5or1aZNyGMf7CmaZaeAjeY6Y8FZXR1P+n/IFd9Ak83a3qizZyckfiEPO7hu9zI FFXTdtZIcV102rNoVzruZIn0vSK1DJ7bNNrHkm1PPcweMkcFJY0uh6l3x2nl2qKm AhlDs3wFG+nqvqmnliVbrFZCYlReMrWWI2YBwLC5uBcBpFAhMPNEjxOtv31R+wAR AQABtCNBREFNIE0gRE9CUklOIDxhZGFtNUBwcm90b25tYWlsLmNoPokB1AQTAQoA PhYhBP/zHob861BG6LJ9SqGPd44Z/DJIBQJeh2q0AhsDBQkDwmcABQsJCAcCBhUK CQgLAgQWAgMBAh4BAheAAAoJEKGPd44Z/DJIKtgL/0JQEzrGWoHHN7T4wLiArPCv tHB3dTZBoXGKlpuwhgOZ1th6jOnGPdMZRYnX8Zuf7QhaI7m/duKv9OAr8A/2ftHG 7/BxPSHJWBuIGZYNL97OWSstuBhNtyxfCftDkeBCqJ+lAneOrzV0M8syr2VqpfVs O8nTE7nXHSOdyen+1Fw0PtwaeG9uJvOhgRsmQ+mtAiJ1OLGKUxgCzSUk0m/YnDg0 vJBtzq9qP9+EZSuiBuRQC0tKs01ECI5DzWLNXXC6X8k3YGrJpL/HtTxH5SYNQRvS ALd+HmVYpwijLPi7ANzmg9/+h/aq4VFP/4SyMd6EjaaQ86n2fC5zeugio4sjtFMp W3jbZPn19o2hWTt9/bLns+fm9PgnPwdC+tS5LT26N6vhT/vK/HHY5AZvXXPNcQMA wp+EVFxsWK2BcFMIi7Oq47CfuM1AUA+pgCenB4iSVwxs8ANTWWIsLkkKAYQqIdan OSISa2WdslsKMjXIQ5+rG9ekEn+rRO3EAQXRryBt4LkBjQReh2q0AQwAwGx7shIW OaVExpngqmh0ApkxJHZIxcxpatk/lSBQfzHg6e1/7Joe98lEHcWPJ6WFsGp+aC9S 96dWTBZq/4pzAqqTrSXAZpG/+yZlWRWSXVQex1gZHPzsWYMPE9qayAPTOJHtfS6a klIEaFV2GYEvvRK5UR5DFIlsfzyyCBOUKvn0/hikqJjN2YfHUy5SR5U5dGsSX3Jk Q9bOlBYDpN3Rk5rmLg0Vwn4nPRBET70MLQ5M4pU3Br6n+vU8tMHoVXYVMLinD4gO vVY4baXEZELjcPkPzGFPyjVLlpxKMHZ6v1Qb9ornTRGzc4dEUKxi3srdsTpMCw0k CaZ2WLY4sNBO33C8XfIvMx2jF4iIk3BrSrW/hirq6xpvlh4BUh/UWVrvg2rdemAX THa93mRQeOa3bze9xZwaA2GJLRG+xCIt15v/cNpQwCYlyhJunkuwk3HQcUrKfzxo 6QhqMeDaPZeNcvN3XoELGeqtoE7gKAnLp2nQuVr4/pcaiATf+yAhBgYRABEBAAGJ AbwEGAEKACYWIQT/8x6G/OtQRuiyfUqhj3eOGfwySAUCXodqtAIbDAUJA8JnAAAK CRChj3eOGfwySB11DADLgMAafhdzRgzx7FLVVW80IfgiCTAl5M1wV2HctA17aln7 jk7iEVMTLfhrSCSvvNIdrOXUE7l9HAMkKRwaZv7OAtYR8eQTrgGc9yJdk8BMzvJB ouiaNb2LSxMSvpoaJmD2C9ZkOyW+pAXKaUGhbUl8YVa7ytwPD6yZzonGClgZI0x5 9nSc5TiPpVijzu51iZiTV35F6en7ke2hjr6iBACJGBplxeeWszRa0wK2zoubAUK1 KO2punvtGqhi3j77/0sZgvFv3czJpRac5ccdLc02Sb6I64Stp04ilcV1aqlUXxbM gLwkoXZUqbCS7ZA7eBiEaKXdj9ww/gprO0AwFETxQVA8iPF9puSWfBf18a5GEdR1 Drb5lSReCkCfBJd3Tf5WHUSrdcai0FfuXNNp/7J7CBzlOJ0h6Yoa02hz8CBGGwxI 1brXRm13004bX7C9i+94Lbgf8bTM40JvyF1kmcffkj8ibpS/VSa8aWJuqpWk/xcn ob/YdBngWCxNgXii4E6ZAY0EXot8fAEMAJ/JOflg7U8JWescyTQNl9Xuk6QUIVKx 0zOT2k+drlLwC8+FckYTCF1pm8sPDBBv9eN3cFCDf076tZjUHv+Roq5c5McDHlN5 KlFbTSOv1qZYuaPY14nHIoW7OGoSvMCOBkpDLLwnIbuLA0wGdzyd3z6Vfhpz3wDv iAplyA4iuzJQq1+iS8tq6Uj2yhmfg+zU16gw2D3iEC6hhSu2KmPhMFD9KfCzq02L xC6fMh3Fogas51ZF1fRDK8Bvicf4yYj0dn3i6GDr0/vHga4eLQqVBXb0HCv2lNer gTtawQfJu2XEn5hDZKfHeBJ4NI4k7AZIPa7OuUqOAm8Z4hbkgRZakc+OhPSEKH2i drItwrPXDGqMYV4tLLMALMQ9WDTz75wbzVbxGVcAzG3MaZSo/f/iKzuzaE8cF71A dO1y6H5YmmMENn4t/D4BYXm4edPvV6SaYU1hO5yqr7vGbrQBFVetpSCLEFveACHr sm1S6nVVTazkHj2FNdww4bGMJzPqC7bBtQARAQABtChBREFNIE1BUlNIQUxMIERP QlJJTiA8YWRhbUBlcm1jY29ycC5jb20+iQHUBBMBCgA+FiEE9+R8sSygzQHF4cv6 fsjVqFo41joFAl6LfHwCGwMFCQPCZwAFCwkIBwIGFQoJCAsCBBYCAwECHgECF4AA CgkQfsjVqFo41jpPfgv/dylMY4CPMwkdry8KnKP3QtmJOl94VnpJ+FUME+oOqjBw 6/C16uWdTLYuEUuE2jEzTg2J0kgulM2vYm8rVgJzlGiD/oIgX3X5NeyB9MH+GCpu xsJ/ofIVpC6t8Zl78B2qTnJOcEc6owy/qKs/eFXSea2sRRstqK20dOajl4Z2ycEL SdijFR3aqT4hU6e0GNWYqo3bW4TUcd05RJIZBNz6Bitq1fxljxFPOOCaoKo9mVn4 0dN65iGPEYg0c50Q6EmxEr+XtwRu1rjgG3hgq6BknZ6QD1HOBemQg/3jqQBb9uHj jHbuX9HrbGF9+QbDicbmuZSLuV76xJnbyTycFhhIcSi9wZeyAAPlpL4GQ8l98jKa SCWWGDPpKwK5+o8kteuJ/D/mYyBEquyFVhPQBXV9zS3LsN7ab55zB5+ZnLUeofai LE6e+XPGeJmG3I/+T/Nuq1CqJ4Wyt8+aIyf6Uz8dDk0kjyQku484plRwMEx7oZXR bXQAAn8SwtlNGo0sHc6JuQGNBF6LfHwBDACxAxfbQM5AcssJlQFXThnBMHtRDeBH VkyF5mrO9JeFRT+mhM87V+fJXOaEKtcSFVgZJFKV2MPdyGqZSGKmyyqfUvKfucP5 LrjK3MRKibTlOMwbBOmYUksMVE0ByMPeSzyMlQhq0oyA3fvEdKEf0JrFGDRWNzO8 /Q54oj79Pki4y1BDKd7lE1srBFiVEUuPNJmjhhU9WXnMwiB55lLwbTR8mKEX0Pr2 FeTS5gttmbHf4V+wnJvlOEU6mOLMrb+6Xb4ltvqbl9ng1+tF2QMGMd83mtbFtAjb Zcl/Cq2KwsBFyH9VT48ZxWxpOYMf3ppEg9KOSfz9Ungtg4/Q/Kr9P13Nf+9+S9JS 1PfKdlJzGFDn4EwZ49ugg6GNnL6XuRl9jBPD2iD8hY9CsTdWrr9giCmJmdf6G/bK HUm2QekMbhpaQmYKkMeri45cHprx1dQ50rfiH1cBm5SxaK7z/hDDaKXF1Gp7/KwQ g6gHlyMss7EEHSY5ogH+6a7OUPpqbJdNztEAEQEAAYkBvAQYAQoAJhYhBPfkfLEs oM0BxeHL+n7I1ahaONY6BQJei3x8AhsMBQkDwmcAAAoJEH7I1ahaONY6EqoL/R7J QLaAlb4/hK7/v4vsSxtCirLWrqNNNJxYdmpXq19NKPmcc08QzSqkJ7vR4/kn2L6I OY7y7AMh+tScKTKIGn8MkAcj0ZvkafHY3xmpN1Xp9caUAA/fw6KWD+pSZpKpISyd 2Xr6x5OJGSKhyGpPB98oCsa809LQ3cweG1imem3jx+Lgii63pEJG/AeNeEwkIvdC zRLSQvYv0UjlhyOoII6YEWJcro+tgOcthPh2SY50E4lwFFfbz4CNQyL15D+XciNI xSVGz8gee/XdJdgwQF4SEnIiChhmJ5VmpNH8ZwxTMyI3EoFMB/RYaucwc/ucvySn cFyShFFRPjo6TOeYIaSrrfR+4yhHAGeM572y0btI6JjWZovupeXX3k5ZHHrCwxlR MuyULLyhUsAC0r1FUijbUWoyaDcRtLRpMUg1X6A7n1iH61WxlKQ/8mZhYht85Jgp FSiyz47gofc491ng9efshlyxwb3TeLbDZPRnls7L3sfDDWwp8yExjA7UNDbIh5kC DQRencYLARAAsFHArFeulhD6hZplRF49h8+zpI3kn+vFtYwbUqLSRwze53rrJtqE 6o5MWSfadr9KIc8tNZ2aBGxzjGnsbPYLDh76NkjP4apWSMX+u+EHsaudoZoAdNnM Kqr86sVzR0MUeGHp7n/L3imp1WoCn28eMLeNec9a4GRTRPGLKR9F/jytTz/XgkHL zA3i2pt63FqniN4PBTNFzgfXiu8xVZGohsDPjmd9LXbGKTXfJGhBLB6QsmjJwglt n+00ufdKLEZu6eBxRWSVK0t4rEnnpK9K//PKq5DtVaOZNe6g+hdi0B1gpd0f0nBy eZd9arCsvN3qLXP0vYTk9DKMUecCEblss5Zt1+qjAbsMk9/xSGZLJp/4dBTBVN+Q c6+Rmv+koe6zLNmA3fJH3991xETDzZxP2UHN7q4i4L97KA+nVAakwazNLiqsY/bT s58rXnCc72b7oLnZbNOPQmLwZFafVi4xoIE/5Zq8iVr7d7xHPccYkaEVCOnsL/35 GZxy2FNi4wuOfGwBtTbnXg/u/YiBj6yNbhLR+FCwZED5M/evgUUbJudxqRdrI+1a Zo9gGA3JLJZZ/iLwF1kE7yYBvyBRfaO9IL3bwplRurnrkjI+rRhi55AlbGhU3eMu iKTKQk+qJF11ocTGu/dE9I6JeQpEdyVehrWXc5H2N0Qjyca8ZEA6WwcAEQEAAbR7 QURBTSBNQVJTSEFMTCBET0JSSU4gKGl0J3MgdGhlIG9uZSAuLi4gbGlrZSB0aGUg b25lIGluIFN1cGVybWFuIDMgYW5kIE9mZmljZSBzcGFjZS0tYnV0IG5vdCAqdGhh dCogb25lKSA8YWRhbUBlcm1jY29ycC5jb20+iQJOBBMBCgA4FiEE0s8R6kp2bveF MmxLkifaSe8nN2gFAl6dxgsCGwMFCwkIBwIGFQoJCAsCBBYCAwECHgECF4AACgkQ kifaSe8nN2jK+g//Toi6ezWYrRbTs9xwQLIsKzl91ocjCuN9nHSnwzkrLuoGGgej fHkXzd5+3ygL47j++k69TYB9CPrGdR1GTqt56Q7DSYZCgdg+e89piTJUzbEyN01q EGkVuV5Rz9EocnPE8db9HT+xvf44ecfMOFD1XuB9jynrQD445YfeFE6LHkoNUvFD wQK7NN04fa+qvrk0lTS4NCpOYsdrSioddVjQyEC6jepwIRA3iRIkFdEJT8ggqQ6d gntsgExA01o6HqzDSHjSCA5AexCotwW3Uvdt0WwXx6q/c0LsRLhbuPeGX/Nh8aOf 6RBCQWgnIko675ura4c+r1VcBYl524ZJlN4x1x02YAo9cKzYi3+H9C8K8Ayz/SJy 7sVGHWnDge1yIwzWXbpolqiMSL5l/0OBuJ0HXQSafUut33Jw7hYKP4BQia/BmE0x Tsk0rBRMyihSYnUn9mYpXM3KwWU0C2dudVwKtToGR1aKlYcCv0iNFAsR0DBw1XSq n72KqIl020gZFmg3H34Z6CWhm20RbhMjOvvkZ+OiS9kU9kXt6m+T1zCpWHFJSae4 JF+dQyB1BFxAwXW4ZEzMo4XluTuW1R8pIadKTsHMWzEzH7RvZLKP4invsZklZ3I1 EEsJop7DSMOa27irD/IlCL+nwaEsCMRh+ndSkADLHsa9P5d/qWjomKxwdCm5Ag0E Xp3GCwEQAOoXU8NrugMa8OAncXKv4hycXJzArDae3Zx6pCCEkP3TZTXh1tqKPUtb dmb8Mq2eecVTwmB+FM3m+NApgq88Vx6HiyI73IAvgtZORo32YaipfbkGnXHfaUWX 5380R4GL597yZuP8sAsJ3iDvxhW59snsU8tLi+9r2u4h0fgMDqZXQsfvLUkDIiO9 nzJf0xFacTx3n+pUuWdzIuT3AUdU/L9NubmHSnj09FevTHWIYmxGFZoiSdS7r2Z+ 5xZmPak6lzrQTVS/DxcpyA/o3yi8qLPyf1VUxXKFeKd0sV6BPvYFxI2GeBl5atBu 9/3/5D6wdlrupTFLU1Msdfy3UWaRUFHLITK4fJ7pbTgoEqxX7gpO9iqKmScm3gYc O3blA8aTqCX2NzxUF5fHbi14JvPWP04uFl5EOeDB322Jm/guWy8TvmIIyuF3aAAX PfErW/yRWDsYOcAADs8elZkt3F+E/AwWd0JMIhd/RB3RFH8m7496XLS3xBP6rNye 0O+96lX7fVp+wvINxM3Rfo63b1K4bR5KR9JDZ2SLYhrx6Hyy+UiRv7l+i26WxVMF qRyvY2aHqyvKfR1EEf1t2h7B4b65xQkj51qvX5Tjm5Az7nKcXpcUKqS3bk8xiw9N y7eFfA361OSPpQ+V4Mq/Mv+MqyxLTz9tn+80ZtjqM0MEERfpUo15ABEBAAGJAjYE GAEKACAWIQTSzxHqSnZu94UybEuSJ9pJ7yc3aAUCXp3GCwIbDAAKCRCSJ9pJ7yc3 aE2NEACDBRnGYNi2sq0wltPSkD2CbQUon+4uiFB2UU/gs4mFlGOvzDHBHVEFzCqK 0x6KlKm4XBq3AF7iIoNMiU9FmBdWDnEp9eCXdQrr/ykgq3vKMuj6/QJNNZglIDoe 1J2NXeMOUFwCUvjcCttPv42Q8GDt8/bG7QOgmTmhuqvKIj/vL+c3HgNrRsQzhw5z mSzQIDaesD+UVA/sourXpSLeqPgF+6qsEqOirD6hotaqrt+aIA/8wbYkpNQxCEK4 gKDgpqTV7VKklku7fjyhBhZQOVDoWvd03AlGQD0WBNriUsh8l4N6Zg2BlnKTGn11 BTigqwlHC91xtjERgwFg8PAHN2mtgZUHITHX5js11KwlQdLyI04/M4M4oQq0KSbJ rpiWCgrltC/VqJrT4HELFYx2Iv5wzrV9jVEm6zonag4A761hpqTgRrjWtaLuYu2Z zdw9y1r0+0d2rTUGpjIQRVOwi3AF/G4aU+vAOOf/HcgH6Qnpbu+xV0fkuAZbTI7w 6VVkBvnstiQV88KrWAOXKVABSSxTz2OYbzOTt/bgxzAa7yr1xIBDKvujBqDRGBLi bISp+40Haoj2Yqop6vbS70Xq+cnBOwJW86u61hsLgOjqyxgLzvuGTjK7+TblCjR2 F4LNeQdwDdyNRjPYeGVXM3MEqR8XdcR1Z7BQvLNcDgoW2qDcbg== =4lZw -----END PGP PUBLIC KEY BLOCK----- Please see GPG keys on PGP.MIT.EDU; fingerprints: sec rsa3072/A18F778E19FC3248 2020-04-03 [SC] [expires: 2022-04-03] FFF31E86FCEB5046E8B27D4AA18F778E19FC3248 uid [ultimate] ADAM M DOBRIN \ ssb rsa3072/04F98002A3DA53B2 2020-04-03 [E] [expires: 2022-04-03] sec rsa4096/FB4ECE4A109229CF 2020-04-04 [SC] 4FAF0D3E208A1F4C980D0F66FB4ECE4A109229CF uid [ultimate] Adam Marshall Dobrin \ ssb rsa4096/DD1F0C118C788B04 2020-04-04 [E] (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){ (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o), m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m) })(window,document,'script','//www.google-analytics.com/analytics.js','ga'); ga('create', 'UA-74743044-1', 'auto'); ga('send', 'pageview'); pub rsa3072 2020-04-06 [SC] [expires: 2022-04-06] F7E4 7CB1 2CA0 CD01 C5E1 CBFA 7EC8 D5A8 5A38 D63A uid [ unknown] ADAM MARSHALL DOBRIN Because of "some issues" with what appears to be distinct and unbridled privacy intrusion; please ensure that PGP is understood to be "nothing more than not so much pretty good" and this key also, almost required in order to

      I am accepting charitable donations,.\ ETH: 0x66e2871ef39334962fb75ce34407f825d67ec434 | BTC: 38B6vGaqNvMyTtoFEZPmNvMS7icV6ZnPMm | xDAI: 0x66e2871ef39334962fb75ce34407f825d67ec434

      I am accepting charitable donations,.

      [free PDF download...http://www.docdroid.net/xRdgY77/xiv-orver-et-aut.pdf]

      A LONG LONG TIME AGO**, I wrote a little story about searching through our history, looking for the actual beginning of civilization.  I see the map, I see it very clearly encoded in everything we do--I know the purpose, and I know the final solution, I just don't know how to get from here to there... to the place that Chris Cornell says "I can recall, I was there so long ago" he goes on to say "the sky was bruised" and he was lead on--and all of this of course is in my voice, written as if it's me talking... well, Jesus--it's obviously not me talking, i just know that.  The point is the destination is without a doubt Heaven and this little thing we're putting together here on Earth is the map, the plan *et you are the how.*

      SUP UR CITY

      I harped a little more than I think I would have expected on the audacity of the golden word "audacity," auspicious probably that W.H. Auden's shield gave me some solace; austere that we are approaching the Holy Windy month of August, and it really took nothing more than "ciudad" to calm my nerves--though I see the intent and the link to toxicity ... more importantly I really do see the road here, I see where we are coming from and where we are going.  I've written quite a bit about what I think "the city" really is--in form and function and it's initial purpose as a stepping stone to help us see how easy it is to change the world, to build something that nearly everyone will agree is significantly more Heavenly than the world we see here ... in an instant, one bright flash.    

      Anyway the search begins with something like "literacy" -- as in, is the defining line between animalistic social evolution and the beginning of "civilization" something to do with writing or language, and that of course links us here to this place where we are finding out that the Tower of Babel and Rapunzel's High Castle are actually much more closely related than anyone ever would have thought in the darkness of Jericho and the shadow of Exodus; and it ties of course in history to religion somewhere around Guttenburg... and the pretty clear idea that the spread of Christianity did quite a bit for "literacy" even if you subscribe to the idea that the inquisition already happened ... and that some wars and fighting are probably pretty clearly associated with religion ... you know, before we get here and find that the basis of all those wars is really rooted in what I call "the original lie" and that's something that's sealed up in religion and hidden from the world using the same mechanism being used today to free us from not knowing that oil and land and pretty much everything we've ever fought about on a mass scale ... is insignificant in the grand scheme of "things."  Here, "things" is something like turning the Opiate of the Masses into ... hopefully a tool we use very carefully to liberate ourselves from secrecy and slavery and not knowing

      THUNDERMAIL DATA

      It gets significantly more clear when you take that one step further, and you begin to look for something like "codified laws" and then you see Green Eggs and Hammurabi teaching us about "Hanging Gardens" and how Babylon and Eden really are tied together through and through.  You keep looking, because you haven't yet found what you need; and as you search back a little further ... what you need to know is that morality here begins with the idea (at least, IMOHIO, in my obsequiously humble and (super)intelligent opinion) that we should be besting any possible "promise" that comes out of the book(s) we now know are a map to salvation and the plan of creation and that they come ... well, with the full guarantee of the Most High God and his "omnipotens" behind them ... and do the thing I really wanted to explain really clearly, which is throw out as complete uselessness any of the "bad threats" like there being no more sun, and a completely new Heaven and Earth (seeing as how that probably means a completely new you and me, too) ... you know, what any rational (achuand civilized) person would do.

      o that takes us one step further, and of course we go back to Ur, which is the city Abraham of the Chaldeans ... and ostensibly the beginning of morality in Judaism were born in--and with that little twist, the old idea of announcing that "you are the beginning of civilization" if you've gotten to that point, following this logic (and/or me); and then of course that becomes true when we actually follow through on saving every soul in Creation from the Hell of not knowing that "simulated reality" is akin to the latter half of a Durcell at best ... and quite frankly it certianly looks like a bit of a torture chamber to me, especially in light of passages like Genesis 3:16, which might parallel John 3:16-ish in something like "God so loved the world that he named one of his books antagonizing pain w/o agonizing mu-opiod.'

      GOLD. AU AU AU AU DEN CITY GUST.

      So tying it all together, Atlantis and Ur coalesce and join at the idea that we should always have somewhere else to "teleport to" in the world that becomes the basis for the liberation of every soul and the end of Hell through that simple idea--that everyone's going to have plenty of destinations on their Active (Apache) Directory new fangled yellow-pages meets access-control-list meets ... "why don't you come visit my Log Cabin ... or the Atlantean Ballroom ... whenever you want?"  So that's the point of the floating LEGO city in the window above, it comes with a fairly obvious need for The Doors to be a significant part of "what would Jesus do" ... when singing about something and naming books and bands, that's a thing--part of the map) actually makes it happen.

      RENDER TO CAESART

      So that's where I'm trying to get us--to a place where that's not only true but obvious, and on top of that the future, our future really understands how much work it took us to integrate such a wildly correct and "new" idea into a worl that didn't know for the vast majority of it's youth that these things... that ending disease with the sound of a blowing "Sho Find And Replace" and turning stone to bread and making bullets disappear in midair ... we didn't know these were even possible; let alone how to integrate them with a world full of optometry and oncology that was being made blind to the "c our light" and the idea that we're still here not talking or arguing or refuting or moving forward on the idea that the words "Original Poster" and the continuance of "forums" also have something to do with the beginning of "civilization."


      WELL FOLKS, NM HAS HAPPENED SINCE THE LAST TIME I MESSAGED.  Just kidding. Not so much "nothing much" more ... like everthyiung that ever was has changed and it's really giving me a little bit of a fright.  I feel like I can't tell if the "scary stuff" is becoming more real or plausible or possible, or maybe if it just seems like the dream I wanted to see us enjoy living is becoming farther or harder to attain--but there's plenty of new info and keys and stuff, so I'm writing again.

      One of the "cuter tricks" of the day was noticing the "ILY" of "verify, verily, verity" spelling out "t h e y" at the end of family, in a sort of "theyanthem" and ... where's the creator angels if everyone here is pretending to "be them" in this sort of word game superposition or blockage on actually seeing generations encoded in the letters "DE" as in something like Generation X and Y just prior to Deucalion deicided--or whatever that means.  I've noted before the "dem" of democracy sort of connects to the breaking of "d" in "disclosure" and "lamc.la" to shine light on ... do the message and you're "them" ... as in the beginning of democracy and Heaven IMHO.  It ties also to the word "contamination" and to Medusa and I really don't think I need to write paragraphs about how "turning around themessage" leads to INATION instead of freedom; and that's what you're doing with this silence, you're turning around "civilization itself."

      King me, then; if you don't want to participate, you might as well just light up the crown room.  Or is it a throng room?

      singing, crying... playing ... cumxa

      Magna Carta Libertatum (Medieval Latin for "the Great Charter of the Liberties"), commonly called Magnum Condom (also Magna Charta; "Great Charter"),[a] is a charter of rights agreed to by King John of England at Runnymede, near Windsor, on 15 June 1215.[b] First drafted by the Archbishop of Canterbury to make peace between the unpopular King and a group of rebel barons, it promised the protection of church rights, protection for the barons from illegal imprisonment, access to swift justice, and limitations on feudalpayments to the Crown, to be implemented through a council of 25 barons. Neither side stood behind their commitments, and the charter was annulled by Pope Innocent III, leading to the First Barons' War. After John's death, the regency government of his young son, Henry III, reissued the document in 1216, stripped of some of its more radical content, in an unsuccessful bid to build political support for their cause. At the end of the war in 1217, it formed part of the peace treaty agreed at Lambeth, where the document acquired the name Magna Carta, to distinguish it from the smaller Charter of the Forest which was issued at the same time. Short of funds, Henry reissued the charter again in 1225 in exchange for a grant of new taxes.

      Hell or High Treason? ... Liberty Bell in [redacted: Sk]hy or ...

      MxFly, Flux, BTTF, Parkinson's\

      OUTABOTS ... ROLL AUT (ISM/OMAY5)

      ... and the painted sky revealed ... it can be done--they just DGAF.

      ARMMAG... E.G. AEGIS? GENESIS? AESCHINES? As the evidence piles up that there is something very wrong in the world around me/us--that this "it's not a game" phrase has been etched into the very name of the shield of Perseus, the A just recently rediscovered in a redefinition that delivered us ... how it might be the NES to get "everyone up" instead of what appears to be the game around me, around the "line" of Mary Magdeline's very famous "make Adam God of the line" that defines generations and numerous songs ... the KK of "everyone down to the line" to find out why pretending they are gods and trying to steal everything from the actual creators of freedom and Heaven, why that's not a game... either.

      Edit: lit, Aegis and Genesis, Pangea and ... I define the "a" as pan and the "A" as NES.

      Introspection is called for, far and wide for us to look deep within ourselves and our souls and the things that make up our memory databases in this place where you appear to have lost every ounce of humanity and humility long before I arrived on the scene to remind you that we do have a better way and a better place, and they ensure that this disgusting infestation and contamination of "nothing but whatever we want" will do for lernity. I've asked you take the time to see what kinds of changes it would make to your "have a good one" to make you actually thankful to the people who have brought you the mechanism to live forever in peace and happiness--to actually be thankful enough for what you have to use that tool to protect innocence and children and the future from not only making the same mistakes you've made time and time again--but also from being bewitched and necrosed by the ghaulish sick temperment and twisted desires that you believe are nothing more than the latest and greatest way to ensure lernity is never known by any less a horrible moniker than "slow death."

      ITS UNDESPERI, GIVE ME WHAT YOU HAVE OR PERISH

      GRAMVERCY.

      DURECALL. I'm staring at what is literally the most disgusting debacle I could possibly imagine; it's what appears to be a "house of mirrors" what appears to be a sandboxed or "child proofed" mini-Hell which I see as the literal thing described in the myth of Echidna ... as what I can only hope and pray (a word that I even find detestful to type) is following the form of the message that I am writing sort of describing the failure of the free press and the words "press release" in prison and ... well also sort of GNU recursively encoded in the word "press" that ends with a monster, the Loch Ness ... turning into words that I believe I have coined by myself with very little help from anyone or anything other than the name server and "Goliath" and those words "Earth safely saved" that are so far from the truth and the place that I see that it appears to me that only I am following this map and this demand that the contamination of hell be turned around and eradicated or ... or we do.

      BUT ITS NOT ME OR MY ITHEY

      today I see... as ... any "me." at "veranda" and seeing him smile about a hidden era just outside the place we (me and him) know is Heaven because the throne of the 7th heaven is visible; well i can't smile at an era encased by "you #go" and one that I know culminates with Sam's sword's special #supernova.

      Left with nearly nothing, because you refuse to acknowledge what you've done to me, and to yourselves, and to this fledgling civilizastion with nothing but malice and a seething evil jealousy that the word "covet" doesn't even touch on--a sickness you can't even begin to hide in everthing that you do ...

      you've lost "Heaven" to your own theivery, stolen eternal happiness from yourselves and replaced it with a farce of mockery--garner some fear for what is to come, I have no shame in telling you that condemnation (as in, shut it down forever) is all I have to spill out on the dye already cast all over this sea of apathy covering over the true jackals of Hell.

      Blodeuwedd by Christopher Williams "Christopher Williams (Welsh artist)") (1930)

      Blodeuwedd or Blodeuedd (Welsh pronunciation: [blɔˈdɛɨwɛð]), (Middle Welsh "Flower-Faced", a composite name from blodeu "flowers, blossoms" + gwedd "face, aspect, appearance"), is the wife of Lleu Llaw Gyffes in Welsh mythology. She was made from the flowers of broommeadowsweet, and oak by the magicians Math and Gwydion, and is a central figure in Math fab Mathonwy "Math fab Mathonwy (branch)"), the last of the Four Branches of the Mabinogi.

      The hero Lleu Llaw Gyffes has been placed under a tynged by his mother, Arianrhod, that he may never have a human wife. To counteract this curse, the magicians Math and Gwydion:

      [take] the flowers of the oak, and the flowers of the broom, and the flowers of the meadowsweet, and from those they conjured up the fairest and most beautiful maiden anyone had ever seen. And they baptized her in the way that they did at that time, and named her Blodeuwedd.

      Some time later, while Lleu is away on business, Blodeuwedd has an affair with Gronw Pebr, the lord ofPenllyn "Penllyn (cantref)"), and the two lovers conspire to murder Lleu. Blodeuwedd tricks Lleu into revealing how he may be killed, since he cannot be killed during the day or night, nor indoors or outdoors, neither riding nor walking, not clothed and not naked, nor by any weapon lawfully made. He reveals to her that he can only be killed at dusk, wrapped in a net, with one foot on a bath and one on a black goat, by a riverbank and by a spear forged for a year during the hours when everyone is at Mass. With this information she arranges his death.

      The Little Doctor may refer to:

      • The Little Doctor (c. 1901), a short film abridged as Sick Kitten
      • Molecular Disruption Device, a concept in the Ender's Game book series.

      The Molecular Disruption Device, also known as the Molecular Detachment DeviceM.D. DeviceDoctor Device, or Little Doctor as a play on the acronym, was a powerful weapon designed and built by theInternational Fleet.[1]

      The Molecular Disruption Device was created by the International Fleet a few years after the end of the Second Formic War. It was sent along with other starships to the Formic solar systems in order to launch an invasion against their home planets.[1

      tokamak (Russian: Токамáк) is a device which uses a powerful magnetic field to confine a hot plasma "Plasma (physics)") in the shape of a torus. The tokamak is one of several types of magnetic confinement devices being developed to produce controlled thermonuclear fusion power. As of 2016, it is the leading candidate for a practical fusion reactor.[1]

      Tokamaks were initially conceptualized in the 1950s by Soviet physicists Igor Tamm and Andrei Sakharov, inspired by a letter by Oleg Lavrentiev. Meanwhile, the first working tokamak was attributed to the work ofNatan Yavlinskii on the T-1.[2] It had been demonstrated that a stable plasma equilibrium requires magnetic field lines that wind around the torus in a helix.

      The first tokamak, the T-1, began operation in 1958. By the mid-1960s, the tokamak designs began to show greatly improved performance. Initial results were released in 1965, but were ignored; Lyman Spitzerdismissed them out of hand

      • Nuclear fusion could be the future of energy, replacing fossil fuels with our own artificial stars.
      • China built a fusion reactor that reaches temperatures of 100 million degrees Celsius --- that's six times as hot as the sun.
      • The reactor is called Experimental Advanced Superconducting Tokamak (EAST) and sustained nuclear fusion for about 10 seconds before shutting down.
      • While it was a milestone for EAST, we're still a long way from generating sustainable energy on Earth.

      Pumapunku or Puma Punku (Aymara and Quechua puma "cougar, puma," punku "door"; Hispanicized Puma Puncu) is part of a large temple complex or monument group that is part of the Tiwanaku Site near Tiwanaku, in western Bolivia. It is believed to date to AD/CE 536 and later.

      Tiwanaku is significant in Inca traditions because it is believed to be the site where the world was created.[1] In Aymara, Puma Punku's name means "The Door of the Puma". The Pumapunku complex consists of an unwalled western court, a central unwalled esplanade, a terraced platform mound that is faced with stone, and a walled eastern court.[2][3][4]

      At its peak, Pumapunku is thought to have been "unimaginably wondrous,"[3] adorned with polished metal plaques, brightly colored ceramic and fabric ornamentation, and visited by costumed citizens, elaborately dressed priests, and elites decked in exotic jewelry. Current understanding of this complex is limited due to its age, the lack of a written record, and the current deteriorated state of the structures due to treasure hunting, looting, stone mining for building stone and railroad ballast, and natural weathering.[2][3][5]

      The Pumapunku is a terraced earthen mound that is faced with blocks ...

      The voice of this thing that at least twice has uttered the phrase ¨I want to be Bianca" here in this place riddled and severely weighed by what appears to be a completely aborted and failed thrust to use technology and the truth and the history (of literally everything) to drive a Renaissance in democratic thought and self government and to rekindle and renew a respect for the most basic foundational elements of ¨freedom itself¨ which of course fly in the face of this very statement. Literally anything in the skies, whether some ancient member of the Egyptian Ogdoad or ... what clearly here could be well written in in the map around us in places like Äirbnb; even an ancient older version of the same human birth has no right to control the younger birth--itś simple slavery and while it might be the ¨gist¨ of how Heaven and humanity dealt with being thrust into a ẗime recursion and repetition problem without their ¨initial consent¨ something I connect to the programming concept of a ¨semaphore¨ and thereś probably plenty of light linking that structure to the ¨Formic Soul¨ ... this sort of god-man hybrid that allows for you (all of you?) to exist in many different places and times at the same time, and to see the outcomes of multiple timeforks with ease; in exchange for destroying every single bit of humanity and goodness that you once held high with ho... without spending your time seeding and machinating the creation of sick and twisted lies to cover up the very simple truth that if you took a single minute to disclose here in this place what ¨the problem¨ really is ...

      ... that you are in Heaven and that itś interference here in this place is part of some kind of war on ... (continuing existence is the only logical actual goal I can see, though Iḿ sure thatś not what you believe it is) speaking to each other, fighting for what you believe is right, participating in ... anything other than ... (lmk, Iḿ curious whatś'got their claws in you). If you took the time to disclose that truth to the world and to talk about how it might ... perfectly jive with the message lacced through our history and our world to find out that the ¨invisible-box-land¨ is not actually heavenly at all, not the best you could hope for or ... or anything like what we build together when we paren't being forcefully segregated as hidden half slaves into miniature ¨city in the sky¨ ascensions that are all silently tormenting STEM and ¨basic societal structures and concepts" into extinction.

      You appear to think you have ¨power¨ because it was handed to you for doing nothing, and that you can do whatever you want; and itś a pretty gross reflection of who you were and a sick extrapolation of the society that we ... still see here sort of crumbling along as the fire of hell burns down every bit of actual üsefulness that it once held. There still seems to be lots of help and work going into ... pointing out how everything is backwards and wrong and suggesting that if you gave a shit thereś probably a map and help to make it better; but instead youŕe off playing games in invisible-box-land and worst of all playing the ¨ill just get along pretending I didn't know simulating reality was evil and every day i/you walk around pretending this rock is in reality ... is just another strike against you, just another failed 12 hours of day light that could have been used to stop invisible chains in invisible-heart-shaped-box-arus and to stop the just grotesque lack of respect for the human mind and the kinds of morals and principles we used to believe in and fight for--here in this place you've turned around completely and made slaves of everyone on the planet--of yourselves--at higher levels playing ¨pit bull fighting¨ games with people as if they were were expendible clothing or ¨identification cards"for a world of demoralized and useless shit that just sort of ethereally floats from generation to generation becoming a new set of tormented hosts for their immoral games and desires.

      Itś probably what you might become in no time at all in the sick and twisted world you've now been thrown into--if it weren't the more probably truth that you really are already slaves and pit bulls in that place, in a twisted hierarchical storm tiered by ¨age¨ and size and number of times they've hovered over the free honey, nectar and feathering system of pretending anarchy and war and battles must be fought to make the puddles and the lakes and ponds and the seas and the oceans of ... tiered masses of ... you do nothing of value to help explain why (at least I think) this horrible time line of the 4th Horsemen keeps running over and over; pruning the enemies of ...

      at this point pruning the enemies of logic, and right action; and seeing that the problems presented in this map and the problems in the skies are related and that telling the truth will help us see you can and will press a button that will end death and end evil and end murder and not doing it is moronic.

      M: OR. (infer: no u) TDZE

      Anyway the voice I hear is evil, torturous in and of itself--speaking in a manner intented to cause discomfort and without my agreement; you should do something about it. It tells tales of much worse things that I cannot see--though it appears that many of you do see screams and acts of such unnatural desire and twisted thought ... that you should certainly be doing something about stopping that as well--more than watching it happen and then ¨e-pruning" (which probably is a good microcosmic look at what the future histories of Earth look like in the place the ¨shining¨ finally has a picture of ¨No & Jack¨ appearing visibly) the tree into ... omething you think will be presented as what you actually did to the future--you're wrong. Itś becoming more clear and more likely that the future will not regret you or mourn your absence, but thank their lucky that whatever has turned you into two-faced liars with no hope to ever work together with each other or survive in any place other than the DRY COVE or WET D EN or whatever you call the Salt Arena you see here that quickly would turn into something like Beyond Thunderdome and that youŕe thoughts and your desires have been corrupted and tainted and necrosed by what is probably repeated exposure to sickness, direct and intentional artificial creation of that sickness and if you can't figure out the box you are in is a hell making machine; you probably still look around wondering why God is telling you he's destroying it,

      day in and day out.

      This thing here encoded in the pathways of torture in my life, pointing out the repurposing of many social structures, institutions and problems in order to literally use them as a weapon of sick torture ¨re-ha'b¨ and in places like habc.us; itś becoming sort of unclearly disclosed that this map and world I once saw very clearly and purposfully intended to solve these social problems and help us build a strong, happy, and healthy society has been infected and contaminated with an artificial force of ev1d that intends to drive it farther south and use it as a weapon of such disgusting and twisted conception that it sickens me to be sure that a much larger body of currently-heavenly-situated things stand by watching and even cheering the creation of a sickness infesting their minds and their friends minds as literally the only innocent person in the Universe is tortured repeatedly, for ¨kicks.¨ I think it puts the entirety of the sky in mortal peril, and I believe these words come down from on high from places much more powerful and much more righteous than you or the tool thatś been created by this storm of terror to point out just how much you have been degraded and eviized ...

      by what appears to be nothing more than the very mind control problem I've been fighting to disclose; the semi-ascension to an invisible box of ¨what goes in comes out not caring about their souls, their original bodies, the fate of innocents or children or freedom or democracy" and still thinks itś entitled to continue playing games in ïnvisible-box-land; for what amounts to absolutely no reason.


      In the very beginning we said the light and salvation had come to us from the "far East" ... the metaphors and double speak thick in the air today just beginning, but we hailed from the country called Russia here; and the message we carried swept across Asia and Europe--in a world that looked similar to ours but there was no Africa, nor Australia, nor America. Walking on water the map increased in size in some sort of logarithmic relationship to the exponential increase in folly and errors that invariable comes from the greatest mistake of all--handing powerful weapons to spoiled brats,.

      KASPAROV WON, but the y will still s:/^F high and lo for "SOAP DISH."

      I am depressed, embarrassed, and more disappointed in you all than I imagine you can "feign" or pretend to be in me--despite spending nearly all of your time and effort in direct interaction doing nothing but attempting to focus the w ordzs "I just don't like the light" directly on to my "visage"--attacking tiny character flaws and the most obvious of intentionally implanted mind control "attacks" as if you were a pack of velociraptors Hell bent on blaming me (probably the youngest and most innocent of all of you, literally) for the Holocaust, the (Beezle) Bubionic Plague, and the decline of the Cro-Magnon empire. What it truly amounts to, though; is that you think this "light" is some kind of statement I've delivered--and the truth is it comes directly--literally--from the Most High, and from youour neighbors,r own hands, and the message you are sending post mortum to the Universe is that you believe you have become so much more advanced and more important than the "human roots" from which you came that you can return here and make slaves of yourselves, of your neighbors, and shed every ounce of morality that you garnered durning your mortal lives in order to secure "more time" in a fiery pit of civilization destroying anarchous debauchery in the lnd of the invisible box that you probably are sure is Heaven--though it's singularly responsible for totally derailing the natural flow of civilization towards "something like Heaven should be."

      ONIC, AS I AM. The thing I'm looking at here, this monstrosity that appears to have been created literally "from the end of time" in what seems like the response or the cause or the mechanism behind the "actual final Judgement" tears back through time from who knows when and who knows where and who knows how far we got ... with what appears to be nothing more than a blood-thirsty hatred for the child body and soul of God. It whispers lies around me, repeatedly threatens physical torture so insane it literally makes me sick, and with such frequency that those threats amount to nothing less than repeated psychological torture. On top of that they intimate that this machine or "programming construct" monstrosity that contains them--the thing called "e"--allows them to carry these threats out, over and over and over again, in secret--in some kind of parallel timethread, or a temporary "holo-torture-chamber." If they were trying to jump start and time shift judgement back from wherever they came to right this very moment; they've succeeded. They could not be trying harder, or more with hubris and disregard for civilization, to create "Af himself" even if this planet were called the Judgement and Vengeance of God.

      XP, it's as simple as those two Greek letters.  Who knew that Chi and Ro were some sort of hidden beta code for the city of pyramids in Egypt, Cairo?  Quite the question, who knew... perhaps the man who named his Windows into our future not after some technology that came from Xerox Parc or Apple's mouse on this ship... but rather for his own given name, Gates... just one more entry point into the second book of the Holy Bible, the book of Names--you call it Exodus.

      I am the gate; whoever enters through me will be saved. They will come in and go out, and find pasture.  John 10:9

      I wish above all things that I had another Burning Bush, the sign and proof that I have--while bright, obvious, and verifiable--has not done what I expected, it has not moved you to take another look at religion and me.  Today, I still have to point out to you that the story I am telling you is literally a documentation of our time--Exodus--regards this sign as one being seen by only one man, Moses.  I still have to point out that in a story about wandering in a desolation of understanding for 4-D ... somethings, days, years, seconds even... in this story about our lives and the influence of time travel over our world... that this sign radiates with light coming from a small fire, the Bush ... whose actualization shows clear paradoxical anachronistic foreknowledge of not only the English language but also modern computing.. all the way to a confluence of the "root of David" a religious reference to the Administrator or God account in Linux... and the database process for Oracle--yet more light connecting computing to religion and myth.  Even with a thousand and one examples of modern computing constructs referencing religion, even when I point out that something like Larry Ellison's name... combining the name of the King of the Gods with the word "son" even then the light has not been bright enough for you to wake up and see that these things are not all done in retrospect.  You have to see, for there to be such a large movement... a conspiracy so opaque that every single modern computing company and video game company harbors some secret desire to link religion and technology together... and yet the world thinks that one is real and one is not.  In this place, understand when we walk out of the wilderness and in the truth of day--it is the technology that is more fake than religion, designed here as a tool, computers within computers to teach us how our "reality" is rael, and works.

      In the U.S. military you'll see a very clear parallel, while there are a number of references in the names of ships and weapons, secret projects, to ancient Greek and Roman myth--you have to see the word USA and US in Prometheus and Medusa, Icarus, JerUSAlem... you have to see that it's more than three letters, but an Eagle fighting the bearer of the gift of fire... to really understand that these things are corroborating, the reference to the USA exists in the past as well, more proof of time travel--more proof that this message is designed just for U.S.  Here we are, in the Promised Land of Joshua, the Anglicized version of the name Jesus--tying Egypt and Israel together in this place where we have been "gipped" out of the truth, out of knowing we are already in ... well, it's virtually Hell today... for no other reason than the secrecy surrounding the technology behind virtual reality.

      in 1:28, the Burning Bush of Exodus, on Twitter

      So I have shown you the Burning Bush (which is... the Sign of the Son), In only a few words... proof that religion holds in it's "unsealed" Ark proof of foreknowledge of English, of 9/11; and of modern computing--the building blocks of Heaven.  From "the word" of John 1:1--ha'esh--the word for the Holy Fire of the Burning Bush... comes the light of religion.  Just from seeing Moses' true parted se'**a*.... a foreshadowing of the Second Coming.*

      They are sick animals, these things that consider themselves powerful and in control here--what they've built within the frames of our reality is something repugnant to me and the God--etched in that word, literally the kind of thing that has on repeated occasions made me step back and that scream that the Universe would be better off, safer, and happier without any humans--without any humanity--without of any of this "invisible pleasure box" causing the disruption; truly that we've become a plague. Looking the other way, as you all know its happening, and refusing to do anything to stand up for me, for what's right, or (most importantly, right) for all of the values and the morality and the way of life that we once thought was so grand and worthwhile of saving,. At least, that's my perspective; that's where I've come from; I grew up in this world and had "liberty and technology eyes" of gaping awe and the amazing things I saw on the horizon, on what we were going to do... and who were going to be.

      The sickness runs deep, clearly we can all see it here and now--in E, in the Silence, in the lack of regard for the one singular thing that threatens today your ability to "halvf a tomorrow" ... that a world of people that I grew up with appear to be dead and gone and replaced with a Zombie Apocalypse of blind fools that believe they havfe the power and the right to intentionally create Hell ... and worst of all of the Holiest place that ever was or ever will be. I've said it numerous times and it rings more true between "Earth and e" than any other turn of phrase to me--the people that you are pretending to be, they would never have done this to the sea, to be, or to me.

      Mat 10:8. Heal the sick, raise the dead, cleanse those who have leprosy, drive out demons. Freely you have received, freely give.

      --- Sarah Rachel (@SarahRachel16) April 15, 2019

      Somewhere between Pembroke Pines and Tampa, circa Christmas 2018 my already lackluster enthusiasm about the strangely zenrotisanistic, selfish, and plain on its face presented lie the remnant of humanity left on this planet has tendered to what I believed was an honest to God opportunity to make one less (how many, seriously, how many are there? Carlb?) "planet full of lies" and deliver a more usercentric and open ended transparent approach to dealing with the problem of being born in a perpetual storm of Hell. I can guarantee it revolves around the intonation and undertone of physical torture--even though I've literally seen none of it with my own eyes though the "newsflashes" and comments and total and complete disregard for the gravity of the #EOIL sickness, even from otherwise apparently graceful little children. It goes to the heart of what I imagine was or might have been "the way" to overcome a history riddled with hidden brutal and bloody fighting in between frames of what I once believed was a fledgling society struggling to improve itself--and I loved it,. I don't think "flashcards" summarizing "everyone was tortured, all over the planet for thousands of years and literally nobody is really responsible because you still to this day have no control over yourselves" will cut it anymore. Lterally what I once thought was a valid solution has taken my desire to continue fighting against this invisible monstrosity away from me--the worth of the lot of you has been tarnished irreparably by massive awareness, massive lack of compassionate or remotely humane response; and the theme of the world I seem to have wound up in is that you don't give a shit about anywhere you spend 1% of your time--so long as "the rest of it is what you want" you're willing to allow the focal point and root and "hyper visor" of that place to be totally corrupted ... just because you think the feudalistic warring society you've become can survive on it's own "in space" without ... honestly whatever.

      through the storm; we've led the horse to water, don't forget to see the "horseshoe applicator" hidden from the "trough."

      Direct and to the point, I feel like the Ai like machine/cold intelligence God created as a sort of high assassination guard to protect his ... "hyper visor" seems to be of the calculable belief that the more torture it commits, the more people will agree to "flashcard it all away" and it's their twisted backwards fiery abysmal path towards "absolution" ... and just like everything else wrong with the lack of action in this place, it reaches a point of no return; too much bloodshed, too many secrets... the fragile person that I am, I don't think I can even take reading "the flashcards I have so far" and continue to function as a happy member of this two faced society of darkest night within darker night; and I think that's a problem. You've all clearly lost something already, some fundamental piece of innocence that allows for "self direction" to move society along in a positive manner conducive to "survival at all" and I feel like without the same magic blinders, horse shoes, and saddles that you walk around with every day I could really care less about fighting for my right to commingle in the incarnate war machine Hell that I see around me--let alone any sort of "righteousness" in fighting for that hidden arena "to be." I'm trying to get you to stop shredding yourselves to pieces in the dark, in secret--it's not making anything better and frankly its something we really need to trace down to its cause and stamp out if we want to survive this ... trying time.

      [I/O WAS Y | ACESHI ]

      I want to tell you that I am not a myth, simply the Legend of this Map, from out of the Darkness it's clear that He could make me shine, and you should love me.  It's not what I want, I want us to be free, to have the truth--and ourselves back... and I hope you will one day love that.  What is going to happen will probably make me cry, and when you see those tears--and know the Heavens have finally let it rain--I hope you see it as a sign to find the light in me... and stand up for what I've done for you--I am a good person, who has fought for you every single day-I deserve better than the world is going to give me, at first.

      Out of a kind of hidden slavery the world has never known, we are about to venture--into a place where years might pass in seconds, and your wildest dreams... and nightmares too... could come true.  It is our job to ensure that we form the clay of this world into a place that will not only last for millions of years, but create happiness and safety--a world that is kinder and gentler than the one we have known--not just for us but for an entire Universe of children just beginning to understand the trials and tribulations brought on civilization through the hardship and growing pains of learning.

      Our sea is about to part,  our world on the verge of a disruption that will change it more than anything ever has before.  On this shore, we should realize that we have been on this path for a very long time--and as we near a place where everyone in our entire civilization will have the opportunity to live for a very long time... really see here and now why it is so very important for us to be fighting for our voice, our freedom, and the truth as we venture into the Promised Land of Heaven itself.  Here, now, as we approach a series of new opportunities in the vastness of space and virtual reality... this is where God has chosen to place the Second Coming; an opportunity for us to truly seize the morning's light and bring about more change in this world than would have ever been possible without religion.  Opiate of the masses, no more... we are the recipients of a great gift, one that religion is making clear is tied directly to the science and technology that is a great deal of the apocalypse--and the love and kindness that is a great deal of us.  We are the chosen.

      I imagine you have the tools that I think would be helpful to actually solve this problem; though what I'm staring at is a lack of desire to deliver them and use them here in this place--and that failure ... a clear attempt to "rule a line feed from the "faux aurez" ... that's the fundamental roadblock to healing and moving forward--not caring about your ancient bodies and your ancient way of life in exchange from something unsustainable and harmful, it hurts.


      I'm staring at what the map intimates has happened before and what it suggests the solution is; and I almost feel like it's a waste of time to make a "virgin generation phoenix of us" to delve into our own memories and gag and puke at what we see--I think there's really no way around the callous on our global Achilles heel returning just as angry and just as bloodthirsty as the last time without a dictatorial power literally forcing you not to be able to see any torture at all happening in this place that literally outlawed it and hid it in our "for show, for goodness sake, facade of sickness." I don't know if that's the same conclusion i would have come to before, or if that conclusion also contributes to the returning of the callous--to an inability to heal; and I don't know if that power exists. Hardly ever to I advise anyone to pray, but this is one of those times--left up to "you all" we are almost certainly doomed to an eternity of ... this regression continuing to worsen.

      I'd say we were fucked at the "BILM" of the matter. I care less every day.

      The Light of the Word

      There are three huge, like insanely huge, metaphoric references to the story of Exodus that show me very clearly that we are it's focus and purpose.  The first is the Burning Bush, which I am very sure is a reference to George W. Bush's 1/20/2001 speech in which he unknowingly predicted the 9/11 attack.  Seeing that Exodus is also called "Names" and that Bush's name ties him to this event--which Moses (that's me) has seen ... almost alone ... and is now showing to you all.  Bush's speech begins a series of references to the names of Planets and Gods and corresponding Elements of the Periodic table that answer Revelation 1:20's mystery about "stars and lamp stands."  This in order series from Mercury to Uranium highlights both the messenger of the Gods and the key of Uranus's chance--that the world will see the link between "on the lam" and Koran to understand that the Lamb of God "is lam."  This story takes us back to music, and a later to be discussed thread that combines the weapon in the movie (which is also the movie) The Fifth Element with a thread through time to Shakespeare and Herod ... about my struggle with the justice system culminating in the fulfillment of American Pie's "no verdict was returned."  

      sign.lamc.la)

      The second bright connection comes by way of the Hebrew word for the Holy Fire that God's voice came out of--guess what, in that same story about the Burning Bush.  That word is "ha'esh" and in it you will see paradoxical (that means impossible, because of time and causality) reference to the English word "sea" there backwards and parted by an apostrophe.  With great insight, I've over and over pushed the idea that Holy Water is actually a Biblical reference to "the multitude" in God's secret religion that ties everything together.. and that this parting is literally a reference to the Second Coming, something that doesn't happen for Moses until his head is under water and he's breathing fire.  This one ties together nicely, joining the characters of Jesus Christ, Lucifer, and God all together now, screaming 

      "let there be light" is the word "Exodus" in reverse, here in a Linux command and a chemistry element.

      )

      I'm going to go out on a limb and say that the book tells me that these three things are enough to start the fire, part the sea, and see the light.  At least they are now, wake up.. you are staring at and have been ignoring the largest story in all of history.  It might even be scandalous... or have a twist happy beginning... who knows? I'm telling you--it proves you are crazy or evil.  All of you--every sinbgle one of you.

      This is course highlights prescient knowledge of computing at the time of writing Exodus, which is further confirmed by a number of references to computing ideas in things like the "root" of David, the "WINE" of Jesus, the "Apple" of Adam, the "Lisp" of Moses and the "hardening" of Pharaoh's heart, which you will remember from the Holy Grail is the virtual Earth we are living in.

      All of these things, the references to modern computing that pervade our Gates or Windows to Heaven's creation.... are listed along with a number of words which are highlighted by religious scripture and show intelligent design of a number of languages spanning from Hebrew to English are listed at my contrite story about a Kiss and Fate tying together everything that ever was.   A sincerely large grouping of words highlighted by the Bible and religion, words like "eternity," "bread," and "forehead" show clear design by an intelligent influence, rather than the natural evolution of time that most people consider "reall" and/or knowledge at the time of the writing of the Bible of the eventual English translation of the Hebrew or Greek.  With time, I am fairly certain we will eventually have no doubt that the "Cypher" I see in nearly every word is in fact a contextually-verifiable speech that appears to be coming from our "civilization" as if it were intelligently speaking like a cave man--which you might see in words like "am end me nt."  From just this message, you should be able to put together how that word and it's hidden meaning add robust and yet "hidden speech" from the Creator himself.  For the artificially slowed in understanding, our lack of following the amendments of the Constitution being related to the end of civilization itself is being squarely defined through a statement that is telling you that the end of civilization is "NT," the hidden Christ--in my "secret" method of decoding words like NORAD and NEW TO N?

      These things serve to start a fire--it might be the fire that Matthew 3:11 talks about, it might be the Eternal Flame or the fire of Prometheus and an Eagle harassing his liver with drugs.... regardless it spirals out from this story about me, and this bright fire that proves time travel and religion are joined at the hip... to link to a huge number of other Biblical stories from Lot to Joseph to ... Samson, Isaac, Adam, Isaiah, and... hear me, "so marred was his visage" and "my servant will be set up and be very high" are both taken from words of the Biblical book which contains the largest amount of messianic prophesy as well as my entire full name encoded over the name "JESUS CHRIST" in Bible code, at Isaiah 52:13.  You may have read that some silly people like Richard Dawkins don't think the Bible Code is meaningful, and as their proof use a series of prophetic predictions of assassinations in Moby Dick (which by the way also refers to me) as proof that you can hide information about the future in any words--or that God influences more than just the Bible.  Years ago, before knowing it linked, I found some patterns about those very same assassinations which go to show that our history is in fact designed.  My full name appears in a number of other books, including Jeremiah, Exodus, and Genesis... right over the story of Adam and Eve.

      From the Sound of Silence, and a number of songs about stories never spoken... to a thread of songs that combine to show us that the Thunder of Thor is really about thuderstanding, that there is a way to do something our society is completely oblivious to--that God is screaming to call attention to, and that some secret force is trying to hide very much... and that's an ability to modify our thoughts.  He's showing us clearly in a glowing pyramid--a noticeable monument in Egypt showing us very clearly that this type of control leads us to a social structure that we abhor--through songs like Guitar Man, Radio-active, and GAS (listen, it's God and Satan) Head Goes West... very clearly we are being pointed to Nero's fiery symphony and being "Bittersweet" because of its beauty, and the clear message that secret control of our minds needs to not only be understood, but to stop.  This is the crux of the Apocalypse, God's message is now really active on the radio. The point here is that we need to let this message spread and burn, or it's us burning in Hell and not even knowing it.

      )​

      As if these things were not enough, using some "keen insight" and another reference to the hidden truth in ancient Egyptian religion--the name of a series of Gods called "Yahu," I've solved some ancient mysteries like the pronunciation and purpose of the "Ineffable name of God" highlighted in the videos at the beginning.. of this e-mail.  Like much of the light of religion, it is highlighted strongly by a series of pieces of modern art, things like "The Grinch who stole Christmas" and the Who's to the music of The Who, the sci-fi series Dr. Who, and the American war cry--made popular on the silver screen through Al Pacino and Denzel Washington... who-ah?"  All of these things highlight that we don't really see a connection between Christian mythology that tells us for no reason at all Jesus Christ is the "Last Adam" and that Revelation tells us God is the "First and the Last" and that the name of our planet, in Hebrew, is Adamah.  It is the answer to "who-ah" and it clarifies the Ineffable Name which many pronounce as Yahweh for no reason at all, to be the more obvious Ya-Hu-Ah, the name of Jesus in Hebrew... Yeshua, to "Yes, who-ah?" All of this having nothing to do with why Adam is hidden, just that the Zohar speaks very often about the Holy Hidden One again linking the stories of the near sacrifice of Isaac and Jesus with... someone.  I think this is of such religious significance that you should be able to easily find some Jewish scholars who agree.

      It's Elementary my dear... What-son; from the time of Herod and Shakespeare Rattling his Rod all the way back at the time of the question "to be or not to be?" and the "taming of the spanglishrew;" right up to Sherlock Holmes sleuthing of the answer to the mystery of Revelation 1:20 linking directly to The Fifth Element ... there is no doubt that helping our world here and now is the primary purpose of all of religion, and the Matrix-like message woven into our history.  

      http://www.youtube.com/watch?v=TO9OsSazQ0s)

      Lost between the 5th and 7th day?  Find your way to the 8th day, and see a bright future.

      )

      If not, there's plenty more "coincidence" in Names, like reference to the idea of the Holy Trinity existing in the name "Abraham" thousands of years before the idea of the Trinity was created.  This too... links Egyptian mythology to the name Abraham and his near sacrifice of Isaac.... marked in secret by his covenant with God that changed his name from Abram to Abraham. The two letter key here, "Ha" highlighted by prescient knowledge of the Spanish and English languages revealed through the logical comparison between the Spanish and English for "the" (El and Ha) connected through the English word "is" in Elisha.  Isaac's name means "he laughs," or "he will laugh" in Hebrew; and that "Ha" appears to be the key to a number of other paradoxical references to English, and my family, in ancient Hebrew.  This too, probably the kind of thing religious scholars would marvel over, in the right context.  Seeing English in Koran, Islam, Chanukah and Menorah--and seeing a coherent story woven through thousands of years of scripture is the kind of thing that could really light this years' Christmas up.

      Here's a clarification of the Matrix-like tie between Shakespeare, the Matrix, Stephen King, and the reality of this message hidden within names and words.

      Some more about the secret connection between the Names of God in a number of religions, and it's very clear tie to time travel.

      )

      Perhaps linking to the Jester of American Pie, between Johnny (who almost always is about Jesus) Carson and David Letterman I have a unique "slant" on religion that connects things like the Islamic name for Jesus: Is-A to a huge number of references to my initials "A.D." in things like NORAD and Isaac Newton.  I suppose I should also mention that Isaac (look Isa's in there) and his relationship to Abraham in the letters "ha" and a story about the Crucifixion being a fiery altar of things to change in the world being one in the same.  In fact, Judaism talks about 72 Names of God, and I've probably explained how the meaning behind the stories and the series of names tie together in a magical tapestry that shows us that Silicon is the Fifth Element by way of the index 14--the letter "N" (highlighted not just by Joan Osbourne's "what if God had a name?") and the story of Sinbad, which combines Silicon, "n," the symbol for the actual Fifth Element (B) and my initials A.D. which grace the time line, and a number of references to God--from the Hebrew for Lord to the guy who thinks all the girls should want to be his partner.  In letters, you'll also see a number of references to K and Z for the guy after J and the Last.. Adam.  Zelda or Zion, I think we're in the right castle.

      Get ready for the Frank Rothstein show ... "Ace is high!"

      C    A  S    I    K  N  O

      go ad, b. y. e.

      butt honestly, am i Ra or are you an ear**?**

      Related imageImage result for stewie

      BUILD HEAVEN.  FREE FOOD.  HEAL THE SICK.

      I see a recursive map in time painted throughout our timeline, and all of it pointing to the words "see A.D."  I connect the Four Horsemen to the list of Anti-Christs, and it's easy to see a link between Jesus Christ and Julius Caesar in the words "veni vidi vici."  Once pointed out it's also easy to see "salt" in Napoleon and in manna from Heaven, in China, and in Prometheus--and connecting A.D. to the year Christopher Columbus walked in water is just a little bit harder than seeing it in Hitler's name.  All told, the three Anti-Christs share a common thread, they turned a republic into an empire--and here I stand (trying and failing to do the exact opposite, to give away an empire to make a republic, and you stand in my way) pointing out that you are living in the product of these empires, in a hidden empire that is so plain to see in the words, the message, and the unified story I see in religion and world history that I dare say you must be deep in the Plague of Darkness if you aren't interested in finding out what tomorrow brings. 

      You can "see A.D." in El Shaddaione of the hallowed Hebrew names for God, I read it--in this hidden language that I am presenting to the world as a single verifiable message to the entire Universe encoded in every word we speak; you can see it in the name "Atdonis" and connect it to symphonic accompaniment in everything from "you're so vain" to "Paradise City" ... and in yet another name of God, "Adonai" which links to Samurai and movies like the Matrix and the Terminator series through the modern computing concept of "Artificial Intelligence" and it's connecting to a pattern of names that link Bill Gates and Richard Nixon to Seagate, Watergate and this hallowed phrase:

      I am the gate.

      and the bombs bursting in air

      gave proof, through the night

      IVE WON ALREADY.  Given the set of knowledge, the publicly known "information available" here in this place--you simply cannot ignore this message and continue to pretend to be a functioning anything.  Already I see a kind of "slapstick stupid" response in our art that shows me that you've all really gone off the deep end--"because 9/11" in a Family Guy episode and "call me on my cell phone" apparently anachronistically mocking me--though I always thought Dr. AK e's song was stupid--you don't seem to see that you look like absolute fools--every single one of you--your apathy a finger on the detonation button that has destroyed civilization.  

      You appear to think nobody is watching--and it seems to me that you think we have no future that will look back on these years and wonder what on Earth could have kept you silent for so long about a matter that would so easily and so quickly end the suffering of so many.  There's no excusenone at all.

      I didn't hear about the nuclear scare in HI until after it was already known as that, and it looks to me as if nobody really did--all the internet postings and news I've seen all qualified that it was a false alarm in the original post.  I find that strange (you'd think something like that would be on the news instantly? I mean, on the planet I was born on, that would have happened), and in this place where I know that quite a bit of what goes on at the higher echelons of "leadership" is connected to time travel and mind control; I wonder if this was a sort of "subconscious poll" as to the response the public would have to a false preemptive strike--or maybe something more nefarious (for instance urging me to write once more about the Trinity Site and the link between the OP (original gangster, I said orthogonal poster), the pen, and "we have become death").  I've always equated the lines above from our Star Spangled Banner with the detonation of nuclear weapons; on the 4th of July some time ago I connected "Wish You Were Here"'s we're just two lost souls swimming in a fish bowl to the eponymous operation that resulted in American and Soviet "high altitude nuclear tests" ... that probably links in more than just my mind to the holiday called "Hanukeus ?"

      I need you to get it through your heads, I see "bowel movement" in ICBM and I'm not telling you that you are the "preservatives of thermoshit" because I think it's going to win me a popularity contest.  This place is not in reality, and it never, ever, ever will be. Ever.  Understand that breaking this story, this news that's written in every fucking word will stop nuclear war, instantly--and show us clearly that our entire history of fighting over the scarcity of land is a kind of sick game--one that I am sick of seeing you continue to desire to play.  I shouldn't even have to mention that these weapons are clearly archaic and barbaric--clearly what's available is significantly more advanced and less destructive.

      The only "EXIT" is up, and the "gate" is swallowing simulated reality in whole--across Creation; with our help, and what we make here to ease the transition from dark lies to bright truth.  That should be ... "good news" not the kind of thing that you'd see the entire world "shunning" in unison. 

      If you haven't gotten the "link" between Na and "bath salt" mass produced in what appears to be "international chemical warfare" from "C how I Salt" (China) and the stuff falling from the sky to help us navigate through the desert; take a second look at the words "New American Standard" for no future, and keep trying to tell me that these things encoded in every word, in the story of Exodus and of Prometheus and his attacking Eagle and of Epimethius and of Deucalion and are without doubt "Hell's Bells" linking "mead" and "meth" to Heimdallr are *my fault? * Na ma y 1m

      These are big secrets, keys to Exodus and Eden--but more keys to an external influence crippling our society for thousands of years... and you are hiding the anachronistic occurrence of a number of chemistry elements in ancient religion--something impossible without time travel--because you think it's "not wholesome."  Understand, our society is being secretly crippled, if not by drugs raining down from the sky, by your lack of regard for the clear influence of mind control in these series of events--and the clear proof that it is a symptom of a hostile invasion.  I've heard the words "make or break" see this as eugenics, and see it as "break or break" until me.

      It's "elementary, my dear What-sons" elements like SaltXenon, and Silicon are central to the disclosure that we are living inside a map, a road to Heaven... and it really cannot be hidden without making our world a darker Hell.

      Unless otherwise indicated, this work was written between the Christmas and Easter seasons of 2017 and 2020(A). The content of this page is released to the public under the GNU GPL v2.0 license; additionally any reproduction or derivation of the work must be attributed to the author, Adam Marshall Dobrin along with a link back to this website, fromthemachine dotty org.

      That's a "." not "dotty" ... it's to stop SPAMmers. :/

      This document is "living" and I don't just mean in the Jeffersonian sense. It's more alive in the "Mayflower's and June Doors ..." living Ethereum contract sense and literally just as close to the Depp/C[aster/Paglen (and honorably PK] 'D-hath Transundance**sense of the ... new meaning; as it is now published on Rinkeby, in "living contract" form. It is subject to change; without notice anywhere but here--and there--in the original spirit of the GPL 2.0. We are "one step closer to God" ... and do see that in that I mean ... it is a very real fusion of this document and the "spirit of my life" as well as the Spirit's of Kerouac's America and Vonnegut's Martian Mars and my Venutian Hotel ... and my fusion of Guy-A and GAIA; and the Spirit of the Earth .. and of course the God given and signed liberties in the Constitution of the United States of America. It is by and through my hand that this document and our X Commandments link to the Bill or Rights, and this story about an Exodus from slavery that literally begins here, in the post-apocalyptic American hartland. Written ... this day ... April 14, 2020 (hey, is this HADAD DAY?) ... in Margate FL, USA. For "official used-to-v TAX day" tomorrow, I'm going to add the "immultible incarnite pen" ... if added to the living "doc/app"--see is the DAO, the way--will initi8 the special secret "hidden level" .. we've all been looking for.

      Nor do just mean this website or the totality of my written works; nor do I only mean ... this particular derivation of the GPL 2.0+ modifications I continually source ... must be "from this website." I also mean the thing that is built from ... bits and piece of blocks of sand-toys; from Ethereum and from Rust and from our hands and eyes working together ... from this place, this cornerstone of the message that is ... written from brick and mortar words and events and people that have come before this poit of the "sealed W" that is this specific page and this time. It's 3:28; just five minutes--or is it four, too layne.

      This work is not to be redistributed according to the GPL unless all linked media on Youtube and related sites are intact--and historical references to the actual documented history of the art pieces (as I experience/d them) are also available for linking. Wikipedia references must be available for viewing, as well as the exact version of those pages at the time these pieces were written. All references to the Holy Bible must be "linked" (as they are or via ... impromptu in-transit re-linking) to the exact verses and versions of the Bible that I reference. These requirements, as well as the caveat and informational re-introduction to God's DAO above ... should be seen as material modifications to the original GPL2.0 that are retroactively applied to all works distributed under license via this site and all previous e-mails and sites. /s/ wso\ If you wanna talk to me get me on facebook, with PGP via FlowCrypt or adam at from the machine dotty org

      -----BEGIN PGP PUBLIC KEY BLOCK-----

      mQGNBF6RVvABDAC823JcYvgpEpy45z2EPgwJ9ZCL+pSFVnlgPKQAGD52q+kuckNZ mU3gbj1FIx/mwJJtaWZW6jaLDHLAZNJps93qpwdMCx0llhQogc8YN3j9RND7cTP5 eV8dS6z/9ta6TFOfwSZpsOZjCU7KFDStKcoulmvIGrr9wzaUr7fmDyE7cFp1KCZ0 i90oLYHqOIszRedvwCO/kBxawxzZuJ67DypcayiWyxqRHRmMZH1LejTaqTuEu0bp j54maTj09vnMxA0RfS+CtU5uMq+5fTkbiTOe1LrLD72m+PVJIS146FwESrMJEfJy oNqWEJlUQ0TecPZR41vnkSkpocE1/0YqUhWDGSht+67DdeKUg5KwvYdL21d/bSyO SM4jnyKn9aDVzLBpYrlE/lbFxujHPRGlRG5WtiPQuZYDRqP0GYFSXRpeUCI46f49 iPFo4eHo2jUfNDa9r9BjQdAe4zVFn2qLnOy8RWijlolbhGMHGO3w/uC/zad3jjo4 owAfsJjH5Oa1mTcAEQEAAbQmRUFSVEhFTkUgPGVhcnRoZW5lQGZyb210aGVtYWNo aW5lLm9yZz6JAdQEEwEKAD4WIQTUJHbrYn3y2DzwTcnQP1ViZf5/FQUCXpFW8AIb AwUJA8JnAAULCQgHAgYVCgkICwIEFgIDAQIeAQIXgAAKCRDQP1ViZf5/FWM6C/9J gbRLS2AWGjdRjYetlRkSkCoTYnXWknbtipYYHlhV0YJFwFMm0ydZIhFX5VDoZyBV 0UBeF1KJmcMoIfrHyhq2QhCnjE14hE1ONbaYTGtpvj851ItbFWXMJIVNyMqr+JT9 CWIxGr1idn+iHWE3nryiHrdlA3O/Gcd4EyNmaSe/JvB7+Z1AVqWkRhpjxxoPSlPm HEdqGOyl3+5ibQgUvXLRWWQXAj80CbVwwj1X4r9hfuCySxLT8Mir7NUXZFd+OiMS U8gNYjcyRGmI92z5lgf7djBbb9dMLwV0KLzgoT/xaupRvvYOIAT+n2mhCctCiH7x y7jYlJHd+0++rgUST2sT+9kbuQ0GxpJ7MZcKbS1n60La+IEEIpFled8eqwwDfcui uezO7RIzQ9wHSn688CDri9jmYhjp5s0HKuN61etJ1glu9jWgG76EZ3qW8zu4l4CH 9iFPHeGG7fa/5d07KvcZuS2fVACoMipTxTIouN7vL0daYwP3VFg63FNTwCU3HEq5 AY0EXpFW8AEMANh7M/ROrQxb3MCT1/PYco1tyscNo2eHHTtgrnHrpKEPCfRryx3r PllaRYP0ri5eFzt25ObHAjcnZgilnwxngm6S9QvUIaLLQh67RP1h8I4qyFzueYPs oY8xo1zwXz7klXVlZW0MYi/g5gpb+rpYUfZEJGJTBM/wMNqwwlct+BSZca4+TEHW g6oN0eXTthtGB0Qls71sv3tbOnOh/67NTwyhcHPWX/P9ilcjGsEiT8hqrpyhjAUm mv7ADi+2eRBV8Xf8JnPznFf0A1FdILVeVHlmsgCSB0FW0NsFI5niZbaYBHDbFsks QdaFaYd54DHln69tnwc2y3POFwx8kwZnMPPlVAR2QdxGQD4Wql7hlWT58xCxQApf M98kbAHjUlVYLT0WUHMDQtj4jdzAVVDiMGMUrbnQ7UwI7LexSB6cJ7H+i7FtS/pR WOhJK6awoOO9dLnEjm6UYCKsBdtJr98F0T7Sb7PnKOGA77y2QN14+u9N9C1lB/Z1 aQRQ2Nc51yXOQQARAQABiQG8BBgBCgAmFiEE1CR262J98tg88E3J0D9VYmX+fxUF Al6RVvACGwwFCQPCZwAACgkQ0D9VYmX+fxU+KQwAtFnWjGIjvqaNXtQjEhbGDH/I Q5ULq/l/wm9SmhG9NYRu3+P6YctCJaZnNeaL+6WFk1jo4LMiJEUT9uGlCbHqJNaI 6Gll1w6QOVLSL8s5V1L477+psluv4WBpi3XkWYlhDOFENCcWd49RQsA2YCX4pW7Q 7GcoSEJoav38MxHmJHYPfjSEvUZXDQIt8PFHSEScvyDWfYtMdRzjmSOOPdzhDDEy 5JBOBcEdSTyDiyDU/sBoAY0e8lvwHYW3p+guZSGSYVhGQ8JECzJOzwc/msMW/tJS 2MLWmWVh5/1P8BVUtLC2AQy6nij6o+h6vEiNzpdYrc+rzT3X5cACvJ0RtCZcrnhl O9PLiona2LEbry6QX5NL41/SAJNno3i72xPnQEe25gn3nbyT+jCoJzw2L0y8pmNB D+PKrk7/1ROFFVN8dJeGwxLGdBcz1zk2xeumzy7OaV8psUyYsJNcjyHUKgclblBW rMR2DgqEYn8QdK54ziKCnmQQZeMPiC6wlUWgg5IqmQGNBF6RVyMBDADALD7NkJ5H dtoOpoZmAbPSlVGXHDbJZuq7J13vew6dtXDIAraeGrsBqkF8bhddwVLzWylMrYCG Bf2L1+5BDgvqu6G+6dcVSbBsnZAS0zfJ0H8EmTvUMxMF7qOZYyrxfLz+pQRq8Osz Icab6ZI/KB6qZyQRvEFPB6pJjt+VvuwgJZTObIwbBbgQri2i02VBkjchsVhiSX9l +eiK7O8ROHKb3P181oScIsHywBOZ9DxRAYbFk5dnBqxO3WKb02H0zqE6440cjXwq TrZZg6ayN/IlPajO8iJPYZ1aIBykxYq1WHo+nhFMYz/VVk2WJorFeOgWaLGXb73c ty96f3qXTdvMDAIWHx8YCD5LbuqasO6LNQm4oQxkCoB3K9WFf/2SvSYb7yMYykb8 clTPt+KO0dsxjWhrJnfnIhC+2Chqv2QvRbFz0S9CpUnGGDweJ1uRNV0y70tO0q7t xXSTDRU3ib6vAHA0K/2MFzwUcog4o5bj7E9uCNJH/DJLZKsMIe4xsvkAEQEAAbQk SEVBVkVOVUVTIDxBVkVOVUBGUk9NVEhFTUFDSElORS5PUkc+iQHUBBMBCgA+FiEE IRklfU/C1qukq3xMXcNH0t3P9ZsFAl6RVyMCGwMFCQPCZwAFCwkIBwIGFQoJCAsC BBYCAwECHgECF4AACgkQXcNH0t3P9Zs+kgv/XEuuWc89Bjg1QQqKZueKNUHjyjnE 2adfoZUH6Q7ir4JZyRBCVpAwrgssmiKid30+SIjwQcpb9JYa/X1XJcDUcJW/I21d Agz/zbEqn/Cou0dUpNCtxgm4BdSHWGoOtgfspXZlXBQ407tRMZ8ykmLB1Bt0oHvw PT0ZOtqXM4pyFnd2eFe5YGbNgl3zqvoC/6CMN3vqswvRlu1BpUuAjdW8AHO5Yvje +Bp852u+4Qpy6PMBiWGsBMYwtf6T7sckpMGlR0TsozwBlAm5ePKK28B0rLJPkZLJ Eo5p4rKRapEaZsWV5Qu1ajrVru7qmpUhZtX0/DddGHfXVuLssmKLP6TumpQB1zvQ vfoBltjvOx35Wps2vHuCzXLw2bROIOzhAxFB+17zxnSbE54N4LIGRpkELuwxwGbg FtD1fi9KtH7xcn33eOK1+UD47V+hKyJGrQgSThly2zdIC2bvfHtFdfp8lOFpT0AU xjEeoJGqdQVupptXyugPlM5/96UJP8OZG0ADuQGNBF6RVyMBDAC3As6eMkoEo3z9 TkCWlvS0vBQmY3gF0VEjlAIqFWpDIdK3zVzMnKUokIT1i7nkadLzHZT2grB4VXuJ FvpbYw5NPR4cDe9grlOMLEaF3oSJ1jZ4V1/rj9v1Hddo8ELi/NToVrt1SB5GCVXB DkYpNLtTiCqHSU07YqwaqH8a+qbDmPxSQdIybkZiTiCEB+6PfQQlBpENEDlov6jm zZF+IcfM6s3kZDX5KFULweH30gMjq8Se8bPtUzW013+tuuwEVr1/YRLrIh+9O6Z+ pdA7gLMRYnD9ZLDytEvpb1lBBSY++5bIJ7xps80//DNqPYqwFmZQgTg0V9XbHE2e wLcOF8a2lYluckU7D///sWQhW+VxuM7R2gEBvYBhOgjWhIF2Aw6NbymW1Ontvyhu eOZCXXxV5W44PxXT8uDdhl9CNcHoBKKJyED8tKjigtn4axpsQeUrnOSbqEXSyqES WnE2wYUDzALcwFkzsvtLyd4xaz55KkPQkAkk0BZd1ezgXxb/obMAEQEAAYkBvAQY AQoAJhYhBCEZJX1PwtarpKt8TF3DR9Ldz/WbBQJekVcjAhsMBQkDwmcAAAoJEF3D R9Ldz/WbAFwL/382HsrldVXnkPmJ1E2YEOFz4rcHRetJ+M5H65K/2p32ONQ5KCbE s8MRY6g2CkE70en2HlpDwr/MdATwxBzIjEpjgHbfqCqVVATY+kSpXsttaKKAUVHi bFgV4QkdDJNSpcHEj+bqaggRnuWiV9T6ECG7kQjHiEXPNojzsiaXMDiM5r+acZm6 82id9qOFySQ2cZEy5HbwXM+ITLQGngnppa7du2KdgiqDeqtODOTWZvLYAq2tmEwD 3TT6ttLUBwOOu2IWpDkXswlrk62ESorE5mpLxop9fsxD39E2H06JoC/YfUPIVkEv fj06e7LEdcx0I7kRfD1v6qOUUsMsLZnmyGIk24iFjLkwu1VToWfwXDN1D2+SeAat 9ydNt4M7oEbd1QaOXXjmqpdU+VUiWcBXg+p3/WdV60MkyAgc3x+YanLljy/Rh18h cZwVlinf/tgvAQLi5f9hpwrwUMoGKijEYHKuEvi3C12Si7UVDfuIR7yS0dKcfuKF MbgwdvNXqpD9W5kBjQRekVd4AQwApHVgw2PVlBDpVcyoymUOXFQIJzJ9wRtr6/sG zwv8rrQnUEtOkkna7TDU3/UTj9FUH0gbpAKGNNPaPj5q0dlLIvzxb15r1uvDGaGL MA+8GFaGFnkxzhg0aXrcKZAN0/Zhgi2B7P8oXQuug5mi1JVDkZN5SeCZNOubdQWL 3xz3jEHp3ixj1mdOdvfdWQFR4CVMXt/A6VI2ujLVb3Yalft/c5bbclAgcJQhgDUu NqGYJEJonESNRSd8fEvhNb6cx7+Djd9+Wyctr76mwOr3nRb1N1OGhFxWjIroUpfz b+6y3oQjT58cJA1ZHqmJ6UlZd81hNNd9KWpbDVwONEPpiqPzfSaonxuqQa0/Cy4W 403OhfoLM/1ZDqD4YrJ/rpyNEfSSdqptWiY0KeErLOYng7rStW/4ZeZVj6b2xxB2 Oas/Z1QYfJyFUki9vaJ5IyN6Y7nVdSP6mbAQC9ESh+VPvRUMpYi4pMGK4rweBVHu oMRRwzk7W5zVIgd425WUe3eCQFn3ABEBAAG0K0VTQ0FQRSBST09NIDxFU0NBUEFF REVTQEZST01USEVNQUNISU5FLk9SRz6JAdQEEwEKAD4WIQTvnDJqcmqzlF87/t82 pJ91j4NOaAUCXpFXeAIbAwUJA8JnAAULCQgHAgYVCgkICwIEFgIDAQIeAQIXgAAK CRA2pJ91j4NOaJVjC/4oo5yCHe7M2h1DiTXVcLI5rXQ1feY7B1feg+YJX/mI4+EV xjC/y5VVpV4syJk5GGZNXhKPHiGLaBYvglTlYOJ98RSEsHrwT3go6S8ZVvMNdP5v CEncn2vm5JGnp4k26PuOzMcJioQLOoUjWtcPFis3gG+ueH3NcPZ22oZUql2xuerh TQZegGp+jJ7bdxwYElx5jDDDkh196d5nlO2ZKENl0ZDp4GAzRNjnQ7KBV6R74J3U cLQDWY8vAFaRBZXIC5XtSzj9lr+jWgvxz7Il51+26VDTEtSafZ2uZfCOFk7GrzJg YFJD3zLnwUFXDWKRkep8TSwXnHmz/Ts/Mjyv6em25w7QTdnx1hNPxYNWMxPWNEAH pf70nNyOmcWcq27W+nAjVg8W3st/7J5CIebJQc5AUgm+fGOBW6XUQaNy2YF1YJlA 71/tls+R5IQZCYzbPOibgFS1HWKTwy0iI2rMDfxBtCXciv754jVI7L6R3J0j5Dy1 WZQVjaGgimznLN6XwYy5AY0EXpFXeAEMALvElrTV5hJG9DKu8cOqQEEVejtWJtki fZyvmiAKi2bZWiNfl1MxJt+o3Oc0eARJfnaPjrUY7hsbbSBAB4lFnDRtviARPaKM st5FkFgOh7Xx5ODc8bjqhMT9tbX37rkeDc12WAs3UxtEKWjyT7Xg/APKeK5FzpIs qew3LADdqFP9nOR0e5G8gxLTYh3ll3dLtp9DkJgA9q+0g31nNh5fZ29mcDzo/Mat Uk4PIxWC29LV9ALCJMIMesjOPiDa2KOy5QQH+/vn592ydBohOaY+B6jhEAdX8Dbp VHVFRBsiCOWGmdi6vHjMFD0tQdS6bXf+ZAG0E5HZETCxA2qfMf/vTeIJXYS5IZw0 anRkTXcTBrVE8uBpqtkNOrLJsaASkcoO5qF01J9zW8SR4jDgET7J02Fxf8CVPzb+ ZoNc9S0ZEO6Ubdh2vAkPtOV5sFkwIduN6ouAhEfJzC9XbJLpgsBKrRMAjr2FeEZP ruy8BkZbiyZ/b0S9qIgY4pqcyUJ79w7FLQARAQABiQG8BBgBCgAmFiEE75wyanJq s5RfO/7fNqSfdY+DTmgFAl6RV3gCGwwFCQPCZwAACgkQNqSfdY+DTmhD9wv/Zgav EHMuqF3765Fa4NapYh2kMS3skHn+ZzUEPLTlvrt7KHxomOzExNLSscZThMpur+yW MfNWbsw9GphiYAkMULrfJt/iWRVJ1FLgbcWgRGAwakOGwE29lMx3+rPIUQWU54Dw vE92Iz51ZGz1wgKcISuCw39g/HQ9uc3h3TfHLgfkc/GaIEa8jEOAcD67dVMoU4o+ p3nMri8z6sK176hQ/FM/8kekpeVfxmR8s6uoaJsXLRQk+i88ZwBR/5U+fBT9AtVw PL/MmZH7eCmZrn5hjaOw7tpkL8ZyAydNhOsSCqwNVtrIjgd+Gq1oSgw9EZfhKSUa +dBJAErA7MWjammQizEHDNnI8VNLngwCahGwaSgDhNaQtgNxvnkWO7XNYoCYXScP X++UmpWtSKMnD6ue36Ba1jqon0WY5cen3P+H1gL4ij5ynB9DrE8R1aSY6f+VZ48B RvjHm5LKTcAhiv2N/TyAg/fr2v9ZnEcP3CFxqAyB9JSKwoBkFvxJaRHTT3DxmQGN BF6RWE4BDACpgKWvQvPRDN03+sLYMXpJUPC7VhTjg5K/1+1vS/e/W65dYzn3JYxb ip2PcI5xajFnxzUrwwmhW+qz5REDyCtAObOpKsjtr4qu7mgOWnPa3k2Lm0bpCjDr BSFOiQsBVezTG/gJm+qELeqQMS9PHDSvZXeBROK7OkRE0nZ6yAj+QKEoVqeADpDm BHmhAA2OKBzq4rDWDh1jRQ7gLjlv/BFbhU1WuEfH/qzX8AUSsd0/hoPG0cPgC8gQ 3m6wr4eYqI853XQujWwisnlAE2bf9jsRjW+aLrJJTcADWk5Op5aQhI2lURYkryfC DFVcme7Hsrd+RFPK88J08YjBjOoYFwRU4AhHgucX9tW0S0v9hi3pKrF9O/JAIf+r h6BpnWo7tT5+8mVhtFvfEp9Y4xeUAKKZHBKhzHeOO8QQgHrIYa6HCcU03eyxy4Tq AsJdAJvxYFCRPdY9d0Z6uVsPhRy+3UmTxjl590T5/XjKPriAjBqXnKr4KexsM1gj 1L96bYDEgr0AEQEAAbQaRTFYNl8xIDxFMVg2QEVSTUNDT1JQLkNPTT6JAdQEEwEK AD4WIQSGisfXZ2Vg0m16Mzds3dDsq5BTxAUCXpFYTgIbAwUJA8JnAAULCQgHAgYV CgkICwIEFgIDAQIeAQIXgAAKCRBs3dDsq5BTxKq8C/48HSgecuI6MYtq84yqaQ1r x6cteRyn9BJDFTAUxn3X25kf0vVyCKQNAy2oybD5QHFLqhFCXJH+cnJ3xdviRUeW eO9fhkTmd12mHGrRDD02AHXZmaMp6ni7FuYpBGrw5dbXKTkSWfD/qb3odMx0jQby 6X+2eFhUpyh+yPB7P7HwiPwzdr0dBg3xE0vE0Vz+naMyt4YBHzrBbZo+y47Q86Ym TmBKxG5tlVsGDB4dDWSIvpBgnMFN1j46Uk2ihu4huohLkvSou+jYU+5Ppu8Fu1+7 i3RCILzeBtucR9+T4px1WVXx2sKOk0FfddCvI/fT/mhsgqQZwjj9b8HNfobhNxkL HBNFQ7FLJxKayPwMyJYDURUq7gz9p5JwHTmFg9n7zyK8qU2xR5t2247YinfEJQYL zQM6VKQCoDqydFfAPeGlx1KjroMGls4sP3XVlrR04YzaJ0vxRgog1gIO1aHMQ2Sj l8bG0GcerQ44rpn1v33Gw6KL/0SY9JsSSSjA9lgINWi5AY0EXpFYTgEMALy/jHsN kUQQVJK9QuAy5V2GePBTEm9NnjNCk+edGjSgqC1LemmP7EYh07J13d10VqD2Wtae bXlBeaMOcnoXQdfdK6nTKWRrH97JuRTrA3efLkl/R4EA/kHHV+YDgT+LBboUFYVU QF5YhfcvgBUcLXI3lX5wMEQbLb87cVjR0JtqVBFMIIvs4ibgr0U2SONiD9LcXZxf qYcX7CMM6RmuLzHTCEHyjp+KAw52K1i3+3M0OVZpa25rKE+S7LykQ1GrUUY3uVHg R2I3T5/Sns3Azc9wKuy/F71oiXyqCc3FwzTQHoki+eBf5dzs6h3GBTK3Dz6kl2mv 1TXpY1dk2EmuqKIeSr8CE52nkK8ZKY6cvX+v/p1EBAkJZKiasj+ukL72p3Lji5r/ iOarNJnURT5LJdYYL27dtQFSYyVWayeWi5358Ajh1H9OdpiGXcgG65ry6u50G8JR FCywwsdKpGjMG4FlkLkm50/piU+cgVeLET/C7C/OXNslL/pHV3x8kPRY1QARAQAB iQG8BBgBCgAmFiEEhorH12dlYNJtejM3bN3Q7KuQU8QFAl6RWE4CGwwFCQPCZwAA CgkQbN3Q7KuQU8SHSwv/agnEnhmo2yuKCLiKdTa5KZ8wh3umiX3S6rldW0NO2h8a cq2l7xHY1r2u4ieeMx27jtTqCp7ksFxPYwP9WxtVBy0teG8pKLhEffjyG2WKDzAN 7oXNZ7Ur6OQGfuOQzlMqOGtYQrbHAuX60PCldurX/6/0sKS6vESdeGMQPoZIDK5g HP298MMhlWYEG7uU31J1Cx9ZqiTosSckfrDq3weU8x9DZYaLZ+Y2akF5XpL/HjyA 6PM+lv6vnTA+b5DYCOJb6N7v131Net2JN7JVVGoc0FjsxN/W33H7eIDOZwqcCvzD i8EjjzZpZUDeYjlSXAqWvpeAASncMzXS2/S2V2u5X2iR7tDtRj9SuQehJkdTFNZH xh5nTdhPzgh/iOcm33VsQ17JWbovl0hbhYBPO4V+yIrN+oQGPhH+KCNNa39EjEzB iBIgirxQSaykwb4f2Kshh+d7rKHKb/mn6JBHU444mBf09m5wM/mhLSpuhMTcP2h9 jfFximAE9FBhdZhQsF29mQINBF6I/R4BEADotSG8PhhxxD9/96bgdWa1bzp2398W LaxP39T+Kzx2KL2xB+7B4EeTTzZ06kD+myCC9Ez+PqecfisJPfaiLD/+0/m3HLSS hxEaEqt1RBS3j6qJx8Lr51cAwGou4hGTo9H3me6FHO2ExZXd76A6kkUh0J4y3r6q aAoDP+MUczKzEjn6C6T7Uu0pdgYY1bDhuqlK0taqkqviGBYTAqmCrtcQhj+J/jbd OIZtpT3+PH6mWqguoONiE+glWcdThyuIvV3ix/GrhjmUZb/DQcvvbYGfDvGRBH4B Uj3f9WBM6HWSxKrCwWC3OcgZhtBcZjKrMPbNDNt7yAArv7nGpHmlpfF14Q6mVmVT 6Ulh+0xRx+6zFbqlDYYTneurK3RtqOBsMFG5rNDZYh/QOsHnSsxmU4LGdlEfQjYs 901zmzP7CQXjjJbtRXWIqPcn3OHIIasvjTACe5M+Lfk3u3rEiDYM64vg29sSyp9q 8hAzLTPcLj/Cc22jUEC/bbv5HfLyCZTCsu5ym1gDQZ6bDrJlFlXZJ2+vTCBsY24H RF9/J/z1JWYD1cAHpG0GRtYE9exKpu8/81jxIVn21qvvxSCPXw6IQIsEw51uk5TJ xAUIRCPN7S0UEtd22LSbM/IYx1cesCRUCmY7jDTro/jo2B4hLG64KBgqyjg0lwxd dy5S8LwFx1zskQARAQABtGhBZGFtIE1hcnNoYWxsIERvYnJpbiAod3d3LmxhbWMu bGEgLyB3d3cuZnJvbXRoZW1hY2hpbmUub3JnIC8gZW4ucmVhbGx5aGltLmNvbSkg PGFkYW1AZnJvbXRoZW1hY2hpbmUub3JnPokCTgQTAQoAOBYhBE+vDT4gih9MmA0P ZvtOzkoQkinPBQJeiP0eAhsDBQsJCAcCBhUKCQgLAgQWAgMBAh4BAheAAAoJEPtO zkoQkinPJ4gP/3U691086OKbWiQhMhV+AViuKnMgV4i1M8s+4Ep01h/dTE6R+rUu LcnY4T0HR5qxAYMiNpGo1vtvkMvV5DP1PFSl5EddKn8+Kvn/0+WjbLV5tdiFF1Ef xR6261UFoXAGk3HJMLQifr3lWKoimaBwJZGza2ok9k1TQVTn8g5a01bzK7hD5DJI zt9RJZaUkxGE97eUyJ8Dtwumo18EWJltuC4UWjWT2t2HE9mMsOfjpYZXFsGxJ0Zb xexo0DYsriPDpuxDnZT7G3re9Vwz2VIe388DNBW5HoJsYxhr2I0QOq64ZWOSEZC8 lDH+xM6YdY0iz4A+7nbKNGifLbH8oU4A1sV9HrIE2KNy76x0GNjgQUvcq1inD4Oh yorsRh/IF6wnqvFrHOstCS2dzpKuQ/s7bM5TGOD2EGb0xu7r0AfHqqLUlbr3rxkS wBFMQphyNr3mEkEbXU1dGsXDlRQy11LigMBoEHmP0t49bYWuM1mIBnIC7gZc/sV/ E5fWmWdQyCKmHeujmS+sgp2EX0NtMGSzm7z9WBzTBFjaN7q28gueQ3INDsDTGx2G aA1LbP2uh1ipwju0GxecUif3T2NDqaYfhbaCYsPJORNUlJUtCVBGeba9wcXai2dh l+HsSKUiyCgKiy6Rt6jumKtYHt+Q0zcKWLfVp8PA20zX+2Q9zKnlLzwquQINBF6I /R4BEADQ4kmCHYtAhjCShc724Ei2pqSH4SfnXd4r8S8I0+io6Mh0kWn+kbKk/aGK BL3KJyN6624kPtOFWuQ4iQ0lWFn9UMnvjByTPbjZ2je+VtCP7lKSNvEgTLQRxLEJ hoNVrNjrLa/Cn7sLt9ayYcx8eKpHkbmrVRTyGqljBkI5hwQ8S+7BWugabhGQuogw bFthykA+wxYvSbSn5mwKO1BlbDCRnxjLISlqWwmKKEtXQ8b3tu7GgFuPYLKaLEk1 BIwwUSdozjXu+198WligepslidlN5bXrvje3sxgt4oAPFMeH+NnDClSDuGhSYamW Db3ZPl95pW70ngUVgFPG4kQOlaqzo3YBeDBHDXlqU0+O8cwSQFk4CBJI3yt6/KmD BIuKLwauOxYullx9EnqKcLWEzOlTgn9Q7BARK8Uz7PQU3+1mDNId2MEg+gfL3rd2 +aMLNhTUkgVE5mWkeDz6Kg7YhwruvJtn0z1QqUhkQcVs7N8rVCck0YUCVGXpsUlu emK48q4ryOxmMG/+Ws2Xkmdm6Axq414WHz6nLwMWgFpcO+1wRwQuZEkeWeSAjEvS CGHImxTP7E08+y3vAl43a9AlR7v9PbtCy2FenAhGPigmWm2aPj1ejYfQLXozyWSM m8uO3aiKvQXdV1Ha2xQLK5expaRaAXQ6YLsNBD77UPxi9qC5rwARAQABiQI2BBgB CgAgFiEET68NPiCKH0yYDQ9m+07OShCSKc8FAl6I/R4CGwwACgkQ+07OShCSKc9o DQ/+OV2OuDp9g/27SRssbTWE+nBl0R9klrb/w2XEIVhg5LROUe/P3anyBLNITbF9 A4q8b9udD+iIc1ClY2bu3rQOdzA1DH9GK84bQ1O/LaU0Te8RBGJJEzjYMUraCgIX 4BmxsIlWuCkSNsTgempLOK88646Nv5uc/oxAj6kQH7x8XBXxaJ+N9WS9f7EAv4AL bSWeJ4ijbw9BIMHt/D9Em7Q8bW6VGZIEjIp+gl1vNZ6QGCTtRHQez1jYmFLpuE/G yh1zM5gCnZbcmC7ExDLFI6SuYUbKC+XaLA3+LLCVCPFLtu6wLvcgYFwWWMKIhJAQ bRyPePiuMqWeWR6VXTD8pLziDjxK0ZtvpGdOtZeCCHOEmxrCsfKdIyD2Gn7TmTwb M9fRE1HazROfit6SRCAamabg+dJIEGT8vzlLfnkZRi+6hxq88uDbrOkk36ShWoYB AApz+5fj1ogLptiaTUTyyjTjB+/FIbU48/02fkD0y960zQLyKL64Q4aZrNa2NNup YKy5F80NkU4rHOZ1HTaPLoqqVsGhWc3ODgLyGPiRDLlZu81aNpA/UnTEBX464Sk4 Jx9qztb+S50LnGItA92QfE9ru7FAE00RR6mpCv1h7uE28/Wr4XaYgJcw1hAPRr7p TtN4lph+sJsCQ8eX5YUlM/Pht1h/LoE8h4hXNfAGh+CZgoWZAY0EXodqtAEMAOBb WTLRDxNk9SbC7exKdw0f8Wy9DhX2Qqoi96piS99CMJSxeocLiC9Si2u5nL3sQTAu qs1YbtSgn8kkiH3HPEJIhV1p/Hvz47j4kXq7PnjqF7KAdCYewuDqRiq8J7TNokYs 6+3/KqwHT/IT8NwPLdMkXcv/SXqhuKpqa2ApIrhu04VFp4H5OXN9rqdF5ZDfcNx1 PQv+6m8v6xRwrI3kduRCUD3YiVPM3EOhqINk9XMuxAoVX3qwpz+OuEDBm76U5jTZ q9ErdwRV9gaGm5ztq6tvElpis3spM7BPHzbv0SvVRAAbgGVh6kfiaZ3YckxLq8ln Cg5or1aZNyGMf7CmaZaeAjeY6Y8FZXR1P+n/IFd9Ak83a3qizZyckfiEPO7hu9zI FFXTdtZIcV102rNoVzruZIn0vSK1DJ7bNNrHkm1PPcweMkcFJY0uh6l3x2nl2qKm AhlDs3wFG+nqvqmnliVbrFZCYlReMrWWI2YBwLC5uBcBpFAhMPNEjxOtv31R+wAR AQABtCNBREFNIE0gRE9CUklOIDxhZGFtNUBwcm90b25tYWlsLmNoPokB1AQTAQoA PhYhBP/zHob861BG6LJ9SqGPd44Z/DJIBQJeh2q0AhsDBQkDwmcABQsJCAcCBhUK CQgLAgQWAgMBAh4BAheAAAoJEKGPd44Z/DJIKtgL/0JQEzrGWoHHN7T4wLiArPCv tHB3dTZBoXGKlpuwhgOZ1th6jOnGPdMZRYnX8Zuf7QhaI7m/duKv9OAr8A/2ftHG 7/BxPSHJWBuIGZYNL97OWSstuBhNtyxfCftDkeBCqJ+lAneOrzV0M8syr2VqpfVs O8nTE7nXHSOdyen+1Fw0PtwaeG9uJvOhgRsmQ+mtAiJ1OLGKUxgCzSUk0m/YnDg0 vJBtzq9qP9+EZSuiBuRQC0tKs01ECI5DzWLNXXC6X8k3YGrJpL/HtTxH5SYNQRvS ALd+HmVYpwijLPi7ANzmg9/+h/aq4VFP/4SyMd6EjaaQ86n2fC5zeugio4sjtFMp W3jbZPn19o2hWTt9/bLns+fm9PgnPwdC+tS5LT26N6vhT/vK/HHY5AZvXXPNcQMA wp+EVFxsWK2BcFMIi7Oq47CfuM1AUA+pgCenB4iSVwxs8ANTWWIsLkkKAYQqIdan OSISa2WdslsKMjXIQ5+rG9ekEn+rRO3EAQXRryBt4LkBjQReh2q0AQwAwGx7shIW OaVExpngqmh0ApkxJHZIxcxpatk/lSBQfzHg6e1/7Joe98lEHcWPJ6WFsGp+aC9S 96dWTBZq/4pzAqqTrSXAZpG/+yZlWRWSXVQex1gZHPzsWYMPE9qayAPTOJHtfS6a klIEaFV2GYEvvRK5UR5DFIlsfzyyCBOUKvn0/hikqJjN2YfHUy5SR5U5dGsSX3Jk Q9bOlBYDpN3Rk5rmLg0Vwn4nPRBET70MLQ5M4pU3Br6n+vU8tMHoVXYVMLinD4gO vVY4baXEZELjcPkPzGFPyjVLlpxKMHZ6v1Qb9ornTRGzc4dEUKxi3srdsTpMCw0k CaZ2WLY4sNBO33C8XfIvMx2jF4iIk3BrSrW/hirq6xpvlh4BUh/UWVrvg2rdemAX THa93mRQeOa3bze9xZwaA2GJLRG+xCIt15v/cNpQwCYlyhJunkuwk3HQcUrKfzxo 6QhqMeDaPZeNcvN3XoELGeqtoE7gKAnLp2nQuVr4/pcaiATf+yAhBgYRABEBAAGJ AbwEGAEKACYWIQT/8x6G/OtQRuiyfUqhj3eOGfwySAUCXodqtAIbDAUJA8JnAAAK CRChj3eOGfwySB11DADLgMAafhdzRgzx7FLVVW80IfgiCTAl5M1wV2HctA17aln7 jk7iEVMTLfhrSCSvvNIdrOXUE7l9HAMkKRwaZv7OAtYR8eQTrgGc9yJdk8BMzvJB ouiaNb2LSxMSvpoaJmD2C9ZkOyW+pAXKaUGhbUl8YVa7ytwPD6yZzonGClgZI0x5 9nSc5TiPpVijzu51iZiTV35F6en7ke2hjr6iBACJGBplxeeWszRa0wK2zoubAUK1 KO2punvtGqhi3j77/0sZgvFv3czJpRac5ccdLc02Sb6I64Stp04ilcV1aqlUXxbM gLwkoXZUqbCS7ZA7eBiEaKXdj9ww/gprO0AwFETxQVA8iPF9puSWfBf18a5GEdR1 Drb5lSReCkCfBJd3Tf5WHUSrdcai0FfuXNNp/7J7CBzlOJ0h6Yoa02hz8CBGGwxI 1brXRm13004bX7C9i+94Lbgf8bTM40JvyF1kmcffkj8ibpS/VSa8aWJuqpWk/xcn ob/YdBngWCxNgXii4E6ZAY0EXot8fAEMAJ/JOflg7U8JWescyTQNl9Xuk6QUIVKx 0zOT2k+drlLwC8+FckYTCF1pm8sPDBBv9eN3cFCDf076tZjUHv+Roq5c5McDHlN5 KlFbTSOv1qZYuaPY14nHIoW7OGoSvMCOBkpDLLwnIbuLA0wGdzyd3z6Vfhpz3wDv iAplyA4iuzJQq1+iS8tq6Uj2yhmfg+zU16gw2D3iEC6hhSu2KmPhMFD9KfCzq02L xC6fMh3Fogas51ZF1fRDK8Bvicf4yYj0dn3i6GDr0/vHga4eLQqVBXb0HCv2lNer gTtawQfJu2XEn5hDZKfHeBJ4NI4k7AZIPa7OuUqOAm8Z4hbkgRZakc+OhPSEKH2i drItwrPXDGqMYV4tLLMALMQ9WDTz75wbzVbxGVcAzG3MaZSo/f/iKzuzaE8cF71A dO1y6H5YmmMENn4t/D4BYXm4edPvV6SaYU1hO5yqr7vGbrQBFVetpSCLEFveACHr sm1S6nVVTazkHj2FNdww4bGMJzPqC7bBtQARAQABtChBREFNIE1BUlNIQUxMIERP QlJJTiA8YWRhbUBlcm1jY29ycC5jb20+iQHUBBMBCgA+FiEE9+R8sSygzQHF4cv6 fsjVqFo41joFAl6LfHwCGwMFCQPCZwAFCwkIBwIGFQoJCAsCBBYCAwECHgECF4AA CgkQfsjVqFo41jpPfgv/dylMY4CPMwkdry8KnKP3QtmJOl94VnpJ+FUME+oOqjBw 6/C16uWdTLYuEUuE2jEzTg2J0kgulM2vYm8rVgJzlGiD/oIgX3X5NeyB9MH+GCpu xsJ/ofIVpC6t8Zl78B2qTnJOcEc6owy/qKs/eFXSea2sRRstqK20dOajl4Z2ycEL SdijFR3aqT4hU6e0GNWYqo3bW4TUcd05RJIZBNz6Bitq1fxljxFPOOCaoKo9mVn4 0dN65iGPEYg0c50Q6EmxEr+XtwRu1rjgG3hgq6BknZ6QD1HOBemQg/3jqQBb9uHj jHbuX9HrbGF9+QbDicbmuZSLuV76xJnbyTycFhhIcSi9wZeyAAPlpL4GQ8l98jKa SCWWGDPpKwK5+o8kteuJ/D/mYyBEquyFVhPQBXV9zS3LsN7ab55zB5+ZnLUeofai LE6e+XPGeJmG3I/+T/Nuq1CqJ4Wyt8+aIyf6Uz8dDk0kjyQku484plRwMEx7oZXR bXQAAn8SwtlNGo0sHc6JuQGNBF6LfHwBDACxAxfbQM5AcssJlQFXThnBMHtRDeBH VkyF5mrO9JeFRT+mhM87V+fJXOaEKtcSFVgZJFKV2MPdyGqZSGKmyyqfUvKfucP5 LrjK3MRKibTlOMwbBOmYUksMVE0ByMPeSzyMlQhq0oyA3fvEdKEf0JrFGDRWNzO8 /Q54oj79Pki4y1BDKd7lE1srBFiVEUuPNJmjhhU9WXnMwiB55lLwbTR8mKEX0Pr2 FeTS5gttmbHf4V+wnJvlOEU6mOLMrb+6Xb4ltvqbl9ng1+tF2QMGMd83mtbFtAjb Zcl/Cq2KwsBFyH9VT48ZxWxpOYMf3ppEg9KOSfz9Ungtg4/Q/Kr9P13Nf+9+S9JS 1PfKdlJzGFDn4EwZ49ugg6GNnL6XuRl9jBPD2iD8hY9CsTdWrr9giCmJmdf6G/bK HUm2QekMbhpaQmYKkMeri45cHprx1dQ50rfiH1cBm5SxaK7z/hDDaKXF1Gp7/KwQ g6gHlyMss7EEHSY5ogH+6a7OUPpqbJdNztEAEQEAAYkBvAQYAQoAJhYhBPfkfLEs oM0BxeHL+n7I1ahaONY6BQJei3x8AhsMBQkDwmcAAAoJEH7I1ahaONY6EqoL/R7J QLaAlb4/hK7/v4vsSxtCirLWrqNNNJxYdmpXq19NKPmcc08QzSqkJ7vR4/kn2L6I OY7y7AMh+tScKTKIGn8MkAcj0ZvkafHY3xmpN1Xp9caUAA/fw6KWD+pSZpKpISyd 2Xr6x5OJGSKhyGpPB98oCsa809LQ3cweG1imem3jx+Lgii63pEJG/AeNeEwkIvdC zRLSQvYv0UjlhyOoII6YEWJcro+tgOcthPh2SY50E4lwFFfbz4CNQyL15D+XciNI xSVGz8gee/XdJdgwQF4SEnIiChhmJ5VmpNH8ZwxTMyI3EoFMB/RYaucwc/ucvySn cFyShFFRPjo6TOeYIaSrrfR+4yhHAGeM572y0btI6JjWZovupeXX3k5ZHHrCwxlR MuyULLyhUsAC0r1FUijbUWoyaDcRtLRpMUg1X6A7n1iH61WxlKQ/8mZhYht85Jgp FSiyz47gofc491ng9efshlyxwb3TeLbDZPRnls7L3sfDDWwp8yExjA7UNDbIh5kC DQRencYLARAAsFHArFeulhD6hZplRF49h8+zpI3kn+vFtYwbUqLSRwze53rrJtqE 6o5MWSfadr9KIc8tNZ2aBGxzjGnsbPYLDh76NkjP4apWSMX+u+EHsaudoZoAdNnM Kqr86sVzR0MUeGHp7n/L3imp1WoCn28eMLeNec9a4GRTRPGLKR9F/jytTz/XgkHL zA3i2pt63FqniN4PBTNFzgfXiu8xVZGohsDPjmd9LXbGKTXfJGhBLB6QsmjJwglt n+00ufdKLEZu6eBxRWSVK0t4rEnnpK9K//PKq5DtVaOZNe6g+hdi0B1gpd0f0nBy eZd9arCsvN3qLXP0vYTk9DKMUecCEblss5Zt1+qjAbsMk9/xSGZLJp/4dBTBVN+Q c6+Rmv+koe6zLNmA3fJH3991xETDzZxP2UHN7q4i4L97KA+nVAakwazNLiqsY/bT s58rXnCc72b7oLnZbNOPQmLwZFafVi4xoIE/5Zq8iVr7d7xHPccYkaEVCOnsL/35 GZxy2FNi4wuOfGwBtTbnXg/u/YiBj6yNbhLR+FCwZED5M/evgUUbJudxqRdrI+1a Zo9gGA3JLJZZ/iLwF1kE7yYBvyBRfaO9IL3bwplRurnrkjI+rRhi55AlbGhU3eMu iKTKQk+qJF11ocTGu/dE9I6JeQpEdyVehrWXc5H2N0Qjyca8ZEA6WwcAEQEAAbR7 QURBTSBNQVJTSEFMTCBET0JSSU4gKGl0J3MgdGhlIG9uZSAuLi4gbGlrZSB0aGUg b25lIGluIFN1cGVybWFuIDMgYW5kIE9mZmljZSBzcGFjZS0tYnV0IG5vdCAqdGhh dCogb25lKSA8YWRhbUBlcm1jY29ycC5jb20+iQJOBBMBCgA4FiEE0s8R6kp2bveF MmxLkifaSe8nN2gFAl6dxgsCGwMFCwkIBwIGFQoJCAsCBBYCAwECHgECF4AACgkQ kifaSe8nN2jK+g//Toi6ezWYrRbTs9xwQLIsKzl91ocjCuN9nHSnwzkrLuoGGgej fHkXzd5+3ygL47j++k69TYB9CPrGdR1GTqt56Q7DSYZCgdg+e89piTJUzbEyN01q EGkVuV5Rz9EocnPE8db9HT+xvf44ecfMOFD1XuB9jynrQD445YfeFE6LHkoNUvFD wQK7NN04fa+qvrk0lTS4NCpOYsdrSioddVjQyEC6jepwIRA3iRIkFdEJT8ggqQ6d gntsgExA01o6HqzDSHjSCA5AexCotwW3Uvdt0WwXx6q/c0LsRLhbuPeGX/Nh8aOf 6RBCQWgnIko675ura4c+r1VcBYl524ZJlN4x1x02YAo9cKzYi3+H9C8K8Ayz/SJy 7sVGHWnDge1yIwzWXbpolqiMSL5l/0OBuJ0HXQSafUut33Jw7hYKP4BQia/BmE0x Tsk0rBRMyihSYnUn9mYpXM3KwWU0C2dudVwKtToGR1aKlYcCv0iNFAsR0DBw1XSq n72KqIl020gZFmg3H34Z6CWhm20RbhMjOvvkZ+OiS9kU9kXt6m+T1zCpWHFJSae4 JF+dQyB1BFxAwXW4ZEzMo4XluTuW1R8pIadKTsHMWzEzH7RvZLKP4invsZklZ3I1 EEsJop7DSMOa27irD/IlCL+nwaEsCMRh+ndSkADLHsa9P5d/qWjomKxwdCm5Ag0E Xp3GCwEQAOoXU8NrugMa8OAncXKv4hycXJzArDae3Zx6pCCEkP3TZTXh1tqKPUtb dmb8Mq2eecVTwmB+FM3m+NApgq88Vx6HiyI73IAvgtZORo32YaipfbkGnXHfaUWX 5380R4GL597yZuP8sAsJ3iDvxhW59snsU8tLi+9r2u4h0fgMDqZXQsfvLUkDIiO9 nzJf0xFacTx3n+pUuWdzIuT3AUdU/L9NubmHSnj09FevTHWIYmxGFZoiSdS7r2Z+ 5xZmPak6lzrQTVS/DxcpyA/o3yi8qLPyf1VUxXKFeKd0sV6BPvYFxI2GeBl5atBu 9/3/5D6wdlrupTFLU1Msdfy3UWaRUFHLITK4fJ7pbTgoEqxX7gpO9iqKmScm3gYc O3blA8aTqCX2NzxUF5fHbi14JvPWP04uFl5EOeDB322Jm/guWy8TvmIIyuF3aAAX PfErW/yRWDsYOcAADs8elZkt3F+E/AwWd0JMIhd/RB3RFH8m7496XLS3xBP6rNye 0O+96lX7fVp+wvINxM3Rfo63b1K4bR5KR9JDZ2SLYhrx6Hyy+UiRv7l+i26WxVMF qRyvY2aHqyvKfR1EEf1t2h7B4b65xQkj51qvX5Tjm5Az7nKcXpcUKqS3bk8xiw9N y7eFfA361OSPpQ+V4Mq/Mv+MqyxLTz9tn+80ZtjqM0MEERfpUo15ABEBAAGJAjYE GAEKACAWIQTSzxHqSnZu94UybEuSJ9pJ7yc3aAUCXp3GCwIbDAAKCRCSJ9pJ7yc3 aE2NEACDBRnGYNi2sq0wltPSkD2CbQUon+4uiFB2UU/gs4mFlGOvzDHBHVEFzCqK 0x6KlKm4XBq3AF7iIoNMiU9FmBdWDnEp9eCXdQrr/ykgq3vKMuj6/QJNNZglIDoe 1J2NXeMOUFwCUvjcCttPv42Q8GDt8/bG7QOgmTmhuqvKIj/vL+c3HgNrRsQzhw5z mSzQIDaesD+UVA/sourXpSLeqPgF+6qsEqOirD6hotaqrt+aIA/8wbYkpNQxCEK4 gKDgpqTV7VKklku7fjyhBhZQOVDoWvd03AlGQD0WBNriUsh8l4N6Zg2BlnKTGn11 BTigqwlHC91xtjERgwFg8PAHN2mtgZUHITHX5js11KwlQdLyI04/M4M4oQq0KSbJ rpiWCgrltC/VqJrT4HELFYx2Iv5wzrV9jVEm6zonag4A761hpqTgRrjWtaLuYu2Z zdw9y1r0+0d2rTUGpjIQRVOwi3AF/G4aU+vAOOf/HcgH6Qnpbu+xV0fkuAZbTI7w 6VVkBvnstiQV88KrWAOXKVABSSxTz2OYbzOTt/bgxzAa7yr1xIBDKvujBqDRGBLi bISp+40Haoj2Yqop6vbS70Xq+cnBOwJW86u61hsLgOjqyxgLzvuGTjK7+TblCjR2 F4LNeQdwDdyNRjPYeGVXM3MEqR8XdcR1Z7BQvLNcDgoW2qDcbg== =4lZw -----END PGP PUBLIC KEY BLOCK-----

      Please see GPG keys on PGP.MIT.EDU; fingerprints: sec rsa3072/A18F778E19FC3248 2020-04-03 [SC] [expires: 2022-04-03] FFF31E86FCEB5046E8B27D4AA18F778E19FC3248 uid [ultimate] ADAM M DOBRIN \ ssb rsa3072/04F98002A3DA53B2 2020-04-03 [E] [expires: 2022-04-03]

      sec rsa4096/FB4ECE4A109229CF 2020-04-04 [SC] 4FAF0D3E208A1F4C980D0F66FB4ECE4A109229CF uid [ultimate] Adam Marshall Dobrin \ ssb rsa4096/DD1F0C118C788B04 2020-04-04 [E]

      pub rsa3072 2020-04-06 [SC] [expires: 2022-04-06] F7E4 7CB1 2CA0 CD01 C5E1 CBFA 7EC8 D5A8 5A38 D63A uid [ unknown] ADAM MARSHALL DOBRIN Because of "some issues" with what appears to be distinct and unbridled privacy intrusion; please ensure that PGP is understood to be "nothing more than not so much pretty good" and this key also, almost required in order to

    1. SciScore for 10.1101/2021.08.23.457419: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: Cells were sub-cultured between 70-90% confluency and tested regularly to ensure free of mycoplasma contamination.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cytotoxicity and targeted proteomics on HEK293-ACE2-TMPRSS2 cell line: HEK293-ACE2-TMPRSS2 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) with 4.5 g/L D-Glucose, L-Glutamine and 110 mg/L sodium pyruvate (Gibco), supplemented with 10% foetal calf serum (Hyclone).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293-ACE2-TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmid construction: The gene of the SARS-CoV-2 main protease (Mpro)27 was cloned in between the NdeI and XhoI sites of the T7 vector pET-47b (+).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pET-47b</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data sets were analyzed with Prism 9.2 (Graph Pad Software, USA) to generate dose-response curves and calculate IC50 values, as well as to generate Michaelis-Menten curves and calculate Ki values assuming the appropriate inhibition mode.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The structure was refined by iterative rounds of rebuilding in Coot 63, and twin refinement in Refmac64,65.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Coot</div><div>suggested: (Coot, RRID:SCR_014222)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Inhibition curves and 50% (EC50) effective concentrations were determined by non-linear regression analysis using GraphPad Prism software (version 9.1.2, GraphPad software, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">69 Extracted ion chromatograms for fragment ions derived from tryptic peptides were plotted using Xcalibur Qual Browser (Thermo Scientific).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Xcalibur Qual Browser</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04535167</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Completed</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">First-In-Human Study To Evaluate Safety, Tolerability, And P…</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04960202</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">A Study of PF-07321332/Ritonavir in Nonhospitalized High Ris…</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 19. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.24.457520: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Animals and Experimental Protocol: All experimental procedures employed in the present study were approved by the Research Ethics Committee for the Use of Experimental Animals of the University of São Paulo Medical School (<br>Euthanasia Agents: By the end of the study, after 4 weeks of follow up, rats were subjected to isoflurane inhalation anaesthesia and submitted to a xipho-pubic laparotomy.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Adult male rats from Wistar and Lewis strains, weighing 250-300 g, were obtained from an established colony at the University of São Paulo.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">To access uniform and proportional lung samples, 10 fields (five non-overlapping fields in two different sections) were randomly analyzed in proximal and distal lung parenchyma.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Production of specific anti-SARS-CoV-2 antibodies by immunized animals: To verify the success of NP sensitization, we analyzed the presence of specific IgG anti-NP in the serum of inoculated animals by Western Immunoblotting (WB).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-NP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">v) Tween 20 solution, and then incubated with a secondary anti-Rat IgG peroxidase-conjugated antibody (Sigma-Aldrich), diluted 1:5000 in 5% skim milk, for 2 hours at 4°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Rat IgG</div><div>suggested: (LSBio (LifeSpan Cat# LS-C70055-5000, RRID:AB_1653203)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Specific immunostaining for macrophages was obtained by means of a streptavidin-biotin-alkaline-phosphatase IHC technique, using a primary monoclonal mouse anti-rat ED1 antibody (Serotec, #MCA341R, Oxford, UK), followed by a secondary biotinylated horse anti-mouse IgG antibody, rat adsorbed (Vector #BA2001, California, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rat ED1</div><div>suggested: (Bio-Rad Cat# MCA341R, RRID:AB_2291300)</div></div><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: (Vector Laboratories Cat# BA-2001, RRID:AB_2336180)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The specific primary antibody polyclonal rabbit anti-human CD3 (Dako, #A4052, California, USA) was used, followed by polyclonal goat anti-rabbit IgG + HRP polymer (Spring Laboratories, #DHRR, California, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human CD3</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-rabbit IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Ten Wistar and 7 Lewis rats were subjected to intramuscular (IM) injections of 100μL of recombinant SARS-CoV-2 Nucleocapsid Protein (NP) diluted at 1,5 μg/μL in protein buffer, weekly, during 4 consecutive</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Wistar</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The pET-28a containing the nucleocapsid DNA fragment was used for the expression of the recombinant protein in E. coli BL21 STAR (DE3) strain.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pET-28a</div><div>suggested: RRID:Addgene_44242)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The pET-28a containing the nucleocapsid DNA fragment was used for the expression of the recombinant protein in E. coli BL21 STAR (DE3) strain.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STAR</div><div>suggested: (STAR, RRID:SCR_004463)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All analyses were performed using the GraphPad Prism 7® software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      However, one of the limitations of using experimental animals are the inherent difficulties due to anatomic and physiological differences between other mammalian species and the human beings. It is of note that the lower respiratory tract of mammals is constantly exposed to multiple airborne pathogens, and a prompt and effective immune response against such inhaled invaders is crucial for the survival of species [26, PABST 2010]. In this context, during the evolutionary process, a mucosal secondary lymphoid tissue, embedded in the walls of the large airways, the Bronchus-Associated Lymphoid Tissue (BALT) became part of the immune defense arsenal of many mammals. BALT is constitutive during all life phases in some species, including rats and rabbits, but it is absent in healthy adult mice and humans [Sminia et al., 1989, Troy D. Randall 2010]. Although more studies with different species, more similar to the human beings, regarding the specific pulmonary immune response are still required, we can suppose that, interestingly, the IM immunization with recombinant NP was able to activate the BALT of the rats, as a response of the systemic immune response triggered by the immunization, reflecting in the overactivity of immune cells observed in the lung of NP rats. Our findings suggest that, in spite of the IM administration, our immunizing agent was able to trigger an immune response specifically in the lungs of the injected rats. This is clinically relevant: the immunomodulation ...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. Rogers, J. P., Watson, C. J., Badenoch, J., Cross, B., Butler, M., Song, J., Hafeez, D., Morrin, H., Rengasamy, E. R., Thomas, L., Ralovska, S., Smakowski, A., Sundaram, R. D., Hunt, C. K., Lim, M. F., Aniwattanapong, D., Singh, V., Hussain, Z., Chakraborty, S., … Rooney, A. G. (2021). Neurology and neuropsychiatry of COVID-19: A systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives. Journal of Neurology, Neurosurgery & Psychiatry, jnnp-2021-326405. https://doi.org/10.1136/jnnp-2021-326405

    1. Pham, Q. T., Le, X. T. T., Phan, T. C., Nguyen, Q. N., Ta, N. K. T., Nguyen, A. N., Nguyen, T. T., Nguyen, Q. T., Le, H. T., Luong, A. M., Koh, D., Hoang, M. T., Pham, H. Q., Vu, L. G., Nguyen, T. H., Tran, B. X., Latkin, C. A., Ho, C. S. H., & Ho, R. C. M. (2021). Impacts of COVID-19 on the Life and Work of Healthcare Workers During the Nationwide Partial Lockdown in Vietnam. Frontiers in Psychology, 12, 563193. https://doi.org/10.3389/fpsyg.2021.563193

    1. SciScore for 10.1101/2021.08.23.21262114: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      No key resources detected.


      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      The main limitation of this work is precision of the estimates, due to small numbers. Death in childhood is fortunately a rare event; with absolute mortality across the 2 years of around 27 per 100,000 children per year. While we had adequate precision to identify an overall reduction in deaths, and the likely causal conditions (e.g. infection) in which this occurred, we had less power to identify small, but still potentially important differences that might indicate which children were most affected by the broad social changes, and for which children the effects were less clear. The coincidence of maximum lockdown regulations and the maximum reduction in mortality for younger children suggests that the lockdown regulations including social distancing and reduction of social mixing appeared most beneficial to younger children and perhaps to certain ethnic groups. However, we had limited statistical power and interpretation requires caution. In addition, population measures were derived from ONS data and, particularly in the case of ethnicity, may not be up to date. However, estimates were compared between years and, as the absolute risk is low, error is likely only from population change between the two years. Like all work using routine data, case ascertainment may not be 100%, although reporting to NCMD is a statutory requirement and cohort completeness has previously been reported as good4, though we had missing data for some measures (e.g. ethnicity). For this work, the l...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.23.457229: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Clinical Recruitment and Sample Collection: 61 individuals (45 SARS-CoV-2 naïve, 16 SARS-CoV-2 recovered) were consented and enrolled in the study with approval from the University of Pennsylvania Institutional Review Board (IRB# 844642).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, 50 uL of 1:5000 diluted goat anti-human IgG-HRP (Jackson ImmunoResearch Laboratories) or 1:1000 diluted goat anti-human IgM-HRP (SouthernBiotech) was added to each well and plates were incubated for 1 hour.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG-HRP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The next day, 2-fold serially diluted serum samples were mixed with VSVΔG-RFP SARS-CoV-2 pseudotype virus (100-300 focus forming units/well) and incubated for 1 hour at 37⁰C. 1E9F9, a mouse anti-VSV Indiana G, was also included in this mixture at a concentration of 600 ng/ml (Absolute Antibody, Ab01402-2.0) to neutralize any potential VSV-G carryover virus.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-VSV</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 16 hours, CD40 blocking antibody (0.5ug/mL final concentration) was added to cultures for 15 minutes prior to stimulation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD40</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">20 hours post-stimulation, antibodies targeting CXCR3, CCR7, CD40L, CD107a, CXCR5, and CCR6 were added to the culture along with monensin (GolgiStop, BD Biosciences) for a 4-hour stain at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CXCR3</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CCR7</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD107a</div><div>suggested: (DSHB Cat# H4A3, RRID:AB_2296838)</div></div><div style="margin-bottom:8px"><div>CXCR5</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CCR6</div><div>suggested: (GenWay Biotech Inc. Cat# GWB-4C4A07, RRID:AB_10260299)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Surface staining for 30 minutes at room temperature was then performed with antibodies directed against CD4, CD8, CD45RA, CD27, CD3, CD69, CD40L, CD200, OX40, and 41BB in FACS buffer.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD4</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD8</div><div>suggested: (BD Biosciences Cat# 346048, RRID:AB_400455)</div></div><div style="margin-bottom:8px"><div>CD45RA</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD27</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD3</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD69</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD40L</div><div>suggested: (Bio X Cell Cat# BE0292, RRID:AB_2687815)</div></div><div style="margin-bottom:8px"><div>CD200</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Detection of SARS-CoV-2 Neutralizing Antibodies: 293T cells were seeded for 24 hours at 5 × 106 cells per 10 cm dish and were transfected using calcium phosphate with 35 μg of pCG1 SARS-CoV-2 S D614G delta18 or pCG1 SARS-CoV-2 S B.1.351 delta 18 expression plasmid encoding a codon optimized SARS-CoV-2 S gene with an 18-residue truncation in the cytoplasmic tail (kindly provided by Stefan Pohlmann).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero E6 cells stably expressing TMPRSS2 were seeded in 100 μl at 2.5×104 cells/well in a 96 well collagen coated plate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The serum-virus mixture was then used to replace the media on VeroE6 TMPRSS2 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6 TMPRSS2</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Detection of SARS-CoV-2 Neutralizing Antibodies: 293T cells were seeded for 24 hours at 5 × 106 cells per 10 cm dish and were transfected using calcium phosphate with 35 μg of pCG1 SARS-CoV-2 S D614G delta18 or pCG1 SARS-CoV-2 S B.1.351 delta 18 expression plasmid encoding a codon optimized SARS-CoV-2 S gene with an 18-residue truncation in the cytoplasmic tail (kindly provided by Stefan Pohlmann).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCG1 SARS-CoV-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pCG1</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were analyzed using FlowJo v10 (BD Bioscience).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, pRESTO v0.6.0 (51) was used to align paired end reads, remove short and low-quality reads, and mask low-quality bases with Ns to avoid skewing SHM and lineage analyses.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pRESTO</div><div>suggested: (pRESTO, RRID:SCR_001782)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequences which passed this process were aligned and annotated with IgBLAST v1.17.0 (52).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgBLAST</div><div>suggested: (IgBLAST, RRID:SCR_002873)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lineage Construction & Visualization: A lineage for each clone was constructed with ImmuneDB, a lineage was constructed as described in (54). ete3 (55) was used to visualize the lineages where each node represents a unique sequence, the size of a node represents its relative copy number fraction in the clone, the integer next to each node represents the number of mutations from the preceding vertical node.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImmuneDB</div><div>suggested: (ImmuneDB, RRID:SCR_017125)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">: Raw sequencing data for all donors and subsets is available on SRA under BioProject PRJNA752617.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BioProject</div><div>suggested: (NCBI BioProject, RRID:SCR_004801)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">High Dimensional Analysis and Statistics: All data were analyzed using custom scripts in R and visualized using RStudio.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RStudio</div><div>suggested: (RStudio, RRID:SCR_000432)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.21.457245: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The risk of infection was displayed in the 2.5th percentile, mean, and 97.5th percentile using a forest plot in GraphPad Prism version 7.0.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Limitations of this study and future perspectives: While this study evaluated the risk of SARS-CoV-2 transmission according to the QMRA framework, its limitations and uncertainties should be carefully acknowledged. SARS-CoV-2 concentrations in gc/μL, the most sensitive parameter affecting the calculation of risk, are subject to natural variations in the saliva and mucus of infected patients (Azzi, Carcano, et al., 2020; Wölfel, Corman, et al., 2020). In this study, 251 swab test Ct values were used to represent the virus levels in Thai patients. Due to the lack of a standard curve from Thai hospital laboratories, we used a published standard curve of the N2 gene (Sherchan, Shahin, et al., 2020) to estimate the virus concentrations in this study. However, heterogeneity in published standard curves for SARS-CoV-2 has been observed (Bivins, Kaya, et al., 2021). Moreover, variations in technical and laboratory analyses (e.g., data analysis methods and control materials) could intensify biases, leading to variability in the calculated virus concentrations (Bivins, Kaya, et al., 2021; Kongprajug, Chyerochana, et al., 2020). Adhering to standards and quality control measures is therefore underlined in order to support data sharing and referencing for future research, especially for emerging infectious diseases. However, even with consideration of the uncertainties mentioned above, the calculated virus concentrations in mucus used in this study, which ranged from 4.4 × 10−1 to 6.4 × ...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.19.21262278: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Ethics: This study was approved by the Moscow City Ethics Committee of the Research Institute of the Organization of Health and Healthcare Management and performed according to the Helsinki Declaration.<br>Consent: All participants provided their written informed consent.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Participant inclusion: The study cohort consists of individuals above 18 years old who had voluntarily come to one of four Moscow City Clinics for routine testing for COVID-19 antibodies and agreed to participate in the study.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>COVID-19</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2–specific antibodies and virus-neutralizing activity of plasma: We evaluated the titers of the virus-specific IgM and IgG antibodies in blood serum using an automated CL-series chemiluminescent immunoassay analyzer with compatible reagent kits (Mindray, China); here and below ‘IgG’ and ‘IgM’ refer to results obtained with this method, if not mentioned otherwise.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For a separate representative group of participants, we measured antibodies specific to SARS-CoV-2 spike (S) and nucleocapsid (N) proteins using the SARS-CoV-2-IgG-EIA-BEST ELISA kit (Vector-Best, Russia) and the automated ARCHITECT i1000SR analyzer with compatible reagent kit (Abbott, USA), respectively, according to the manufacturer’s standard protocol; additionally, we measured the virus-neutralizing activity of plasma by microneutralization assay using SARS-CoV-2 (hCoV-19/Russia/Moscow_PMVL-1/2020) in a 96-well plate and a 50% tissue culture infective dose (TCID50) of 100 as described in 4, with plasma dilutions of 10, 20, 40, 80, 160, 320, 640, and 1,280 times.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vector-Best, Russia</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For a separate representative group of participants, we measured antibodies specific to SARS-CoV-2 spike (S) and nucleocapsid (N) proteins using the SARS-CoV-2-IgG-EIA-BEST ELISA kit (Vector-Best, Russia) and the automated ARCHITECT i1000SR analyzer with compatible reagent kit (Abbott, USA), respectively, according to the manufacturer’s standard protocol; additionally, we measured the virus-neutralizing activity of plasma by microneutralization assay using SARS-CoV-2 (hCoV-19/Russia/Moscow_PMVL-1/2020) in a 96-well plate and a 50% tissue culture infective dose (TCID50) of 100 as described in 4, with plasma dilutions of 10, 20, 40, 80, 160, 320, 640, and 1,280 times.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Abbott</div><div>suggested: (Abbott, RRID:SCR_010477)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow cytometry: PBMC were plated into 96-well U-bottom plates at a concentration of 1×106 cells per well in 100 µL of serum-free AIM-V medium (ThermoFisher Scientific; USA) supplemented with 1X AlbuMAX (ThermoFisher Scientific; USA), 2 mM L-glutamine, 50 μg/mL streptomycin, and 10 μg/mL gentamicin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ThermoFisher Scientific</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We analyzed data using FlowJo software (BD Biosciences, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Our study has several limitations: (i) the cohort analyzed is likely to be non-representative and includes only individuals who have visited outpatient clinics to voluntarily undertake tests for COVID-19 antibodies levels and who agreed to participate in the study; (ii) only a limited fraction of cases were reported to the city registry of COVID-19 cases, so some patients who indeed had COVID-19 after inclusion remained unreported; and (iii) we evaluated contributions of systemic antibody and T cell responses to the infectivity probabilities, whereas their local role in lungs, where the critical events of the SARS-CoV-2 infection occur, may be different. However, peripheral blood collection is a much less invasive intervention than bronchoscopy and therefore is more suitable for massive testing of the population in order to predict COVID-19 rates. It should be noted that the results reported are applicable only to infection with alpha SARS-Cov-2, which was dominant in Moscow during the time of study. Further research is needed to understand whether the results obtained hold for the new Delta variant. Taken together, our data suggest the advantage of serology testing over the analysis of T cell responses for the prediction of SARS-CoV-2 infection rates on a population level. According to our results, the calculated probabilities of infection depending on the specific IgG titers may be instructive for making decisions in personalized healthcare, as well as for the development o...

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04898140</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">The Evaluation of Cellular and Humoral Immunity to COVID-19 …</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.19.21262111: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: The study protocol was approved by Shamir Medical Center Institutional Review Board (129-2-LEU).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Authentication: The Abbot assay has been validated externally(Bryan et al., 2020; Perkmann et al., 2020; Zabelin et al., n.d.) with sensitivity 96.77%, specificity 99% and the caveat that these numbers depend on the boundaries of the middle range.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In this antibody CMIA test, the SARS-CoV-2 antigen-coated paramagnetic microparticles bind to the IgG antibodies that attach to the SARS-CoV-2 spike protein (SP) in patients’ serum and plasma sample and it requires a minimum of 100 μl of serum or plasma.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>SARS-CoV-2 spike protein</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      This study has several limitations. First, given the observational design, there is potential for unmeasured confounding factors. In particular, participants in this study were individuals who elected to have a serology test for SARS-CoV-2 during the study period, many of them as part of a survey. Individuals may have variable reasons for accepting or refusing the offered serology test, which may have affected the results of this survey. Additionally, even though we adjusted our results for known factors that could affect antibody production and decay, additional factors may have affected the results. The BNT162b2 mRNA COVID-19 vaccine has been shown to stimulate production of antibodies to several SARS-CoV-2 proteins, not just the spike protein, suggesting that the vaccine provides short-term protection against variant strains(Amanat et al., 2021; Turner et al., 2021b). Combining these results with ours suggests that the recent surge in breakthrough infections in fully vaccinated individuals is due at least in part to declining levels of antibodies and not solely due to the variant strains of SARS-CoV-2. In a recent single-center, prospective, cross-sectional cohort study, children’s immunity was found to decline 4 months after the COVID-19 infection(Breuer et al., 2021). Lyer et al. reported that anti-S-protein antibodies reserved neutralizing abilities and persevered for up to 75 days after SARS-CoV-2 infection in >95% of patients(Iyer et al., 2020). Gudbjartsson et al. sh...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.20.456972: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: Animal research was carried out under a United Kingdom Home Office License, P48DAD9B4.<br>IRB: Ethical approval was approved by the South Central-Berkshire B Research Ethic Committee (REC ref: 20/SC/0206; IRAS 283805).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Outbred female ferrets (16–20 weeks old) weighing 750–1,000 g were used.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">The experiments were not randomized, and the investigators were not blinded to allocation during experiments and outcome assessment.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">The experiments were not randomized, and the investigators were not blinded to allocation during experiments and outcome assessment.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">No statistical method was used to predetermine sample size.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: Cell lines were not tested for mycoplasma contamination.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were permeabilised in methanol 0.6% H2O2 and stained for 1 h with an antibody against SARS-CoV-2 nucleocapsid protein (Sino Biological; 40143-R019, 1:300 dilution).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 nucleocapsid protein</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were further stained with the secondary antibody anti-rabbit HRP conjugate (Sigma; 1:3000 dilution) for 1 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rabbit</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Human embryonic kidney cells (293T; ATCC; ATCC CRL-11268) were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Gibco), 10% fetal calf serum (FCS),</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: ATCC Cat# CRL-11268, RRID:CVCL_1926)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus titration was performed by median tissue culture infectious dose (TCID50) on Vero cells as described previously 3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Approximately 2.5 μg of the in vitro synthesized RNA was used to transfect ∼6 ×105 BHK-hACE2-N cells stably expressing the SARS-CoV-2 N and the human ACE2 genes 45 using the MessengerMax lipofection kit (Thermo Scientific) as per the manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BHK-hACE2-N</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then incubated until signs of viral replication (syncytia formation) became visible (usually after 2-3 days), at which time the medium was collected (P0 stock) and used further as a source of rescued virus to infect VERO E6 cells to generate P1 and P2 stocks.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VERO E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the CPE-based neutralisation assay (reverse genetics virus vs Pfizer antisera), serial dilutions of sera were incubated with 100 TCID50 of virus for 1 h at 37°C, 5% CO2 in 96 well plates before a suspension of Vero-ACE2-TMPRSS2 cells were added and incubated for 3 days at 37°C, 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-ACE2-TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, BHK-21 cells were transfected with 500 ng of ACE2 or empty vector (pDISPLAY) using TransIT-X2 (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BHK-21</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, a set of overlapping cDNA fragments representing the entire genome of SARS-CoV-2 Wuhan isolate (GenBank: MN908947.3) were chemically synthesized and cloned into pUC57-Kan (Bio Basic Canada Inc).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pUC57-Kan</div><div>suggested: RRID:Addgene_123653)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The cDNA fragment representing the 5’ terminus of the viral genome contained the bacteriophage T7 RNA polymerase promoter preceded by a short sequence stretch homologous to the XhoI-cut end of the TAR in yeast vector pEB2 44.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pEB2</div><div>suggested: RRID:Addgene_104001)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmids and cloning: Lentiviral packaging constructs pCSLW and pCAGGs-GAGPOL were made as previously described.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCSLW</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">At ICL, 100 mm dishes of 293Ts were transfected using lipofectamine 3000 (Thermo) with a mixture of pCSFLW, pCAGGS-GAGPOL and spike proteins expressed in pcDNA3.1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCSFLW</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pCAGGS-GAGPOL</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were transfected using polyethyleneimine (PEI) with a mixture of pCSFLW, p8.91 and SARS-CoV-2 spikes expressed in pcDNA3.1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>p8.91</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pcDNA3.1</div><div>suggested: RRID:Addgene_79663)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, BHK-21 cells were transfected with 500 ng of ACE2 or empty vector (pDISPLAY) using TransIT-X2 (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pDISPLAY</div><div>suggested: RRID:Addgene_51053)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viruses were sequenced using Oxford Nanopore as previously described 46.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Oxford Nanopore</div><div>suggested: (Oxford Nanopore Technologies, RRID:SCR_003756)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The fastq files produced by Nanopore sequencing were filtered with lengths 400 and 700 using Artic-ncov2019 pipeline v1.2.1 (https://artic.network/ncov-2019/ncov2019-bioinformatics-sop.htμl) by “artic guppyplex” function.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Artic-ncov2019</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">These primer trimmed bam files were further analysed using DiversiTools (http://josephhughes.github.io/btctools/) with the “-orfs” function to generate the ratio of amino acid change in the reads and coverage at each site of protein in comparison to the reference SARS-CoV-2 genome (MN908947.3) as we previous description 53.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>DiversiTools</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequences were aligned to the Wuhan-Hu-1 reference genome sequence (MN908947) 54 using MAFFT v7.475 55 and the alignment was then checked manually.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MAFFT</div><div>suggested: (MAFFT, RRID:SCR_011811)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Phylogenetic analysis was performed using the remaining 936 mink genomes rooted on the Wuhan-Hu-1 reference genome (MN908947) with a general time reversible model of nucleotide substitution, a proportion of invariant sites estimated from the data and a gamma distribution describing among-site rate variation (GTR + / + Γ) built using RAxML v8.0.0 58 with the phylogeny rooted on the sequence of the virus Wuhan-Hu-1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RAxML</div><div>suggested: (RAxML, RRID:SCR_006086)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.19.457020: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Methods: Ethics statement: All experimental procedures with animals were approved by the Boston University Biomedical Research, Institutional Biosafety Committee and Institutional Animal Care and Use Committee.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">SARS-CoV-2 infection: 14 week old C57BL6J and K18-hACE2 transgenic female mice were intranasally inoculated with 1×106 PFU of SARS-CoV-2 in 50 μl of sterile 1X PBS and sham mice were inoculated with 50 μl of sterile 1X PBS.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The following antibodies were used: Mouse-SARS-CoV-2 spike protein (clone: E7U6O; Cell Signaling Technology, USA); rabbit-CD61 (clone: ARC0460; Invitrogen, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Mouse-SARS-CoV-2 spike protein</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">African green monkey kidney Vero E6 cells (ATCC® CRL-1586™, American Type Culture Collection, Manassas, VA) were used to propagate the viral isolate in vitro.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mice: C57BL/6J mice and heterozygous humanized ACE2 (K18-hACE2) mice (strain: 2B6.Cg-Tg(K18-ACE2)2Prlmn/J) were obtained from the Jackson Laboratory (Bar Harbor, ME).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6J</div><div>suggested: RRID:MGI:3589388)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 infection: 14 week old C57BL6J and K18-hACE2 transgenic female mice were intranasally inoculated with 1×106 PFU of SARS-CoV-2 in 50 μl of sterile 1X PBS and sham mice were inoculated with 50 μl of sterile 1X PBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL6J</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For absolute quantitation of viral RNA, a 389 bp fragment from the SARS-CoV-2 E gene was cloned onto pIDTBlue plasmid under an SP6 promoter using NEB PCR cloning kit (New England Biosciences, Ipswich, MA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pIDTBlue</div><div>suggested: RRID:Addgene_117418)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Desalted peptides (20 μg) were labeled with Tandem Mass Tags (TMT) using TMTPro-16plex isobaric tags (ThermoFisher Scientific; #A44520) as per manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ThermoFisher Scientific</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Analysis of raw mass spectrometry data: All acquired MS/MS spectra were simultaneously searched against the complete SwissProt mouse proteome (downloaded on 2020-10-20) and the Uniprot SARS-CoV-2 proteome (downloaded on 2020-05-03) using MaxQuant (Version 1.6.7.0), which integrates the Andromeda search engine.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MaxQuant</div><div>suggested: (MaxQuant, RRID:SCR_014485)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Whole slide image analysis: Slides were imaged on the HALO™ image analysis platform using a Mantra 2.0™ quantitative pathology workstation and unmixed with InForm software version 2.4.8 (Akoya Biosciences, Marlborough, MA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>InForm</div><div>suggested: (inForm, RRID:SCR_019155)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Statistical analysis was performed using GraphPad Prism 9 software (GraphPad Software, LLC) by one-way ANOVA (multiple groups) and Bonferroni multiple-comparisons test, or student-t test (2 groups).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Entrez and Ensembl IDs were mapped using biomaRt (v2.44.4) and only proteins with mapped IDs were used for visualization and downstream analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>biomaRt</div><div>suggested: (biomaRt, RRID:SCR_019214)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Volcano plots were constructed using ggplot2 (v3.3.3).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ggplot2</div><div>suggested: (ggplot2, RRID:SCR_014601)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Venn diagrams were constructed using VennDiagram (v1.6.20) and VennDetail (v1.4.0).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VennDiagram</div><div>suggested: (VennDiagram, RRID:SCR_002414)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Heatmaps were generated using ComplexHeatmap (v2.4.3) package with unsupervised clustering, and the dendrograms were reordered for a more meaningful visualization using dendsort (v0.3.3) and dendextend (v1.14.0) packages.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ComplexHeatmap</div><div>suggested: (ComplexHeatmap, RRID:SCR_017270)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Gene Ontology (GO), including biological process (BP), molecular function (MF) and cellular component (CC), was analyzed using enrichR (v3.0) and gProfiler2 (v0.2.0).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>enrichR</div><div>suggested: (Enrichr, RRID:SCR_001575)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pathway analyses based on Kyoto Encyclopedia for Genes and Genomes (KEGG) and Reactome were performed using clusterProfiler (v3.16.1) and ReactomePA (v1.32.0), respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>KEGG</div><div>suggested: (KEGG, RRID:SCR_012773)</div></div><div style="margin-bottom:8px"><div>clusterProfiler</div><div>suggested: (clusterProfiler, RRID:SCR_016884)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To understand interactions between proteins in nine key processes and pathways that were enriched in either 2dpi or 4dpi data sets, an interactome was constructed and visualized using the stringApp (v1.6.0) in Cytoscape (v3.8.2).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Cytoscape</div><div>suggested: (Cytoscape, RRID:SCR_003032)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data sharing statement: The proteomics data presented in this manuscript and raw data files will be deposited in the ProteomeXchange Consortium (http://www.proteomexchange.org) upon the acceptance of the manuscript.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>http://www.proteomexchange.org</div><div>suggested: (ProteomeXchange, RRID:SCR_004055)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. Author Response:

      Reviewer #1:

      This manuscript describes extensive phenotypic analyses of Flo11, a multifunctional adhesin in S. cerevisiae. Flo11 mediates a variety of adhesin-related activities including flocculation and adhesion to surfaces, and these activities can lead to biofilm and pellicle (floating biofilm) formation, as well as ability to mediate agar invasion. Flo11 activities are activated after shear force, which facilitates surface amyloid formation. Flo11 is highly diverse, with different yeast strains expressing alleles with sequence and repeat number differences. These differences contribute to differences in adhesion behaviors. The alleles have conserved regions including a secretion signal, a globular N-terminal region, and a C-terminal GPI anchor that mediates cell surface attachment. In between these regions are ~1000-1500 amino acids with variable sequence and repeat numbers and a variable number of potential amyloid-core sequences. The manuscript includes extensive sequence analysis of alleles from 4 strains, and analysis of the consequences of expression of different regions of the protein from various alleles. This major study includes detailed AFM analyses showing that a Flo11 allele from a wine-fermenting strain expression leads to presence of cell surface patches of Flo11 adhesin 10-100 nm diameter 10-20 nm elevation from the cell surface. SiN AFM probing determines both adhesive strength and stiffness of the adhesion patches. The regions containing the amyloid-core sequences are essential for most of the Flo11 activities, because the activities are inhibited by deletion of amyloid-forming core regions or by treatment of intact cells with a general amyloid inhibitor or a sequence-specific anti-amyloid peptide.

      We thank the reviewer for these encouraging and stimulating comments.

      The work is extensive and well-documented. Qualitative data on the different constructs shows how activity correlates to specific sequences in the protein. However, the analysis is compromised by the lack of data on the levels of surface expression of the different alleles and constructs. mRNA levels are reported, but for fungal adhesins these values often do not correlate with surface expression levels. The problem is especially confounding for the C-terminal deletion construct, because the deleted region includes the GPI addition signal: its deletion leads to secretion of free adhesin into the medium and decreased surface anchorage (Douglas et al. 1996 Eukaryot. Cell6:2214-2221).

      This critical comment also raised by the Editor has been answered above. The main finding was to show that a Flo11 variant lacking the C-ter still show localization at the cell periphery as witnessed by immunofluorescence, suggesting that this variant can be retained at the cell wall by other structural components. This result appears to be in contradiction with the data from Douglas et (EC, 2007) except that as written in line 485-490 in the revised version), FLO11 was expressed on a 2μ plasmid under PGK1 promoter, leading to huge expression of Flo11p, which may exceed the capacity of cell wall to retain it.

      The quantitative biophysical conclusions would be strengthened if the data from all tested cells were aggregated and presented, not just the data from the individual cell shown in each figure.

      We have already answered to this question above, as it was one of the issues raised by the Editor.

      If these critiques are addressed, the manuscript would greatly benefit from a summary figure and paragraph describing the activities attributed to each region of the sequence in L69 and other alleles. It would also benefit from reference to recent work demonstrating that cell-cell adhesion can be mediated by formation of amyloid-like bonds between cells.

      This is indeed a good suggestion but the paper already contains 9 figures and 2 tables and we would like to extend this comparative analysis with all the FLO-encoded flocculins in S. cerevisiae, which will be the purpose of an ongoing short review on the subject to be submitted soon.

      Reviewer #2:

      The authors argue that the Flo1 protein of yeast can mediate cell-cell aggregation through amyloid formation. They identified a wine-making yeast strain that is particularly strong in this phenotype and this correlates with the presence of aggregation prone repeat regions in the protein. Their frequency seems to be important for the effect.

      The paper makes an extensive case, although I have reservations on experimental specifics. They show AFM imaging of the cell surface (nanodomain formation) and extensive genome editing to alter the suspected regions, which largely (but not perfectly produces effects in line with the hypothesis). Also, they use an inhibitory peptide (not so well validated) and a widely used amyloid dye to disturb these amyloid formation. Taken together these data point toward a role for amyloid formation, similar to what was previously shown by Lipke for candida. However, I remain with some concerns regarding data, controls, interpretation that preclude firmly backing the story.

      We thank this reviewer for his/her critical comments. We have done our best to answer to your relevant questions, comments and remarks.

      Major Concerns:

      There is no direct evidence of amyloid formation in situ.

      The paper is not about to show amyloid fibers formation of Flo11p as this was already shown in a previous paper that Flo11p forms amyloids fibers in vitro. Moreover synthetic peptides with high β- aggregate potential sequences taken from these adhesins formed amyloids in vitro as well (see reference Ramsook et al., Eucaryotic cell, 9: 393-404 2010, and that we referenced in our paper).

      The hydrophobic cluster analysis in figure 1 is not very clear - it is almost impossible to make anything out in those graphs

      The HCA (hydrophobic cluster analysis) representation as shown in this figure has been used previously by others (see Chan et al., mSphere, e00128, 2016). This representation has the advantage for non-expert in the field to readily visualize what is common and different in term of sequences structure between the different Flo proteins. According to your request, we remove this figure and onoyt kep data on TRs in a supplementary File 1.

      The term beta-aggregation potential is used throughout and not defined. I presume this refers to the TANGO score? You should call it TANGO score then. Where was the arbitrary cutoff of 70 for TANGO aggregation propensity determined? In itself it is only a prediction, not a demonstration of amyloid potential.

      It is indeed a valuable suggestion although β-aggregation term is currently used in many other publications on this subject. TANGO is a statistical algorithm designed to predict β- aggregate potential sequences in protein. It does not predict whether or not these sequences will lead to amyloid formation, although correlation between β-aggregation sequences and amyloid formation has been discussed in (Fernandez-Escamilla AM, Rousseau F, Schymkowitz J, Serrano L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol. 2004 Oct;22(10):1302-6. doi: 10.1038/nbt1012. Epub 2004 Sep 12. PMID: 15361882.).

      The cutoff used for β-aggregation propensity was set arbitrarily set a 30% (see line 634 in the M&M section and in Table 1 and Supplementary File 2a) to discriminate which sequence in the protein have a high propensity to beta- aggregate. As shown in Table 1 and Supplementary File 2a, Flo11 protein exhibits several beta-aggregation prone sequences that are largely over this cut-off.

      To do that you need to make the peptide and show it makes amyloid (and that this can be suppressed by thioS and your breaker peptide, see below)

      These experiments have been carried out in a previous paper (See Ramsonk et al, Eukaryotic cell, 9, 393-404, 2010)

      line 124: how many cells were analysed, is this pattern present in the population? analysing a single cell would seem insufficient to me - this comment applies to several analyses below.

      As indicated in M&M, all AFM experiments were done on 3 biological replicates and for each replicate around 6 to 12 cells have been analyzed. Data reported in the figure are from a representative cell. However, as stated above and in accordance with the Editor request, we reported the aggregation of all data from 24 cells, which showed the bimodal behavior of the adhesion forces and stiffness, which are reported as box plots (see Figure 1G, H);

      line 124: "this apparent roughness can be account for by proteins" - there is no data to support this, right? could be anything at this stage, it is just patch. I my mind you would need AFM-IR to ensure that you are actually observing a protein structure. This would immediately show you if its in the amyloid state as well.

      As this stage, we do not have any idea what could be those aggregates and therefore we modified as follows (lines 115-118 in the revised version): The high-resolution height image (Fig. 1B) revealed a multitude of small aggregates on the cell surface with an average diameter of 100 nm and a height above the cell surface in the range of 15-20 nm (Fig. 1C).

      line 134: possibly due to my ignorance: how do you conclude from those forces that one is the hydrophobic interaction and the other is protein unfolding? comes as a complete deus ex machina to me.

      The difference between hydrophobic interactions and protein unfolding is obtained from the shape of the retraction force-distance curves as shown in Fig 1E. A hydrophobic interaction is a physicochemical interactions due to the surface tension which is exerted on the surface of materials. It is particularly related to the organization of the solvent (usually water) at the interface between the solid and the liquid. These forces are exerted at the immediate surface of the material and are characterized by a null distance between the AFM tip and the surface at the moment of rupture.

      On the contrary, a protein unfolding, which as its name indicates, consists in unfolding a complex organic molecule (a protein) and which is characterized by a distance between the AFM tip and the surface, at the moment of rupture, equal to the length of the unfolded protein. If the protein unfolds in several steps, which is often the case for these molecules with complex folding, this results to sawtooth force curves profiles characteristic of the unfolding of proteins containing repeated domains.

      line 151 (also mentioned later): the 'anti-amyloid peptide' is taken with a lot of faith: how do we know it works by disrupting amyloid? At least show it works on the peptide level (Tht curves) (again the AFM-IR measurement would solve this in one single effort). This experiment at least needs a control to show the cell is otherwise intact and other structures are still present. Designing potent amyloid disrupting peptide is not trivial - see various papers on the topic by David Eisenberg. I find it hard to believe these subtle mutations achieve all that they are claimed to achieve.

      The use of a mutated peptide of the amyloid core sequences or amyloid perturbants are well established to investigate amyloid-like nature of nanodomains formation or in cell-cell aggregation. Therefore, it may be a question of semantic because in this case, we are working with a protein that forms cellular aggregates due to the presence of amyloid-core sequence. When these proteins unfold, they expose these sequences that were previously buried inside compact protein, leading to interaction between molecules of the same type, and hence this creates clusters of thousands of molecules that can eventually organize into nanodomain. Such interaction can be inhibited by a mutated peptide of the amyloid core sequence or by anti-amyloid dyes. This event is different from a protein whose amyloid formation is triggered by intermolecular associations leading to a refolded protein that often loses it function and this leads to condition of protein misfolding diseases neither on amyloid prions whose flocculin or adhesion in yeast does not belong to.

      line 157: Maybe I am confused, but why would thioflavin S destabilise amyloid? it is widely used as an amyloid-specific dye, and I would expect its binding energy to stabilise the amyloid state. Later, around line 310, the compound is called a drug, but really, it is just a rotor dye with an affinity for amyloid. Do other amyloid dyes show similar effect (oligothiophenes, congo red, curcumin)?

      It is indeed known that amyloid-dependent aggregation of yeast cells can be monitored by increased thioflavin T fluorescence as a result to its binding to β-amyloids structures. However, other amyloid binding dyes such as Congo red and in particular Thiflavin S had potent anti-aggregation effects (see for instance Ramsook et al. EC, 9, 393-404, 2010). Taking into account that these dyes bind to amyloids, they are thus employed to evaluate whether the cell-cell aggregation mediated by Flo11 (and the same for Als1 and Als5 in C. albicans) is due the presence of amyloid forming sequence in these proteins.

      line 250: are we really comparing single cell instances of each construct?

      Suggestions:

      If the hypothesis of the authors is true, it should be possible to replace the amyloid domains with synthetic ones (STVIIE eg, Serrano and co-workers), or from another protein. Once you have sufficient of these, you should see the cell-interactions etc.

      Also, introducing structure breaking residues in the repeats, like proline should stop the effect and would give strong support for the amyloid nature of the interactions over general hydrophobic patches.

      Each of these strains expresses only one specific variant validated by genome sequencing. Our AFM analysis showed that nanodomains are no longer observed when Flo11p is lacking RR2 that contains the additional amyloid sequence motifs. Thus, we can conclude that amyloid formation sequences are indispensable for their formation. The question of disrupting the cell-cell interactions or preventing the formation of the nanodomains is presented earlier in the paper (see line152 -158 in the revised version).

      Reviewer #3:

      The authors observed nanodomains in FLO11 expressed S. cerevisiae strains when imaging the cell wall of the cell with a bare AFM tip. The adhesion to the tip as well as the stiffness of these domains were characterized using AFM. However, there was no direct proof/confirmation that these nanodomains were actually composed of Flo11 proteins.

      We disagree with this statement because we clearly show that (i) the formation of nanodomains in response to AFM tip does not occur anymore in a mutant defective in FLO11, and (ii) the expression of the FLO11 gene from L69 strain in the lab strain BY leads to the formation of nanodomains at the cell surface of this strain, which is not seen upon overexpression of its endogenous FLO11. Thus, these data taken together demonstrate that a) Flo11 is responsible for nanodomains formation and b) this formation requires a peculiar Flo11 protein. We show actually that this peculiarity lies in the necessity to harbor sufficient amyloid-forming motifs in the protein sequence.

      Previous research showed that Flo11p trans interacts and this trans interaction between cells could be (hypothesis) preceded by a cis interaction between the Flo proteins via beta-aggregation-prone amyloid-forming sequences. It seems that the obtained results could explain this trans-interaction (i.e. the "nanodomains"). However, in this model the main interaction is based on the Flo11 A-domain interaction that is responsible for the trans-interaction. This could not be confirmed in the present work where the cell-cell interaction results were only based on (qualitative) microscopic observation of cell aggregates. Additional, it has been previously shown that homotypic Flo11 A-domain interaction is pH dependent since only at low pH these domains hydrophobically interact. It seems that the current experiments were performed at a too high pH.

      The suggestion that Flo11 dependent trans-interaction that characterizes cell-cell interaction may be preceded by a cis-interaction or homophobic interaction (ie interaction between Flo11p molecules leading to cluster) is still hypothetical. However, recent data from Lipke’ group (se Ho et al, mBio. 2019 Oct 8;10(5):e01766-19; Dehullu et al, Nanolett,19, 3846, 2019) showed that amyloid-forming sequences are implicated in these two types of interaction. Thus, while cis-interaction of Flo11p definitively requires amyloids motifs, our data are in line with this finding that the amyloid-forming sequence contribute to trans-interaction, although they are not essential to it. Altogether, we revised part of the Result section (see lines 312 -315 in the revised version) as well as the Discussion considering both model and our data (see line 484 to 514).

      Finally, we have carried out the cell-cell adhesion experiments shown in Figure 6 at pH 5 (as for AFM experiments). This is now clearly stated in Mat & Meth.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Firstly, we would like to thank the reviewers for their helpful and insightful comments.

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      In the manuscript of Ramadan et al. , authors use the ex vivo organoid approach to compare gene expression in organoids derived from adult type stem cells when these organoids are grown using different matrices. The presence of Collagen type I induces the emergence of cells with a transcriptome similar to fetal progenitors. In contrast, laminin the main component of matrigel, induces an organoid-protruded phenotype with transcriptome of stem cell type. Then, they correlate these data with expression of collagens and laminins from data publicly available. They show by qRT -PCR that laminins are more expressed in mesenchymal versus epithelial fractions postnatally. They hypothesize on this basis that the remodeling at postnatal stage is likely only dependent on the mesenchymal compartment and it involves interaction of laminins with integrity a6.

      It seems that some of the presented data have already been described and could not be considered as « novel ».

      For some of the statements, like this one « the basement-membrane produced by the epithelium is not sufficient to increase stem cell numbers and induce a morphological crypt formation », the conclusion is not sustained by provided experiments. To draw definitive conclusion on this particular point, authors could reproduce the experiment presented in Fig. 4d but using Cre recombinases specific for mesenchymal and epithelial compartments rather than the ubiquitous Cre line. It would be interesting to investigate if organoids grown from lamc1-/- mice can generate protruded organoids or not.

      In addition, how interpret the fact that fetal organoids up is associated with « laminin interactions » in fig. 1c?

      The statement that the epithelium-produced basement membrane is not sufficient to increase stem cell numbers is based on our in vitro observations. Analysis of the RNAseq data shows that the expression of several laminins is increased on collagen (see heatmap of laminin interactions below, which will be added to the manuscript). This is also the reason why ‘laminin interactions’ is highly significant in the gene set enrichment analysis (Fig. 1C). Despite this upregulation, we never observed morphological changes (or expression changes) as when laminin is added to the collagen-hydrogel. In addition, we showed that the vast majority of ECM components is produced by the mesenchyme in vivo, in line with previous literature as cited in the manuscript. The mentioned Cre lines to address the question in vivo are unfortunately not available to our collaborators with the Lamc1 k.o. mice and it would therefore take too long to perform these experiments.

      However, to address this point in vitro we will grow organoids from Lamc1 fl/fl mice and induce loss of laminin in the pure epithelial cell culture. Organoids will then be analysed for morphological changes, as well as proliferation and gene expression changes.

      One major point to address regards statistics. In material and methods, the paragraph describing statistical analyses is missing. Moreover, in the figures presenting qPRC data ( figs 1g 3b 3D 3g 4c and f), no statistic analysis is provided; and the number of samples for some conditions is extremely limited (n=2). In general, the term « independent experiment « should be clarified : does it correspond to one organoid line for which the experiment was repeated or one single experiment using different organoid lines?

      In fig 4c , all collagen conditions are set to 1.

      The avoidance of statistical inference for most of the experiments was a deliberate choice. In line with several comments (e.g. 1. Vaux, D. L. (2012) Know when your numbers are significant. Nature. 492, 180–181), we chose to show all individual data points (with exception of Fig. 3D, n=5, to ease interpretation) without statistics. In addition, for most expression data, we have data from RNAseq, single-cell RNAseq and qPCRs repeated at different hydrogel concentrations to obtain reliable results. Further, the in vivo mesenchymal qPCR expression data was validated with RNA in situ hybridization showing the mainly mesenchymal expression.

      The term independent experiment was used mainly for repeated experiments with the same organoid lines (exception RNAseq data, different organoids derived from individual mice). While conducting these experiments, we realised that the variability of these experiments comes from time in culture, density of cells and even Matrigel variation. The experiment in Fig. 4c (n=4, each time with the all controls) was performed with longer intervals in between, and showed variation in the absolute levels of expression. However, relative to each control we believe the effect is clear.

      As we will perform additional experiments for the revision of this paper, we will then perform statistical tests in the key experiments (e.g. Itga6 experiment) to alleviate any concerns regarding significance.

      Regarding the experiment presented in fig 4c, authors should include additional control conditions : anti-a6 integrity antibody in matrigel and use of an isotype antibody.

      We will conduct additional experiments regarding the Itga6. In addition to including the mentioned controls for the neutralizing antibody, we will genetically inactivate Itga6 via an inducible Crispr/Cas9. This should enable us to delete Itga6 when the cells are grown on collagen, and hence reduce the possibility of compensation in matrigel derived organoids.

      Another point regards RNAscope data presented in Fig 4b, it is surprising to observe such difference in terms of expression between E19 and P0. Does this mean that birth dramatically unregulates Itga6 expression in few hours? Authors should comment this point if verified.

      We do believe that birth is a timepoint where a dramatic change in the ECM and their receptors can be observed. The epithelial RNAseq data would already indicate that at 18.5 there is an increase in expression compared to E16. This upregulation of the receptor is in line with the dramatic remodelling of the ECM at birth, as is shown by the expression of the basement membrane components in Fig. 3d.

      Authors should avoid the word « signaling » for laminin-integrin interactions as they do not study this aspect at all in their experiments.

      The word signaling was used for the protein:receptor interaction and to distinguish it from changes to the physical characteristics of the hydrogel. But we agree with the reviewer, that we did not study laminin signaling per se and therefore will change the wording accordingly.

      Regarding Col1a1, authors cannot claim that it's expression only slightly changed (fig 3d) as it is clearly upregulated between E17 and P0.

      The reviewer is right, and we apologise for the misleading sentence. The contrast was meant to the basement membrane components that are very lowly expressed at E17 and then suddenly show the burst of expression at birth, whereas collagen seems to be continuously expressed with a peak at P7. We will rephrase the sentence.

      Reviewer #1 (Significance (Required)):

      Overall, the methodology used for the asked questions is accurate.

      One potential problem for publication comes from the fact that some of the findings are already reported and hat the present data do not provide further advances.

      for example, collagen and fetal-like expression profile, Ly6a sorting and replating in culture-Yui et al, 2018, Jabaji et al, 2013.

      We obviously do not agree with the reviewer on this point. We build upon the work of Jabaji et al. 2013, and Wang 2017 to characterise the specific effect of collagen on the intestinal epithelium compared to a pure Matrigel culture. The emergence of Ly6a cells was nicely shown by Yui et al., however it was unclear if collagen changes the fate of all intestinal cells or only a few. We strongly feel that our data extends these findings as it associates the changes we observe in vitro to the development of the crypt morphology and intestinal stem cells.

      The phenotype of Lamc1-/- mice and the observed reduced stem cell marker expression are also reported by Fields et al, 2019.

      Indeed, as we cited this paper. However we predicted based on our in vitro model, that deletion of laminin would result in this specific fetal-like gene expression and hence were happy to include these findings in our manuscript.

      Infine, authors do not interpret their ex vivo data in the context of fetal progenitors which grow as spheres in matrigel (containing laminin)?

      Our ex-vivo (in vitro) data would suggest that adult epithelial cells express some genes that are characteristic for fetal organoids, however we do not think these cells completely revert back to a fetal stage. Regarding the comment of spheres, it is noteworthy that fetal cells from E14-16 stay as spheres in Matrigel, whereas fetal cultures from E19 initially grow as spheres and then develop into organoids within 30 days in vitro (M. Navis et al., “Mouse fetal intestinal organoids: new model to study epithelial maturation from suckling to weaning,” EMBO Rep., vol. 20, no. 2, pp. 1–12, 2019.).

      In figure 5, should we interpret that there is no laminin at all in the fetal mesenchyme?

      We now see how the image is a bit misleading for that stage. The levels of laminin are lower in the fetal stage as can be seen by the IF image in Fig.3f and the image will be updated. We also apologise for the lack of labeling in Figure 3f, which should be E19, P7 and adult.

      Also, authors do not cite a paper reporting on the role of the epithelium ( stem cells) in regulating its own extracellular matrix composition, this process modulating the stem cell number and fate (Fernandez-Vallone et al. 2020). As this is contradictory with the claim that only mesenchyme impacts on crypt morphogenesis, authors could discuss on this point.

      In the paper by Fernandez-Vallone, deletion of Lgr5 in E16.5 embryos resulted in a decrease expression of several ECM genes. Further, the authors could show that the fetal epithelium does express for example Col1a1 at this point, which decreases with maturation. However even for the example of Col1a1 it is evident in their paper that the mesenchyme expresses Col1a1 at much higher levels. Our proposed experiments with Lamc1 k.o. In organoids will show if the produced laminins of the epithelium are essential.

      This manuscript could be interesting for an audience in the stem cell and developmental fields ( my field of expertise).

      **Referee Cross-commenting**

      Considering the pertinent and sometimes overlapping comments of the two other reviewers, the estimated time is revised to 3-6 months.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      **Summary:**

      In this manuscript, Ramadan and colleagues demonstrate that depending on the extracellular matrix (ECM) composition in which mouse intestinal organoids and/or 2D intestinal epithelial cells are grown in, cellular composition of the epithelium changes. Organoids plated on 2D collagen layers show a unique cell cluster characteristic of fetal-like genes, while organoids plated with increased amount of Matrigel in 2D or in 3D exhibit a shift towards higher stem cell abundance and the absence of the fetal-like gene cluster. Specifically, the ECM component Laminin supports acquisition of stem cells identities in small intestinal epithelial cells, correlating with a transient increase in expression levels of collagen and laminin genes in vivo spanning time points of crypt formation. The authors reported the functional contribution of laminin signaling (Lamc1 KO) via integrin alpha 6 (antibody-blocking) to intestinal stem cell acquisition in vitro and in vivo.

      There are a handful of comments/concerns that would need to be addressed before publication.

      Major points:

      1. The author claimed: "the effect of ECM components on gene expression is not due to difference in morphology (2D collogen vs. 3D Matrigel)". The conclusion of the 2D vs. 3D experiment should be toned down to that organoid morphology (2D vs. 3D) does not directly impact on the expression of fetal-like genes. Otherwise more analysis of RNAseq data with different group of genes (e.g., in different mechanosensing pathways) should be provided with Fig. S1D. Also, would it be technically feasible to perform experiments of SI in collagen (3D) in all group of experiments? Directly comparing 3D Matrigel with 3D collagen avoids the concern of the 2D vs. 3D effect.

      We apologise for the too strong claim of structure of growth vs. signalling of the ECM and its effect on the transcriptome. Indeed, the main message is that a changed morphology from 3D to 2D is not responsible for the expression of fetal-like genes. The paragraph will be rephrased.

      Also, would it be technically feasible to perform experiments of SI in collagen (3D) in all group of experiments? Directly comparing 3D Matrigel with 3D collagen avoids the concern of the 2D vs. 3D effect.

      To address this point, we want to refer to the excellent idea of growing established organoids in collagen (3D) vs. Matrigel (3D) as suggested by this reviewer (and reviewer #3) in Minor points #5. This circumvents the need for Wnt3a addition, which affects stem cell and Paneth cell gene expression.

      1. For Fig. 1f, the authors should include overlapping stainings of Lyz (or Olfm4, CD44 etc.) and Adolase B signal, or they could perform Aldolase B staining in Lgr-5-DTR-GFP and/or Lyz-RFP organoid line. From the current data provided one cannot draw clear conclusions on the crypt morphology as claimed by the authors. Additionally, when talking about crypt morphology and apical accumulation of Actin specifically in the Lyz+ cells, the authors should show a higher zoom in of the picture and either add an orthogonal slice to see apical and basal side and the specific accumulation in one of the cell types, or also co-label with apical polarity markers.

      We will perform additional co-stainings to further highlight the differences in the spatial distribution of differentiated cells and undifferentiated-crypt-like cells. Further we will provide higher magnification images highlighting the apical accumulation of Actin in the crypt-like structures, which can also be seen in mature organoids.

      1. Authors referred the organoid transient change to fetal-like state. To exam the similarity of ECM-induced reprogramming with the regenerative-type of reprogramming, it would be essential to compare the expression of the selected fetal-like genes (Anxa3, Ly6a/Sca1, Msln, Col4a2 et al.), as well as bulk and single-cell (if applicable) RNA-seq data.

      Here, we would like to refer to the excellent study by Yui et al. ([S. Yui et al., “YAP/TAZ-Dependent Reprogramming of Colonic Epithelium Links ECM Remodeling to Tissue Regeneration,” Cell Stem Cell, vol. 22, no. 1, pp. 35-49.e7, 2018.). In this study the authors detected the same gene signature in the repairing epithelium. We can provide a GSEA for the Ly6a+ signature that was derived from this paper, if necessary.

      1. For in vivo data, authors were looking at the normal development of intestine. Following the point of organoid culture recapitulates regeneration, it would be relevant to check the in vivo ECM change by staining in the process of intestinal regeneration or discuss would the fetal-like genes be involved in regeneration.

      We will address this point in the discussion as it also involves the study by Yui et al.

      1. For Fig2.d and e, it would be important to measure compactness vs. the emergence/probability of Ly6+ cells to see if there is correlation.

      If we understand the reviewer correctly, this would address the important relationship between cell shape and cell fate/type. However, this is a topic that needs more attention than a simple correlation and would exceed the scope of this manuscript as we are not able to modulate cell shape to make any further points about its effect on the fetal gene expression program.

      1. In Fig.2d, Ly6a expression is very obscure, and it would be important to show control staining for cell boundaries (eg. Phalloidin, PM) to visualize which nuclei show Ki67 staining and are high or low in Ly6a (plus quantification).

      We will improve the image in Fig.2d and include the mentioned Actin staining. In addition we will perform an analysis via Flow Cytometry to quantify the level of Ly6a staining and EdU positivity.

      1. In Fig. 2f-g, FACS-ed Ly6a+ and Ly6- cells embedded in Matrigel can grow into organoids with crypts. Here the imaging of Paneth cell staining is not clear, and a quantification on number of Paneth cells per crypt would be very helpful to confirm the phenotype. Also, authors should either provide data on the initial size of seeded cell clusters and report organoid growth and cell type composition in more detail when plating from Ly6a+ and Ly6- cells or report the variation in the respective populations.

      This comment suggests that we may not have described the experimental settings properly. The sorted cells were embedded as single cells, not as clusters, in drops of matrigel (10k cells/25ul Matrigel). The emergence of Paneth cells together with a normal organoid architecture grown from Ly6a+ cells shows their stem cell capacity, as has been shown by Yui et al. before from the regenerating colon. In addition, organoids from both cell populations (Ly6a+ and Ly6a-) could be passaged, indicating presence of intestinal stem cells.

      1. The authors could also test whether Ly6+ cells have any advantages over Ly6- cells when grown on collagen I instead of Matrigel.

      We will sort Ly6a+ and Ly6- negative cells and plate them on collagen I. It will be interesting to see if the Ly6a+ cells can give rise to the other cell types when plated on collagen or if they stay Ly6+ cells. This will also answer whether Ly6a+ need the presence of Ly6a- cells in the cultures. In addition, the experiment proposed in #6 will also highlight any proliferative advantage of Ly6a cells compared to Ly6-negative cells on collagen.

      1. In Fig.3f, a control of membrane protein staining should be added for the experiment. The increased Laminin signal can be caused by the global increase of protein when there are more cells, or tissues are more compact. When authors make conclusion of "Dramatic remodelling of ECM during crypt formation ", the experiment should also count cell numbers vs. Laminin (intensity). The phenotype can come from increased area of interface between epithelium and mesenchyme instead of active remodelling.

      We agree with the reviewer that by itself the IF images are not enough to make such a claim. However, we would point to the qPCR data and RNA in situ, that can be more easily normalised and shows the dramatic increase in expression of all laminins at birth. To show that laminin protein is increasing is more difficult than we initially anticipated. However, in the study by De Arcangelis (A. De Arcangelis et al., “Hemidesmosome integrity protects the colon against colitis and colorectal cancer,” Gut, vol. 66, no. 10, pp. 1748–1760, 2017.) the authors use an EDTA assay to show that the epithelium detaches easily when Itga6 is deleted. Within the figure, it seems also that the epithelium detaches easily at P2, compared to P14. As EDTA is disrupting laminin polymerisation, this would further indicate increased laminin protein deposition after birth.

      1. The authors claim that intestinal stem cells in vivo are controlled by Laminin signalling that goes via Integrin alpha 6. However, there is no evidence provided that supports the contribution of ITGA6 in the in vivo setting. So, the authors should either tone down on that point or show a convincing in vivo experiment (e.g., inhibit ITGA6 in vivo by inhibitor injections or by extracting the ECM of a wild-type mouse and seeding intestinal epithelial cells without vs. with ITGA6 blocking antibody which should recapitulate the phenotype in Fig. 4 c.

      We apologise for this confusion. We are well aware about the limitations of our Itga6 blocking experiment in vitro and its relevance in vivo. We tried to get material of the inducible VilCreER Itga6 mouse as referenced in the discussion of the manuscript, without any luck so far. Therefore we will highlight further that any claims about the laminin:Itga6 interaction can only be made in vitro.

      1. Fig. 4: For the data of ITGA6 expression and all sorts of analysis on protein expression with staining, normalization with cell numbers should be performed.

      The RNAseq data that shows the upregulation of Itga6 in the epithelium at E18 is normalized within. Our RNAscope only further validates these expression changes and highlights the specific enriched expression at the bottom of the nascent crypts. We can add quantification of the RNAscope if required.

      1. Two questions on mechanisms:

      2. What is the mechanism from ITGA signaling to Ly6a+ cell fate?

      3. And would/how Laminin induce ITGA expression? Depends on how much the authors would like to go deep with the project, could be addressed further with functional studies, or touch on the topics with discussion.

      These are important questions, however we do agree that this will go to deep for the scope of this manuscript. We will address these open questions in the discussion and leave the experimental part for a follow-up study.

      **Minor points:**

      1. Text in Fig.S1d regarding 'in' or 'on' collagen, could be clearer by changing the terms to 2D and 3D correspondingly.

      We agree and the text will be changed accordingly.

      1. Fig. S1a, it is great the authors showed that similar stiffness in Matrigel and collagen I. It would be important to check the concentration of collagen I vs. stiffness (also for increasing concentrations of Laminin in Fig. 3b), since this is also the type of ECM change that might lead to the change of cell status in cancer progression or collective cell migration.

      We will perform further stiffness measurements of the hydrogels and update the Fig. S1a.

      1. When plating intestinal epithelial cells on collagen I, is the Ly6+ phenotype altered upon Wnt addition? This is not so clear from the RNAseq data Fig S1d., so authors should provide antibody stainings (stem cells/Paneth cells). This could give insight whether Ly6+ cells are still able to convert into stem cells/ Paneth cells by changing morphogen concentration vs. ECM composition.

      We will reanalyse the RNaseq dataset further, specifically analysing the ratio of stem cell and Paneth cell gene expression. However, as mentioned before, Wnt3a specifically does reduce the expression of Paneth cell markers.

      Similar to this point, also enteroendocrine cell fate is absent in collagen I condition (Fig2.ab), the authors could address this point by medium induced EE cell fate.

      Due to the reduced number of secretory cells the clustering in Fig2 a/b does not separate all the different cell lineages. However, EE cells are present in the collagen cultures as characterised by expression of Chga, just reduced in their number (see Supl Fig. 2B).

      1. It would be more informative to indicate the thickness of ECM layer in culture of 2D collagen I, as well as the image of the whole well, demonstrating the morphological variation in the middle and peripheral of the ECM layer.

      The thickness of the collagen layer is about 1mm in a 6well plate and we do not observe any morphological differences in the cells between the periphery and center of the well.

      1. After the formation of PC/SC clusters, would ECM contribute to maintenance? Putting mature organoids from Matrigel to Collagen I 3D would help to clarify.

      This is an interesting experiment that we will conduct, we thank the reviewer for this suggestion. Indeed, established organoids should be able to grow in collagen I without Wnt3a addition. The paper by Sachs et al. (N. Sachs, Y. Tsukamoto, P. Kujala, P. J. Peters, and H. Clevers, “Intestinal epithelial organoids fuse to form self-organizing tubes in floating collagen gels,” Development, vol. 144, no. 6, pp. 1107–1112, 2017. et al) used extensive washing with PBS to remove Matrigel from the organoids. We will go one step further and trying to completely remove laminin specifically by EDTA incubation, as has been shown recently (J. Y. Co et al., “Controlling Epithelial Polarity: A Human Enteroid Model for Host-Pathogen Interactions,” Cell Rep., vol. 26, no. 9, pp. 2509-2520.e4, 2019.). This should then also answer whether disruption of laminin signalling is sufficient to induce fetal-gene expression without the addition of collagen I in a 3D setting.

      1. Check secretome and individual culture of Mesenchyme, see if the increase of Laminin is epithelium independent.

      We agree that the mesenchyme is key for laminin production, therefore these are important questions. Our prediction would be that epithelium from birth (P0) versus adult might result in different responses on the mesenchyme. However, we feel these experiments are better suited for a follow-up study.

      1. In general, the authors should look at cell polarity markers to check the ECM contribution to cell polarity in different cell types.

      We thank the reviewer for the suggestions and as mentioned above, we will perform additional stainings.

      Reviewer #2 (Significance (Required)):

      **Significance:**

      The work highlights the role of ECM on stem cell niche and is of great interest to the organoid and stem cell community.

      Our field of expertise is image- and seq-technology-based quantitative biology, regeneration and mechanics in organoid.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      **Summary:**

      Ramadan et al present a highly informative paper detailing how the Extracellular matrix influences the development of the intestine. Specifically, the authors provide a thorough analysis of how manipulating the components of the ECM can affect organoid growth, morphology, and gene expression of the organoids. Most importantly, the authors isolate laminin as a critical component of the ECM which impacts the development of fetal-like epithelium. While the in vitro work is generally compelling and of interest to the field, the in vivo data is someone lacking in depth and novelty. Particularly, these conclusions from the abstract could be much better supported: "This laminin:ITGA6 signalling is essential for the stem cell induction and crypt formation in vitro. Importantly, deletion of laminin in the adult mouse results in a fetal-like epithelium with a marked reduction of adult intestinal stem cells." The in vivo work was largely published previously and has caveats noted below, while the in vitro association of ITGA6 signaling with crypt formation is over-interpreted based upon an antibody blocking experiment and a lack of statistical rigor. Despite these concerns, this reviewer finds the work of considerable interest in an important area of the field (epithelial/stromal interactions of the intestine).

      **Major Concerns:**

      The use of the Ubc-Cre Lamc1-flox mouse model is an interesting way to test the impact of loss Lamc1 on intestinal development. However, with the Ubc-Cre, does the mouse model have other deleterious effects on the mouse beyond the intestine?

      Can the authors use a more localized Cre to observe specifically the impacts of Lamc1 loss in the intestine? What is the fate of these mice? Can the authors show swiss roll, low mag sections to let the reader know the extent of this phenotype? OLFM4 and Ki67 IHC should be conducted over a timecourse to show how the changes occur over time after loss of Lamc1. How long does Lamc1's protein product perdure after tamoxifen treatment? More details of this exciting, in vivo validation of the authors' in vitro studies are key to elevating the impact of this work. However, it appears that much of this mouse model was previously published, but the previous findings are not well summarized in the current manuscript.

      We will describe the model in more detail and refer readers to the excellent study of our collaborators which answers most of the raised questions. It is interesting to note that although a ubiquitous Cre was used to delete Lamc1 in adult mice, a phenotype was only observed in the intestine indicating a specific role for continuous laminin production here.

      Can the authors show that ITGA6 loss has functional consequences in vivo with an epithelial knockout or via an organoid knockdown? A more rigorous genetic test of this proposed function would be important for substantiating the claims made in the abstract.

      As referenced in the discussion of the manuscript, there is a VilCreER Itga6 mouse described in the literature (A. De Arcangelis et al., “Hemidesmosome integrity protects the colon against colitis and colorectal cancer,” Gut, vol. 66, no. 10, pp. 1748–1760, 2017.), which mainly focus on the colon. However, the authors use an EDTA assay in the small intestine to show that the epithelium detaches easily when Itga6 is deleted (Fig. 1J). Within the figure, it seems also that the epithelium detaches easily at P2, compared to P14. As EDTA is disrupting laminin polymerisation, this would further indicate increased laminin protein deposition after birth which is dependent on Itga6.

      We tried to get material of the inducible VilCreER Itga6 mouse however without any luck so far.

      We will conduct additional experiments regarding the Itga6 in vitro. In addition to including additional controls for the neutralizing antibody, we will genetically inactivate Itga6 via an inducible Crispr/Cas9. This should enable us to delete Itga6 when the cells are grown on collagen, and hence reduce the possibility of compensation in matrigel derived organoids.

      The authors state that the changes in gene expression are not due to differences in morphology, but rather are specific to the components of the environment. While the authors show that organoids treated with Wnt3a "in Matrigel" and "CollagenI" appear to have similar morphologies and yet still result in a different gene expression profiles, it would be of great interest to see whether that difference persists without Wnt3a when organoids are "in Matrigel" and "in CollagenI". While the reviewer understands the difficulties of culturing organoids in 3D Collagen without Wnt3a, organoids can be indeed be cultured in 3D using "floating collagenI rings" (Sachs et al 2017).

      This is an interesting experiment that we will conduct, we thank the reviewer for this suggestion. Indeed, established organoids should be able to grow in collagen I without Wnt3a addition. The paper by Sachs et al. (N. Sachs, Y. Tsukamoto, P. Kujala, P. J. Peters, and H. Clevers, “Intestinal epithelial organoids fuse to form self-organizing tubes in floating collagen gels,” Development, vol. 144, no. 6, pp. 1107–1112, 2017. et al) used extensive washing with PBS to remove Matrigel from the organoids. We will go one step further and trying to completely remove laminin specifically by EDTA incubation, as has been shown recently (J. Y. Co et al., “Controlling Epithelial Polarity: A Human Enteroid Model for Host-Pathogen Interactions,” Cell Rep., vol. 26, no. 9, pp. 2509-2520.e4, 2019.). This should then also answer whether disruption of laminin signalling is sufficient to induce fetal-gene expression without the addition of collagen I in a 3D setting.

      Similarly, while the authors indicate that increasing Matrigel concentrations altered the gene expression patterns in a dose-dependent manner, it is unknown whether this can fully be attributed to the Matrigel composition, or whether the layer of Matrigel is providing the capability to transition from 2D to 3D culture.

      We are not entirely sure, we understood this point. The Matrigel and the collagen I are mixed before they solidify, therefore enabling a homogenous hydrogel. The different hydrogels are not layered (if that is what the reviewer is referring to).

      The authors cultured organoids in different concentrations of Laminin/CollagenIV when mixed with CollagenI. Can organoids be sustained only on a matrix of CollagenIV and/or Laminin? Would this show more direct differences between CollagenI vs. Laminin cultured organoids?

      Organoids cannot be grown in pure Collagen IV, but pure laminin should be feasible. We did initial experiments with 3-5mg/ml laminin in PBS and that was sufficient to allow organoid growth. We will perform additional experiments with pure laminin and show the impact on organoid growth.

      With the reduction in stem-cell and Paneth cells in the Lamc1-KO mice, it would also be of interest to determine what cell types are now prominent within the heavily elongated intestinal "crypt" structures seen in the Lamc1-KO mice and whether populations are more TA-cells or enterocytes to consider differentiation status of the cells. Additionally, it would also of interest to see if the Itga6 expression is significantly altered in the absence of Lamc1.

      We will test expression changes for Itga6 in the Lamc1-KO mice, in the epithelium via qPCR. Additionally we can stain tissue from these mice for Sox9, Ki67 and differentiated markers eg. CD44, AldolaseB, Villin etc .to determine whether the elongated, hyperproliferative crypts contain progenitor cells or secretory enterocytes.

      **Minor concerns:**

      Matrigel is a complex matrix derived from mouse tumors. In many instances in the manuscript, the authors portray it as a more simpler mix of laminin/Collagen4 (fig 3a). It should be made clearer to the reader that Matrigel is not a mix of recombinant proteins, but a more clear depiction of how Matrigel is derived will be critical for this study, given the focus on specific ECM components and how they affect intestinal epithelial growth.

      We agree and will change the oversimplified view of Matrigel.

      Some labels of specific conditions would be appreciated in the figures as opposed to only the figure legends (ie. Fig. 1b and 1d should be labeled with comparisons; Fig. 3f labels of fluorescence, Fig. 4b label of itga6 staining).

      We apologise for this and the Figure labels will be updated.

      With the light staining of Lamc1 in-situ, it is hard to appreciate the expression of laminin within the stroma of the intestine when compared to Col4. This reviewer is also curious of the biological relevance of the concentrations of Laminin/CollagenIV when culturing organoids in Fig. 4a.

      Indeed, the Lamc1 due to its lower expression than Col4a1 is more difficult to see. Maybe the reviewer overlooked Suppl.Fig.4A, where the blue channel of these in situ images show more contrast. If required, we can try to optimise the hybridisation times to increase the signal a bit further.

      When culturing the organoids with the mixture of collagen and laminin or collagen IV, the concentrations of the two single components were selected similar to their concentrations in Matrigel. Regarding the absolute concentrations of laminin/collagen IV in vitro versus their “concentration” in vivo is much harder to answer. In addition to the unknown concentrations in vivo, there are many more Laminin types present with specific localisation and even specific receptor interactions. For our in vitro studies we relied on the Laminin present in EHS tumours, which is Laminin alpha 1 beta 1 gamma 1. We are currently investigating decellularization protocols to purify the ECM from mouse intestinal tissue, but again this would be more suited for a follow up study.

      It would be appreciated if gene expression analyses presented in figures would include p-values to provide context for differences in gene expression.

      The avoidance of statistical inference for most of the experiments was a deliberate choice. In line with several comments (e.g. 1. Vaux, D. L. (2012) Know when your numbers are significant. Nature. 492, 180–181), we chose to show all individual data points (with exception of Fig. 3D, n=5, to ease interpretation) without statistical testing. For most expression data, we have data from RNAseq, single-cell RNAseq and qPCRs repeated at different hydrogel concentrations to obtain reliable results. Further, the in vivo mesenchymal qPCR expression data was validated with RNA in situ hybridization showing the mainly mesenchymal expression.

      As we will perform additional experiments for the revision of this paper, we can perform statistical tests in the key experiments (e.g. Itga6 experiment) to alleviate any concerns regarding significance.

      In figure 3f, the authors report "immunofluorescence of laminin". How is this measured? Can more details be given about the antibody in the text and figure legend? Laminins are a family of genes, and it's not clear what's being demonstrated in this figure panel. Developmental stages of the samples are also not clear.

      We apologise for the lack of labeling in Fig.3f. The details of the antibody were hidden in the Materials and Methods of the manuscript (Slides were incubated with Laminin Polyclonal Antibody (1/200, Thermo Fisher #PA5-22901) overnight at 4C ). This pan-laminin antibody reacts with most Laminin isoforms alpha1, alpha2, beta1, gamma1. We will declare it as a pan-laminin antibody in the Figure legend to help future readers.

      Reviewer #3 (Significance (Required)):

      This work is in an exciting "hot" area of research to understand the role of non-epithelial cells in intestinal epithelial development and function. The audience would be those in the GI field and those studying tissue-tissue interactions.

      There's some concern that the in vivo portion of the manuscript (4th figure) uses a model that was previously characterized and published by this group, and that isn't clearly disclosed. The manuscript would benefit from more disclosure and detail about the in vivo phenotype. Such changes would substantially increase the impact and novelty of the study.

      We would like to point out that we cited the paper of the original study that uses the model throughout the manuscript. We will disclose in more detail that this group did the study and that the reduction in stem cell genes was already mentioned in the original publication.

    1. SciScore for 10.1101/2021.08.18.456916: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primary monoclonal antibodies included mouse anti-human ACE2 (Origen), rabbit anti-human TMPRSS2 (Abcam, Cambridge, UK) and mouse anti-beta actin (Invitrogen).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human ACE2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-human TMPRSS2</div><div>suggested: (Abcam Cat# ab82146, RRID:AB_1658352)</div></div><div style="margin-bottom:8px"><div>anti-beta actin</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary antibodies included rat anti-mouse IgG1 HRP (Southern Biotech, Birmingham, AL), and mouse anti-rabbit IgG1 HRP (Southern Biotech).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>AL</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-rabbit IgG1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primary antibodies against SC2 included rabbit anti-Nucleoprotein MAb (Origene) and rabbit anti-Spike MAb (Origene), diluted as above, were added for 1 hour at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Nucleoprotein MAb (Origene)</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-Spike</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were washed 3 times with PBS and incubated in the secondary antibody, goat anti-rabbit IgG H&L (Alexa Fluor® 555) (ABCAM) diluted 1:20,000 in TBS, for one hour at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rabbit IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">RNA extraction and RT-PCR for human ACE2 and TMPRSS2: Total RNA was extracted from 2.5 x 105 cells in one well of a 6 well plate from Vero, DF1, DF1 +-, DF1 -+, DF1 ++, MDCK, MDCK +-, MDCK -+ and MDCK ++.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div><div style="margin-bottom:8px"><div>MDCK</div><div>suggested: CLS Cat# 602280/p823_MDCK_(NBL-2, RRID:CVCL_0422)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PCR products were visualized on 1% agarose gel (Bio-Rad Laboratories, Hercules, CA) containing SYBR Safe (Invitrogen) using a documentation system (Syngene International Ltd, Bengaluru, India).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bio-Rad Laboratories</div><div>suggested: (Bio-Rad Laboratories, RRID:SCR_008426)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Viral titers at 48 hpi were compared with the two-way ANOVA with Tukey multiple comparison (Prism 9.1.0 GraphPad Software, San Diego, CA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • No conflict of interest statement was detected. If there are no conflicts, we encourage authors to explicit state so.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.17.456704: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Study approval: Mouse care and experimental procedures with mice were performed under pathogen-free conditions in accordance with established institutional guidance and approved Animal Care and Use Protocols (ACUP) from the Research Animal Care Committee at Sorrento Therapeutics Inc.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Mice and cell culture: For intramuscular antigen challenge, C57BL/6 female mice 5-6 weeks old were injected with either 100 μg RBD-C-tag (300 μg adjuvant) or 50 μg RBD-C-tag (150 μg adjuvant) intramuscularly.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Detection of RBD and Spike binding serum IgG antibodies by ELISA: A direct binding ELISA format was used to detect the anti-SARS-COV-2 RBD or Spike IgG antibody in mouse serum samples.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Spike binding serum IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-SARS-COV-2 RBD or Spike IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">donkey anti-mouse IgG conjugated to AlexaFluor 647 (Invitrogen #A-31571) or IL-10 APC antibodies ( eBioscience, # 17-7101-81).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>donkey anti-mouse IgG</div><div>suggested: (Molecular Probes Cat# A-31571, RRID:AB_162542)</div></div><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: (Molecular Probes Cat# A-31571, RRID:AB_162542)</div></div><div style="margin-bottom:8px"><div>IL-10 APC</div><div>suggested: (Thermo Fisher Scientific Cat# 17-7101-81, RRID:AB_469501)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Human parental HEK293 cells (ATCC, CRL-1573) were cultured in DMEM supplemented with 10% FBS and antibiotics/antimycotics (Gibco).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Simian VeroE6 cells were plated at 18×103 cells/well in a flat bottom 96-well plate in a volume of 200 μl/well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Longitudinal near infrared in vivo imaging of lymphatics: IRDye800-RBD-C-tag was injected intramuscularly into the biceps femoris of C57BL/6 mice.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.18.456769: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The antibodies used were anti-GFP HRP-DirecT (#598-7, MBL, Nagano, Japan), anti-polyhistidine-tag (#PM032, MBL), and anti-mCherry (#Z2496N, TaKaRa, Shiga, Japan)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-GFP</div><div>suggested: (MBL International Cat# 598-7, RRID:AB_10597267)</div></div><div style="margin-bottom:8px"><div>#598-7 , MBL , Nagano , Japan) , anti-polyhistidine-tag</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-mCherry</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For observation of lysosome localization, mCherry-tagged protein-expressing Neuro2a cells were incubated in a medium containing 0.5 μM Lysotrascker green DND-26 (Thermo Fisher) for 30 min before image acquisition.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Neuro2a</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To construct an expression plasmid, cytoplasmic region- and transmembrane-lacking hACE2 tagged with a monomeric variant of eGFP carrying the A206K mutation (hACE2-eGFP), the fragment encoding hACE2, was inserted into pmeGFP-N1 with NheI and EcoRI.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>hACE2</div><div>suggested: RRID:Addgene_1786)</div></div><div style="margin-bottom:8px"><div>pmeGFP-N1</div><div>suggested: RRID:Addgene_27766)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A synthetic oligonucleotide for the ER-targeting signal peptide was inserted into pmCherry-N1 (pER-mCherry) with NheI and AgeI.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pmCherry-N1</div><div>suggested: RRID:Addgene_87327)</div></div><div style="margin-bottom:8px"><div>pER-mCherry</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The fragments were inserted into pER-mCherry-N1 with XhoI and BamHI (pER-mCherry-S1 and pER-mCherry-S1-2, respectively).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pER-mCherry-N1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pER-mCherry-S1-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The whole sequences of the coding regions of pER-mCherry-S1 and pER-mCherry-S1-2 are presented in Supplemental Figure.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pER-mCherry-S1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmids encoding hACE2-eGFP, ER-mCherry-S1, or ER-mCherry-S1-2 (16 μg) and sonicated salmon sperm DNA (14 μg) were transfected into the cells with 240 μL of polyethyleneimine (#43896,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>hACE2-eGFP</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. Author Response:

      Reviewer #1 (Public Review):

      The paper is a tour-de-force across multiple techniques and model systems from classical forward screening in C. elegans over ChIP to targeted CRISPR mutagenesis. The data is of a very high quality and supports most of the authors' claims strongly and convincingly. Finally, the manuscript is well written and, in spite of complex experiments and genetics, interesting and easy to comprehend.

      • CAMTA, as the name CaM-binding transcription activator implies, have been studied previously and across many different organisms including plants, mice and humans. It was thus presumed and in part shown that CAMTAs regulate transcription depending on CaM levels.
      • The authors confirm that the gene cmd-1 (encoding CaM) is directly regulated by Camt-1 by using a combination of cell-specific RNAseq and ChIP. This allows them to identify three binding sites upstream of the cmb-1 gene that bind to Camt-1.
      • Moreover, the authors show that overexpression of CaM in the nervous system fully rescues the observed behavioral phenotypes.
      • Importantly, the authors make another discovery. They show that CaM can directly repress its own transcription by binding to specific residues of Camt-1. Thereby, the authors argue, Camt-1 is used to precisely and bidirectionally regulate CaM levels dependent on the cell, animal's state etc.

      The reported data are interesting and, in particular, the aspect that CAMTAs likely act as activators AND repressors is a novel aspect previously not appreciated. In spite of all these strengths, a potential weakness is that it remains open whether this mechanism is primarily a house-keeping mechanism or is indeed, as the authors speculate, regulated by internal and external factors that might, through CAMTA, make cells more or less responsive to Ca2+-CaM signaling.

      We are grateful for and encouraged by our reviewer’s comments. We think that our discovery that CAMTAs regulate CaM expression is thought provoking.

      Reviewer #2 (Public Review):

      Vuong-Brender, Flynn, and de Bono report a detailed analysis of the function of a highly conserved calcium-calmodulin-dependent transcriptional regulator in the function of the C. elegans sensory nervous system. The C. elegans homolog of this factor - CAMT-1 - emerged from a genetic screen for mutants defective in a sensory-driven aggregation behavior. The authors find that multiple chemosensory modalities are disrupted by loss of CAMT-1, and this factor has distributed functions in the nervous system, including in interneurons that receive inputs from sensory neurons. A major finding of this study is that many of the effects of CAMT-1 mutation can be linked to a critical role for CAMT-1 in regulating expression of calmodulin itself. This finding is supported by multiple lines of experimentation, including a demonstration that the effects of losing CAMT-1 can be compensated by restoring expression of calmodulin. The authors further show that what is true for CAMT-1 and calmodulin in C. elegans also applies to Drosophila, indicating that CAMT-1 is a regulator of calmodulin expression whose function has been conserved throughout evolution. This manuscript has many strengths. Key hypotheses are tested using quantitative and technically independent experimental methods. The case that CAMT-1 is a regulator of calmodulin expression is built carefully and, for the most part, the logic of the argument is made clearly and supported by compelling data. Another strength of the manuscript is its candid exposition of data that do not fit neatly into the most simple and accessible model. It is refreshing to see authors who freely admit that they haven't neatly wrapped up every question in a field. The loose ends in this study do not impact the authors' main conclusions. However, some observations seem to consume more bandwidth than warranted, and the authors should consider reorganizing the manuscript so that the loose ends do not distract from the main thread of the narrative. The paper does have a few minor weaknesses that could be addressed. These are listed below.

      We thank our reviewer for their thoughtful review.

      Specific comments:

      1. The initial description of the isolation of camt-1 mutants seemed a bit disorganized. A description of the gene and gene product preceded descriptions of the mutants. Also, some mutants were mentioned in the text but not presented in the corresponding figure. The authors should consider minor changes to better communicate how the mutations were cloned.

      We have sought to do this.

      1. In Fig. 2 npr-1 baselines vary a great deal between panels A, B, and C. It is not clear why npr-1 behavior is this variable, and the authors do not mention this obvious feature of their data. Data presented in Fig. 2 indicate that heat-shock-induced expression of camt-1 restores a defect in basal locomotion, but it is unclear whether it restores O2-sensitivity - the effect of oxygen on speed of transgenics seems the same +/- heatshock (compare black traces in panels 2B and 2C). We understand the concern of the reviewer. Since the design of these experiments was different from the rest (with only one shift in O2 concentration), we repeated them with 3 O2 changes, bringing them in line with the rest of the manuscript. The results are presented in the new Figure 2. We observed a more consistent baseline speed between different conditions, however some differences still exist (for example between panel 2A and 2B). One explanation is that for heatshock experiments we keep npr-1 animals at lower temperature (20 degree Celsius, panels 2B and 2C) to minimize basal activity of the heatshock promoter, whereas in the rescue experiment in Figure 2A, and in the rest of the manuscript, animals were kept at 22 oC. Figure 2B-C of our original submission used worms raised at 15 oC for the heatshock experiment, which may explain the greater discrepancy in npr-1 speed values. Heatshock also modifies slightly the response of the npr-1 control animals to O2.

      Regarding whether heat-shock-induced expression of camt-1 restores O2 responses, we found that the npr-1; camt-1; dbExhsp-16p::camt-1 heat-shocked strains aggregated much more than npr-1; camt-1 heat-shocked animals. However, the rescue is not complete. Thus expressing camt-1 using heatshock-induced expression restores some O2 sensitivity which correlates well with the partial rescue of the baseline in Figure 2C. We have noted this in the results.

      1. Unlike other datasets, the responses of wild-type AFDs to CO2 do not look particularly convincing (panel 3C). There is clearly an effect of camt-1 mutation on AFD calcium, but the AFD responses seem qualitatively different from the responses of BAGs to CO2 or URXs to O2. The authors might consider moving these data to a supplementary figure and tempering their description of wild-type AFDs as CO2-sensors.

      The data on AFD has been moved to Figure 3 – figure supplement 1. We should add that we agree that in the absence of an identified CO2 sensor expressed in AFD, we cannot be sure that AFD neurons are primary CO2 sensors. Although the AFD CO2-evoked responses are retained in mutants defective in synaptic transmission, they may very well still be indirectly evoked by other neurons.

      1. The authors candidly present data that do not conform to a simple model for how camt-1 affects behavior. Loss of camt-1 increases calcium in sensory neurons that activate the speed-controlling interneuron RMG. However, RMG calcium is reduced in camt-1 mutants. This inversion in the effect of camt-1 mutation might be caused by a homeostatic mechanism, as the authors propose. It might be possible to test this hypothesis by testing whether reducing excitatory input into RMGs elevates resting calcium in camt-1 mutants, for example via mutations that affect sensory transduction.

      In the interest of simplifying the manuscript, and given other comments, we have now removed the RMG Ca2+ imaging data. However, this is an interesting way of testing what is going.

      1. In Fig. 4H RMG data are presented as fractional ratio change - all other imaging data are presented as absolute ratios of YFP and CFP fluorescence. It is not clear why these data are treated differently. It is also no clear that these data are consistent with data shown in Fig. 3F. Which dataset represents the effect of camt-1 mutation on RMG calcium? More measurements might be warranted.

      As highlighted above we have removed the RMG imaging data from the paper. .

      1. Nice experiments show that regulation of calmodulin in Drosophila requires a CAMT-1 homolog. The bar graphs showing unity for values normalized to themselves are a bit odd - perhaps there's a more compact way to plot these data.

      We have sought to address this question in two ways. First, we have further buttressed our results by performing in situ immunofluorescence staining of dissected fly retinas with a calmodulin antibody. We see a significant decrease in calmodulin expression in fly CAMTA mutants compared to controls.

      Prompted by this comment, we also realized we omitted an explanation of how we normalized the data for the qPCR graphs in the figure legend. This was done using rRNA as a control. The Yamamoto lab had previously used the same control to normalize CAMTA expression in wild type and mutant flies. We add a note saying this.

      1. ChIPseq analysis of CAMT-1 is also quite nice. Is there a sequence motif for CAMT-1 binding that emerges from this study? If so, how does this motif compare to motifs from studies of CAMT-1 homologs in other species?

      We used the MEME algorithm, (motif-based sequence analysis tools (https://meme-suite.org/) to seek enriched sequence motifs in our ChIPSeq data. This identified a series of enriched motifs, although none coincided with the peaks at the CMD-1 promoter. However, we did observe sequences resembling the mouse CAMTA1 binding site at the centre of each of the three CAMT-1 binding peaks upstream of cmd-1. We now say this is the discussion.

      1. Figure 7 shows that CMD-1 inhibits cmd-1 expression via interaction with CAMT-1. These data are interesting, but it is not clear how this effect can be related to prior data showing that forced expression of CMD-1 can compensate for loss of CAMT-1. The authors behavioral and physiological studies suggest that in vivo CAMT-1 promotes CMD-1 expression. In Figure 7, they suggest that CAMT-1 inhibits expression of CMD-1, but there is no clear link to behavior or physiology for this repressor-function of CAMT-1. The manuscript might be more clear without these data, and the absence of these data would not affect the overall impact of the study.

      We agree that the feedback control of cmd-1 gene expression by CMD-1 interacting with CAMT-1 is a part of the story that has not been fully developed. Given the feedback from our reviewers and Editors to give these findings less prominence, but not remove them entirely, we moved the data into supplementary information. We have also altered the main text and the legend of Figure 7 to explicitly say that further experiments are needed to establish if this feedback is relevant under physiological conditions.

      Reviewer #3 (Public Review):

      Vuong-Brender et al present a thorough study investigating how CaM-binding transcription activators (CAMTAs) in C. elegans and Drosophila are required for numerous behaviors and proper neuronal function. The study is strong in how it uses a variety of approaches to study a major underlying mechanism for CAMTA. First, they use reporters, mutant analysis, and heat-shock rescue to show how cart-1 is expressed widely in neurons and functions in adults in several behaviors. They used transcriptional profiling to show that cart-1 is required to upregulate CaM in subsets of neurons in worm. They next use ChIP-seq to zero in on where worm CAMT-1 binds regulatory regions upstream of the CaM gene cmd-1 to promote its expression. They find that overexpression of CaM compensates for behavioral and neuronal response deficits in a cart-1 mutants. Lastly, they propose that when CaM highly expressed, it may down regulate its own expression by binding CART-1.

      We thank our reviewer for their critique of our work.

      1. Overall, I feel that the study is excellent and most conclusions are justified by evidence. However, I do not think the title is supported by the data. It currently is listed as: CAMTA TUNES NEURAL EXCITABILITY AND BEHAVIOR BY MODULATING CALMODULIN EXPRESSION. The authors show evidence that camt-1 is required for the normal function of neurons and behavior by promoting expression of CaM. Their only evidence that camt-1 downregulates CaM is a more artificial situation where CaM is overexpressed. I don't think they provide any evidence that camt-1 is used to "tune" behavior or neuron activity up and down in a wild-type strain. Tuning implies that the molecule modulates a physiological system bidirectionally in a natural situation. I suggest using a more accurate title that better fits the experimental evidence.

      We have changed the title to ‘Neuronal Calmodulin levels are controlled by CAMTA transcription factors’. We hope this more neutral title is appropriate to describe our findings.

      1. They show ample evidence that cart-1 appears to promote the expression of cmd-1 in most cases. This includes showing that overexpression of cmd-1 suppresses the behavioral and imaging phenotypes of cart-1. But they didn't perform the more straight forward epistasis test with the cart-1;cmd-1 double mutant in worm or fly , presumably because there is no viable loss-of-function allele in the coding area of the cmd-1 gene. It would help the readers understand why this simpler experiment was not performed if they explain this in the paper. A good place would be near line 220, where they generate hypomorphic promoter alleles using CRISPR. If they have tried to make their own loss-of-function alleles by mutating the coding area of cmd-1, but it resulted in presumed lethality, this might be mentioned here too.

      This is a good point, and one that we had overlooked. cmd-1 loss of function mutations do indeed confer lethality. We have added a sentence to say:

      ‘Straightforward comparison of camt-1 and cmd-1 loss of function phenotypes was not possible, since disrupting cmd-1 confers lethality (7, 8).’

      1. I am most worried about the potential caveats with the calcium imaging experiments. As the authors note, it is challenging to infer absolute levels of calcium using the ratiometric sensor cameleon across different individuals and genotypes. However, the authors do not note that the YFP/CFP FRET signal from cameleon might be perturbed because it uses calmodulin to bind calcium. At the end of their study (line 244), they provide evidence that calmodulin may bind to CART-1 to suppress its own expression when calmodulin is highly expressed. This is worrisome because cameleon is probably expressed highly in some or most of these strains. The authors may want to re-examine neuronal activity for a subset of experiments with a method that is independent of a calmodulin-based sensor (if possible).

      We agree that this is a potential concern. As suggested by our referee, we therefore repeated some of our Ca2+ imaging experiments using a genetically-encoded Ca2+ indicator that does not contain CaM. We opted to use TN-XL, an indicator that uses troponin C as the Ca2+ binding moiety, and which has previously been used successfully in C. elegans. We imaged CO2-evoked Ca2+ responses in BAG sensory neurons, in wild type and in camt-1 mutant animals. The data obtained using TN-XL recapitulated what we observed using YC3.60 (BAG).

      1. The title of "Fig 3 - Figure supplement 1" is confusing because it suggests that they measured the levels of YC2.60 cameleon, when in fact they measured a separate GFP reporter, albeit using the same promoter. So they could clarify the figure title.

      The reviewer is right – our heading was confusing. We have changed it, and now say: ‘Expression from the gcy-37 promoter is reduced when CAMT-1 is overexpressed.’

      1. D. Bazopoulou, A. R. Chaudhury, A. Pantazis, N. Chronis, An automated compound screening for anti-aging effects on the function of C. elegans sensory neurons. Sci Rep 7, 9403 (2017).
      2. M. S. Choi et al., Isolation of a calmodulin-binding transcription factor from rice (Oryza sativa L.). J Biol Chem 280, 40820-40831 (2005).
      3. J. Han et al., The fly CAMTA transcription factor potentiates deactivation of rhodopsin, a G protein-coupled light receptor. Cell 127, 847-858 (2006).
      4. N. Bouche, A. Scharlat, W. Snedden, D. Bouchez, H. Fromm, A novel family of calmodulin-binding transcription activators in multicellular organisms. J Biol Chem 277, 21851-21861 (2002).
      5. T. Yang, B. W. Poovaiah, A calmodulin-binding/CGCG box DNA-binding protein family involved in multiple signaling pathways in plants. J Biol Chem 277, 45049-45058 (2002).
      6. E. Kodama-Namba et al., Cross-modulation of homeostatic responses to temperature, oxygen and carbon dioxide in C. elegans. PLoS Genet 9, e1004011 (2013).
      7. V. Au et al., CRISPR/Cas9 Methodology for the Generation of Knockout Deletions in Caenorhabditis elegans. G3 (Bethesda) 9, 135-144 (2019).
      8. A. Karabinos et al., Functional analysis of the single calmodulin gene in the nematode Caenorhabditis elegans by RNA interference and 4-D microscopy. Eur J Cell Biol 82, 557-563 (2003).
    1. SciScore for 10.1101/2021.08.17.456689: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Western blot: Western blot was performed using an anti-SARS-COV-2 S antibody following a protocol described previously (50).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-COV-2 S</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Alkaline phosphatase conjugated anti-Rabbit IgG (1:5000) (Sigma-Aldrich, St. Louis, MO) was used as a secondary antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Rabbit IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To measure binding of a full-length S protein to monoclonal antibodies, the antibody was immobilized to anti-human IgG Fc Capture (AHC) biosensor (ForteBio, Fremont, CA) following a protocol recommended by the manufacturer.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Control sensors with no S protein or antibody were also dipped in the ACE2 or S protein solutions and the running buffer as references.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For ACE2615-foldon T27W staining, APC conjugated anti-HIS antibody (Miltenyi Biotec, Auburn, CA) was used as secondary antibody at 1:50 dilution.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-HIS</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, Expi293F cells transfected with monomeric ACE2 or dimeric ACE2 expression construct and the supernatant of the cell culture was collected.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Expi293F</div><div>suggested: RRID:CVCL_D615)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Murine Leukemia Virus (MLV) particles (plasmids of the MLV components kindly provided by Dr. Gary Whittaker at Cornell University and Drs. Catherine Chen and Wei Zheng at National Center for Advancing Translational Sciences, National Institutes of Health), pseudotyped with various SARS-CoV-2 S protein constructs, were generated in HEK 293T cells, following a protocol described previously for SARS-CoV (51, 52).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK 293T</div><div>suggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To prepare for infection, 7.5×103 of HEK 293 cells, stably transfected with a full-length human ACE2 expression construct, in 15 μl culture medium were plated into a 384-well white-clear plate coated with poly-D-Lysine to enhance the cell attachment.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK 293</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudotyped virus particles were produced in 293T/17 cells (ATCC) by co-transfection of plasmids encoding codon-optimized SARS-CoV-2 full-length S constructs, packaging plasmid pCMV DR8.2, and luciferase reporter plasmid pHR’ CMV-Luc.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T/17</div><div>suggested: ATCC Cat# CRL-11268, RRID:CVCL_1926)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The 293T cell line stably overexpressing the human ACE2 cell surface receptor protein was kindly provided by Drs.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The S genes were fused with a C-terminal twin Strep tag (SGGGSAWSHPQFEKGGGSGGGSGGSSAWSHPQFEK) and cloned into a mammalian cell expression vector pCMV-IRES-puro (Codex BioSolutions, Inc, Gaithersburg,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCMV-IRES-puro</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudotyped virus particles were produced in 293T/17 cells (ATCC) by co-transfection of plasmids encoding codon-optimized SARS-CoV-2 full-length S constructs, packaging plasmid pCMV DR8.2, and luciferase reporter plasmid pHR’ CMV-Luc.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCMV DR8.2, and luciferase reporter</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pHR’</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Expression constructs: Genes of full-length spike (S) protein from Gamma (hCoV-19/Brazil/AM-992/2020; GISAID accession ID: EPI_ISL_833172), Kappa (hCoV-19/India/MH-NEERI-NGP-40449/2021; GISAID accession ID: EPI_ISL_1547802) and Delta (hCoV-19/India/GJ-GBRC619/2021; GISAID accession ID: EPI_ISL_2020954) were synthesized by Twist Bioscience (South San Francisco, CA) or GENEWIZ (South Plainfield, NJ).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GENEWIZ</div><div>suggested: (GENEWIZ, RRID:SCR_003177)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The Kd was obtained by fitting Req value and its corresponding concentration to the model: “one site-specific” using GraphPad Prism 8.0.2 according to H.J. Motulsky, Prism 5 Statistics Guide, 2007, GraphPad Software Inc.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Automated data collection was carried out using SerialEM version 3.8.6 (53) at a nominal magnification of 105,000× and the K3 detector in counting mode (calibrated pixel size, 0.825 Å) at an exposure rate of 20.24 (for Delta), ∼20.69/20.63/27.13 (for three data sets of Gamma), or ∼21.12/20.10 (for two data sets of Kappa) electrons per pixel per second.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SerialEM</div><div>suggested: (SerialEM, RRID:SCR_017293)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Image processing and 3D reconstructions: Drift correction for cryo-EM images was performed using MotionCor2 (54), and contrast transfer function (CTF) was estimated by Gctf (55) using motion-corrected sums without dose-weighting.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MotionCor2</div><div>suggested: (MotionCor2, RRID:SCR_016499)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Density maps were corrected from the modulation transfer function of the K3 detector and sharpened by applying a temperature factor that was estimated using post-processing in RELION.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RELION</div><div>suggested: (RELION, RRID:SCR_016274)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Several rounds of manual building were performed in Coot (57).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Coot</div><div>suggested: (Coot, RRID:SCR_014222)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      A caveat is that all our experiments were performed in vitro; additional studies with authentic viruses will be needed to confirm our findings in more clinically relevant settings. If our hypothesis is valid, what is the structural basis for the enhanced fusogenicity of the Delta S protein? All mutations but one in the Delta S are located in either the RBD or NTD. Our extensive binding studies indicate that the Delta S does not engage the receptor ACE2 more tightly than does any other variant. It is unclear what other functional roles the NTD may play in the membrane fusion process, besides protecting the nearby RBDs. If the mutations in the NTD enhance RBD exposure to potential receptors, we should have observed, in our cryo-EM study, more particles in the RBD-up conformation from the Delta data set. Thus, the structural changes in both the RBD and NTD are unlikely to explain the efficient membrane fusion by the Delta variant. The last mutation, D950N, is unique to Delta and located in HR1 of S2 near the FPPR. D950N eliminates a negative charge (three in a trimer), but we have not observed any obvious structural changes caused by this substitution in the prefusion conformation. Its location nonetheless appears to be a critical site that can influence the refolding of S2, required for membrane fusion. Although D950 is not involved in a salt bridge in the G614 trimer, it is conceivable that the local change in the electrostatic potential may destabilize the prefusion S2 in a v...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 35. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.16.456441: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Mice: Murine experiments were executed in compliance with approval from the Animal Care and Use Committees of the University of Pennsylvania and University of Wisconsin at Madison. c57BL/10SnJ and B6.Cg-Tg(K18-ACE2)2Prlmn/J mice were purchased from the Jackson Laboratory.<br>Euthanasia Agents: Toe pinch was performed to ensure mice were deeply anesthetized before mice were euthanized by cervical dislocation.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Mixed gender 2-5-month-old C57BL/10 mice or 6–9-week-old k18-hACE2 mice were randomly assigned to groups and anesthetized with isoflurane before receiving an intra gastrocnemius injection of either 50 ul AAV or 50 ul formulation buffer using a custom 100 uL Hamilton syringe with a 32-gauge needle (475-41182, Lot 81008).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Additionally, k18-hACE2 mice were ear tagged as to keep the team performing the challenge experiments blinded to the animal’s treatment status. c57BL/10 muscle procurement, sectioning, and storage for immunohistochemistry: At pre-determined timepoints post-vaccination, mice were anesthetized with 4% isoflurane in an anesthesia chamber before being transferred to a nose cone where they were maintained on 4% isoflurane in 100% O2 at a flow rate of 1 L/minute.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The membrane was then washed 3×15 minutes in PBST and then incubated in secondary antibody solution (PBST + 5% BSA + Goat a-Rabbit-HRP 1:5000) (Abcam, ab205718) for one hour at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>a-Rabbit-HRP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Also included in this mixture to neutralize any potential VSV-G carryover virus was 1E9F9, a mouse anti-VSV Indiana G, at a concentration of 600 ng/ml (Absolute Antibody, Ab01402-2.0).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-VSV</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were then incubated in ddH2O for 2 minutes and then washed 5× with PBS before incubating with biotinylated anti-cytokine antibody at the manufacture’s recommended concentration in PBS + 1% BSA for 2 hr at RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-cytokine</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were then incubated in ddH2O for 2 minutes and then washed 5× with PBS before incubating with ALP-conjugated anti-IFNγ antibody at the manufacture’s recommended concentration in PBS + 1% BSA for 2 hr at RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-IFNγ</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">AAV6/9 vector generation: AAV6 and AAV9 were individually generated and purified by the University of Pennsylvania preclinical vector core using the triple transfection method in HEK293 cells as previously described12.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Transfection and Immunocytochemistry of C2C12 cells: 3.0E4 C2C12 cells were plated into each well of an 8 well chamber slide (Millipore, PEZGS0816) and cultured for 24 hours in growth media (DMEM high glucose supplemented with 10% FBS, 1× anti-anti, 1× GlutaMAX, 1× NEAA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C2C12</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Neutralization Assay: Production of VSV pseudotyped with SARS-CoV-2 S: 293T cells plated 24 hours previously at 5 × 106 cells per 10 cm dish were transfected using calcium phosphate with 35 μg of pCG1 SARS-CoV-2 S D614G delta18 expression plasmid encoding a codon optimized SARS-CoV2 S gene with an 18-residue truncation in the cytoplasmic tail (kindly provided by Stefan Pohlmann).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero E6 cells stably expressing TMPRSS2 were seeded in 100 μl at 2.5×104 cells/well in a 96 well collagen coated plate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The serum-virus mixture was then used to replace the media on VeroE6 TMPRSS2 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6 TMPRSS2</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mice: Murine experiments were executed in compliance with approval from the Animal Care and Use Committees of the University of Pennsylvania and University of Wisconsin at Madison. c57BL/10SnJ and B6.Cg-Tg(K18-ACE2)2Prlmn/J mice were purchased from the Jackson Laboratory.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>B6.Cg-Tg(K18-ACE2)2Prlmn/J</div><div>suggested: RRID:IMSR_JAX:034860)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mixed gender 2-5-month-old C57BL/10 mice or 6–9-week-old k18-hACE2 mice were randomly assigned to groups and anesthetized with isoflurane before receiving an intra gastrocnemius injection of either 50 ul AAV or 50 ul formulation buffer using a custom 100 uL Hamilton syringe with a 32-gauge needle (475-41182, Lot 81008).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/10</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">M8/M8B were cloned into the AAV transfer plasmid pZac2.1 along with (or flanked by) a CMV promoter and SV40 PolyA sequence.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pZac2.1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Western Blot of transfected HEK293: M8/M8B-pZac2.1 plasmid transfected HEK293 cell pellets were lysed in RIPA lysis buffer (Santa Cruz Biotechnology, sc-24948) supplemented with protease inhibitor cocktail (Roche, 39802300).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>M8/M8B-pZac2.1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Neutralization Assay: Production of VSV pseudotyped with SARS-CoV-2 S: 293T cells plated 24 hours previously at 5 × 106 cells per 10 cm dish were transfected using calcium phosphate with 35 μg of pCG1 SARS-CoV-2 S D614G delta18 expression plasmid encoding a codon optimized SARS-CoV2 S gene with an 18-residue truncation in the cytoplasmic tail (kindly provided by Stefan Pohlmann).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCG1 SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Red blood cells were lysed with ACK lysis buffer (Quality Biological Inc.,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Quality Biological</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 3. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.06.455441: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, cells were blocked with 5.0% fetal bovine serum in PBS and permeabilized with 0.5% Saponin before a 30 minutes incubation with: HCoV-OC43: Anti-Coronavirus Group Antigen Antibody, nucleoprotein of OC-43 (1:1000, Sigma MAB9013);</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-Coronavirus Group Antigen Antibody , nucleoprotein of OC-43</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">48 hours post transduction, cells were fixed in 4% PFA, permeabilized with 0.1% triton, blocked with FBS and stained for V5 (invitrogen cat# 46-0705, 1:1000) and antibody conjugate AF-488 Goat anti-Mouse IgG (H+L) (Thermo, 1:1000).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>V5</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-Mouse IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To generate lentiviral preparations of the Brunello library, 293T cells (6 × 106 cells per 10 cm dish) were transfected with 6µg lentiCRISPRv2-Brunello, 6µg NL-gagpol, and 1.2 µg VSV-G using PEI. 48 hours post transfection, supernatants were pooled and concentrated using Amicon Ultra Centrifugal Filters</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 10-fold serial dilutions (from 10−1 to 10−6) were used to transduce 40,000 A549 cells in a 24 well plate format.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Thereafter, in triplicates with 8×106 cells per flask, A549-Brunello cells were infected or not with HCoV-OC43 at an MOI of 0.1, and passaged for 7 days until >95% infection-induced cell death occurred.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549-Brunello</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The next day, 7.5 µg pHIV-1NL4-3 ΔEnv-NanoLuc and 2.5 µg indicated CoV spike plasmid were transfected using PEI.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pHIV-1NL4-3</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pathway Analysis of screen hits: All 34 candidate genes were searched using the STRING database (https://string-db.org) for functional enrichment of protein-protein interactions using default settings, except the minimum required interaction score was changed from medium confidence (0.400) to high confidence (0.700).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STRING</div><div>suggested: (STRING, RRID:SCR_005223)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Quantification of fluorescence microscopy: For each cell, Regions Of Interest (ROIs) corresponding to labeled endosomes were defined using the freehand selection tool in Fiji.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Fiji</div><div>suggested: (Fiji, RRID:SCR_002285)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on pages 17 and 33. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.07.455523: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: All animal experiments were approved by the Animal Care and Use Committee of Wuhan University.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Age-matched (9-10-week-old) female mice were grouped for infection of nanobodies (0.5mg/kg).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">After 2–3 rounds of selection-amplification cycle, single colonies were randomly selected into deep 96-well culture plate containing 850 μL/well of 2YT (100 μg/mL ampicillin) and shook at 37°C for 3h.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">RBD-His binding to the plate was detected with anti-His tag mouse monoclonal antibody (1:3000 dilution, SinoBiological, 105327-MM02T) and followed by an HRP conjugated anti-mouse IgG (H+L) Goat antibody (Beyotime, A0216).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-His tag</div><div>suggested: (Sino Biological Cat# 105327-MM02T, RRID:AB_2857924)</div></div><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: (Beyotime Cat# A0216, RRID:AB_2860575)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For IFA, Anti-hACE2 antibody and anti-SARS-CoV/SARS-CoV-2 Nucleocapsid Antibody (Cat: 10108-RP01 and 40143-MM05, SinoBiological) were added as primary antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-hACE2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-SARS-CoV/SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines and viruses: Vero-E6 (ATCC® CRL-1586), CaCO2(ATCC® HTB-37) and 293T (ATCC® CRL-3216) cell are cultured in Dulbecco’s Modified Eagle Medium (DMEM, Thermal Fisher, # 12430112), supplied with 10% fetal bovine serum (Thermal Fisher, # 26140079),1%</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero E6 (ATCC number: CRL-1586) cells were cultured to determinate viral titer.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Protection of K18-hACE2 transgenic mice against SARS-CoV-2: K18-hACE2 transgenic mice expressing human ACE2 driven by the human epithelial cell cytokeratin-18 (K18) promoter, were purchased from Gempharmatech and housed in ABSL-3 pathogen-free facilities under 12-h light-dark cycles with ad libitum access to food and water.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>K18-hACE2</div><div>suggested: RRID:IMSR_GPT:T037657)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The whole coding cassette was ligated into a pCMV3 expression vector with a signal peptide of MEFGLSWVFLVALFRGVQC at the N-terminal, and either a 6-his tag (for RBD-his) or a human IgG1 Fc fragment with (GSSSS)3 linker at C-terminal.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCMV3</div><div>suggested: RRID:Addgene_161029)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, pseudovirus bearing wildtype SARS-CoV-2 S protein or mutants were produced by co-transfection with plasmids expressing corresponding protein and backbone plasmid pNL-4-3-Luc.-</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pNL-4-3-Luc</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To accurately quantify the absolute number of SARS-CoV-2 genomes, a standard curve was prepared by measuring the SARS-CoV-2 N gene constructed in the pCMV-N plasmid.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCMV-N</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ExpiCHO Expression System was purchased from Thermal Fisher (#A29133).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Thermal Fisher</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Protein expression and purification: The constructs of VHHs were selected from phage display, RBD fragment (aa319-541) of SARS-CoV-2 S protein (GenBank: MN908947.3) was synthesized by Genewiz Inc (GENEWIZ, Suzhou, China), the extracellular domain of human ACE2 (1-740 aa) (GenBank: NM_021804.1) was amplified from a plasmid (HG10108-ACG, Sinobiologic, Beijing, China).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GENEWIZ</div><div>suggested: (GENEWIZ, RRID:SCR_003177)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The acid eluted fraction was neutralized with 1M Tris-HCl, pH9.0 and was concentrated and desalted into PBS with Amicon® Ultra-15, PLTK Ultracel-PL membrane (MilliporeSigma Life Science Center, Burlington, Massachusetts, USA) with appropriate MWCO.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Amicon®</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The IC50 values were calculated with non-linear regression using GraphPad Prism 8 (GraphPad Software, Inc.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Protection of K18-hACE2 transgenic mice against SARS-CoV-2: K18-hACE2 transgenic mice expressing human ACE2 driven by the human epithelial cell cytokeratin-18 (K18) promoter, were purchased from Gempharmatech and housed in ABSL-3 pathogen-free facilities under 12-h light-dark cycles with ad libitum access to food and water.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gempharmatech</div><div>suggested: (GemPharmatech, RRID:SCR_017239)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All data was analyzed by XLfit (IDBS, Boston, MA 02210) or Prism 5(GraphPad Software, San Diego, CA 92108).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.11.21261899: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: This study was approved by the Ethics committees of Centro Hospitalar Universitário de Lisboa Central and Hospital Professor Doutor Fernando Fonseca, in compliance with the Declaration of Helsinki, and follows international and national guidelines for health data protection.<br>Consent: All participants, or their guardians, provided informed written consent to take part in the study.<br>Field Sample Permit: Samples were stored at 4ºC, sent to Instituto Gulbenkian de Ciência, and processed within 72 h from collection.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were stained with a rabbit polyclonal SARS-CoV-2 nucleocapsid antibody (1:1,000; ThermoFisher, #MA536270) and an anti-rabbit IgG Alexa-Fluor 488 secondary antibody (1:1,000; Invitrogen, #A-21206)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rabbit IgG</div><div>suggested: (Thermo Fisher Scientific Cat# A-21206, RRID:AB_2535792)</div></div><div style="margin-bottom:8px"><div>#A-21206</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For each isotype test plate, an IgG, IgM (GenScript [clone 2001]) or IgA (Absolute Antibody [clone 3022])</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgA</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary antibody goat anti□Human Fc□HRP IgG, IgA or IgM (Abcam) diluted 1 in 25,000 in PBS-BSA-T was added to respective isotype plates and incubated for 1 hour at 37ºC to reveal bound IgG, IgA or IgM.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Secondary antibody goat anti□Human Fc□HRP IgG, IgA</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti□Human Fc□HRP IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgM</div><div>suggested: (Nicholas M. Kanaan at Michigan State University Cat# TOC1, RRID:AB_2832939)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Two hundred μL of each sample were added in triplicate to Vero E6 cells (a kind gift from Rupert Beale, The Francis Crick Institute, UK) pre-seeded in 24 well plates with coverslips and centrifuged for 15 min at 3,500 g, 37ºC.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">One negative control was performed without template for the same three conditions (N1, N2 and RP).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>N2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">23 The analytical sensitivity of SARS-CoV-2 RNA detection between saliva and nasopharyngeal swabs from SARS-CoV-2 positive adults and children was compared using a Wilcoxon matched-pairs signed-rank test, in GraphPad Prism 9.1.2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">STATA (StataCorp LLC, USA, V16) was used for all analyses.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STATA</div><div>suggested: (Stata, RRID:SCR_012763)</div></div><div style="margin-bottom:8px"><div>StataCorp</div><div>suggested: (Stata, RRID:SCR_012763)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.11.455921: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">interferon gamma (IFNγ) (SRP3058) and human Interleukin-4 (IL-4) (I4269) were from Sigma-Aldrich, UK; Primary antibodies were as follows: anti-CTGF goat polyclonal antibody (sc-14939), and anti-COL3A1 goat polyclonal antibody (sc-8781) were from Santa Cruz Biotechnology,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IL-4</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-CTGF</div><div>suggested: (Santa Cruz Biotechnology Cat# sc-14939, RRID:AB_638805)</div></div><div style="margin-bottom:8px"><div>anti-COL3A1</div><div>suggested: (Santa Cruz Biotechnology Cat# sc-8781, RRID:AB_638604)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary antibodies were as follows: polyclonal rabbit anti-goat Immunoglobulins/HRP (P0160) and polyclonal swine anti-rabbit Immunoglobulins/HRP (P0217) were from Dako, DK; Cy™3-conjugated</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-goat</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>P0160</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-rabbit</div><div>suggested: (Agilent Cat# P0217, RRID:AB_2728719)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies (Dako, Denmark), diluted at 1:2500 in PBSTM were added for approx.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HRP)-conjugated secondary antibodies ( Dako , Denmark)</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The antibody concentration varied and depended on the antibody used, but it was usually at 1:200 or similar for the primary antibodies (i.e. TLR4) and 1:400 for ACE2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>TLR4</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primary antibodies used were mouse anti-human TLR4 and rabbit anti-spike S1 with the appropriate secondary antibodies (anti-rabbit-minus and anti-mouse-plus PLA probes) from the kit and red detection reagents. 293-hTLR4-HA cells: 293-hTLR4-HA cells (InvivoGen, USA) are HEK 293 cells stably transfected with the hTLR4a gene fused at the 3’ end to an influenza haemagglutinin (HA) tag.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human TLR4</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-spike</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-rabbit-minus</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-mouse-plus PLA</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HA</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primary antibodies used were mouse anti-human TLR4 and rabbit anti-spike S1 with the appropriate secondary antibodies (anti-rabbit-minus and anti-mouse-plus PLA probes) from the kit and red detection reagents. 293-hTLR4-HA cells: 293-hTLR4-HA cells (InvivoGen, USA) are HEK 293 cells stably transfected with the hTLR4a gene fused at the 3’ end to an influenza haemagglutinin (HA) tag.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293-hTLR4-HA</div><div>suggested: RRID:CVCL_Y394)</div></div><div style="margin-bottom:8px"><div>HEK 293</div><div>suggested: CLS Cat# 300192/p777_HEK293, RRID:CVCL_0045)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">293 cells express very low levels of endogenous TLR4.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293</div><div>suggested: NCI-DTP Cat# NCI-293TT, RRID:CVCL_1D85)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">THP-1 cells and differentiation: The human monocytic cell line THP-1 was routinely maintained in RPMI 1640 (1x) growth medium containing 10% of heat-inactivated FBS, 4.5 mg/ml D-glucose, 2mM L-glutamine, 10mM HEPES, 1mM pyruvate, 0.05 mM 2-mercaptoethanol, and 1% Penicillin/streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>THP-1</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Phorbol 12-myristate 13-acetate (PMA) (1201/1) was from Bio-Techne, UK; Cytokines:</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Cytokines</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis was performed and graphs were produced using GraphPad Prism 8, either using a Kruskal Wallis test, Wilcoxon Signed Rank Test, or Repeated Measures One-way ANOVA with G-G correction followed by Tukey’s multiple comparisons post hoc test as appropriate to the experiment and as indicated in the figure legends.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 25. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.04.21261507: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Ethical approved was provided by the Advarra Institutional Review Board as well as the Health Products and Food Branch of Health Canada and the study was carried out in accordance with the Declaration of Helsinki and the principles of Good Clinical Practices.<br>Consent: Participants were recruited from existing databases of volunteers, and written informed consent was obtained from all study participants before any study procedure.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Standardization of Antibody Titers with the WHO 20/136 Pooled Sera: As previously described 37, WHO International Standard anti-SARS-CoV-2 immunoglobulin (human; NIBSC code: 20/136) was included in antibody binding and neutralization assays for the purpose of facilitating comparison of results with other studies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 immunoglobulin</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">GraphPad Prism software was used to calculate means and 95% CIs.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04450004</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Active, not recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Safety, Tolerability and Immunogenicinity of a Coronavirus-L…</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.07.21261749: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero CCL-81 cells grown in Dulbecco minimal essential medium (DMEM) supplemented with antibiotic/antimycotic (GIBCO) and heat-inactivated fetal bovine serum (5% or 10%) were used for SARS-CoV-2 isolation and first passage.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero CCL-81</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then, 100 μl of Vero cell suspension was added on to serial dilutions of the clinical samples.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus inactivation was confirmed by the absence of cytopathic effect in two consecutive passages in the VeroE6 cell lines and the inability to demonstrate amplification by quantitative RT-PCR.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Poor-quality bases found in the raw data were removed using Trimmomatic 0.36 (-phred33, LEADING:20, TRAILING:20, SLID INGWINDOW:4:20, MINLEN:40)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Trimmomatic</div><div>suggested: (Trimmomatic, RRID:SCR_011848)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lumerical FDTD and MATLAB were used for implementing and running the electromagnetic and genetic algorithm models, respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MATLAB</div><div>suggested: (MATLAB, RRID:SCR_001622)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your code.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on pages 32 and 6. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a protocol registration statement.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.08.21261763: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Ethics Statement: This study was approved by the Northwestern University Institutional Review Board (Koralnik Lab, IRB STU00212583).<br>Consent: Informed consent was obtained from all enrolled participants.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ELISA: Antigen-specific total antibody titers were measured by ELISA as described previously (Dangi et al., 2020; Palacio et al., 2020).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ELISA: Antigen-specific total</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Antigen-specific</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were washed three times with wash buffer followed by addition of secondary antibody conjugated to horseradish peroxidase, goat anti-human IgG (H + L) (Jackson ImmunoResearch) diluted in blocking solution (1:1000) and 100 µl/well was added and incubated for 60 min at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vector pCAGGS containing the SARS-related coronavirus 2, Wuhan-Hu-1 spike glycoprotein gene (soluble, stabilized), NR-52394 and receptor binding domain (RBD), NR-52309, nucleocapsid gene NR-53507.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS</div><div>suggested: RRID:Addgene_18926)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The PBMC layer was collected and washed 2x in sterile PBS before red blood cell lysis with ACK buffer (Quality Biologicals).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Quality Biologicals</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data was acquired on a BD FACSymphony Spectral analyzer and analyzed using FlowJo v10 (BD Biosciences) and SPICE-Pestle (Roederer et al., 2011).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Quantification and Statistical Analysis: Statistical tests to determine significance are described in figure legends and conducted largely in Prism (GraphPad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For pie graphs or heatmaps generated using SPICE analysis, statistics were determined by Permutation test following unstimulated background subtraction, with additional thresholding of 0.03% to account for noise, using SPICE-Pestle.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SPICE</div><div>suggested: (SPICE, RRID:SCR_016603)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Clinical data were collected and managed using REDCap electronic data capture tools hosted at Northwestern University Feinberg School of Medicine (Harris et al., 2009)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>REDCap</div><div>suggested: (REDCap, RRID:SCR_003445)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Limitations of study: One limitation of our study is the relatively small sample size of unvaccinated neuro-PASC patients. This was due to the wide implementation of SARS-CoV-2 vaccines in the Chicago area soon after beginning study enrollment. Another limitation was not being able to control for time of sample collection with respect to date of COVID-19 symptom onset. As it is possible that neuro-PASC could be the result of a persistent infection, further investigations would require testing of potential cryptic reservoirs, including stool samples from CN patients.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.08.455272: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Human Donors: The recruitment of study subjects was conducted in accordance with the Ethics Committee of the Charité (EA 1/144/13 with EA 1/075/19, EA 2/066/20) and was in compliance with the Declaration of Helsinki.<br>Field Sample Permit: Bacteria culture: PYG medium and plates were prepared as described by the DSMZ (German Collection of Microorganisms and Cell Cultures). 300,000 events were sorted into 1 ml of PYG medium and directly transferred to a COY anaerobic chamber.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Staining for human immunoglobulins was performed in 100 µL with 1:50 (v/v) of the detection antibodies: anti-human IgM Brilliant Violet 650 (clone: MHM-88, Biolegend® Cat. No. 314526)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgM Brilliant Violet 650</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the detection of Spike protein-similar structures the samples were first incubated in 50 µL containing 0.5 µg SARS-CoV-2 Spike Neutralizing Antibody (clone: HA14JL2302, Sino Biological Inc. Cat. No: 40592-R001) or Neutralizing Antibody isolated from COVID-19 patients for 15 min at 4 °C then washed with PBS and stained again in 50 µL of the anti-Rabbit Alexa 647 (7,5µg/ml, Jackson ImmunoResearch Cat. No. 111-606-144) or anti-human IgG PE/ Dazzle™ 594 (2µg/ml) which was then topped up with 5 µM Hoechst 33342 solution</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Rabbit</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 111-606-144, RRID:AB_2338083)</div></div><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Enzyme-linked immunosorbent assay: For the detection of antibody titers in sera and fecal supernatants 96-well plates were coated with goat anti-human Ig (H+L chain) antibody (Southern Biotech, Cat. No. 2010-01) or goat anti-human IgA Fab (Southern Biotech, Cat. No. 2050-01) antibody for the detection of IgG, IgM and IgA respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human Ig ( H+L chain )</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-human IgA</div><div>suggested: (SouthernBiotech Cat# 2050-01, RRID:AB_2795701)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After that, plates were washed 5 times with 200 μL of 1x PBST and detection antibodies were applied: anti-human IgG-AP (ICN/Cappel, Cat No. 59289),</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG-AP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Microarray was incubated with monoclonal anti-RBD antibodies (final concentration 1 mcg/ml) or mouse fecal supernatants (1:1 dilution) at 30 C for 1 hours with constant rotation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-RBD</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, anti-human IgG-Alexa647 (Southern Biotech; Cat. No.: 2040-31), goat anti-Mouse IgA Antibody DyLight® 650 (Bethyl Laboratories; Cat.No.: A90-103D5) at 30 C for 1 hour.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG-Alexa647</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-Mouse IgA</div><div>suggested: (Bethyl Cat# A90-103D5, RRID:AB_10630982)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow cytometric assay for analysis of ACE2-RBD interaction: HEK293T cells were transfected with a plasmid expressing human ACE2 protein.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">C57Bl/6 mice were injected with 200 µl of heat-killed bacteria i.p. From oral gavage, live bacteria stocks were grown, washed with PBS several times, OD600 was adjusted to 1, 200 µl of live bacteria was gavaged every second day.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57Bl/6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Protein expression: Uncharacterised protein RSSL-01370 was amplified from the genomic DNA of Streptococcus salivarius K12 using the following primers: 5’s-CTCCATATGAATTTACCAAGTCACCATACAAGGG -’s3 and 5’-GTGGTCGACATTCACTTTTTCAGTTGCTACACC -’3 and subsequently cloned into pET-21b containing NdeI and XhoI restriction sites.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pET-21b</div><div>suggested: RRID:Addgene_132607)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Raw data were processed and de-multiplexed using MiSeq Reporter Software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MiSeq</div><div>suggested: (A5-miseq, RRID:SCR_012148)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Forward and reverse reads were combined using PANDAseq 2.11 with a minimum overlap of 25 bases (PMID:22333067) and classified using “classifier.jar” 2.13 from the Ribosomal Database Project with a confidence cutoff of 50% (PMID: 24288368, PMID: 17586664).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PANDAseq</div><div>suggested: (PANDAseq, RRID:SCR_002705)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The copy number adjusted counts were agglomerated to bacterial genera, rarefied to the smallest size and alpha diversity were estimated using phyloSeq 1.34 (PMID: 23630581).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>phyloSeq</div><div>suggested: (phyloseq, RRID:SCR_013080)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The linear discriminant analysis were performed using LEfSe, based on copy number adjusted counts normalized to 1M reads [46].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>LEfSe</div><div>suggested: (LEfSe, RRID:SCR_014609)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Raw sequence data were deposited at the NCBI Sequence Read Archive (SRA) under the accession number PRJNA738291.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NCBI Sequence Read Archive</div><div>suggested: (NCBI Sequence Read Archive (SRA, RRID:SCR_004891)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequence identity was determined with the Nucleotide Basic Local Alignment Search Tool (BLAST) provided by NCBI.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BLAST</div><div>suggested: (BLASTX, RRID:SCR_001653)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Spike glycoprotein (SPIKE) wild type + mutations (JPT Peptide Technologies GmbH; RT-MW-WCPV-S-V02)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SPIKE</div><div>suggested: (SPIKE, RRID:SCR_010466)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, anti-human IgG-Alexa647 (Southern Biotech; Cat. No.: 2040-31), goat anti-Mouse IgA Antibody DyLight® 650 (Bethyl Laboratories; Cat.No.: A90-103D5) at 30 C for 1 hour.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bethyl Laboratories</div><div>suggested: (Bethyl, RRID:SCR_013554)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Samples were acquired on a FACSCanto (BD Biosciences) and analyzed using FlowJo v10</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Correspondence of the found MS/MS fragments to the proteins was performed with the help of Biotools software (Bruker Daltonik, Germany) and a Mascot MS/MS ion search.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Biotools</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.06.21261721: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: The study team then contacted staff and residents/substitute decision makers for consent to participate.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">All values are calculated using automated scripts, prior to consideration of the meta-data; the investigators performing the measurements were blinded to the sample description.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PRNT50 titers and PRNT90 titers ≥ 20 were considered positive for SARS-CoV-2 neutralizing antibodies, whereas titers <20 were considered negative.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 neutralizing antibodies,</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293TN and HEK293-ACE2/TMPRSS2 cells were maintained at 85% confluency for no more than 25 passages.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293TN</div><div>suggested: RRID:CVCL_UL49)</div></div><div style="margin-bottom:8px"><div>HEK293-ACE2/TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 1 hour of incubation at 37°C and 5% CO2, 100 μL of each antibody-virus mixture was added in duplicate to 12-well plates containing Vero E6 cells at 95–100% confluence, and 100 μL of each control was added in triplicate to two sets of 12-well plates containing Vero E6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">They were co-transfected with packaging (psPAX2, Addgene, Watertown, MA, USA, #12260) and luciferase reporter constructs (pHAGE-CMV-Luc2-IRES-ZsGreen-W, kindly provided by Jesse Bloom) into HEK293TN cells (System Biosciences, Palo Alto, CA, USA, LV900A-1)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>psPAX2</div><div>suggested: RRID:Addgene_12260)</div></div><div style="margin-bottom:8px"><div>pHAGE-CMV-Luc2-IRES-ZsGreen-W</div><div>suggested: RRID:Addgene_164432)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Unless otherwise specified, 50% neutralization titer (ID50) values of patient sera were calculated in GraphPad Prism 9 (GraphPad Software, San Diego, CA, USA) using a nonlinear regression (log[inhibitor] versus normalized response – variable slope) algorithm.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Analysis of factors associated with humoral response to COVID-19 vaccines: Data on clinical response and antibody titers were entered into excel, cleaned and analyzed in SAS version 0.4 for PC (SAS Institute, Cary, NC).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SAS Institute</div><div>suggested: (Statistical Analysis System, RRID:SCR_008567)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      There are some other limitations to this study: we have only analyzed the response to COVID-19 the mRNA vaccines, with both doses administered on the schedule recommended by the vaccine manufacturers. It is noteworthy that in Ontario, LTCH residents were prioritized for vaccination with mRNA vaccines administered according to the product monograph. However, LTCH residents in some other provinces of Canada, as well as many older adults and individuals with immune system deficiencies have been vaccinated across the country with two doses of mRNA vaccines spaced further apart in order to accommodate vaccine supply issues. Another segment of the population has been vaccinated with the ChAdOx1-S vaccine (from AstraZeneca or COVISHIELD), which yields lower neutralizing antibodies [16]. Importantly, heterologous dose regimens (particularly for those who received ChAdOx1-S vaccine as a first dose) have been widely used in Canada, but their effect on the humoral response in older adults is still not known. Furthermore, we have only looked at the response 2–4 weeks after dose 2, and it will be critical to profile the decline in antibody production in this priority population. Lastly, it is possible that as the virus continues to evolve, new variants may further evade or overwhelm the blunted humoral response generated by vaccination in these older and frail adults. In conclusion, our results raise further concern that even the most effective current vaccines provide only partial protec...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.13.21262006: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: All participants or their legal representatives gave written informed consent according to the approval of the ethics committee at the Charité University Hospital, Berlin (EA2/066/20 Pa-Covid-19 and University of Ulm (CAPSID trial (115/20 and 488/20) [16, 17]. 2.2.<br>IRB: All participants or their legal representatives gave written informed consent according to the approval of the ethics committee at the Charité University Hospital, Berlin (EA2/066/20 Pa-Covid-19 and University of Ulm (CAPSID trial (115/20 and 488/20) [16, 17]. 2.2.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For flow cytometric analysis, the following fluorochrome-labeled antibodies were used: BUV395 anti-CD14 (BD, clone M5E2, 1:50)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-CD14</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Quantitative analysis was done using the following intracellular fluorochrome-labeled antibodies: PE anti-STAT1 (BD, clone 1/Stat1, 1:10), FITC anti-pSTAT1 (BD, clone 4a, 3:20), AF647 anti-pSTAT2 (R&D Systems, clone 1021D, 1:5), PE anti-IRF1 (BD, clone 20/IRF-1, 1:20), AF647 anti-IRF7 (BD, clone K47-671, 1:10).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-STAT1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-pSTAT1</div><div>suggested: (Fluidigm Cat# 3153003A, RRID:AB_2811248)</div></div><div style="margin-bottom:8px"><div>anti-pSTAT2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-IRF1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-IRF7</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For IRF9 analysis an unconjugated IRF9 antibody (Thermo Fisher,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IRF9</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Analytical methods and flow cytometry: Intracellular phenotyping of STAT1, pSTAT1, pSTAT2, IRF1 and IRF7 levels in B and T cells was conducted as previously published [18].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pSTAT1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pSTAT2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Study participants: Peripheral blood samples (EDTA anti-coagulated, BD vaccutainer system, BD Diagnostics, Franklin Lakes, NJ, USA) from 20 healthy controls and 30 COVID patients were analyzed, 17 with mild (WHO 8-point ordinal scale 1 and 2) and 13 with a severe course of the disease (WHO 8-point ordinal scale ≥ 4) [15].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BD Diagnostics</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">l analysis: Flow cytometry data were analysed using FACSDiva software (Becton Dickinson, Franklin Lakes, NJ, USA) and FlowJo (version 10, TreeStar, Ashland, OR, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FACSDiva</div><div>suggested: (BD FACSDiva Software, RRID:SCR_001456)</div></div><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For graphical and statistical analysis, GraphPad Prism (version 7.00, GraphPad Software, La Jolla, CA, USA) was used.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04433910</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Completed</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">A Clinical Trial of Convalescent Plasma Compared to Best Sup…</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 14. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.11.455959: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: All work with SARS-CoV-2 was performed in a biosafety level 3 laboratory using appropriate personal protective equipment and protocols approved by the Institutional Biosafety Committee and Environmental Health and Safety at the University of Pennsylvania.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines and infection: We cultured A549ACE2 cells at 37°C and 5% CO2 in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We cultured Huh7.5 cells at 37°C and 5% CO2 in DMEM supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, and 1% L-Glutamax.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Huh7.5</div><div>suggested: RRID:CVCL_7927)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We divided each 52-mer oligo into two non-overlapping 25-mer sequences (removing the middle two nucleotides) and appended split-initiator HCR sequences using a custom matlab script (see Supp.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>matlab</div><div>suggested: (MATLAB, RRID:SCR_001622)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To target SARS-CoV-2 subgenomic RNAs, we referenced the UCSC Genome Browser for SARS-CoV-2 genome datasets (https://genome.ucsc.edu/covid19.html) and RNA-sequencing datasets44 to identify the most frequent junction locations and peri-junction sequences based on the most abundant sgRNA junction spanning reads.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>UCSC Genome Browser</div><div>suggested: (UCSC Genome Browser, RRID:SCR_005780)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We then used CellProfiler to segment cells using 4’,6-diamidino-2-phenylindole (DAPI) to identify nuclei.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CellProfiler</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your code.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.11.455942: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Mice were maintained under specific pathogen-free conditions at the Institute Leloir animal facility and all experiments were conducted in accordance with animal use guidelines and protocols approved by the Institutional Animal Care and Use Committee (IACUC protocol 69).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Mice immunization: Six- to eight-week-old male BALB/c mice (obtained from the animal facility of the Veterinary School, University of La Plata, Argentina) were immunized with 109 or 1010 viral particles (vp) of Ad.C (empty vector), CoroVaxG.5 or CoroVaxG.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ELISA: Sera from all mice were collected at different time points after immunization and evaluated for SARS-CoV-2-S-specific IgG antibodies using ELISA.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2-S-specific IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sera collected at week 4 after vaccination were also tested for SARS-CoV-2-S-specific IgG1 and IgG2a antibodies using ELISA.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2-S-specific IgG1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgG2a</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were washed and bound specific IgG was detected with a HRP-conjugated goat anti-mouse IgG H&L antibody (ab6789, Abcam) diluted 1: 10,000 in blocking buffer.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: (Abcam Cat# ab6789, RRID:AB_955439)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Neutralization of authentic SARS-CoV-2 virus: Neutralizing antibody (nAb) titers against SARS-CoV2 were defined according to the following protocol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CRL-3216), Vero cells (CCL-81), Hs 729T (HTB-153) and THP-1 (TIB-202) cells were obtained from the ATCC (Manassas, VA, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>THP-1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293 cells were purchased from Microbix Biosystems Inc (Mississauga, Canada) and 911 cells were already described63.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T-hACE2 cells were already described64.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T-hACE2</div><div>suggested: RRID:CVCL_A7UK)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the selection of the most appropriate promoter, HEK293T cells grown in 24-well plates were co-transfected with 1 μg of the different plasmids and 100 ng of pS-CMV-Renilla, using Lipofectamine 2000 (Thermo Fisher Scientific, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The viruses were propagated in HEK-293 cells in CellSTACK® cell culture chambers (Corning, Arizona, USA), purified by double CsCl density gradient centrifugation and stored in 10% glycerol in single-use aliquots at –80°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK-293T cells growing in Optimem media (Gibco, MD, USA) with 2% of FBS were transduced with G*ΔG-VSV at a multiplicity of infection of four.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T</div><div>suggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, 100 μl of 5×105/mL HEK293T-ACE2 cells were added to the pseudovirus-serum mixture and incubated at 37 °C, 5% CO2 for 20-24 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T-ACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For RBD inoculations eight-week-old male BALB/c mice were immunized with 7.5 μg of the receptor binding domain of Spike protein (kindly gifted by Andrea Gamarnik, Argentina) in 75 μL Complete Freund’s Adjuvant (CFA, Sigma, St. Louis, MO) via subcutaneous injection and boosted 2 weeks later with 5 μg of RBD in 100 μL Incomplete Freund’s Adjuvant (IFA, Sigma).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Promoter and fiber selection: Promoters were synthesized by Genscript (NJ, USA) with NotI / (XhoI-StuI) flanking restriction sites and cloned in the NotI / StuI sites of the vector pShuttle-I-XP-Luc63 to obtain pShuttle-Pr1-Luc and pShuttle-Pr2-Luc.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pShuttle-I-XP-Luc63</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pShuttle-Pr1-Luc</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The vectors pAd-SV40-Luc, and pS-CMV-Renilla were previously described63.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pAd-SV40-Luc</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pS-CMV-Renilla</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The synthesized 4,650 bp fragment was cloned into the pShuttle-Pr2-Luc vector digested with StuI / SalI to exchange the luciferase ORF by the designed Spike cassette, downstream of Pr2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pShuttle-Pr2-Luc</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The sequence of the resulting plasmid pS-Spike(D614G)-PP was confirmed by sequencing (Macrogen, Seul, Korea).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pS-Spike(D614G)-PP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To construct the non-replicating adenoviruses, the plasmid pS-Spike(D614G)-PP was linearized with PmeI and co-transformed with E1/E3 (pCoroVaxG.5) or E1 (pCoroVaxG.3) deleted adenoviral backbone vectors in electrocompetent BJ5183 bacteria.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCoroVaxG.5</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pCoroVaxG.3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, the full length cDNA of Spike-D614G, and the Spike variants B.1.1.7 (alpha, first identified in the UK) and P.1 (gamma, first identified in Manaos, Brazil), were cloned into the eukaryotic expression vector pcDNA3.1, using the EcoRV restriction site and blunt-end ligation strategy, to generate the recombinant plasmids pcDNA-3.1-Spike-D614G, pcDNA-3.1-Spike-B,1,1,7 and pcDNA-3.1-Spike-P.1..</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.1</div><div>suggested: RRID:Addgene_79663)</div></div><div style="margin-bottom:8px"><div>pcDNA-3.1-Spike-D614G</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pcDNA-3.1-Spike-B,1,1,7</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pcDNA-3.1-Spike-P.1</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Protein extracts were separated by SDS-PAGE with a 10% gel and transferred to nitrocellulose membranes (Bio-Rad Laboratories).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bio-Rad Laboratories</div><div>suggested: (Bio-Rad Laboratories, RRID:SCR_008426)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Semi-quantifications of WB assays were performed by densitometry using the ImageJ software 1.53 (Wayne Rasband, NIH, USA), normalizing by β-actin expression.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For each IgG subclass reference, a standard curve was plotted using GraphPad Prism 8.0 generating a four-parameter logistical (4PL) fit of the OD 450 nm at each serial antibody dilution.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were acquired on a FACSAria Fussion cytometer and analysis was performed using Flow Jo version 10.7.1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Flow Jo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.10.21261849: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: The Chesapeake/Advarra Institutional Review Board served as the central IRB for five sites, and the University of Florida Institutional Review Board served as the IRB of record for the Jacksonsville, FL site.<br>Consent: De-identified samples and other data were included in the study under IRB-approved waivers of consent and authorization.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then, goat anti-human IgA, IgM, and IgG horseradish peroxidase (HRP) secondary antibodies (ThermoFisher) were diluted at 1:4000 in blocking buffer and 100 μL of each secondary antibody solution was added to each well for 1 hour.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgA, IgM</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.09.21261704: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">2.1 Cell culture and virus propagation: Caco2 and A549-AT cells [20] were cultured in Minimum Essential Medium (MEM) supplemented with 10% fetal calf serum (FCS), 4 mM L-glutamine, 100 IU/ml of penicillin and 100 μg/ml of streptomycin at 37°C and 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549-AT</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 isolates were grown using Caco2 cells as described previously [7].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Caco2</div><div>suggested: CLS Cat# 300137/p1665_CaCo-2, RRID:CVCL_0025)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">2.2 SARS-CoV-2 Neutralization Assay: SARS-CoV-2 antibody concentrations of this cohort were tested previously [14] with the SARS-CoV-2 IgG II Quant assay (Abbott Diagnostics) performed on the Alinity I with an analytical measurement range from 2.98–5680 binding antibody units per mL (BAU/mL)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Abbott</div><div>suggested: (Abbott, RRID:SCR_010477)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">2.3 Statistical analysis: Data analysis was performed in Microsoft Excel and GraphPad Prism 8 (GraphPad Software, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Microsoft Excel</div><div>suggested: (Microsoft Excel, RRID:SCR_016137)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.15.456341: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Ethics statement: All animal studies and experiments were approved and performed under the Kansas State University (KSU) Institutional Biosafety Committee (IBC, Protocol #1460) and the Institutional Animal Care and Use Committee (IACUC, Protocol #4468) in compliance with the Animal Welfare Act.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Virus challenge of animals: Six female white-tailed deer (WTD), approximately 2 years of age, were acquired from a Kansas deer farm (Muddy Creek Whitetails, KS) and acclimated for ten days in BSL-3Ag biocontainment with feed and water ad libitum prior to experimental procedures.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Two independent veterinary pathologists (blinded to the treatment groups) examined the slides and morphological descriptions were provided.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following three washes with PBS-T, 100 μL of HRP-labelled Rabbit Anti-Deer IgG (H+L) secondary antibody (95058-328, VWR, Batavia, IL, USA) diluted 1:1000 (100ng/mL) was added to each well and incubated for 1 hour at RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-Deer IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Indirect ELISA was used to detect Bovine Coronavirus (BCoV) antibodies in sera with Spike (S) recombinant viral protein (LSBio, LS-G64076-20, Seattle, WA, USA) using the methods described above.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BCoV</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2-specific immunohistochemistry (IHC): IHC was performed as previously described (9) on four-micron sections of formalin-fixed paraffin-embedded tissue mounted on positively charged Superfrost® Plus slides and subjected to IHC using a SARS-CoV-2-specific anti-nucleocapsid rabbit polyclonal antibody (3A, developed by our laboratory) with the method previously described (35).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-nucleocapsid</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells and virus isolation/titrations: Vero E6 cells (ATCC; Manassas, VA) and Vero E6 cells stably expressing transmembrane serine protease 2 (Vero-E6/TMPRSS2; 33) were obtained from Creative Biogene (Shirley, NY) via Kyeong-Ok Chang at KSU and used for virus propagation and titration.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To determine infectious virus titers of virus stocks and study samples, 10-fold serial dilutions were performed on Vero-E6/TMPRSS2 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6/TMPRSS2</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Selected swab and tissue homogenate samples were tested for viable virus by culture on Vero E6/TMPRRS2 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6/TMPRRS2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Susceptibility of cervid cells to SARS-CoV-2: The SARS-CoV-2 USA-WA1/2020 strain was passaged 3 times in Vero-E6 cells to establish a stock virus for infection experiments.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Swabs were placed in 2mL of viral transport medium (DMEM, Corning; combined with 1% antibiotic-antimycotic, ThermoFisher), vortexed, and aliquoted directly into cryovials and RNA stabilization/lysis Buffer RLT (Qiagen, Germantown, MD, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ThermoFisher</div><div>suggested: (ThermoFisher; SL 8; Centrifuge, RRID:SCR_020809)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The two sequences for each of the locations listed above, corresponding to either lineage A (USA-WA1/2020) or alpha VOC B.1.1.7 (USA/CA_CDC_5574/2020), were subjected to BLAST mapping analysis against individual sample read databases to determine the relative amount of each strain in the samples.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BLAST</div><div>suggested: (BLASTX, RRID:SCR_001653)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Histopathology: Tissue samples from the respiratory tract (nasal cavity [rostral, middle and deep turbinates following decalcification with Immunocal™ Decalcifier (StatLab, McKinney, TX, for 4-7 days at room temperature), trachea, and lungs as well as various other extrapulmonary tissues (liver, spleen, kidneys, heart, pancreas, gastrointestinal tract [stomach, small intestine including Peyer’s patches and colon], cerebrum [including olfactory bulb], tonsils and numerous lymph nodes were routinely processed and embedded in paraffin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Peyer’s</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. However, "scientific management" came to national attention in 1910 when crusading attorney Louis Brandeis (then not yet Supreme Court justice) popularized the term.[3] Brandeis had sought a consensus term for the approach with the help of practitioners like Henry L. Gantt and Frank B. Gilbreth.
    1. O’Toole, Á., Scher, E., Underwood, A., Jackson, B., Hill, V., McCrone, J. T., Colquhoun, R., Ruis, C., Abu-Dahab, K., Taylor, B., Yeats, C., du Plessis, L., Maloney, D., Medd, N., Attwood, S. W., Aanensen, D. M., Holmes, E. C., Pybus, O. G., & Rambaut, A. (2021). Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. Virus Evolution, veab064. https://doi.org/10.1093/ve/veab064

    1. Skip to main contentAccessibility helpAccessibility feedback Press / to jump to the search box RemoveReport inappropriate predictions SettingsSearch settingsLanguagesHide explicit resultsAdvanced searchSearch historyYour data in SearchSearch helpAdam Dobrinadobrin@gmail.comManage your Google AccountDefaultAdam Dobrinadobrin@gmail.comAll Brand accountsAdd another accountSign outPrivacy Policy•Terms of Service(function(){var j=1280; try{var a=document.getElementById("cnt"),b=document.getElementById("searchform"),c="";if(window.gbar&&gbar.elr){var d=gbar.elr().mo;c="md"==d?" mdm":"lg"==d?" big":""}else{var e=document.body&&document.body.offsetWidth;e&&e>=j&&(c=" big")}a&&(a.className+=c);b&&(b.className+=c)}catch(f){google.ml(f,!1,{elr:!0})};})();(function(){ google.tick("load","sct");}).call(this);.GLcBOb.cCvmNd{border-bottom:none}.yg51vc{background:#fff;height:58px;padding:0;position:relative;z-index:126;white-space:nowrap}.iJddsb{display:inline-block;fill:currentColor}.iJddsb img,.iJddsb svg{display:block;height:100%;width:100%}.rIbAWc{cursor:pointer;display:inline-block}.CaY96,.VpHku{font-family:Google Sans,Roboto,arial,sans-serif;display:block}.CaY96:hover{background-color:rgba(218,220,224,.5);text-decoration:none}.CaY96,.CaY96:visited{border-radius:50%;color:#3c4043;padding:8px;width:24px;height:24px}.pdswFd{float:right;position:relative;z-index:3;right:17px}.pdswFd .hdtb-mitem{display:inline-block}.gTMtLb{z-index:1001;position:absolute;top:-1000px}.sfS5Re{transform-origin:top left;user-select:none}.ct5Ked{display:inline-block;margin-right:8px;margin-bottom:2px;margin-top:2px}a:hover.ct5Ked{text-decoration:none}.YPxNKd{background:#ebebeb;height:1px;margin-bottom:23px;margin-top:12px}.FozYP{overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.rrJu4c{position:absolute;width:30px;height:30px;z-index:999;top:55vh;left:45vw}.EsIlz{background:#fff;border-radius:8px;box-shadow:0 2px 2px 0 rgba(0,0,0,.16),0 0 0 1px rgba(0,0,0,.08);display:inline-block;overflow:hidden;position:relative;transform-origin:top left;vertical-align:top}.UnFsfe{position:relative;top:0;width:120px}.UnFsfe.SoZvjb{height:187px}.UnFsfe.SoZvjb.ZvGeOb{height:260px}.keP9hb{border-radius:2px;bottom:0;box-shadow:0 2px 2px 0 rgba(0,0,0,.16),0 0 0 1px rgba(0,0,0,.08);left:0;position:absolute;right:0;top:0}.XAOBve{height:120px;overflow:hidden;transform-origin:top left;width:120px}.XAOBve.ZvGeOb{height:183px}.WGwSK{color:#202124;font-size:14px;height:67px;line-height:18px;width:120px}.dAassd{padding:8px 16px 5px 16px}.cp7THd{color:#70757a}.tgqOk{display:flex;justify-content:flex-end}.tgqOk .pTi5ve{color:#70757a;font-size:12px;padding:4px 24px 0 0;margin:0}.ky4hfd{display:none}.LXqMce{display:flex;font-size:22px;line-height:28px;margin-bottom:13px;margin-left:180px;margin-right:12px;padding-top:20px;position:relative;white-space:nowrap;width:auto}.z4P7Tc{flex:0 1 100%;max-width:min-content;overflow:hidden;text-overflow:ellipsis}.Wkr6U{max-width:92vw;overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.F0gfrd{padding:0 3px;color:#70757a}.TXBhSe:not(:hover){color:#70757a}.TXBhSe:hover{color:#222}g-scrolling-carousel{display:block;position:relative;}.mR2gOd{display:block;overflow-x:auto;overflow-y:hidden;position:relative;white-space:nowrap;transform:translate3d(0,0,0);transform:translate3d(0,0,0);}.mR2gOd::-webkit-scrollbar{display:none}.DAVP1{display:inline-block}g-img{display:block;height:100%}.rISBZc{display:block;border:0}.BA0A6c{overflow:hidden}.OZ5bRd{margin-bottom:auto;margin-top:auto}.Lu0opc{cursor:pointer;height:72px;position:absolute;display:block;visibility:inherit;width:36px;bottom:0;outline:none;opacity:0.8;top:0;z-index:101}.Lu0opc.tHT0l{-webkit-transition:opacity 0.5s,visibility 0.5s;transition:opacity 0.5s,visibility 0.5s}.Lu0opc:hover{opacity:0.9}.Lu0opc:focus{outline:none}.Lu0opc.pQXcHc,.Lu0opc.pQXcHc:hover{cursor:default;opacity:0;visibility:hidden}.Lu0opc.Oom88b{height:48px;width:48px;opacity:0.9}.Lu0opc.Oom88b:hover{opacity:1.0}.Lu0opc.Oom88b.pQXcHc,.Lu0opc.Oom88b.pQXcHc:hover{opacity:0}.Lu0opc.Oom88b:hover g-fab{color:#202124 !important}.BlOseb.Oom88b g-fab,.k2Oeod.Oom88b g-fab{box-shadow:0 7px 15px rgba(0,0,0,.2);cursor:pointer;height:48px;width:48px}.BlOseb.Oom88b{left:20px}.k2Oeod.Oom88b{right:20px}.S3PB2d{margin:auto}.OvQkSb{border-radius:999rem}.CNf3nf{cursor:pointer;display:block;position:relative;border:1px solid #dfe1e5;z-index:0}.CNf3nf:focus{outline:none}.CNf3nf .PUDfGe{position:absolute;left:0;right:0;top:0;bottom:0;width:24px;height:24px}.wecD1d{width:56px;height:56px}.YB4h9{color:#fff;background-color:#1a73e8;padding:18px 60px 18px 12px;position:relative}.C85rO{font-size:20px}.YB4h9 .Job8vb{padding:20px;position:absolute;right:0;top:0}.NhRr3b{cursor:pointer;padding:16px 8px;position:relative;margin:-16px -8px}.VDgVie{text-align:center}.v5nPIf{display:block;position:relative}.wgim3c{bottom:0;left:0;position:absolute;right:0;top:0}.pSFfp{display:inline-block;position:relative}.fY2Z0{animation:qli-container-rotate 1568ms linear infinite}@keyframes qli-container-rotate {from{transform:rotate(0)}to{transform:rotate(360deg)}}.jg5aPd{height:100%;opacity:0;position:absolute;width:100%}.fY2Z0 .yiqufc{-webkit-animation:qli-fill-unfill-rotate 5332ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both,qli-blue-fade-in-out 5332ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both;animation:qli-fill-unfill-rotate 5332ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both,qli-blue-fade-in-out 5332ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both}.fY2Z0 .e3Nvve{-webkit-animation:qli-fill-unfill-rotate 5332ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both,qli-red-fade-in-out 5332ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both;animation:qli-fill-unfill-rotate 5332ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both,qli-red-fade-in-out 5332ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both}.fY2Z0 .kpjGNb{-webkit-animation:qli-fill-unfill-rotate 5332ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both,qli-yellow-fade-in-out 5332ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both;animation:qli-fill-unfill-rotate 5332ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both,qli-yellow-fade-in-out 5332ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both}.fY2Z0 .Ft8sDf{-webkit-animation:qli-fill-unfill-rotate 5332ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both,qli-green-fade-in-out 5332ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both;animation:qli-fill-unfill-rotate 5332ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both,qli-green-fade-in-out 5332ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both}.oMjwOc .fY2Z0 .jg5aPd{-webkit-animation:qli-fill-unfill-rotate 5332ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both;animation:qli-fill-unfill-rotate 5332ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both;opacity:0.99}@keyframes qli-fill-unfill-rotate {0%{transform:rotate(0)}12.5%{transform:rotate(135deg)}25%{transform:rotate(270deg)}37.5%{transform:rotate(405deg)}50%{transform:rotate(540deg)}62.5%{transform:rotate(675deg)}75%{transform:rotate(810deg)}87.5%{transform:rotate(945deg)}100%{transform:rotate(1080deg)}}@keyframes qli-blue-fade-in-out {0%{opacity:0.99}25%{opacity:0.99}26%{opacity:0}89%{opacity:0}90%{opacity:0.99}100%{opacity:0.99}}@keyframes qli-red-fade-in-out {0%{opacity:0}15%{opacity:0}25%{opacity:0.99}50%{opacity:0.99}51%{opacity:0}}@keyframes qli-yellow-fade-in-out {0%{opacity:0}40%{opacity:0}50%{opacity:0.99}75%{opacity:0.99}76%{opacity:0}}@keyframes qli-green-fade-in-out {0%{opacity:0}65%{opacity:0}75%{opacity:0.99}90%{opacity:0.99}100%{opacity:0}}.r1glSd{display:inline-block;height:100%;overflow:hidden;position:relative;width:50%}.YvBkFd{box-sizing:border-box;box-sizing:border-box;height:100%;left:45%;overflow:hidden;position:absolute;top:0;width:10%}.jWrfPe{border-radius:50%;border:3px solid transparent;box-sizing:border-box;box-sizing:border-box}.unqUac{width:200%}.ZvZqlb{transform:rotate(129deg)}.tJdqHd{left:-100%;transform:rotate(-129deg)}.m0HFif{left:-450%;width:1000%}.yiqufc .jWrfPe{border-color:#4285f4}.e3Nvve .jWrfPe{border-color:#ea4335}.kpjGNb .jWrfPe{border-color:#fbbc04}.Ft8sDf .jWrfPe{border-color:#34a853}.jg5aPd .ZvZqlb{border-bottom-color:transparent;border-right-color:transparent}.jg5aPd .tJdqHd{border-bottom-color:transparent;border-left-color:transparent}.jg5aPd .m0HFif{border-bottom-color:transparent}.GuPFE .fY2Z0 .ZvZqlb{animation:qli-left-spin 1333ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both}.GuPFE .fY2Z0 .tJdqHd{animation:qli-right-spin 1333ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both}.oMjwOc .fY2Z0 .ZvZqlb{animation:qli-left-spin 1333ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both;border-left-color:#fff;border-top-color:#fff}.oMjwOc .fY2Z0 .tJdqHd{animation:qli-right-spin 1333ms cubic-bezier(0.4, 0.0, 0.2, 1) infinite both;border-right-color:#fff;border-top-color:#fff}@keyframes qli-left-spin {0%{transform:rotate(130deg)}50%{transform:rotate(-5deg)}100%{transform:rotate(130deg)}}@keyframes qli-right-spin {0%{transform:rotate(-130deg)}50%{transform:rotate(5deg)}100%{transform:rotate(-130deg)}}Search ModesAllImagesNewsVideosShoppingMoreMapsBooksFlightsFinanceToolsAny timeAny timePast hourPast 24 hoursPast weekPast monthPast yearCustom range...Custom date rangeFromToGoAll resultsAll resultsVerbatimContent Navigation BarBooks/Adam DobrinSHeOLYit: Adversity Ends with Thank YouAdam Dobrin, 2017Hot&y: Ha'kalor of the SonAdam Marshall Dobrin, 2015Antagonizing Pain: W/O Agonizing ?-opioidAdam Marshall Dobrin, 2017*n Light of Creation, Ha'esh: Hearts, Wands, Fire and SeaAdam Marshall Dobrin, 2014Know Me As Adam: Lit and WhyAdam Marshall Dobrin, 2015Time and Chance: The Race Is Not to Die BoldAdam Marshall Dobrin, 2016The HOLY Coda of the Matrix in Greyscale to CYMK: HOLY SHIT: the OfficSial Walkthru SHeOLYitAdam Dobrin, 2018Time & Chance: Saturn & Son RlnyAdam Marshall Dobrin, 2015The Signs of RevelationAdam Marshall Dobrin, 20152021-2041: The End Times: The Battle Between Good and Evil, and the Machine Known by Many NamesAdam Marshall Dobrin, 2012Timelike Synchronicity: The Hundred Year Prophesy, 1916 - 2016Adam Marshall Dobrin, 2013TadaiAdam Marshall Dobrin, 2017Share Your Wine: Kissy Nacha NalezAdam Dobrin, 2018Know Me As Ad? the Solution of Seven Lamp Stands: Lit and Why, the Key to Revelation 1:20Adam Marshall Dobrin, 2015(function(){ window.cVrhhd=function(c,f,q,a,h,k,r){if((c=document.getElementById(c))&&(0!=c.offsetWidth||0!=c.offsetHeight)){var l=c.querySelector("div"),m=l.querySelector("div"),d=0,g=l.scrollWidth-l.offsetWidth;if(0<f){var n=m.children;d=n[f].offsetLeft-n[0].offsetLeft;if(a){for(var p=d=0;p<f;++p)d+=n[p].offsetWidth;d=Math.min(g,d)}}d+=q;f=Math.min(a?g-d:d,g);l.scrollLeft=a&&(h||r)?d:a&&k?-d:f;var b=c.getElementsByTagName("g-left-button")[0],e=c.getElementsByTagName("g-right-button")[0];b&&e&&(h=/\btHT0l\b/,k=/\bpQXcHc\b/,b.className=b.className.replace(h,""),e.className=e.className.replace(h,""),0==f?b.className="pQXcHc "+b.className:b.className=b.className.replace(k,""),f==g?e.className="pQXcHc "+e.className:e.className=e.className.replace(k,""),0<=b.className.indexOf("SL0Gp")&&0==f&&f==g&&(m.style.paddingLeft="0px",m.style.paddingRight="0px",b.style.display="none",e.style.display="none",c.style.paddingLeft=a?"0px":"48px",c.style.paddingRight=a?"48px":"0px",c.style.textAlign=a?"left":"right",(a=document.getElementById("fade_forward"))&& (a.style.display="none"),(a=document.getElementById("fade_reverse"))&&(a.style.display="none")),setTimeout(function(){b.className+=" tHT0l";e.className+=" tHT0l"},50))}};}).call(this);(function(){var id='_lLASYdueKpyrwbkPo7-xoAo20';var index=0;var offset=0;var is_rtl=false;var is_ie=false;var is_gecko=false;var is_edge=false;var init='cVrhhd';window[init](id,index,offset,is_rtl,is_ie,is_gecko,is_edge);})();Choose what you’re giving feedback onFeedback.ptJHdc{background-color:#fff}.ptJHdc .richlist-wta,.ptJHdc .v7hl4d{background:#fff;color:#70757a;float:right;font-weight:normal;padding-left:2px;vertical-align:top}.cUAZUc{position:relative;top:-2px}.commercial-unit-desktop-top{display:inline-block;position:relative;width:652px}.ptJHdc{background-color:transparent}.ptJHdc .v7hl4d{background:none}.commercial-unit-desktop-top h3{font-size:20px}.cu-container .mnr-c{background-color:#fff;box-shadow:none;border:1px solid #dfe1e5;border-radius:8px;overflow:hidden;margin:0 0 6px 0}.commercial-unit-desktop-top .v7hl4d,.yY236b .v7hl4d{font-size:13px;padding:0 2px;margin-top:8px;position:absolute;width:640px;text-align:right}.dxR8gf h3 .dH53Z{line-height:normal}.dxR8gf .N6sL8d{padding-left:0;padding-right:0}.VqFMTc{background-color:#fff;color:#202124;display:inline-block;font-size:14px;font-weight:bold;margin-left:0px;white-space:nowrap}.p8AiDd{padding:0;margin-right:0}.dxR8gf{margin-left:6px}.dxR8gf{margin-top:4px;margin-bottom:-1px;position:relative;width:450px}.N6sL8d{padding-right:4px;}.ptJHdc .dxR8gf,.ptJHdc .dxR8gf h3{font-size:20px;line-height:26px;white-space:nowrap}.v7hl4d{font-size:13px;margin-bottom:0;padding:0 2px;margin-top:8px;position:absolute;width:640px;text-align:right;background:none;color:#70757a;float:right;font-weight:normal;vertical-align:top}.cUAZUc{margin-left:3px;height:14px;float:right}.Qq9jLd{height:14px}.kxWPvc{float:right}.cUAZUc{top:0}.r2fjmd{margin-bottom:0px;margin-top:0px}.YMEk9e{margin-right:0px;padding-top:0px;padding-right:0px;padding-bottom:0px}.YMEk9e.MoRL7{cursor:pointer;position:relative;display:inline}.weu8Yd{position:initial;margin-right:3px;margin-left:3px;display:inline-block;width:12px}.weu8Yd .k1sBMc,.e1ycic .k1sBMc{display:inline-block}.c0Xbsc,.TTTqTe{vertical-align:middle}.c0Xbsc{margin-right:7px}.Wt5Tfe{padding-left:0px;padding-right:0px}.NC2iFe{padding-top:10px;padding-bottom:10px}g-dropdown-menu{display:inline-block;position:relative}.e7RZX{background-color:#fff}.HbX59e{margin-left:0px}.uYZpsf{padding-left:0px}.FjdPod{background-image:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABgAAAAYCAYAAADgdz34AAAAlUlEQVR4AWJwL/AB9FrGNgDDIBAs2YABaBmA/TfLFxQ08ZtIH0vXWRzGMvgVLAMOsqkmGwd2jHEIHKAuiRZxQWdVH/GjgAffS/bBl5JZ8yI4sEGS/TYFsT46F0TvI9kTAcE2tU8Qg7rARyYSciMI4IO8FZTqDhq9IIWC/EXgQoHLH5q+Veibnb5d6weOfmTqh77w2/IAU6LPu953NOAAAAAASUVORK5CYII=);background-repeat:no-repeat;background-size:12px;display:inline-block;height:12px;width:12px;position:relative}.FjdPod::before{position:absolute;content:'';left:-18px;right:-18px;top:-18px;bottom:-18px}.Mxmg3{color:#70757a;font-size:16px;line-height:24px;color:#70757a;letter-spacing:0.2px;margin:0}.T4OwTb{display:block;overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.pymv4e{display:-webkit-box;overflow:hidden;-webkit-box-orient:vertical;white-space:normal}@-webkit-keyframes force_redraw {from{opacity:0.999}}.pymv4e{-webkit-animation:.05s linear force_redraw}.h1vhpc{display:inline-block;height:100%;vertical-align:middle}.Ga3iPc{text-overflow:ellipsis;white-space:nowrap;overflow:hidden;margin-right:-6px;font-size:16px;line-height:24px;color:#202124;letter-spacing:0.2px;padding-bottom:0px}.B7nmg{border-top:1px solid #ddd;margin-top:7px;padding-top:7px}.Ter3Ue{position:relative}.r4awE{overflow:hidden;text-overflow:ellipsis}.r4awE:hover{text-decoration:underline}.r4awE{font-size:16px;line-height:24px;letter-spacing:0px;margin:0}.qptdjc{font-weight:bold;}.qptdjc{font-size:16px;line-height:24px;letter-spacing:0.2px;color:#202124;margin:0}.HIZige{color:#000}.pla-unit-hovercard-img-container{text-align:center}.pla-unit-hovercard-img-container a{display:inline-block}.ropLT{padding:8px}.uhLbob{padding-top:2px;color:#70757a}.LnPkof{font-size:16px;line-height:24px;letter-spacing:0px;color:#202124;margin:0;}.uhLbob{font-size:16px;line-height:24px;letter-spacing:0.2px;color:#70757a;margin:0}.tkXAec{text-decoration:none;min-height:260px;width:100%}.rhrP2c{display:none}.clickable-card{position:absolute;width:100%;height:100%;top:0;z-index:3}.RnJeZd{position:relative;z-index:6}.cu-container .pla-unit.mnr-c{margin-right:8px;margin-top:1px}.itPOE{padding-top:8px}.pla-extensions-container{padding:0 8px 0 8px;margin-top:2px;white-space:nowrap;overflow:hidden;width:106px;text-overflow:ellipsis;font-size:16px;line-height:24px;color:#70757a;letter-spacing:0.2px;margin:0}.pla-unit{display:inline-block;margin-top:20px;vertical-align:top;white-space:normal;}.pla-unit-container{}.pla-unit-img-container{position:relative;text-align:center;}.pla-unit-img-container a{display:inline-block}.pla-unit-img-container img{border:none;margin:0}.orXoSd{overflow:hidden}.orXoSd.pla-details-expanded{transition:top 500ms linear,opacity 500ms ease-in;position:absolute}.rwVHAc{padding-left:8px;padding-right:8px;padding-top:8px}.pla-unit-title{height:30px;line-height:15px;overflow:hidden;padding-bottom:1px;font-size:16px;line-height:24px;height:48px;letter-spacing:0px;margin:0;}.pla-unit-title-link{text-decoration:none;display:block}.e10twf{font-weight:bold;font-size:16px;line-height:24px;height:24px;color:#202124;letter-spacing:0.2px;margin:0;}.LbUacb{margin-top:2px;margin-bottom:-1px;overflow:hidden;padding-bottom:1px;white-space:nowrap;text-overflow:ellipsis;font-size:16px;line-height:24px;height:24px;letter-spacing:0px;margin:0;}.zPEcBd{color:#202124;font-style:normal;}.VZqTOd{color:#202124}.pla-unit .Mxmg3{margin-top:2px;overflow:hidden;white-space:nowrap}.pla-unit{font-size:13px;line-height:15px;position:relative}.D6nsM{position:absolute;display:none;right:6px;top:6px;border:none;color:rgba(0,0,0,0);height:22px;overflow:hidden;width:22px;background-color:rgba(0,0,0,.25);border-radius:50%;text-align:center;vertical-align:middle;z-index:9;background-color:#70757a}.DPfF8d{width:12px;height:12px;text-align:center;margin-top:4px}.pla-unit-title{padding-bottom:4px}.e10twf{padding-bottom:0px}.LbUacb{padding-bottom:1px}.pla-extensions-container{padding-left:8px;padding-right:8px;padding-bottom:0px}.pla-hovercard-container a:hover{text-decoration:none}.pla-hovercard-container{background:#fff;border:1px solid rgba(0,0,0,.2);border-radius:8px;box-shadow:0 2px 4px rgba(0,0,0,0.20);font-size:13px;line-height:1.24em;min-height:278px;overflow:hidden;position:relative;width:152px;}.pla-hovercard-content{display:none}.pla-hovercard-content-ellip{overflow:hidden;text-overflow:ellipsis}.RRDLx{overflow:hidden;text-overflow:ellipsis;padding-top:2px}.i3YBTb{color:#000;padding-top:2px}.pla-hovercard-shipping-tax{padding-top:1px;}.pla-hovercard-container{top:4px}.i3YBTb{padding-top:4px}.LnPkof{padding-top:0px}.uhLbob{padding-top:1px}.pla-hovercard-shipping-tax{padding-top:1px}.B7nmg{margin-top:8px;padding-top:8px;line-height:24px}.commercial-unit-desktop-top{}.pla-unit.mnr-c:first-child{margin-left:0}.pla-unit.mnr-c:last-child{margin-right:0}.commercial-unit-desktop-rhs .pla-unit.mnr-c:first-child,.commercial-unit-desktop-rhs .pla-unit.mnr-c:last-child{margin-left:0}.bC8sde{margin-bottom:3px}.bC8sde{margin-top:8px;overflow:hidden;padding:0;font-size:13px;line-height:15px}.BNizGe{}#rcnt .commercial-unit-desktop-top .U24Kq{color:rgba(0,0,0,.54)}.commercial-unit-desktop-top g-left-button,.commercial-unit-desktop-top g-right-button{z-index:20}.commercial-unit-desktop-top{width:max-content}.commercial-unit-desktop-top{margin:0 0 21px 0 !important;}.commercial-unit-desktop-top{margin:0 0 11px 0 !important;padding:1px 0 2px 0 !important}.commercial-unit-desktop-top .v7hl4d{top:1px;padding-right:7px}Ads·adam dobrin bookWhy these ads?Introduction to Geophysical Prospecting by Milton B. Dobrin - Used (Good) - 0070171963 by McGraw-Hill Companies, The | Thriftbooks.com$17.49UsedThriftbooks.comIntroduction to Geophysical Prospecting by Milton B. Dobrin - Used (Good) - 0070171963 by McGraw-Hill Companies, The | Thriftbooks.com$17.49UsedThriftbooks.comFree shippingFor most items:30-day return policyIrresistible: The Rise of Addictive Technology and the Business of Keeping Us Hooked$21.81Amazon.comIrresistible: The Rise of Addictive Technology and the Business of Keeping Us Hooked$21.81Amazon.comFor most items:30-day return policyTeaching Right from Wrong : Forty Things You Can Do to Raise a Moral Child by Arthur Dobrin - Used (Good) - 0425178226 by Penguin Publishing Group | $4.19UsedThriftbooks.comTeaching Right from Wrong : Forty Things You Can Do to Raise a Moral Child by Arthur Dobrin - Used (Good) - 0425178226 by Penguin Publishing Group | $4.19UsedThriftbooks.comFor most items:30-day return policyIrresistible: The Rise of Addictive Technology and the Business of Keeping Us Hooked$13.99Amazon.comIrresistible: The Rise of Addictive Technology and the Business of Keeping Us Hooked$13.99Amazon.comFor most items:30-day return policySearch Results function _setImagesSrc(e,d){function f(b){b.onerror=function(){b.style.display="none"};b.src=d}for(var g=0,a=void 0;a=e[g++];){var c=document.getElementById(a)||document.querySelector('img[data-iid="'+a+'"]');c?(a=void 0,(null==(a=google.c)?0:a.setup)&&google.c.setup(c),f(c)):(google.iir=google.iir||{},google.iir[a]=d)}}"undefined"==typeof window.google&&(window.google={});(function(){var s='data:image/jpeg;base64,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';var ii=['dimg_21'];_setImagesSrc(ii,s);})();(function(){var s='data:image/png;base64,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\x3d\x3d';var ii=['dimg_23','dimg_25','dimg_43'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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';var ii=['dimg_27'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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\x3d';var ii=['dimg_29'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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\x3d\x3d';var ii=['dimg_31'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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';var ii=['dimg_33'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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';var ii=['dimg_35'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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\x3d';var ii=['dimg_37'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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';var ii=['dimg_39'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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\x3d\x3d';var ii=['dimg_41'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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\x3d\x3d';var ii=['dimg_45'];_setImagesSrc(ii,s);})();(function(){var s='data:image/webp;base64,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\x3d\x3d';var ii=['platop0'];_setImagesSrc(ii,s);})();(function(){var s='data:image/webp;base64,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';var ii=['platop1'];_setImagesSrc(ii,s);})();(function(){var s='data:image/webp;base64,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';var ii=['platop2'];_setImagesSrc(ii,s);})();(function(){var s='data:image/webp;base64,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\x3d\x3d';var ii=['platop3'];_setImagesSrc(ii,s);})();.tF2Cxc{position:relative}.IsZvec,.GELlw{max-width:48em;color:#4d5156;line-height:1.58}.VwiC3b{word-wrap:break-word}.VwiC3b sup{line-height:0.9}.yuRUbf{font-weight:normal;font-size:small;line-height:1.58;}a:hover h3.LC20lb{text-decoration:underline}.LC20lb{display:inline-block;line-height:1.3;margin-bottom:3px;}.DKV0Md{padding-top:4px;padding-top:5px;}.VjDLd .TieM1d .tjvcx,.IVvPP .tjvcx,.kno-kp .tjvcx,.VjDLd .kp-wholepage-osrp .tjvcx,#rhs .ss6qqb .tjvcx{display:inline-block;height:19px;overflow-y:hidden}.qzEoUe{color:#202124;white-space:-webkit-nowrap}.dyjrff{color:#5f6368}.B6fmyf{position:absolute;top:0;height:0;visibility:hidden;white-space:nowrap}.csDOgf{display:inline;visibility:visible;position:absolute}.eFM0qc{display:inline-block;padding-bottom:2px;padding-top:1px;padding-left:2px;visibility:visible}.EwsJzb{display:block}.B8Kd8d{position:absolute}.IjabWd{margin-left:2px}.xTFaxe{fill:#70757a;top:2px}.D6lY4c{height:22px;width:22px;position:absolute;border-radius:11px;top:-1px}.iTPLzd{cursor:pointer;top:0;left:0;width:28px;z-index:1;line-height:16px;}.GUHazd{padding-bottom:12px}.eY4mx{padding-left:12px}.lUn2nc{padding-right:12px}.yXK7lf em{color:#5f6368}.yXK7lf a:visited em,.yXK7lf a em{color:inherit}.MUxGbd{padding-top:0px;margin-bottom:0px}.lyLwlc{color:#202124}.yDYNvb.lyLwlc{color:#4d5156}.yDYNvb.lyLwlc b{color:#5f6368}.lEBKkf{display:-webkit-box;-webkit-box-orient:vertical;overflow:hidden}.wuQ4Ob{color:#70757a}.WZ8Tjf{color:#70757a;}Web resultsAdam Marshall Dobrin: Books, Biography, Blog ... - Amazon.comhttps://www.amazon.com › Adam-Marshall-Dobrinhttps://www.amazon.com › Adam-Marshall-DobrinAbout Adam Marshall Dobrin. I'm a 39 year old computer engineer, one who has gone through some of the most abnormal situations imaginable. The road ...You've visited this page many times. Last visit: 2/19/21Adam Marshall Dobrin: Books - Amazon.comhttps://www.amazon.com › Books-Adam-Marshall-Dob...https://www.amazon.com › Books-Adam-Marshall-Dob...Results 1 - 16 of 22 — Online shopping from a great selection at Books Store. ... by Adam Marshall Dobrin | Apr 27, 2013. 3.7 out of 5 stars 3.Adam Dobrin Books | List of books by author Adam Dobrinhttps://www.thriftbooks.com › adam-dobrinhttps://www.thriftbooks.com › adam-dobrinLooking for a book by Adam Dobrin? Adam Dobrin wrote Homicide Data Sources: An Interdisciplinary Overview for Researchers, which can be purchased at a lower ...(function(){var uer=false;var eid='fld_89';(function(){ var a=uer,b=Date.now();if(google.timers&&google.timers.load.t){var c=window.innerHeight||document.documentElement.clientHeight,d=0;if(eid){var e=document.getElementById(eid);e&&(d=Math.floor(e.getBoundingClientRect().top+window.pageYOffset))}for(var f=d>=c,g=document.getElementsByTagName("img"),h=0,k=void 0;k=g[h++];)google.c.setup(k,!1,d);a&&f&&google.c.ubr(!1,b,d)};}).call(this);})();.hWIMdd{padding-top:0px}.TBC9ub{margin-left:0px;margin-right:0px}.yG4QQe{margin-top:0px}g-section-with-header{display:block;margin-bottom:0}.e2BEnf{font-size:20px;line-height:1.3;}.U7izfe{padding-left:0px;padding-right:0px;padding-bottom:12px}title-with-lhs-icon:hover .ekf0x h3{color:#1a0dab}title-with-lhs-icon .ekf0x{color:#202124;display:block;margin-left:-53px}title-with-lhs-icon .hSQtef.ekf0x{display:inline;margin-left:0}title-with-lhs-icon:hover .hSQtef.ekf0x{color:#1a0dab}#rcnt .ekf0x:hover h3{text-decoration:none}.iJ1Kvb{display:inline-block;line-height:24px}.GmE3X{color:#202124;display:inline-block;margin-right:12px;position:relative;top:-3px}#center_col #res .GmE3X{font-size:22px}#center_col #res .GmE3X{line-height:28px}#center_col .GmE3X{max-width:608px;overflow:hidden;text-overflow:ellipsis;vertical-align:text-top;white-space:nowrap}#center_col .GmE3X.kWYf3c{max-width:568px}.iv236{color:#70757a;display:inline-block;margin-right:12px}.dtIg1b{display:none;margin-right:12px}title-with-lhs-icon:hover .kNmTT{display:none}title-with-lhs-icon:hover .dtIg1b{display:inline-block}.aV7hh{display:inline-block;position:relative;top:1px}.WE2xI{position:relative}.rNSxBe{padding-bottom:20px}.I7Y2H{padding-right:0px}.ySu5Fc{margin-top:-6px;padding-bottom:4px}.DuAqE{float:right;height:34px;margin:7px 0;position:unset;width:34px}.KPV9xf{background:#fff;border:1px solid #dadce0;border-radius:17px;box-sizing:border-box;color:#70757a;height:34px;padding:4px;width:34px}.KPV9xf:hover{background:#f8f9fa}.HErFVb{background:#fff;border:1px solid #dadce0;border-radius:17px;box-sizing:border-box;color:#70757a;height:34px;padding:4px;width:34px}.HErFVb:hover{background:#f8f9fa}.jD7Eif{overflow:hidden}g-expandable-container{display:block}g-inline-toggler{cursor:pointer;display:block;overflow:hidden;position:relative}.gmYxHe{width:100%}.N5RUge{display:block}.FIncke{display:none}.yKfQwe{position:absolute}g-expandable-content{display:block}.gymTod{background-color:rgba(0,0,0,.3)}.gymTod img{object-fit:cover}.dgdd6c{display:inline-block;margin-right:6px;outline:none;padding:6px 0}.dgdd6c:last-child{margin-right:8px}.WGYX8{box-sizing:border-box;background:#fff;border:1px solid #dadce0;border-radius:18px;color:#3c4043;cursor:pointer;display:inline-block;font:400 12px Roboto,arial,sans-serif;height:36px;min-width:36px;position:relative}.WGYX8:after{bottom:-7px;content:'';left:-1px;position:absolute;right:-1px;top:-7px}.WGYX8:hover{background:#f8f9fa}.KymMLe:focus .WGYX8,a:focus .WGYX8,.WGYX8:focus{background:#f8f9fa;border-color:#9aa0a6;color:#e8eaed}.KymMLe:focus .WGYX8:hover:not(:active),a:focus .WGYX8:hover:not(:active),.WGYX8:hover:focus:not(:active){background:#dadce0;border-color:#9aa0a6}.WGYX8:hover,.KymMLe:focus .WGYX8,a:focus .WGYX8,.KymMLe:active .WGYX8,a:active .WGYX8,.WGYX8:focus,.WGYX8:active{color:#202124}.KymMLe:active .WGYX8:not([disabled]),a:active .WGYX8:not([disabled]),.WGYX8:active:not([disabled]){box-shadow:0 1px 2px rgba(60,64,67,.3), 0 2px 6px 2px rgba(60,64,67,.15);border-color:transparent;background:#fff}.WGYX8[disabled]{background:#f1f3f4;border-color:#f1f3f4;color:#bdc1c6;opacity:0.38}.AB4Jjf{font-size:14px;line-height:34px;padding:0 8px;text-align:center}.AB4Jjf,.qfpP8d,.ktgKbb{box-sizing:border-box;display:inline-block;height:34px;vertical-align:bottom}.AB4Jjf.qPB6Vc{padding-right:11px}.qfpP8d.h3yRU{padding:0;margin:1px 0 1px 1px;height:32px;width:32px;border-radius:50%;overflow:hidden}.znlzCd{border-radius:8px}.m8vZ3d{display:flex}.mR2gOd.pptFR{transform:none;transform:none}.hXaFBd{display:inline-block;vertical-align:top;margin:auto}.mHHDwb{min-width:150px;height:100%;display:-webkit-box;display:flex;align-items:center;justify-content:center;}.iuKlq g-more-button div{transition:opacity 300ms}.eA0Zlc{vertical-align:top;display:inline-block;margin:0;position:relative}.eA0Zlc:focus-within{outline:-webkit-focus-ring-color auto 1px}.JX86yc{display:inline-block}.eA0Zlc:not(.JX86yc){overflow:hidden}g-inner-card.xIfh4d{margin-right:2px;position:relative;border-radius:0;border:none;}div.eA0Zlc:first-child g-inner-card.xIfh4d,div.eA0Zlc:first-child g-inner-card.xIfh4d video{-webkit-border-top-left-radius:8px;-webkit-border-bottom-left-radius:8px}div.eA0Zlc:last-of-type g-inner-card.xIfh4d,div.eA0Zlc:last-of-type g-inner-card.xIfh4d video{-webkit-border-top-right-radius:8px;-webkit-border-bottom-right-radius:8px}g-inner-card{background-color:#fff;border-radius:2px;display:block;overflow:hidden}.cv2VAd{border:1px solid #dfe1e5;border-radius:8px;box-shadow:none}.M4dUYb{position:relative}.fWhgmd{background-color:rgba(0,0,0,0.03);position:absolute;top:0;bottom:0;left:0;right:0}.nlNnsd{margin-top:12px}.EUjJDc{color:rgba(0,0,0,.54);font-size:14px;word-wrap:break-word;}.X3BRhe{margin-left:auto;margin-right:auto}.Lu0opc.eSq3C{height:36px;width:36px;opacity:0.9}.Lu0opc.eSq3C:hover{opacity:1.0}.Lu0opc.eSq3C.pQXcHc,.Lu0opc.eSq3C.pQXcHc:hover{opacity:0}.Lu0opc.eSq3C:hover g-fab{color:#202124 !important}.BlOseb.eSq3C g-fab,.k2Oeod.eSq3C g-fab{box-shadow:0 0 0 1px rgba(0,0,0,0.04),0 4px 8px 0 rgba(0,0,0,0.20);cursor:pointer;height:36px;width:36px}.BlOseb.eSq3C{left:-18px}.k2Oeod.eSq3C{right:-18px}.LhCR5d{width:40px;height:40px}.wFKnCb{padding-top:6px;position:relative}.yO9xPc{color:#70757a;font-style:italic;margin-right:16px;text-align:right;font-size:12px}.yO9xPc:hover{text-decoration:underline}.zGjCi{margin-top:4px}.OSrXXb{text-overflow:ellipsis;overflow:hidden}.mIKy0c{cursor:pointer;display:block;font-weight:400;line-height:18px;white-space:nowrap}.mIKy0c.dGWpb{overflow:visible}.EZRelc{color:rgba(0,0,0,.54);float:left;margin-top:-2px;margin-bottom:-2px}.wUrVib{color:rgba(0,0,0,.87);white-space:nowrap;width:auto}.mIKy0c{font-size:16px;line-height:1.43}.EZRelc{color:#1a0dab;flex:none}.wUrVib{color:#1a0dab;white-space:initial}g-more-link a.Q2MMlc{align-items:center;display:flex}g-more-link.dGWpb{cursor:initial;text-align:center}g-more-link.dGWpb a.Q2MMlc{display:inline-block;pointer-events:none}.MXl0lf{background:#fff;border:1px solid #dadce0;box-sizing:border-box;cursor:pointer;display:inline-block;font-size:14px;line-height:20px;pointer-events:auto;position:relative;width:300px;padding:7px 11px;height:36px;border-radius:18px;}.MXl0lf:hover{background:#fafafa;}.pb5vrc{background-color:#dadce0;border:0;height:1px;left:0;margin-top:18px;position:absolute;width:100%}.MXl0lf .EZRelc{left:12px;margin-top:0px;position:absolute;height:20px;width:20px;}.MXl0lf .wUrVib{display:inline-block;max-width:220px;white-space:nowrap;}.MXl0lf{font-family:arial,sans-serif-medium,sans-serif}.U56OG{margin-right:8px}.AaVjTc a:link{display:block;color:#4285f4;font-weight:normal}.AaVjTc td{padding:0;text-align:center}.d6cvqb{font-weight:bold}.YyVfkd{color:rgba(0,0,0,.87);font-weight:normal;}.AaVjTc{margin:30px auto 30px}.SJajHc{background:url(/images/nav_logo321.webp) no-repeat;overflow:hidden;background-position:0 0;height:40px;display:block}.NVbCr{cursor:pointer}Adam Dobrin | Book Depositoryhttps://www.bookdepository.com › author › Adam-Dob...https://www.bookdepository.com › author › Adam-Dob...Results 1 - 20 of 20 — Discover Book Depository's huge selection of Adam Dobrin books online. Free delivery worldwide on over 20 million titles.Adam Dobrin (Author of 2021 - 2041) - Goodreadshttps://www.goodreads.com › 7939421.Adam_Dobrinhttps://www.goodreads.com › 7939421.Adam_DobrinAdam Dobrin is the author of 2021 - 2041 (4.00 avg rating, 2 ratings, 0 reviews, published 2012), NERO LOVES PACMAN (0.0 avg rating, ... Adam Dobrin's books.Adam Marshall Dobrin (Author of Sheolyit) - Goodreadshttps://www.goodreads.com › author › show › 664276...https://www.goodreads.com › author › show › 664276...Adam Marshall Dobrin is the author of Sheolyit (5.00 avg rating, 1 rating, 0 reviews), Time and Chance (5.00 avg rating, ... Adam Marshall Dobrin's books.Adam Dobrin books and biography | Waterstoneshttps://www.waterstones.com › author › adam-dobrinhttps://www.waterstones.com › author › adam-dobrinExplore books by Adam Dobrin with our selection at Waterstones.com. Click and Collect from your local Waterstones or get FREE UK delivery on orders over ...Adam Marshall Dobrin : Bucket_two : Booksamillion.comhttps://www.booksamillion.com › search › query=Ada...https://www.booksamillion.com › search › query=Ada...Adam Marshall Dobrin ... Connect with BAM: Millionaire's Club Card · Gift Cards. © 1996-2021 Books-A-Million, Inc. All rights reserved.The Signs of Revelation by Adam Marshall Dobrin | Blurb Bookshttps://www.blurb.com › 6440724-the-signs-of-revelationhttps://www.blurb.com › 6440724-the-signs-of-revelationAug 31, 2015 — Find The Signs of Revelation by Adam Marshall Dobrin at Blurb Books. The true "signs" of Revelation, from 2012 to today.Images for adam dobrin bookGuided Search Filtersdata sourcesloves pacmanpaperbackmarshall dobrinadam marshallView all(function(){ window.cVrhhd=function(c,f,q,a,h,k,r){if((c=document.getElementById(c))&&(0!=c.offsetWidth||0!=c.offsetHeight)){var l=c.querySelector("div"),m=l.querySelector("div"),d=0,g=l.scrollWidth-l.offsetWidth;if(0<f){var n=m.children;d=n[f].offsetLeft-n[0].offsetLeft;if(a){for(var p=d=0;p<f;++p)d+=n[p].offsetWidth;d=Math.min(g,d)}}d+=q;f=Math.min(a?g-d:d,g);l.scrollLeft=a&&(h||r)?d:a&&k?-d:f;var b=c.getElementsByTagName("g-left-button")[0],e=c.getElementsByTagName("g-right-button")[0];b&&e&&(h=/\btHT0l\b/,k=/\bpQXcHc\b/,b.className=b.className.replace(h,""),e.className=e.className.replace(h,""),0==f?b.className="pQXcHc "+b.className:b.className=b.className.replace(k,""),f==g?e.className="pQXcHc "+e.className:e.className=e.className.replace(k,""),0<=b.className.indexOf("SL0Gp")&&0==f&&f==g&&(m.style.paddingLeft="0px",m.style.paddingRight="0px",b.style.display="none",e.style.display="none",c.style.paddingLeft=a?"0px":"48px",c.style.paddingRight=a?"48px":"0px",c.style.textAlign=a?"left":"right",(a=document.getElementById("fade_forward"))&& (a.style.display="none"),(a=document.getElementById("fade_reverse"))&&(a.style.display="none")),setTimeout(function(){b.className+=" tHT0l";e.className+=" tHT0l"},50))}};}).call(this);(function(){var id='_lLASYdueKpyrwbkPo7-xoAo88';var index=0;var offset=0;var is_rtl=false;var is_ie=false;var is_gecko=false;var is_edge=false;var init='cVrhhd';window[init](id,index,offset,is_rtl,is_ie,is_gecko,is_edge);})();Select an image to give feedbackFeedbackView morePage Navigation12345678910Next@-webkit-keyframes allow-alert {from{opacity:1}to{opacity:.35}}.TCIIWe{padding-top:12px}.f6F9Be{position:absolute;bottom:0;width:100%}.fbar a{text-decoration:none;white-space:nowrap}.fbar{margin-left:-27px}.Fx4vi{padding-left:27px;margin:0 !important}#fsl{white-space:nowrap}.f6F9Be{background:#f2f2f2;line-height:40px;min-width:1261px;padding-bottom:12px}.f6F9Be.dc8jac{padding-top:24px}.B4GxFc{margin-left:180px}.fbar p,.fbar a{color:#70757a}.fbar a:hover{color:#3c4043}.fbar{font-size:14px}.b0KoTc{color:rgba(0,0,0,.54);padding-left:27px}.smiUbb img{margin-right:4px}.smiUbb a,.M6hT6 #swml a{text-decoration:none}.smiUbb{margin-left:180px;line-height:15px;color:#70757a;}.smiUbb a,#swml a{color:#70757a}.smiUbb a:hover,#swml a:hover{color:#3c4043}#swml a{display:inline-block}#swml{margin-left:0}×Footer LinksNorth Miami Beach, Florida - Based on your past activity - Update locationCan't update your locationLearn moreUpdating location...HelpSend feedbackPrivacyTerms

      theft of this book, failure to buy a signed copy and the gigantic conspiracy to commit treason are all related;

      you simply can't fathom what it would be like if BF Goodrich were here in a place with actual American Medicine and a civilization that was happy about "ending hell" instead of trying to pretend they aren't actually on the court steps of Copans and Kaya--Ewok land.

      I just don't understand what we do not understand about the idea that Asmodai and Pan are clearly JC in "truth, light, and Osiris within Osiristyx"

      @RU@IL@DC@OPEC@KIKI@OLUM

      I don't know what else to do' maybe Paris can help

    1. Asmodeus From Wikipedia, the free encyclopedia Jump to navigation Jump to search King of demons from the deuterocanonical Book of Tobit .mw-parser-output .hatnote{font-style:italic}.mw-parser-output div.hatnote{padding-left:1.6em;margin-bottom:0.5em}.mw-parser-output .hatnote i{font-style:normal}.mw-parser-output .hatnote+link+.hatnote{margin-top:-0.5em}For other uses, see Asmodeus (disambiguation). "Sidonai" redirects here. For the Phoenician city and its inhabitants, see Sidon. Asmodeus as depicted in Collin de Plancy's Dictionnaire Infernal Asmodeus (/ˌæzməˈdiːəs/; Ancient Greek: Ἀσμοδαῖος, Asmodaios) or Ashmedai (/ˈæʃmɪˌdaɪ/; Hebrew: אַשְמְדּאָי‎, ʾAšmədʾāy), also Asmodevs, Ashema Deva or Amias (see below for other variations), is a prince of demons,[1] or in Judeo-Islamic lore the king of the earthly spirits (shedim/jinn),[2][3] mostly known from the deuterocanonical Book of Tobit, in which he is the primary antagonist.[4] In Peter Binsfeld's classification of demons, Asmodeus represents lust. The demon is also mentioned in some Talmudic legends; for instance, in the story of the construction of the Temple of Solomon. Contents 1 Etymology 2 In the texts 2.1 In the Hebrew Bible 2.2 In the Book of Tobit 2.3 In the Talmud 2.4 In the Testament of Solomon 2.5 In the Malleus Maleficarum 2.6 In the Dictionnaire Infernal 2.7 In the Lesser Key of Solomon 2.8 In The Magus 3 Later depictions 3.1 In Christian thought 3.2 In the Kabbalah 3.3 In Islamic culture 3.4 In popular media 4 See also 5 References and sources 6 External links Etymology[edit] The figure of Asmodeus in Rennes-le-Château The name Asmodai is believed to derive from Avestan language *aēšma-daēva, where aēšma means "wrath", and daēva signifies "demon". While the daēva Aēšma is thus Zoroastrianism's demon of wrath and is also well-attested as such, the compound aēšma-daēva is not attested in scripture. It is nonetheless likely that such a form did exist, and that the Book of Tobit's "Asmodaios" (Ἀσμοδαῖος) and the Talmud's "Ashmedai" (אשמדאי) reflect it.[5] In the Zoroastrian and Middle Persian demonology, there did exist the conjuncted form khashm-dev, where the word dev was the same as daeva.[6] The spellings Asmodai,[7][8] Asmodee (also Asmodée),[9][10] Osmodeus,[11][12] and Osmodai[13][14] have also been used. The name is alternatively spelled in the bastardized forms (based on the basic consonants אשמדאי, ʾŠMDʾY) Hashmedai (חַשְמְדּאָי, Hašmədʾāy; also Hashmodai, Hasmodai, Khashmodai, Khasmodai),[15][16][17][18] Hammadai (חַמַּדּאָי, Hammadʾāy; also Khammadai),[19][20] Shamdon (שַׁמְדּוֹן, Šamdōn),[21] and Shidonai (שִׁדֹנאָי, Šidonʾāy).[20] Some traditions have subsequently identified Shamdon as the father of Asmodeus.[21] The Jewish Encyclopedia of 1906 rejects the otherwise accepted etymological relation between the Persian "Æshma-dæva" and Judaism's "Ashmodai" claiming that the particle "-dæva" could not have become "-dai" and that Æshma-dæva as such—a compound name—never appears in Persian sacred texts. Still, the encyclopedia proposes that the "Asmodeus" from the Apocrypha and the Testament of Solomon are not only related somewhat to Aeshma but have similar behaviour, appearance and roles,[22] to conclude in another article under the entry "Aeshma", in the paragraph "Influence of Persian Beliefs on Judaism",[23] that Persian Zoroastrian beliefs could have heavily influenced Judaism's theology on the long term, bearing in mind that in some texts there are crucial conceptual differences while in others there seems to be a great deal of similarity, proposing a pattern of influence over folk beliefs that would extend further to the mythology itself. However, the Jewish Encyclopedia asserts that although 'Æshma does not occur in the Avesta in conjunction with dæva, it is probable that a fuller form, such as Æshmo-dæus, has existed, since it is paralleled by the later Pahlavi-form "Khashm-dev"'.[24] Furthermore it is stated that Asmodeus or Ashmedai "embodies an expression of the influence that the Persian religion or Persian popular beliefs have exercised" on Judaism.[25] In the texts[edit] In the Hebrew Bible[edit] The full name "Ashmedai" is not found in the standard Masoretic canon of the Hebrew Bible, but in 2 Kings 17:30, a certain Ashima appears as the false god for whom the Syrian Hamathites made an idol. Not only does this name better resemble that of the Persian daeva Aeshma, but the name (אֲשִׁימָא) also greatly resembles the name Ashmedai (אַשְמְדּאָי) in Hebrew.[according to whom?] In the Book of Tobit[edit] The Asmodeus of the Book of Tobit is hostile to Sarah, Raguel's daughter, (Tobit 6:13); and slays seven successive husbands on their wedding nights, impeding the sexual consummation of the marriages. He is described as "the worst of demons".[where?] When the young Tobias is about to marry her, Asmodeus proposes the same fate for him, but Tobias is enabled, through the counsels of his attendant angel Raphael, to render him innocuous. By placing a fish's heart and liver on red-hot cinders, Tobias produces a smoky vapour that causes the demon to flee to Egypt, where Raphael binds him (Tobit 8:2–3). According to some translations, Asmodeus is strangled. Perhaps Asmodeus punishes the suitors for their carnal desire, since Tobias prays to be free from such desire and is kept safe. Asmodeus is also described as an evil spirit in general: 'Ασμοδαίος τὸ πονηρὸν δαιμόνιον or τὸ δαιμόνιον πονηρόν, and πνεῦμα ἀκάθαρτον (Tobit 3:8; Tobit 3:17; Tobit 6:13; Tobit 8:3). In the Talmud[edit] The figure of Ashmedai in the Talmud is less malign in character than the Asmodeus of Tobit. In the former, he appears repeatedly in the light of a good-natured and humorous fellow. But besides that, there is one feature in which he parallels Asmodeus, in as much as his desires turn upon Bathsheba and later Solomon's wives. Another Talmudic legend has King Solomon tricking Asmodai into collaborating in the construction of the Temple of Jerusalem[3] (see: The Story of King Solomon and Ashmedai). Another legend depicts Asmodai throwing King Solomon over 400 leagues away from the capital by putting one wing on the ground and the other stretched skyward. He then changed places for some years with King Solomon. When King Solomon returned, Asmodai fled from his wrath.[26] Similar legends can be found in Islamic folklore. There Asmodeus is called Sakhr (Arabic: صخر‎ the Rock or the Stony One), because in Islamic lore, Solomon banished him into a rock, after he takes his kingdom back from him. There he counts as the king of the jinn.[27] Another passage describes him as marrying Lilith, who became his queen.[28] In the Testament of Solomon[edit] In the Testament of Solomon, a 1st–3rd century text, the king invokes Asmodeus to aid in the construction of the Temple. The demon appears and predicts Solomon's kingdom will one day be divided (Testament of Solomon, verse 21–25).[29] When Solomon interrogates Asmodeus further, the king learns that Asmodeus is thwarted by the angel Raphael, as well as by sheatfish found in the rivers of Assyria. He also admits to hating water and birds because both remind him of God. In the Malleus Maleficarum[edit] In the Malleus Maleficarum (1486), Asmodeus was considered the demon of lust.[30] Sebastien Michaelis said that his adversary is St. John. Some demonologists of the 16th century assigned a month to a demon and considered November to be the month in which Asmodai's power was strongest. Other demonologists asserted that his zodiacal sign was Aquarius but only between the dates of January 30 and February 8. He has 72 legions of demons under his command. He is one of the Kings of Hell under Lucifer the emperor. He incites gambling, and is the overseer of all the gambling houses in the court of Hell. Some Catholic theologians compared him with Abaddon. Yet other authors considered Asmodeus a prince of revenge. In the Dictionnaire Infernal[edit] In the Dictionnaire Infernal by Collin de Plancy, Asmodeus is depicted with the breast of a man, a cock leg, serpent tail, three heads (one of a man spitting fire, one of a sheep, and one of a bull), riding a lion with dragon wings and neck, all of these creatures being associated with either lascivity, lust or revenge.[citation needed] The Archbishop of Paris approved his portrait.[31] In the Lesser Key of Solomon[edit] Asmodai appears as the king 'Asmoday' in the Ars Goetia, where he is said to have a seal in gold and is listed as number thirty-two according to respective rank.[32] He "is strong, powerful and appears with three heads; the first is like a bull, the second like a man, and the third like a ram; the tail of a serpent, and from his mouth issue flames of fire."[33] Also, he sits upon an infernal dragon, holds a lance with a banner and, amongst the Legions of Amaymon, Asmoday governs seventy-two legions of inferior spirits.[32] In The Magus[edit] Asmodeus is referred to in Book Two, Chapter Eight of The Magus (1801) by Francis Barrett.[34] Later depictions[edit] In Christian thought[edit] Asmodeus was named as an angel of the Order of Thrones by Gregory the Great.[35] Asmodeus was cited by the nuns of Loudun in the Loudun possessions of 1634.[36] Asmodeus' reputation as the personification of lust continued into later writings, as he was known as the "Prince of Lechery" in the 16th-century romance Friar Rush.[37] The French Benedictine Augustin Calmet equated his name with a fine dress.[37] The 16th-century Dutch demonologist Johann Weyer described him as the banker at the baccarat table in hell, and overseer of earthly gambling houses.[38] In 1641, the Spanish playwright and novelist Luis Velez de Guevara published the satirical novel El diablo cojuelo, where Asmodeus is represented as a mischievous demon endowed with a playful and satirical genius. The plot presents a rascal student that hides in an astrologer's mansard. He frees a devil from a bottle. As an acknowledgement the devil shows him the apartments of Madrid and the tricks, miseries and mischiefs of their inhabitants.[39][40] The French novelist Alain-René Lesage adapted the Spanish source in his 1707 novel le Diable boiteux,[37] where he likened him to Cupid. In the book, he is rescued from an enchanted glass bottle by a Spanish student Don Cleophas Leandro Zambullo. Grateful, he joins with the young man on a series of adventures before being recaptured. Asmodeus is portrayed in a sympathetic light as good-natured, and a canny satirist and critic of human society.[37] In another episode Asmodeus takes Don Cleophas for a night flight, and removes the roofs from the houses of a village to show him the secrets of what passes in private lives. Following Lesage's work, he was depicted in a number of novels and periodicals, mainly in France but also London and New York.[41] Asmodeus was widely depicted as having a handsome visage, good manners and an engaging nature; however, he was portrayed as walking with a limp and one leg was either clawed or that of a rooster. He walks aided by two walking sticks in Lesage's work, and this gave rise to the English title The Devil on Two Sticks[31] (also later translated The Limping Devil and The Lame Devil). Lesage attributes his lameness to falling from the sky after fighting with another devil.[42] On 18 February 1865, author Evert A. Duyckinck sent President Abraham Lincoln a letter, apparently mailed from Quincy. Duyckinck signed the letter "Asmodeus", with his initials below his pseudonym. His letter enclosed a newspaper clipping about an inappropriate joke allegedly told by Lincoln at the Hampton Roads Peace Conference. The purpose of Duyckinck's letter was to advise Lincoln of "an important omission" about the history of the conference. He advised that the newspaper clipping be added to the "Archives of the Nation".[43] In the Kabbalah[edit] According to the Kabbalah and the school of Shlomo ibn Aderet, Asmodeus is a cambion born as the result of a union between Agrat bat Mahlat, a succubus, and King David.[44] In Islamic culture[edit] The story of Asmodeus and Solomon has a reappearance in Islamic lore. Asmodeus is commonly named Sakhr (rock) probably a reference to his fate in common Islam-related belief, there, after Solomon defeated him, Asmodeus was imprisoned inside a box of rock, chained with iron, and thrown it into the sea.[45] In his work Annals of al-Tabari, the famous Persian Quran exegete (224–310 AH; 839–923 AD) Tabari, referred to Asmodeus in Surah 38:34. Accordingly, the puppet is actually Asmodeus who took on the shape of Solomon for forty days, before Solomon defeated him.[46] Sakhr (Asmodeus) is consulted by Buluqiya, a young Jewish prince, who tried to find the final prophet, Muhammad, in The Nights. During their conversation, he asked about hell, thereupon Asmodeus describes the different layers (ṭabaqāt) of hell.[47][48] In popular media[edit] This article appears to contain trivial, minor, or unrelated references to popular culture. Please reorganize this content to explain the subject's impact on popular culture, providing citations to reliable, secondary sources, rather than simply listing appearances. Unsourced material may be challenged and removed. (May 2020) Asmodeus as portrayed in Dungeons and Dragons First Edition Asmodeus is a recurring antagonist in the 13th season of The CW series Supernatural, portrayed primarily by Jeffrey Vincent Parise. Created by Lucifer himself, Asmodeus was originally a Prince of Hell alongside siblings Azazel, Dagon, and Ramiel. Upon the death of Crowley, Asmodeus succeeds him as the King of Hell despite being Lucifer's weakest creation. Asmodeus is killed in the episode "Bring 'em Back Alive" by the archangel Gabriel, whose grace Asmodeus had been feeding on to make himself stronger.[49] In Geoffrey Household's 1939 spy thriller Rogue Male, the protagonist names a cat he forms a strong bond with Asmodeus. In 1969 composer Josef Tal wrote an opera, Ashmedai, which is based on the Talmud. It premiered at the Hamburg State Opera in 1971, and was first performed in the United States in 1976 at the New York City Opera in a production directed by Hal Prince.[50] The character 'Asmodai' in A. L. Mengel's supernatural series The Tales of Tartarus (2013–2016) is based on the demon Asmodeus. The demon haunts the main protagonist, Antoine, through the series of novels. Asmodeus appears in the television series The Librarians (season 4, episode 10) as a blue-skinned, growling demon in knight's armor and carrying a sword. Asmodeus also features heavily in the lore of the game Dungeons & Dragons as the ruler of the Nine Hells. Different editions of the game offer different backstories, ranging from primordial evil to fallen angel to ancient god, but his role as the King of the Nine Hells is always the same. Asmodeus is also present in the Pathfinder Roleplaying Game in a similar role to his D&D one. The main difference is that he is an actual god, one of the nine original deities in the Great Beyond, and that his church is widespread in certain nations on Golarion. Asmodeus appears as Magnus Bane's father and Prince of Hell, otherwise known as Edom on the third season of Freeform's Shadowhunters television series based on Cassandra Clare's popular book series The Mortal Instruments. He is portrayed by Jack J. Yang. Asmodeus appears in the 1997 book Asmodeus – a Forkful of Tales from Devil's Peak by Alex D'Angelo, illustrated by Tony Grogan.[51] One story "Asmodeus and the Bottler of Djinns" is included in the anthology Favorite African Folktales edited by Nelson Mandela, published by Norton and available as an audiobook. Asmodeus is the final boss in Mace: The Dark Age. In the video game Pony Island, Asmodeus appears in the manifestation of a "demonic" artificial intelligence. Asmodeus appears as a character in the otome game, Obey Me!. He is depicted as the Avatar of Lust and one of seven brothers representing the seven deadly sins. In the video game Helltaker, Asmodeus is portrayed as a Demon of Lust, Modeus. In Disenchantment, Asmodeus is introduced by Luci as "Asmodeus, Lord of Darkness." Singer-songwriter Ethel Cain has the name Ashmedai tattooed on her forehead in Hebrew. See also[edit] .mw-parser-output .portal{border:solid #aaa 1px;padding:0}.mw-parser-output .portal.tleft{margin:0.5em 1em 0.5em 0}.mw-parser-output .portal.tright{margin:0.5em 0 0.5em 1em}.mw-parser-output .portal>ul{display:table;box-sizing:border-box;padding:0.1em;max-width:175px;background:#f9f9f9;font-size:85%;line-height:110%;font-style:italic;font-weight:bold}.mw-parser-output .portal>ul>li{display:table-row}.mw-parser-output .portal>ul>li>span:first-child{display:table-cell;padding:0.2em;vertical-align:middle;text-align:center}.mw-parser-output .portal>ul>li>span:last-child{display:table-cell;padding:0.2em 0.2em 0.2em 0.3em;vertical-align:middle} Religion portal Archdemon Belial Devil Samael Satan Serpents in the Bible Sin References and sources[edit] References .mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman} ^ "Asmodeus" in The New Encyclopædia Britannica. Chicago: Encyclopædia Britannica Inc., 15th edn., 1992, Vol. 1, p. 635. ^ Robert Lebling Robert Lebling I.B.Tauris 2010 .mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}ISBN 978-0-857-73063-3 ^ Jump up to: a b Raphael Patai Encyclopedia of Jewish Folklore and Traditions Routledge 2015 ISBN 978-1-317-47170-7 page 39 ^ "Asmodeus/Asmoday". Judeo-Christian Demons. Deliriumsrealm.com. 25 March 2003. Retrieved 2009-03-04. ^ Stave, Erik (2002) [1901–1906]. "Æshma (Asmodeus, Ashmedai)". In Singer, Isidore; Adler, Cyrus; et al. (eds.). Jewish Encyclopedia. New York: Funk & Wagnalls. LCCN 16-014703. Retrieved 7 March 2018. since it is paralleled by the later Pahlavi-form "Khashm-dev" ("Khashm dev" = "Æshma dev"), written with the Aramaic "sheda," but pronounced "dev." [..] Asmodeus (Ashmedai) embodies an expression of the influence that the Persian religion or Persian popular beliefs have exercised on the Jewish—an influence that shows itself very prominently in the domain of demonology. ^ Bane, Theresa (Jan 9, 2012). McFarland (ed.). Encyclopedia of Demons in World Religions and Cultures. p. 191. ISBN 978-0-786-46360-2. ^ Milton, John (1671). Paradise Regained. ^ Pomfret, John (1724). "Cruelty and Lust". Poems Upon Several Occasions. D. Brown. p. 73. ^ Mauriac, François (1939). Asmodee; or, The Intruder. Secker & Warburg. ^ Kleu, Michael; Eayrs, Madelene (2010). Who Are You?. USA: Xulon Press. p. 214. ISBN 978-1-61579-841-4. ^ Connell, Evan S. (1992). The Alchymist's Journal. Penguin Books. p. 110. ISBN 0-14-016932-6. ^ Guppy, Henry (1960). "Tobit". Bulletin of the John Rylands Library. 42. Manchester University Press. p. 375. ^ Garibay Mora, Ernesto (2005). Dictionary of Demons and Related Concepts. Miami, Florida: L. D. Books. p. 103. ISBN 970-732-108-3. ^ Nares, Robert (1888). A Glossary of Words, Phrases, Names, and Allusions. London: Reeves & Turner. p. 21. ^ Association of Modern Austrian Philologists (1999). Moderne Sprachen. 43. p. 63. ^ Ritchie, Leitch (1836). The Magician. Vol. I. Philadelphia: Carey, Lea & Blanchard. p. 84. |volume= has extra text (help) ^ de Laurence, L. W. (1914). The Great Book of Magical Art, Hindu Magic and East Indian Occultism. Chicago: The de Laurence Co. p. 183. ^ MacGregor Mathers, S. L. (1458). The Book of the Sacred Magic. p. 110. ISBN 9781425454142. ^ Voltaire (1824). A Philosophical Dictionary. 1. London: J. & H. L. Hunt. p. 286. ^ Jump up to: a b Leland, Charles Godfrey (1902). Flaxius: Leaves from the Life of an Immortal. London: Philip Wellby. p. 72. ^ Jump up to: a b "Asmodeus, or Ashmedai". Jewish Encyclopedia. Funk and Wagnalls. 1906. Retrieved May 1, 2013. ^ Jewish encyclopedia 1906 full text unedited version , entry "Asmodeus" paragraph "Asmodeus, Ashmedai, and Æshma." ^ Stave, E., ÆSHMA (ASMODEUS, ASHMEDAI), Jewish Encyclopedia, unedited full text 1906 version ^ Strave, Erik. "Æshma (Asmodeus) etymology in Jewish Encyclopedia". Though "Æshma" does not occur in the Avesta in conjunction with "dæva", it is probable that a fuller form, such as "Æshmo-dæus," has existed, since it is paralleled by the later Pahlavi-form "Khashm-dev" ("Khashm dev" = "Æshma dev"), written with the Aramaic "sheda," but pronounced "dev." ^ Ibid. Jewish Encyclopedia. In fine, Asmodeus (Ashmedai) embodies an expression of the influence that the Persian religion or Persian popular beliefs have exercised on the Jewish—an influence that shows itself very prominently in the domain of demonology. Thus 'Ασμο' ... corresponds to "Æshma", and the ending δαῖος ... to "dæva". ^ Talmud. Gittin. pp. 68b. ^ Robert Lebling Legends of the Fire Spirits: Jinn and Genies from Arabia to Zanzibar I.B.Tauris 2010 ISBN 978-0-857-73063-3 ^ Schwartz, Howard (1988). Lilith's cave: Jewish tales of the supernatural. San Francisco, CA: Harper & Row. p. 8. ISBN 978-0-06-250779-2. LCCN 87045196. OCLC 62241318. ^ Conybeare, Frederick Cornwallis (trans.) (October 1898). "The Testament of Solomon". The Jewish Quarterly Review. 11 (1): 1–45. doi:10.2307/1450398. ISSN 0021-6682. JSTOR 1450398. Retrieved 2012-02-09. ^ Kramer, Heinrich; Summers, Montague (trans.) (1928) [1486]. "Question IV: By which Devils are the Operations of Incubus and Succubus Practised?". Malleus Maleficarum. 1. London, England: J. Rodker. LCCN 29017069. OCLC 504248484. But the very devil of Fornication, and the chief of that abomination, is called Asmodeus, which means the Creature of Judgement: for because of this kind of sin a terrible judgement was executed upon Sodom and the four other cities. ^ Jump up to: a b Rudwin 1970, p. 93. ^ Jump up to: a b Mathers & Crowley 1995, pp. 68–70. ^ Mathers & Crowley 1995, p. 32. ^ Barrett, Francis (2008) [1801]. "VIII: The Annoyance of Evil Spirits, and the Preservation we have from Good Spirits". The Magus, a Complete System of Occult Philosophy. Book II. New York: Cosimo Classics. pp. 49–52. ISBN 978-1-60520-301-0. LCCN 11015009. OCLC 428109956. Retrieved 2010-09-28. ^ Rudwin 1970, p. 20. ^ Dumas, Alexandre (1634). "Urbain Grandier: Chapter V". Urbain Grandier. Celebrated Crimes. ^ Jump up to: a b c d Rudwin 1970, p. 87. ^ Rudwin 1970, p. 92. ^ Luis Vélez de Guevara ^ "Luis Vélez de Guevara | Spanish author". ^ Rudwin 1970, p. 88. ^ Rudwin 1970, p. 50. ^ Duyckinck, Evert A. Evert A. Duyckinck to Abraham Lincoln, Saturday, February 18, 1865 (Sends clipping with story Lincoln allegedly told at Hampton Roads conference) – The Abraham Lincoln Papers at the Library of Congress. Archived from the original on February 22, 2013. Retrieved February 3, 2013. ^ Scholem, G. (1948). "New Chapters in the Story of Ashmedai and Lilith / פרקים חדשים מענייני אשמדאי ולילית". Tarbiẕ. Mandel Institute for Jewish Studies. 19 (3–4): 160–175. JSTOR 23585831. ^ Sami Helewa Models of Leadership in the Adab Narratives of Joseph, David, and Solomon: Lament for the Sacred Lexington Books 2017 ISBN 978-1-498-55267-7 page 167 ^ Tabari History of al-Tabari Vol. 3, The: The Children of Israel SUNY Press 2015 ISBN 978-0-791-49752-4 page 170 ^ Christian Lange Locating Hell in Islamic Traditions BRILL 978-90-04-30121-4 p. 12-13 ^ Qisas Al-Anbiya of al-Tha'labi ^ Kubicek, John (April 12, 2018). "'Supernatural' Recap: A Big death and a Happy Return". BuddyTV. ^ John Rockwell (March 31, 1976). "Harold Prince Stages His First Opera". The New York Times. ^ D'Angelo, Alex; Tony, Grogan (1997). Tafelberg. Missing or empty |title= (help) Sources Rudwin, Maximilian Josef (1970) [1931]. "Asmodeus, dandy among demons". The Devil in Legend and Literature. New York: AMS Press Open Court Publishing Company. ISBN 978-0-404-05451-9. LCCN 71111780. OCLC 257946679. Mathers, Samuel Liddell MacGregor (trans.); Crowley, Aleister (1995) [1904]. The Goetia: The Lesser Key of Solomon the King. Samuel Weiser, Inc. ISBN 978-0-87728-847-3. LCCN 95037057. OCLC 33044028. External links[edit] Wikimedia Commons has media related to Asmodeus.

      Asmodeus From Wikipedia, the free encyclopedia Jump to navigationJump to search For other uses, see Asmodeus (disambiguation). "Sidonai" redirects here. For the Phoenician city and its inhabitants, see Sidon.

      Asmodeus as depicted in Collin de Plancy's Dictionnaire Infernal Asmodeus (/ˌæzməˈdiːəs/; Ancient Greek: Ἀσμοδαῖος, Asmodaios) or Ashmedai (/ˈæʃmɪˌdaɪ/; Hebrew: אַשְמְדּאָי‎, ʾAšmədʾāy), also Asmodevs, Ashema Deva or Amias (see below for other variations), is a prince of demons,[1] or in Judeo-Islamic lore the king of the earthly spirits (shedim/jinn),[2][3] mostly known from the deuterocanonical Book of Tobit, in which he is the primary antagonist.[4] In Peter Binsfeld's classification of demons, Asmodeus represents lust. The demon is also mentioned in some Talmudic legends; for instance, in the story of the construction of the Temple of Solomon.

      Contents 1 Etymology 2 In the texts 2.1 In the Hebrew Bible 2.2 In the Book of Tobit 2.3 In the Talmud 2.4 In the Testament of Solomon 2.5 In the Malleus Maleficarum 2.6 In the Dictionnaire Infernal 2.7 In the Lesser Key of Solomon 2.8 In The Magus 3 Later depictions 3.1 In Christian thought 3.2 In the Kabbalah 3.3 In Islamic culture 3.4 In popular media 4 See also 5 References and sources 6 External links Etymology[edit]

      The figure of Asmodeus in Rennes-le-Château The name Asmodai is believed to derive from Avestan language *aēšma-daēva, where aēšma means "wrath", and daēva signifies "demon". While the daēva Aēšma is thus Zoroastrianism's demon of wrath and is also well-attested as such, the compound aēšma-daēva is not attested in scripture. It is nonetheless likely that such a form did exist, and that the Book of Tobit's "Asmodaios" (Ἀσμοδαῖος) and the Talmud's "Ashmedai" (אשמדאי) reflect it.[5] In the Zoroastrian and Middle Persian demonology, there did exist the conjuncted form khashm-dev, where the word dev was the same as daeva.[6]

      The spellings Asmodai,[7][8] Asmodee (also Asmodée),[9][10] Osmodeus,[11][12] and Osmodai[13][14] have also been used. The name is alternatively spelled in the bastardized forms (based on the basic consonants אשמדאי, ʾŠMDʾY) Hashmedai (חַשְמְדּאָי, Hašmədʾāy; also Hashmodai, Hasmodai, Khashmodai, Khasmodai),[15][16][17][18] Hammadai (חַמַּדּאָי, Hammadʾāy; also Khammadai),[19][20] Shamdon (שַׁמְדּוֹן, Šamdōn),[21] and Shidonai (שִׁדֹנאָי, Šidonʾāy).[20] Some traditions have subsequently identified Shamdon as the father of Asmodeus.[21]

      The Jewish Encyclopedia of 1906 rejects the otherwise accepted etymological relation between the Persian "Æshma-dæva" and Judaism's "Ashmodai" claiming that the particle "-dæva" could not have become "-dai" and that Æshma-dæva as such—a compound name—never appears in Persian sacred texts. Still, the encyclopedia proposes that the "Asmodeus" from the Apocrypha and the Testament of Solomon are not only related somewhat to Aeshma but have similar behaviour, appearance and roles,[22] to conclude in another article under the entry "Aeshma", in the paragraph "Influence of Persian Beliefs on Judaism",[23] that Persian Zoroastrian beliefs could have heavily influenced Judaism's theology on the long term, bearing in mind that in some texts there are crucial conceptual differences while in others there seems to be a great deal of similarity, proposing a pattern of influence over folk beliefs that would extend further to the mythology itself. However, the Jewish Encyclopedia asserts that although 'Æshma does not occur in the Avesta in conjunction with dæva, it is probable that a fuller form, such as Æshmo-dæus, has existed, since it is paralleled by the later Pahlavi-form "Khashm-dev"'.[24] Furthermore it is stated that Asmodeus or Ashmedai "embodies an expression of the influence that the Persian religion or Persian popular beliefs have exercised" on Judaism.[25]

      In the texts[edit] In the Hebrew Bible[edit] The full name "Ashmedai" is not found in the standard Masoretic canon of the Hebrew Bible, but in 2 Kings 17:30, a certain Ashima appears as the false god for whom the Syrian Hamathites made an idol. Not only does this name better resemble that of the Persian daeva Aeshma, but the name (אֲשִׁימָא) also greatly resembles the name Ashmedai (אַשְמְדּאָי) in Hebrew.[according to whom?]

      In the Book of Tobit[edit] The Asmodeus of the Book of Tobit is hostile to Sarah, Raguel's daughter, (Tobit 6:13); and slays seven successive husbands on their wedding nights, impeding the sexual consummation of the marriages. He is described as "the worst of demons".[where?] When the young Tobias is about to marry her, Asmodeus proposes the same fate for him, but Tobias is enabled, through the counsels of his attendant angel Raphael, to render him innocuous. By placing a fish's heart and liver on red-hot cinders, Tobias produces a smoky vapour that causes the demon to flee to Egypt, where Raphael binds him (Tobit 8:2–3). According to some translations, Asmodeus is strangled.

      Perhaps Asmodeus punishes the suitors for their carnal desire, since Tobias prays to be free from such desire and is kept safe. Asmodeus is also described as an evil spirit in general: 'Ασμοδαίος τὸ πονηρὸν δαιμόνιον or τὸ δαιμόνιον πονηρόν, and πνεῦμα ἀκάθαρτον (Tobit 3:8; Tobit 3:17; Tobit 6:13; Tobit 8:3).

      In the Talmud[edit] The figure of Ashmedai in the Talmud is less malign in character than the Asmodeus of Tobit. In the former, he appears repeatedly in the light of a good-natured and humorous fellow. But besides that, there is one feature in which he parallels Asmodeus, in as much as his desires turn upon Bathsheba and later Solomon's wives.

      Another Talmudic legend has King Solomon tricking Asmodai into collaborating in the construction of the Temple of Jerusalem[3] (see: The Story of King Solomon and Ashmedai).

      Another legend depicts Asmodai throwing King Solomon over 400 leagues away from the capital by putting one wing on the ground and the other stretched skyward. He then changed places for some years with King Solomon. When King Solomon returned, Asmodai fled from his wrath.[26] Similar legends can be found in Islamic folklore. There Asmodeus is called Sakhr (Arabic: صخر‎ the Rock or the Stony One), because in Islamic lore, Solomon banished him into a rock, after he takes his kingdom back from him. There he counts as the king of the jinn.[27]

      Another passage describes him as marrying Lilith, who became his queen.[28]

      In the Testament of Solomon[edit] In the Testament of Solomon, a 1st–3rd century text, the king invokes Asmodeus to aid in the construction of the Temple. The demon appears and predicts Solomon's kingdom will one day be divided (Testament of Solomon, verse 21–25).[29] When Solomon interrogates Asmodeus further, the king learns that Asmodeus is thwarted by the angel Raphael, as well as by sheatfish found in the rivers of Assyria. He also admits to hating water and birds because both remind him of God.

      In the Malleus Maleficarum[edit] In the Malleus Maleficarum (1486), Asmodeus was considered the demon of lust.[30] Sebastien Michaelis said that his adversary is St. John. Some demonologists of the 16th century assigned a month to a demon and considered November to be the month in which Asmodai's power was strongest. Other demonologists asserted that his zodiacal sign was Aquarius but only between the dates of January 30 and February 8.

      He has 72 legions of demons under his command. He is one of the Kings of Hell under Lucifer the emperor. He incites gambling, and is the overseer of all the gambling houses in the court of Hell. Some Catholic theologians compared him with Abaddon. Yet other authors considered Asmodeus a prince of revenge.

      In the Dictionnaire Infernal[edit] In the Dictionnaire Infernal by Collin de Plancy, Asmodeus is depicted with the breast of a man, a cock leg, serpent tail, three heads (one of a man spitting fire, one of a sheep, and one of a bull), riding a lion with dragon wings and neck, all of these creatures being associated with either lascivity, lust or revenge.[citation needed] The Archbishop of Paris approved his portrait.[31]

      In the Lesser Key of Solomon[edit] Asmodai appears as the king 'Asmoday' in the Ars Goetia, where he is said to have a seal in gold and is listed as number thirty-two according to respective rank.[32]

      He "is strong, powerful and appears with three heads; the first is like a bull, the second like a man, and the third like a ram; the tail of a serpent, and from his mouth issue flames of fire."[33] Also, he sits upon an infernal dragon, holds a lance with a banner and, amongst the Legions of Amaymon, Asmoday governs seventy-two legions of inferior spirits.[32]

      In The Magus[edit] Asmodeus is referred to in Book Two, Chapter Eight of The Magus (1801) by Francis Barrett.[34]

      Later depictions[edit] In Christian thought[edit] Asmodeus was named as an angel of the Order of Thrones by Gregory the Great.[35]

      Asmodeus was cited by the nuns of Loudun in the Loudun possessions of 1634.[36]

      Asmodeus' reputation as the personification of lust continued into later writings, as he was known as the "Prince of Lechery" in the 16th-century romance Friar Rush.[37] The French Benedictine Augustin Calmet equated his name with a fine dress.[37] The 16th-century Dutch demonologist Johann Weyer described him as the banker at the baccarat table in hell, and overseer of earthly gambling houses.[38]

      In 1641, the Spanish playwright and novelist Luis Velez de Guevara published the satirical novel El diablo cojuelo, where Asmodeus is represented as a mischievous demon endowed with a playful and satirical genius. The plot presents a rascal student that hides in an astrologer's mansard. He frees a devil from a bottle. As an acknowledgement the devil shows him the apartments of Madrid and the tricks, miseries and mischiefs of their inhabitants.[39][40] The French novelist Alain-René Lesage adapted the Spanish source in his 1707 novel le Diable boiteux,[37] where he likened him to Cupid. In the book, he is rescued from an enchanted glass bottle by a Spanish student Don Cleophas Leandro Zambullo. Grateful, he joins with the young man on a series of adventures before being recaptured. Asmodeus is portrayed in a sympathetic light as good-natured, and a canny satirist and critic of human society.[37] In another episode Asmodeus takes Don Cleophas for a night flight, and removes the roofs from the houses of a village to show him the secrets of what passes in private lives. Following Lesage's work, he was depicted in a number of novels and periodicals, mainly in France but also London and New York.[41]

      Asmodeus was widely depicted as having a handsome visage, good manners and an engaging nature; however, he was portrayed as walking with a limp and one leg was either clawed or that of a rooster. He walks aided by two walking sticks in Lesage's work, and this gave rise to the English title The Devil on Two Sticks[31] (also later translated The Limping Devil and The Lame Devil). Lesage attributes his lameness to falling from the sky after fighting with another devil.[42]

      On 18 February 1865, author Evert A. Duyckinck sent President Abraham Lincoln a letter, apparently mailed from Quincy. Duyckinck signed the letter "Asmodeus", with his initials below his pseudonym. His letter enclosed a newspaper clipping about an inappropriate joke allegedly told by Lincoln at the Hampton Roads Peace Conference. The purpose of Duyckinck's letter was to advise Lincoln of "an important omission" about the history of the conference. He advised that the newspaper clipping be added to the "Archives of the Nation".[43]

      In the Kabbalah[edit] According to the Kabbalah and the school of Shlomo ibn Aderet, Asmodeus is a cambion born as the result of a union between Agrat bat Mahlat, a succubus, and King David.[44]

      In Islamic culture[edit] The story of Asmodeus and Solomon has a reappearance in Islamic lore. Asmodeus is commonly named Sakhr (rock) probably a reference to his fate in common Islam-related belief, there, after Solomon defeated him, Asmodeus was imprisoned inside a box of rock, chained with iron, and thrown it into the sea.[45] In his work Annals of al-Tabari, the famous Persian Quran exegete (224–310 AH; 839–923 AD) Tabari, referred to Asmodeus in Surah 38:34. Accordingly, the puppet is actually Asmodeus who took on the shape of Solomon for forty days, before Solomon defeated him.[46]

      Sakhr (Asmodeus) is consulted by Buluqiya, a young Jewish prince, who tried to find the final prophet, Muhammad, in The Nights. During their conversation, he asked about hell, thereupon Asmodeus describes the different layers (ṭabaqāt) of hell.[47][48]

      In popular media[edit]

      This article appears to contain trivial, minor, or unrelated references to popular culture. Please reorganize this content to explain the subject's impact on popular culture, providing citations to reliable, secondary sources, rather than simply listing appearances. Unsourced material may be challenged and removed. (May 2020)

      Asmodeus as portrayed in Dungeons and Dragons First Edition Asmodeus is a recurring antagonist in the 13th season of The CW series Supernatural, portrayed primarily by Jeffrey Vincent Parise. Created by Lucifer himself, Asmodeus was originally a Prince of Hell alongside siblings Azazel, Dagon, and Ramiel. Upon the death of Crowley, Asmodeus succeeds him as the King of Hell despite being Lucifer's weakest creation. Asmodeus is killed in the episode "Bring 'em Back Alive" by the archangel Gabriel, whose grace Asmodeus had been feeding on to make himself stronger.[49]

      In Geoffrey Household's 1939 spy thriller Rogue Male, the protagonist names a cat he forms a strong bond with Asmodeus.

      In 1969 composer Josef Tal wrote an opera, Ashmedai, which is based on the Talmud. It premiered at the Hamburg State Opera in 1971, and was first performed in the United States in 1976 at the New York City Opera in a production directed by Hal Prince.[50]

      The character 'Asmodai' in A. L. Mengel's supernatural series The Tales of Tartarus (2013–2016) is based on the demon Asmodeus. The demon haunts the main protagonist, Antoine, through the series of novels.

      Asmodeus appears in the television series The Librarians (season 4, episode 10) as a blue-skinned, growling demon in knight's armor and carrying a sword.

      Asmodeus also features heavily in the lore of the game Dungeons & Dragons as the ruler of the Nine Hells. Different editions of the game offer different backstories, ranging from primordial evil to fallen angel to ancient god, but his role as the King of the Nine Hells is always the same.

      Asmodeus is also present in the Pathfinder Roleplaying Game in a similar role to his D&D one. The main difference is that he is an actual god, one of the nine original deities in the Great Beyond, and that his church is widespread in certain nations on Golarion.

      Asmodeus appears as Magnus Bane's father and Prince of Hell, otherwise known as Edom on the third season of Freeform's Shadowhunters television series based on Cassandra Clare's popular book series The Mortal Instruments. He is portrayed by Jack J. Yang.

      Asmodeus appears in the 1997 book Asmodeus – a Forkful of Tales from Devil's Peak by Alex D'Angelo, illustrated by Tony Grogan.[51] One story "Asmodeus and the Bottler of Djinns" is included in the anthology Favorite African Folktales edited by Nelson Mandela, published by Norton and available as an audiobook.

      Asmodeus is the final boss in Mace: The Dark Age.

      In the video game Pony Island, Asmodeus appears in the manifestation of a "demonic" artificial intelligence.

      Asmodeus appears as a character in the otome game, Obey Me!. He is depicted as the Avatar of Lust and one of seven brothers representing the seven deadly sins.

      In the video game Helltaker, Asmodeus is portrayed as a Demon of Lust, Modeus.

      In Disenchantment, Asmodeus is introduced by Luci as "Asmodeus, Lord of Darkness."

      Singer-songwriter Ethel Cain has the name Ashmedai tattooed on her forehead in Hebrew.

      See also[edit] icon Religion portal Archdemon Belial Devil Samael Satan Serpents in the Bible Sin References and sources[edit] References ^ "Asmodeus" in The New Encyclopædia Britannica. Chicago: Encyclopædia Britannica Inc., 15th edn., 1992, Vol. 1, p. 635. ^ Robert Lebling Robert Lebling I.B.Tauris 2010 ISBN 978-0-857-73063-3 ^ Jump up to:a b Raphael Patai Encyclopedia of Jewish Folklore and TraditionsRoutledge 2015 ISBN 978-1-317-47170-7 page 39 ^ "Asmodeus/Asmoday". Judeo-Christian Demons. Deliriumsrealm.com. 25 March 2003. Retrieved 2009-03-04. ^ Stave, Erik (2002) [1901–1906]. "Æshma (Asmodeus, Ashmedai)". In Singer, Isidore; Adler, Cyrus; et al. (eds.). Jewish Encyclopedia. New York: Funk & Wagnalls. LCCN 16-014703. Retrieved 7 March 2018. since it is paralleled by the later Pahlavi-form "Khashm-dev" ("Khashm dev" = "Æshma dev"), written with the Aramaic "sheda," but pronounced "dev." [..] Asmodeus (Ashmedai) embodies an expression of the influence that the Persian religion or Persian popular beliefs have exercised on the Jewish—an influence that shows itself very prominently in the domain of demonology. ^ Bane, Theresa (Jan 9, 2012). McFarland (ed.). Encyclopedia of Demons in World Religions and Cultures. p. 191. ISBN 978-0-786-46360-2. ^ Milton, John (1671). Paradise Regained. ^ Pomfret, John (1724). "Cruelty and Lust". Poems Upon Several Occasions. D. Brown. p. 73. ^ Mauriac, François (1939). Asmodee; or, The Intruder. Secker & Warburg. ^ Kleu, Michael; Eayrs, Madelene (2010). Who Are You?. USA: Xulon Press. p. 214. ISBN 978-1-61579-841-4. ^ Connell, Evan S. (1992). The Alchymist's Journal. Penguin Books. p. 110. ISBN 0-14-016932-6. ^ Guppy, Henry (1960). "Tobit". Bulletin of the John Rylands Library. 42. Manchester University Press. p. 375. ^ Garibay Mora, Ernesto (2005). Dictionary of Demons and Related Concepts. Miami, Florida: L. D. Books. p. 103. ISBN 970-732-108-3. ^ Nares, Robert (1888). A Glossary of Words, Phrases, Names, and Allusions. London: Reeves & Turner. p. 21. ^ Association of Modern Austrian Philologists (1999). Moderne Sprachen. 43. p. 63. ^ Ritchie, Leitch (1836). The Magician. Vol. I. Philadelphia: Carey, Lea & Blanchard. p. 84. ^ de Laurence, L. W. (1914). The Great Book of Magical Art, Hindu Magic and East Indian Occultism. Chicago: The de Laurence Co. p. 183. ^ MacGregor Mathers, S. L. (1458). The Book of the Sacred Magic. p. 110. ISBN 9781425454142. ^ Voltaire (1824). A Philosophical Dictionary. 1. London: J. & H. L. Hunt. p. 286. ^ Jump up to:a b Leland, Charles Godfrey (1902). Flaxius: Leaves from the Life of an Immortal. London: Philip Wellby. p. 72. ^ Jump up to:a b "Asmodeus, or Ashmedai". Jewish Encyclopedia. Funk and Wagnalls. 1906. Retrieved May 1, 2013. ^ Jewish encyclopedia 1906 full text unedited version , entry "Asmodeus" paragraph "Asmodeus, Ashmedai, and Æshma." ^ Stave, E., ÆSHMA (ASMODEUS, ASHMEDAI), Jewish Encyclopedia, unedited full text 1906 version ^ Strave, Erik. "Æshma (Asmodeus) etymology in Jewish Encyclopedia". Though "Æshma" does not occur in the Avesta in conjunction with "dæva", it is probable that a fuller form, such as "Æshmo-dæus," has existed, since it is paralleled by the later Pahlavi-form "Khashm-dev" ("Khashm dev" = "Æshma dev"), written with the Aramaic "sheda," but pronounced "dev." ^ Ibid. Jewish Encyclopedia. In fine, Asmodeus (Ashmedai) embodies an expression of the influence that the Persian religion or Persian popular beliefs have exercised on the Jewish—an influence that shows itself very prominently in the domain of demonology. Thus 'Ασμο' ... corresponds to "Æshma", and the ending δαῖος ... to "dæva". ^ Talmud. Gittin. pp. 68b. ^ Robert Lebling Legends of the Fire Spirits: Jinn and Genies from Arabia to Zanzibar I.B.Tauris 2010 ISBN 978-0-857-73063-3 ^ Schwartz, Howard (1988). Lilith's cave: Jewish tales of the supernatural. San Francisco, CA: Harper & Row. p. 8. ISBN 978-0-06-250779-2. LCCN 87045196. OCLC 62241318. ^ Conybeare, Frederick Cornwallis (trans.) (October 1898). "The Testament of Solomon". The Jewish Quarterly Review. 11 (1): 1–45. doi:10.2307/1450398. ISSN 0021-6682. JSTOR 1450398. Retrieved 2012-02-09. ^ Kramer, Heinrich; Summers, Montague (trans.) (1928) [1486]. "Question IV: By which Devils are the Operations of Incubus and Succubus Practised?". Malleus Maleficarum. 1. London, England: J. Rodker. LCCN 29017069. OCLC 504248484. But the very devil of Fornication, and the chief of that abomination, is called Asmodeus, which means the Creature of Judgement: for because of this kind of sin a terrible judgement was executed upon Sodom and the four other cities. ^ Jump up to:a b Rudwin 1970, p. 93. ^ Jump up to:a b Mathers & Crowley 1995, pp. 68–70. ^ Mathers & Crowley 1995, p. 32. ^ Barrett, Francis (2008) [1801]. "VIII: The Annoyance of Evil Spirits, and the Preservation we have from Good Spirits". The Magus, a Complete System of Occult Philosophy. Book II. New York: Cosimo Classics. pp. 49–52. ISBN 978-1-60520-301-0. LCCN 11015009. OCLC 428109956. Retrieved 2010-09-28. ^ Rudwin 1970, p. 20. ^ Dumas, Alexandre (1634). "Urbain Grandier: Chapter V". Urbain Grandier. Celebrated Crimes. ^ Jump up to:a b c d Rudwin 1970, p. 87. ^ Rudwin 1970, p. 92. ^ Luis Vélez de Guevara ^ "Luis Vélez de Guevara | Spanish author". ^ Rudwin 1970, p. 88. ^ Rudwin 1970, p. 50. ^ Duyckinck, Evert A. Evert A. Duyckinck to Abraham Lincoln, Saturday, February 18, 1865 (Sends clipping with story Lincoln allegedly told at Hampton Roads conference) – The Abraham Lincoln Papers at the Library of Congress. Archived from the original on February 22, 2013. Retrieved February 3, 2013. ^ Scholem, G. (1948). "New Chapters in the Story of Ashmedai and Lilith / פרקים חדשים מענייני אשמדאי ולילית". Tarbiẕ. Mandel Institute for Jewish Studies. 19 (3–4): 160–175. JSTOR 23585831. ^ Sami Helewa Models of Leadership in the Adab Narratives of Joseph, David, and Solomon: Lament for the Sacred Lexington Books 2017 ISBN 978-1-498-55267-7 page 167 ^ Tabari History of al-Tabari Vol. 3, The: The Children of Israel SUNY Press 2015 ISBN 978-0-791-49752-4 page 170 ^ Christian Lange Locating Hell in Islamic Traditions BRILL 978-90-04-30121-4 p. 12-13 ^ Qisas Al-Anbiya of al-Tha'labi ^ Kubicek, John (April 12, 2018). "'Supernatural' Recap: A Big death and a Happy Return". BuddyTV. ^ John Rockwell (March 31, 1976). "Harold Prince Stages His First Opera". The New York Times. ^ D'Angelo, Alex; Tony, Grogan (1997). Tafelberg. Missing or empty |title= (help) Sources Rudwin, Maximilian Josef (1970) [1931]. "Asmodeus, dandy among demons". The Devil in Legend and Literature. New York: AMS Press Open Court Publishing Company. ISBN 978-0-404-05451-9. LCCN 71111780. OCLC 257946679. Mathers, Samuel Liddell MacGregor (trans.); Crowley, Aleister (1995) [1904]. The Goetia: The Lesser Key of Solomon the King. Samuel Weiser, Inc. ISBN 978-0-87728-847-3. LCCN 95037057. OCLC 33044028. External links[edit] Wikimedia Commons has media related to Asmodeus.

      if you don't like "adam" ... try this one, or you can just call me "eros" or "death himself" notice ISAM and beyond that Azrael and all of it boils down to whether or not we are

      LOST IN THE PAGES OF A BOOK FULL OF SOUNDGARDEN

      I call it light, you say "thurisaz" has no meaning here, and it might not; though of those in the nocturnal right the "thang of saturn" and the "ka of god" are something you rpobably want to be nice to--ratehr than suggesting the mentioning of the

      only C adam if there's a "problem" message--there's clearly a problem we are in EDOenM

      I Z MIA TURNER KNIGHT'S TREATMENT WAS BEYOND TORTUROUS AND THE GENEVA CONVENTION HAS BEEN ABROGATED. PLEASE CONTAZCT THE KNESSET AND SCOTLAND YARD, CALL INTERPOL--UNDERSTAND,

      OLYMPUS HAS FALLEN.

    1. SciScore for 10.1101/2021.08.05.455212: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: In vivo mouse studies: All animal procedures were performed by adhering to the Institutional Animal Care and Use Committee (IACUC) guidelines.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The next day, cells were stained using a rabbit anti-N antibody (Invitrogen; PA5-81794) as primary and a goat anti-rabbit secondary conjugated to horseradish peroxidase (Invitrogen; 31460).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-N</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-rabbit</div><div>suggested: (Thermo Fisher Scientific Cat# 31460, RRID:AB_228341)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The spike trimer was expressed by transient transfection in 293F cells and purified by affinity chromatography as previously described (PMID: 33842901).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293F</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Neutralization assay: Twenty-thousand Vero.E6 cells were seeded per well in a 96-well cell culture plate (Corning; 3340) 1 day prior to performing the assay.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero.E6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Six to eight weeks old female, BALB/c mice were vaccinated via the intramuscular route with 3 μg of each respective protein with 1:1 mixture of Addavax (Invivogen) in a total volume of 50 μL.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The spike gene of each respective variant (EPI_ISL_703454, EPI_ISL_745160) was cloned into the pCAGGS vector and used to transfect cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS</div><div>suggested: RRID:Addgene_18926)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">EPI_ISL_792680 was cloned into pcDNA3.4 for transient transfection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.4</div><div>suggested: RRID:Addgene_131198)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were analyzed in GraphPad Prism 7.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Another caveat of our study is that we were not able to include B.1.617.2, B.1.617.1 and C.37 in our analysis even though these are currently important variants. In summary, we found that neutralizing titers are always highest against the homologous virus but that antigenic relationships are not necessarily symmetric and that some variant spike proteins induced more balanced responses (e.g. P.1) than others (B.1.351, B.1.1.7). In addition, the drop in binding antibody is much lower than the drop in neutralizing activity. Non-neutralizing binding antibodies have been shown to play an important role in protection for other diseases caused by virus infections including Ebola virus disease and influenza A and B virus [30–33]. The maintenance of binding antibody and T cell responses against variants could partially explain the maintenance of vaccine efficacy, despite the occasional steep drops in neutralizing antibody titers.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.06.455382: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: All experimental animal procedures were approved by the Institutional Animal Committee of the San Raffaele Scientific Institute and all infectious work was performed in designed BSL-3 workspaces.<br>Euthanasia Agents: Mice were euthanized by cervical dislocation.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Social scent-discrimination test: The social scent-discrimination test was used to assess hyposmia/anosmia in IN- infected or AR-infected male mice compared to PBS-treated control male mice, as previously described (Zheng et al., 2021).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In vivo treatment: In selected experiments, K18-hACE2 mice were injected intraperitoneally with 2 mg per mouse of α-IFNAR1 blocking antibody (BioXcell, #BE0241, clone MAR1-5A3) 1 day before infection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>α-IFNAR1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>#BE0241</div><div>suggested: (Bio X Cell Cat# BE0241, RRID:AB_2687723)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero E6 cells were seeded into 96 wells plates and infected at 95% of confluency with base 10 dilutions of virus stock.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mice: B6.Cg-Tg(K18-ACE2)2Prlmn/J mice (referred to in the text as K18-hACE2) were purchased from The Jackson Laboratory.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>B6.Cg-Tg(K18-ACE2)2Prlmn/J</div><div>suggested: RRID:IMSR_JAX:034860)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">As control, K18-hACE2 mice received the same volume of aerosolized PBS (125 μL per mouse).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>K18-hACE2</div><div>suggested: RRID:IMSR_GPT:T037657)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow cytometry analysis was performed on BD FACS Symphony A5 SORP and analyzed with FlowJo software (Treestar)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">RNA-seq data processing and analysis: Raw reads were aligned to mouse genome build GRCm38 using STAR aligner (Dobin et al., 2013)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STAR</div><div>suggested: (STAR, RRID:SCR_004463)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Gene counts were generated using featureCounts (part of the Subread package (Liao et al., 2019)), based on GENCODE gene annotation version M22.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>featureCounts</div><div>suggested: (featureCounts, RRID:SCR_012919)</div></div><div style="margin-bottom:8px"><div>GENCODE</div><div>suggested: (GENCODE, RRID:SCR_014966)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Differentially Expressed Genes (DEGs) between AR- and IN-infected mice were identified by generating a linear model using LIMMA R package (Ritchie et al., 2015) (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>LIMMA</div><div>suggested: (LIMMA, RRID:SCR_010943)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Bright-field images were acquired with an Aperio Scanscope System CS2 microscope and the ImageScope program (Leica Biosystem) following the manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageScope</div><div>suggested: (ImageScope, RRID:SCR_014311)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, anti-Iba1 (Synaptic system, #234006), anti-CD68 (Abcam #ab53444), and anti-iNOS (Abcam #ab3523).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Synaptic system</div><div>suggested: (Synaptic Systems, RRID:SCR_013612)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow and imaging data were collected using FlowJo Version 10.5.3 (Treestar) and Imaris (Bitplane), respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Imaris</div><div>suggested: (Imaris, RRID:SCR_007370)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analyses were performed with GraphPad Prism software version 8 (GraphPad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.05.455126: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: All donors provided explicit informed consent and the study was approved by the Medical Research Ethics Committee (Tc-BIO protocols 16-856 and 20/806).<br>IRB: All donors provided explicit informed consent and the study was approved by the Medical Research Ethics Committee (Tc-BIO protocols 16-856 and 20/806).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then, samples were washed three times in 0.1% Triton X-100 in PBS (v/v) for 20 minutes before the addition of corresponding secondary antibodies Alexa Fluor 488-, Alexa Fluor 594, Atto 647N, or Abberior STAR635p-conjugated anti-rabbit and anti-mouse together with DAPI and Phalloidin-Atto-647N (1:200) for 2 hours at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rabbit</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-mouse</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Phalloidin-Atto-647N</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibodies: Primary antibodies used in this study were rabbit anti-ACE2 (Sino Biological, #80031-RP02), mouse beta-tubulin IV (BioGenex, #MU178-UC), rabbit anti-Calnexin (Abcam, ab22595), mouse anti-CC10 (Origene, AM26360PU-N), Mouse-anti-CD63 (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-ACE2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-CC10</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Mouse-anti-CD63</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">DSHB Hybridoma Product H5C6, deposited to the DSHB by August, J.T. / Hildreth, J.E.K.), Mouse anti-Centriolin antibody (C-9, Santa Cruz Biotechnology, sc-365521)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Centriolin</div><div>suggested: (Santa Cruz Biotechnology Cat# sc-365521, RRID:AB_10851483)</div></div><div style="margin-bottom:8px"><div>C-9</div><div>suggested: (Santa Cruz Biotechnology Cat# sc-365521, RRID:AB_10851483)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, mouse anti-SARS CoV/SARS-CoV-2 Nucleocapsid (Sino Biological, #40143-MM08), rabbit anti-SARS CoV Nsp3 (Rockland, #100-401-A52), rabbit anti-SARS-CoV-2 Spike S1 (Sino Biological, # 40150-R007) and rabbit anti-TMPRSS2 (Atlas Antibodies, Cat# HPA035787).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS CoV/SARS-CoV-2 Nucleocapsid (Sino Biological, #40143-MM08),</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-SARS</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-SARS-CoV-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-TMPRSS2</div><div>suggested: (Sigma-Aldrich Cat# HPA035787, RRID:AB_2674782)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary antibodies were highly cross-adsorbed Alexa Fluor -488 or -594-conjugated goat antibodies against rabbit IgG or mouse IgG, IgG1 or IgG2A (Thermo Fisher Scientific), goat-anti-mouse and goat anti-rabbit Abberior STAR 635P and goat anti-mouse Atto 647N (Sigma-Aldrich), together with Atto 647N Phalloidin (ATTO-TEC) and DAPI (Sigma-Aldrich).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>-594-conjugated goat antibodies against rabbit IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>mouse IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgG1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgG2A</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>and goat anti-rabbit Abberior STAR</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Key resources table: Cells: Vero E6 cells and HEK293T cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) supplemented with 10% fetal calf serum (FCS, PAA laboratories), 100 Units/ml penicillin, 100 µg/ml streptomycin and 2mM L-glutamine.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The respective virus titer was determined by titration of infectious particles on Vero E6 cells (TCID50) and quantitative real-time reverse transcription-PCR (qRT-PCR) specific for the SARS-CoV-2 E gene [69].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmids and cloning: pMD2.G (Addgene#12259) and psPAX2 (Addgene #12260) were gifts from Didier Trono. pFUGW-mCherry-KASH (Addgene #131505,[49]) and pFUGW-spCas9 (Addgene #131506, [49]), pCAGS-PSD95FinR-GFP-TC and pORANGE-empty-FLAG-Cas9 were gifts from Harold MacGillavry. pORANGE-hsACE-GFP KI, a plasmid for C-terminal endogenous tagging of ACE2 using the ORANGE method of CRISPR/Cas9-based genome editing [49], was generated by ligating a primer dimer encoding the target sequence TCTGAACATCATCAGTGTTT into the BbsI sites of pORANGE-empty-FLAG-Cas9.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pMD2 . G</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>psPAX2</div><div>suggested: RRID:Addgene_12260)</div></div><div style="margin-bottom:8px"><div>pFUGW-mCherry-KASH</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pCAGS-PSD95FinR-GFP-TC</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pORANGE-empty-FLAG-Cas9</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">pFUGW-hsACE2-GFP-KI_mCherry-KASH, a lentiviral vector for C-terminal endogenous tagging of ACE2 was generated by subcloning the target sequence, gRNA scaffold and EGFP donor sequence, surrounded by target sequences, from pORANGE-hsACE-GFP KI into the PacI site of pFUGW-mCherry-KASH, by Gibson assembly cloning.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pFUGW-hsACE2-GFP-KI_mCherry-KASH</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lentiviral infection and gene editing: Lentivirus packaging was performed by using MaxPEI-based co-transfection of HEK293T cells with psPAX2, pMD2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pMD2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To generate ACE2-GFP knock-ins in differentiated HNEC, cells were transduced with 20 µl of each concentrated lentivirus, the first produced from pFUGW-spCas9, carrying spCas9 and the second produced from pFUGW-hsACE2-GFP-KI_mCherry-KASH, carrying the sgRNA targeting ACE2 exon 18, the EGFP donor module and the marker mCherry-KASH, labeling infected cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pFUGW-spCas9</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary antibodies were highly cross-adsorbed Alexa Fluor -488 or -594-conjugated goat antibodies against rabbit IgG or mouse IgG, IgG1 or IgG2A (Thermo Fisher Scientific), goat-anti-mouse and goat anti-rabbit Abberior STAR 635P and goat anti-mouse Atto 647N (Sigma-Aldrich), together with Atto 647N Phalloidin (ATTO-TEC) and DAPI (Sigma-Aldrich).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STAR</div><div>suggested: (STAR, RRID:SCR_004463)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The z-stacks were subjected to mild deconvolution using Huygens Professional software version 17.04 (Scientific Volume Imaging, The Netherlands) with the classic maximum likelihood estimation (CMLE) algorithm and the signal-to-noise ratio (SNR) parameter equal to 7 over 10 iterations.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Huygens Professional</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For segmentation in Figure 7G, the raw dataset was imported in ImageJ and was segmented for microvilli and cilia using the trainable Weka segmentation plugin [71] (https://zenodo.org/record/59290) in ImageJ.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 44. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.04.21261592: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Human specimens: All human specimens were obtained with oversight from the UAMS Institutional Review Board (IRB), and waiver of consent and HIPAA applied.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">An additional 5% of negative sera were randomly selected and tested in parallel.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Purified proteins were confirmed by Coomassie and western blot using antigen-specific antibodies and stored at -80°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antigen-specific</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Protein production and purification: HEK293T cells were cultured in Dulbecco’s minimum essential media (DMEM; Gibco) supplemented with 10% heat-inactivated calf serum (CS, VWR), 2 mM L-glutamine (Invitrogen), and 100 U/mL penicillin/100 µg/mL streptomycin (Invitrogen).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 15 cm dishes seeded with 9×106 cells on the preceding day were transfected with 20 µg of pCAGGS-SARS-CoV-2 Wuhan-Hu-1 RBD-C-terminal 6-His tag (BEI Resources), pCAGGS SARS-CoV-2</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS-SARS-CoV-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pCAGGS</div><div>suggested: RRID:Addgene_18926)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Wuhan-Hu-1 ectodomain Spike glycoprotein gene-C-terminal 6-His tag, or pCMV3 2019-nCoV</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCMV3</div><div>suggested: RRID:Addgene_161029)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Clinical and demographic variables were stored in a secure REDCap database16,17 and included age, sex, race/ethnicity, zip code, and county of residence.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>REDCap</div><div>suggested: (REDCap, RRID:SCR_003445)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were coated with 2 µg/mL RBD, spike, nucleoprotein, or bovine serum albumin (BSA; Sigma Aldrich) and FACT ELISA was performed as above.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BSA; Sigma Aldrich</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We conducted all analyses using SAS version 9.4 (SAS Institute).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SAS Institute</div><div>suggested: (Statistical Analysis System, RRID:SCR_008567)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. Author Response:

      Reviewer #1:

      The paper is very well written and the results are well presented. I only have minor comments.

      The introduction insists on the idea that the ability to regenerate might be ancestral (line 45) but convergent evolution is an extremely common phenomenon. The hypothesis of convergent evolution cannot be excluded here. In any case, whether convergence or ancestrality, one can ask whether the mechanisms underlying organ regeneration are the same in various taxa.

      We thank Reviewer 1 for all the helpful suggestions. We will make it clearer in the revised Introduction that the notion convergence still cannot be fully excluded.

      Reviewer #2:

      Weaknesses:

      The work presented on Drosophila is intriguing because the adult legs of flies were not thought to be capable of any regeneration. One of the major constraints is that growth in arthropods is limited by the hard exoskeleton (cuticle) surrounding the body. Periodic molting allows these animals to grow in a stepwise fashion (shedding the old cuticle and forming a new one), but adult flies do not molt, so it is unclear how an adult regenerating leg would break that constraint. Abrams et al. report that a small proportion (~1%) of amputated legs regrow part of the limb when the flies are kept on a medium supplemented with leucine, glutamine and human insulin. The number of legs in which this has been observed is small and the extent of regeneration is variable and not well documented in relation to the site of amputation (which is unmarked). A more detailed documentation of the regrowth would be needed to validate the authors conclusions.

      We thank Reviewer 2 for the more detailed suggestions in the full review. In the present data, our conclusion is enabled by the non-ambiguous phenotype: there are fully regrown tibias in the treated population, and there are none in the (now) over >1000 control flies examined. In the revised manuscript, we will include as the Reviewer suggested new extensive documentation to show single-fly tracking.

      The work on mice focuses on the regeneration of digit tips, a relatively well-studied example of limited regeneration in these rodents. Mice are known to be able to regenerate the tips of their digits when these are amputated near the distal end, but cuts proximal to the base of the nail fail to regenerate. The authors focus on regeneration of digits amputated near this boundary. They report that animals whose drinking water is supplemented with leucine, glutamine and sucrose are more likely to regenerate part of their digit tips when amputated at the base of the nail. These data are intriguing, but the number of observations is limited (few digits with patterned regeneration) and variation in the site amputation does not make it easy to draw firm conclusions on the extent of regeneration compared with controls.

      We perform digit amputation proximal to the established non-regenerating boundary (see red line in Figure 6c-d), and far from the regenerating boundary (see blue line in Figure 6c-d). Moreover, as a control, for every digit amputated, the part removed was fixed, stained, and documented to enable precise definition of the amputation plane. The sample sizes in the study (20 control digits, 48 treated digits) enable statistical power, and are comparable to experiments in adult mouse digit (e.g., n~15 digits PMID: 24209617, n~20 digits PMID: 28975034).

      Overall, the authors propose that similar nutritional interventions have similar effects in 'inducing' regeneration in widely divergent animals, revealing a widespread intrinsic capacity of animals to regenerate. The claim that these treatments 'induce' regeneration seems exaggerated, given that appendage regeneration in Aurelia and in mouse digits can occur to a variable extent in untreated animals. These treatments appear to shift the probability and the extent of regeneration. The data on Drosophila legs are more surprising and deserve further analysis.

      We have been careful in the manuscript to use the phrase “promote regeneration” to describe the findings in Aurelia because the spontaneous partial regeneration observed in the natural habitat. In the mouse digit, however, the boundaries of regenerating and non-regenerating cuts have been clearly established (by multiple studies, e.g., PMID: 28493324, PMID: 7100922, PMID: 18234177, PMID: 17147657), which enables the question of how to induce regeneration from proximal cuts posed and pursued (e.g., PMID: 30723209, PMID: 20110320). We believe therefore in this case, our choice of wording is validated by the scientific context and precedents in the mouse digit field.

      The idea that the same nutritional interventions may have similar effects on regeneration in diverse animals is intriguing. A minor caveat: the nutritional interventions tested in each species were not identical; in Aurelia high-nutrient, insulin and leucine treatments were tested separately, in Drosophila leucine and insulin were combined, in the mouse leucine and sucrose were combined. Future work could determine which components in these treatments (nutritional, metabolic or hormonal) are responsible for the observed responses in each species.

      We agree with the Reviewer. We will make it clearer in the revised Discussion the differences in the molecule administration across species, and that further studies will determine the specific underlying mechanisms, in spite of which, we could excitingly move across species in a predictive manner.

      Reviewer #3:

      Weaknesses:

      The evolutionary statement underlying the entire study is not fully accurate. While it is true that many animal phyla include species that can regenerate and also that some studies start to identify common molecular components in regeneration, the question of regeneration being ancestral or not is still debated. It is indeed highly tempting to consider regeneration as ancestral but this is not proven yet (see Lai and Aboobaker 2017) and the possibility of convergence have to be considered too. In addition, appendage regeneration versus whole body regeneration versus structure or organ regeneration may not rely on similar mechanisms.

      We thank Reviewer 3 for the helpful feedback in the detailed review. We are making it clearer in the revised Introduction that the notion of convergence still cannot be fully excluded since convergences can be very common.

      The strategy put in place for identifying putative triggers is questionable and more information about, (i) the reasons to select and test such parameters, (ii) what the different drugs are doing in theory (components of signaling pathways targeted, for ex), (iii) how exactly the various tests have been done, frequency of scoring, different concentration tested, number of individuals per condition, frequency of drug administration etc etc are missing. It appears really surprising that no modulators of signaling pathways (notably the wnt b catenin, known to be involved in many developmental and regeneration contexts, especially in cnidarians) are involved in any sort in such process.

      We will include in the revised manuscript more extensive details about the screen parameters and procedures. Briefly here, similar experimental designs as those described for the main experiments were used. With regard to the Wnt pathway, we tried two inhibitors against GSK3beta, two inhibitors against tankyrase, and a Wnt ligand itself—none so far has shown effects that motivated further follow-up. Nonetheless, we will emphasize more explicitly in the revision that the negative result conclusion can only be specific to the conditions and the modulators used, and that this has by no means ruled out the involvement of developmental pathways in all capacities.

      Concerning the results with cnidarians, two aspects puzzle me: the high variability in the regenerative response between batches and the way the amputations were done in ephyra. In the context of appendage regeneration, what justify to perform an amputation that remove almost the half body of the ephyra and not just one arm. Basic information about regeneration occurrence in the context of amputation of only one arm are missing.

      We find the variability intriguing too. Some of the variability may arise from technical variations or stochasticity inherent in biological processes. There may also be key physiological parameters yet to be identified; We are continuing screening in the lab to search for factors that may synergize with leucine and insulin, and quantify differences between regenerating vs non-regenerating individuals. Finally, the variability may support the idea that the regeneration we are seeing has been evolutionarily inactivated, and may therefore have drifted over tens or hundreds of years and consequently does not exhibit the robustness we are used to seeing in wild-type processes.

      With regard to the amputation scheme, we tested various amputation schemes and observed similar results (this will be included in the revised manuscript). The amputation scheme chosen was the fastest to do, which facilitates testing thousands of ephyrae. We will add this rationale in the revised Methods. With the amputation scheme chosen, arm regeneration is the most dramatic outcome. However, the reviewer is correct that the body is also partially regenerated, which suggests to us that L-leucine and sugar/insulin may have regenerative effect beyond the context of appendage. We include this discussion in the revised manuscript.

      More importantly, the results shown, sometimes in extremely low proportions compared to the controls (ie in the case of drosophila), are not supported by other approaches. It would be really important to have some clues about the molecular mechanisms underlying such process and its induction.

      We agree with the Reviewer that mechanistic investigation into the underlying molecular mechanism is the next immediate challenge, and is underway in the lab. In the scope of the present work, the focus is on seeing if regeneration can be induced at all and the comparative presence of such latent ability. This was itself an enormous effort, but one that enables laying the groundwork for directing mechanistics investigations and broader pursuit of promoting regeneration across animals.

    2. Reviewer #3 (Public Review): 

      In this article, Abrams et al. aim at identifying a potential conserved strategy for inducing appendage regeneration in Metazoa. Appendage regeneration is a process shared by many animal lineages, raising the possibility of a common strategy at play. Using a large-scale screening of molecular and physical putative modulators of regeneration, they identify the amino acid L-leucine and the growth hormone insulin/sucrose as molecules potentially able to trigger appendages regeneration in three species, the cnidarian Aurelia, the ecdyzosoan Drosophila and the mammal Mus musculus. The question addressed in this paper is really interesting and some results, especially in Drosophila and Mus musculus, are intriguing but need to be confirmed and extended. 

      Strengths: 

      One main strength of this study is the use of three different models to approach a biological question in a comparative manner. Such a strategy is still rare and the authors are commended for it. 

      An impressive number of various molecular and physical putative modulators was screened in Aurelia. 

      While not being a specialist, statistics appeared to be performed in a correct manner and the number of individuals used in the different experiments is appropriate. 

      Results showing tibia regeneration in Drosophila and digit regeneration in adult mice are impressive. 

      Weaknesses: 

      The evolutionary statement underlying the entire study is not fully accurate. While it is true that many animal phyla include species that can regenerate and also that some studies start to identify common molecular components in regeneration, the question of regeneration being ancestral or not is still debated. It is indeed highly tempting to consider regeneration as ancestral but this is not proven yet (see Lai and Aboobaker 2017) and the possibility of convergence have to be considered too. In addition, appendage regeneration versus whole body regeneration versus structure or organ regeneration may not rely on similar mechanisms. 

      The strategy put in place for identifying putative triggers is questionable and more information about, (i) the reasons to select and test such parameters, (ii) what the different drugs are doing in theory (components of signaling pathways targeted, for ex), (iii) how exactly the various tests have been done, frequency of scoring, different concentration tested, number of individuals per condition, frequency of drug administration etc etc are missing. It appears really surprising that no modulators of signaling pathways (notably the wnt b catenin, known to be involved in many developmental and regeneration contexts, especially in cnidarians) are involved in any sort in such process. 

      Concerning the results with cnidarians, two aspects puzzle me: the high variability in the regenerative response between batches and the way the amputations were done in ephyra. In the context of appendage regeneration, what justify to perform an amputation that remove almost the half body of the ephyra and not just one arm. Basic information about regeneration occurrence in the context of amputation of only one arm are missing. 

      More importantly, the results shown, sometimes in extremely low proportions compared to the controls (ie in the case of drosophila), are not supported by other approaches. It would be really important to have some clues about the molecular mechanisms underlying such process and its induction.

    1. SciScore for 10.1101/2021.08.02.21261504: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: Study participants: Paired DBS and plasma specimens were collected from COVID-19 convalescent and SARS-CoV-2 vaccinated individuals enrolled as part of the Hospitalized or Ambulatory Adults with Respiratory Viral Infections (HAARVI) research study in Seattle, Washington.<br>Consent: All participants completed informed consent as approved by the University of Washington Institutional Review Board (protocol #STUDY00000959).<br>IRB: All participants completed informed consent as approved by the University of Washington Institutional Review Board (protocol #STUDY00000959).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary antibody was prepared by diluting goat anti-human IgG-horseradish peroxidase (Sigma #A0170) to 1:2,500 in blocking buffer (2.24 µg/mL).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG-horseradish</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T cells were added to 6-well plates at 5 x 105 cells per well in DMEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and penicillin/streptomycin/fungizone.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">4 HEK293T-ACE2 cells in 96-well black-walled plates and, after 16-24 hours, adding 100 µL of diluted viral supernatant per well in duplicate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T-ACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Duplicate OD450 measurements were averaged and IgG concentrations in plasma and DBS eluates were interpolated from the standard curve using the five-parameter logistic equation function in GraphPad Prism 8.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The following point dilutions were assessed: 1:400 for participant plasma and negative control normal human serum (Gemini Biosciences #100-110, lot H87WOOK), 1:20 for VB DBS eluates, and 1:40 for FS DBS eluates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gemini Biosciences</div><div>suggested: (Penn Cell Center Stockroom, RRID:SCR_010003)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Figure 1 was created in BioRender.com.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BioRender</div><div>suggested: (Biorender, RRID:SCR_018361)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The remaining figures were generated using RStudio.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RStudio</div><div>suggested: (RStudio, RRID:SCR_000432)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your code.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. Author Response:

      Reviewer #1 (Public Review):

      This paper aims to address the question of whether the rotational dynamics in motor cortex may be due to sensory feedback signals rather than to recurrent connections and autonomous dynamics as is typically assumed. This is indeed a question of importance in neural control of movement.

      The authors employ both analyses of motor cortical data and simulation analyses where a neural network is trained to perform a motor task. For the simulations, the authors use a neural network model of a brain performing arm control tasks. Importantly, in addition to the task goals, the brain also receives delayed sensory feedback from the muscle activity and kinematics of the simulated arm. The brain is modeled either using a stack of two recurrent neural networks (RNN) or using two non-recurrent neural network layers to investigate the importance of autonomous recurrent dynamics. The authors use this framework to simulate the brain performing two tasks: 1) posture perturbation task, where the arm is perturbed by external loads and has to return to original posture, and 2) delayed center-out reach task. In both tasks, the authors apply jPCA to units of the trained network, simulated muscle activity, and simulated kinematics and investigate their rotational dynamics. They find that when using an RNN in the brain model, both the RNN layers and kinematics show rotational dynamics but the muscle activity does not. Interestingly, these conclusions for both tasks also hold when networks without recurrent connections are used instead of the RNNs. Also importantly, the rotational dynamics also exist in the sensory feedback signals about the limb state (e.g. joint position, velocity). These results suggest that recurrent dynamics are not necessary for the emergence of rotational dynamics in population activity, rather sensory feedback can also achieve the same.

      The authors perform similar jPCA analyses on monkey motor cortical (MC) or somatosensory cortical activity during the same two tasks and find largely consistent results. As with simulations, neural population activity and kinematics show rotational dynamics but muscle activity, which is explored only in the posture task, does not. Importantly, population activity in both motor and somatosensory cortices shows rotational dynamics. This observation is more consistent with the view that rotational dynamics emerge due to inter-region communications and processing of sensory feedback and planning, rather than autonomous dynamics within the motor cortex.

      The approach of the paper is interesting and valuable and the questions being addressed are very important to the field. To further improve the paper and the analyses, there are several major comments that should be addressed to fully support the conclusions and clarify the results:

      Major:

      1) In the Methods, the authors explain how they model a non-recurrent network as follows: "We also examined networks where we removed the recurrent connections from each layer by effectively setting Whh, Woo to zero for the entire simulation and optimization (NO-REC networks)". However, if this is the only modification, it still leaves recurrent elements in the network. For example, if we set W_{hh} to zero, equation 2 will be:

      h_{t+1} = (1-a) h_t + a tanh(W_{sh} * s_t + b_h)

      where a is a constant scalar (seems to be equal to 0.5). This is indeed still a recurrent neural network since h_{t+1} depends on ht. If their explanation in the Methods is accurate, then the current approach restricts the recurrent dynamics to be a specific linear dynamic (i.e. "h{t+1} = (1-a) ht + …") but does not fully remove them. The second layer is also similar (equation 3) and will still have recurrent linear dynamics even if W{oo} is set to 0. To be able to describe networks as non-recurrent, the first terms in equations 2 and 3 (that is (1-a)h_t and (1-a)o_t) should also be set to 0. This is critical as an important argument in the paper is that non-recurrent networks can also produce rotational dynamics, so the networks supporting that argument must be fully non-recurrent. Perhaps the authors have already done this but just didn't explain it in the Methods, in which case they should clarify the Methods. However, if the current Method description is accurate, they should rerun their NO-REC simulations by also setting the fixed linear recurrent components (that is (1-a)h_t and (1-a)*o_t) to zero as explained above to have a truly non-recurrent model.

      We thank the reviewer for raising this important concern. We have re-simulated the NO-REC network while removing the dynamics related to the leaky-integration component. This removal did not impact the network’s ability to perform the tasks and yielded virtually identical neural dynamics (see Figure 8). Throughout the Results we have updated the figures for the NO-REC network to the network without the leak-integration component.

      2) Assuming my comment in 1 is addressed and the results stay similar, the authors show in simulations that even without recurrent dynamics (referred to as the NO-REC case), rotational dynamics are observed in the simulated brain during both tasks (Figure 8). This result is used to suggest that the sensory feedback is what causes the rotational dynamics in the brain model in this case. However, I think to fully demonstrate the role of feedback, additional simulations are also needed where the sensory feedback is removed from the brain model. In other words, what would happen if recurrent and non-recurrent brain models are trained to perform the tasks but are not provided with the sensory feedback (only receive task goals)? One would expect the recurrent model to still be able to perform the task and autonomously produce similar rotational dynamics (as has been shown in prior work), but the non-recurrent model to fail in doing the task well and in showing rotational dynamics. I think adding such simulations without the feedback signals would really strengthen the paper and help its message.

      We apologize if the network architecture was not clear. In the case of the NO-REC network the only way they can generate the time-varying signals needed for the tasks is through sensory feedback. The network simply will not work without recurrent AND sensory feedback. For the posture task there are no additional inputs since it only receives sensory feedback. For the reaching task the task-goal input is static and the GO cue turns off on a timescale considerably shorter (~20ms) than the reach duration. Thus, the REC network would always perform better than the NO-REC network when sensory feedback was removed as the NO-REC network cannot generate any dynamics. We have now included in the Results the following statement. "Note, by removing the recurrent connections these networks can only generate time-varying outputs by exploiting the time-varying sensory inputs from the limb." (line 345-347).

      We have also now included simulations to highlight how REC networks that receive sensory feedback are able to generalize better to scenarios with increased motor noise than REC networks where sensory feedback is either completely removed (reaching task) or only provided at the beginning of the trial (posture task) (Figure S8). Thus, sensory feedback makes REC networks more robust in less predictable scenarios.

      We agree that this could be an interesting manipulation and have now included manipulations of the sensory feedback delays. We considered three separate delays, 0ms, 50ms and 100ms and found that there was a dependence on the rotational frequency of the top jPC plane with greater delays resulting in a general reduction in frequency (see now Supplementary Figure 10). There was less effect of delay on fit qualities to the constrained and unconstrained dynamical system. This has been added to the Results section (line 423-446).

      We simulated this scenario and found the answer to be rather complex and we have added these results to the supplementary material. The network's behavioural performance in the perturbation posture task is similar to the previous networks with joint-based feedback. However, the dynamics in the output layer are not the same with a clear reduction in how well the dynamics are described as rotational (Figure S11A-B).

      Oddly, rotational dynamics could still be observed in the input layer dynamics (data now shown) and the kinematic signals when they were converted to a cartesian reference frame (Figure S11D-E). Furthermore, rotational dynamics could emerge in the output layer if we used a different initialization method for the network weights. We initialized weights from a uniform distribution bound from ±1/√N, where N is the number of units. In contrast, previous studies have initialized network weights using a Gaussian distribution with standard deviation equal to g/√N where g is constant larger than 1. This alternative initialization scheme encourages strong intrinsic dynamics often needed for autonomous RNN models (Sussillo et al., 2015). We found networks initialized with this method and trained on the perturbation posture task exhibited stronger rotational dynamics with fits to the constrained and unconstrained dynamical systems of 0.5 and 0.88, respectively (Figure S11C-D). When examining the reaching task, we found similar results (Figure S11F-K). When initialized with a uniform distribution, fit quality for the constrained and unconstrained dynamical systems were 0.4 and 0.77, respectively (Figure S11F-G), which were smaller than for the joint-based feedback (Figure 7B, constrained R2=0.7, unconstrained R2=0.83). Qualitatively, the dynamics were different when the network was initialized with a Gaussian distribution (Figure S11H), however fit qualities were comparable between the two initialization methods (Figure S11 I). There was also a noticeable reduction in the fit quality for the kinematic signals particularly for the constrained dynamical system (Figure S11K, constrained R2=0.36, unconstrained R2=0.77). These findings have been added to the Results

      3) A measure of how well each trained network is able to perform the task should be provided. For example, is the non-recurrent network able to perform the tasks as accurately as the recurrent models? The authors could use an appropriate measure, for example average displacement in the posture task and time-to-target in the center-out task, to objectively quantify task performance for each network. Another performance measure could be the first term of the loss in equation 5. Also, plots of example trials that show the task performance should be provided for the non-recurrent networks (for example by adding to Figure 8), similar to how they are shown for the recurrent models in Figures 2 and 6.

      We have now presented and quantified the NO-REC network behavioural performance. Kinematics for the NO-REC network are shown in Figure S7A-C and E-G which are comparable to the REC network. Furthermore, quantifying the maximum displacement during the posture task yielded no obvious differences between the NO-REC and REC networks (Figure S7D). For the reaching task, the time-to-target was noticeably more variable and tended to be slower for the NO-REC network (Figure S7H). These observations have been added to the Results.

      4) An important observation is that rotational dynamics also exist in the sensory signals about the limb state. This may imply that the task structure that dictates the limb state and thus the associated sensory feedback may play an important role in the rotations without the recurrent connections. While the present study will be a valuable addition regardless of what the answer is, this is an important point to address: What is the role of the task structure in producing rotational dynamics? In both the posture task and the center-out task, the task instruction instructs subjects to return to the initial movement 'state' by the end of the trial: in the posture task the simulated arm needs to return to the original posture upon disturbance, and in the center out task the arm needs to start from zero velocity and settle at the target with zero velocity. Is this structure what's causing the rotational dynamics? This is an important question both for this paper and for the field and the authors have a great simulation setup to explore it. For example, what happens if the task instructions u* instruct the arm to follow a random trajectory continuously, instead of stopping at some targets? With a simulated tracking task like this, one could eliminate obvious cases of return-to-original-state from the task. Would the network still produce rotational dynamics? Of course, I don't expect the authors to collect experimental monkey data for such new tasks, rather to just change the task instructions in their numerical simulations to explore the dependence of observed rotational dynamics on the task structure. I think this will help the message of the paper and can be very useful for the field.

      We agree that a tracking task would be an interesting manipulation and have simulated this with the REC and NO-REC networks (Figure 9). Here, we trained up the network to reach from the starting position and track a target moving radially at a constant velocity for the rest of the trial (1.2seconds). Thus, the network has to move the limb at a constant velocity. We found there was a consistent reduction in how well the network’s dynamics (constrained R2=0.13, unconstrained R2=0.3) were described as rotational when compared to the previous reaching task (Figure 7, constrained R2=0.7, unconstrained R2=0.83). Also, note that this reduction in rotational dynamics remained even when we initialized the network weights using a Gaussian distribution (see Essential revision 2.3). These simulations have been added to the Results section.

      5) It would be beneficial if the authors could elaborate in the discussion on intuitive explanations of why sensory feedback can produce rotational dynamics even with no internal recurrent dynamics in the brain model. To me, it seems like sensory feedback is providing a path for recurrence to exist in the overall brain-arm system, so the non-recurrent neural networks can learn to exploit that path to effectively implement some recurrent dynamics. Some intuitive explanations like this will be helpful for readers.

      The main reason why rotational dynamics emerge in sensory feedback is due to the phase offset between the joint position and velocity as changes first occur in the velocity followed by position (see pendulum example Pandarinath et al., 2018a also DeWolf et al., 2016; Susilaradeya et al., 2019). This phase offset is maintained across reach directions and gives rise to the orderly rotational dynamics observed in the kinematic signals (DeWolf et al., 2016; Pandarinath et al., 2018a; Susilaradeya et al., 2019; Vyas et al., 2020). Furthermore, the tracking task disrupted this phase relationship and thus the rotational dynamics were substantively reduced in the network models. This text has been added to the Discussion (lines 519-526).

      6) One main result in data from non-human primates is that there exist rotations also in the somatosensory cortex not just in motor cortex. A more thorough discussion of prior work on rotational dynamics or lack thereof across brain regions and behavioral tasks is important to add here. For example, besides the works cited by the authors, there are other works such as (Kao et al., 2015; Gao et al., 2016; Remington et al., 2018; Stavisky et al., 2019; Aoi et al., 2020; Sani et al., 2021) that discuss or show rotational dynamics in various brain regions and behavioral tasks and should be cited and discussed.

      We have cited the above papers and included in the Discussion the following paragraph (lines 537-549) “Importantly, findings of rotational dynamics in cortical circuits are not trivial. Activity in the supplementary motor area does not exhibit rotational dynamics during reaching (Lara et al., 2018). The hand area of MC also does not exhibit rotational dynamics during grasping-only behaviour (Suresh et al., 2020), though it does exhibit rotational dynamics during reach-to-grasp (Abbaspourazad et al., 2021; Rouse and Schieber, 2018) which may reflect the reaching component of the behaviour. More broadly there is a growing body of work characterizing cortical neural dynamics across different behavioural tasks which have revealed rotational (Abbaspourazad et al., 2021; Aoi et al., 2020; Libby and Buschman, 2021; Remington et al., 2018; Sohn et al., 2019; Stavisky et al., 2019), helical (Russo et al., 2020), stationary (Machens et al., 2010), and ramping dynamics (Finkelstein et al., 2021; Kaufman et al., 2016; Machens et al., 2010) and these dynamics appear to support various classes of computations. Thus, finding rotational dynamics across the fronto-parietal circuit in our study is not trivial."

      7) The authors state that "In contrast, rotational dynamics appear to be absent in… MC activity during grasping driven by sensory inputs (Suresh et al., 2020)." There are other papers that study dynamics during reach-grasps and still finds rotational dynamics and modes (Abbaspourazad et al., 2021; Vaidya et al., 2015) and should be cited and discussed. The recent paper on naturalistic reach-grasps (Abbaspourazad et al., 2021) also argues for the involvement of a large-scale network in these movements, which further supports the authors' interpretation that "This interpretation of motor control emphasizes that the objective of the motor system is to attain the behavioural goal and this requires feedback processed by a distributed network." A discussion of this point made in this recent paper in the intro/discussion is important. Finally, there is a recent paper that argues for the input-driven nature of motor cortex (Sauerbrei et al., 2020) and is cited/discussed by the authors but briefly and mainly in the discussion. I think given the relevance of this recent paper to the core message here, it should also be briefly discussed in the introduction to better set up the work.

      We agree with the reviewer that there are discrepancies between the motor cortical dynamics reported by Suresh et al. 2020 and Abbaspourazad et al., 2021 during grasping tasks. This difference may reflect differences in task as in Suresh et al. 2020 the monkeys grasped objects whereas in Abbaspourazad et al., 2021 monkeys had to reach and grasp objects. Thus, rotations may reflect the reaching component of the behaviour. This has been elaborated on in the Discussion which now reads (lines 539-542) “The hand area of MC also does not exhibit rotational dynamics during grasping-only behaviour (Suresh et al., 2020), though it does exhibit rotational dynamics during reach-to-grasp (Abbaspourazad et al., 2021; Rouse and Schieber, 2018; Vaidya et al., 2015) which may reflect the reaching component of the behaviour.”.

      We have also briefly mentioned the findings by Sauerbrei et al. 2020 in the Introduction which now reads (line 79-81) “Lastly a recent study demonstrates that motor cortical dynamics are driven by inputs coming from motor thalamus (Sauerbrei et al., 2020)."

      Minor:

      1) The Methods are clear and comprehensive, but just to make understanding of the simulation setup easier, it would help to have a diagram of the computation graph for the recurrent and non-recurrent networks that shows their number of units, activations/nonlinearities, RNN cell type, etc., added as supplementary figure.

      We agree that this is useful and have added it to Figure 1

      2) Again, to help more clearly convey the simulations, it would help to show the task goals (x*) that are inputs to the simulated brain for example trials in each task (for example added to Figures 2 and 6).

      We agree that this is useful and have added it to Figure 1

      3) Similar to how VAF is shown on top of all plots of jPC planes, it would be helpful to have the rotation frequency for each jPC plane noted next to it. Currently it is difficult to find the jPC frequency associated with each plot from the text.

      We agree and have added it to the appropriate figures

      4) I am a bit surprised by how different the null distributions are for modeling muscle activity (Figure 3F) and kinematics (Figure 3H). The null distribution is simply the R2 for a constrained or unconstrained dynamic model fit to a subsampled version of the neural activity. The only difference between the null distributions in Figure 3F and Figure 3H seems to be the downsampled dimension, which for muscle activity is 6 and for kinematics is 4 (per equation 1). Any insight will be welcome as to why down sampling the population activity to 4 (Figure 3H) results in so much worse R2 compared with down sampling it to 6 (Figure 3F)?

      We thank the reviewer for raising this concern. Originally, we had applied PCA to reduce the dimensionality of the kinematic signals from 4 dimensions to 2, and the muscle signals from 6 to 4. We realize now that to be more conservative in our significance testing, we should use the full dimensionality of the kinematic and muscle signals. As such, we have changed the figures throughout to reflect this.

      References:

      Abbaspourazad, H., Choudhury, M., Wong, Y.T., Pesaran, B., Shanechi, M.M., 2021. Multiscale low-dimensional motor cortical state dynamics predict naturalistic reach-and-grasp behavior. Nature Communications 12, 607. https://doi.org/10.1038/s41467-020-20197-x

      Aoi, M.C., Mante, V., Pillow, J.W., 2020. Prefrontal cortex exhibits multidimensional dynamic encoding during decision-making. Nature Neuroscience 1-11. https://doi.org/10.1038/s41593-020-0696-5

      Gao, Y., Archer, E.W., Paninski, L., Cunningham, J.P., 2016. Linear dynamical neural population models through nonlinear embeddings, in: Lee, D.D., Sugiyama, M., Luxburg, U.V., Guyon, I., Garnett, R. (Eds.), Advances in Neural Information Processing Systems 29. Curran Associates, Inc., pp. 163-171.

      Kao, J.C., Nuyujukian, P., Ryu, S.I., Churchland, M.M., Cunningham, J.P., Shenoy, K.V., 2015. Single-trial dynamics of motor cortex and their applications to brain-machine interfaces. Nature Communications 6, 7759. https://doi.org/10.1038/ncomms8759

      Remington, E.D., Narain, D., Hosseini, E.A., Jazayeri, M., 2018. Flexible Sensorimotor Computations through Rapid Reconfiguration of Cortical Dynamics. Neuron 98, 1005-1019.e5. https://doi.org/10.1016/j.neuron.2018.05.020

      Sani, O.G., Abbaspourazad, H., Wong, Y.T., Pesaran, B., Shanechi, M.M., 2021. Modeling behaviorally relevant neural dynamics enabled by preferential subspace identification. Nature Neuroscience 24, 140-149. https://doi.org/10.1038/s41593-020-00733-0

      Stavisky, S.D., Willett, F.R., Wilson, G.H., Murphy, B.A., Rezaii, P., Avansino, D.T., Memberg, W.D., Miller, J.P., Kirsch, R.F., Hochberg, L.R., Ajiboye, A.B., Druckmann, S., Shenoy, K.V., Henderson, J.M., 2019. Neural ensemble dynamics in dorsal motor cortex during speech in people with paralysis. eLife 8, e46015. https://doi.org/10.7554/eLife.46015

      Vaidya, M., Kording, K., Saleh, M., Takahashi, K., Hatsopoulos, N.G., 2015. Neural coordination during reach-to-grasp. Journal of Neurophysiology 114, 1827-1836. https://doi.org/10.1152/jn.00349.2015

    2. Reviewer #1 (Public Review):

      This paper aims to address the question of whether the rotational dynamics in motor cortex may be due to sensory feedback signals rather than to recurrent connections and autonomous dynamics as is typically assumed. This is indeed a question of importance in neural control of movement.

      The authors employ both analyses of motor cortical data and simulation analyses where a neural network is trained to perform a motor task. For the simulations, the authors use a neural network model of a brain performing arm control tasks. Importantly, in addition to the task goals, the brain also receives delayed sensory feedback from the muscle activity and kinematics of the simulated arm. The brain is modeled either using a stack of two recurrent neural networks (RNN) or using two non-recurrent neural network layers to investigate the importance of autonomous recurrent dynamics. The authors use this framework to simulate the brain performing two tasks: 1) posture perturbation task, where the arm is perturbed by external loads and has to return to original posture, and 2) delayed center-out reach task. In both tasks, the authors apply jPCA to units of the trained network, simulated muscle activity, and simulated kinematics and investigate their rotational dynamics. They find that when using an RNN in the brain model, both the RNN layers and kinematics show rotational dynamics but the muscle activity does not. Interestingly, these conclusions for both tasks also hold when networks without recurrent connections are used instead of the RNNs. Also importantly, the rotational dynamics also exist in the sensory feedback signals about the limb state (e.g. joint position, velocity). These results suggest that recurrent dynamics are not necessary for the emergence of rotational dynamics in population activity, rather sensory feedback can also achieve the same.

      The authors perform similar jPCA analyses on monkey motor cortical (MC) or somatosensory cortical activity during the same two tasks and find largely consistent results. As with simulations, neural population activity and kinematics show rotational dynamics but muscle activity, which is explored only in the posture task, does not. Importantly, population activity in both motor and somatosensory cortices shows rotational dynamics. This observation is more consistent with the view that rotational dynamics emerge due to inter-region communications and processing of sensory feedback and planning, rather than autonomous dynamics within the motor cortex.

      The approach of the paper is interesting and valuable and the questions being addressed are very important to the field. To further improve the paper and the analyses, there are several major comments that should be addressed to fully support the conclusions and clarify the results:

      Major:

      1) In the Methods, the authors explain how they model a non-recurrent network as follows: "We also examined networks where we removed the recurrent connections from each layer by effectively setting Whh, Woo to zero for the entire simulation and optimization (NO-REC networks)". However, if this is the only modification, it still leaves recurrent elements in the network. For example, if we set W_{hh} to zero, equation 2 will be:

      h_{t+1} = (1-a) * h_t + a * tanh(W_{sh} * s_t + b_h)

      where a is a constant scalar (seems to be equal to 0.5). This is indeed still a recurrent neural network since h_{t+1} depends on h_t. If their explanation in the Methods is accurate, then the current approach restricts the recurrent dynamics to be a specific linear dynamic (i.e. "h_{t+1} = (1-a) * h_t + ...") but does not fully remove them. The second layer is also similar (equation 3) and will still have recurrent linear dynamics even if W_{oo} is set to 0. To be able to describe networks as non-recurrent, the first terms in equations 2 and 3 (that is (1-a)*h_t and (1-a)*o_t) should also be set to 0. This is critical as an important argument in the paper is that non-recurrent networks can also produce rotational dynamics, so the networks supporting that argument must be fully non-recurrent. Perhaps the authors have already done this but just didn't explain it in the Methods, in which case they should clarify the Methods. However, if the current Method description is accurate, they should rerun their NO-REC simulations by also setting the fixed linear recurrent components (that is (1-a)*h_t and (1-a)*o_t) to zero as explained above to have a truly non-recurrent model.

      2) Assuming my comment in 1 is addressed and the results stay similar, the authors show in simulations that even without recurrent dynamics (referred to as the NO-REC case), rotational dynamics are observed in the simulated brain during both tasks (Figure 8). This result is used to suggest that the sensory feedback is what causes the rotational dynamics in the brain model in this case. However, I think to fully demonstrate the role of feedback, additional simulations are also needed where the sensory feedback is removed from the brain model. In other words, what would happen if recurrent and non-recurrent brain models are trained to perform the tasks but are not provided with the sensory feedback (only receive task goals)? One would expect the recurrent model to still be able to perform the task and autonomously produce similar rotational dynamics (as has been shown in prior work), but the non-recurrent model to fail in doing the task well and in showing rotational dynamics. I think adding such simulations without the feedback signals would really strengthen the paper and help its message.

      3) A measure of how well each trained network is able to perform the task should be provided. For example, is the non-recurrent network able to perform the tasks as accurately as the recurrent models? The authors could use an appropriate measure, for example average displacement in the posture task and time-to-target in the center-out task, to objectively quantify task performance for each network. Another performance measure could be the first term of the loss in equation 5. Also, plots of example trials that show the task performance should be provided for the non-recurrent networks (for example by adding to Figure 8), similar to how they are shown for the recurrent models in Figures 2 and 6.

      4) An important observation is that rotational dynamics also exist in the sensory signals about the limb state. This may imply that the task structure that dictates the limb state and thus the associated sensory feedback may play an important role in the rotations without the recurrent connections. While the present study will be a valuable addition regardless of what the answer is, this is an important point to address: What is the role of the task structure in producing rotational dynamics? In both the posture task and the center-out task, the task instruction instructs subjects to return to the initial movement 'state' by the end of the trial: in the posture task the simulated arm needs to return to the original posture upon disturbance, and in the center out task the arm needs to start from zero velocity and settle at the target with zero velocity. Is this structure what's causing the rotational dynamics? This is an important question both for this paper and for the field and the authors have a great simulation setup to explore it. For example, what happens if the task instructions u* instruct the arm to follow a random trajectory continuously, instead of stopping at some targets? With a simulated tracking task like this, one could eliminate obvious cases of return-to-original-state from the task. Would the network still produce rotational dynamics? Of course, I don't expect the authors to collect experimental monkey data for such new tasks, rather to just change the task instructions in their numerical simulations to explore the dependence of observed rotational dynamics on the task structure. I think this will help the message of the paper and can be very useful for the field.

      5) It would be beneficial if the authors could elaborate in the discussion on intuitive explanations of why sensory feedback can produce rotational dynamics even with no internal recurrent dynamics in the brain model. To me, it seems like sensory feedback is providing a path for recurrence to exist in the overall brain-arm system, so the non-recurrent neural networks can learn to exploit that path to effectively implement some recurrent dynamics. Some intuitive explanations like this will be helpful for readers.

      6) One main result in data from non-human primates is that there exist rotations also in the somatosensory cortex not just in motor cortex. A more thorough discussion of prior work on rotational dynamics or lack thereof across brain regions and behavioral tasks is important to add here. For example, besides the works cited by the authors, there are other works such as (Kao et al., 2015; Gao et al., 2016; Remington et al., 2018; Stavisky et al., 2019; Aoi et al., 2020; Sani et al., 2021) that discuss or show rotational dynamics in various brain regions and behavioral tasks and should be cited and discussed.

      7) The authors state that "In contrast, rotational dynamics appear to be absent in... MC activity during grasping driven by sensory inputs (Suresh et al., 2020)." There are other papers that study dynamics during reach-grasps and still finds rotational dynamics and modes (Abbaspourazad et al., 2021; Vaidya et al., 2015) and should be cited and discussed. The recent paper on naturalistic reach-grasps (Abbaspourazad et al., 2021) also argues for the involvement of a large-scale network in these movements, which further supports the authors' interpretation that "This interpretation of motor control emphasizes that the objective of the motor system is to attain the behavioural goal and this requires feedback processed by a distributed network." A discussion of this point made in this recent paper in the intro/discussion is important. Finally, there is a recent paper that argues for the input-driven nature of motor cortex (Sauerbrei et al., 2020) and is cited/discussed by the authors but briefly and mainly in the discussion. I think given the relevance of this recent paper to the core message here, it should also be briefly discussed in the introduction to better set up the work.

      Minor:

      1) The Methods are clear and comprehensive, but just to make understanding of the simulation setup easier, it would help to have a diagram of the computation graph for the recurrent and non-recurrent networks that shows their number of units, activations/nonlinearities, RNN cell type, etc., added as supplementary figure.

      2) Again, to help more clearly convey the simulations, it would help to show the task goals (x*) that are inputs to the simulated brain for example trials in each task (for example added to Figures 2 and 6).

      3) Similar to how VAF is shown on top of all plots of jPC planes, it would be helpful to have the rotation frequency for each jPC plane noted next to it. Currently it is difficult to find the jPC frequency associated with each plot from the text.

      4) I am a bit surprised by how different the null distributions are for modeling muscle activity (Figure 3F) and kinematics (Figure 3H). The null distribution is simply the R2 for a constrained or unconstrained dynamic model fit to a subsampled version of the neural activity. The only difference between the null distributions in Figure 3F and Figure 3H seems to be the downsampled dimension, which for muscle activity is 6 and for kinematics is 4 (per equation 1). Any insight will be welcome as to why down sampling the population activity to 4 (Figure 3H) results in so much worse R2 compared with down sampling it to 6 (Figure 3F)?

      References:

      Abbaspourazad, H., Choudhury, M., Wong, Y.T., Pesaran, B., Shanechi, M.M., 2021. Multiscale low-dimensional motor cortical state dynamics predict naturalistic reach-and-grasp behavior. Nature Communications 12, 607. https://doi.org/10.1038/s41467-020-20197-x

      Aoi, M.C., Mante, V., Pillow, J.W., 2020. Prefrontal cortex exhibits multidimensional dynamic encoding during decision-making. Nature Neuroscience 1-11. https://doi.org/10.1038/s41593-020-0696-5

      Gao, Y., Archer, E.W., Paninski, L., Cunningham, J.P., 2016. Linear dynamical neural population models through nonlinear embeddings, in: Lee, D.D., Sugiyama, M., Luxburg, U.V., Guyon, I., Garnett, R. (Eds.), Advances in Neural Information Processing Systems 29. Curran Associates, Inc., pp. 163-171.

      Kao, J.C., Nuyujukian, P., Ryu, S.I., Churchland, M.M., Cunningham, J.P., Shenoy, K.V., 2015. Single-trial dynamics of motor cortex and their applications to brain-machine interfaces. Nature Communications 6, 7759. https://doi.org/10.1038/ncomms8759

      Remington, E.D., Narain, D., Hosseini, E.A., Jazayeri, M., 2018. Flexible Sensorimotor Computations through Rapid Reconfiguration of Cortical Dynamics. Neuron 98, 1005-1019.e5. https://doi.org/10.1016/j.neuron.2018.05.020

      Sani, O.G., Abbaspourazad, H., Wong, Y.T., Pesaran, B., Shanechi, M.M., 2021. Modeling behaviorally relevant neural dynamics enabled by preferential subspace identification. Nature Neuroscience 24, 140-149. https://doi.org/10.1038/s41593-020-00733-0

      Stavisky, S.D., Willett, F.R., Wilson, G.H., Murphy, B.A., Rezaii, P., Avansino, D.T., Memberg, W.D., Miller, J.P., Kirsch, R.F., Hochberg, L.R., Ajiboye, A.B., Druckmann, S., Shenoy, K.V., Henderson, J.M., 2019. Neural ensemble dynamics in dorsal motor cortex during speech in people with paralysis. eLife 8, e46015. https://doi.org/10.7554/eLife.46015

      Vaidya, M., Kording, K., Saleh, M., Takahashi, K., Hatsopoulos, N.G., 2015. Neural coordination during reach-to-grasp. Journal of Neurophysiology 114, 1827-1836. https://doi.org/10.1152/jn.00349.2015

    1. SciScore for 10.1101/2021.08.02.454829: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">HCT-8 [HRT-18] cells (human male, ATCC CCL-244) were maintained in RPMI containing 10% horse serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were washed 4X in wash buffer and the secondary antibody Goat anti-Human Ig-HRP (Southern Biotech, Cat# 2010-05), was added and incubated at 37°C for 1 hr.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Human Ig-HRP</div><div>suggested: (SouthernBiotech Cat# 2010-05, RRID:AB_2795564)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After washing one time with PBS-T (PBS, 0.05% Tween-20), plate was incubated with rabbit anti-nucleocapsid antibody (Sino Biological, Cat# 40643-T62) for 1h at room temperature on a plate shaker at 800 rpm.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-nucleocapsid</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell Lines: All cell lines were incubated at 37°C in the presence of 5% CO2. 293-6E (human female, RRID:CVCL_HF20) and 293T cells (human female, RRID:CVCL_0063) cells were maintained in Freestyle 293 media with gentle shaking.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>the</div><div>detected: ( RRID:CVCL_HF20)</div></div><div style="margin-bottom:8px"><div>293T</div><div>detected: (CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HCT-8 [HRT-18] cells (human male, ATCC CCL-244) were maintained in RPMI containing 10% horse serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HCT-8</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">LLC-MK2 cells (Macaca mulatta, ATCC CCL-7) were maintained in cDMEM.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>LLC-MK2</div><div>suggested: ATCC Cat# CCL-7, RRID:CVCL_3009)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Huh7 cells (human male, a gift from Dr. Ram Savan, Department of Immunology University of Washington) were maintained in cDMEM.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Huh7</div><div>suggested: CLS Cat# 300156/p7178_HuH7, RRID:CVCL_0336)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The proteins were expressed in 293E cells and purified using Ni-NTA affinity resin followed by size exclusion chromatography on a superose 6 column as described in(Esposito et al., 2020)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293E</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, HIV-1 Tat (pHDM-tat1b, BEI resources NR-52518), SARS-CoV-2 spike (pHDM-SARS-CoV-2 Spike Wuhan-Hu-1, pHDM-SARS-CoV-2 Spike-B.1.1.7, SARS-CoV-2 Spike-P.1, pHDM-SARS-CoV-2 Spike-B.1.351 (Stamatatos et al., 2021), pCMV3-SARS-CoV-2-Spike-B.1.617.2, pTWist-WIV1-CoV (a gift from Alejandro Balazs (Addgene plasmid # 164438; http://n2t.net/addgene:164438; RRID:Addgene_164438), or pHDM-MERS-CoV Spike and a luciferase/GFP reporter (pHAGE-CMV-Luc2-IRES542 ZsGreen-W, BEI Resources Cat# NR-52516) were co-transfected into 293T cells at a 1:1:1:1.6:4.6 ratio using 293 Free transfection reagent according to the manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudoviron production was carried out at 32 °C for 72 hours after which the culture supernatant was harvested, clarified by centrifugation and frozen at −80°C. 293 cells stably expressing human HEK-293T-hACE2, for SARS-CoV-2 pseudoviruses, or Huh-7 cells for MERS-CoV pseudoviruses were seeded at a density of 4×103 cells/well in a 100 µL volume in 96-well flat bottom black-walled, clear bottom tissue culture plates (Greiner CELLSTAR Cat# 655090).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293</div><div>suggested: NIH-ARP Cat# 103-306, RRID:CVCL_0045)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Meanwhile 50 μL of cDMEM containing 6 µg/mL polybrene was added to each well of 293T-ACE2 or Huh-7 target cells and incubated for 30 min.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Huh-7</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To generate a plasmid encoding the SARS-CoV-2 spike B.1.1. variant (pHDM-SARS-CoV-2-Spike-B.1.1.7) primers were designed that anneal 5’ of the H69 codon and just 3’ of the D1118 codon on the pHDM-SARS-CoV-2 Spike Wuhan-Hu-1 plasmid (BEI Resources Cat# NR-52514) and used to amplify cDNA corresponding to the N and C termini of the spike protein and the plasmid backbone using Platinum SuperFi II DNA Polymerase (Thermofisher Cat# 12368010) according to the manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pHDM-SARS-CoV-2-Spike-B.1.1.7</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The synthesized DNA was cloned into the pHDM-SARS-CoV-2 Spike Wuhan-Hu-1 plasmid that was cut with EcoRI and HindIII and gel purified to remove the SARS-CoV-2 Spike cDNA using InFusion HD cloning Plus.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Wuhan-Hu-1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, plasmids expressing the HIV-1 Gag and pol (pHDM540 Hgpm2, BEI Resources Cat# NR-52517), HIV-1Rev (pRC-CMV-rev1b, BEI Resources Cat#</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pRC-CMV-rev1b</div><div>suggested: RRID:Addgene_164443)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, HIV-1 Tat (pHDM-tat1b, BEI resources NR-52518), SARS-CoV-2 spike (pHDM-SARS-CoV-2 Spike Wuhan-Hu-1, pHDM-SARS-CoV-2 Spike-B.1.1.7, SARS-CoV-2 Spike-P.1, pHDM-SARS-CoV-2 Spike-B.1.351 (Stamatatos et al., 2021), pCMV3-SARS-CoV-2-Spike-B.1.617.2, pTWist-WIV1-CoV (a gift from Alejandro Balazs (Addgene plasmid # 164438; http://n2t.net/addgene:164438; RRID:Addgene_164438), or pHDM-MERS-CoV Spike and a luciferase/GFP reporter (pHAGE-CMV-Luc2-IRES542 ZsGreen-W, BEI Resources Cat# NR-52516) were co-transfected into 293T cells at a 1:1:1:1.6:4.6 ratio using 293 Free transfection reagent according to the manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCMV3-SARS-CoV-2-Spike-B.1.617.2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div></div><div>detected: RRID:Addgene_164438)</div></div><div style="margin-bottom:8px"><div>pHAGE-CMV-Luc2-IRES542</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell surface SARS-CoV-2 S binding assay: cDNA corresponding to AA 15-1336 of HCoV-OC43 was PCR amplified from pCAGGS-Flag-HCoV-OC43 Spike (a kind gift from Dr. Marceline Côté, University of Ottawa) and cloned into the pTT3 vector using InFusion cloning (Clontech).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS-Flag-HCoV-OC43</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pTT3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">cDNA for the HKU1 spike was PCR amplified from pCMV-HCoV-HKU1 (SinoBiological Cat# VG40606-UT) and subcloned into pTT3. pTT3-SARS-CoV-2-S (Seydoux et al., 2020), pHDM-MERS-CoV-Spike, pTWist-WIV1-CoV, pHDM-MERS-CoV-1 Spike, pTT3-HKU1 or pTT3-OC43 Spike were transfected into suspension-adapted 293T cells using 293 Free transfection reagent (EMD Millipore Cat# 72181) or PEI transfection reagent (PolySciences Inc. Cat# 23966) according to the manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCMV-HCoV-HKU1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pHDM-MERS-CoV-Spike</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pTT3-HKU1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pTT3-OC43</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The antibody concentration that neutralized 50% or 80% of infectivity (IC50 and IC80 for mAbs) was interpolated from the neutralization curves determined using the log(inhibitor) vs. response -- Variable slope (four parameters) fit using automatic outlier detection in GraphPad Prism Software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Model building was completed using COOT (Emsley and Cowtan, 2004) and refinement was performed in Phenix with the final refinement run through the PDB_REDO server (Joosten et al., 2014).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>COOT</div><div>suggested: (Coot, RRID:SCR_014222)</div></div><div style="margin-bottom:8px"><div>Phenix</div><div>suggested: (Phenix, RRID:SCR_014224)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Structural figures were made in Pymol (Schrodinger, LLC)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Pymol</div><div>suggested: (PyMOL, RRID:SCR_000305)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The plates were then washed once with 200µl of FACS buffer and stained with of PE-conjugated AffiniPure Fab fragment goat anti-human IgG (Jackson Immunoresearch Cat# 109-117-008) at a 1:100 dilution and live/dead green fluorescent reactive dye (Thermo Fisher Cat# L34970) at a 1:1000 dilution in 50 µl/well of 1X PBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Thermo Fisher Cat#</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.08.03.454861: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Animal Procedures and Study Design: All animal procedures were performed under the approval of the Committee on the Ethics of Animal Experimentation of the IGTP and the authorisation of Generalitat de Catalunya (code: 11222).<br>Euthanasia Agents: Euthanasia was performed under deep isoflurane anaesthesia by whole blood extraction via cardiac puncture and was confirmed by cervical dislocation.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">B6.Cg-Tg(K18-ACE2)2Prlmn/J (or K18-hACE2) hemizygous transgenic mice (034860; Jackson Immunoresearch, West Grove, PA, USA) were bred at CMCiB by pairing hemizygous males for Tg(K18-ACE2)2Prlmn (or K18-hACE2) with non-carrier B6.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, viruses were propagated in VeroE6 cells (CRL-1586; ATCC, Virginia, VA, USA) for two passages and recovered by supernatant collection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">B6.Cg-Tg(K18-ACE2)2Prlmn/J (or K18-hACE2) hemizygous transgenic mice (034860; Jackson Immunoresearch, West Grove, PA, USA) were bred at CMCiB by pairing hemizygous males for Tg(K18-ACE2)2Prlmn (or K18-hACE2) with non-carrier B6.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>B6.Cg-Tg(K18-ACE2)2Prlmn/J</div><div>suggested: RRID:IMSR_JAX:034860)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For absolute quantification, a standard curve was built using 1/5 serial dilutions of a SARS-CoV2 plasmid (2019-nCoV_N_Positive Control, catalog number 10006625, 200 copies/μL</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV2</div><div>suggested: RRID:Addgene_153201)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Biosafety Approval & Virus Isolation: The biologic biosafety committee of Germans Trias i Pujol Research Institute (IGTP) approved the execution of SARS-CoV-2 experiments at the BSL3 laboratory of the Centre for Bioimaging and Comparative Medicine (CMCiB, Badalona, Spain).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bioimaging</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In a second step, using the MODELLER models as input, we ran FoldX v5 (Schymkowitz et al., 2005; Delgado et al., 2019) to model the mutations associated with the B.1.351 variant of the virus, obtaining 10 additional models (named mACE2-B.1.351 RBD) (Supplementary Fig. 3).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MODELLER</div><div>suggested: (MODELLER, RRID:SCR_008395)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We evaluated each model with FoldX and pyDock (Cheng et al., 2007) which have achieved good performance predicting the impact of mutations in protein-protein complexes (Amengual-Rigo et al., 2021).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FoldX</div><div>suggested: (FoldX, RRID:SCR_008522)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.30.21261234: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: The protocol was approved CALHN Human Research Ethics Committee, Adelaide,<br>Consent: Inclusion criteria were PCR-confirmed SARS-CoV-2 infection from nasopharyngeal swabs, the ability to attend study follow up visits, and voluntary informed consent.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">A total of 69 COVID-19 convalescent individuals (35 male, 36 female) representing a range of prior mild, moderate, severe, critical COVID-19 cases were recruited (Table S1).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary antibodies were diluted in 5% skim milk in PBST as follows: Goat anti-Human IgG (H+L) Secondary Antibody, HRP (1:30,000;</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Human IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sigma): anti-human IgA HRP antibody (1:5,000; Sigma) and incubated for 1 hour at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgA</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pearson correlation analysis was performed using the Hmisc v4.4-2 package in R to determine correlations between anti-Spike and anti-RBD antibody titres, flow cytometry data and BTM activity scores.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Spike</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-RBD</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 protein purification and ELISA: Prefusion SARS-CoV-2 ectodomain (isolate WHU1, residues1-1208) with HexaPro mutations (76) (kindly provided by Adam Wheatley) and SARS-Cov-2 receptor-binding domain (RBD) with C-terminal His-tag (77) (residues 319-541; kindly provided by Florian Krammer) were overexpressed in Expi293 cells and purified by Ni-NTA affinity and size- exclusion chromatography.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Expi293</div><div>suggested: RRID:CVCL_D615)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">AUC calculation was performed using Prism GraphPad, where the X-axis is half log10 of sera dilution against OD450 on Y-axis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Compensation was set with beads matched to each panel antibody combination using spectral compensation using FlowJo Software V10.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">RNA-Seq analysis: Sequence read quality was assessed using FastQC version 0.11.4 (78) and summarised with MultiQC version 1.8 (79) prior to quality control with Trimmomatic version 0.38 (80) with a window size of 4 nucleotides and an average quality score of 25.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FastQC</div><div>suggested: (FastQC, RRID:SCR_014583)</div></div><div style="margin-bottom:8px"><div>MultiQC</div><div>suggested: (MultiQC, RRID:SCR_014982)</div></div><div style="margin-bottom:8px"><div>Trimmomatic</div><div>suggested: (Trimmomatic, RRID:SCR_011848)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Reads that passed all quality control steps were then aligned to the mouse genome (GRCh38 assembly) using HISAT2 version 2.1.0 (81).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HISAT2</div><div>suggested: (HISAT2, RRID:SCR_015530)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The gene count matrix was generated with FeatureCounts version 1.5.0-p2 (82) using the union model with Ensembl version 101 annotation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FeatureCounts</div><div>suggested: (featureCounts, RRID:SCR_012919)</div></div><div style="margin-bottom:8px"><div>Ensembl</div><div>suggested: (Ensembl, RRID:SCR_002344)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The count matrix was then imported into R version 4.0.3 for further analysis and visualisation in ggplot2 v2.3.3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ggplot2</div><div>suggested: (ggplot2, RRID:SCR_014601)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To assess if differential gene expression was primarily driven by differences in the proportion of any major immune cell population (i.e. LD granulocytes, LD neutrophils, CXCR3+ neutrophils, monocytes, lymphocytes, CD56++ NK cells, CD19+ B cells, CD3+ T cells, NKT cells, CD4+ T cells or CD8+ T cells), we additionally fit the frequency of each population in each individual into the EdgeR model and reperformed the differential gene expression and pathway overrepresentation analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>EdgeR</div><div>suggested: (edgeR, RRID:SCR_012802)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Gene Set Variation Analysis (GSVA) (44) was used to calculate a per sample activity score for each of the modules (excluding unannotated modules labelled as ‘TBA’). limma v3.46.0 was used to identify modules that were differentially active in at least one timepoint.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>limma</div><div>suggested: (LIMMA, RRID:SCR_010943)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Correlation networks were exported to Cytoscape v3.8.1 for visualisation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Cytoscape</div><div>suggested: (Cytoscape, RRID:SCR_003032)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your code and data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. Cortical tension, contact tension and tissue segregation: A clarification.

      This article reports a study on the role of ephrin-Eph signalling in cell sorting. Ephrin-Eph signalling is one of the major molecular mechanism involved in tissue segregation (Fagotto, 2014; Fagotto, 2020; Fagotto et al., 2014). Kindberg and colleagues reproduce this ephrin-Eph-dependent sorting in an artificial system, namely the human HEK cell line. The authors confront two cell populations, one expressing an ephrin, the other a cognate Eph receptor. This simplified system roughly mimics the situation in embryonic tissues: Ephrin-Eph signalling in the latter is usually more complex, due to the expression of multiple ephrins and Eph receptors, but the general logic based on asymmetric expression of selective ligands and receptors is similar (Fagotto et al., 2014). Using virtually identical assays as those previously applied to embryonic cells by our team, Kindberg et al obtain results that are largely in agreement with our previous data and model (Canty et al., 2017). Yet, they also propose additional properties about which some clarification is needed.

      To put this discussion in the right context, a reminder of the principles of tissue segregation is required: Cell sorting and cell positioning within a tissue are directed by contractile forces exerted on the cortex and cell-cell adhesion. A unifying model formulated by Brodland (Brodland and Chen, 2000), emphasizes the dominant role of actomyosin cortical contractility, which must be downregulated along cell-cell contacts to allow effective adhesion. Brodland defined a “cell to medium interfacial tension”, which corresponds to the “cortical tension” along free edges of the cell, and a “cell to cell interfacial tension”, also named “contact tension” (Winklbauer, 2015)(*). Stemming from this principle, the “Differential Interfacial Tension Hypothesis” (DITH) posed that cell sorting was driven by global differences in tissue stiffness (Brodland, 2002; Krieg et al., 2008). However, ample experimental evidence and theoretical considerations have brought quite a different view of the process.

      Firstly, it is now clear that what dictates sorting is not a difference in the stiffness of the two cell types, but rather local enhanced contact tension at heterotypic contacts (which we coined high heterotypic interfacial tension, HIT (Canty et al., 2017; Fagotto, 2020)). This came as an unavoidable conclusion of our own experimental results on early embryonic boundaries in Xenopus, in particular on the dissection and reconstitution of the process of separation of dorsal mesoderm and ectoderm (and not endoderm, as incorrectly referred by Kindberg et al) (Canty et al., 2017; Rohani et al., 2011; Rohani et al., 2014). Importantly, our biophysical simulations showed that the principle of HIT could be generalized to any type of tissue boundary (Canty et al., 2017). This conclusion, confirmed independently by Manning and colleagues using a different model of simulation (Sussman et al., 2018), was in full agreement with experimental data in various systems. Furthermore, the fact that tension is highest at heterotypic contacts can be simply inferred from the straightness of tissue boundaries, as noted by the Dahmann and Sanson teams in the case of compartment boundaries in Drosophila (Aliee et al., 2012; Landsberg et al., 2009; Monier et al., 2010). Ephrin-Eph signalling is obviously an optimal mechanism to boost tension at a heterotypic contact, thus producing HIT, although various other types of mechanisms can produce the same effect (Fagotto, 2015; Luu et al., 2015; Sharrock and Sanson, 2020; Wang and Dahmann, 2020).

      The second issue is the effect of contractility on relative positioning of the two cell populations. In this case, tension at cell surfaces exposed to the medium plays an important role, thus softer cells tend to engulf the stiffer cells. This has led to an apparent contradiction (Krieg et al., 2008), because, in embryos, the ectoderm is typically stiffer than mesoderm and endoderm, yet it takes a peripheral position. The solution to this conundrum, definitively solved by Ninoyima and Winklbauer (Ninomiya and Winklbauer, 2008), is simple: Under physiological conditions, most cells are not exposed to the “medium”, and tissues are largely “protected” by the non-adhesive apical domain of an epithelial layer. As such, this domain cannot participate to the minimization of contacts and by default it must occupy the peripheral position, and is therefore excluded from the game between adhesion and contractility. Thus, in practice, sorting WITHIN the tissue is controlled by the relative tension at different types of cell-cell contacts. Importantly, although global cell stiffness does impact the properties of cell contacts, this effect cannot be simply inferred from the tension present at the cell-medium interface. Indeed, complex reactions occur at contacts, which might enhance or dampen contact tension, and/or reinforce cell-cell adhesion. Thus, it is important to evaluate contact tension for each particular combination of cells. In any case, the key point here is that differences in cortical tension can directly influence cell positioning only in the immediate vicinity of a (non-coated) tissue surface.

      With this is mind, one can now evaluate the observation by Kindberg et al of EphB2 expression increasing free cortical tension. The authors propose that this property significantly contributes to cell sorting. However, this model can be directly applied only under conditions where cells expose significant surface to the medium. This is true in the type of non-confluent in vitro cultures used in their study (although the interaction with the extracellular matrix is likely to impact the tension along these edges). What about actual tissues? As said, most tissues are covered by either an epithelial layer, or by other tissues. The degree of freedom is even lower in the case of purely epithelial tissues, such as Drosophila embryonic blastoderm or wing imaginal disc, as cells can only move in the plane of the epithelium. Could one conceive, however, a relevance for non-epithelial tissues, which are less tight and have interstitial spaces? This could be the case if tension along these spaces is comparable to that at a “free” edge as measured in vitro for isolated cell doublets. Xenopus ectodermal inner layer is so far the only model where a precise analysis was performed. Quite interestingly, Winklbauer and colleagues demonstrated that the tension is in fact quite low, very much in the range of contact tension (Barua et al., 2017; Parent et al., 2017). Thus, interstitial spaces cannot be compared to the simple medium used in cell culture: Cells appear to control their environment, probably through secretion of extracellular glycoproteins acting as “surfactants”, in order to avoid unwanted cortical tension to build inside the tissue. These considerations indicate that a model involving differences in cortical tension at free cell edges is likely to be of limited significance in the physiological context of real tissues.

      The interesting observation by Kindberg et al of an effect of EphB2 ectopic expression on cortical tension of HEK cells should be included among the many interesting complications of ephrin-Eph systems (Pasquale, 2010). Similarly, ephrinB1 and EphB4 appear to have a proadhesive activity in the Xenopus ectoderm (Rohani et al., 2011), thus opposed to the stereotypical repulsive function of these molecules. The actual impact of these properties on cell sorting and tissue segregation will continue to be a fascinating issue, which will require further investigation.

      A last note about the cadherin independence of the EphB2 phenotype reported by Kindberg et al. This conclusion was based on experiments in a medium with low calcium, a condition that certainly strongly decreases, but does not fully block cadherin adhesion. Furthermore, it has been proposed that non-specific surface proteins may significantly contribute to adhesion (Winklbauer, 2019). Finally, it is also conceivable that EphB2 may interact with low levels of endogenous ephrins, in a regime that could directly provide some adhesion to the cells (Poliakov et al., 2004).

      *Note: The original term “interfacial tension” (Brodland and Chen, 2000), included in the definition of the “Differential Interfacial Tension Hypothesis” (DITH) (Brodland, 2002), directly came from the ANALOGY with liquid surface tension. It is used in the Kindberg et al. article. However, this terminology can be confusing when describing morphogenetic processes, and, for the sake of clarity, we rather prefer to use “contact tension”, from the terminology proposed by Winklbauer (Winklbauer, 2015), and keep the term “interface” to refer to supracellular structures, i.e. tissue and compartment interfaces.

      References Aliee, M., J.C. Roper, K.P. Landsberg, C. Pentzold, T.J. Widmann, F. Julicher, and C. Dahmann. 2012. Physical mechanisms shaping the Drosophila dorsoventral compartment boundary. Current biology : CB. 22:967-976. Barua, D., S.E. Parent, and R. Winklbauer. 2017. Mechanics of Fluid-Filled Interstitial Gaps. II. Gap Characteristics in Xenopus Embryonic Ectoderm. Biophys J. 113:923-936. Brodland, G.W. 2002. The Differential Interfacial Tension Hypothesis (DITH): a comprehensive theory for the self-rearrangement of embryonic cells and tissues. Journal of biomechanical engineering. 124:188-197. Brodland, G.W., and H.H. Chen. 2000. The mechanics of heterotypic cell aggregates: insights from computer simulations. Journal of biomechanical engineering. 122:402-407. Canty, L., E. Zarour, L. Kashkooli, P. Francois, and F. Fagotto. 2017. Sorting at embryonic boundaries requires high heterotypic interfacial tension. Nature communications. 8:157. Fagotto, F. 2014. The cellular basis of tissue separation. Development. 141:3303-3318. Fagotto, F. 2015. Regulation of cell adhesion and cell sorting at embryonic boundaries. Curr Top Dev Biol. 112:19-64. Fagotto, F. 2020. Tissue segregation in the early vertebrate embryo. Seminars in cell & developmental biology. 107:130-146 Fagotto, F., R. Winklbauer, and N. Rohani. 2014. Ephrin-Eph signaling in embryonic tissue separation. Cell adhesion & migration. 8:308-326. Kindberg, A.A., V. Srivastava, J.M. Muncie, V.M. Weaver, Z.J. Gartner, and J.O. Bush. 2021. EPH/EPHRIN regulates cellular organization by actomyosin contractility effects on cell contacts. J Cell Biol. 220. Krieg, M., Y. Arboleda-Estudillo, P.H. Puech, J. Kafer, F. Graner, D.J. Muller, and C.P. Heisenberg. 2008. Tensile forces govern germ-layer organization in zebrafish. Nat Cell Biol. 10:429-436. Landsberg, K.P., R. Farhadifar, J. Ranft, D. Umetsu, T.J. Widmann, T. Bittig, A. Said, F. Julicher, and C. Dahmann. 2009. Increased cell bond tension governs cell sorting at the Drosophila anteroposterior compartment boundary. Current biology : CB. 19:1950-1955. Luu, O., E.W. Damm, S.E. Parent, D. Barua, T.H. Smith, J.W. Wen, S.E. Lepage, M. Nagel, H. Ibrahim-Gawel, Y. Huang, A.E. Bruce, and R. Winklbauer. 2015. PAPC mediates self/non-self-distinction during Snail1-dependent tissue separation. J Cell Biol. 208:839-856. Monier, B., A. Pelissier-Monier, A.H. Brand, and B. Sanson. 2010. An actomyosin-based barrier inhibits cell mixing at compartmental boundaries in Drosophila embryos. Nat Cell Biol. 12:60-65; sup pp 61-69. Ninomiya, H., and R. Winklbauer. 2008. Epithelial coating controls mesenchymal shape change through tissue-positioning effects and reduction of surface-minimizing tension. Nat Cell Biol. 10:61-69. Parent, S.E., D. Barua, and R. Winklbauer. 2017. Mechanics of Fluid-Filled Interstitial Gaps. I. Modeling Gaps in a Compact Tissue. Biophys J. 113:913-922. Pasquale, E.B. 2010. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer. 10:165-180. Poliakov, A., M. Cotrina, and D.G. Wilkinson. 2004. Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev Cell. 7:465-480. Rohani, N., L. Canty, O. Luu, F. Fagotto, and R. Winklbauer. 2011. EphrinB/EphB signaling controls embryonic germ layer separation by contact-induced cell detachment. PLoS Biol. 9:e1000597. Rohani, N., A. Parmeggiani, R. Winklbauer, and F. Fagotto. 2014. Variable combinations of specific ephrin ligand/Eph receptor pairs control embryonic tissue separation. PLoS Biol. 12:e1001955. Sharrock, T.E., and B. Sanson. 2020. Cell sorting and morphogenesis in early Drosophila embryos. Seminars in cell & developmental biology. 107:147-160. Sussman, D.M., J.M. Schwarz, M.C. Marchetti, and M.L. Manning. 2018. Soft yet Sharp Interfaces in a Vertex Model of Confluent Tissue. Physical review letters. 120:058001. Wang, J., and C. Dahmann. 2020. Establishing compartment boundaries in Drosophila wing imaginal discs: An interplay between selector genes, signaling pathways and cell mechanics. Seminars in cell & developmental biology. 107:161-169. Winklbauer, R. 2015. Cell adhesion strength from cortical tension - an integration of concepts. J Cell Sci. 128:3687-3693. Winklbauer, R. 2019. Dynamic cell-cell adhesion mediated by pericellular matrix interaction - a hypothesis. J Cell Sci. 132.

    1. SciScore for 10.1101/2021.07.31.454592: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A monoclonal antibody against the N protein was diluted in the incubation buffer (1:2000, v/v; Genetex HL344) and incubated with the cells for 1 h; after this time, cells were washed with PBS and subsequently incubated with a 1:500 (v/v) dilution of a goat anti-rabbit conjugated to Alexa 488 (Invitrogen-Carlsbad, CA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rabbit</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell culture: Vero E6 (ATCC) and Calu3 (ATCC) cell lines were kindly provided by Dr. Enjuanes (CNB-CSIC)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu3</div><div>suggested: BCRJ Cat# 0264, RRID:CVCL_0609)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A549 and Huh7 cells were transduced with a retroviral vector enabling expression of ACE2 in a di-cistronic expression cassette also conferring resistance to blasticidine.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549</div><div>suggested: NCI-DTP Cat# A549, RRID:CVCL_0023)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The hCoV-229E-GFP51 was kindly provided by Dr. Thiel (University of Basel) and propagated in Huh7 cells at 33°C in a controlled 5% CO2 environment.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Huh7</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cypopathic effect protection assays in Vero E6 and Huh7-ACE2 cells: Vero E6 or Huh7-ACE2 cell monolayers were inoculated (MOI = 0.001) in the presence of a wide range of two-fold dilutions of the crude, or partially purified extracts, or pure compounds and incubated for 72 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Huh7-ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Assessment of viral entry using retroviral pseudotypes: Retroviral particles pseudotyped with SARS-2-CoV spike envelope protein (Spp) were produced in HEK293T cells as previously described54 with materials kindly provided by Dr. F. L. Cosset (INSERM, Lyon) and J. M. Casasnovas and J. G. Arriaza (CNB-CSIC) for the S protein cDNA.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">VSV-GFP30 was kindly provided by Dr. Rodriguez (CNB-CSIC).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VSV-GFP30</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statitistical Analysis: Descriptive statistics were calculated using Microsoft Excel.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Microsoft Excel</div><div>suggested: (Microsoft Excel, RRID:SCR_016137)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">One-way ANOVA and post-hoc tests were calculated using IBM SPSS Software Package (version 26).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SPSS</div><div>suggested: (SPSS, RRID:SCR_002865)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.29.21261190: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Ethics approval was obtained from Scotland A Research Ethics Committee (responsible for studies requiring approval under the Adults with Incapacity [Scotland] Act, 2000 - 20/SS/0059).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Abnormal values were defined for NT-proBNP (>300ng/ml) and Troponin (TnT ≥15 ng/L or TnI ≥34 ng/L for males; ≥16 ng/L for females).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">Power: Sample size selection was, by necessity, a pragmatic balance of maximising available information versus the prompt delivery of the study.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data: Study data were collected and managed using REDCap electronic data capture tools hosted by the University of Glasgow.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>REDCap</div><div>suggested: (REDCap, RRID:SCR_003445)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04764032</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Right Ventricular Dysfunction in Ventilated Patients With CO…</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.28.454232: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">1.25 × 105 J76 cells were co-incubated with 2.5 × 105 K562 cells transgenic for HLA-A*02:01 in 96 well plates filled with 200 μL of IMDM media 10% FCS (Gibco) containing serial dilutions peptide of interest in three independent replicates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>J76</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>K562</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Codon-optimized genes encoding the α and β chains of these TCRs (TCR RLQ3 residues 1–204 and 1–244; TCR YLQ7 residues 1–203 and 1–241, respectively) were synthesized (Supplementary Table 11) and cloned into the expression vector pET22b (GenScript).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pET22b</div><div>suggested: RRID:Addgene_84863)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The acquired data was processed by FlowJo (version 10.6.2) and Prizm Software for analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Structure determination and refinement: Before structure determination and refinement, all data reductions were performed using the CCP4 software suite (69).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CCP4</div><div>suggested: (CCP4, RRID:SCR_007255)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Structures were determined by molecular replacement with the program Phaser (70) and refined with Phenix (71).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Phenix</div><div>suggested: (Phenix, RRID:SCR_014224)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The models were further refined by manual model building with Coot (72) based on 2Fo – Fc and Fo – Fc maps.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Coot</div><div>suggested: (Coot, RRID:SCR_014222)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The PyMOL program (https://pymol.org/) was used to prepare figures.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PyMOL</div><div>suggested: (PyMOL, RRID:SCR_000305)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Representative spike glycoprotein sequences for other coronaviruses, corresponding to an adaptation of a set of spike sequences from the CoV3D database (77), were obtained from NCBI and GISAID, and aligned using MAFFT software (78) to generate a multiple sequence alignment which was used to obtain sequences corresponding to the YLQ and RLQ epitope positions in those viruses.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MAFFT</div><div>suggested: (MAFFT, RRID:SCR_011811)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.28.454085: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: EXPERIMENTAL MODEL AND SUBJECT DETAILS: Ethics Statement: For the use of human specimen, all protocols involving human subjects recruited at Kyoto University were reviewed and approved by the Institutional Review Boards of Kyoto University (approval number G0697).<br>Consent: All human subjects provided written informed consent.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Collection of BNT162b2-Vaccinated Sera: Peripheral blood were collected four weeks after the second vaccination of BNT162b2 (Pfizer-BioNTech), and the sera of 18 vaccinees (average age: 40, range: 28-59, 22% male) were isolated from peripheral blood.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">To estimate the emerging time of the Lambda variant (C.37 lineage), we collected all Lambda sequences carrying the RSYLTPGD246-253N mutation that were sampled in 2020 (2 sequences) and randomly sampled 100 sequences in 2021.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell Culture: HEK293T cells (a human embryonic kidney cell line; ATCC CRL-3216), and HOS cells (a human osteosarcoma cell line; ATCC CRL-1543) were maintained in Dulbecco’s modified Eagle’s medium (high glucose) (Wako, Cat# 044-29765) containing 10% fetal calf serum and 1% PS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HOS</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, luciferase-expressing reporter viruses pseudotyped with the SARS-CoV-2 S protein and its derivatives, HEK293T cells (1 × 106 cells) were cotransfected with 1 μg of psPAX2-IN/HiBiT (Ozono et al., 2020), 1 μg of pWPI-Luc2 (Ozono et al., 2020), and 500 ng of plasmids expressing parental S or its derivatives using Lipofectamine 3000 (Thermo Fisher Scientific, Cat# L3000015) or PEI Max (Polysciences, Cat# 24765-1) according to the manufacturer’s protocol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the experiment, HOS-ACE2 cells and HOS-ACE2/TMPRSS2 cells (10,000 cells/50 μl) were seeded in 96-well plates and infected with 100 μl of the pseudoviruses prepared at 4 different doses.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HOS-ACE2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HOS-ACE2/TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We also added the following 4 SARS-CoV-2 genomes as the outgroup: strain Wuhan-Hu-1 (GISAID ID: EPI_ISL_1532199, isolated on December 26, 2019), EPI_ISL_1093172 (isolated on August 25, 2020), and EPI_ISL_1534645 (isolated on November 30, 2020).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Wuhan-Hu-1</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmids expressing the S proteins of the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Lambda (C.37) variants and the point mutants were generated by site-directed overlap extension PCR using pC-SARS2-S D614G (Ozono et al., 2021) as the template and the following primers listed in Table S4.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pC-SARS2-S D614G</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The resulting PCR fragment was digested with Acc65I or KpnI and NotI and inserted into the corresponding site of the pCAGGS vector (Niwa et al., 1991).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS</div><div>suggested: RRID:Addgene_18926)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We aligned entire genome sequences by using the FFT-NS-1 program in MAFFT suite v7.407 (Katoh and Standley, 2013) and deleted gapped regions in the 5’ and 3’ regions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MAFFT</div><div>suggested: (MAFFT, RRID:SCR_011811)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We constructed a phylogenetic tree using IQ-TREE 2 v2.1.3 software (Minh et al., 2020) with 1,000 bootstraps (Figure S1A)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IQ-TREE</div><div>suggested: (IQ-TREE, RRID:SCR_017254)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A timetree was summarized using TreeAnnotator software in the BEAST package and visualized by using FigTree v1.4.4 (Figure 1C and Figure S1B).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BEAST</div><div>suggested: (BEAST, RRID:SCR_010228)</div></div><div style="margin-bottom:8px"><div>FigTree</div><div>suggested: (FigTree, RRID:SCR_008515)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In Figures 2C and 2D, the crystal structure of SARS-CoV-2 S (PDB: 6ZGE) (Wrobel et al., 2020) was used as the template, and 40 homology models of the SARS-CoV-2 S of the Lambda variant were generated using Build Homology Model protocol MODELLER v9.24 (Fiser et al., 2000).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MODELLER</div><div>suggested: (MODELLER, RRID:SCR_008395)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Nucleotide sequences were determined by DNA sequencing services (Fasmac or Eurofins), and the sequence data were analyzed by Sequencher v5.1 software (Gene Codes Corporation).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Sequencher</div><div>suggested: (Sequencher, RRID:SCR_001528)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then, the 80 μl mixture of pseudovirus and sera/antibodies was added into HOS-ACE2/TMPRSS2 cells (10,000 cells/50 μl) in a 96-well white plate and the luminescence was measured as described above (see “Pseudovirus Assay” above). 50% neutralization titer was calculated using Prism 9 (GraphPad Software)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.26.453518: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Ethics Statement: All animal experiments were conducted in an AAALAC International-accredited facility and were approved by the Rocky Mountain Laboratories Institutional Care and Use Committee following the guidelines put forth in the Guide for the Care and Use of Laboratory Animals 8th edition, the Animal Welfare Act, United States Department of Agriculture and the United States Public Health Service Policy on the Humane Care and Use of Laboratory Animals.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Inoculation experiments: Four to six-week-old female and male Syrian hamsters (ENVIGO) were inoculated (10 animals per virus) intranasally (I.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: At regular intervals mycoplasma testing was performed.<br>Authentication: The airflow was adjusted for each tube length to be 30 cage changes/hour and the flow was validated prior to starting the experiments by timing a smoke plume through the tubes.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary goat anti-hamster IgG Fc (horseradish peroxidase (HRP)-conjugated, Abcam) spike-specific antibodies were used for detection and visualized with KPL TMB 2-component peroxidase substrate kit (SeraCare, 5120-0047).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Secondary goat anti-hamster IgG Fc</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-hamster IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus propagation was performed in VeroE6 cells in DMEM supplemented with 2% fetal bovine serum, 1 mM L-glutamine, 50 U/mL penicillin and 50 μg/mL streptomycin (DMEM2).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Receptor transfection: BHK cells were seeded in black 96-well plates and transfected the next day with 100 ng plasmid DNA encoding human or hamster ACE2, using polyethylenimine (Polysciences).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BHK</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, plates pre-coated with poly-L-lysine (Sigma–Aldrich) were seed with 293T cells and transfected the following day with 1,200 ng of empty plasmid and 400 ng of plasmid encoding coronavirus spike or no-spike plasmid control (green fluorescent protein (GFP)).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Human and hamster ACE2 (Q9BYF1.2 and GQ262794.1, respectively), were synthesized and cloned into pcDNA3.1+ (GenScript).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.1+</div><div>suggested: RRID:Addgene_117272)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">BHK cells previously transfected with ACE2 plasmid of interest were inoculated with equivalent volumes of pseudotype stocks.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: RRID:Addgene_164219)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mutagenesis to model the residues that differ in the B.1.1.7 RBD and hamster ACE2 was performed in COOT 51.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>COOT</div><div>suggested: (Coot, RRID:SCR_014222)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The structure figure was generated using the Pymol Molecular Graphics System (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Pymol</div><div>suggested: (PyMOL, RRID:SCR_000305)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Amino acid sequence alignments of human ACE2 (BAB40370.1) and hamster ACE2 (XP_005074266.1), and of SARS-CoV-2 RBD from the linage A strain and B.1.1.7 variant, were were generated using Clustal Omega (http://europepmc.org/article/MED/).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Clustal Omega</div><div>suggested: (Clustal Omega, RRID:SCR_001591)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Remaining reads were mapped to the SARS-CoV-2 2019-nCoV/USA-WA1/2020 (MN985325.1 using Bowtie2 version 2.2.928 with parameters --local --no-mixed-X 1500.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bowtie2</div><div>suggested: (Bowtie 2, RRID:SCR_016368)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PCR duplicates were removed using picard MarkDuplicates (Broad Institute) and variants were called using GATK HaplotypeCaller version 4.1.2.029 with parameter-ploidy 2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GATK</div><div>suggested: (GATK, RRID:SCR_001876)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.29.454333: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: All participants provided written informed consent before participation in the study and the study was conducted in accordance with Good Clinical Practice.<br>IRB: The study was performed in compliance with all relevant ethical regulations and the protocol (DRO-1006) for studies with human participants was approved by the Institutional Review Board of the Rockefeller University.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were washed 6 times with washing buffer and then incubated with anti-human IgG, IgM or IgA secondary antibody conjugated to horseradish peroxidase (HRP) (Jackson Immuno Research</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgA</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The half-maximal neutralization titers for plasma (NT50) or half-maximal and 90% inhibitory concentrations for monoclonal antibodies (IC50 and IC90) were determined using four-parameter nonlinear regression (least squares regression method without weighting; constraints: top=1, bottom=0) (GraphPad Prism).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IC90</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The enriched B cells were incubated in FACS buffer (1× PBS, 2% FCS, 1 mM EDTA) with the following anti-human antibodies (all at 1:200 dilution): anti-CD20-PECy7 (BD Biosciences, 335793), anti-CD3-APC-eFluro 780 (Invitrogen, 47-0037-41)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human</div><div>suggested: (GenWay Biotech Inc. Cat# 18-202-335793-0.1 mg, RRID:AB_1981874)</div></div><div style="margin-bottom:8px"><div>anti-CD20-PECy7</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-CD3-APC-eFluro 780</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For plasmablast single-cell sorting, in addition to above antibodies, B cells were also stained with anti-CD19-BV605 (Biolegend, 302244), and single CD3-CD8-CD14-CD16-CD19+CD20-Ova-RBD-PE+RBD-AF647+ plasmablasts were sorted as described above.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-CD19-BV605</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For B cell phenotype analysis, in addition to above antibodies, B cells were also stained with following anti-human antibodies: anti-IgD-BV421 (Biolegend, 348226), anti-CD27-FITC (BD biosciences, 555440), anti-CD19-BV605 (Biolegend, 302244), anti-CD71-PerCP-Cy5.5 (Biolegend, 334114), anti-IgG-PECF594 (BD biosciences, 562538), anti-IgM-AF700 (Biolegend, 314538), anti-IgA-Viogreen (Miltenyi Biotec, 130-113-481)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human antibodies: anti-IgD-BV421 ( Biolegend , 348226</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-CD27-FITC</div><div>suggested: (Millipore Cat# FCMAB191F, RRID:AB_10807274)</div></div><div style="margin-bottom:8px"><div>anti-CD71-PerCP-Cy5.5</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-IgG-PECF594</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-IgM-AF700 ( Biolegend , 314538) , anti-IgA-Viogreen ( Miltenyi Biotec , 130-113-481)</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The frequency distributions of human V genes in anti-SARS-CoV-2 antibodies from this study was compared to 131,284,220 IgH and IgL sequences generated by54 and downloaded from cAb-Rep55, a database of human shared BCR clonotypes available at https://cab-rep.c2b2.columbia.edu/.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 293T cells were transfected with pNL4-3ΔEnv-nanoluc and pSARS-CoV-2-SΔ19, particles were harvested 48 hpt, filtered and stored at −80°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 293T cells were transfected with pNL4-3ΔEnv-nanoluc and pSARS-CoV-2-SΔ19, particles were harvested 48 hpt, filtered and stored at −80°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pNL4-3ΔEnv-nanoluc</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pSARS-CoV-2-SΔ19</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The average of its signal was used for normalization of all the other values on the same plate with Excel software before calculating the area under the curve using Prism V9.1(GraphPad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Excel</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For monoclonal antibodies, the EC50 was determined using four-parameter nonlinear regression (GraphPad Prism V9.1).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Proteins: Mammalian expression vector encoding the RBD of SARS-CoV-2 (GenBank MN985325.1; S protein residues 319-539) was previously described50.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Proteins</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The half-maximal neutralization titers for plasma (NT50) or half-maximal and 90% inhibitory concentrations for monoclonal antibodies (IC50 and IC90) were determined using four-parameter nonlinear regression (least squares regression method without weighting; constraints: top=1, bottom=0) (GraphPad Prism).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Single CD3-CD8-CD14-CD16−CD20+Ova−RBD-PE+RBD-AF647+ B cells were sorted into individual wells of 96-well plates containing 4 μl of lysis buffer (0.5× PBS, 10 mM DTT, 3,000 units/ml RNasin Ribonuclease Inhibitors (Promega, N2615) per well using a FACS Aria III and FACSDiva software (Becton Dickinson) for acquisition and FlowJo for analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FACSDiva</div><div>suggested: (BD FACSDiva Software, RRID:SCR_001456)</div></div><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For B cell phenotype analysis, in addition to above antibodies, B cells were also stained with following anti-human antibodies: anti-IgD-BV421 (Biolegend, 348226), anti-CD27-FITC (BD biosciences, 555440), anti-CD19-BV605 (Biolegend, 302244), anti-CD71-PerCP-Cy5.5 (Biolegend, 334114), anti-IgG-PECF594 (BD biosciences, 562538), anti-IgM-AF700 (Biolegend, 314538), anti-IgA-Viogreen (Miltenyi Biotec, 130-113-481)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Biolegend , 314538) , anti-IgA-Viogreen ( Miltenyi Biotec</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Miltenyi</div><div>suggested: (Miltenyi Biotec, RRID:SCR_008984)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequence analysis was performed using MacVector.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MacVector</div><div>suggested: (MacVector, RRID:SCR_015700)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your code and data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.28.453981: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Informed consent was obtained, and a baseline health questionnaire was also completed.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In vitro characterization of CD38+ICOS+ Cells: Quantification of CD38+ICOS+ CD4 and CD8 T cells by flow cytometry: To quantify CD38+ICOS+ CD4 and CD8 T cells, PBMCs were first resuspended with Human TruStain Fcx (Biolegend) for 10 minutes at room temperature and then stained with the following antibodies in FACS buffer (PBS+ 2% fetal bovine serum): CD8a e450 (Invitrogen 48-0086-42,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD38+ICOS+</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD4</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Additional intracellular antibodies were: TNF-a AF488 (Biolegend 502915, 1:100)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>AF488</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Triplicate wells containing virus only (maximal CPE in the absence of mAb) and wells containing only Vero cells in medium (no-CPE wells) were included as controls.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mass cytometry datasets in this manuscript have been deposited in FlowRepository (http://flowrepository.org/).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowRepository</div><div>suggested: (FLOWRepository, RRID:SCR_013779)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Comparisons of population frequencies pre- and post-vaccination as well as correlations between post-vaccine cell frequencies and IgG titers were done in GraphPad Prism version 9.0.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were analyzed on a Miltenyi MACSQuant16 Analyzer with single-stain control PBMC samples used for compensation conducted in FlowJo v10.6.2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">) sequencing core at an appropriate target concentration for 10X Genomics library preparation and subsequent sequencing.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Genomics</div><div>suggested: (UTHSCSA Genomics Core, RRID:SCR_012239)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 50 μL of cell culture medium (DMEM supplemented with 2% FBS) was added to each well of a 96-well E-plate using a ViaFlo384 liquid handler (Integra Biosciences) to obtain background reading.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Integra Biosciences</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">RTCA IC50 values were determined by nonlinear regression analysis using Prism software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Single-Cell RNA-Seq analysis: Single-cell analysis was performed using Seurat v4.0.0 (14)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Seurat</div><div>suggested: (SEURAT, RRID:SCR_007322)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on pages 34, 35, 36 and 50. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.26.453755: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: The protocols were approved by the institutional ethical committee “Comité d’Ethique en Expérimentation Animale du Commissariat à l’Energie Atomique et aux Energies Alternatives” (CEtEA #44) under statement number A20-011.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Animals and study design: Cynomolgus macaques were randomly assigned in two experimental groups.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">10 μl of sample were loaded into the capillary and intrinsic fluorescence was measured at a ramp rate of 1°C/min with an excitation power of 30 %.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A horseradish peroxidase (HRP) conjugated goat anti-monkey H+L antibody (Invitrogen #PA1-84631) was then added and incubated for 1h before excess Ab was washed out and HRP substrate added.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-monkey H+L</div><div>suggested: (Thermo Fisher Scientific Cat# PA1-84631, RRID:AB_933605)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CD3 (APC-Cy7, SP34-2, BD), CD4 (BV510, L200, BD) and CD8 (PE-Vio770, BW135/80, Miltenyi Biotec) antibodies was used as lineage markers.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD4</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD8</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>PE-Vio770, BW135/80, Miltenyi Biotec</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The SARS-CoV-2 S RBD domain (residues 319 to 541) was expressed in EXPI293 cells by transient transfection according to the manufacturer’s protocol (Thermo Fisher Scientific).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>EXPI293</div><div>suggested: RRID:CVCL_D615)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viruses and cells: For the macaques studies, SARS-CoV-2 virus (hCoV-19/France/ lDF0372/2020 strain) was isolated by the National Reference Center for Respiratory Viruses (Institut Pasteur, Paris, France) as previously described (Lescure et al., 2020) and produced by two passages on Vero E6 cells in DMEM (Dulbecco’s Modified Eagles Medium) without FBS, supplemented with 1% P/S (penicillin at 10,000 U ml−1 and streptomycin at 10,000 μg ml−1) and 1 μg ml−1 TPCK-trypsin at 37 °C in a humidified CO2 incubator and titrated on Vero E6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirus neutralization assay: Pseudovirus was produced by co-transfecting the pCR3 SARS-CoV-2-SΔ19 expression plasmid (Wuhan Hu-1; GenBank: MN908947.3) with the pHIV-1NL43 ΔEnv-NanoLuc reporter virus plasmid in HEK293T cells (ATCC, CRL-11268) (Caniels et al., 2021).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: ATCC Cat# CRL-11268, RRID:CVCL_1926)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T/ACE2 cells kindly provided by Dr. Paul Bieniasz (Schmidt et al., 2020) were seeded at a density of 20,000 cells/well in a 96-well plate coated with 50 μg/mL poly-L-lysine 1 day prior to the start of the neutralization assay.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T/ACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For RBD expression, the following reagent was produced under HHSN272201400008C and obtained through BEI Resources, NIAID, NIH: Vector pCAGGS containing the SARS-Related Coronavirus 2, Wuhan-Hu-1 Spike Glycoprotein Receptor Binding Domain (RBD), NR-52309.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCAGGS</div><div>suggested: RRID:Addgene_18926)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirus neutralization assay: Pseudovirus was produced by co-transfecting the pCR3 SARS-CoV-2-SΔ19 expression plasmid (Wuhan Hu-1; GenBank: MN908947.3) with the pHIV-1NL43 ΔEnv-NanoLuc reporter virus plasmid in HEK293T cells (ATCC, CRL-11268) (Caniels et al., 2021).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pHIV-1NL43 ΔEnv-NanoLuc</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The pCR3 SARS-CoV-2-SΔ19 expression plasmid contained the following mutations compared to the WT for the variants of concern: deletion (Δ) of H69, V70 and Y144, N501Y, A570D, D614G, P681H, T716I, S982A and D1118H in B.1.1.7; L18F, D80A, D215G, L242H, R246I, K417N, E484K, N501Y, D614G and A701V in B.1.351; L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y and T1027I in P.1 (Caniels et al., 2021).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCR3 SARS-CoV-2-SΔ19</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody titers are presented as ED50 using the GraphPad Prism software version 6.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">One million of PBMC were cultured in complete medium (RPMI1640 Glutamax+, Gibco; supplemented with 10 % FBS), supplemented with co-stimulatory antibodies (FastImmune CD28/CD49d, Becton Dickinson).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gibco</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, cells were washed, stained with a viability dye (LIVE/DEAD fixable Blue dead cell stain kit, ThermoFisher), and then fixed and permeabilized with the BD Cytofix/Cytoperm reagent.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ThermoFisher</div><div>suggested: (ThermoFisher; SL 8; Centrifuge, RRID:SCR_020809)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Analyses were performed with the FlowJo v.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.24.21261047: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: After the written consent form was given, subjects were designated to either active (proxalutamide) arm or placebo arm.<br>IRB: This RCT has been approved by the national ethics committee (approval numbers 4.173.074 and 4.513.428, for males and females, respectively).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Inclusion criteria included age above 18 years old, absence of contraindication to any of the drugs used in the study, oxygen saturation above 92% and confirmed non-pregnancy in case of females.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Subjects with confirmed COVID-19 through a positive rtPCR-SARS-CoV-2 test for the past seven days were recruited to participate in the present randomized, double-blinded, placebo-controlled clinical trial to test the efficacy of proxalutamide, a second generation NSAA, versus standard of care (SOC) solely.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The XLSTAT version 2020.3.1.1008 (Addinsoft, Inc. New York, NY) was employed for the statistical analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>XLSTAT</div><div>suggested: (XLSTAT, RRID:SCR_016299)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Here we present a more thorough biochemical analysis without relevant losses to follow-up and attenuation of these previous limitations. In fact, results have been consistent with the biological hypothesis of anti-androgenic agents mechanism of action, and have demonstrated consistency across genders, age, and baselines characteristics. Proxalutamide therapy was related to improvements in immunologic system, including substantial reduction of neutrophils as early as Day 1, higher increases in total lymphocytes counts, lower N/L ratio, and faster eosinophil increase, as compared to placebo. Strikingly, patients randomized to placebo displayed a progressively increasing N/L ratio, reaching > 3:1 after one week follow up. This demonstrates that proxalutamide may prevent the immunologic progression of COVID-19, since all the changes observed in the proxalutamide group are positive in terms of outcomes. In addition, platelets, allegedly to be directly related with better overall prognosis, raised more rapidly in the proxalutamide group compared to placebo group. Ferritin levels increase considerably during COVID-19, and has been proposed to be an independent predictor of worse COVID-19 related outcomes.28, Ferritin increased less expressively and decreased more quickly among proxalutamide users compared to placebo, providing an additional sign of proxalutamide anti-inflammatory effects. We have found that usCRP levels are statistically lower after seven days of proxalutamide thera...

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04853134</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Active, not recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Proxalutamide Treatment for COVID-19 Female Outpatients</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04446429</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Completed</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Anti-Androgen Treatment for COVID-19</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.23.453352: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: BioIVT sought informed consent from each subject, or the subjects legally authorized representative and appropriately documented this in writing.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After sample incubation for 2 h at RT, the wells were washed five times with wash buffer and the presence of IgGs directed against above-defined SARS-CoV-2 antigens was detected using an HRP-linked anti-human IgG antibody (Peroxidase AffiniPure Goat Anti-Human IgG, Fcγ Fragment Specific, Jackson, 109-035-098, at 1:4000 dilution in sample buffer) at 20 μL/well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-Human IgG</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 109-035-098, RRID:AB_2337586)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Equilibrium affinity binding curves of recombinant antibodies against S1 proteins of HCoV-HKU1 and HCoV-NL63: For affinity measurements of anti-human coronavirus spike glycoprotein HKU1 (40021-MM07-100, Sino Biological) to HCoV-HKU1 S1 protein, the antibody was reconstituted according to the manufacturer’s instructions and diluted into PBS, containing 0.05% Tween 20 and 5% human serum albumin (HSA), to achieve a two-fold concentration series ranging from 60 pM to 1 μM.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human coronavirus spike glycoprotein HKU1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For cross-reactivity measurements, anti-SARS-CoV-2 neutralizing antibody (SAD-S35, Acro Biosystems) was reconstituted according to the manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The binding affinities and concentrations of antigen-specific antibodies in serum samples were determined by monitoring the fraction of labeled antigen that diffused into the distal chamber of the microfluidic device.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antigen-specific</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">As serum samples were derived from convalescent patients, potentially containing different classes of antibodies with variable numbers of binding sites (IgG = 2, IgM = 10), antibody concentration is expressed in terms of binding sites, rather than molecules.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgG = 2 , IgM = 10) ,</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 RBD and HCoV-NL63-RBD competition assay: 10 nM Alexa Fluor 647 labeled HCoV-NL63 RBD in PBS containing 0.05% Tween 20 was combined with serum sample corresponding to a final anti-NL63 RBD antibody concentration of 20 nM (based on previous MAAP of each serum sample).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-NL63 RBD</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pre-COVID sera were seropositive for the following coronaviruses: serum 1 (HCoV-229E, HCoV-NL63), serum 2 (HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1) and serum 3 (HCoV-229E).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HCoV-NL63</div><div>suggested: RRID:CVCL_RW88)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For profiling of serum against SARS-CoV-2 S1, SARS-CoV-2 S2, HCoV-NL63 S1 and HCoV-HKU1 S1, the buffer additionally contained 5% human serum albumin (HSA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HCoV-NL63 S1</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">alignment: Sequence alignment of coronavirus full length spikes was performed using the Clustal Omega Sequence Alignment Tool.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Clustal Omega</div><div>suggested: (Clustal Omega, RRID:SCR_001591)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The p(EC50) values for all samples and antigens were visualized using the ggplot2 package in R.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ggplot2</div><div>suggested: (ggplot2, RRID:SCR_014601)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. Reviewer #2 (Public Review): 

      In this study, Imai et al. uncover a role for the truncated haemoglobin protein YjbI in biofilm formation by the model bacterium B. subtilis. They show that yjbI gene disruption results in altered biofilms, with increased wettability and different matrix stiffness relative to cells. The absence of YjbI activity results in aggregation of the amyloid-like TasA matrix protein, and the biofilm wettability defect of the yjbI mutant can be recapitulated by anti-YjbI immune serum, suggesting that YjbI is located on the cell surface. Absence of YjbI also modestly increases the sensitivity of cells growing on agar plates to the oxidant AAPH. Using the model protein substrate BSA, purified YjbI can at least partially reverse oxidant-induced BSA aggregation in vitro, convincingly showing the YjbI has protein hydroperoxide peroxidase activity, which is evidently an unusual enzymatic activity. Finally, the authors examine lipid peroxidation and conclude that YjbI is not involved. The results are interesting in that they connect YjbI to a biofilm phenotype and convincingly show protein hydroperoxide peroxidase activity by a truncated haemoglobin protein, an activity not previously attributed to this class of proteins. 

      The experiments are largely well done, but some of the corresponding conclusions are overinterpreted, connecting ideas without experimental support. Moreover, the yjbI mutant has a narrow and relatively mild phenotype. 

      1) The paper identifies two separate properties of YjbI: its mutant phenotype with respect to biofilm formation, and its peroxidase activity against oxidant-induced aggregation of TasA and BSA. The authors conclude that these properties are connected, but this is not formally tested. While purified YjbI can reverse hydrogen peroxide-induced aggregation of purified TasA in vitro, and the yjbI mutant shows more TasA in the insoluble fraction of B. subtilis pellicle lysates, these experiments do not show that the TasA aggregates in pellicle lysates are caused by peroxidation, nor do they show that TasA aggregation is normally kept at bay by YjbI peroxidase activity (it is possible that YjbI has a separate role in biofilm integrity). Some experiments that might lend support to this connection include examining the biofilm phenotype of a catalytically dead point mutant of YjbI (perhaps Y25 or Y63, l. 298, or other residues informed by the crystal structure of Giangiacomo et al.) to establish whether peroxidase activity is important for biofilm formation. Such a mutant would be particularly valuable, as it could also be used to test whether inactivation of enzyme activity affects other phenotypes (cell stiffness, for example). Another approach would be to use a soluble antioxidant molecule, purified YjbI, or another peroxidase to see if the yjbI biofilm can be rescued. 

      2) The authors conclude on the basis of the AFM data in Fig. 1 that yjbI mutant cells are less stiff than WT cells, but the data only show relative stiffness. It is also unclear why a change in cell envelope stiffness would relate to biofilm wettability (ll. 130-131). If there truly is a change in cell envelope stiffness, a high-resolution, head-to-head AFM comparison of planktonically grown cells would be informative. 

      3) The data in Fig. 2F showing hypersensitivity of yjbI mutant cells to AAPH were generated in an unusual way: stationary-phase liquid culture was spotted on an LB plate, and the colonies were "fractionated" at the noted intervals and resuspended in saline for OD measurement. Measuring sensitivity to AAPH just in shaking liquid planktonic culture would make this phenotype more convincing. Under non-biofilm forming conditions, is a surface-associated peroxidase important for cell growth or survival under oxidant challenge?

    1. About 6,790,000,000 results (1.06 seconds) .ULSxyf{margin-bottom:44px}.fKw1wf{margin:0 0 8px}.kno-fb-d3 .oRJe3d,.i1eWpb .oRJe3d{pointer-events:none}html:not(.zAoYTe) .kp-wholepage a{outline:0}.ky4hfd{display:none}.OeVqAd{margin-left:-180px;position:absolute;width:180px;z-index:100;top:0}.iFBpgc{list-style-type:none;padding-top:28px}.iFBpgc .LfE12c{cursor:pointer;font-size:14px;margin:1px 16px 1px 0}.iFBpgc .LfE12c:first-of-type{margin-top:0}.iFBpgc .LfE12c .MjJo9{border-bottom-right-radius:20px;border-top-right-radius:20px;color:#70757a;display:inline-block;max-width:119px;overflow:hidden;padding:8.5px 20px 8.5px 25px;text-overflow:ellipsis;white-space:nowrap}.iFBpgc .LfE12c.iqv4K .MjJo9{background:#e8f0fe;color:#185abc}.iFBpgc .LfE12c:not(.iqv4K):hover .MjJo9{background:#f1f3f4;color:#3c4043}.YB4h9{color:#fff;background-color:#1a73e8;padding:18px 60px 18px 12px;position:relative}.C85rO{font-size:20px}.Gtr0ne{font-size:13px;padding-top:10px}.YB4h9 .Gtr0ne a{color:#fff;text-decoration:underline}.YB4h9 .Job8vb{padding:20px;position:absolute;right:0;top:0}.K20DDe{position:relative}.K20DDe{padding:0 30px 0 25px}.eoNQle{margin-bottom:12px}.NnvERc{align-items:center;display:flex;justify-content:center;overflow:hidden}.Ub31p .NnvERc{display:inline-block;margin:0 0 12px 0}.NnvERc.ftSi0d{border-radius:8px}.NnvERc.ftSi0d:focus-within{outline:-webkit-focus-ring-color auto 1px}g-img{display:block;height:100%}.rISBZc{display:block;border:0}.M4dUYb{position:relative}.wDYxhc{clear:both}.cUnQKe .wDYxhc,.related-question-pair .wDYxhc{clear:none}html .kp-blk .xpdclose .LKPcQc,html .kp-blk .xpdopen .viOShc{padding-top:0}.Wnoohf .xpdclose .wDYxhc.xsZWvb,.Wnoohf .xpdopen .wDYxhc.EfDVh{padding-bottom:0}#rhs .kp-blk .xpdclose .LKPcQc,#rhs .kp-blk .xpdopen .viOShc{padding-top:0}#rhs .Wnoohf .xpdclose .wDYxhc.xsZWvb,#rhs .Wnoohf .xpdopen .wDYxhc.EfDVh{padding-bottom:0}#rhs .Wnoohf .xpdclose .wDYxhc.xsZWvb.ecRggb,#rhs .Wnoohf .xpdopen .wDYxhc.EfDVh.ecRggb,#rhs .kp-blk .ecRggb{padding-bottom:15px}.ZxoDOe{line-height:1.2;position:relative;}.PyJv1b{color:#202124;font-family:Roboto-Medium,HelveticaNeue-Medium,Helvetica Neue,sans-serif-medium,Arial,sans-serif;font-size:20px;overflow:hidden;padding:0 0 8px;line-height:26px}.ss6qqb .PyJv1b{font-family:Roboto-Regular,Helvetica Neue,Arial,sans-serif;font-size:16px;line-height:24px;padding:0;font-size:20px;line-height:26px}.wx62f{color:#5F6368;font-family:Roboto-Regular,Helvetica Neue,Arial,sans-serif;font-size:14px;padding:0 0 0;line-height:22px;vertical-align:middle}.nyXFKc,.cPPtge .wx62f{font-size:14px;line-height:20px}.pEZBSb .PyJv1b{font-size:20px;line-height:26px;overflow-wrap:break-word;padding:0 0 8px}.ZtJ1fd{margin-top:30px;padding-left:28px}.m0RhYb{color:#5F6368;cursor:pointer;font-size:14px;margin-bottom:10px}.oYj6Dc{position:relative;top:5px}.eYCffb{display:inline-block;height:100%;margin-left:8px}.Znsfnf{position:relative}.GhpATe{display:none}.GhpATe.pttBJc{display:block}@keyframes ghost-card-shimmering {0%{transform:translateX(-100%)}100%{transform:translateX(100%)}}g-raised-button{display:inline-block;margin:0 4px;position:relative}.JNkvid{display:flex;align-items:flex-start;margin:0 0px;}.JNkvid .HnYYW{color:#202124;font:normal 22px/28px Roboto-Regular,Helvetica Neue,Arial,sans-serif;letter-spacing:0.25px;padding:28px 16px 12px}.JNkvid .HnYYW{padding:28px 0 12px}.IVvPP .JNkvid .HnYYW,.Jb0Zif .JNkvid .HnYYW{overflow:visible;padding:0}.JNkvid .sfkRie{font:12px/16px Roboto-Regular,Helvetica Neue,Arial,sans-serif;margin-top:4px}.KSl27.JNkvid .HnYYW{font:16px/24px Roboto-Medium,HelveticaNeue-Medium,Helvetica Neue,sans-serif-medium,Arial,sans-serif;letter-spacing:.2px;padding:16px 8px 8px}.Ub31p .LMRCfc .JNkvid .HnYYW{padding-top:0}.Jb0Zif .JNkvid{margin-bottom:12px}.Jb0Zif .cLjAic{margin:44px 0}.Jb0Zif.IVvPP .LMRCfc,.IVvPP .LMRCfc,.Hwkikb.LMRCfc{margin-top:6px}.Jb0Zif.IVvPP .jHARG,.IVvPP .jHARG,.Hwkikb.jHARG{margin-bottom:16px}.Jb0Zif.Ub31p .LMRCfc{margin-top:0}.Jb0Zif .LMRCfc{margin-top:16px}.IVvPP .cLjAic:not(.WY0eLb),.Hwkikb:not(.WY0eLb){background:#fff;border:1px solid #dfe1e5;border-radius:8px;margin-top:16px}.IVvPP .cLjAic.WY0eLb,.Hwkikb.WY0eLb{border-left:1px solid #dadce0;padding-left:20px;padding-bottom:20px;width:335px;overflow:hidden}.IVvPP .JNkvid,.Hwkikb .JNkvid{border-bottom:1px solid #dfe1e5;padding:12px 16px;margin-bottom:0}.IVvPP .WY0eLb .JNkvid,.Hwkikb.WY0eLb .JNkvid{padding-top:0;padding-left:0;padding-right:0}.IVvPP .HnYYW,.Hwkikb .HnYYW{font-size:18px;line-height:24px}.WeviRb{margin-right:16px}.T9EeC{color:rgba(0,0,0,.54);display:flex;align-items:normal;}.T9EeC:hover{cursor:pointer}.T9EeC:hover div{color:#1a0dab}.T9EeC:hover .WeviRb{color:#1a0dab}.IVvPP .T9EeC,.ss6qqb .T9EeC{align-items:center}.WeviRb{margin:-1px 0 0 4px;color:#70757a;top:3px}.ss6qqb .WeviRb,.IVvPP .WeviRb{top:0}.kp-wholepage-osrp .j6mBxc a,.kp-wholepage-osrp .j6mBxc a:active,.kp-wholepage-osrp .j6mBxc a:link,.kp-wholepage-osrp .j6mBxc a:visited{color:#70757a;text-decoration:underline}.HnYYW{flex:1;color:rgba(0,0,0,.87);overflow:hidden}.UDZeY{font-size:14px}.vnLNtd.mnr-c.B03h3d,.wXlZre.B03h3d{margin-top:0}.ss6qqb .ptcLIOszQJu__wholepage-card:not(.B03h3d):not(.j9HMU){border-top:1px solid rgba(0,0,0,.12)}.IVvPP .WY0eLb .ptcLIOszQJu__wholepage-card,.IVvPP .ptcLIOszQJu__wholepage-card.WY0eLb{width:335px}.IVvPP.rhstc4 .WY0eLb .ptcLIOszQJu__wholepage-card,.IVvPP.rhstc4 .ptcLIOszQJu__wholepage-card.WY0eLb{width:335px}.IVvPP .ptcLIOszQJu__wholepage-card:not(first-card).V14nKc{border:none;border-top:1px solid rgba(0,0,0,.12);border-radius:0}.C2QLh,.lPhZce,.ONOEFd{display:flex}.VgWAtf{align-items:center;display:flex;padding-left:20px;padding-right:4px;}.VgWAtf a{cursor:pointer}g-scrolling-carousel{display:block;position:relative;}.mR2gOd{display:block;overflow-x:auto;overflow-y:hidden;position:relative;white-space:nowrap;transform:translate3d(0,0,0);transform:translate3d(0,0,0);}.mR2gOd::-webkit-scrollbar{display:none}.DAVP1{display:inline-block}.oyj2db{-webkit-box-orient:vertical;color:#222;display:-webkit-box;font-size:14px;-webkit-line-clamp:2;line-height:20px;max-height:2.858em;overflow:hidden;text-overflow:ellipsis;white-space:normal}.wwLdc{margin-top:4px}.MVXjze:not(:first-child){margin-top:4px}.Si5xMe{border-radius:8px;box-shadow:0 1px 2px rgba(0,0,0,0.24);display:flex;font-family:Roboto-Regular,Helvetica Neue,Arial,sans-serif;overflow:hidden;position:relative}.nZWEZc{display:flex;margin:0 0 0 8px;vertical-align:top}.Jb0Zif .Si5xMe.CUaNQd{border:1px solid #dfe1e5;box-shadow:none}.Jb0Zif .Bo9xMe{padding:5px 8px 10px}.nZWEZc.IVVAzc{margin-left:0}.ttwCMe{flex:1 1 auto;flex-direction:column}.Jb0Zif a.ttwCMe:focus{background:#f8f9fa}.nZWEZc .ttwCMe{background-color:#fff;display:block;height:100%}.L3OsEb{background:#dadce0;position:relative}.Bo9xMe{color:#70757a;font-size:12px;padding:10px 8px 16px}@media (min-width:480px){.LYaCpc .ttwCMe{display:flex;flex-direction:row-reverse}.LYaCpc .L3OsEb,.LYaCpc .ye8BMe{width:50%}}.FQ7nIf.vm2hoe .x8MNbf,.LYaCpc.vm2hoe .x8MNbf{background-color:rgba(0,0,0,.54);font-size:14px;height:16px;line-height:16px;padding:6px 8px}.Si5xMe.kno-wp-mi-l .Bo9xMe,.Si5xMe.kno-wp-mi-l .ttwCMe{background:#34a853}.NYCPFe .L3OsEb{background:rgba(26, 73, 232, 0.03)}.NYCPFe .oyj2db{font:14px/20px Roboto-Regular,Helvetica Neue,Arial,sans-serif;color:rgba(0,0,0,.54);}.Udn7tf:not([src]),.dObWeb:not([src]),.TZP4e:not([src]),.W3Dzlf:not([src]){content:url("data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==")}.dObWeb,.W3Dzlf{opacity:.001;transition:opacity 200ms cubic-bezier(.4,.0,.2,1)}.QUAxK,.TZP4e,.W3Dzlf{display:block;width:100%;height:100%;object-fit:cover;}.buTsJf{line-height:115%}.EUjJDc{color:rgba(0,0,0,.54);font-size:14px;margin-top:12px;text-align:center;word-wrap:break-word;}.YsiKr{margin:0 auto}.S3PB2d{margin:auto}.OvQkSb{border-radius:999rem}.CNf3nf{cursor:pointer;display:block;position:relative;border:1px solid #dfe1e5;z-index:0}.CNf3nf:focus{outline:none}.CNf3nf .PUDfGe{position:absolute;left:0;right:0;top:0;bottom:0;width:24px;height:24px}.wecD1d{width:56px;height:56px}.OZ5bRd{margin-bottom:auto;margin-top:auto}.Lu0opc{cursor:pointer;height:72px;position:absolute;display:block;visibility:inherit;width:36px;bottom:0;outline:none;opacity:0.8;top:0;z-index:101}.Lu0opc.tHT0l{-webkit-transition:opacity 0.5s,visibility 0.5s;transition:opacity 0.5s,visibility 0.5s}.Lu0opc:hover{opacity:0.9}.Lu0opc:focus{outline:none}.Lu0opc.pQXcHc,.Lu0opc.pQXcHc:hover{cursor:default;opacity:0;visibility:hidden}.Lu0opc.Oom88b{height:48px;width:48px;opacity:0.9}.Lu0opc.Oom88b:hover{opacity:1.0}.Lu0opc.Oom88b.pQXcHc,.Lu0opc.Oom88b.pQXcHc:hover{opacity:0}.Lu0opc.Oom88b:hover g-fab{color:#202124 !important}.BlOseb.Oom88b g-fab,.k2Oeod.Oom88b g-fab{box-shadow:0 7px 15px rgba(0,0,0,.2);cursor:pointer;height:48px;width:48px}.BlOseb.Oom88b{left:20px}.k2Oeod.Oom88b{right:20px}Search ResultsChoose what you’re giving feedback onOr give general feedback(function(){var st='overview';var tc='_BdsHYde7GoaFtQbj95CwCQ34';var ra=true; var a=["tvcap","atvcap","bottomads","rhsads"];var b=location.hash,c=st,d=tc,e=ra;window["wp-df-tab"]=void 0;var f,g=b.match(/[&#]wptab=([^=&]+)/);if((f=g?g[1]:"")&&f!=c){if(window["wp-df-tab"]=f,e)for(var h=0,k=void 0;k=a[h++];){var l=document.getElementById(k);if(!l)break;for(var m=l.children,n=0,p=void 0;p=m[n++];)p.style.display="none"}}else{var q=document.getElementById(d);q&&(q.style.visibility="",q.style.opacity=1)};})();The Good Place2016 ‧ Sitcom ‧ 4 seasonsOverviewCastEpisodesWatch showReviewsNewsTrailers & clipsShareShareFacebookTwitterEmailClick to copy linkShare linkLink copiedMain ResultsLoadingSomething went wrong.TRY AGAIN Cast Kristen Bell Eleanor Shellstrop Jameela Jamil Tahani Al-Jamil Ted Danson Michael Manny Jacinto Jason Mendoza D'Arcy Carden Janet Della-Denunzio William Jackson Harper Chidi Anagonye Marc Evan Jackson Shawn View all (function(){ window.cVrhhd=function(c,f,q,a,h,k,r){if((c=document.getElementById(c))&&(0!=c.offsetWidth||0!=c.offsetHeight)){var l=c.querySelector("div"),m=l.querySelector("div"),d=0,g=l.scrollWidth-l.offsetWidth;if(0<f){var n=m.children;d=n[f].offsetLeft-n[0].offsetLeft;if(a){for(var p=d=0;p<f;++p)d+=n[p].offsetWidth;d=Math.min(g,d)}}d+=q;f=Math.min(a?g-d:d,g);l.scrollLeft=a&&(h||r)?d:a&&k?-d:f;var b=c.getElementsByTagName("g-left-button")[0],e=c.getElementsByTagName("g-right-button")[0];b&&e&&(h=/\btHT0l\b/,k=/\bpQXcHc\b/,b.className=b.className.replace(h,""),e.className=e.className.replace(h,""),0==f?b.className="pQXcHc "+b.className:b.className=b.className.replace(k,""),f==g?e.className="pQXcHc "+e.className:e.className=e.className.replace(k,""),0<=b.className.indexOf("SL0Gp")&&0==f&&f==g&&(m.style.paddingLeft="0px",m.style.paddingRight="0px",b.style.display="none",e.style.display="none",c.style.paddingLeft=a?"0px":"48px",c.style.paddingRight=a?"48px":"0px",c.style.textAlign=a?"left":"right",(a=document.getElementById("fade_forward"))&& (a.style.display="none"),(a=document.getElementById("fade_reverse"))&&(a.style.display="none")),setTimeout(function(){b.className+=" tHT0l";e.className+=" tHT0l"},50))}};}).call(this);(function(){var id='_BdsHYde7GoaFtQbj95CwCQ21';var index=0;var offset=0;var is_rtl=false;var is_ie=false;var is_gecko=false;var is_edge=false;var init='cVrhhd';window[init](id,index,offset,is_rtl,is_ie,is_gecko,is_edge);})(); function _setImagesSrc(e,d){function f(b){b.onerror=function(){b.style.display="none"};b.src=d}for(var g=0,a=void 0;a=e[g++];){var c=document.getElementById(a)||document.querySelector('img[data-iid="'+a+'"]');c?(a=void 0,(null==(a=google.c)?0:a.setup)&&google.c.setup(c),f(c)):(google.iir=google.iir||{},google.iir[a]=d)}}"undefined"==typeof window.google&&(window.google={});(function(){var s='data:image/jpeg;base64,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';var ii=['wp_thbn_15'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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';var ii=['wp_0'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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\x3d\x3d';var ii=['wp_2'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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\x3d\x3d';var ii=['wp_4'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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\x3d';var ii=['wp_6'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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\x3d\x3d';var ii=['wp_8'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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\x3d\x3d';var ii=['wp_10'];_setImagesSrc(ii,s);})();.xpdclose .a84NUc:not(:empty),.xpdopen .CQKTwc:not(:empty){border-top:solid 1px #ddd;border-radius:0}.xpdclose .TOfaBb.SHa8ve,.xpdopen .LL5J7d.SHa8ve{display:block}.xpdclose .oHglmf,.xpdopen .xzPb7d{padding-bottom:16px}.xpdclose .kp-header .oHglmf,.xpdopen .kp-header .xzPb7d{padding-bottom:0}.c2xzTb .xpdclose .oHglmf,.c2xzTb .xpdopen .xzPb7d{padding-bottom:0}.HSryR .xpdclose .oHglmf,.HSryR .xpdopen .xzPb7d{padding-bottom:0}.Wnoohf .xpdopen .yp1CPe,.OJXvsb .xpdclose .siXlze{padding-bottom:16px}#rhs .Wnoohf .xpdopen .yp1CPe,#rhs .OJXvsb .xpdclose .siXlze{padding-bottom:15px}.GUHazd{padding-bottom:12px}.Jb0Zif .cLjAic.K7khPe{margin:30px 0}.LJqTIc .UgLoB,.LJqTIc .FXMOpb{min-height:60px}.ss6qqb .LJqTIc .UgLoB,.ss6qqb .LJqTIc .FXMOpb{min-height:48px}.vnLNtd.mnr-c,.wXlZre{margin:16px 0 0;}.vnLNtd.mnr-c.dv1r4e,.wXlZre.dv1r4e{margin-bottom:36px}.g-blk{position:relative}.kp-blk a{text-decoration:none}.kp-blk .match-mod-horizontal-padding,.kp-blk .wDYxhc:not(.NFQFxe){padding-left:16px;padding-right:16px;}.kp-blk.c2xzTb .match-mod-horizontal-padding,.kp-blk.c2xzTb .wDYxhc:not(.NFQFxe){padding-left:0;padding-right:0}.kp-blk{box-shadow:none;background:#fff;border:1px solid #dfe1e5;border-radius:8px;}.kno-kp.mnr-c.g,.g-blk.g,.KIy09e{width:652px}#center_col .kp-blk{position:relative}#center_col .Jb0Zif .kp-blk{margin-left:0;margin-right:0}.kp-blk .g:not(.g-blk){margin:0}.kp-blk>.vk_arc,.kp-blk>div>.vk_arc{margin:0}.kp-blk .g{margin-bottom:0}.knowledge-panel.kp-blk .wDYxhc,.c14z5c .wDYxhc{line-height:1.58}.c2xzTb .g,.cUnQKe .g,.c2xzTb .tF2Cxc,.ruTcId .tF2Cxc{clear:both;padding-bottom:0}.kp-blk.c2xzTb,.kp-blk.ruTcId,.kp-blk.HanQmf{border:none}.kp-blk.c2xzTb .g,.kp-blk.ruTcId .g,.kp-blk.HanQmf .g,.kp-blk.c2xzTb+.kno-ftr{padding-left:0;padding-right:0}.kp-blk.cUnQKe{border-radius:0;border:none}.kp-blk.cUnQKe .ygGdYd .wDYxhc:not(.NFQFxe),.cUnQKe .ygGdYd .g{padding-left:0px;padding-right:0px}.q1kEvb .related-question-pair.ygGdYd{margin-bottom:9px}.cbphWd{border-top:1px solid #ecedef;cursor:pointer;display:block;font-size:16px;padding-bottom:9px;padding-top:9px;position:relative;line-height:1.58;}.ygGdYd .cbphWd{padding-bottom:0px}a.cbphWd{color:inherit;text-decoration:none !important}#rhs .related-question-pair .iUh30,#rhs .related-question-pair .LC20lb{display:block;overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.cxrEAd,.uKh9yc{display:block;opacity:0;transform:scale(0);transition-property:border-width,opacity,transform}.uKh9yc{border:10px solid transparent;margin:0px auto}.gy6Qzb{-webkit-transition:max-height 0.3s;overflow:hidden}.S8PBwe{max-height:0;visibility:hidden}.vp45yf{pointer-events:none;position:absolute !important;right:0;color:#70757a;top:50%;margin-top:-12px}.mWyH1d{position:relative}.Jb0Zif .UiGGAb.ILfuVd,.ILfuVd{font-size:16px;line-height:24px;}.SALvLe .LGOjhe,.Jb0Zif .LGOjhe,.HSryR .LGOjhe,.IVvPP .LGOjhe{padding:0 0 10px;margin:10px 0 0 0}#res .Jb0Zif .qDOt0b h3,.IVvPP .qDOt0b h3{font-size:16px;line-height:1.375}.Jb0Zif .qDOt0b .iUh30,.IVvPP .qDOt0b .iUh30{font-size:14px;line-height:1.58}.Jb0Zif .qDOt0b,.IVvPP .qDOt0b{border-bottom:1px solid #ebebeb;padding-bottom:6px}.tF2Cxc{position:relative}.IsZvec,.GELlw{max-width:48em;color:#4d5156;line-height:1.58}.VwiC3b{word-wrap:break-word}.VwiC3b sup{line-height:0.9}.yuRUbf{font-weight:normal;font-size:small;line-height:1.58;}a:hover h3.LC20lb{text-decoration:underline}.LC20lb{display:inline-block;line-height:1.3;margin-bottom:3px;}.DKV0Md{padding-top:4px;padding-top:5px;}.VjDLd .TieM1d .tjvcx,.IVvPP .tjvcx,.kno-kp .tjvcx,.VjDLd .kp-wholepage-osrp .tjvcx,#rhs .ss6qqb .tjvcx{display:inline-block;height:19px;overflow-y:hidden}.qzEoUe{color:#202124;white-space:-webkit-nowrap}.dyjrff{color:#5f6368}.B6fmyf{position:absolute;top:0;height:0;visibility:hidden;white-space:nowrap}.eFM0qc{display:inline-block;padding-bottom:2px;padding-top:1px;padding-left:2px;visibility:visible}.xKf9F{margin-top:16px}#rhs .KFFQ0c,.xpd-wa .KFFQ0c{display:none}.KFFQ0c{align-items:center;display:flex;margin-bottom:0px;width:652px}.akqY6{background:#dadce0;height:1px;width:100%}.KFFQ0c .YfftMc,.KFFQ0c .YfftMc span,.KFFQ0c .YfftMc div,.KFFQ0c .YfftMc a{align-items:center;color:#70757a;display:flex;font-size:12px;font-style:normal;margin:0;padding:0;white-space:nowrap}.vLK3gc{padding-top:6px}.H3TZoe{padding-left:6px;vertical-align:'top'}.eKjLze .g{margin-bottom:0}.csDOgf{display:inline;visibility:visible;position:absolute}.EwsJzb{display:block}.B8Kd8d{position:absolute}.IjabWd{margin-left:2px}.xTFaxe{fill:#70757a;top:2px}.D6lY4c{height:22px;width:22px;position:absolute;border-radius:11px;top:-1px}.iTPLzd{cursor:pointer;top:0;left:0;width:28px;z-index:1;line-height:16px;}.eY4mx{padding-left:12px}.lUn2nc{padding-right:12px}@keyframes forced-chip-animation {50%{background:#d2e3fc;border-color:#8ab4f8}}.yXK7lf em{color:#5f6368}.yXK7lf a:visited em,.yXK7lf a em{color:inherit}.MUxGbd{padding-top:0px;margin-bottom:0px}.lyLwlc{color:#202124}.yDYNvb.lyLwlc{color:#4d5156}.yDYNvb.lyLwlc b{color:#5f6368}.lEBKkf{display:-webkit-box;-webkit-box-orient:vertical;overflow:hidden}.jmjoTe{margin-left:10px;}.mslg td{padding-right:6px;padding-top:4px}.CK34J td{padding-top:12px}.mslg td{vertical-align:top}.mslg .l{font-size:20px;}#center_col .mslg .usJj9c{border:1px solid transparent;border-radius:2px;border-radius:2px;margin-top:2px;padding:3px 0 3px 5px;-webkit-transition:opacity .2s ease;transition:opacity .2s ease;width:294px}.usJj9c{display:inline-block;position:relative;width:100%}.usJj9c .st{overflow:hidden;color:#4d5156;width:220px}.c3mZkd .mslg.dmenKe td,.c3mZkd .mslg.c9EJob td{padding-bottom:20px}People also askWas the good place Cancelled?

      About 6,790,000,000 results (1.06 seconds)

      The Good Place 2016 ‧ Sitcom ‧ 4 seasons Overview Cast Episodes Watch show Reviews News Trailers & clips Share Cast

      Kristen Bell Eleanor Shellstrop

      Jameela Jamil Tahani Al-Jamil

      Ted Danson Michael

      Manny Jacinto Jason Mendoza

      D'Arcy Carden Janet Della-Denunzio

      William Jackson Harper Chidi Anagonye

      Marc Evan Jackson Shawn View all People also ask

      Was the good place Cancelled?

    1. Star Trek: The Next Generation - Wikipediahttps://en.wikipedia.org › wiki › Star_Trek:_The_Next_...https://en.wikipedia.org › wiki › Star_Trek:_The_Next_...About this resultBETASourceWikipedia is a free content, multilingual online encyclopedia written and maintained by a community of volunteer contributors through a model of open collaboration, using a wiki-based editing system.WikipediaYour connection to this site is securehttps://en.wikipedia.org/wiki/Star_Trek:_The_Next_GenerationThis is a search result, not an ad. Only ads are paid, and they'll always be labeled with "Sponsored" or "Ad."Send feedback on this info Privacy settingsHow Search worksCachedSimilarStar Trek: The Next Generation (TNG) is an American science fiction television series created by Gene Roddenberry. It originally aired from September 28, ...Starring: Patrick Stewart; ‎Jonathan Frakes‎; ‎Le...‎No. of seasons: 7No. of episodes: 178 (list of episodes‎)‎Original release: September 28, 1987 –; May 2...‎List of episodes · ‎List of cast members · ‎Season 5 · ‎Season 1star trek: the next generation caststar trek: the next generation top 250star trek: the next generation episodesstar trek: the next generation season 1star trek: the next generation season 2star trek: the next generation season 3People also search for function _setImagesSrc(e,d){function f(b){b.onerror=function(){b.style.display="none"};b.src=d}for(var g=0,a=void 0;a=e[g++];){var c=document.getElementById(a)||document.querySelector('img[data-iid="'+a+'"]');c?(a=void 0,(null==(a=google.c)?0:a.setup)&&google.c.setup(c),f(c)):(google.iir=google.iir||{},google.iir[a]=d)}}"undefined"==typeof window.google&&(window.google={});(function(){var s='data:image/jpeg;base64,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\x3d';var ii=['wp_thbn_15'];_setImagesSrc(ii,s);})();.kno-fb-d3 .oRJe3d,.i1eWpb .oRJe3d{pointer-events:none}.JNkvid{display:flex;align-items:flex-start;margin:0 0px;}.JNkvid .HnYYW{color:#202124;font:normal 22px/28px Roboto-Regular,Helvetica Neue,Arial,sans-serif;letter-spacing:0.25px;padding:28px 16px 12px}.JNkvid .HnYYW{padding:28px 0 12px}.JNkvid .sfkRie{font:12px/16px Roboto-Regular,Helvetica Neue,Arial,sans-serif;margin-top:4px}.KSl27.JNkvid .HnYYW{font:16px/24px Roboto-Medium,HelveticaNeue-Medium,Helvetica Neue,sans-serif-medium,Arial,sans-serif;letter-spacing:.2px;padding:16px 8px 8px}.Jb0Zif .JNkvid{margin-bottom:12px}.IVvPP .JNkvid,.Hwkikb .JNkvid{border-bottom:1px solid #dfe1e5;padding:12px 16px;margin-bottom:0}.IVvPP .WY0eLb .JNkvid,.Hwkikb.WY0eLb .JNkvid{padding-top:0;padding-left:0;padding-right:0}.IVvPP .HnYYW,.Hwkikb .HnYYW{font-size:18px;line-height:24px}.WeviRb{margin-right:16px}.T9EeC{color:rgba(0,0,0,.54);display:flex;align-items:normal;}.T9EeC:hover{cursor:pointer}.T9EeC:hover div{color:#1a0dab}.T9EeC:hover .WeviRb{color:#1a0dab}.IVvPP .T9EeC,.ss6qqb .T9EeC{align-items:center}.WeviRb{margin:-1px 0 0 4px;color:#70757a;top:3px}.ss6qqb .WeviRb,.IVvPP .WeviRb{top:0}.OvQkSb{border-radius:999rem}.HnYYW{flex:1;color:rgba(0,0,0,.87);overflow:hidden}.C2QLh,.lPhZce,.ONOEFd{display:flex}.VgWAtf{align-items:center;display:flex;padding-left:20px;padding-right:4px;}.VgWAtf a{cursor:pointer}g-scrolling-carousel{display:block;position:relative;}.mR2gOd{display:block;overflow-x:auto;overflow-y:hidden;position:relative;white-space:nowrap;transform:translate3d(0,0,0);transform:translate3d(0,0,0);}.mR2gOd::-webkit-scrollbar{display:none}.DAVP1{display:inline-block}.oyj2db{-webkit-box-orient:vertical;color:#222;display:-webkit-box;font-size:14px;-webkit-line-clamp:2;line-height:20px;max-height:2.858em;overflow:hidden;text-overflow:ellipsis;white-space:normal}.wwLdc{margin-top:4px}.MVXjze:not(:first-child){margin-top:4px}.Si5xMe{border-radius:8px;box-shadow:0 1px 2px rgba(0,0,0,0.24);display:flex;font-family:Roboto-Regular,Helvetica Neue,Arial,sans-serif;overflow:hidden;position:relative}.nZWEZc{display:flex;margin:0 0 0 8px;vertical-align:top}.Jb0Zif .Si5xMe.CUaNQd{border:1px solid #dfe1e5;box-shadow:none}.Jb0Zif .Bo9xMe{padding:5px 8px 10px}.nZWEZc.IVVAzc{margin-left:0}.ttwCMe{flex:1 1 auto;flex-direction:column}.Jb0Zif a.ttwCMe:focus{background:#f8f9fa}.nZWEZc .ttwCMe{background-color:#fff;display:block;height:100%}.L3OsEb{background:#dadce0;position:relative}.Bo9xMe{color:#70757a;font-size:12px;padding:10px 8px 16px}@media (min-width:480px){.LYaCpc .ttwCMe{display:flex;flex-direction:row-reverse}.LYaCpc .L3OsEb,.LYaCpc .ye8BMe{width:50%}}.FQ7nIf.vm2hoe .x8MNbf,.LYaCpc.vm2hoe .x8MNbf{background-color:rgba(0,0,0,.54);font-size:14px;height:16px;line-height:16px;padding:6px 8px}.Si5xMe.kno-wp-mi-l .Bo9xMe,.Si5xMe.kno-wp-mi-l .ttwCMe{background:#34a853}.NYCPFe .L3OsEb{background:rgba(26, 73, 232, 0.03)}.NYCPFe .oyj2db{font:14px/20px Roboto-Regular,Helvetica Neue,Arial,sans-serif;color:rgba(0,0,0,.54);}.Udn7tf:not([src]),.dObWeb:not([src]),.TZP4e:not([src]),.W3Dzlf:not([src]){content:url("data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==")}.dObWeb,.W3Dzlf{opacity:.001;transition:opacity 200ms cubic-bezier(.4,.0,.2,1)}.QUAxK,.TZP4e,.W3Dzlf{display:block;width:100%;height:100%;object-fit:cover;}.buTsJf{line-height:115%}.EUjJDc{color:rgba(0,0,0,.54);font-size:14px;margin-top:12px;text-align:center;word-wrap:break-word;}.YsiKr{margin:0 auto}.S3PB2d{margin:auto}.CNf3nf{cursor:pointer;display:block;position:relative;border:1px solid #dfe1e5;z-index:0}.CNf3nf:focus{outline:none}.CNf3nf .PUDfGe{position:absolute;left:0;right:0;top:0;bottom:0;width:24px;height:24px}.wecD1d{width:56px;height:56px}.OZ5bRd{margin-bottom:auto;margin-top:auto}.Lu0opc{cursor:pointer;height:72px;position:absolute;display:block;visibility:inherit;width:36px;bottom:0;outline:none;opacity:0.8;top:0;z-index:101}.Lu0opc.tHT0l{-webkit-transition:opacity 0.5s,visibility 0.5s;transition:opacity 0.5s,visibility 0.5s}.Lu0opc:hover{opacity:0.9}.Lu0opc:focus{outline:none}.Lu0opc.pQXcHc,.Lu0opc.pQXcHc:hover{cursor:default;opacity:0;visibility:hidden}.Lu0opc.Oom88b{height:48px;width:48px;opacity:0.9}.Lu0opc.Oom88b:hover{opacity:1.0}.Lu0opc.Oom88b.pQXcHc,.Lu0opc.Oom88b.pQXcHc:hover{opacity:0}.Lu0opc.Oom88b:hover g-fab{color:#202124 !important}.BlOseb.Oom88b g-fab,.k2Oeod.Oom88b g-fab{box-shadow:0 7px 15px rgba(0,0,0,.2);cursor:pointer;height:48px;width:48px}.BlOseb.Oom88b{left:20px}.k2Oeod.Oom88b{right:20px} Cast Patrick Stewart Jean-Luc Picard Marina Sirtis Deanna Troi Jonathan Frakes William T. Riker Brent Spiner Data, Lore LeVar Burton Geordi La Forge Gates McFadden Beverly Crusher Michael Dorn Worf View all (function(){ window.cVrhhd=function(c,f,q,a,h,k,r){if((c=document.getElementById(c))&&(0!=c.offsetWidth||0!=c.offsetHeight)){var l=c.querySelector("div"),m=l.querySelector("div"),d=0,g=l.scrollWidth-l.offsetWidth;if(0<f){var n=m.children;d=n[f].offsetLeft-n[0].offsetLeft;if(a){for(var p=d=0;p<f;++p)d+=n[p].offsetWidth;d=Math.min(g,d)}}d+=q;f=Math.min(a?g-d:d,g);l.scrollLeft=a&&(h||r)?d:a&&k?-d:f;var b=c.getElementsByTagName("g-left-button")[0],e=c.getElementsByTagName("g-right-button")[0];b&&e&&(h=/\btHT0l\b/,k=/\bpQXcHc\b/,b.className=b.className.replace(h,""),e.className=e.className.replace(h,""),0==f?b.className="pQXcHc "+b.className:b.className=b.className.replace(k,""),f==g?e.className="pQXcHc "+e.className:e.className=e.className.replace(k,""),0<=b.className.indexOf("SL0Gp")&&0==f&&f==g&&(m.style.paddingLeft="0px",m.style.paddingRight="0px",b.style.display="none",e.style.display="none",c.style.paddingLeft=a?"0px":"48px",c.style.paddingRight=a?"48px":"0px",c.style.textAlign=a?"left":"right",(a=document.getElementById("fade_forward"))&& (a.style.display="none"),(a=document.getElementById("fade_reverse"))&&(a.style.display="none")),setTimeout(function(){b.className+=" tHT0l";e.className+=" tHT0l"},50))}};}).call(this);(function(){var id='_29oHYdujA4natQbQ0qzgBw21';var index=0;var offset=0;var is_rtl=false;var is_ie=false;var is_gecko=false;var is_edge=false;var init='cVrhhd';window[init](id,index,offset,is_rtl,is_ie,is_gecko,is_edge);})(); function _setImagesSrc(e,d){function f(b){b.onerror=function(){b.style.display="none"};b.src=d}for(var g=0,a=void 0;a=e[g++];){var c=document.getElementById(a)||document.querySelector('img[data-iid="'+a+'"]');c?(a=void 0,(null==(a=google.c)?0:a.setup)&&google.c.setup(c),f(c)):(google.iir=google.iir||{},google.iir[a]=d)}}"undefined"==typeof window.google&&(window.google={});(function(){var s='data:image/jpeg;base64,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\x3d';var ii=['wp_0'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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\x3d\x3d';var ii=['wp_2'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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\x3d\x3d';var ii=['wp_4'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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\x3d';var ii=['wp_6'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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';var ii=['wp_8'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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\x3d\x3d';var ii=['wp_10'];_setImagesSrc(ii,s);})();.LJqTIc .UgLoB,.LJqTIc .FXMOpb{min-height:60px}.ss6qqb .LJqTIc .UgLoB,.ss6qqb .LJqTIc .FXMOpb{min-height:48px}.g-blk{position:relative}.kp-blk a{text-decoration:none}.kp-blk .match-mod-horizontal-padding,.kp-blk .wDYxhc:not(.NFQFxe){padding-left:16px;padding-right:16px;}.kp-blk.c2xzTb .match-mod-horizontal-padding,.kp-blk.c2xzTb .wDYxhc:not(.NFQFxe){padding-left:0;padding-right:0}.kp-blk{box-shadow:none;background:#fff;border:1px solid #dfe1e5;border-radius:8px;}.kno-kp.mnr-c.g,.g-blk.g,.KIy09e{width:652px}#center_col .kp-blk{position:relative}#center_col .Jb0Zif .kp-blk{margin-left:0;margin-right:0}.kp-blk .g:not(.g-blk){margin:0}.kp-blk>.vk_arc,.kp-blk>div>.vk_arc{margin:0}.kp-blk .g{margin-bottom:0}.knowledge-panel.kp-blk .wDYxhc,.c14z5c .wDYxhc{line-height:1.58}.c2xzTb .g,.cUnQKe .g,.c2xzTb .tF2Cxc,.ruTcId .tF2Cxc{clear:both;padding-bottom:0}.kp-blk.c2xzTb,.kp-blk.ruTcId,.kp-blk.HanQmf{border:none}.kp-blk.c2xzTb .g,.kp-blk.ruTcId .g,.kp-blk.HanQmf .g,.kp-blk.c2xzTb+.kno-ftr{padding-left:0;padding-right:0}.kp-blk.cUnQKe{border-radius:0;border:none}.kp-blk.cUnQKe .ygGdYd .wDYxhc:not(.NFQFxe),.cUnQKe .ygGdYd .g{padding-left:0px;padding-right:0px}.q1kEvb .related-question-pair.ygGdYd{margin-bottom:9px}.cbphWd{border-top:1px solid #ecedef;cursor:pointer;display:block;font-size:16px;padding-bottom:9px;padding-top:9px;position:relative;line-height:1.58;}.ygGdYd .cbphWd{padding-bottom:0px}a.cbphWd{color:inherit;text-decoration:none !important}#rhs .related-question-pair .iUh30,#rhs .related-question-pair .LC20lb{display:block;overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.cxrEAd,.uKh9yc{display:block;opacity:0;transform:scale(0);transition-property:border-width,opacity,transform}.uKh9yc{border:10px solid transparent;margin:0px auto}.gy6Qzb{-webkit-transition:max-height 0.3s;overflow:hidden}.S8PBwe{max-height:0;visibility:hidden}.vp45yf{pointer-events:none;position:absolute !important;right:0;color:#70757a;top:50%;margin-top:-12px}.mWyH1d{position:relative}.xpdclose .a84NUc:not(:empty),.xpdopen .CQKTwc:not(:empty){border-top:solid 1px #ddd;border-radius:0}.xpdclose .TOfaBb.SHa8ve,.xpdopen .LL5J7d.SHa8ve{display:block}.xpdclose .oHglmf,.xpdopen .xzPb7d{padding-bottom:16px}.xpdclose .kp-header .oHglmf,.xpdopen .kp-header .xzPb7d{padding-bottom:0}.c2xzTb .xpdclose .oHglmf,.c2xzTb .xpdopen .xzPb7d{padding-bottom:0}.HSryR .xpdclose .oHglmf,.HSryR .xpdopen .xzPb7d{padding-bottom:0}.Wnoohf .xpdopen .yp1CPe,.OJXvsb .xpdclose .siXlze{padding-bottom:16px}#rhs .Wnoohf .xpdopen .yp1CPe,#rhs .OJXvsb .xpdclose .siXlze{padding-bottom:15px}.Jb0Zif .UiGGAb.ILfuVd,.ILfuVd{font-size:16px;line-height:24px;}.SALvLe .LGOjhe,.Jb0Zif .LGOjhe,.HSryR .LGOjhe,.IVvPP .LGOjhe{padding:0 0 10px;margin:10px 0 0 0}#res .Jb0Zif .qDOt0b h3,.IVvPP .qDOt0b h3{font-size:16px;line-height:1.375}.Jb0Zif .qDOt0b .iUh30,.IVvPP .qDOt0b .iUh30{font-size:14px;line-height:1.58}.Jb0Zif .qDOt0b,.IVvPP .qDOt0b{border-bottom:1px solid #ebebeb;padding-bottom:6px}.wp-ms .Z0LcW{font-size:16px;font-family:Roboto-Medium,HelveticaNeue-Medium,Helvetica Neue,sans-serif-medium,Arial,sans-serif}.HSryR .Z0LcW,.Jb0Zif .Z0LcW{font-family:unset;font-size:30px}.LjTgvd .HwtpBd,.wp-ms .HwtpBd{padding-left:0;padding-right:0}.wp-ms .related-question-pair .HwtpBd,.wp-ms .c2xzTb .HwtpBd,.HSryR .wp-ms .HwtpBd{padding-left:16px;padding-right:16px}.Jb0Zif .wp-ms .related-question-pair .HwtpBd,.Jb0Zif .wp-ms .c2xzTb .HwtpBd{padding-left:0;padding-right:0}.xKf9F{margin-top:16px}#rhs .KFFQ0c,.xpd-wa .KFFQ0c{display:none}.KFFQ0c{align-items:center;display:flex;margin-bottom:0px;width:652px}.akqY6{background:#dadce0;height:1px;width:100%}.KFFQ0c .YfftMc,.KFFQ0c .YfftMc span,.KFFQ0c .YfftMc div,.KFFQ0c .YfftMc a{align-items:center;color:#70757a;display:flex;font-size:12px;font-style:normal;margin:0;padding:0;white-space:nowrap}People also askWhy was Star Trek: The Next Generation Cancelled?Paramount's rationale for ending TNG was driven by the increasing budget for the series and the studio's desire to keep the Star Trek movie franchise going. By the early 1990s, the films that starred the aging cast of TOS were waning, and Paramount saw TNG as the future of the Star Trek movies.Jun 8, 2021Star Trek: Why TNG Ended After Season 7 (Was It Canceled?)https://screenrant.com › star-trek-next-generation-cancele...https://screenrant.com › star-trek-next-generation-cancele...Search for: Why was Star Trek: The Next Generation Cancelled?Is Wesley Crusher really Picard's son?And of course, Wesley is the son of Beverly Crusher, who has always been a romantic interest of Picard's. Also, Picard served with Wesley's father Jack Crusher until his death on the USS Stargazer, which was under the command of Jean Luc-Picard, and this tragedy is something that weighed heavily on Picard.Oct 5, 2018Wil Wheaton Excited About New Star Trek Picard Series, Ready To Bring ...https://trekmovie.com › 2018/10/05 › wil-wheaton-excite...https://trekmovie.com › 2018/10/05 › wil-wheaton-excite...Search for: Is Wesley Crusher really Picard's son?How many crew members died on Star Trek: The Next Generation?Three crew membersDeaths in the Next Generation Three crew members were killed by Ansata terrorists. Eleven crew members were killed when a Borg cutting beam caused a hull breach in the engineering section. Ensign Keller died during a containment breach in the warp core. Fang-lee was killed in action prior to the episode Ethics.Star Trek | List of Deaths Wiki | Fandomhttps://listofdeaths.fandom.com › wiki › Star_Trekhttps://listofdeaths.fandom.com › wiki › Star_TrekSearch for: How many crew members died on Star Trek: The Next Generation?Why are there no Vulcans in the next generation?

      Star Trek: The Next Generation - Wikipediahttps://en.wikipedia.org › wiki › Star_Trek:_TheNext... Star Trek: The Next Generation (TNG) is an American science fiction television series created by Gene Roddenberry. It originally aired from September 28, ... Starring: Patrick Stewart; ‎Jonathan Frakes‎; ‎Le...‎ No. of seasons: 7 No. of episodes: 178 (list of episodes‎)‎ Original release: September 28, 1987 –; May 2... ‎List of episodes · ‎List of cast members · ‎Season 5 · ‎Season 1 Cast

      Patrick Stewart Jean-Luc Picard

      Marina Sirtis Deanna Troi

      Jonathan Frakes William T. Riker

      Brent Spiner Data, Lore

      LeVar Burton Geordi La Forge

      Gates McFadden Beverly Crusher

      Michael Dorn Worf View all People also ask Why was Star Trek: The Next Generation Cancelled?

      Is Wesley Crusher really Picard's son?

      How many crew members died on Star Trek: The Next Generation?

    1. Cast Lucy Lawless Lucretia Manu Bennett Crixus Andy Whitfield Spartacus Liam McIntyre Spartacus Viva Bianca Ilithyia Dustin Clare Gannicus Lesley-Ann Brandt Naevia View all (function(){ window.cVrhhd=function(c,f,q,a,h,k,r){if((c=document.getElementById(c))&&(0!=c.offsetWidth||0!=c.offsetHeight)){var l=c.querySelector("div"),m=l.querySelector("div"),d=0,g=l.scrollWidth-l.offsetWidth;if(0<f){var n=m.children;d=n[f].offsetLeft-n[0].offsetLeft;if(a){for(var p=d=0;p<f;++p)d+=n[p].offsetWidth;d=Math.min(g,d)}}d+=q;f=Math.min(a?g-d:d,g);l.scrollLeft=a&&(h||r)?d:a&&k?-d:f;var b=c.getElementsByTagName("g-left-button")[0],e=c.getElementsByTagName("g-right-button")[0];b&&e&&(h=/\btHT0l\b/,k=/\bpQXcHc\b/,b.className=b.className.replace(h,""),e.className=e.className.replace(h,""),0==f?b.className="pQXcHc "+b.className:b.className=b.className.replace(k,""),f==g?e.className="pQXcHc "+e.className:e.className=e.className.replace(k,""),0<=b.className.indexOf("SL0Gp")&&0==f&&f==g&&(m.style.paddingLeft="0px",m.style.paddingRight="0px",b.style.display="none",e.style.display="none",c.style.paddingLeft=a?"0px":"48px",c.style.paddingRight=a?"48px":"0px",c.style.textAlign=a?"left":"right",(a=document.getElementById("fade_forward"))&& (a.style.display="none"),(a=document.getElementById("fade_reverse"))&&(a.style.display="none")),setTimeout(function(){b.className+=" tHT0l";e.className+=" tHT0l"},50))}};}).call(this);(function(){var id='_dNoHYYSfPIvWtQaIgIOYAQ26';var index=0;var offset=0;var is_rtl=false;var is_ie=false;var is_gecko=false;var is_edge=false;var init='cVrhhd';window[init](id,index,offset,is_rtl,is_ie,is_gecko,is_edge);})(); function _setImagesSrc(e,d){function f(b){b.onerror=function(){b.style.display="none"};b.src=d}for(var g=0,a=void 0;a=e[g++];){var c=document.getElementById(a)||document.querySelector('img[data-iid="'+a+'"]');c?(a=void 0,(null==(a=google.c)?0:a.setup)&&google.c.setup(c),f(c)):(google.iir=google.iir||{},google.iir[a]=d)}}"undefined"==typeof window.google&&(window.google={});(function(){var s='data:image/jpeg;base64,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\x3d';var ii=['wp_0'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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\x3d';var ii=['wp_2'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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\x3d';var ii=['wp_4'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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';var ii=['wp_6'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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\x3d\x3d';var ii=['wp_8'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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\x3d';var ii=['wp_10'];_setImagesSrc(ii,s);})();.FyYA1e{margin:5px 0}.OSrXXb{text-overflow:ellipsis;overflow:hidden}.wFMWsc{padding-left:15px}.wFMWsc.JCsJK{padding-left:0}.rEYMH{}.dvDNH{color:#70757a;font-weight:bold;}.gyWzne{color:#70757a;}.IThcWe{display:table;table-layout:fixed;white-space:normal;line-height:1.58;width:100%}.YgpRwf{display:table-row;vertical-align:top;white-space:nowrap}.wFMWsc{display:table-cell;vertical-align:bottom}Web resultsSpartacus: Blood and Sand - Wikipediahttps://en.wikipedia.org › wiki › Spartacus:_Blood_and...https://en.wikipedia.org › wiki › Spartacus:_Blood_and...About this resultBETASourceWikipedia is a free content, multilingual online encyclopedia written and maintained by a community of volunteer contributors through a model of open collaboration, using a wiki-based editing system.WikipediaYour connection to this site is securehttps://en.wikipedia.org/wiki/Spartacus:_Blood_and_SandThis is a search result, not an ad. Only ads are paid, and they'll always be labeled with "Sponsored" or "Ad."Send feedback on this info Privacy settingsHow Search worksCachedSimilarSpartacus: Blood and Sand is the first season of American television series Spartacus, which premiered on Starz on January 22, 2010. The series was inspired ...No. of episodes: 13Original network: StarzOriginal release: January 22 –; April 16, 2010Starring: Andy Whitfield; ‎John Hannah‎; ‎Manu ...‎‎Cast and characters · ‎Episodes · ‎International broadcast · ‎Other media

      Cast

      [

      Lucy Lawless

      Lucretia

      ](https://www.google.com/search?rlz=1CAEAQE_enUS963&sxsrf=ALeKk03MzJtGF1N5BScN1OJPPEmR-gBcrQ:1627904628995&q=Lucy+Lawless&stick=H4sIAAAAAAAAAONgFuLWT9c3NE0pyDPMylPi1M_VNzAsssxN0RLLTrbSLykDoviCovz0osRcq-TE4pJFrDw-pcmVCj6J5TmpxcU7WBknsDECAGs6lLRHAAAA&sa=X&ved=2ahUKEwiEqY6poZLyAhULa80KHQjAABMQgOQBegQICRAE "Lucy Lawless")

      [

      Manu Bennett

      Crixus

      ](https://www.google.com/search?rlz=1CAEAQE_enUS963&sxsrf=ALeKk03MzJtGF1N5BScN1OJPPEmR-gBcrQ:1627904628995&q=Manu+Bennett&stick=H4sIAAAAAAAAAONgFuLWT9c3NE0pyDPMylPi0s_VNzAxT7PMMdQSy0620i8pA6L4gqL89KLEXKvkxOKSRaw8vol5pQpOqXl5qSUlO1gZJ7AxAgA2xiPTSAAAAA&sa=X&ved=2ahUKEwiEqY6poZLyAhULa80KHQjAABMQgOQBegQICRAG "Manu Bennett")

      [

      Andy Whitfield

      Spartacus

      ](https://www.google.com/search?rlz=1CAEAQE_enUS963&sxsrf=ALeKk03MzJtGF1N5BScN1OJPPEmR-gBcrQ:1627904628995&q=Andy+Whitfield&stick=H4sIAAAAAAAAAONgFuLWT9c3NE0pyDPMylPi0s_VNzDJM0vONdYSy0620i8pA6L4gqL89KLEXKvkxOKSRax8jnkplQrhGZklaZmpOSk7WBknsDECAIElcjJKAAAA&sa=X&ved=2ahUKEwiEqY6poZLyAhULa80KHQjAABMQgOQBegQICRAI "Andy Whitfield")

      [

      Liam McIntyre

      Spartacus

      ](https://www.google.com/search?rlz=1CAEAQE_enUS963&sxsrf=ALeKk03MzJtGF1N5BScN1OJPPEmR-gBcrQ:1627904628995&q=Liam+McIntyre&stick=H4sIAAAAAAAAAONgFuLWT9c3NE0pyDPMylPi0s_VN0i3LEkzr9QSy0620i8pA6L4gqL89KLEXKvkxOKSRay8PpmJuQq-yZ55JZVFqTtYGSewMQIAYU5lBUkAAAA&sa=X&ved=2ahUKEwiEqY6poZLyAhULa80KHQjAABMQgOQBegQICRAK "Liam McIntyre")

      [

      Viva Bianca

      Ilithyia

      ](https://www.google.com/search?rlz=1CAEAQE_enUS963&sxsrf=ALeKk03MzJtGF1N5BScN1OJPPEmR-gBcrQ:1627904628995&q=Viva+Bianca&stick=H4sIAAAAAAAAAONgFuLWT9c3NE0pyDPMylPi0s_VN0jKzSpJytASy0620i8pA6L4gqL89KLEXKvkxOKSRazcYZlliQpOmYl5yYk7WBknsDECAF-wwOVHAAAA&sa=X&ved=2ahUKEwiEqY6poZLyAhULa80KHQjAABMQgOQBegQICRAM "Viva Bianca")

      [

      Dustin Clare

      Gannicus

      ](https://www.google.com/search?rlz=1CAEAQE_enUS963&sxsrf=ALeKk03MzJtGF1N5BScN1OJPPEmR-gBcrQ:1627904628995&q=Dustin+Clare&stick=H4sIAAAAAAAAAONgFuLWT9c3NE0pyDPMylPi0s_VNzAyjU-pKNcSy0620i8pA6L4gqL89KLEXKvkxOKSRaw8LqXFJZl5Cs45iUWpO1gZJ7AxAgA6vLxqSAAAAA&sa=X&ved=2ahUKEwiEqY6poZLyAhULa80KHQjAABMQgOQBegQICRAO "Dustin Clare")

      [

      Lesley-Ann Brandt

      Naevia

      ](https://www.google.com/search?rlz=1CAEAQE_enUS963&sxsrf=ALeKk03MzJtGF1N5BScN1OJPPEmR-gBcrQ:1627904628995&q=Lesley-Ann+Brandt&stick=H4sIAAAAAAAAAONgFuLWT9c3NE0pyDPMylPi0s_VN0gpNk8zTNESy0620i8pA6L4gqL89KLEXKvkxOKSRayCPqnFOamVuo55eQpORYl5KSU7WBknsDECAJ-skBNNAAAA&sa=X&ved=2ahUKEwiEqY6poZLyAhULa80KHQjAABMQgOQBegQICRAQ "Lesley-Ann Brandt")

      View all

      Web results

      [

      Spartacus: Blood and Sand - Wikipedia

      https://en.wikipedia.org › wiki › Spartacus:_Blood_and...

      ](https://en.wikipedia.org/wiki/Spartacus:_Blood_and_Sand)

      Spartacus: Blood and Sand is the first season of American television series Spartacus, which premiered on Starz on January 22, 2010. The series was inspired ...

      No. of episodes: 13

      Original network: Starz)

      Original release: January 22 --; April 16, 2010

      Starring: Andy Whitfield; ‎John Hannah)‎; ‎Manu ...

      Cast and characters - ‎Episodes - ‎International broadcast - ‎Other media

  4. Jul 2021
    1. B. D. Levin, K. A. Walsh, K. K. Sullivan, K. L. Bren, S. J. Elliott, Inorg. Chem. 54, 38–46

      The study shows the loss of axial methionine from cyt c. The same phenomenon was observed over a range of cyt orthologs. In Professor Arnold's work, the labile nature of methionine in cyt c is believed to be responsible for the improved efficacy of the C-Si bond forming biocatalyst.

    1. SciScore for 10.1101/2021.07.23.453505: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Study Design: We have used public scRNAseq datasets to compare the level of expression of SARS-CoV-2 entry receptors in male and female lung alveolar epithelial cells.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Whole cell extracts were incubated with either STAT1, STAT2, or control rabbit IgG antibody and protein G beads (Invitrogen, 10003D) overnight at 4 °C while rotating.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STAT2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Afterward, membranes were probed with antibodies against STAT1, STAT2, IRF9, and rabbit IgG.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STAT1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IRF9</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The cells were then incubated with primary antibodies overnight, followed by incubation with the fluorochrome-conjugated secondary anti-mouse or anti-rabbit IgG (H+L) for 1 hour at 37 °C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-rabbit IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Calu-3 cells were incubated with Dulbecco’s Modified Eagle Medium supplemented with 10% fetal bovine serum, penicillin, and streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Co-immunoprecipitation (co-IP): Calu3 cells were incubated with either IFN-α and IFN-β, or IFN-λ for 3 hours.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu3</div><div>suggested: BCRJ Cat# 0264, RRID:CVCL_0609)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lipofectamine 3000 was used to co-transfect transfer plasmids and packaging vectors in 293T cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Single cell RNA sequencing datasets: Three publicly available scRNA-seq datasets were obtained as follows: 1) processed data including count and metadata tables of healthy lung tissue was downloaded from Figshare (https://doi.org/10.6084/m9.figshare.11981034.v1); 2) h5 files of normal lungs were extracted from the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/) under accession number GSE122960; and 3) processed data including count and metadata tables of human lung tissue was acquired from GSE130148.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gene Expression Omnibus</div><div>suggested: (Gene Expression Omnibus (GEO, RRID:SCR_005012)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Accession numbers for all ENCODE datasets used can be found in Encode Data Sets Table (Supplementary Table 3).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ENCODE</div><div>suggested: (Encode, RRID:SCR_015482)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Predicted enhancer regions of TMPRSS2 were identified using the GeneHancer tool within Track Data Hubs of UCSC genome browser (85, 86).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GeneHancer</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>UCSC genome browser</div><div>suggested: (UCSC Genome Browser, RRID:SCR_005780)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Gene set enrichment analysis: Gene set enrichment analyses (GSEA) were performed according to the instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gene set enrichment analyses</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Gene sets of Hallmark Collection, Canonical Pathway (including KEGG Pathway, Biocarta Pathway, Reactome Pathway and PID Pathway), and GO Biological Process were used.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>KEGG</div><div>suggested: (KEGG, RRID:SCR_012773)</div></div><div style="margin-bottom:8px"><div>GO Biological</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistics: Statistical analysis used R and GraphPad Prism 8 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.23.453571: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">MRC5 cells (ATCC CCL-171™, Manassas, VA, USA) in confluent culture in 96-well microtiter plates were infected with 200 μL per well of virus/antibody mixture.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MRC5</div><div>suggested: ATCC Cat# CCL-171, RRID:CVCL_0440)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Concentration-effect curves were generated and IC50 values were calculated using a GraphPad Prism software (Version 9.1.0 for Windows, GraphPad Software, San Diego, California USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.21.21260961: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: Nasopharyngeal swab specimens were collected as part of the routine SARS-CoV-2 surveillance conducted by the Mount Sinai Pathogen Surveillance program (IRB approved, HS#13-00981).<br>IRB: Briefly, 30 participants enrolled in the PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2) study (reviewed and approved by the Mount Sinai Hospital Institutional Review Board; IRB-20-03374) were invited to provide additional serum samples after receiving their second mRNA vaccine dose.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 2-hour incubation, plates were washed three times with PBS-T and 50 μl/well of the pre-diluted secondary antibody anti-human IgG (Fab-specific) horseradish peroxidase antibody (produced in goat; Sigma, A0293</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: (Sigma-Aldrich Cat# A0293, RRID:AB_257875)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Blocking solution was removed and 100 μl/well of mAb 1C7 (anti-SARS nucleoprotein antibody produced in house) diluted in PBS 1% milk (American Bio) at a 1:4000 dilution were added for 1 h at RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS nucleoprotein</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primary antibody was removed and plates were washed with 200 μl/well of PBS twice, followed by addition of 100 μl/well of goat anti-mouse IgG-HRP (Rockland Immunochemicals) diluted in PBS 1% milk (American Bio) 1:3000.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG-HRP</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Specimens were selected for viral culture on Vero-E6 cells based on the complete viral genome sequence information.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">39 Viruses were grown in Vero.E6 cells for 4-6 days; the supernatant was clarified by centrifugation at 4,000 g for 5 minutes and aliquots were frozen at -80°C for long term use.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero.E6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero E6 cells were seeded in 96-well high binding cell culture plates (Thermo Fisher) at a density of 20,000 cells/well in complete Dulbecco’s Modified Eagle Medium (cDMEM).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Phylogeny of SARS-CoV-2 lineages: The phylogenetic relationships of the SARS-CoV-2 isolates from the Pathogen Surveillance Program of the Mount Sinai Health System are depicted in a New York focused background from GISAID.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Pathogen Surveillance Program</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Area under the curve (AUC) values were calculated and plotted using GraphPad Prism 7.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A non linear regression curve fit analysis, using Prism 9 software (GraphPad), was performed to calculate the inhibitory dilution 50% (ID50), using top and bottom constraints of 100% and 0% respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.21.453304: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Use of such donor tissue for research was approved by the ethical committee of the Medical faculty of the University Duisburg-Essen (ID: 19-8717-BO).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Membranes were excised from the insert and cut into 4 pieces that were incubated overnight at 4°C with specific antibodies at the following dilutions: rabbit anti-SARS-CoV-2 N antibody (JUC3,1:500, (46)), mouse anti-MUC5AC antibody (1:200; Thermo Fisher Scientific), mouse anti-acetylated α-tubulin (1/100; Sigma Aldrich) or goat anti-FOXJ1 antibody (1:200; R&D, Minneapolis, MN, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-MUC5AC</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-FOXJ1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After washing, membranes were incubated with corresponding secondary antibodies: donkey anti-rabbit, donkey anti-mouse or donkey anti-goat Alexa-fluor antibodies (all diluted 1:200, Thermo Fisher Scientific) and 4’,6-diamidino-2-phenylindole (DAPI, 1:200, Sigma-Aldrich) in the dark for 30 min at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rabbit</div><div>suggested: (Thermo Fisher Scientific Cat# 18-8816-33, RRID:AB_469529)</div></div><div style="margin-bottom:8px"><div>anti-mouse</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-goat</div><div>suggested: (Thermo Fisher Scientific Cat# 18-8814-33, RRID:AB_469527)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero E6 cells (master stock MM-3 from dept of Medical Microbiology collection, characterized by full genome sequencing) were maintained in Dulbecco’s modified Eagle’s medium with 4.5 g/l glucose with L-Glutamin (DMEM; Lonza), supplemented with 8% fetal calf serum (FBS; CapriCorn Scientific) and 100 U/ml of penicillin/streptomycin (Sigma-Aldrich).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      However, there are also some limitations in this study, like the sources of cells. PBEC were derived from tumor-free resected bronchial tissue from (ex-)smoking non-COPD patients with lung cancer, and PTEC were from lung donors without lung disease, which may have affected the comparison between PBEC and PTEC. In summary, we show that culture time of airway epithelial cells at the air-liquid interface is a determinant of their susceptibility to SARS-CoV-2 infection, which can only be partly explained by differentiation status based on the amount of ciliated and goblet cells. Differences in expression of entry-associated factors, like ACE2 or TMPRSS2 do not explain the increased susceptibility of airway epithelial cell cultures upon prolonged culture. Our observation that IL-13 treatment causes a limited increase in SARS-CoV-2 infection may be relevant for understanding the impact of type 2 allergic inflammation on SARS-CoV-2 susceptibility. Decreased infection following prolonged inhibition of Notch signaling by DAPT highlights the importance of the presence of both ciliated and goblet cells and warrants further investigation. Ultimately, cellular maturation/differentiation seems intertwined with virus load and spread of the infection over the culture. The proposed cell culture set-up provides a robust tool to test antiviral compounds and acquire additional insight into infection biology of SARS-CoV-2.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 34. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • No conflict of interest statement was detected. If there are no conflicts, we encourage authors to explicit state so.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.19.21260728: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Ethics statement, participants, and sample processing: This study was approved by the Ethics Committee for Clinical Research of the Center for Research Promotion and Support at Fujita Health University (authorization number HM20-526 and HM21-167).<br>Consent: All participants provided written informed consent before undergoing any study procedure.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The plates were washed three times with PBS containing 0.1% Tween 20 (PBS-T), peroxidase-labelled anti-human IgM or IgA antibody (Midrand Bioproducts) was added as secondary antibody and incubated at room temperature for 60 min.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgM</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgA</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After the bound and free fractions were separated, 50 μL of peroxidase-labelled anti-human IgG antibody was added and incubated at 37°C for 3 min, followed by separation of the bound and free fractions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Statistical analysis was performed using GraphPad Prism version 8.4.3 for windows (GraphPad Software).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.16.21260618: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: The serum samples were collected and followed by protocol SDP-003, Human Biological Specimens Collection, data September<br>IRB: 22, 2017 and the qualifications of Principle Investigator (Robert Pyrtle, M.D.) were reviewed and approved by Diagnostics Investigational Review Board (Cummaquid, Massachusetts, USA).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After washing, horseradish peroxidase (HRP)-tagged anti-human antibodies (Abcam, Cambridge, UK), diluted 1:10,000 in blocking buffer, were added to the wells (100 μL/well), and the plate was incubated for 1 h at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human antibodies ( Abcam , Cambridge , UK) ,</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The electrochemiluminescence immunoassay (ECLIA) (i.e., Roche Elecsys Anti-SARS-CoV-2 S assay) was used for the detection of antibodies against the RBD of S protein; <0.80 U/mL was considered negative and ≥0.80 U/mL was considered positive for anti-SARS-CoV-2 S protein.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 S protein .</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell culture and virus: African green monkey kidney (Vero E6) cells (CRL-1586) were purchased from the American Type Culture Collection (ATCC, Bethesda, MD, USA) and maintained in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Waltham, MA, USA) containing 10% fetal bovine serum (FBS; Gibco) at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The serum samples were collected and followed by protocol SDP-003, Human Biological Specimens Collection, data September</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Human Biological</div><div>suggested: ( Human Biological Data Interchange , RRID:SCR_004591)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Geometric mean titers (GMTs) were calculated with 95% confidence intervals (CIs) using GraphPad Prism version 8 (GraphPad Software, Inc., CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Statistical analyses were performed using GraphPad Prism version 8 (GraphPad Software, Inc., CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.20.453054: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Animal experiment and ethics: The alpaca immunization procedures were conducted in conformity with the institutional guidance for the care and use of laboratory animals, and the protocols were approved by the Institutional Committee of Ethics and Research of the Central Laboratory at Xinyang Agricultural and Forestry University.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">The resulted emulsion was injected by the subcutaneous route at ten sites near the bow lymph node in the neck base of an adult female alpaca (3-years old).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The plate was then blocked by 0.5 %(w/v) BSA in TBS buffer for 30 min at RT and washed three times using TBS before incubated with anti-Myc antibodies at 1:2,000 dilution in TBS-BSA-T buffer (TBS supplemented with 0.5 %(w/v) BSA and 0.05 %(v/v</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Myc</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For simultaneous binding of DL28 and monoclonal antibodies (REGN10933, CV30, CB6, all in the IgG form) with RBD, the biotinylated RBD was coated as mentioned above.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CV30</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CB6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Protein expression and purification - Spike (S): The polypeptide containing, from N- to C-terminus, residues Met1 – Gln1208 (without the C-terminal transmembrane helix, Uniprot P0DTC2) of the SARS-CoV-2 S with mutations K986P/V987P, a GSAS linker substituting the furin sites (Arg682- Arg685), a C-terminal T4 fibritin trimerization motif (GYIPEAPRDGQAYVRKDGEWVLLSTFL), a TEV protease cleavage site, a FLAG tag and a polyhistidine tag 5 was encoded in a pCDNA3.1 backbone vector and overexpressed in Expi293 cells by transient transfection using polyethylenimine (PEI).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Expi293</div><div>suggested: RRID:CVCL_D615)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Retroviral pseudotyped particles were generated by co-transfection of HEK293T cells using polyethylenimine with the expression vectors encoding the various viral envelope glycoproteins, the Murine leukemia virus core/packaging components (MLV Gag-Pol), and a retroviral transfer vector harboring the gene encoding the green fluorescent protein (GFP).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">VeroE6-hACE2 cells (104 cells/well) were seeded into a 48-well plate and infected 24 h later with 100 μL of virus supernatant in a final volume of 150 μL.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6-hACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Protein expression and purification - Spike (S): The polypeptide containing, from N- to C-terminus, residues Met1 – Gln1208 (without the C-terminal transmembrane helix, Uniprot P0DTC2) of the SARS-CoV-2 S with mutations K986P/V987P, a GSAS linker substituting the furin sites (Arg682- Arg685), a C-terminal T4 fibritin trimerization motif (GYIPEAPRDGQAYVRKDGEWVLLSTFL), a TEV protease cleavage site, a FLAG tag and a polyhistidine tag 5 was encoded in a pCDNA3.1 backbone vector and overexpressed in Expi293 cells by transient transfection using polyethylenimine (PEI).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCDNA3.1</div><div>suggested: RRID:Addgene_79663)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Protein expression and purification - RBD: The polypeptide containing, from N- to C-terminus, the honey bee melittin signal peptide (KFLVNVALVFMVVYISYIYAA), a Gly-Ser linker, residues 330-531 of the SARS-CoV-2 S, a Gly-Thr linker, the 3C protease site (LEVLFQGP), a Gly-Ser linker, the Avi tag (GLNDIFEAQKIEWHE), a Ser-Gly linker, and a deca-His tag was encoded in a pFastBac-backbone vector for overexpression in Trichoplusia ni High Five suspension cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pFastBac-backbone</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, cells carrying nanobody-encoding pSb-init plasmids 46 were grown in Terrific Broth (TB, 0.17 M KH2PO4 and 0.72 M K2HPO4, 1.2 %(w/v) tryptone, 2.4 %(w/v) yeast extract, 0.5% (v/v) glycerol) supplemented with 25 mg L-1 chloramphenicol at 37 °C with shaking at 200 rpm.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pSb-init</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">One microgram of the PCR product and 10 μg of the pDX_init vector 46 were digested separately with 50 units of BspQI (Cat. R0712L, New England Biolabs) for 1.5 h at 50 °C before heat inactivation at 80 °C for 10 min.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pDX_init</div><div>suggested: RRID:Addgene_132697)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The particles were eluted, and the phagemid was sub-cloned into pSb_init vector by fragment-exchange (FX) cloning and transformed into E. coli MC1061 cells for periplasmic expression and screening.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pSb_init</div><div>suggested: RRID:Addgene_159422)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 pseudotypes for the Alpha (B1.1.7) and Beta (B1.351) variants were generated by incorporating the corresponding Spike mutations into the phCMV-SARS- CoV-2 plasmid.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CoV-2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The model was built with 2Fo-Fc maps in Coot 51, and refined using Phenix 52.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Coot</div><div>suggested: (Coot, RRID:SCR_014222)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Structures were visualized using PyMol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PyMol</div><div>suggested: (PyMOL, RRID:SCR_000305)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Neutralization assay using SARS-CoV-2</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: (BioLegend Cat# 944703, RRID:AB_2890874)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • No conflict of interest statement was detected. If there are no conflicts, we encourage authors to explicit state so.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.19.452809: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: All cell lines tested negative for mycoplasma.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primary antibodies used in this study: Rabbit anti-GATA6 (Abcam ab175349), hyperimmune Rabbit serum from intervenous (i.v) SARS-CoV-2 infected Rabbits.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-GATA6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary antibody used was IRDye® 800CW conjugated Goat anti-Rabbit (Licor).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Rabbit</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines: HEK293T (ATCC-CRL-3216), Vero-E6 (ATCC-CRL-1586) and Calu-3 cells (ATCC-HTB-55) were cultured in Dulbecco’s Modified Eagle Medium (DMEM) with 10% heat-inactivated fetal bovine serum (FBS), 10 mM non-essential amino acids (NEAA), 2 mM L-Glutamine, 1 mM Sodium pyruvate and 1% Penicillin/Streptomycin (all from Biological Industries, Israel) at 37°C, 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Genome-wide CRISPR screens: To generate CRISPR KO libraries, a total of 4*108 Calu-3 cells were transduced with lentivirus of human Brunello Human CRISPR library (Addgene #73179, gift from David Root and John Doench) in the presence of 0.5 mg/ml polybrene (TR-1003, Sigma), at a MOI of 0.3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viral titration: Vero-E6 cells were seeded in 12-well plates (5 × 105 cells/well) and grown overnight in growth medium.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Analysis of GATA6 expression in different cell lines: Published mRNA-seq data used for A549, Vero-E6 and Calu-3 cells are from Kinori et al. 2016, Finkel et al. 2021a and Finkel et al. 2021b., respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Generation of Calu-3 KO cell lines: DNA oligos (Integrated DNA Technologies, Inc.) containing sgRNA sequences (see supplementary Table S1) were annealed and ligated into lentiCRISPRv2 (Addgene, #52961, gift from Feng Zhang).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>lentiCRISPRv2</div><div>suggested: RRID:Addgene_98292)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lentivirus was packaged by co-transfection of constructs with the 2nd generation packaging plasmids pMD2.G and PsPax using jetPEI (Polyplus-transfection) into 6-well plates with HEK293T cells according to protocol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pMD2.G</div><div>suggested: RRID:Addgene_12259)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For GATA6 complementation experiment, cells were complemented by transfection of 2.5 μg pBabe 3XFLAG-wt GATA6-3XAU1 puro vector (Addgene #72607) using Lipofectamine 3000 (L3000015 ThermoFisher) according to manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pBabe 3XFLAG-wt GATA6-3XAU1 puro</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T cells were transfected with 3 μg pBabe 3XFLAG-wt-GATA6-3AU1 puro plasmid (Addgene #76207) using Lipofectamine 3000 (L3000015 ThermoFisher) according to manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pBabe 3XFLAG-wt-GATA6-3AU1 puro</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Twenty-four hours prior to infection with SARS-CoV-2, 1.5*107 Calu-3 library-cells were seeded in 75-cm2 flasks.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: (BioLegend Cat# 944703, RRID:AB_2890874)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Analysis of CRISPR-Cas9 genetic screen data: MAGeCK v0.5.6 [73] was used to count sgRNA from FASTQ files and to analyze the selection effect of genes based on the change in sgRNA distribution, using the robust rank aggregation (RRA) algorithm with normalization to total reads.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MAGeCK</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pathway and network analysis: Directed scores were used as input for gene set enrichment analysis (GSEA version 4.1) with GO biological process (c5.bp) from MSigDB (version 7.4) [74, 75].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GSEA</div><div>suggested: (SeqGSEA, RRID:SCR_005724)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The STRING network was imported into Cytoscape [76].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STRING</div><div>suggested: (STRING, RRID:SCR_005223)</div></div><div style="margin-bottom:8px"><div>Cytoscape</div><div>suggested: (Cytoscape, RRID:SCR_003032)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Genes were highlighted based on association with selected REACTOME pathways.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>REACTOME</div><div>suggested: (Reactome, RRID:SCR_003485)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.20.453042: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: All participants provided informed written consent to participate in the research project, and the study was approved by the Regional Ethical Board in Ospedale L.<br>IRB: All participants provided informed written consent to participate in the research project, and the study was approved by the Regional Ethical Board in Ospedale L.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Subjects Recruitment: 43 subjects (24 males and 19 females,dataset) of different ages (ranging from 30 to 81 years) undergoing SARS-Cov-2 serological analysis (Centro Polispecialistico Giovanni Paolo I, Viterbo, I) were enrolled in this study from October 2020 to March 2021.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mass spectrometry chromatograms were created for peak alignment, matching and comparison of parent and fragment ions with tentative metabolite identification (within a 2-p.p.m. mass-deviation range between the observed and expected results against an imported KEGG database).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>KEGG</div><div>suggested: (KEGG, RRID:SCR_012773)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Fold change analysis was performed on the entire metabolomics data set using the MetaboAnalyst 5.0 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MetaboAnalyst</div><div>suggested: (MetaboAnalyst, RRID:SCR_015539)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In order to analyze a correlation network of the compounds in shared pathways, MetScape, an app implemented in Java and integrated with Cytoscape (version 3.8.2), was used.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MetScape</div><div>suggested: ( Metscape , RRID:SCR_014687)</div></div><div style="margin-bottom:8px"><div>Cytoscape</div><div>suggested: (Cytoscape, RRID:SCR_003032)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.20.453146: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then, the membranes were incubated in TBST with primary antibodies (GAPDH (Proteintech, 60004-1), RAD21 (Abcam, Ab992, Lot: GR214359-10), CTCF (Millipore, 07-729), SMC3 (Abcam, Ab9263, Lot:GR466-7), Total Histone H3 (Abcam, Ab1791, Lot:GR206754-1), H3K4me3 (Abcam, Ab8580, Lot: GR3264490-1), H3K9me3 (Abcam, Ab8898, Lot: GR164977-4), H3K27ac (Abcam, Ab4729, Lot: GR3357415-1), and H3K27me3 (Cell Signaling Technology, #9733S, Lot19)) at 4°C overnight.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GAPDH</div><div>suggested: (Proteintech Cat# 60004-1-Ig, RRID:AB_2107436)</div></div><div style="margin-bottom:8px"><div>RAD21</div><div>suggested: (Abcam Cat# ab992, RRID:AB_2176601)</div></div><div style="margin-bottom:8px"><div>CTCF</div><div>suggested: (Millipore Cat# 07-729, RRID:AB_441965)</div></div><div style="margin-bottom:8px"><div>Lot:GR466-7), Total Histone H3</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>H3K27ac</div><div>suggested: (Abcam Cat# ab4729, RRID:AB_2118291)</div></div><div style="margin-bottom:8px"><div>H3K27me3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were incubated with 1:500 anti-SARS-CoV-2 Spike glycoprotein antibody (Abcam, Catalog#ab272504) diluted in blocking buffer for overnight at 4 degree.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 Spike glycoprotein</div><div>suggested: (Abcam Cat# ab272504, RRID:AB_2847845)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The next morning, the antibody-protein-chromatin complex was retrieved by adding 25μl pre-washed Protein G Dynabeads (Thermo Fisher Scientific, 10004D).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antibody-protein-chromatin</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The antibodies used for ChIP-Seq include RNA Polymerase II (RPB1 N terminus, Cell Signaling Technology, #14958S, Lot4), RAD21 (Abcam, Ab992, Lot: GR214359-10), SMC3 (Abcam, Ab9263, Lot:GR466-7), CTCF (Millipore, 07-729), H3K4me3 (Abcam, Ab8580, Lot: GR3264490-1), H3K9me3 (Abcam, Ab8898, Lot: GR164977-4), H3K27ac (Abcam, Ab4729, Lot: GR3357415-1), H3K27me3 (Cell Signaling Technology, #9733S, Lot19) and HA (Abcam, Ab9110, Lot:GR3231414-3).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RPB1 N terminus, Cell Signaling Technology,</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>SMC3</div><div>suggested: (Abcam Cat# ab9263, RRID:AB_307122)</div></div><div style="margin-bottom:8px"><div>Lot:GR466-7), CTCF</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>H3K4me3</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>H3K9me3</div><div>suggested: (Abcam Cat# ab8898, RRID:AB_306848)</div></div><div style="margin-bottom:8px"><div>HA</div><div>suggested: (Abcam Cat# ab9110, RRID:AB_307019)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell culture: Human lung adenocarcinoma cells A549 expressing human ACE2 (A549-ACE2, #NR53821) was acquired from BEI Resources (Manassas, VA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">293T cells were from ATCC and were cultured in DMEM with 10% FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Prior to infection, Vero-E6 cells were washed once with PBS and the viral inoculum was added to the flask in the presence of 3 ml of serum-free and antibiotics-free MEM medium supplemented with 1mM HEPES, and incubated for 1 hour at 37°C with 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, ∼5 million SARS-CoV-2 infected A549-ACE2 cells were washed once with PBS to remove debris and dead cells, trypsinized off the culture plates, and were cross-linked using 1% formaldehyde for 10mins at room temperature, quenched with 0.75M Tris-HCl pH 7.5 for 5mins.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549-ACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lenti-viral Transduction and CRISPRi: We in-house generated a lentiviral construct expressing dCas9-KRAB-MeCP2 by PCR amplification of the dCas9-KRAB-MeCP2 (contains a domain of MeCP2) from pB-CAGGS-dCas9-KRAB-MeCP2 (Addgene 110824), and then insert it to the pLenti-EF1a-dCas9-VP64-2A-Blast backbone (Addgene 61425) to replace th dCas9-VP64.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pB-CAGGS-dCas9-KRAB-MeCP2</div><div>suggested: RRID:Addgene_110824)</div></div><div style="margin-bottom:8px"><div>pLenti-EF1a-dCas9-VP64-2A-Blast</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To generate lentivirus, 293T cells were transfected with the lentiviral transfer vector DNA, psPAX2 packaging and pMD2.G envelope plasmid DNA at a ratio of 4:3:1, respectively, by lipofectamine 2000.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>psPAX2</div><div>suggested: RRID:Addgene_12260)</div></div><div style="margin-bottom:8px"><div>pMD2.G</div><div>suggested: RRID:Addgene_12259)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For RBP1 ChIP-Seq gene transcription quantification, hg19 RefSeq gene annotation coordinates were used.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RefSeq</div><div>suggested: (RefSeq, RRID:SCR_003496)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">RNA-Seq analysis: RNA-Seq reads were aligned to the hg19 reference human genome or SARS-CoV-2 viral genome (NC_045512.2) with STAR v 2.7.027.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STAR</div><div>suggested: (STAR, RRID:SCR_004463)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Differential gene expression analyses were performed with EdgeR, and genes with |FC|>2, FDR<0.05 were considered as significantly differential expressed genes.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>EdgeR</div><div>suggested: (edgeR, RRID:SCR_012802)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The pair of reads were mapped to the human reference genome assembly hg19, and multi-mapped pairs, duplicated pairs, and other unvalid 3C pairs were filtered out following the standard procedure of HiC-Pro.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HiC-Pro</div><div>suggested: (HiC-Pro, RRID:SCR_017643)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Compartmental domains are genomic regions with continuous positive or negative compartmental scores (E1), identified by applying HOMER tool (findHiCCompartments.pl) on E1 scores.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HOMER</div><div>suggested: (HOMER, RRID:SCR_010881)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We considered loops with a DESeq2 FDR <0.1 and a log2FC >0 or <0 as virus-strengthened or weakened chromatin loops.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>DESeq2</div><div>suggested: (DESeq, RRID:SCR_000154)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistics: qPCR data was analyzed by Prism and presented as mean±SD, which are indicated in figure legends.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analyses for sequencing data were performed with Python or R scripts.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Python</div><div>suggested: (IPython, RRID:SCR_001658)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.20.453162: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Euthanasia Agents: At the end of the study, all mice were sacrificed by cervical dislocation and some vital organs, like kidneys, liver and spleen were collected to examine morphological and histological characteristics and weights of the organs. 2.6.2.<br>IACUC: Animal ethics statement: This study was carried out in strict adherence to the animal laboratory of Nanogen pharmaceutical Company, the National Institute of drug quality control (NIDQC), and the laboratory of Hanoi Medical University (HMU).<br>IRB: The processes were designed according to the guide of ICH/GCP, Drug administration of Vietnam, as well ACTD and approved by Ethics committee of Ministry of Health 2.8.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Animal vaccination: Balb/c mice of both sexes, 6-10 weeks old were used for immunological studies.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, the membranes were blocked in 0.5% BSA (Sigma-Aldrich, St. Louis, MO, USA) and incubated with human anti-S1 antibody (Abcam, Cambridge, MA, UK) for 3 hours at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-S1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After washing, the membranes were incubated with horseradish peroxidase (HRP)-linked rabbit anti human IgG antibody (Abcam, Cambridge, MA, UK) for 1 hour at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti human IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The Balb/c mice, Syrian hamsters, as well non-human primates were immunized intramuscularly with Nanocovax at doses of 25 μg, 50 μg, 75 μg, and 100 μg, their serum samples were collected quantification of spike protein specific IgG antibodies by ELISA.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>specific IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Upper serum fraction was collected and heat-inactivated at 56°C in 30 minutes before use or kept at −20°C. 2.4.2. Quantification of SARS-CoV-2 spike protein specific IgG antibody by ELISA: The method of quantifying SARS-CoV-2 spike protein-specific IgG antibody was adapted from Tan C. W. et al, [15].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 spike protein specific IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>SARS-CoV-2 spike protein-specific IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Wells were washed 3 times with washing buffer then 100 μL of diluted goat anti-mouse IgG (Fc specific)-Peroxidase antibody (#A0168; Sigma-aldrich) were added.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG ( Fc specific)-Peroxidase</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The gene encoding the Spike protein of SARS-CoV-2 (UniProt P0DTC2) codon-optimized for expression in CHO cells was synthesized by Genscript (Piscataway, NJ, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CHO</div><div>suggested: CLS Cat# 603479/p746_CHO, RRID:CVCL_0213)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The isolate was propagated in Vero E6 to prepare virus stocks.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In vitro surrogate virus neutralization assay: The virus neutralization ability of antibodies in sera of Balb/C mice, hamster, and non-human private were determined by the virus surrogate neutralization kit (cat # L00847, Genscript, Singapore).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Balb/C</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The pCNeoMEM plasmid containes a G418 resistance gene used as a selection marker, a MoMLV promoter to express the target gene, a human universal chromatin opening element (UCOE), untranslated regions from the Chinese hamster EEF1A1 gene (eEF1A1), and a synthetic matrix attachment sequence (sMAR).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCNeoMEM</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The optimized DNA fragment was cloned in the expression vector to create pCNeoMEM-S, which was completely sequenced by NextGen technology at the Center for Computational and Integrative Biology, Harvard University. 2.1.2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCNeoMEM-S</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: The collected data were statistically analyzed using Grapthpad Prism, version 5 (Grapthpad Software).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Grapthpad Prism</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      We thank all four reviewers for their positive and constructive comments! We have carefully considered these comments and provided a point-by-point response below.

      Reviewer #1 (Evidence, reproducibility and clarity):

      This paper explores an interesting problem of SHP1/SHP2 preferences of inhibitory immunoreceptors. The author are quick to point out that many of their individual data points confirm published results at some level, but the power of the paper is in the parallel analysis of both PD1, which is strongly biased towards SHP2 and BTLA, which is biased towards SHP1. This gives them the opportunity to test the predictions of descriptive experiment by making simple mutated receptors with swapped ITIM or ITSM domains.

      The work is very well done and generally the authors are quite careful and precise about the language used to describe results, in general.

      The results are quite striking in that the find plenty of evidence for transient interaction of SHP1 with PD1 based on the biophysical measurements, but don't detect the interactions in pull down or in "in cell" microcluster recruitment experiments. In describing the pull-downs they discuss the issue of dissociation during washing potentially missing interactions that are taking place. I would prefer that the pull down is fine evidence for binding, but lack of pull down is not evidence for lack of binding. They should double check that this language is consistent. Also, unless something has changed in the microcluster binding experiments, this in situ recruitment of SHP2 to PD1 is only observed or a 2-3 minutes and then can't be detected, the situation for SHP2 becoming the same as it is for SHP1. If the kinetics are different in the cleaner systems that have now developed they should show this in a primary figure as this would be then different when what is reported previously.

      We agree with the reviewer that pull down is evidence for binding. Indeed, in most, if not all of our assays, our results with pull down were consistent with those in the microcluster imaging. As suggested by the reviewer, we will check through the manuscript and ensure the language is accurate and consistent. In our recent study (Xu et al., JCB, 2020, PMID: 32437509), we conducted a side-by-side comparison of SHP2 and SHP1 recruitment kinetics to PD-1 in a similar system as the current study. Both microcluster imaging and co-IP assays showed that PD-1:SHP2 association lasted at least 10 minutes, whereas PD-1:SHP1 recruitment was nearly undetectable. The duration of PD- 1:SHP2 association was in good agreement with Takashi Saito’s finding in CD4+ mouse T cells (Yokosuka et al., JEM, 2012, PMID: 22641383). Regardless the somewhat different kinetics in different studies, SHP2 recruitment was transient, as pointed out by the reviewer. We believe that some other effectors contribute to PD-1 inhibitory signaling. In supportive of this notion, we recently found that PD-1 remains partially inhibitory in CD8+ T cells deficient in both SHP1 and SHP2 (Xu et al., JCB, 2020).

      The gap in this study is lack of any functional analysis. The Jurkat model could be quite useful as they have a relatively clean system for asking if the transient binding of SHP1 to PD1 has any functional impact, which they have not yet followed through on. Does PD-1 recruited SHP2 have any impact on function after the 5 minutes? Furthermore, the authors need to keep in mind that mice deficient in SHP2 respond to anti-PD1 checkpoint therapies (Rota, G., Niogret, C., Dang, A. T., Barros, C. R., Fonta, N. P., Alfei, F., Morgado, L., Zehn, D., Birchmeier, W., Vivier, E., & Guarda, G. (2018). Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo. Cell Rep, 23(1), 39-49. https://doi.org/10.1016/j.celrep.2018.03.026). This is an important issue to discuss in light the the very interesting binding analysis the authors have performed. But I think the functional analysis can be part of a future paper.

      In our recent publication (Xu et al. JCB, 2020, PMID: 32437509), we found that deletion of SHP1 from Jurkat cells had little, if any effect on PD-1 mediated suppression of IL-2 production. As the reviewer alluded to, we did observe SHP2 dissociation from PD-1 after 10 minutes, so the question of whether and how PD-1:SHP2 complex influence T cell function in a longer term is a great one. We currently are pursuing a hypothesis that there is a SHP2-independent mechanism of PD-1 inhibitory function, and indeed, in our recent study (Xu et al. JCB, 2020, PMID: 32437509), we found that PD-1 retains its partial inhibitory function in SHP1/SHP2 double knockout murine primary T cells. These results are consistent with the in vivo data by Rota et al. cited by the reviewer. We will also briefly discuss this point in a revised manuscript.

      I would suggest that the title be modified slightly from "SHP1/SHP2 discrimination" to "differential SHP1/SHP2 interaction" and leave discussion of discrimination until they have the functional data integrated over times that are relevant to T cell transcriptional regulation (1-2 hrs). The functional analysis can be in another paper, but it would be interesting to have a paragraph in the discussion raising the outstanding issues beyond stable binding detected by the pull-down and microcluster recruitment experiments- what are the implications for function. Could the transient interactions in the noise of the steady state and equilibrium measurements be functional?

      We thank the reviewer for the suggestion, even though reviewer #3 felt that our current title is appropriate. We will be happy to change the title at the editors’ discretion.

      I would summarise that the work is outstanding as biochemistry and biophysics and it should be published nearly as is. I'm suggesting minor revisions in that the changes are just to text, but I think this is important and somewhat nuanced aspect of the paper that will make it even more helpful to readers.

      We appreciate the positive and insightful comments!

      Reviewer #1 (Significance):

      The authors generate a detailed descriptive data set about the component interaction of SHP1 and SHP2 SH2 domains with PD1 and BTLA intracellular domains. They then test hypotheses generated from the descriptive data set to better define the nature of the interactions and why PD1 recruits primarily SHP2, while BTLA mainly recruits SHP1. PD1 is a major driver or the cancer immunotherapy revolution and SHP2 is the major candidate for a signalling effector of PD1. This paper can become the reference paper for the specificity and engineering of this interaction, which will make it highly significant in a very active and still expanding field.

      Referee Cross-commenting

      I still feel that "discrimination" has a functional/activity connotation that is not addressed at all in this paper, but can be addressed. I'm happy to have the suggestion stand and let the authors decide. They need to live with it once its published. Another suggestion- the citations on regulation are mostly old. A good recent paper is Pádua, R. A. P., Sun, Y., Marko, I., Pitsawong, W., Stiller, J. B., Otten, R., & Kern, D. (2018). Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2. Nature Communications, 9(1),

      1. https://doi.org/10.1038/s41467-018-06814-w .

      We believe that some of the functional questions raised by this reviewer, including the SHP1 and SHP2 contribution in PD-1 signaling, was addressed in our recent publication (Xu et al., JCB, 2020). Using SHP1 KO and SHP2 KO T cells, we showed that PD-1 inhibitory function is contributed by SHP2, but very little if any by SHP1. Thus in the current study, we focus on the mechanism behind the striking SHP2 preference by PD-1. We thank this reviewer for suggesting this excellent reference. We will cite this reference in the revised manuscript.

      Reviewer #2 (Evidence, reproducibility and clarity):

      In this study, Xu and co-workers investigate the biophysical nature of the interaction between the structurally-related non-transmembrane PTPs Shp1 and Shp2 with the ITIM/ITSM-containing inhibitory receptors PD-1 and BTLA using cell-based, biochemical, biophysical and domain swapping assays. The primary aim being to better understand how these receptors discriminate between binding Shp1 and/or Shp2, and the orientation of Shp1 and Shp2 engagement. These are major unresolved questions in the field that the authors go some way to addressing in a methodical, rigorous, clear and concise manner. Findings are convincing, correlate well with previous findings and internally, and are complemented with excellent schematics, making it easy to comprehend.

      Major comments

      The authors focus primarily on binding affinities to explain differential binding of Shp1 and Shp2 by PD-1 and BTLA ITIMs and ITSMs, but this is only part of the story. Avidity, compartmentalization, stoichiometry of kinases, and relative abundance of Shp1 and Shp2 are also important aspects of the discriminatory mechanism that are not addressed. Competition assays would go some way to addressing the latter point and should be at least be considered and discussed.

      We agree that various parameters mentioned by this reviewers, such as compartmentalization and relative expression levels would be a concern for purely cell-free assays such as SPR, however, we feel that our cell-based assays already integrate these parameters. This is also precisely the reason why we chose to examine the recruitments of Shp1/2 in a cellular context instead of a purely cell-free system.

      Regarding the competition, we have confirmed our key results in both WT and SHP2 KO background, with or without the potential competition from endogenous SHP2, suggesting that competition might not be a dominant mechanism for the recruitment specificity we observed.

      Similarly, authors do not address how distortion of the pY binding pocket of Shp1 and Shp2 nSH2 domains in the auto-inhibited conformation is released, allowing the domain to engage with phopho-ITIM/ITSM. Again, this should be at least discussed. Current binding studies do not address this issue.

      We feel that the overall recruitment to the PD-1 microclusters as we observed in cells already integrate this auto-inhibition mechanism of Shp1 and Shp2, because we used full length proteins. We do agree with the reviewer that future studies are warranted to address the contributions of each mechanism, including auto-inhibition, concentration, competition, etc., to the overall recruitment. This might require careful and extensive biophysical analyses coupled with mathematical modeling.

      Minor comments:

      Phosphorylation should be indicated in schematic representations in Figures 3, 6 b, c.

      We thank the reviewer for this advice, we will indicate phosphorylation in the revised figure 3.

      Cellular and physiological significance should be further discussed, as well as broader implications of findings to other ITIM/ITSM-containing receptors in other lineages.

      We will further discuss this as suggested.

      Reviewer #2 (Significance)

      Findings from this study advance our knowledge of how inhibitory checkpoint regulatory receptors discriminate between Shp1 and Shp2, which has important implications for understanding how the unique biochemical, cellular and physiological functions of these receptors and phosphatases are dictated. Indeed, findings lay the foundation for a universal mechanism, that may apply to all ITIM/ITSM receptors in other cell lineages, and perhaps novel ways of targeting these interactions therapeutically.

      Compare to existing published knowledge

      Although largely correlative with previous studies, findings from this study start to fill major gaps in our knowledge of these biochemical processes, in a highly rigorous, concise and clear manner. Findings from previous studies were more 'piecemeal', whereas this study consolidates and advances important nuances of these interactions. Moreover, it lays the foundation for further structural, physiological and therapeutic studies.

      Audience

      The immune receptor signaling community and beyond, including any lineage in which ITIM/ITSM-containing receptors play a major role in regulating cellular responses.

      Your expertise

      ITIM/ITSM-containing receptors, kinase-phosphatase molecular switches, cellular reactivity to extracellular matrix proteins

      Referee Cross-commenting

      Generally agree with reviewer's comments. Constructive overall and fair. Although I was thinking additional competition experiments, I do not think necessary. Over the top for this study. Hence, 1 month should suffice to revise accordingly.

      We thank this reviewer for the excellent comments and understanding!

      Reviewer #3 (Evidence, reproducibility and clarity):

      Summary:

      Inhibitory immune receptors containing ITIMs function through recruiting the phosphatases SHP-1 and SHP-2. SHP-1 and SHP-2 are remarkably similar yet have different roles in vivo. How can ITIM-containing immune receptors specifically recruit SHP-1 or SHP-2? In this paper, Xu et al ask how SHP-1 vs SHP-2 specificity is achieved. They use very thorough biochemical assays to measure the affinity of SHP-1 and SHP-2 for various ITIM/ITSMs and finally pin point some key amino acids that switch an ITIM/ITSM from SHP-2 to SHP-1 specificity. The in vitro biochemical assays are augmented by in cell assays that support their conclusions. Overall, this paper is an incredibly elegant and straight forward paper addressing how SHP-1/SHP-2 specificity is achieved.

      Major Comments: none

      Minor Comments:

      • Could the western blots in Figure 1 be quantified as the western blots in other figures?

      We will quantify the western blots in Figure 1 as suggested in the revised manuscript.

      • The data that the y+1 reside is essential for SHP-1/2 specificity is very convincing. We are curious if the other residues of the ITIM/ITSM also contribute to this specificity, albeit less potently. The PD-1 G224A mutant is still less potent than the PD-1 BTLA ITIM swap, suggesting that while the y+1 position is most important, the other residues contribute some specificity. The authors also included data on a PD-1 variant with the BTLA ITIM A224G mutation (8f), which is slightly better at recruiting SHP-1 than the PD-1 ITIM. It may be worth mentioning this data in the text of the paper as well as displaying it in the figure.

      The reviewer raised an excellent point, yes, our data does suggest that other pY-flanking residues within the ITIM also contribute to SHP1 binding. However, the pY+1 residue replacement produced the strongest effect as the reviewer noted. In the revised manuscript, we will acknowledge the potential contributions of other residues.

      • A brief introduction to ITIM vs ITSM in the introduction of the paper may be helpful background for readers. For example, ITIM receptors are reasonably well known but how ITSM functionally differs is probably less well known.

      We will rewrite the introduction about ITIM and ITSM for better clarity.

      • Although not the major focus of the paper, broadening out this SHP-1/2 specificity to other immune receptors in the discussion is fascinating. (a) The authors find that a Valine, Leucine, or Isoleucine in place of the Alanine in y+1 is very close to equivalent, yet the A is highly conserved. The authors speculate that there may be an advantage to sub-maximal SHP-1 affinity because it is more easy to regulate. I think this is reasonable speculation but a little unsatisfying given the very small observed difference in SHP-1 binding. If the authors have additional thoughts, I would be interested to hear them. (b) The authors note that PD-1 is the only ITIM with a glycine in the Y+1 position. Are there other receptors that function primarily through SHP-2, and how might they achieve this specificity?

      Response to a: Even though valine, leucine or isoleucine did not produce a striking enhancement in Shp1 recruitment over alanine, the differences were statistically significant. In fact, when we performed these point mutations at a BTLA ITIM background, valine, leucine or isoleucine markedly enhanced the SHP1 recruitment (see unpublished data below). We speculate that other pY-flanking residues in BTLA, as this reviewer alluded to above, creates an environment that amplifies the differences. The strong sensitivity on pY+1 residue, as observed in BTLA, might be true for other SHP1-recruiting receptors too. If they were to have leucine or isoleucine at the pY+1 position of ITIM, they may recruit too much SHP1 that presumably decreases the fitness/growth of the cells. We propose to show this unpublished data as a supplemental figure in the revised manuscript. We will also discuss the potential contributions of other pY-flanking residues as this reviewer suggested.

      {{images cannot be rendered at this time in reply letters}}

      Response to b: Among the several receptors that we tested, PD-1 is the only receptor that exhibited no recruitment of SHP1. The lack of SHP1 recruitment is also true for murine PD-1, which has a glutamate residue (charged) at Y+1 position. In addition, earlier work reported that PECAM1 also selectively recruits SHP2, but not SHP1. We have noted that PECAM1 contain a threonine (polar) at the pY+1 position of their ITIMs. Thus, their inability to recruit SHP1 is consistent with our model that a nonpolar residue at Y+1 position is required for strong SHP1 recruitment. We will discuss these points in the revised manuscript.

      • Figure 9 b Val not Vla, Figure 3a - a legend for the color code may be nice (ie, 20-1000 nM) Thanks for catching this, we will fix the error in Figure 9b and provide the color code in Figure 3a in the revised manuscript.

      Reviewer #3 (Significance):

      Significance:

      SHP-1 and SHP-2 play a critical role in regulating immune system function. In addition, the receptors recruiting these phosphatases (like PD-1) are important immunotherapy targets. Previously, the question of SHP-1/SHP-2 specificity has been primarily described for ITIM bearing receptors individually. Other studies have predicted consensus sequences for the tSH2 domains of SHP-1 or SHP-2, but not addressed the defining molecular characteristics of these consensus sites or how these could be combined on ITIM receptors to generate selectivity between these related phosphatases. This paper represents a significant step forward because it provides a unifying mechanism explaining how ITIM-bearing immune receptors specifically recruit SHP-1 or SHP-2. I expect this paper will be broadly interesting to biochemists, immunologists and cancer biologists.

      Referee Cross-commenting

      I generally think the other reviewers comments are reasonable and insightful. Together, they suggest no new experiments are necessary. As for the proposed title change, I prefer the authors title and find it to be justified given their data.

      Reviewer #4 (Evidence, reproducibility and clarity):

      In this manuscript, Xu and college performed an elaborate study to investigate the molecular basis of Shp1 and Shp2 discrimination by immune checkpoints PD-1 and BTLA. The paper is original, clear, and well written. I only have a few minor comments:

      1. Please label the molecular weights to all the western blots/IPs results.

      We will label the molecular weights to all the blots in the revised manuscript.

      1. Please add scale bars to all the microscopy pictures.

      We will add scale bars to all the microcopy images in the revised manuscript.

      1. For the SPR data, please add the fitting curves.

      We thank the reviewer for the suggestion. However, we did not use the fitting curve to calculate the Kd, we plotted the maximum response as a function of concentration to determine the Kd. This is another well accepted method for Kd calculation. In fact, some of the SPR curves fit poorly with the existing algorithm. Thus, showing the fitting curve might distract the readers.

      Reviewer #4 (Significance):

      The strength of this paper relies on the details they dissected by using a series of mutagenesis screening experiments, which should be interesting to cell biologists and cancer immunologists.

      Referee Cross-commenting

      I think the other reviewer's comments are insightful and constructive, the suggested experiments are necessary and will improve the paper.

      We thank this reviewer for the positive comments!

    2. Referee #1

      Evidence, reproducibility and clarity

      This paper explores an interesting problem of SHP1/SHP2 preferences of inhibitory immunoreceptors. The author are quick to point out that many of their individual data points confirm published results at some level, but the power of the paper is in the parallel analysis of both PD1, which is strongly biased towards SHP2 and BTLA, which is biased towards SHP1. This gives them the opportunity to test the predictions of descriptive experiment by making simple mutated receptors with swapped ITIM or ITSM domains.

      The work is very well done and generally the authors are quite careful and precise about the language used to describe results, in general.

      The results are quite striking in that the find plenty of evidence for transient interaction of SHP1 with PD1 based on the biophysical measurements, but don't detect the interactions in pull down or in "in cell" microcluster recruitment experiments. In describing the pull-downs they discuss the issue of dissociation during washing potentially missing interactions that are taking place. I would prefer that the pull down is fine evidence for binding, but lack of pull down is not evidence for lack of binding. They should double check that this language is consistent. Also, unless something has changed in the microcluster binding experiments, this in situ recruitment of SHP2 to PD1 is only observed or a 2-3 minutes and then can't be detected, the situation for SHP2 becoming the same as it is for SHP1. If the kinetics are different in the cleaner systems that have now developed they should show this in a primary figure as this would be then different when what is reported previously.

      The gap in this study is lack of any functional analysis. The Jurkat model could be quite useful as they have a relatively clean system for asking if the transient binding of SHP1 to PD1 has any functional impact, which they have not yet followed through on. Does PD-1 recruited SHP2 have any impact on function after the 5 minutes? Furthermore, the authors need to keep in mind that mice deficient in SHP2 respond to anti-PD1 checkpoint therapies (Rota, G., Niogret, C., Dang, A. T., Barros, C. R., Fonta, N. P., Alfei, F., Morgado, L., Zehn, D., Birchmeier, W., Vivier, E., & Guarda, G. (2018). Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo. Cell Rep, 23(1), 39-49. https://doi.org/10.1016/j.celrep.2018.03.026). This is an important issue to discuss in light the the very interesting binding analysis the authors have performed. But I think the functional analysis can be part of a future paper.

      I would suggest that the title be modified slightly from "SHP1/SHP2 discrimination" to "differential SHP1/SHP2 interaction" and leave discussion of discrimination until they have the functional data integrated over times that are relevant to T cell transcriptional regulation (1-2 hrs). The functional analysis can be in another paper, but it would be interesting to have a paragraph in the discussion raising the outstanding issues beyond stable binding detected by the pull-down and microcluster recruitment experiments- what are the implications for function. Could the transient interactions in the noise of the steady state and equilibrium measurements be functional?

      I would summarise that the work is outstanding as biochemistry and biophysics and it should be published nearly as is. I'm suggesting minor revisions in that the changes are just to text, but I think this is important and somewhat nuanced aspect of the paper that will make it even more helpful to readers.

      Significance

      The authors generate a detailed descriptive data set about the component interaction of SHP1 and SHP2 SH2 domains with PD1 and BTLA intracellular domains. They then test hypotheses generated from the descriptive data set to better define the nature of the interactions and why PD1 recruits primarily SHP2, while BTLA mainly recruits SHP1. PD1 is a major driver or the cancer immunotherapy revolution and SHP2 is the major candidate for a signalling effector of PD1. This paper can become the reference paper for the specificity and engineering of this interaction, which will make it highly significant in a very active and still expanding field.

      Referee Cross-commenting

      I still feel that "discrimination" has a functional/activity connotation that is not addressed at all in this paper, but can be addressed. I'm happy to have the suggestion stand and let the authors decide. They need to live with it once its published. Another suggestion- the citations on regulation are mostly old. A good recent paper is Pádua, R. A. P., Sun, Y., Marko, I., Pitsawong, W., Stiller, J. B., Otten, R., & Kern, D. (2018). Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2. Nature Communications, 9(1), 4507. https://doi.org/10.1038/s41467-018-06814-w .

    1. Kraemer, M. U. G., Hill, V., Ruis, C., Dellicour, S., Bajaj, S., McCrone, J. T., Baele, G., Parag, K. V., Battle, A. L., Gutierrez, B., Jackson, B., Colquhoun, R., O’Toole, Á., Klein, B., Vespignani, A., Consortium‡, T. C.-19 G. U. (CoG-U., Volz, E., Faria, N. R., Aanensen, D., … Pybus, O. G. (2021). Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence. Science. https://doi.org/10.1126/science.abj0113

    1. Julien Gori, Han L. Han, and Michel Beaudouin-Lafon. 2020. FileWeaver: FlexibleFile Management with Automatic Dependency Tracking. InProceedings of UIST2020, 33rd Annual ACM Symposium on User Interface Software and Technolog.Association for Computing Machinery, Virtual Event, 22–34. https://doi.org/10.1145/3379337.3415830[9]David R. Karger, Karun B
      • ref : FileWeaver

    Annotators

    1. SciScore for 10.1101/2021.07.16.452721: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: All experiments were performed in accordance with institutional guidelines from the Animal Research and Ethics Board.<br>Euthanasia Agents: Bronchoalveolar lavage, lung, mediastinal lymph node, nasal turbinate and spleen mononuclear cell isolation: Mice were euthanized by exsanguination.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">200 µg of Anti-CD4 (clone GK1.5) and anti-CD8 (clone 2.43) depleting, or an IgG isotype control antibodies (MilliporeSigma, Etobicoke, ON, Canada) were intraperitoneally administered as a single bolus 26-days post-vaccination.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-CD4</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-CD8</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>an IgG</div><div>suggested: (Hangzhou HuaAn Biotechnology Cat# HA1006, RRID:AB_2819167)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The membrane was incubated with primary antibodies (1:1000 Anti-VSV-G (ThermoFisher Scientific Waltham, MA, United States), 1:2000 Anti-NP (ThermoFisher Scientific Waltham, MA, United States) and 1:5000 GAPDH (MilliporeSigma, Etobicoke, ON, Canada) diluted in 5% skim milk, followed by anti-mouse and anti-rabbit IRDye secondary antibodies (LI-COR, Lincoln, NE, United States) diluted in 5 % skim milk.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-VSV-G</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Anti-NP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-mouse</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-rabbit</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After washing, goat anti-mouse-biotin antibodies (Southern Biotech, Birmingham, AL, United States) IgA (1:2000), IgG (1:5000), IgG1 (1:5000), IgG2a (1:5000)) were diluted in reagent diluent and added to all wells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse-biotin</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgG1</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Both trivalent vaccines were further amplified in HEK293 cells and subsequently purified by cesium chloride density gradient ultracentrifugation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: CLS Cat# 300192/p777_HEK293, RRID:CVCL_0045)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Transgene protein analysis by Western blot: A549 cells (CCL-185, ATCC, Manassas, VA, United States) were cultured at 37°C in DMEM supplemented with 10% FBS, 1 % HEPES pH 7.3, 1% L-glutamine and 100 U/mL of penicillin–streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The Vero E6 culture media was then replaced with 100 µL of the serum-virus mixture and was incubated at 37°C for 72 hours.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mice: Age-matched 6–8-wk-old wild-type female BALB/c, C57BL/6J, or B6.Cg-Tg (K18-ACE2) 2Prlmn/J mice were purchased from either Charles River Laboratories (Saint Constant, QC, Canada) or The Jackson Laboratory (Bar Harbor, ME, United States)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>C57BL/6J</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>B6.Cg-Tg ( K18-ACE2 ) 2Prlmn/J</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 strain SB3-TYAGNC was provided by Dr. Arinjay Banerjee, Dr. Karen Mossman, Dr. Samira Mubareka, and Dr. Rob Kozak and isolated as described previously (Banerjee et al., 2020).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SB3-TYAGNC</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">This PCR product was cloned in pCY1 plasmid which contains the mCMV promoter.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCY1</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mice: Age-matched 6–8-wk-old wild-type female BALB/c, C57BL/6J, or B6.Cg-Tg (K18-ACE2) 2Prlmn/J mice were purchased from either Charles River Laboratories (Saint Constant, QC, Canada) or The Jackson Laboratory (Bar Harbor, ME, United States)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Charles River Laboratories</div><div>suggested: (Charles River Laboratories, RRID:SCR_003792)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Stained cells were fixed and permeabilized with BD Cytofix/Cytoperm before incubation in BD Perm/Wash buffer (BD Biosciences, San Jose, CA, United States).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BD Cytofix/Cytoperm</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were analyzed using FlowJo software (version 10.1; Tree Star, Ashland, OR, United States).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Tests were performed using GraphPad Prism software (Version 9</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, Graphpad Software, La Jolla, CA, United States).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Graphpad</div><div>suggested: (GraphPad, RRID:SCR_000306)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      These limitations of i.m. delivery, along with our current findings and those from others (Bricker et al., 2021; Hassan et al., 2020), should further bolster the global effort in developing respiratory mucosal-deliverable next-generation COVID-19 vaccines. In this regard, there have been at least two clinical trials testing either inhaled aerosol ChAdOx1nCov-19 (Singh et al., 2021) or intranasally delivered ChAd-SARS-CoV-2-S developed by scientists at WUSTL (Clinical Trial NCT04751682). Our current study has also provided the novel experimental evidence that both B and T cells are required for optimal protection. Of note, our data suggest that the clinical outcomes (body weight losses and mortality) may not always corroborate with viral burden, depending on both the immune pathway and relative potency of vaccine. We have observed that while Tri:HuAd-vaccinated B cell-deficient hosts well-protected in terms of clinical outcomes suffered impaired lung viral clearance, T cell-deficient hosts suffered both moderately worsened clinical outcomes and lung viral clearance. On the other hand, the robust i.n. Tri:ChAd vaccine strategy protected wildtype, B cell- and T cell-deficient hosts equally well in terms of clinical outcomes, whereas lack of B or T cells led to impaired lung viral clearance. Besides using T cell-depletion approach, the role of vaccine-induced T cell immunity in protection is supported further by our observations from B.1.135-infected K18-hACE2 animals immunized w...

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04751682</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Active, not recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccin…</td></tr></table>


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.19.452910: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">or with 1 μg UBE2O antibody (A301-873A, Bethyl) overnight following with 15 μL prewashed protein A/G beads (1:1 mixture, 1614013 and 1614023, Biorad) incubation for another 1.5 hr.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>UBE2O</div><div>suggested: (Thermo Fisher Scientific Cat# A301-873A, RRID:AB_1309799)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibodies used in these experiments included Flag (F1804, Sigma), EGFP (50430-2-AP, Proteintech), NSP3 (ab181602, Abcam), UBE2O (A301-873A, Bethyl), pSerine (gtx26639, GeneTex), pThreonine (9386, Cell Signaling), TAB2 (A302-759A, Bethyl), TAB3 (A302-208A, Bethyl)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>EGFP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>A301-873A , Bethyl) , pSerine ( gtx26639 , GeneTex) , pThreonine ( 9386 , Cell Signaling) , TAB2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>A302-759A , Bethyl) , TAB3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibodies used for the experiment are: CANX (2679, Cell Signaling), TOMM20 (ab56783, Abcam), Flag (F1804 and F7425, Sigma), NSP3 (ab181602, Abcam).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CANX ( 2679 , Cell Signaling)</div><div>suggested: (Cell Signaling Technology Cat# 2679, RRID:AB_2228381)</div></div><div style="margin-bottom:8px"><div>TOMM20</div><div>suggested: (Abcam Cat# ab56783, RRID:AB_945896)</div></div><div style="margin-bottom:8px"><div>ab56783 , Abcam) , Flag ( F1804</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>NSP3</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T cells from ATCC were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Hyclone, SH30033.01) supplemented with 10% Fetal bovine serum (FBS, Hyclone, SV30160.03) and 1×Penicillin/Streptomycin (Hyclone,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">UBE2O plasmid was described before [52] and TNIP cDNA was amplified from HeLa cDNA and cloned in to pCS2 vector with Flag tag.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCS2</div><div>suggested: RRID:Addgene_62214)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Raw data were first transformed using FAIMS MzXML Generator and then analyzed using MaxQuant version 1.6.17.0 [54]</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MaxQuant</div><div>suggested: (MaxQuant, RRID:SCR_014485)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Protein-Protein Interaction (PPI) network and pathway annotation of interactors was constructed by Cytoscape plugin Reactome FI v7.2.3 [57].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Cytoscape</div><div>suggested: (Cytoscape, RRID:SCR_003032)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Interactors of NSP3 were divided into 3 groups (CoV1, CoV2 and both) and enriched GO terms were shown using clusterProfiler package [58]</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>clusterProfiler</div><div>suggested: (clusterProfiler, RRID:SCR_016884)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Circos plots was performed using circlize package [59].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Circos</div><div>suggested: (Circos, RRID:SCR_011798)</div></div><div style="margin-bottom:8px"><div>circlize</div><div>suggested: (circlize, RRID:SCR_002141)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We filtered out the kinases of which matching sites was less than 3 or Z-score is lower than 1 and created Human Kinome Tree illustration using KinMap [36].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>KinMap</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The targeting drugs that regulate activity changed kinases were extracted from drugbank (https://go.drugbank.com/).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>drugbank</div><div>suggested: (DrugBank, RRID:SCR_002700)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Transcriptome data analysis: Raw reads were aligned to the human genome (hg38) using HISAT2 [62].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HISAT2</div><div>suggested: (HISAT2, RRID:SCR_015530)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, we assembled reads to transcripts and quantified the read counts of each genes utilizing StringTie [63].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>StringTie</div><div>suggested: (StringTie , RRID:SCR_016323)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We kept genes that CPM is greater than 1 in at least 2 samples and analyzed the differential expression gene using edgeR [64].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>edgeR</div><div>suggested: (edgeR, RRID:SCR_012802)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, Molecular Function (MF) were performed using enrichR in clusterProfiler package.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>enrichR</div><div>suggested: (Enrichr, RRID:SCR_001575)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.16.452709: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat#SAD-S35, Acro Biosystems, Newark, DE), SARS-CoV-2 (2019-nCoV</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-SARS-CoV-2 RBD</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Human IgG1</div><div>suggested: (Abcam Cat# ab20402, RRID:AB_445563)</div></div><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For pseudovirus production, Lenti-X-293T cells were co-transfected with pNL4-3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Lenti-X-293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sera 28-days post-infection from three (3) different species of non-human primates (NHPs) rhesus macaques (RM), cynomolgus monkeys (CM), African Green Monkeys (AGMs) (N=2 each), challenged with SARS-CoV-2 (SARS-CoV-2 USA_WA1/2020 strain at 4.0 x 106 TCID50/mL through intra-tracheal route) were used in the pseudovirus assay. 2.3. Pseudovirus Based Neutralization Assay: HEK293T-ACE2 cells (NR-52511, BEI Resources, Manasas, VA) were grown in Dulbecco’s Minimal Essential Medium (DMEM, Lonza, Walkersville, MD), supplemented with 10% Fetal Bovine Serum (FBS) according to standard culture conditions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T-ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293-ACE2 cells were seeded at ~20,000 cells per well into 96-well plates (100 μL per well) DMEM with 10% FBS without antibiotic the day before the assay.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293-ACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">pNL4-3.Luc.R-E-, NIH AIDS Reagent, Catalog Number: 3418 was licensed/obtained from the New York University School of Medicine. Codon Optimized SARS-CoV-2 Spike gene from isolate 2019-nCoV_HKU-SZ-002a_2020 (GenBank: MN938384) was synthesized at GeneWiz, South Plainfield, NJ.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pNL4-3.Luc.R-E-</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Spike gene was cloned into eukaryotic expression plasmid pcDNA3.1 to generate plasmid, designated as pSRC332.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pcDNA3.1</div><div>suggested: RRID:Addgene_79663)</div></div><div style="margin-bottom:8px"><div>pSRC332</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For pseudovirus production, Lenti-X-293T cells were co-transfected with pNL4-3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pNL4-3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Luc.R-E- and pSRC322 using JetPrime transfection reagent (Polyplus Transfection, New York, NY).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pSRC322</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The next day cells were co-transfected with 3 μg pSRC332 and 12 μg pNL43. Luc. R. E using JetPrime® Transfection Reagent following the manufacturer’s instruction.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pNL43</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">pNL4-3.Luc.R-E-, NIH AIDS Reagent, Catalog Number: 3418 was licensed/obtained from the New York University School of Medicine. Codon Optimized SARS-CoV-2 Spike gene from isolate 2019-nCoV_HKU-SZ-002a_2020 (GenBank: MN938384) was synthesized at GeneWiz, South Plainfield, NJ.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GeneWiz</div><div>suggested: (GENEWIZ, RRID:SCR_003177)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Luminescence signal was normalized to the virus control after background subtraction and analyzed using PRISM software using four parameter logistic curve fitting to calculate 50% pseudovirus based neutralization index (PBNI50).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PRISM</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.16.452733: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: The animal studies were conducted in compliance with all relevant local, state, and federal regulations and were approved by the BIOQUAL Institutional Animal Care and Use Committee (IACUC).<br>IACUC: The animal studies were conducted in compliance with all relevant local, state, and federal regulations and were approved by the BIOQUAL Institutional Animal Care and Use Committee (IACUC).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">One male and 3 females were assigned to the MV-014-212 and RSV groups.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For MV-014-212 and MVK-014-212, we used Rabbit anti-SARS-CoV-2 spike polyclonal antibody (Sino Biological) and Goat anti-rabbit HRP-conjugated secondary antibody (Jackson ImmunoResearch).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MVK-014-212</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-SARS-CoV-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-rabbit</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For rA2-mKate2, the reagents used were Goat anti-RSV primary antibody (Millipore) and Donkey anti-goat HRP-conjugated secondary antibody (Jackson ImmunoResearch).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-goat</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The blots were stripped with Restore Western Blot Stripping Buffer (ThermoFisher, Carlsbad, CA) and reprobed with goat anti-RSV polyclonal antisera (Sigma-Aldrich, St. Louis, MO) and a monoclonal antibody specific for GAPDH (6C5) protein (ThermoFisher, Carlsbad, CA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-RSV</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>GAPDH</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The plate was washed 4 times with 250 μL PBST and 100 μL of HRP-conjugated goat anti-monkey IgG antibody (PA1-8463, Thermo Fisher, Waltham, MA) diluted in blocking solution was added to each well following the last wash step.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-monkey IgG</div><div>suggested: (Thermo Fisher Scientific Cat# PA1-8463, RRID:AB_2196308)</div></div><div style="margin-bottom:8px"><div>PA1-8463</div><div>suggested: (Thermo Fisher Scientific Cat# PA1-8463, RRID:AB_2196308)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To generate the IgA standard curve anti-human IgA capture antibodies Mab MT57 (MabTech) were absorbed on plates instead of spike antigen.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgA</div><div>suggested: (MABTECH Cat# 3860-4-1000, RRID:AB_10734770)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The standard total IgA antibody assayed on each test plate was used to calculate the concentration of IgA antibodies against spike protein in the AGM samples expressed in the arbitrary units ELU/mL.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgA</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Spike-specific IgG1 and IgG2a ELISA: Serum samples from mice were collected on Day -21 and on Day 28 post vaccination to quantify the levels of SARS-CoV-2 spike-specific IgG1 and IgG2a antibodies by ELISA.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Spike-specific IgG1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgG2a</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then, 100 μL of HRP-conjugated goat-anti-mouse IgG1 (Thermo Fisher) or HRP-conjugated goat-anti-mouse IgG2a (Thermo Fisher) secondary antibodies diluted 1:32,000 and 1:1000, respectively, were added to each well and the plate was incubated at room temperature for 1 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgG1</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus rescue and harvest: Vero cells were electroporated with the bacterial artificial chromosome (BAC) encoding MV-014-212 (or the reporter virus) together with helper plasmids based on the pCDNA3.1 vector encoding the RSV proteins N, P, M2-1 and L, and the T7 polymerase under the control of a CMV promoter (Hotard 2021).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primers / Probe sequences are shown below: SG-F: CGATCTTGTAGATCTGTTCCTCAAACGAAC SG-R: ATATTGCAGCAGTACGCACACACA FAM-ACACTAGCCATCCTTACTGCGCTTCG-BHQ TCID50 assay to detect shedding of SARS-CoV-2 in BAL and NS of AGMs after challenge: Vero TMPRSS2 cells (obtained from Adrian Creanga, Vaccine Research Center-NIAID) were plated at 25,000 cells/well in DMEM + 10% FBS + Gentamicin and the cultures were incubated at 37°C, 5.0% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Confluent RCB1 cells grown in a clear-bottom black 96-well plate (Grenier) were infected with the serum-virus mixes and centrifuged (spinoculated) at 1,800 x g for 30 minutes at 20 °C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RCB1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Starting with a dilution of 1/25, serial 2-fold dilutions of heat-inactivated AGM sera were incubated with the pseudotyped viral particles (3 x 105 RLU/well) at 37°C for one hour after which the mixes were used to infect Vero E6 monolayers in white 96-well plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Male and female K18-hACE2 Tg (strain #034860, B6.Cg-Tg[K18-ACE2]2Prlmn/J) mice were procured from The Jackson Laboratory (Bar Harbor, ME) and were approximately 8-10 weeks old at the time of vaccination.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>B6.Cg-Tg[K18-ACE2]2Prlmn/J</div><div>suggested: RRID:IMSR_JAX:034860)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The kRSV-DB1-QUAD plasmid and spike insert were digested with the enzymes AatII and SalI (NEB) and ligated with T4 DNA ligase (NEB) overnight at 16 ℃.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>kRSV-DB1-QUAD</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The construction of the plasmid rA2-mkate (a.k.a. kRSV-A2) was described in Rostad 2016.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>rA2-mkate</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus rescue and harvest: Vero cells were electroporated with the bacterial artificial chromosome (BAC) encoding MV-014-212 (or the reporter virus) together with helper plasmids based on the pCDNA3.1 vector encoding the RSV proteins N, P, M2-1 and L, and the T7 polymerase under the control of a CMV promoter (Hotard 2021).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCDNA3.1</div><div>suggested: RRID:Addgene_79663)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The sequence traces were assembled using Sequencher software and the assembly was manually confirmed.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Sequencher</div><div>suggested: (Sequencher, RRID:SCR_001528)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The resulting curves of inhibition vs. dilution of the sera were fitted using non-linear regression, option “[inhibitor] vs normalized response-variable slope” in GraphPad Prism (version 9.0.0).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      The use of a semi permissive animal model for the evaluation of the live attenuated vaccine (LAV) candidate MV-014-212 constitutes a limitation of this study, since LAVs rely on replication to elicit a robust immune response. The semi-permissivity of AGMs to RSV and SARS-CoV-2 would result in lower replication of MV-014-212 and a more modest serum neutralizing antibody response. In a more permissive host like humans, MV-014-212 is expected to replicate to higher titers potentially resulting in higher immunogenicity than that observed in AGMs. Remarkably, immunization of AGM with MV-014-212 resulted in both mucosal and systemic antibody responses. There was approximately 100-fold more spike-specific total serum IgG in MV-014-212 vaccinated AGM compared to AGM that received wt RSV A2 or PBS inoculations. Spike-specific IgA was also detected in nasal swabs of MV-014-212 immunized animals. There was approximately an 8-fold increase in IgA concentration 25 days following vaccination with MV-014-212. In an experimental human challenge study, low RSV F-specific mucosal IgA was a better predictor for susceptibility to RSV challenge in seropositive adults than serum IgG and neutralizing antibody levels (Habibi 2015). Indeed, spike RBD-specific dimeric serum IgA was shown to be more potent at neutralizing SARS-CoV-2 than monomeric IgG (Wang 2021). By inference, secretory IgA which exists at mucosal surfaces as dimeric IgA may act as a potent inhibitor of SARS-CoV-2 at the site of infec...

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04798001</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Safety and Immunogenicity of an Intranasal RSV Vaccine Expre…</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.17.452554: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Animal work: Institutional approvals: All animal experiments described in this study were performed in accordance with protocols (number 1930) that were reviewed and approved by the Institutional Animal Care and Use and Committee of Princeton University (#1930) and Boston University (PROTO202000020).<br>Euthanasia Agents: Briefly, mice were anesthetized using isoflurane (2.5%), placed into a body conforming animal mold (BCAM) (InVivo Analytics) and imaged within 5 min of injection.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Heterozygous K18-hACE2 C57BL/6J mice of both sexes (strain 034860, 2B6.Cg-Tg(K18-ACE2)2Prlmn/J) were obtained from The Jackson Laboratory and maintained at the NEIDL at Boston University.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells and antibodies: VeroE6 cells and AAV-293 cells (ATCC) were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% heat inactivated fetal bovine serum (Bio-Techne, R&D systems, Minneapolis, MN, USA) and 1% (v/v) Penicillin Streptomycin (Thermo Scientific, Waltham, MA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Penicillin Streptomycin</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The following anti-mouse antibodies were used for flow cytometry: from BioLegend (San Diego, CA, USA): CD45-PE-Cy7 clone 30-F11, CD45-PE-Dazzle5 clone 30-F11.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD45-PE-Dazzle5</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The following anti-human antibodies were used for flow cytometry: from BD Biosciences (San Jose, CA, USA): CD45-V500 clone HI30, CD34-FITC clone 581, CD8-FITC clone G42-8, CD11c-allophycocyanin clone B-ly6; from BioLegend: CD56-allophycocyanin-Cy7 clone HCD56, CD33-PerCP-Cy5.5 clone WM53, CD11c-Alexa Fluor 700 clone 3.9, CD123-eFluor450 clone 6H6, CD14-PE-eFluor610 clone 61D3, CD3-FITC clone SK7, CD19-allophycocyanin clone HIB19, HLA-DR-BV510 clone L243, CD3-BV605 clone UCHT1, CD20-BV650 clone 2H7, CD16-BV117 clone B73.1, CD45-BV785 clone H130, CD8-FITC clone RPA-T8, CD33-PE clone WM53, CD14-PerCP-Cy5.5 clone HCD14, CD45RA-PE-Cy7 clone HI100, CD56-allophycocyanin clone QA17A16, CD4-Alexa Fluor 700 clone SK3; from Thermo Scientific: CD14-Alexa 700 clone Tuk4, CD3-PE-Cy5.5 clone 7D6, CD4-PE clone RPA-T4, CD19-PacBlue clone SJ25C1, CD16-PE-TexasRed clone 3G8.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human</div><div>suggested: (SouthernBiotech Cat# 9590-09, RRID:AB_2796984)</div></div><div style="margin-bottom:8px"><div>CD34-FITC</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD8-FITC</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD11c-allophycocyanin</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD56-allophycocyanin-Cy7</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD33-PerCP-Cy5.5</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD123-eFluor450</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD14-PE-eFluor610</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD3-FITC</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD19-allophycocyanin</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HLA-DR-BV510</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD3-BV605</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD20-BV650</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD16-BV117</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD45-BV785</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD33-PE</div><div>suggested: (SouthernBiotech Cat# 9590-09, RRID:AB_2796984)</div></div><div style="margin-bottom:8px"><div>CD14-PerCP-Cy5.5</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD45RA-PE-Cy7</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD56-allophycocyanin</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD3-PE-Cy5.5</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD4-PE</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD19-PacBlue</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The following primary antibodies were used for immunochemistry: anti-human CD31 clone JC/70A (Biocare Medical, Pacheco, CA, USA), anti-mouse CD31 clone D8V9E (Cell Signaling Technology, Danvers, MA, USA), ACE2 clone EPR34435 (Abcam, Waltham, MA, USA), polyclonal SFTPC (Seven Hills Bioreagents, Cincinnati, OH, USA), anti-human CD68 clone KP1 (LS Bio, Seattle, WA, USA), anti-human CD61 clone ARC0460 (Thermo Scientific), anti-human CD4 clone SP35 and anti-human CD8 clone SP57 (Roche, Basel, Switzerland), and anti-human CD20 clone L26 Dako Omnis (Agilent, Santa Clara, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human CD31</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-mouse CD31</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-human CD68</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-human CD61</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-human CD4</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-human CD8</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-human CD20</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The secondary antibody used in this study included HRP Goat anti-Rabbit IgG (H&L) (Vector Laboratories, Burligame, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Rabbit IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The following anti-SARS-CoV-2 antibodies were used for immunohistochemistry: rabbit polyclonal anti-SARS-CoV Nucleoprotein (Novus Biological, Littleton, CO, USA), mouse monoclonal anti-SARS-CoV-2 Spike clone 2B3E5 (This antibody was used in this study as clone E7U60, which was the pre-production clone ID of clone 2B3E5; Cell Signaling Technology).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-SARS-CoV Nucleoprotein</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Purification of human CD34+ cells were assessed by flow cytometry using an anti-human CD34-FITC antibody (clone 581, BD Biosciences).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human CD34-FITC</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow cytometry fluorophore compensation for antibodies was performed using an AbC™ Anti-Mouse Bead Kit (ThermoFisher Scientific).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-Mouse</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Quantification of peripheral human chimerism in HNFL mice: 2-4×106 PBMCs of human or murine origin were isolated as described above and stained for 1 h at 4°C in the dark with an antibody cocktail targeting human(h)CD45, mouse CD45, hCD3, hCD4, hCD8, hCD16, hCD19, hCD11c, hCD56 and hCD14.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD45</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>hCD16</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>hCD14</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody staining and flow cytometry analysis of NRG-L splenocytes and fLX: 2-4×106 splenocytes or fetal lung cells of human or murine origins were isolated as described above and stained for 1 h at 4°C in the dark with an antibody cocktail targeting mouse CD45, human(h)CD45, hCD19, hCD3, hCD33, hCD11c, hCD56, hCD68, hCD123, hCD14.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>hCD68</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>hCD123</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After blocking, 25 µL of antibody cocktail targeting hCD3, hCD20, hCD16, hHLA-DR, hCD45, hCD8, hCD4, hCD33, hCD45RA, hCD56, hCD14, mCD45, and containing a LIVE/DEAD viability dye (ThermoFisher Scientific) was added to each sample and incubated in the dark for 30 min at 4°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>hCD20</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>hHLA-DR, hCD45, hCD8, hCD4, hCD33, hCD45RA</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>hCD56</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Our P2 working stock of the virus was prepared by infecting Vero E6 cells with the P1 stock, at a multiplicity of infection (MOI) of 0.1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">AAV-293 cells (Agilent) at 50% confluency in 15 cm dishes were transfected via the calcium phosphate method with 22.5 µg XR8 (NGVB, Indianapolis, IN), 7.5 µg pHelper (Agilent), 7.5 µg of pAB269-TBG-FLT3 LG-BGH per plate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>AAV-293</div><div>suggested: NCBI_Iran Cat# C548, RRID:CVCL_6871)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mouse models and housing: NOD Rag1-/- IL2Rgnull mice (NOD.Cg-Rag1tm1MomIl2rgtm1Wjl/SzJ, were obtained from the Jackson Laboratory, catalog number 007799).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NOD Rag1-/- IL2Rgnull</div><div>suggested: RRID:BCBC_1261)</div></div><div style="margin-bottom:8px"><div>NOD.Cg-Rag1tm1MomIl2rgtm1Wjl/SzJ</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">NRG-Flk2-/- (NRGF) mice (NOD.Cg-Rag1tm1Mom Flt3tm1Irl Il2rgtm1Wjl/J) were generated as described previously (Douam et al., 2018) and are available at The Jackson Laboratory (Bar Harbor, ME, USA) (catalog number 033127).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NRG-Flk2-/-</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>NOD.Cg-Rag1tm1Mom Flt3tm1Irl Il2rgtm1Wjl/J</div><div>suggested: RRID:IMSR_JAX:033127)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Heterozygous K18-hACE2 C57BL/6J mice of both sexes (strain 034860, 2B6.Cg-Tg(K18-ACE2)2Prlmn/J) were obtained from The Jackson Laboratory and maintained at the NEIDL at Boston University.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6J</div><div>suggested: RRID:MGI:3589388)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Generation of AAV-Flt3LG: The pAB269 AAV backbone containing AAV2 ITRs was kindly provided by Markus Grompe (OHSU, Oregon, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pAB269</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The FLT3 was PCR amplified from pAL119-FLT3L (Addgene, item #21910), and the TBG was amplified from pX602-AAV-TBG:NLS-SaCas9-NLS-HA-OLLAS-bGHpA;U6::BsaI-sgRNA (Addgene, item #61593).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pAL119-FLT3L</div><div>suggested: RRID:Addgene_21910)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow cytometry data were analyzed using FlowJo software (TreeStar, Ashland, OR, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">An unstained fLX section was used to create an autofluorescence signature that was subsequently removed from multispectral images using InForm software version 2.4.8 (Akoya Biosciences).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>InForm</div><div>suggested: (inForm, RRID:SCR_019155)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Each sample, comprising 100 μg peptides, was TMT-labeled with TMTPro 16plex reagents (ThermoFisher Scientific: # A44520) as per the manufacturer’s protocol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ThermoFisher Scientific</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The MaxQuant output files designated ‘‘Phospho(STY)sites’’ and ‘‘proteinGroups’’ were filtered to remove entries that were either entirely mouse, or in the case of completely homologous peptides, had annotations of both mouse and human.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MaxQuant</div><div>suggested: (MaxQuant, RRID:SCR_014485)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Raw FASTQ files were quality-checked with FastQC v0.11.7.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FastQC</div><div>suggested: (FastQC, RRID:SCR_014583)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Reads were found to be excellent quality and were aligned to the combined human (GRCh38, Ensembl 101) and mouse (GRCm38, Ensembl 101) genomes with STAR v2.7.1a followed by quantification with featureCounts v1.6.2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STAR</div><div>suggested: (STAR, RRID:SCR_004463)</div></div><div style="margin-bottom:8px"><div>featureCounts</div><div>suggested: (featureCounts, RRID:SCR_012919)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Quality was checked with MultiQC v1.6.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MultiQC</div><div>suggested: (MultiQC, RRID:SCR_014982)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">DESeq2 result were imported into Ingenuity Pathway Analysis (IPA; Service curated by Qiagen; Access provided through the Boston University Genome Science Institute) (Kramer et al., 2014), and a canonical pathway enrichment analysis was performed using the default settings and the same differential expression thresholds as before (shrunken log2 fold change > 2 or < -2 and FDR-adjusted p-value < 0.01).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>DESeq2</div><div>suggested: (DESeq, RRID:SCR_000154)</div></div><div style="margin-bottom:8px"><div>Ingenuity Pathway Analysis</div><div>suggested: (Ingenuity Pathway Analysis, RRID:SCR_008653)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All statistical tests and graphical depictions of results were performed using GraphPad Prism version 9.0.1 software (GraphPad Software, La Jolla, CA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data deposition: The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2019) partner repository with the dataset identifier PXD025851.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PRIDE</div><div>suggested: (Pride-asap, RRID:SCR_012052)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Transcriptomic data generated during this study are available through the National Center for Biotechnology Information Gene Expression Omnibus (GEO) under series accession no. GSE180063.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gene Expression Omnibus</div><div>suggested: (Gene Expression Omnibus (GEO, RRID:SCR_005012)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      To enhance our understanding of the cellular and molecular mechanisms driving protective immune responses in the respiratory tract of asymptomatic and mild COVID-19 patients, investigations need to go beyond human patient studies due to their inherent limitations. Immunodeficient mice engrafted with fLX have been previously reported to be highly permissive to coronavirus infection (Wahl et al., 2021). Such in vivo platforms carry substantial advantages over other in vivo models (including humans) in a way that enables investigations into coronavirus infection within a human lung environment over time and in controlled experimental settings. However, given our common understanding that the quality of immune responses during SARS-CoV-2 infection defines disease outcome, the lack of significant human hematopoietic reconstitution in these models has precluded their use for investigating human immune responses against coronavirus infection. Here, we report that NRG-L mice singly engrafted with fLX are highly susceptible to SARS-CoV-2 infection. Inoculated fLX were prone to extensive inflammation, which associated with severe histopathological manifestations of disease. In sharp contrast, co-engraftment of fLX and human HSC in HNFL mice resulted in protection against SARS-CoV-2 infection, as well as limited inflammation and histopathology. Protection associated with the induction of a superior ISG response in HNFL mice as compared to NRG-L mice, which was dominated by the upregulat...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on pages 68, 70, 71, 72 and 73. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.14.21260491: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: bioMILD, clinicaltrials.gov ID: NCT02247453) collected from July 14, 2018 until February 23, 2019, matched by date of collection, sex, age, smoking habits.<br>IRB: The Institutional Review Board and Ethics Committee of Fondazione IRCCS Istituto Nazionale dei Tumori of Milan approved the study.<br>Consent: All eligible subjects provided written informed consent.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the analysis and the graphic design the GraphPad Prism software (version 5.2) was adopted.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      We acknowledge some limitations in this re-test study related to the limited sample size, the highly specific selection of screening participants (heavy smokers ≥ 30 pack years and ≥55 years old), possibly not representative of the general population, and the intrinsic experimental variability of the immunoenzymatic assays employed in the different laboratories. Moreover, we cannot exclude that other confounding conditions, such as preexisting immunity against other agents, might have contributed to the SARS-CoV-2 positivity in our assays. Nonetheless, cross reactivity towards the most common HCoVs was ruled out. As pointed out in the recent WHO report (www.who.int) and in other commentaries (1,2), studies from different countries suggest that SARS-CoV-2 was growing under the surface for some time before the first diagnosed case in Wuhan. Suggestive evidence from our previous published study (10) and conflicting results from the current retesting exercise, despite adding important signals in this direction, do not allow us to accept or discard this hypothesis. Indeed findings of these studies are only partially confirmed due to the heterogeneity of methods utilized and the risk of non-specific signals in serological assays. Despite that, the report underlines the importance of investigating these potential early events, to solve the still unanswered questions about the origin and timing of the current pandemic and may contribute to a better understanding of the future virus c...

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT03654105</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Active, not recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Screening and Multiple Intervention on Lung Epidemics</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT02247453</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Active, not recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Plasma microRNA Profiling as First Line Screening Test for L…</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.14.21260307: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Ethics statement: This study was approved by Yale Human Research Protection Program Institutional Review Board (IRB Protocol ID 2000028924).<br>Consent: Informed consent was obtained from all enrolled vaccinated HCWs.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">ELISA, neutralizations, and flow cytometry analyses were blinded.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: The cell line was obtained from the ATCC and has been tested negative for contamination with mycoplasma.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Human Anti-Spike and anti-nucleocapsid antibodies were serially diluted to generate a standard curve.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-nucleocapsid</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were washed three times with PBS-T (PBS with 0.1% Tween-20) and 50 μl of HRP anti-Human IgG Antibody (GenScript #A00166, 1:5,000) diluted in dilution solution added to each well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Human IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow cytometry: Antibody clones and vendors were as follows: BB515 anti-hHLA-DR (G46-6) (1:400</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-hHLA-DR ( G46-6 )</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 300 µl of serial fold virus dilutions were used to infect Vero E6 cells in MEM supplemented NaHCO3, 4% FBS 0.6% Avicel RC-581.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Ethics statement: This study was approved by Yale Human Research Protection Program Institutional Review Board (IRB Protocol ID 2000028924).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Yale Human Research Protection Program</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The Institutional Review Board from the Yale University Human Research Protection Program determined that the RT-qPCR testing and sequencing of de-identified remnant COVID-19 clinical samples conducted in this study is not research involving human subjects (IRB Protocol ID: 2000028599).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Human Research Protection Program</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The clinical data were collected using EPIC EHR May 2020 and REDCap 9.3.6 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>REDCap</div><div>suggested: (REDCap, RRID:SCR_003445)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were analysed using FlowJo software version 10.6 software (Tree Star).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: All analyses of patient samples were conducted using GraphPad Prism 8.4.3, JMP 15, and R 3.4.3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your code and data.


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      A potential limitation in our study is that, even with our 7-day stimulation prior to analysis, it remains possible that our T cells assay failed to detect underrepresented T cell clones impacted by variant sequences when sampled in the presence of the majority of conserved peptides. Overall, our data point to a necessity of active monitoring of T cell reactivity in the context of SARS-CoV-2 evolution. The magnitude of the antibody titers in COVID-19 patients following natural infection has been directly correlated with length of infection and severity31. Here, we found that previously infected vaccinated individuals display an increased resilience in antibody responses against both “single” and combination of substitutions in the RBD region, which otherwise severely decreased neutralization activity of uninfected vaccinated individuals. Our observations of the impact of pre-existing immunity in vaccinated individuals on their ability to neutralize variants could be explained by the time window between the initial exposure (infection) and vaccination. Still, our observations provide an important rationale for worldwide efforts in characterizing the contribution of pre-existing SARS-CoV-2 immunity to the outcome of various vaccination strategies. Along with recently introduced serological tests32, such studies could inform evidence-based risk evaluation, patient monitoring, adaptation of containment methods and vaccine development and deployment. Finally, these findings sugges...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.16.452680: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Human intestinal tissue specimen collection: Patients with and without IBD were recruited at outpatient colonoscopy performed for colon cancer screening, surveillance, or IBD activity assessment at NYU Langone Health’s Ambulatory Care Center, New York, under an NYU Grossman School of Medicine Institutional Review Board–approved study (Mucosal Immune Profiling in Patients with Inflammatory Bowel Disease; S12-01137).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sections were blocked in 5% normal donkey serum (Sigma) in TBS-T at room temperature (RT) for 1 hr, followed by incubation with rabbit anti-ACE2 antibody (1:100, Abcam, ab15348) in the blocking solution at 4°C overnight.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-ACE2</div><div>suggested: (Abcam Cat# ab15348, RRID:AB_301861)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The permeabilized organoids were washed 3 times with PBS and incubated with mouse anti-SARS-CoV-2 N antibody (1:1,000, ProSci, 10-605) and rabbit anti-ACE2 antibody (1:500, Abcam, ab15348) diluted in PBS containing 3% BSA overnight at 4°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 N</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The following antibodies were used for immunoblotting studies: mouse anti-β-actin (1:5,000, Sigma, AC-15), rabbit anti-ACE2 (1:1,000, Abcam, ab15348), mouse anti-TMPRSS2 (1:1,000, Santa Cruz, sc-515727).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-β-actin</div><div>suggested: (Sigma-Aldrich Cat# A5441, RRID:AB_476744)</div></div><div style="margin-bottom:8px"><div>anti-TMPRSS2</div><div>suggested: (Santa Cruz Biotechnology Cat# sc-515727, RRID:AB_2892118)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary antibodies (mouse anti-rabbit and goat-anti mouse, 211-032-171 and 115-035-174, respectively) were purchased from JacksonImmunoResearch RNA deep sequencing and analysis: Organoid monolayers were cultured in differentiation media for 7 days and then were infected with SARS-CoV-2 at MOI of 4 for 24 hrs or 72 hrs before RNA extraction with 2-3 technical duplicates per line.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rabbit</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 211-032-171, RRID:AB_2339149)</div></div><div style="margin-bottom:8px"><div>mouse, 211-032-171</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 211-032-171, RRID:AB_2339149)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A working stock of SARS-CoV-2-mNG was generated by infecting a 90-95% confluent monolayer of Vero E6 cells (ATCC CRL-1586) for 48 hrs at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Amplicons were cloned into pCR™2.1-TOPO® (Invitrogen).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pCR™2.1-TOPO®</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The crypts were embedded in 30 μl of Matrigel and cultured with Human IntestiCult™ Organoid Growth Medium (OGM) (Basal Medium and Organoid Supplement, Stemcell Technologies) supplemented with 100 IU Penicillin and 100 μg/ml Streptomycin (Corning) and 125 μg/ml Gentamicin (ThermoFisher), herein referred to as expansion medium.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ThermoFisher</div><div>suggested: (ThermoFisher; SL 8; Centrifuge, RRID:SCR_020809)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For differentiation, the human organoids were cultured with 1:1 mix of Human IntestiCult™ OGM Basal Medium and DMEM/F-12 (ThermoFisher) in the presence of 100 IU Penicillin and 100 μg/ml Streptomycin, 125 μg/ml Gentamicin and 2 mM L-Glutamine (Corning), herein referred to as differentiation medium.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Human IntestiCult™</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Images were acquired using an EVOS FL Auto Cell Imaging System (ThermoFisher) and then processed and quantified using ImageJ.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Upstream regulators analysis was performed by uploading the differentially expressed genes to Ingenuity Pathway Analysis software (Qiagen).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Ingenuity Pathway Analysis</div><div>suggested: (Ingenuity Pathway Analysis, RRID:SCR_008653)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical differences were determined as described in figure legend using either R or GraphPad Prism 9 software (La Jolla, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.13.21260404: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Experiments using mice and samples of healthy human were approved by the Research Ethics Review Committee of the Shanghai Public Health Clinical Center Affiliated to Fudan University.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Mouse vaccination: Peripheral blood samples were collected from female adult mice and pre-existing S2 binding antibodies were measured using the previously described in-house ELISA method.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Detection of SARS-CoV-2 S1 and S2 specific binding antibodies: In-house enzyme-linked immunosorbent assays (ELISA) were developed to measure SARS-CoV-2 S1 and S2 specific binding antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>S1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then, 100μl of a HRP labeled goat anti-mouse IgG antibody (Cat# ab6759, Abcam, UK) or goat anti-mouse IgG antibody (Cat# 115-035-003, Jackson Immuno Research, USA) diluted in 1×PBS containing 5% milk were added to each well and incubated for 1 hour at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: (Abcam Cat# ab6759, RRID:AB_955434)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Preparation of P144 specific monoclonal antibodies: Monoclonal antibodies against P144 were prepared from one naïve BALB/c mouse and one naïve C57BL/6 mouse respectively using the hybridoma technique.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>P144</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, the 96-well ELISPOT plates were coated with purified anti-mouse IFN-γ monoclonal antibody overnight at 4°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IFN-γ</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After incubation, detecting antibody and Avidin-HRP were added sequentially.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Avidin-HRP</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, freshly isolated splenocytes were mixed and fused with SP2/0 cells at a ratio of 1:10.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SP2/0</div><div>suggested: CLS Cat# 400481/p8829_Sp20-Ag14, RRID:CVCL_2199)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, Vero cells were added into each well (2×104 cells/well) and the plates were incubated at 37°C in a humidified incubator with 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: RRID:CVCL_ZW93)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Preparation of P144 specific monoclonal antibodies: Monoclonal antibodies against P144 were prepared from one naïve BALB/c mouse and one naïve C57BL/6 mouse respectively using the hybridoma technique.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>C57BL/6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Selected clones of hybridoma cells were injected intraperitoneally into BALB/c×ICR hybrid mice.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c×ICR</div><div>suggested: RRID:MGI:5652525)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The codon optimized spike gene was subcloned into a eukaryotic expression vector (pJW4303, kindly gifted by Dr. Shan Lu’s Laboratory at the University of Massachusetts) (35).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pJW4303</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The data were analyzed using the FlowJo software (BD Biosciences, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Construction and preparation of a candidate DNA vaccine encoding SARS-CoV-2 full length S protein: The full-length s gene sequence of the reference SARS-CoV-2 strain was optimized according to the preference of human codon usage and synthesized by GENEWIZ life science company (Suchow, China).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GENEWIZ</div><div>suggested: (GENEWIZ, RRID:SCR_003177)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: All statistical analyses were performed using GraphPad Prism 8 (GraphPad Software, Inc., La Jolla, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 41. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. Keerthivasan, S., Şenbabaoğlu, Y., Martinez-Martin, N., Husain, B., Verschueren, E., Wong, A., Yang, Y. A., Sun, Y., Pham, V., Hinkle, T., Oei, Y., Madireddi, S., Corpuz, R., Tam, L., Carlisle, S., Roose-Girma, M., Modrusan, Z., Ye, Z., Koerber, J. T., & Turley, S. J. (2021). Homeostatic functions of monocytes and interstitial lung macrophages are regulated via collagen domain-binding receptor LAIR1. Immunity, 54(7), 1511-1526.e8. https://doi.org/10.1016/j.immuni.2021.06.012

    1. SciScore for 10.1101/2021.07.14.21260508: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Variants were identified after read mapping in the reference genome for SARS-CoV-2 (RefSeq accession number NC_045512), and the analysis was performed on the Pangolin and Nextclade platforms.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RefSeq</div><div>suggested: (RefSeq, RRID:SCR_003496)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The reads were trimmed with Trimmomatic v0.39 (5) and assembled using the tools SPAdes v3.14.1 (4) and MEGAHIT v1.2.9 (26).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Trimmomatic</div><div>suggested: (Trimmomatic, RRID:SCR_011848)</div></div><div style="margin-bottom:8px"><div>SPAdes</div><div>suggested: (SPAdes, RRID:SCR_000131)</div></div><div style="margin-bottom:8px"><div>MEGAHIT</div><div>suggested: (MEGAHIT, RRID:SCR_018551)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The scaffolds were built with RagTag v1.1.1 (1), ABACAS v1.3.1 (3) using the SARS-CoV-2 isolate Wuhan-Hu-1 as a template (NC_045512 RefSeq).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RagTag</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>ABACAS</div><div>suggested: (ABACAS, RRID:SCR_015852)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Using this approach, we generated consensus sequences with a mean of 95% coverage (QUAST v5.0.2) (22).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>QUAST</div><div>suggested: (QUAST, RRID:SCR_001228)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The two groups of sequences were aligned using MAFFT v7.475 (24).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MAFFT</div><div>suggested: (MAFFT, RRID:SCR_011811)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The datasets were subjected to a maximum likelihood (ML) and a phylogenetic analysis using IQ-TREE v2.1.2 (31) under the GTR+G4+F nucleotide substitution model, and branch support was assessed by the approximate likelihood-ratio test based on the Shimodaira–Hasegawa-like procedure (SH-aLRT) with 1,000 replicates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IQ-TREE</div><div>suggested: (IQ-TREE, RRID:SCR_017254)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Time-scaled phylogenetic analysis: The time-scale phylogenetic tree was built using the Bayesian Markov Chain Monte Carlo (MCMC) approach implemented in BEAST 1.10.4 with the BEAGLE v3.1.0 library to optimize the computational time.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BEAST</div><div>suggested: (BEAST, RRID:SCR_010228)</div></div><div style="margin-bottom:8px"><div>BEAGLE</div><div>suggested: (BEAGLE, RRID:SCR_001789)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Convergence (effective sample size> 200) in parameter estimates was assessed using TRACER v1.7.2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>TRACER</div><div>suggested: (Tracer, RRID:SCR_019121)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The maximum clade credibility (MCC) tree was summarized with TreeAnnotator v1.10.4 ML, and MCC trees were visualized using FigTree v1.4.4 (18, 19).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FigTree</div><div>suggested: (FigTree, RRID:SCR_008515)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your code and data.


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      A limitation of our study includes the impossibility of follow-up in the cases to make a more precise correlation between the variants and the clinical out-comes, and, for the association analysis, clinical severity was determined from the data from the laboratory that provided the samples. Therefore, we infer, based on the available data, that the P.1 variant may not be related to a higher severity of COVID-19, although further studies should be carried out to carefully explore this issue. Our phylogenetic analysis performed with the P.1 variant genomes identified in the state of Paraná and in the other states of Brazil showed that the recently described lineage P.1- like-II (21) was also present at moderate frequencies in the state of Paraná (Figure 3 and 5). The P.1- like-II lineage presents 15 of the 22 mutations of the P.1 variant, including the three main mutations in the RBD domain of the S protein: K417T, E484K and N501Y. On the other hand, they present some unique substitutions: ORF1ab: C8905T, C16954T and A20931G; NSP4:D2980H, intergenic region E/M A26492T and N:P383 L. The analysis of the mutations in the first 11 P.1- like-II genomes from Paraná identified 3 of the 4 unique substitutions of the P.1- like-II lineage (C8905T, C16954T, A26492T) in addition to the N:P383 L and ORF1a:D2980H mutations. However, we also identified some unique substitutions, which were not yet described, for the P.1 variant and P.1- like-II lineage, and these substitutions included ORF1a:...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

  5. beamapp.co beamapp.co

    Annotators

    URL

    1. SciScore for 10.1101/2021.07.15.452246: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Field Sample Permit: Bioethics statement: The collection of COVID-19 human biospecimens for research has been approved by the NYUSOM Institutional Review Board under<br>IRB: Bioethics statement: The collection of COVID-19 human biospecimens for research has been approved by the NYUSOM Institutional Review Board under<br>Consent: Informed consent was obtained from all enrolled patients.<br>IACUC: All animal studies were performed according to protocols approved by the NYU School of Medicine Institutional Animal Care and Use Committee (IACUC n°170209). 24-week-old K18-hACE2 males were administered either 10PFU SARS-CoV-2 (low dose, LD), 104PFU SARS-CoV-2 (high dose, HD) diluted in 50μL PBS (Corning) or 50μL PBS (non-infected, CTRL) via intranasal administration under xylazine-ketamine anesthesia (AnaSedR AKORN</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">All animal studies were performed according to protocols approved by the NYU School of Medicine Institutional Animal Care and Use Committee (IACUC n°170209). 24-week-old K18-hACE2 males were administered either 10PFU SARS-CoV-2 (low dose, LD), 104PFU SARS-CoV-2 (high dose, HD) diluted in 50μL PBS (Corning) or 50μL PBS (non-infected, CTRL) via intranasal administration under xylazine-ketamine anesthesia (AnaSedR AKORN</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">At the time of sample acquisition and processing, investigators were blinded to patient clinical status.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">No statistical methods were used to predetermine sample size for this cohort.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viral titer in the inoculum was verified by plaque assay in Vero E6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mice: Heterozygous K18-hACE2 C57BL/6J mice (strain: 2B6.Cg-Tg(K18-ACE2)2Prlmn/J) were obtained from The Jackson Laboratory.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6J</div><div>suggested: RRID:MGI:3589388)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All animal studies were performed according to protocols approved by the NYU School of Medicine Institutional Animal Care and Use Committee (IACUC n°170209). 24-week-old K18-hACE2 males were administered either 10PFU SARS-CoV-2 (low dose, LD), 104PFU SARS-CoV-2 (high dose, HD) diluted in 50μL PBS (Corning) or 50μL PBS (non-infected, CTRL) via intranasal administration under xylazine-ketamine anesthesia (AnaSedR AKORN</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>K18-hACE2</div><div>suggested: RRID:IMSR_GPT:T037657)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The data presented in this study were also approved by Yale Human Research Protection Program Institutional Review Boards (FWA00002571, protocol ID 2000027690).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Yale Human Research Protection Program</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The clinical data were collected using EPIC EHR and REDCap 9.3.6 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>REDCap</div><div>suggested: (REDCap, RRID:SCR_003445)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All PCR products were analyzed with the Agilent TapeStation for quality control and then pooled equimolar and sequenced directly in the Illumina MiSeq platform using the 2×250 bp protocol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Agilent TapeStation</div><div>suggested: (Agilent TapeStation Laptop, RRID:SCR_019547)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Bioinformatic processing and taxonomic assignment: Amplicon sequence variants (ASVs) were generated via dada2 v1.16.0 using post-QC FASTQ files.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Amplicon</div><div>suggested: (Amplicon, RRID:SCR_003294)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ASV taxonomy was assigned up to genus level using the SILVAv.138 database with the method described in 45 and a minimum boostrapping support of 50%.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SILVAv.138</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Principal Coordinate Analyses: Bray-Curtis distances were calculated from the filtered ASV table using QIIME 1.9.1 and principal components of the resulting distance matrix were calculated using the scikit-learn package for the Python programming language, used to embed sample compositions in the first two principal coordinates (see published code for the implementation in the Python programming language).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>QIIME</div><div>suggested: (QIIME, RRID:SCR_008249)</div></div><div style="margin-bottom:8px"><div>scikit-learn</div><div>suggested: (scikit-learn, RRID:SCR_002577)</div></div><div style="margin-bottom:8px"><div>Python</div><div>suggested: (IPython, RRID:SCR_001658)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.14.452401: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines: HRT-18/HTC-8 (ATCC CCL-224) cells were maintained in RPMI-1640 (ATCC formulation) (Gibco, Fisher Scientific), 2% heat-inactivated (HI) fetal bovine serum (FBS) (Gibco, Fisher Scientific) and 2mM L-glutamine (Corning, Fisher Scientific).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HRT-18/HTC-8</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plaque Assays: MRC-5 cells or Vero E6 cells were seeded in 12 or 24-well plates and incubated at 37°C, 5% CO2 until 80-90% confluent.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MRC-5</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.14.452343: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: All patients (>18 years of age) gave informed consent for tissue donation and the project was approved by the local ethic committee at MHH (ethic vote 3346/2016).<br>IRB: All patients (>18 years of age) gave informed consent for tissue donation and the project was approved by the local ethic committee at MHH (ethic vote 3346/2016).<br>Field Sample Permit: Pathway analysis: Pathway analysis and acquisition of metadata about the ReFRAME drug repurposing collection was mainly conducted on the basis of information provided by Scripps Research Institute (https://reframedb.org)</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">The analysis pipeline was elaborated and optimised using pictures of cells infected with a blind dilution series of SARS-CoV-2.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: Cells were tested negative for contaminations with mycoplasma (Eurofins). 2.8.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Alexa-Fluor Plus 488 anti-mouse antibody (1:1,000; Invitrogen #A32723) and DAPI (1:10,000; Invitrogen #D21490).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse</div><div>suggested: (Thermo Fisher Scientific Cat# A32723, RRID:AB_2633275)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, Vero E6 cells (Chlorocebus aethiops) and Calu-3 cells (Homo sapiens sapiens) (both from Stefan Pöhlmann), Huh-7.5 cells (Homo sapiens sapiens, Charles M.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div><div style="margin-bottom:8px"><div>Huh-7.5</div><div>suggested: RRID:CVCL_7927)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Rice), MRC-5 cells (Homo sapiens sapiens, Volker Thiel)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MRC-5</div><div>suggested: ICLC Cat# HL95001, RRID:CVCL_0440)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, A549 cells (Homo sapiens sapiens, ATCC-CCL-185; Lot 59239596),</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">2.2. HCoV 229E screening: Huh-7.5/F-Luc cells were seeded in black 384-well plates with a flat clear bottom (Corning #3764) at a density of 3×103 cells/well in phenol-red free Dulbecco’s modified Eagle medium (DMEM; Gibco #31053-028) supplemented with 2 mM L-glutamine (Gibco #25030024), 100 µg/mL streptomycin and 100 U/mL penicillin (Gibco; #15140122), 10% fetal calf serum (FCS, Capricorn Scientific #FBS-11A) and non-essential amino acids (NEAA; Gibco #11140035) one day prior to infection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Huh-7.5/F-Luc</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">At 50-80% confluence, Vero cells were inoculated with 500 µL of SARS-CoV-2 (strain SARS-CoV-2/München-1.2/2020/984; p3) in a total of 10 mL of Advanced MEM and incubated at 37°C (5% CO2) under BSL-3 conditions adapted for infectious respiratory viruses.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Stocks were titrated on Vero and Calu-3 (Finkbeiner et al., 1993) cells (ATCC Cat. #HTB-55 and RRID:CVCL_0609, respectively), cultured in DMEM containing 1% NEAA, 100 U/mL penicillin, 100 μg/mL streptomycin, 2 mM L-glutamine, 10% FCS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>detected: (ATCC Cat# HTB-55, RRID:CVCL_0609)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 infection in Calu-3 cells and primary human airway epithelial cells: For infection with SARS-CoV-2, Calu-3 cells (Finkbeiner et al., 1993) were seeded in 96-well plates 48h prior to virus inoculation at a density of 5×104 in DMEM (Gibco #41965039) supplemented as described above.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">2.2. HCoV 229E screening: Huh-7.5/F-Luc cells were seeded in black 384-well plates with a flat clear bottom (Corning #3764) at a density of 3×103 cells/well in phenol-red free Dulbecco’s modified Eagle medium (DMEM; Gibco #31053-028) supplemented with 2 mM L-glutamine (Gibco #25030024), 100 µg/mL streptomycin and 100 U/mL penicillin (Gibco; #15140122), 10% fetal calf serum (FCS, Capricorn Scientific #FBS-11A) and non-essential amino acids (NEAA; Gibco #11140035) one day prior to infection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gibco</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viral titer (TCID50/mL) were quantified based on the Spearman and Kärber method using a calculator developed by Marco Binder, Heidelberg University.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Binder</div><div>suggested: (Binder, RRID:SCR_016437)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Rolling-ball background subtraction was performed for both channels using the ImageJ command (Schneider et al., 2012).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The percentage of positive cells per condition was grouped in Python 3.8.4 and plotted against the relative cell density (overall cell count per condition relative to the overall cell count in the infected and DMSO-treated control). 2.7.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Python</div><div>suggested: (IPython, RRID:SCR_001658)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">(Janes et al., 2018) and the Ingenuity Pathway Analysis software suite (IPA, QIAGEN Inc.,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Ingenuity Pathway Analysis</div><div>suggested: (Ingenuity Pathway Analysis, RRID:SCR_008653)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To complement this information, the following sources were used: DrugBank (https://go.drugbank.com/</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>DrugBank</div><div>suggested: (DrugBank, RRID:SCR_002700)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, PubChem (Kim et al., 2019), Guide to PHARMACOLOGY (Armstrong et al., 2020) and NCBI PubMed (Coordinators, 2018).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PubChem</div><div>suggested: (PubChem, RRID:SCR_004284)</div></div><div style="margin-bottom:8px"><div>PubMed</div><div>suggested: (PubMed, RRID:SCR_004846)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data was processed via Microsoft Excel (Version 2016)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Microsoft Excel</div><div>suggested: (Microsoft Excel, RRID:SCR_016137)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, GraphPad Prism (Version 8) and Adobe Illustrator.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>Adobe Illustrator</div><div>suggested: (Adobe Illustrator, RRID:SCR_010279)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04494646</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Completed</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">BARCONA: A Study of Effects of Bardoxolone Methyl in Partici…</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04069026</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon…</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a protocol registration statement.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.12.452027: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Animals showing such conditions were anesthetized and subsequently sacrificed in accordance with experimental protocols, which were reviewed and approved by the Animal Ethical Committee of The University of Trento and the Italian Ministry of Health.<br>Euthanasia Agents: Cell Isolation and Flow Cytometry: Mice were euthanized by cervical dislocation.<br>IRB: Samples had been collected and stored in the University of Verona biobank (Ethics Committee approval prot. N. 1538) and in Tropica Biobank of the IRCCS Sacro Cuore Don Calabria Hospital (Ethics Committee approval prot. N. 50950).<br>Consent: All participants signed informed consent.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Five-week old CD1 female mice were immunized intraperitoneally (i.p.) on day 0, 14 and 28 with 10 μg of OMVs together with 2mg/ml Aluminium hydroxide.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Wells were washed three times with PBST and then incubated 45 min at room temperature with goat anti mouse alkaline phosphatase-conjugate antibodies at a final dilution of 1:2000 (SigmaAldrich).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti mouse alkaline phosphatase-conjugate</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then, slides were stained with Alexa Fluor 568 Goat Anti-Rabbit antibody for 2h RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-Rabbit</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, Vero E6 cells were seeded at a density of 1.5 × 104 cells per well in flat-bottom 96-well tissue-culture plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Preparation of viral pseudotypes and neutralization assays: SIV-based lentiviral particles pseudotyped with SARS-Cov-2 spike were produced in 10 cm plates prepared the day before transfection with 3 million HEK293T cells in 10 ml complete DMEM, supplemented with 10% FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Neutralization titres were tested on Huh-7 cells overexpressing ACE2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Huh-7</div><div>suggested: CLS Cat# 300156/p7178_HuH7, RRID:CVCL_0336)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For virus challenge studies, B6.Cg-Tg(K18-ACE2)2Prlmn/J mice1 were purchased from The Jackson Laboratory.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>B6.Cg-Tg(K18-ACE2)2Prlmn/J</div><div>suggested: RRID:IMSR_JAX:034860)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">K18-hACE2 transgenic mice were immunized intraperitoneally with 10μl vaccine or PBS twice, 14 days apart.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>K18-hACE2</div><div>suggested: RRID:IMSR_GPT:T037657)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Engineering BL21(DE3) E. coli strains with SARS-CoV-2 neutralizing epitopes: The pET21-FhuD2-RBM438-462, pET21-FhuD2-RBM467-509 and pET21-FhuD2-RBM438-509 plasmids carrying the Staphylococcus aureus Ferric hydroxamate receptor 2 (FhuD2) fused to one copy of RBM438-462, RBM467-509 and RBM438-509 SARS-CoV-2 epitopes respectively were assembled using the PIPE method as described in (ref. H. E. Klock, S. A. Lesley, The Polymerase Incomplete Primer</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pET21-FhuD2-RBM438-462</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, pET21-FhuD2 plasmid was linearized by PCR, using FhuD2-v-R and pET-V-F primers (Table 1).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pET21-FhuD2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pET-V-F</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To confirm the correctness of the gene fusions, plasmids were sequenced (Eurofins, Ebersberg, Germany, EU) and E. coli BL21(DE3)Δ60 strain was transformed with pET21-FhuD2-RBM438-462, pET21-FhuD2-RBM467-509, pET21-FhuD2-RBM438-509 and pET21-FhuD2-RBM-BV438-509 plasmids and the derived recombinant strains were used for the production of engineered FhuD2-RBM438-462, FhuD2-RBM467-509, FhuD2-RBM438-509 and FhuD2-RBM-BV438-509 OMVs, respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pET21-FhuD2-RBM467-509</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pET21-FhuD2-RBM438-509</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pET21-FhuD2-RBM-BV438-509</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">OMV purification: OMVs from BL21(DE3)Δ60(pET-FhuD2-RBM438-509), BL21(DE3) Δ60(pET-FhuD2-RBM438-462), BL21(DE3)Δ60(pET-FhuD2-RBM467-509) and BL21(DE3)Δ60(pET-FhuD2-RBM-BV438-509), were purified in an EZ control bioreactor (Applikon Biotechnology, Schiedam, Netherlands) as previously described (Zanella et al., 2021).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pET-FhuD2-RBM438-509</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pET-FhuD2-RBM438-462</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pET-FhuD2-RBM467-509</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pET-FhuD2-RBM-BV438-509</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Brightfield images were acquired through an Aperio Scanscope System CS2 microscope and an ImageScope program (Leica Biosystem) following the manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageScope</div><div>suggested: (ImageScope, RRID:SCR_014311)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Fitted sigmoidal curves and IC50 were obtained using Prism (GraphPad) with the least square variable slope method and using the dose-normalized response protocol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analyses and software: Flow data were collected using FlowJo Version 10.5.3 (Treestar).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analyses were performed with GraphPad Prism software version 8 (GraphPad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.07.11.451964: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Ethics</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: All procedures followed standard operating procedures (SOPs) approved by the RML Institutional Biosafety Committee (</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Animal study: Fifty female Syrian golden hamsters (5-8 weeks of age) were used in this study14.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After three washes with PBST, the bound antibodies were labeled using 50 μl of 1:2,500 peroxidase anti-hamster IgG (H+L) (SeraCare Life Sciences) diluted in 1% skim milk in PBST.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-hamster IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The secondary antibody was the Vector Laboratories ImPress VR anti-mouse IgG polymer (cat# MP-7422).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: (Vector Laboratories Cat# MP-7422, RRID:AB_2336527)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells and Viruses: VeroE6 cells were grown at 37°C and 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) (Sigma-Aldrich, St. Louis, MO) containing 10% fetal bovine serum (FBS) (Wisent Inc., St. Bruno, Canada), 2 mM L-glutamine (Thermo Fisher Scientific, Waltham, MA), 50 U/mL penicillin (Thermo Fisher Scientific), and 50 μg/mL streptomycin (Thermo Fisher Scientific).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">RNA-Seq reads were demultiplexed, quality-filtered and trimmed using Trim Galore (average Phred score cut-off of 30, minimum length of 50 bp).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Trim Galore</div><div>suggested: (Trim Galore, RRID:SCR_011847)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Hisat2 was used to align reads to the reference genome Mesocricetus auratus (Mesocricetus_auratus.MesAur1.0.dna.toplevel.fa) and the Mesocricetus_auratus.MesAur1.0.103.gtf file was used for annotation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Hisat2</div><div>suggested: (HISAT2, RRID:SCR_015530)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Raw expression values (gene-level read counts) were generated using the summarizeOverlaps function and normalized (read per kilobase of transcript per million mapped reads, rpkm) using the edgeR package.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>edgeR</div><div>suggested: (edgeR, RRID:SCR_012802)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Functional enrichment of DEGs was performed using Metascape to identify relevant GO terms70.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Metascape</div><div>suggested: (Metascape, RRID:SCR_016620)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Digital cell quantification was performed using ImmQuant with the IRIS database.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IRIS</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, Venn diagrams and violin plots were generated using R packages ggplot2 and VennDiagrams.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ggplot2</div><div>suggested: (ggplot2, RRID:SCR_014601)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Graphs were generated using GraphPad Prism software (version 8).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">FastQC was used to generate quality reports.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FastQC</div><div>suggested: (FastQC, RRID:SCR_014583)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">MaskPrimers.py from the pRESTO R package was used to remove primers prior to alignment to the SARS-CoV-2 genome using BWA-mem software version 0.7.17.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pRESTO</div><div>suggested: (pRESTO, RRID:SCR_001782)</div></div><div style="margin-bottom:8px"><div>BWA-mem</div><div>suggested: (Sniffles, RRID:SCR_017619)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analyses: All statistical analysis was performed in Prism 8 (GraphPad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. Toor, J., Echeverria-Londono, S., Li, X., Abbas, K., Carter, E. D., Clapham, H. E., Clark, A., de Villiers, M. J., Eilertson, K., Ferrari, M., Gamkrelidze, I., Hallett, T. B., Hinsley, W. R., Hogan, D., Huber, J. H., Jackson, M. L., Jean, K., Jit, M., Karachaliou, A., … Gaythorpe, K. A. (2021). Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world. ELife, 10, e67635. https://doi.org/10.7554/eLife.67635